0001585364-17-000159.txt : 20171109 0001585364-17-000159.hdr.sgml : 20171109 20171109114919 ACCESSION NUMBER: 0001585364-17-000159 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 92 CONFORMED PERIOD OF REPORT: 20170930 FILED AS OF DATE: 20171109 DATE AS OF CHANGE: 20171109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PERRIGO Co plc CENTRAL INDEX KEY: 0001585364 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36353 FILM NUMBER: 171189606 BUSINESS ADDRESS: STREET 1: TREASURY BUILDING STREET 2: LOWER GRAND CANAL STREET CITY: DUBLIN STATE: L2 ZIP: L2 2 BUSINESS PHONE: 269-673-8451 MAIL ADDRESS: STREET 1: 515 EASTERN AVENUE CITY: ALLEGAN STATE: MI ZIP: 49010 FORMER COMPANY: FORMER CONFORMED NAME: PERRIGO Co Ltd DATE OF NAME CHANGE: 20130828 10-Q 1 cy17q310q.htm 10-Q Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_______________________________________________
 FORM 10-Q
_______________________________________________
[X]
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended: September 30, 2017
OR
[  ]
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from              to             
Commission file number 001-36353
_______________________________________________
Perrigo Company plc
(Exact name of registrant as specified in its charter)
_______________________________________________
Ireland
 
Not Applicable
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification No.)
 
 
Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland
 
-
(Address of principal executive offices)
 
(Zip Code)
+353 1 7094000
(Registrant’s telephone number, including area code)
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)
________________________________________ 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such report), and (2) has been subject to such filing requirements for the past 90 days.    YES [X]    NO  [ ]
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    YES  [X]   NO [ ]
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
[X]
 
Accelerated filer
[ ]
 
Non-accelerated filer
[ ]
(Do not check if smaller reporting company)
Smaller reporting company
[ ]
 
Emerging growth company
[ ]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
[ ]
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   [ ]  YES  [X] NO
As of November 3, 2017, there were 140,840,721 ordinary shares outstanding.


PERRIGO COMPANY PLC
FORM 10-Q
INDEX
 
PAGE
NUMBER
 
 
PART I. FINANCIAL INFORMATION
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
 
 
 
2
 
 
 
3
 
 
 
4
 
 
 
5
 
 
 
6
 
 
 
7
 
 
 
8
 
 
 
9
 
 
 
10
 
 
 
11
 
 
 
12
 
 
 
13
 
 
 
14
 
 
 
15
 
 
 
16
 
 
 
 
 
 
 
 
 
 
 
 
PART II. OTHER INFORMATION
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
    
Certain statements in this report are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our, or our industry’s actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by any forward-looking statements. In particular, statements about our expectations, beliefs, plans, objectives, assumptions, future events or future performance contained in this report, including certain statements contained in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” are forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or the negative of those terms or other comparable terminology.

Please see Item 1A of our Form 10-K for the year ended December 31, 2016 for a discussion of certain important risk factors that relate to forward-looking statements contained in this report and Part II, Item 1A of this Form 10-Q. We have based these forward-looking statements on our current expectations, assumptions, estimates and projections. While we believe these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond our control, including: the timing, amount and cost of any share repurchases; future impairment charges; the success of management transition; customer acceptance of new products; competition from other industry participants, some of whom have greater marketing resources or larger market shares in certain product categories than we do; pricing pressures from customers and consumers; potential third-party claims and litigation, including litigation relating to our restatement of previously-filed financial information; potential impacts of ongoing or future government investigations and regulatory initiatives; resolution of uncertain tax positions; the impact of U.S. tax reform legislation; general economic conditions; fluctuations in currency exchange rates and interest rates; the consummation of announced acquisitions or dispositions, and our ability to realize the desired benefits thereof; and the ability to execute and achieve the desired benefits of announced cost-reduction efforts and other initiatives. In addition, we may identify and be unable to remediate one or more material weaknesses in our internal control over financial reporting. Furthermore, we and/or our subsidiaries may incur additional tax liabilities in respect of 2016 and prior years as a result of any restatement or may be found to have breached certain provisions of Irish company legislation in respect of prior financial statements and if so may incur additional expenses and penalties. These and other important factors, including those discussed in our Form 10-K for the year ended December 31, 2016, in this report under “Risk Factors” and in any subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this report are made only as of the date hereof, and unless otherwise required by applicable securities laws, we disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

TRADEMARKS, TRADE NAMES AND SERVICE MARKS

This report contains trademarks, trade names and service marks that are the property of Perrigo Company plc, as well as, for informational purposes, trademarks, trade names, and service marks that are the property of other organizations. Solely for convenience, certain trademarks, trade names, and service marks referred to in this report appear without the ®, ™ and SM symbols, but those references are not intended to indicate that we or the applicable owner, as the case may be, will not assert, to the fullest extent under applicable law, our or their rights to such trademarks, trade names, and service marks.


1
Perrigo Company plc - Item 1

PART I.     FINANCIAL INFORMATION

ITEM 1.        FINANCIAL STATEMENTS (UNAUDITED)

PERRIGO COMPANY PLC
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in millions, except per share amounts)
(unaudited)
 
 
Three Months Ended
 
Nine Months Ended
 
September 30,
2017
 
October 1,
2016
 
September 30,
2017
 
October 1,
2016
Net sales
$
1,231.3

 
$
1,261.6

 
$
3,663.1

 
$
3,949.3

Cost of sales
733.5

 
777.1

 
2,196.4

 
2,385.2

Gross profit
497.8

 
484.5

 
1,466.7

 
1,564.1

 
 
 
 
 
 
 
 
Operating expenses
 
 
 
 
 
 
 
Distribution
21.5

 
21.6

 
64.2

 
65.9

Research and development
38.4

 
50.2

 
120.8

 
142.5

Selling
143.5

 
154.6

 
454.1

 
506.9

Administration
123.3

 
105.4

 
326.9

 
317.2

Impairment charges
7.8

 
1,614.4

 
47.4

 
2,028.8

Restructuring
3.8

 
6.6

 
54.7

 
17.9

Other operating income
(2.9
)
 
—

 
(41.0
)
 
—

Total operating expenses
335.4

 
1,952.8

 
1,027.1

 
3,079.2

 
 
 
 
 
 
 
 
Operating income (loss)
162.4

 
(1,468.3
)
 
439.6

 
(1,515.1
)
 
 
 
 
 
 
 
 
Change in financial assets
2.6

 
377.4

 
24.2

 
1,492.6

Interest expense, net
34.7

 
54.6

 
133.1

 
163.2

Other (income) expense, net
(3.6
)
 
1.0

 
(1.1
)
 
32.4

Loss on extinguishment of debt
—

 
0.7

 
135.2

 
1.1

Income (loss) before income taxes
128.7

 
(1,902.0
)
 
148.2

 
(3,204.4
)
Income tax expense (benefit)
84.2

 
(311.8
)
 
101.8

 
(550.7
)
Net income (loss)
$
44.5

 
$
(1,590.2
)
 
$
46.4

 
$
(2,653.7
)
 
 
 
 
 
 
 
 
Earnings (loss) per share
 
 
 
 
 
 
 
Basic
0.31

 
(11.10
)
 
$
0.33

 
$
(18.53
)
Diluted
$
0.31

 
$
(11.10
)
 
$
0.32

 
$
(18.53
)
 
 
 
 
 
 
 
 
Weighted-average shares outstanding
 
 
 
 
 
 
 
Basic
141.3

 
143.3

 
142.5

 
143.2

Diluted
141.7

 
143.3

 
142.8

 
143.2

 
 
 
 
 
 
 
 
Dividends declared per share
$
0.160

 
$
0.145

 
$
0.480

 
$
0.435


See accompanying Notes to the Condensed Consolidated Financial Statements

2
Perrigo Company plc - Item 1

PERRIGO COMPANY PLC
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(in millions)
(unaudited)
 
Three Months Ended
 
Nine Months Ended
 
September 30,
2017
 
October 1,
2016
 
September 30,
2017
 
October 1,
2016
Net income (loss)
$
44.5

 
$
(1,590.2
)
 
$
46.4

 
$
(2,653.7
)
Other comprehensive income:
 
 
 
 
 
 
 
Foreign currency translation adjustments
69.9

 
27.5

 
289.9

 
71.5

Change in fair value of derivative financial instruments, net of tax
0.1

 
3.6

 
8.7

 
(3.5
)
Change in fair value of investment securities, net of tax
(8.1
)
 
9.8

 
(24.4
)
 
18.4

Change in post-retirement and pension liability, net of tax
(1.2
)
 
(0.2
)
 
(1.2
)
 
0.4

Other comprehensive income, net of tax
60.7

 
40.7

 
273.0

 
86.8

Comprehensive income (loss)
$
105.2

 
$
(1,549.5
)
 
$
319.4

 
$
(2,566.9
)
See accompanying Notes to the Condensed Consolidated Financial Statements


3
Perrigo Company plc - Item 1

PERRIGO COMPANY PLC
CONDENSED CONSOLIDATED BALANCE SHEETS
(in millions, except share and per share amounts)
(unaudited)
 
September 30,
2017
 
December 31,
2016
Assets
 
 
 
Cash and cash equivalents
$
775.9

 
$
622.3

Accounts receivable, net of allowance for doubtful accounts of $6.2 million and $6.3 million, respectively
1,076.6

 
1,176.0

Inventories
821.9

 
795.0

Prepaid expenses and other current assets
297.4

 
212.0

Total current assets
2,971.8

 
2,805.3

Property, plant and equipment, net
822.3

 
870.1

Financial assets
—

 
2,350.0

Goodwill and other indefinite-lived intangible assets
4,255.4

 
4,163.9

Other intangible assets, net
3,347.4

 
3,396.8

Non-current deferred income taxes
22.4

 
72.1

Other non-current assets
423.3

 
211.9

Total non-current assets
8,870.8

 
11,064.8

Total assets
$
11,842.6

 
$
13,870.1

Liabilities and Shareholders’ Equity
 
 
 
Accounts payable
$
477.1

 
$
471.7

Payroll and related taxes
133.4

 
115.8

Accrued customer programs
368.8

 
380.3

Accrued liabilities
274.6

 
263.3

Accrued income taxes
61.5

 
32.4

Current indebtedness
417.1

 
572.8

Total current liabilities
1,732.5

 
1,836.3

Long-term debt, less current portion
3,275.7

 
5,224.5

Non-current deferred income taxes
357.7

 
389.9

Other non-current liabilities
434.9

 
461.8

Total non-current liabilities
4,068.3

 
6,076.2

Total liabilities
5,800.8

 
7,912.5

Commitments and contingencies - Note 14
 
 
 
Shareholders’ equity
 
 
 
Controlling interest:
 
 
 
Preferred shares, $0.0001 par value, 10 million shares authorized
—

 
—

Ordinary shares, €0.001 par value, 10 billion shares authorized
7,900.1

 
8,135.0

Accumulated other comprehensive income (loss)
191.2

 
(81.8
)
Retained earnings (accumulated deficit)
(2,049.6
)
 
(2,095.1
)
Total controlling interest
6,041.7

 
5,958.1

Noncontrolling interest
0.1

 
(0.5
)
Total shareholders’ equity
6,041.8

 
5,957.6

Total liabilities and shareholders' equity
$
11,842.6

 
$
13,870.1

 
 
 
 
Supplemental Disclosures of Balance Sheet Information
 
 
 
Ordinary shares, issued and outstanding (in millions)
140.8

 
143.4


See accompanying Notes to the Condensed Consolidated Financial Statements

4
Perrigo Company plc - Item 1

PERRIGO COMPANY PLC
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in millions)
(unaudited)
 
Nine Months Ended
 
September 30,
2017
 
October 1,
2016
Cash Flows From (For) Operating Activities
 
 
 
Net income (loss)
$
46.4

 
$
(2,653.7
)
Adjustments to derive cash flows
 
 
 
Depreciation and amortization
333.1

 
338.4

Share-based compensation
28.1

 
15.3

Impairment charges
47.4

 
2,028.8

Change in financial assets
24.2

 
1,492.6

Loss on extinguishment of debt
135.2

 
1.1

Restructuring charges
54.7

 
17.9

Deferred income taxes
(16.3
)
 
(674.1
)
Amortization of debt premium
(18.4
)
 
(24.6
)
Other non-cash adjustments, net
(27.2
)
 
34.5

Subtotal
607.2

 
576.2

Increase (decrease) in cash due to:
 
 
 
Accounts receivable
38.4

 
113.0

Inventories
(28.3
)
 
25.1

Accounts payable
(6.0
)
 
(57.7
)
Payroll and related taxes
(36.7
)
 
(40.0
)
Accrued customer programs
(15.8
)
 
(73.7
)
Accrued liabilities
(18.8
)
 
(90.0
)
Accrued income taxes
(61.5
)
 
5.2

Other, net
3.5

 
(9.4
)
Subtotal
(125.2
)
 
(127.5
)
Net cash from operating activities
482.0

 
448.7

Cash Flows From (For) Investing Activities
 
 
 
Proceeds from royalty rights
86.4

 
259.5

Acquisitions of businesses, net of cash acquired
—

 
(436.8
)
Asset acquisitions
—

 
(65.1
)
Additions to property, plant and equipment
(55.2
)
 
(84.6
)
Net proceeds from sale of business and other assets
46.7

 
58.5

Proceeds from sale of the Tysabri® financial asset
2,200.0

 
—

Other investing, net
(5.8
)
 
(1.0
)
Net cash from (for) investing activities
2,272.1

 
(269.5
)
Cash Flows From (For) Financing Activities
 
 
 
Issuances of long-term debt
—

 
1,190.3

Payments on long-term debt
(2,243.7
)
 
(545.8
)
Borrowings (repayments) of revolving credit agreements and other financing, net
—

 
(803.6
)
Deferred financing fees
(4.2
)
 
(2.8
)
Premium on early debt retirement
(116.1
)
 
(0.6
)
Issuance of ordinary shares
0.5

 
8.2

Repurchase of ordinary shares
(191.5
)
 
—

Cash dividends
(68.7
)
 
(62.4
)
Other financing
2.7

 
(17.4
)
Net cash (for) financing activities
(2,621.0
)
 
(234.1
)
Effect of exchange rate changes on cash and cash equivalents
20.5

 
(0.2
)
Net increase (decrease) in cash and cash equivalents
153.6

 
(55.1
)
Cash and cash equivalents, beginning of period
622.3

 
417.8

Cash and cash equivalents, end of period
$
775.9

 
$
362.7


See accompanying Notes to the Condensed Consolidated Financial Statements

5
Perrigo Company plc - Item 1
Note 1



NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

General Information

The Company

Perrigo Company plc was incorporated under the laws of Ireland on June 28, 2013 and became the successor registrant of Perrigo Company, a Michigan corporation, on December 18, 2013 in connection with the acquisition of Elan Corporation, plc ("Elan"). Unless the context requires otherwise, the terms "Perrigo," the "Company," "we," "our," "us," and similar pronouns used herein refer to Perrigo Company plc, its subsidiaries, and all predecessors of Perrigo Company plc and its subsidiaries.

We are a leading global healthcare company, delivering value to our customers and consumers by providing Quality Affordable Healthcare Products®. Founded in 1887 as a packager of home remedies, we have built a unique business model that is best described as the convergence of a fast-moving consumer goods company, a high-quality pharmaceutical manufacturing organization and a world-class supply chain network. We believe we are one of the world's largest manufacturers of over-the-counter (“OTC”) healthcare products and suppliers of infant formulas for the store brand market. We also are a leading provider of branded OTC products throughout Europe and the U.S., as well as a leading producer of generic standard topical products such as creams, lotions, and gels, as well as inhalants and injections ("extended topical") prescription drugs. We are headquartered in Ireland, and sell our products primarily in North America and Europe, as well as in other markets, including Australia, Israel and China.

Basis of Presentation

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The unaudited Condensed Consolidated Financial Statements should be read in conjunction with the consolidated financial statements and footnotes included in our Annual Report on Form 10-K for the year ended December 31, 2016. In the opinion of management, all adjustments (consisting of normal recurring accruals and other adjustments) considered necessary for a fair presentation of the unaudited Condensed Consolidated Financial Statements have been included and include our accounts and the accounts of all majority-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.



6
Perrigo Company plc - Item 1
Note 1


Recent Accounting Standard Pronouncements
    
Below are recent accounting standard updates that we are still assessing to determine the effect on our Condensed Consolidated Financial Statements. We do not believe that any other recently issued accounting standards could have a material effect on our Condensed Consolidated Financial Statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.
Recently Issued Accounting Standards Adopted
Standard
 
Description
 
Date of adoption
 
Effect on the Financial Statements or Other Significant Matters
Clarifying the Definition of a Business
 
This update clarifies the definition of a business and addresses whether transactions should be accounted for as asset acquisitions or business combinations (or divestitures). The guidance includes an initial threshold that an acquired set of assets will not be considered a business if substantially all of the fair value of the assets acquired is concentrated in a single tangible or identifiable intangible asset (or group of similar assets). If the acquired set does not pass the initial threshold, then the guidance requires that, to be a business, the set must include an input and a substantive process that together significantly contribute to the ability to create outputs. Different factors are considered to determine whether the set includes a substantive process, such as the inclusion of an organized workforce. Further, the guidance removes language stating that a business need not include all of the inputs and processes that the seller used in operating the business.
 
January 1, 2017
 
We early adopted this new standard and will apply it prospectively when determining whether transactions should be accounted for as asset acquisitions (divestitures) or business combinations (divestitures). During the nine months ended September 30, 2017, we applied the new guidance when determining whether certain product divestitures represented sales of assets or businesses.

Improvements to Employee Share-Based Payment Accounting
 
This guidance is intended to simplify several aspects of the accounting for share-based payment award transactions. It will require all income tax effects of awards to be recorded through the income statement when the awards vest or settle as opposed to certain amounts being recorded in additional paid-in capital. An entity will also have to elect whether to account for forfeitures as they occur or by estimating the number of awards expected to be forfeited and adjusting the estimate when it is likely to change (as currently required). The guidance will also increase the amount an employer can withhold to cover income taxes on awards.
 
January 1, 2017
 
We adopted this standard as of January 1, 2017. We elected to estimate the number of awards expected to be forfeited and adjust the estimate when it is likely to change, consistent with past practice. We did not change the amounts that we withhold to cover income taxes on awards. As the requirement to record all income tax effects of vested or settled awards through the income statement is prospective in nature, there was no cumulative effect of adopting the standard on our balance sheet.


7
Perrigo Company plc - Item 1
Note 1


Recently Issued Accounting Standards Not Yet Adopted
Standard
 
Description
 
Effective Date
 
Effect on the Financial Statements or Other Significant Matters
Revenue from Contracts with Customers
 
The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: identify the contract(s) with a customer; identify the performance obligations in the contract; determine the transaction price; allocate the transaction price to the performance obligations in the contract; and recognize revenue when (or as) the entity satisfies a performance obligation. This guidance allows for two adoption methods, full retrospective approach or modified retrospective approach.
 
January 1, 2018
 
We continue to evaluate the implications of adoption of the new revenue standard on our Consolidated Financial Statements. We have completed an initial assessment and are in the process of quantifying the adoption impact, if any, related to certain topics identified through our evaluation process. Our assessment of the new revenue standard has been focused on, but has not been limited to, the concepts of over-time versus point-in-time revenue recognition patterns, variable consideration, and identification of performance obligations. We will not complete our final assessment and quantification of the impact of the new revenue standard on our Consolidated Financial Statements until the adoption date. Our analysis indicates that certain contract manufacturing and private label arrangements may require revenue recognition over-time in situations in which we produce products that have no alternative use and we have an enforceable right to payment for performance completed to date, inclusive of a reasonable profit margin. This may result in an acceleration of revenue recognition for certain contractual arrangements as compared to recognition under current accounting literature. We plan to adopt the new revenue standard effective January 1, 2018 using the modified retrospective method.
Intra-Entity Asset Transfers of Assets Other Than Inventory
 
Under the new guidance, the tax impact to the seller on the profit from the transfers and the buyer’s deferred tax benefit on the increased tax basis would be recognized when the transfers occur, resulting in the recognition of expense sooner than under historical guidance. The guidance excludes intra-entity transfers of inventory. For intra-entity transfers of inventory, the Financial Accounting Standards Board ("FASB") decided to retain current GAAP, which requires an entity to recognize the income tax consequences when the inventory has been sold to an outside party.
 
January 1, 2018
 
We are currently evaluating the implications of adoption on our Consolidated Financial Statements.
Financial Instruments - Recognition and Measurement of Financial Assets and Liabilities
 
The objective of this simplification update is to improve the decision usefulness of financial instrument reporting, and it principally affects accounting for equity investments currently classified as available for sale and financial liabilities where the fair value option has been elected. Entities will have to measure many equity investments at fair value and recognize changes in fair value in net income rather than other comprehensive income as required under current U.S. GAAP.
 
January 1, 2018
 
We have identified certain investments that will require an adjustment, however, at this time, we are unable to estimate the impact of adopting this standard as the significance of the impact will depend upon our equity investments as of the date of adoption.

8
Perrigo Company plc - Item 1
Note 1


Recently Issued Accounting Standards Not Yet Adopted (continued)
Standard
 
Description
 
Effective Date
 
Effect on the Financial Statements or Other Significant Matters
Leases
 
This guidance was issued to increase transparency and comparability among organizations by requiring recognition of lease assets and lease liabilities on the balance sheet and disclosure of key information about leasing arrangements. For leases with a term of 12 months or less, lessees are permitted to make an election to not recognize right-of-use assets and lease liabilities. Upon adoption, lessees will apply the new standard as of the beginning of the earliest comparative period presented in the financial statements, however lessees will be able to exclude leases that expire as of the implementation date. Early adoption is permitted.
 
January 1, 2019
 
We are currently evaluating the implications of adoption on our Consolidated Financial Statements and have commenced the first step of identifying a task force to take the lead in implementing the new Lease standard.
Derivatives and Hedging
 
This update was issued to enable entities to better portray the economics of their risk management activities in the financial statements and enhance the transparency and understandability of hedge results. In addition, the amendments simplify the application of hedge accounting in certain situations. Under the new rule, the entity’s ability to hedge non-financial and financial risk components is expanded. The guidance eliminates the requirement to separately measure and report hedge ineffectiveness and also eases certain documentation and assessment requirements. Early adoption is permitted.
 
January 1, 2019
 
We are currently evaluating the implications of adoption on our Consolidated Financial Statements.

Measurement of Credit Losses on Financial Instruments
 
This guidance changes the impairment model for most financial assets and certain other instruments, replacing the current "incurred loss" approach with an "expected loss" credit impairment model, which will apply to most financial assets measured at amortized cost and certain other instruments, including trade and other receivables, loans, held-to-maturity debt securities, and off-balance sheet credit exposures such as letters of credit. Early adoption is permitted.
 
January 1, 2020
 
We are currently evaluating the new standard for potential impacts on our receivables, debt, and other financial instruments.
Intangibles - Goodwill and Other Simplifying the Test for Goodwill
 
The objective of this update is to reduce the cost and complexity of subsequent goodwill accounting by simplifying the impairment test by removing the Step 2 requirement to perform a hypothetical purchase price allocation when the carrying value of a reporting unit exceeds its fair value. If a reporting unit’s carrying value exceeds its fair value, an entity would record an impairment charge based on that difference, limited to the amount of goodwill attributed to that reporting unit. The proposal would not change the guidance on completing Step 1 of the goodwill impairment test. The proposed guidance would be applied prospectively. Early adoption is permitted.
 
January 1, 2020
 
We are currently evaluating the implications of adoption on our Consolidated Financial Statements.



9
Perrigo Company plc - Item 1
Note 2


NOTE 2 – DIVESTITURES

Current Year Divestitures

On January 3, 2017, we sold certain Abbreviated New Drug Applications ("ANDAs") for $15.0 million to a third party, which was recorded as a gain in Other operating income on the Condensed Consolidated Statements of Operations in our Prescription Pharmaceuticals ("RX") segment.

On February 1, 2017, we completed the sale of the animal health pet treats plant fixed assets within our Consumer Healthcare Americas ("CHCA") segment, which were previously classified as held-for sale. We received $7.7 million in proceeds, which resulted in an immaterial loss.

On April 6, 2017, we completed the sale of our India Active Pharmaceutical Ingredients ("API") business to Strides Shasun Limited. We received $22.2 million of proceeds, inclusive of an estimated working capital adjustment, which resulted in an immaterial gain recorded in our Other segment. Prior to closing the sale, we determined that the carrying value of the India API business exceeded its fair value less the cost to sell, resulting in an impairment charge of $35.3 million, which was recorded in Impairment charges on the Consolidated Statements of Operations for the year ended December 31, 2016.

On August 25, 2017, we completed the sale of our Russian business, which was previously classified as held-for-sale, to Alvogen Pharma LLC and Alvogen CEE Kft. The total sale price was €12.7 million ($15.1 million), inclusive of an estimated working capital adjustment, which resulted in an immaterial gain recorded in our Consumer Healthcare International ("CHCI") segment. Prior to closing the sale, we determined that the carrying value of the Russian business exceeded its fair value less the cost to sell, resulting in an impairment charge of $3.7 million, which was recorded in Impairment charges on the Condensed Consolidated Statements of Operations for the three months ended July 1, 2017.

Prior Year Divestitures

On August 5, 2016, we completed the sale of our U.S. Vitamins, Minerals, and Supplements ("VMS") business within our CHCA segment to International Vitamins Corporation ("IVC") for $61.8 million inclusive of an estimated working capital adjustment. Prior to closing the sale, we determined that the carrying value of the VMS business exceeded its fair value less the cost to sell, resulting in an impairment charge of $6.2 million, which was recorded in Impairment charges on the Condensed Consolidated Statements of Operations for the year ended December 31, 2016.

NOTE 3 – GOODWILL AND OTHER INTANGIBLE ASSETS

Goodwill

Changes in the carrying amount of goodwill, by reportable segment, were as follows (in millions):
Reporting Segments:
 
December 31,
2016
 
Business divestitures
 
Re-class to assets held-for-sale
 
Currency translation adjustment
 
September 30,
2017
CHCA
 
$
1,810.6

 
$
—

 
$
—

 
$
2.9

 
$
1,813.5

CHCI
 
1,070.8

 
(4.1
)
 
—

 
122.3

 
1,189.0

RX
 
1,086.6

 
—

 
—

 
6.5

 
1,093.1

Other
 
81.4

 
—

 
(32.6
)
 
7.6

 
56.4

Total goodwill
 
$
4,049.4

 
$
(4.1
)
 
$
(32.6
)
 
$
139.3

 
$
4,152.0


As discussed in our Form 10-K for the year ended December 31, 2016, during the three months ended April 2, 2016 and October 1, 2016, we identified indicators of impairment for our Branded Consumer Healthcare - Rest of World ("BCH-ROW") reporting unit and recorded impairment charges of $130.5 million and $675.6 million, respectively. In addition, during the three months ended October 1, 2016, we identified impairment indicators in our Branded Consumer Healthcare - Belgium ("BCH-Belgium") reporting unit and recorded impairment charges of $62.3 million. The impairment charges for both reporting units were recorded within our CHCI segment.

10
Perrigo Company plc - Item 1
Note 3



Intangible Assets

Other intangible assets and related accumulated amortization consisted of the following (in millions):
 
September 30, 2017
 
December 31, 2016
 
Gross
 
Accumulated Amortization
 
Gross
 
Accumulated Amortization
Definite-lived intangibles:
 
 
 
 
 
 
 
Distribution and license agreements, supply agreements
$
310.2

 
$
157.5

 
$
305.6

 
$
120.4

Developed product technology, formulations, and product rights
1,355.4

 
568.8

 
1,418.1

 
526.0

Customer relationships and distribution networks
1,623.7

 
424.5

 
1,489.9

 
307.5

Trademarks, trade names, and brands
1,317.5

 
111.0

 
1,189.3

 
55.3

Non-compete agreements
14.7

 
12.3

 
14.3

 
11.2

Total definite-lived intangibles
$
4,621.5

 
$
1,274.1

 
$
4,417.2

 
$
1,020.4

Indefinite-lived intangibles:
 
 
 
 
 
 
 
Trademarks, trade names, and brands
$
52.0

 
$
—

 
$
50.5

 
$
—

In-process research and development
51.4

 
—

 
64.0

 
—

Total indefinite-lived intangibles
103.4

 
—

 
114.5

 
—

Total other intangible assets
$
4,724.9

 
$
1,274.1

 
$
4,531.7

 
$
1,020.4


Certain intangible assets are denominated in currencies other than the U.S. dollar; therefore, their gross and accumulated amortization balances are subject to foreign currency movements.

We recorded amortization expense of $88.5 million and $89.7 million for the three months ended September 30, 2017 and October 1, 2016, respectively, and $261.3 million and $263.9 million for the nine months ended September 30, 2017 and October 1, 2016, respectively.

We recorded an impairment charge within our RX segment of $12.7 million on certain In Process Research and Development ("IPR&D") assets during the nine months ended September 30, 2017 due to changes in the projected development and regulatory timelines for various projects. During the nine months ended September 30, 2017, we recorded a decrease in the contingent consideration liability associated with certain IPR&D assets in Other operating income on the Condensed Consolidated Statements of Operations (refer to Note 6).

During the three months ended July 1, 2017, we identified impairment indicators for our Lumara Health, Inc. ("Lumara") product assets. The primary impairment indicators included the decline in our 2017 performance expectations and a reduction in our long-range revenue growth forecast. The assessment utilized the multi-period excess earnings method to determine fair value and resulted in an impairment charge of $18.5 million in Impairment charges on the Condensed Consolidated Statements of Operations within our RX segment, which represented the difference between the carrying amount of the intangible assets and their estimated fair value.

As discussed in our Form 10-K for the year ended December 31, 2016, during the three months ended April 2, 2016, we identified indicators of impairment associated with certain indefinite-lived intangible assets acquired in conjunction with our acquisition of Omega Pharma Invest N.V. ("Omega") and recorded an impairment charge of $273.4 million. In addition, during the three months ended October 1, 2016, we identified indicators of impairment associated with certain indefinite-lived and definite-lived intangible brand category assets acquired in conjunction with the Omega acquisition. As a result of these additional indicators, we recorded impairment charges of $575.7 million on our indefinite-lived assets and $290.9 million on our definite-lived assets. The impairment charges for both the indefinite-lived assets and definite-lived assets were recorded within our CHCI segment.

In addition, due to reprioritization of certain brands in the CHCI segment and change in performance expectations for the cough/cold/allergy, anti-parasite, personal care, lifestyle, and natural health brands, we

11
Perrigo Company plc - Item 1
Note 3


reclassified $364.5 million and $674.4 million of indefinite-lived assets to definite-lived assets with useful lives of 20 years, which we began amortizing during the second and third quarters of 2016, respectively.

NOTE 4 - ACCOUNTS RECEIVABLE FACTORING

We have multiple accounts receivable factoring arrangements with non-related third-party financial institutions (the “Factors”). Pursuant to the terms of the arrangements, we sell to the Factors certain of our accounts receivable balances on a non-recourse basis for credit approved accounts. An administrative fee ranging from 0.14% to 0.15% per invoice is charged on the gross amount of accounts receivables assigned to the Factors, and interest is calculated at the applicable EUR LIBOR rate plus 70 basis points. The total amount factored on a non-recourse basis and excluded from accounts receivable was $24.3 million and $50.7 million at September 30, 2017 and December 31, 2016, respectively.

NOTE 5 – INVENTORIES

Major components of inventory were as follows (in millions):
 
 
September 30,
2017
 
December 31,
2016
Finished goods
$
471.4

 
$
431.1

Work in process
146.8

 
165.7

Raw materials
203.7

 
198.2

Total inventories
$
821.9

 
$
795.0


NOTE 6 – FAIR VALUE MEASUREMENTS

Fair value is the price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The following fair value hierarchy is used in selecting inputs, with the highest priority given to Level 1, as these are the most transparent or reliable.

Level 1:
Quoted prices for identical instruments in active markets.

Level 2:
Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets.

Level 3:
Valuations derived from valuation techniques in which one or more significant inputs are not observable.


12
Perrigo Company plc - Item 1
Note 6


The following table summarizes the valuation of our financial instruments carried at fair value and measured at fair value on a recurring and non-recurring basis by the above pricing categories (in millions):
 
 
 
 
Fair Value
 
 
Fair Value Hierarchy
 
September 30,
2017
 
December 31,
2016
Measured at fair value on a recurring basis:
 
 
 
 
 
 
Assets:
 
 
 
 
 
 
Investment securities
 
Level 1
 
$
6.1

 
$
38.2

 
 
 
 
 
 
 
Foreign currency forward contracts
 
Level 2
 
$
13.1

 
$
3.8

Funds associated with Israeli severance liability
 
Level 2
 
16.1

 
15.9

Total level 2 assets
 
 
 
$
29.2

 
$
19.7

 
 
 
 
 
 
 
Royalty Pharma contingent milestone payments
 
Level 3
 
$
143.2

 
$
—

Financial assets
 
Level 3
 
—

 
2,350.0

Total level 3 assets
 
 
 
$
143.2

 
$
2,350.0

 
 
 
 
 
 
 
Liabilities:
 
 
 
 
 
 
Foreign currency forward contracts
 
Level 2
 
$
3.3

 
$
5.0

 
 
 
 
 
 
 
Contingent consideration
 
Level 3
 
$
44.9

 
$
69.9

 
 
 
 
 
 
 
Measured at fair value on a non-recurring basis:
 
 
 
 
 
 
Assets:
 
 
 
 
 
 
Goodwill(1)
 
Level 3
 
$
—

 
$
1,148.4

Indefinite-lived intangible assets(2)
 
Level 3
 
13.3

 
0.3

Definite-lived intangible assets(3)
 
Level 3
 
11.5

 
758.0

Assets held for sale, net
 
Level 3
 
95.1

 
18.2

Total level 3 assets
 
 
 
$
119.9

 
$
1,924.9


(1) 
As of December 31, 2016, goodwill with a carrying amount of $2.2 billion was written down to its implied fair value of $1.1 billion.
(2) 
As of September 30, 2017, indefinite-lived intangible assets with a carrying amount of $26.0 million were written down to a fair value of $13.3 million. As of December 31, 2016, indefinite-lived intangible assets with a carrying amount of $0.7 million were written down to a fair value of $0.3 million.
(3) 
As of July 1, 2017, definite-lived intangible assets with a carrying amount of $31.1 million were written down to a fair value of $11.5 million. As of December 31, 2016, definite-lived intangible assets with a carrying amount of $2.3 billion were written down to a fair value of $758.0 million. Included in this balance are indefinite-lived intangible assets with a fair value of $364.5 million and $674.2 million that were reclassified to definite-lived assets at April 3, 2016 and October 2, 2016, respectively.

There were no transfers among Level 1, 2, and 3 during the three and nine months ended September 30, 2017 or the year ended December 31, 2016. Our policy regarding the recording of transfers between levels is to record any such transfers at the end of the reporting period (refer to Note 7 for information on our investment securities and Note 8 for a discussion of derivatives).


13
Perrigo Company plc - Item 1
Note 6


Foreign Currency Forward Contracts

The fair value of foreign currency forward contracts is determined using a market approach, which utilizes values for comparable derivative instruments.

Funds Associated with Israel Severance Liability

Israeli labor laws and agreements require us to pay benefits to employees dismissed or retiring under certain circumstances. Severance pay is calculated on the basis of the most recent employee salary levels and the length of employee service. Our Israeli subsidiaries also provide retirement bonuses to certain managerial employees. We make regular deposits to retirement funds and purchase insurance policies to partially fund these liabilities. The funds are determined using prices for recently traded financial instruments with similar underlying terms, as well as directly or indirectly observable inputs, such as interest rates and yield curves, that are observable at commonly quoted intervals.
 
Royalty Pharma Contingent Milestone Payments and Financial Assets

On December 18, 2013, we acquired Elan, which had a royalty agreement with Biogen Idec Inc. ("Biogen"), whereby Biogen conveyed the right to receive royalties that are typically payable on sales revenue generated by the sale, distribution or other use of the drug Tysabri®. Pursuant to the royalty agreement, we were entitled to royalty payments from Biogen based on its Tysabri® sales in all indications and geographies. We received royalties of 12% on worldwide Biogen sales of Tysabri® from December 18, 2013 through April 30, 2014. From May 1, 2014, we received royalties of 18% on annual worldwide Biogen sales of Tysabri® up to $2.0 billion and 25% on annual sales above $2.0 billion.

We accounted for the Tysabri® royalty stream as a financial asset and elected to use the fair value option model. We made the election to account for the Tysabri® financial asset using the fair value option as we believed this method was most appropriate for an asset that did not have a par value, a stated interest stream, or a termination date. The financial asset acquired represented a single unit of accounting. The fair value of the financial asset acquired was determined by using a discounted cash flow analysis related to the expected probability weighted future cash flows to be generated by the royalty stream. The financial asset was classified as a Level 3 asset within the fair value hierarchy, as our valuation utilized significant unobservable inputs, including industry analyst estimates for global Tysabri® sales, probability weighted as to the timing and amount of future cash flows along with certain discount rate assumptions. Cash flow forecasts included the estimated effect and timing of future competition, considering patents in effect for Tysabri® through 2024 and contractual rights to receive cash flows into perpetuity. The discounted cash flows were based upon the expected royalty stream forecasted into perpetuity using a 20-year discrete period with a declining rate terminal value.

In the first quarter of 2016, a competitor's pipeline product, Ocrevus®, received breakthrough therapy designation from the U.S. Food and Drug Administration ("FDA"). Breakthrough therapy designation is granted when a drug is intended alone or in combination with one or more other drugs to treat a serious or life threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. In June 2016, the FDA granted priority review with a target action date in December 2016. A priority review is a designation when the FDA will direct overall attention and resources to the evaluation of applications for drugs that, if approved, would be significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to standard applications. The product was approved late in the first quarter of 2017. The product is expected to compete with Tysabri®, and we expected it to have a significant negative impact on the Tysabri® royalty stream. Industry analysts believe that, based on released clinical study information, Ocrevus® will compete favorably against Tysabri® in the relapsing, remitting multiple sclerosis market segment due to its high efficacy and convenient dosage form.

14
Perrigo Company plc - Item 1
Note 6


Given the new market information for Ocrevus®, we used industry analyst estimates to reduce our first ten year growth forecasts from an average of growth of approximately 3.4% in the fourth calendar quarter of 2015 to an average decline of approximately minus 2.0% in the third and fourth calendar quarters of 2016. In November 2016, we announced we were evaluating strategic alternatives for the Tysabri® asset. As of December 31, 2016, the financial asset was adjusted based on the strategic review and sale process. These effects, combined with the change in discount rate each quarter, led to a reduction in fair value of $204.4 million, $910.8 million, $377.4 million and $1.1 billion in the first, second, third and fourth quarters of 2016, respectively.

On March 27, 2017, we announced the completed divestment of our Tysabri® financial asset to Royalty Pharma for up to $2.85 billion, which consists of $2.2 billion in cash and up to $250.0 million and $400.0 million in milestone payments if the royalties on global net sales of Tysabri® that are received by Royalty Pharma meet specific thresholds in 2018 and 2020, respectively. As a result of this transaction, we transferred the entire financial asset to Royalty Pharma and recorded a $17.1 million gain during the three months ended July 1, 2017. We elected to account for the contingent milestone payments using the fair value option method, and these were recorded at an estimated fair value of $143.2 million as of September 30, 2017. We chose the fair value option as we believe it will help investors understand the potential future cash flows we may receive associated with the two contingent milestones.

We valued the contingent milestone payments using a modified Black-Scholes Option Pricing Model ("BSOPM"). Key inputs in the BSOPM are the estimated volatility and rate of return of royalties on global net sales of Tysabri® that are received by Royalty Pharma over time until payment of the contingent milestone payments is completed. Volatility and the estimated fair value of the milestones have a positive relationship such that higher volatility translates to a higher estimated fair value of the contingent milestone payments. In the valuation of contingent milestone payments performed, we assumed volatility of 30.0% and a rate of return of 8.05% as of July 1, 2017 and volatility of 30.0% and a rate of return of 8.06% as of September 30, 2017. We assess volatility and rate of return inputs quarterly by analyzing certain market volatility benchmarks and the risk associated with Royalty Pharma achieving the underlying projected royalties. During the three and nine months ended September 30, 2017, the fair value of the Royalty Pharma contingent milestone payments decreased $2.9 million and $42.1 million, respectively, as a result of the decrease in the estimated projected Tysabri® revenues due to the launch of Ocrevus® late in the first quarter of 2017.

Our accounts receivable balance at December 31, 2016 included $84.4 million related to the Tysabri® financial asset.

The table below presents a reconciliation for the Royalty Pharma contingent milestone payments measured at fair value on a recurring basis using significant unobservable inputs (Level 3) (in millions). Change in fair value in the table was recorded in Change in financial assets on the Condensed Consolidated Statements of Operations.
 
Three Months Ended
 
Nine Months Ended
 
September 30,
2017
 
September 30,
2017
Royalty Pharma Contingent Milestone Payments
 
 
 
Beginning balance
$
145.8

 
$
—

Additions
—

 
184.5

Foreign currency effect
0.3

 
0.8

Change in fair value
(2.9
)
 
(42.1
)
Ending balance
$
143.2

 
$
143.2


Contingent Consideration

Contingent consideration represents milestone payment obligations obtained through product acquisitions, which are valued using estimates based on probability-weighted outcomes, sensitivity analysis, and discount rates reflective of the risk involved. The estimates are updated quarterly and the liabilities are adjusted to fair value depending on a number of assumptions, including the competitive landscape and regulatory approvals that may impact the future sales of a product. We reduced a contingent consideration liability associated with certain IPR&D assets (refer to Note 3) and recorded a corresponding gain of $17.0 million during the nine months ended September 30, 2017. The liability decrease relates to a reduction of the probability of achievement assumptions and

15
Perrigo Company plc - Item 1
Note 6


anticipated cash flows. Purchases or additions for the nine months ended October 1, 2016 included contingent consideration associated with five transactions.

The table below presents a reconciliation for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) (in millions). Net realized losses in the table were recorded in Other (income) expense, net on the Condensed Consolidated Statements of Operations.
 
Three Months Ended
 
Nine Months Ended
 
September 30,
2017
 
October 1,
2016
 
September 30,
2017
 
October 1,
2016
Contingent Consideration
 
 
 
 
 
 
 
Beginning balance
$
49.7

 
$
44.9

 
$
69.9

 
$
17.9

Net realized losses
(2.9
)
 
(0.4
)
 
(18.5
)
 
(4.0
)
Purchases or additions
—

 
30.6

 
—

 
61.1

Foreign currency effect
0.2

 
—

 
1.5

 
0.1

Settlements
(2.1
)
 
(0.1
)
 
(8.0
)
 
(0.1
)
Ending balance
$
44.9

 
$
75.0

 
$
44.9

 
$
75.0


Goodwill and Indefinite-Lived Intangible Assets

We have seven reporting units for which we assess goodwill for impairment. We utilize a comparable company market approach, weighted equally with a discounted cash flow analysis, to determine the fair value of the reporting units. We utilize either a relief from royalty method or a multi-period excess earnings method ("MPEEM") to value our indefinite-lived intangible assets, and use a consistent set of projected financial information for the goodwill and indefinite-lived asset impairment tests. The discounted cash flow analysis that we prepared for goodwill impairment testing purposes for the year ended December 31, 2016 included long-term growth rates ranging from 2.0% to 3.0%. We also utilized discount rates ranging from 7.0% to 14.5%, which were deemed to be commensurate with the required investment return and risk involved in realizing the projected free cash flows of each reporting unit. In addition, we burdened projected free cash flows with the capital spending deemed necessary to support the cash flows of each reporting unit, and applied the tax rates that were applicable to the jurisdictions represented within each reporting unit. We recorded impairment charges on the Condensed Consolidated Statements of Operations related to goodwill in the BCH-ROW reporting unit and indefinite-lived intangible assets of $130.5 million and $273.4 million, respectively, for the three months ended April 2, 2016. For the three months ended October 1, 2016, we recorded impairment charges related to goodwill on the Condensed Consolidated Statements of Operations of $675.6 million in the BCH-ROW reporting unit and $62.3 million in the BCH-Belgium reporting unit, as well as indefinite-lived intangible asset impairments of $575.7 million (refer to Note 3).

Definite-Lived Intangible Assets

When assessing our definite-lived assets for impairment, we utilize either a MPEEM or a relief from royalty method to determine the fair value of the asset and use the forecasts that are consistent with those used in the reporting unit analysis. Below is a summary of the various metrics used in our valuations:
 
Nine Months Ended
 
September 30, 2017
 
Lumara
5-year average growth rate
(4.1)%
Discount rate
13.5%
Valuation method
MPEEM


16
Perrigo Company plc - Item 1
Note 6


 
Year Ended
 
December 31, 2016
 
Omega - Lifestyle
 
Omega - XLS
 
Entocort® - Branded Products
 
Entocort® - AG Products
 
Herron Trade Names and Trademarks
5-year average growth rate
2.5%
 
3.2%
 
(31.7)%
 
(30.4)%
 
4.6%
Long-term growth rates
2.0%
 
NA
 
(10.0)%
 
(4.7)%
 
2.5%
Discount rate
9.3%
 
9.5%
 
13.0%
 
10.5%
 
10.8%
Royalty rate
NA
 
4.0%
 
NA
 
NA
 
11.0%
Valuation method
MPEEM
 
Relief from Royalty
 
MPEEM
 
MPEEM
 
Relief from Royalty

We recorded Impairment charges on the Condensed Consolidated Statements of Operations related to definite-lived intangible assets of $18.5 million and $290.9 million for the nine months ended September 30, 2017 and October 1, 2016, respectively (refer to Note 3).

Assets Held For Sale

When a group of assets is classified as held-for-sale, the book value is evaluated and adjusted to the lower of its carrying amount or fair value less the cost to sell (refer to Note 9).

Fixed Rate Long-term Debt    

As of September 30, 2017 and December 31, 2016, our fixed rate long-term debt consisted of public bonds, a private placement note, and retail bonds. As of September 30, 2017, the public bonds had a carrying value of
$2.6 billion and a fair value of $2.7 billion. As of December 31, 2016, the public bonds had a carrying value and fair value of $4.6 billion. The fair values of our public bonds for both periods were based on quoted market prices
(Level 1).

As of September 30, 2017, our retail bonds and private placement note had a carrying value of $655.8 million (excluding a premium of $35.6 million) and a fair value of $699.2 million. As of December 31, 2016, our retail bonds and private placement note had a carrying value of $773.1 million (excluding a premium of $49.8 million) and a fair value of $825.0 million. The fair values of our retail bonds and private placement note for both periods were based on interest rates offered for borrowings of a similar nature and remaining maturities (Level 2).

The carrying amounts of our other financial instruments, consisting of cash and cash equivalents, accounts receivable, accounts payable, short-term debt and variable rate long-term debt, approximate their fair value.

NOTE 7 – INVESTMENTS

Available for Sale Securities
    
Our available for sale securities are reported in Prepaid expenses and other current assets. Unrealized investment gains/(losses) on available for sale securities were as follows (in millions):
 
September 30,
2017
 
December 31, 2016
Equity securities, at cost less impairments
$
15.5

 
$
16.5

Gross unrealized gains
—

 
21.7

Gross unrealized losses
(9.4
)
 
—

Estimated fair value of equity securities
$
6.1

 
$
38.2


The factors affecting the assessment of impairments include both general financial market conditions and factors specific to a particular company. During the nine months ended October 1, 2016, we recorded an impairment charge of $1.8 million, which related to other-than-temporary impairments of marketable equity securities due to prolonged losses incurred on each of the investments.

17
Perrigo Company plc - Item 1
Note 7



We have evaluated the near-term prospects of the equity securities in relation to the severity and duration of any impairments, and based on that evaluation, we have the ability and intent to hold these investments until a recovery of fair value.

During the nine months ended September 30, 2017, we sold a number of our investment securities and recorded a gain of $1.6 million. The gain was reclassified out of Accumulated Other Comprehensive Income (loss) ("AOCI") and into earnings.     

Cost Method Investments

Our cost method investments totaled $7.2 million and $6.9 million at September 30, 2017 and
December 31, 2016, respectively, and are included in Other non-current assets.

Equity Method Investments

Our equity method investments totaled $4.8 million and $4.6 million at September 30, 2017 and December 31, 2016, respectively, and are included in Other non-current assets. We recorded net losses of $0.1 million and net gains of $0.2 million during the three and nine months ended September 30, 2017, respectively, and net gains of $0.1 million and net losses of $3.8 million during the three and nine months ended October 1, 2016, respectively, for our proportionate share of the equity method investment earnings or losses. The gains and losses were recorded in Other (income) expense, net on the Condensed Consolidated Statements of Operations.

During the nine months ended October 1, 2016, one of our equity method investments became publicly traded. As a result, we transferred the $15.5 million investment to available for sale and recorded an $8.7 million unrealized gain, net of tax in Other Comprehensive Income ("OCI"). In addition, due to significant and prolonged losses incurred on one of our equity method investments, we recorded a $22.3 million impairment charge in Other (income) expense, net on the Condensed Consolidated Statements of Operations.

NOTE 8 – DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES

We enter into certain derivative financial instruments, when available on a cost-effective basis, to mitigate our risk associated with changes in interest rates and foreign currency exchange rates as follows:

Interest rate risk management - We are exposed to the impact of interest rate changes through our cash investments and borrowings. We utilize a variety of strategies to manage the impact of changes in interest rates, including using a mix of debt maturities along with both fixed-rate and variable-rate debt. In addition, we may enter into treasury-lock agreements and interest rate swap agreements on certain investing and borrowing transactions to manage our exposure to interest rate changes and our overall cost of borrowing.

Foreign currency exchange risk management - We conduct business in several major currencies other than the U.S. dollar and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce cash flow volatility associated with foreign exchange rate changes on a consolidated basis to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments, and anticipated foreign currency sales and expenses.
    
All derivative instruments are managed on a consolidated basis to efficiently net exposures and thus take advantage of any natural offsets. Gains and losses related to the derivative instruments are expected to be offset largely by gains and losses on the original underlying asset or liability. We do not use derivative financial instruments for speculative purposes.

     All of our designated derivatives were classified as cash flow hedges as of September 30, 2017 and December 31, 2016. Designated derivatives meet hedge accounting criteria, which means the fair value of the hedge is recorded in shareholders’ equity as a component of OCI, net of tax. The deferred gains and losses are recognized in income in the period in which the hedged item affects earnings. Any ineffective portion of the change

18
Perrigo Company plc - Item 1
Note 8


in fair value of the derivative is immediately recognized in earnings. All of our designated derivatives are assessed for hedge effectiveness quarterly.

We also have economic non-designated derivatives that do not meet hedge accounting criteria. These derivative instruments are adjusted to current market value at the end of each period through earnings. Gains or losses on these instruments are offset substantially by the remeasurement adjustment on the hedged item.    

Interest Rate Swaps and Treasury Locks

Interest rate swap agreements are contracts to exchange floating rate for fixed rate payments (or vice versa) over the life of the agreement without the exchange of the underlying notional amounts. The notional amounts of the interest rate swap agreements are used to measure interest to be paid or received and do not represent the amount of exposure to credit loss. The differential paid or received on the interest rate swap agreements is recognized as an adjustment to interest expense.

During the three months ended July 1, 2017, we repaid $584.4 million of senior notes with an interest rate of 4.000% due 2023 and $309.5 million of senior notes with an interest rate of 5.300% due 2043 (refer to Note 10). As a result of the senior note repayments on June 15, 2017, the proportionate amount remaining in OCI related to the pre-issuance hedge was reclassified to earnings. Accordingly, we recorded a loss of $5.9 million in Other expense, net, on the Condensed Consolidated Statements of Operations during the three months ended July 1, 2017 for the amount remaining in OCI.

During the six months ended December 31, 2015, we entered into a forward interest rate swap to hedge against changes in the benchmark interest rate between the date the interest rate swap was entered into and the date of expected future debt issuance. The interest rate swap was designated as a cash flow hedge and had a notional amount totaling $200.0 million. The interest rate swap was settled upon the issuance of an aggregate $1.2 billion principal amount of senior notes on March 7, 2016 for a cumulative after-tax loss of $7.0 million in OCI during the three months ended April 2, 2016.
    
Foreign Currency Derivatives

We enter into foreign currency forward contracts, both designated and non-designated, in order to manage the impact of foreign exchange fluctuations on expected future purchases and related payables denominated in a foreign currency, as well as to hedge the impact of foreign exchange fluctuations on expected future sales and related receivables denominated in a foreign currency. Both types of forward contracts have a maximum maturity date of 18 months. The total notional amount for these contracts was $578.3 million and $533.5 million as of September 30, 2017 and December 31, 2016, respectively.

Effects of Derivatives on the Financial Statements
    
The below tables indicate the effects of all derivative instruments on the Condensed Consolidated Financial Statements. All amounts exclude income tax effects and are presented in millions.

The balance sheet location and gross fair value of our outstanding derivative instruments were as follows:
 
Asset Derivatives
 
Balance Sheet Location
 
Fair Value
 
 
 
September 30,
2017
 
December 31,
2016
Designated derivatives:
 
 
 
 
 
Foreign currency forward contracts
Other current assets
 
$
4.6

 
$
3.1

Non-designated derivatives:
 
 
 
 
 
Foreign currency forward contracts
Other current assets
 
$
8.5

 
$
0.7


19
Perrigo Company plc - Item 1
Note 8


 
Liability Derivatives
 
Balance Sheet Location
 
Fair Value
 
 
 
September 30,
2017
 
December 31,
2016
Designated derivatives:
 
 
 
 
 
Foreign currency forward contracts
Accrued liabilities
 
$
2.6

 
$
3.0

Non-designated derivatives:
 
 
 
 
 
Foreign currency forward contracts
Accrued liabilities
 
$
0.7

 
$
2.0


The gains (losses) recorded in OCI for the effective portion of our designated cash flow hedges were as follows:
 
 
Amount of Gain/(Loss) Recorded in OCI
(Effective Portion)
 
 
Three Months Ended
 
Nine Months Ended
Designated Cash Flow Hedges
 
September 30,
2017
 
October 1,
2016
 
September 30,
2017
 
October 1,
2016
Interest rate swap agreements
 
$
—

 
$
—

 
$
—

 
$
(9.0
)
Foreign currency forward contracts
 
1.1

 
3.4

 
6.3

 
4.7

Total
 
$
1.1

 
$
3.4

 
$
6.3

 
$
(4.3
)

The gains (losses) reclassified from AOCI into earnings for the effective portion of our designated cash flow hedges were as follows:
 
 
 
 
Amount of Gain/(Loss) Reclassified from AOCI into Earnings
(Effective Portion)
 
 
 
 
Three Months Ended
 
Nine Months Ended
Designated Cash Flow Hedges
 
Income Statement Location
 
September 30,
2017
 
October 1,
2016
 
September 30,
2017
 
October 1,
2016
Treasury locks
 
Interest expense, net
 
$
—

 
$
—

 
$
—

 
$
(0.1
)
Interest rate swap agreements
 
Interest expense, net
 
(0.4
)
 
(0.6
)
 
(1.7
)
 
(1.7
)
 
 
Other (income) expense, net
 
—

 
—

 
(5.9
)
 
—

Foreign currency forward contracts
 
Net sales
 
—

 
(0.1
)
 
0.9

 
0.3

 
 
Cost of sales
 
1.8

 
0.9

 
3.5

 
1.8

 
 
Interest expense, net
 
(0.7
)
 
(0.4
)
 
(1.8
)
 
(1.3
)
 
 
Other (income) expense, net
 
(1.2
)
 
(1.2
)
 
(1.7
)
 
0.7

Total
 
 
 
$
(0.5
)
 
$
(1.4
)
 
$
(6.7
)
 
$
(0.3
)

The net of tax amount expected to be reclassified from AOCI into earnings during the next 12 months is a $2.8 million gain.


20
Perrigo Company plc - Item 1
Note 8


The gains (losses) recognized against earnings for the ineffective portion of our designated cash flow hedges were as follows:
 
 
 
 
Amount of Gain/(Loss) Recognized against Earnings
(Ineffective Portion)
 
 
 
 
Three Months Ended
 
Nine Months Ended
Designated Cash Flow Hedges
 
Income Statement
Location
 
September 30,
2017
 
October 1,
2016
 
September 30,
2017
 
October 1,
2016
Interest rate swap agreements
 
Other (income) expense, net
 
$
—

 
$
—

 
$
—

 
$
(0.1
)
Foreign currency forward contracts
 
Net sales
 
0.2

 
—

 
0.1

 
0.1

 
 
Cost of sales
 
0.1

 
—

 
0.1

 
—

 
 
Other (income) expense, net
 
—

 
—

 
1.0

 
0.6

Total
 
 
 
$
0.3

 
$
—

 
$
1.2

 
$
0.6


The effects of our non-designated derivatives on the Condensed Consolidated Statements of Operations were as follows:
 
 
 
 
Amount of Gain/(Loss) Recognized against Earnings
 
 
 
 
Three Months Ended
 
Nine Months Ended
Non-Designated Derivatives
 
Income Statement Location
 
September 30,
2017
 
October 1,
2016
 
September 30,
2017
 
October 1,
2016
Foreign currency forward contracts
 
Other (income) expense, net
 
$
10.1

 
$
(0.2
)
 
$
(3.8
)
 
$
(8.7
)
 
 
Interest expense, net
 
(1.8
)
 
(1.0
)
 
(2.9
)
 
(1.5
)
Total
 
 
 
$
8.3

 
$
(1.2
)
 
$
(6.7
)
 
$
(10.2
)

NOTE 9 – ASSETS HELD FOR SALE

Our India API business was classified as held-for-sale beginning as of December 31, 2015. We recorded an impairment charge totaling $6.3 million during the year ended December 31, 2016 after determining the carrying value of the India API business exceeded its fair value less the cost to sell. The India API business is reported in our Other segment. On April 6, 2017, we completed the sale of our India API business (refer to Note 2).

During the three months ended October 1, 2016, management committed to a plan to sell certain fixed assets associated with our animal health pet treats plant. Such assets were classified as held-for-sale beginning at October 1, 2016. On February 1, 2017, we completed the sale of our animal health pet treats plant fixed assets (refer to Note 2). We determined that the carrying value of the fixed assets associated with our animal health pet treats plant exceeded the fair value less the cost to sell. We recorded impairment charges totaling $3.7 million during the year ended December 31, 2016. The assets associated with our animal health pet treats plant are reported in our CHCA segment.

During the three months ended September 30, 2017, management committed to a plan to sell our Israel API business. The business was classified as held-for-sale beginning at September 30, 2017. We determined that the carrying value of the Israel API business exceeded its fair value less the cost to sell. We recorded impairment charges totaling $3.3 million during the three months ended September 30, 2017. The Israel API business is reported in our Other segment.


21
Perrigo Company plc - Item 1
Note 9



The assets held-for-sale are reported within Prepaid expenses and other current assets and liabilities held-for-sale are reported in Accrued liabilities. The amounts consist of the following (in millions):
 
September 30,
2017
 
December 31,
2016
 
Other
 
CHCA
 
Other
Assets held for sale
 
 
 
 
 
Current assets
$
44.0

 
$
—

 
$
5.1

Goodwill
32.6

 
—

 
5.5

Intangible assets
5.5

 
—

 
—

Property, plant and equipment
45.9

 
13.5

 
33.2

Other assets
3.1

 
—

 
3.8

Less: impairment reserves
(3.3
)
 
(3.7
)
 
(35.3
)
Total assets held for sale
$
127.8

 
$
9.8

 
$
12.3

Liabilities held for sale
 
 
 
 
 
Current liabilities
$
7.6

 
$
0.1

 
$
1.9

Other liabilities
25.1

 
—

 
1.9

Total liabilities held for sale
$
32.7

 
$
0.1

 
$
3.8


NOTE 10 – INDEBTEDNESS

Total borrowings outstanding are summarized as follows (in millions):
 
 
 
 
 
September 30,
2017
 
December 31,
2016
Term loans
 
 
 
 
 
 
2014 term loan due December 5, 2019
(1) 
 
$
428.3

 
$
420.7

Notes and Bonds
 
 
 
 
 
 
Coupon
Due
 
 
 
 
 
 
4.500%
May 23, 2017
(1)(2) 
 
—

 
189.3

 
5.125%
December 12, 2017
(1)(2) 
 
354.5

 
315.6

 
2.300%
November 8, 2018

 
—

 
600.0

 
5.000%
May 23, 2019
(1)(2) 
 
141.8

 
126.2

 
3.500%
March 15, 2021

 
280.4

 
500.0

 
3.500%
December 15, 2021

 
309.6

 
500.0

 
5.105%
July 19, 2023
(1)(2) 
 
159.5

 
142.0

 
4.000%
November 15, 2023

 
215.6

 
800.0

 
3.900%
December 15, 2024

 
700.0

 
700.0

 
4.375%
March 15, 2026

 
700.0

 
700.0

 
5.300%
November 15, 2043

 
90.5

 
400.0

 
4.900%
December 15, 2044

 
303.9

 
400.0

 
Total notes and bonds
 
 
3,255.8

 
5,373.1

Other financing
2.9

 
3.6

Unamortized premium (discount), net
24.8

 
33.0

Deferred financing fees
(19.0
)
 
(33.1
)
Total borrowings outstanding
3,692.8

 
5,797.3

 
Current indebtedness
(417.1
)
 
(572.8
)
Total long-term debt less current portion
$
3,275.7

 
$
5,224.5


(1)
Debt denominated in Euros subject to fluctuations in the euro-to-U.S. dollar exchange rate.
(2)
Debt assumed from Omega.


22
Perrigo Company plc - Item 1
Note 10


During the three months ended April 1, 2017, we entered into amendments to the 2014 Revolver (as defined below) and the 2014 term loan to modify provisions of such agreements necessary as a result of the correction in accounting related to the Tysabri® financial asset, as well as waivers of any default or event of default that may have arisen from any restatement of or deficiencies in our financial statements for the periods specified in such amendments and waivers. We are in compliance with all covenants under our debt agreements as of September 30, 2017.

Revolving Credit Agreements

We have a revolving credit agreement with a borrowing capacity of $1.0 billion (the "2014 Revolver"). There were no borrowings outstanding under the 2014 Revolver as of September 30, 2017 and December 31, 2016.

Other Financing

Overdraft Facilities

We have overdraft facilities available that we use to support our cash management operations. We report any balances outstanding in the above table under "Other financing". There were no balances outstanding under the facilities at September 30, 2017 and December 31, 2016.

Debt Repayments and Related Extinguishment

During the nine months ended September 30, 2017, we reduced our outstanding debt through a variety of transactions (in millions):
Date
 
Series
 
Transaction Type
 
Principal Retired
April 1, 2017
 
2014 term loan due December 5, 2019
 
Scheduled quarterly payment
 
$
13.3

July 1, 2017
 
2014 term loan due December 5, 2019
 
Scheduled quarterly payment
 
14.3

September 30, 2017
 
2014 term loan due December 5, 2019
 
Scheduled quarterly payment
 
14.8

May 8, 2017
 
$600.0 2.300% senior notes due 2018
 
Early redemption
 
600.0

May 23, 2017
 
€180.0 4.500% retail bonds due 2017
 
Scheduled maturity
 
201.3

June 15, 2017
 
$500.0 3.500% senior notes due 2021
 
Tender offer
 
190.4

June 15, 2017
 
$500.0 3.500% senior notes due 2021
 
Tender offer
 
219.6

June 15, 2017
 
$800.0 4.000% senior notes due 2023
 
Tender offer
 
584.4

June 15, 2017
 
$400.0 5.300% senior notes due 2043
 
Tender offer
 
309.5

June 15, 2017
 
$400.0 4.900% senior notes due 2044
 
Tender offer
 
96.1

 
 
 
 
 
 
$
2,243.7


As a result of the of the early redemption and tender offer transactions discussed above, we recorded a loss of $135.2 million during the three months ended July 1, 2017 in Loss on extinguishment of debt (in millions):

Premium on debt repayment
 
$
116.1

Transaction costs
 
3.8

Write-off of deferred financing fees
 
10.6

Write-off of remaining discount on bond
 
4.7

Total loss on extinguishment of debt
 
$
135.2



23
Perrigo Company plc - Item 1
Note 11


NOTE 11 – EARNINGS PER SHARE AND SHAREHOLDERS' EQUITY

Earnings per Share

A reconciliation of the numerators and denominators used in the basic and diluted earnings per share ("EPS") calculation is as follows (in millions):
 
Three Months Ended
 
Nine Months Ended
 
September 30,
2017
 
October 1,
2016
 
September 30,
2017
 
October 1,
2016
Numerator:
 
 
 
 
 
 
 
Net income (loss)
$
44.5

 
$
(1,590.2
)
 
$
46.4

 
$
(2,653.7
)
 
 
 
 
 
 
 
 
Denominator:
 
 
 
 
 
 
 
Weighted average shares outstanding for basic EPS
141.3

 
143.3

 
142.5

 
143.2

Dilutive effect of share-based awards*
0.4

 
—

 
0.3

 
—

Weighted average shares outstanding for diluted EPS
141.7

 
143.3

 
142.8

 
143.2

 
 
 
 
 
 
 
 
Anti-dilutive share-based awards excluded from
     computation of diluted EPS*
1.0

 
—

 
0.8

 
—


* In the period of a net loss, diluted shares equal basic shares.

Shareholders' Equity

Shares

We issued shares related to the exercise and vesting of share-based compensation as follows:
Three Months Ended
 
Nine Months Ended
September 30,
2017
 
October 1,
2016
 
September 30,
2017
 
October 1,
2016
99,800

 
185,000

 
146,100

 
283,000


Share Repurchases

On October 22, 2015, the Board of Directors approved a share repurchase plan of up to $2.0 billion (the "2015 Authorization"). During the three and nine months ended September 30, 2017, we repurchased 1.9 million and 2.7 million ordinary shares at an average repurchase price of $71.73 and $71.72 per share, for a total of $133.3 million and $191.5 million, respectively. As of September 30, 2017, there was $1.3 billion still available to be repurchased through December 31, 2018 under the 2015 Authorization. We did not repurchase any shares under the share repurchase plan during the nine months ended October 1, 2016.
 

24
Perrigo Company plc - Item 1
Note 12


NOTE 12 – ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)

Changes in our AOCI balances, net of tax were as follows (in millions):
 
Foreign currency translation adjustments
 
Fair value of derivative financial instruments, net of tax
 
Fair value of investment securities, net of tax
 
Post-retirement and pension liability adjustments, net of tax
 
Total AOCI
Balance at December 31, 2016
$
(67.9
)
 
$
(19.5
)
 
$
15.1

 
$
(9.5
)
 
$
(81.8
)
OCI before reclassifications
289.9

 
4.4

 
(22.8
)
 
(1.2
)
 
270.3

Amounts reclassified from AOCI
—

 
4.3

 
(1.6
)
 
—

 
2.7

Other comprehensive income (loss)
289.9

 
8.7

 
(24.4
)
 
(1.2
)
 
273.0

Balance at September 30, 2017
$
222.0

 
$
(10.8
)
 
$
(9.3
)
 
$
(10.7
)
 
$
191.2

    
NOTE 13 – INCOME TAXES

The effective tax rates were as follows:
Three Months Ended
 
Nine Months Ended
September 30,
2017
 
October 1,
2016
 
September 30,
2017
 
October 1,
2016
65.5
%
 
16.4
%
 
68.7
%
 
17.2
%

The effective tax rate for the nine months ended September 30, 2017 was negatively impacted by non-deductible fees related to our debt cancellation, discrete tax items, and additional valuation allowances recorded against deferred tax assets.

Our tax rate is subject to adjustment over the balance of the fiscal year due to, among other things: the jurisdictions in which our profits are determined to be earned and taxed; changes in the valuation of our deferred tax assets and liabilities; adjustments to estimated taxes upon finalization of various tax returns; adjustments based on differing interpretations of the applicable transfer pricing standards; changes in available tax credits, grants and other incentives; changes in stock-based compensation expense; changes in tax laws or the interpretation of such tax laws (for example, proposals for fundamental U.S. international tax reform); changes in U.S. GAAP; and expiration of or the inability to renew tax rulings or tax holiday incentives.

The total liability for uncertain tax positions was $454.9 million and $398.0 million as of September 30, 2017 and December 31, 2016, respectively, before considering the federal tax benefit of certain state and local items.

We recognize interest and penalties related to uncertain tax positions as a component of income tax expense. The total amount accrued for interest and penalties in the liability for uncertain tax positions was $79.0 million and $63.5 million as of September 30, 2017 and December 31, 2016, respectively.

We file income tax returns in numerous jurisdictions and are therefore subject to audits by tax authorities. Our primary income tax jurisdictions are Ireland, the United States, Israel, Belgium, France, and the United Kingdom.
 
On August 15, 2017, we filed a complaint in the United States District Court for the Western District of Michigan to recover $163.6 million of Federal income tax, penalties, and interest assessed and collected by the Internal Revenue Service (“IRS”), plus statutory interest thereon from the dates of payment, for the fiscal years ended June 27, 2009, June 26, 2010, June 25, 2011, and June 30, 2012 (the “2009 tax year,” “2010 tax year,” “2011 tax year,” and “2012 tax year,” respectively). The IRS audits of those years culminated in the issuances of two statutory notices of deficiency: (1) on August 27, 2014 for the 2009 and 2010 tax years and (2) on April 20, 2017 for the 2011 and 2012 tax years. The statutory notices of deficiency both included un-agreed income adjustments related principally to transfer pricing adjustments regarding the purchase, distribution, and sale of store-brand OTC pharmaceutical products in the United States. In addition, the statutory notice of deficiency for the 2011 and 2012 tax years included the capitalization of certain expenses that were deducted when paid or incurred in defending

25
Perrigo Company plc - Item 1
Note 13


against certain patent infringement lawsuits. We fully paid the assessed amounts of tax, interest, and penalties set forth in the statutory notices and filed timely claims for refund on June 11, 2015 and June 7, 2017 for the 2009-2010 tax years and 2011-2012 tax years, respectively. Our claims for refund were disallowed by certified letters dated August 18, 2015 and July 11, 2017, for the 2009-2010 tax years and 2011-2012 tax years, respectively. The complaint was timely, based upon the refund claim denials, and seeks refunds of tax, interest, and penalties of $37.2 million for the 2009 tax year, $61.5 million for the 2010 tax year, $40.2 million for the 2011 tax year, and $24.7 million for the 2012 tax year. The amounts sought in the complaint for the 2009 and 2010 tax years were recorded as deferred charges on our balance sheet during the three months ended March 28, 2015, and the amounts sought in the complaint for the 2011 and 2012 tax years were recorded as deferred charges on our balance sheet during the three months ended July 1, 2017.

On December 22, 2016, we received a notice of proposed adjustment for the IRS audit of Athena Neurosciences, Inc. (“Athena”), a subsidiary of Elan acquired in 1996, for the years ended December 31, 2011, December 31, 2012, and December 31, 2013. Perrigo acquired Elan in December 2013. This proposed adjustment relates to the deductibility of litigation costs. We disagree with the IRS’s position asserted in the notice of proposed adjustment and intend to contest it.

On July 11, 2017, we received a draft notice of proposed adjustment associated with transfer pricing positions for the IRS audit of Athena for the years ended December 31, 2011, December 31, 2012, and December 31, 2013.  Athena was the originator of the patents associated with Tysabri® prior to the acquisition of Athena by Elan in 1996. The amount of adjustments that may be asserted by the IRS in the final notice of proposed adjustment cannot be quantified at this time; however, based on the draft notice received, the amount to be assessed may be material. We disagree with the IRS’s position as asserted in the draft notice of proposed adjustment and intend to contest it.

We have ongoing audits in multiple other jurisdictions the resolution of which remains uncertain. These jurisdictions include, but are not limited to, the United States, Israel and France. In addition to the matters discussed above, the IRS is currently auditing our fiscal years ended June 29, 2013, June 28, 2014, and June 27, 2015. The Israel Tax Authority is currently auditing our fiscal years ended June 29, 2013 and June 28, 2014. The French Tax Authority is currently auditing the years ended December 2014, December 2015, and December 2016.
    
NOTE 14 – COMMITMENTS AND CONTINGENCIES

In view of the inherent difficulties of predicting the outcome of various types of legal proceedings, we cannot determine the ultimate resolution of the matters described below. We establish reserves for litigation and regulatory matters when losses associated with the claims become probable and the amounts can be reasonably estimated. The actual costs of resolving legal matters may be substantially higher or lower than the amounts reserved for those matters. For matters where the likelihood or extent of a loss is not probable or cannot be reasonably estimated as of September 30, 2017, we have not recorded a loss reserve. If certain of these matters are determined against us, there could be a material adverse effect on our financial condition, results of operations, or cash flows. We currently believe we have valid defenses to the claims in these lawsuits and intend to defend these lawsuits vigorously regardless of whether or not we have a loss reserve. Other than what is disclosed below, we do not expect the outcome of the litigation matters to which we are currently subject individually or in the aggregate, to have a material adverse effect on our financial condition, results of operations, or cash flows. 

Antitrust Violations
    
We have been named as a counterclaim co-defendant in the lawsuit Fera Pharmaceuticals, LLC v. Akorn, Inc., et al., in which Akorn, Inc. (“Akorn”) alleges tortious interference and antitrust violations against us and Fera Pharmaceuticals, LLC (“Fera”). This litigation arises from our acquisition of bacitracin ophthalmic ointment from Fera in 2013. Akorn asserts claims under Sections 1 and 2 of the Sherman Antitrust Act alleging that we and Fera conspired to monopolize, attempted to monopolize, and did unlawfully monopolize the market for sterile bacitracin ophthalmic ointment in the United States through the use of an exclusive agreement with a supplier of sterile bacitracin active pharmaceutical ingredient. The lawsuit is currently pending in the Southern District of New York. Trial was rescheduled from January 2018 to February 2018. Akorn seeks damages, injunctive relief, and attorney’s fees. Any award of antitrust damages would be subject to trebling under antitrust laws. An estimate of any possible loss cannot be determined at this time.

26
Perrigo Company plc - Item 1
Note 14



We believe the claims are without merit and intend to defend them vigorously. We have preserved our indemnification rights against Fera for potential liability, defense costs, and expenses incurred as a result of this litigation.

Price-Fixing Lawsuits

We have been named as a co-defendant with other manufacturers in a number of cases alleging that we and other manufacturers of the same product engaged in anti-competitive behavior to fix or raise the prices of certain drugs starting, in some instances, as early as June 2013. The products in question are Clobetasol, Desonide, and Econazole. These complaints, along with complaints filed against other companies alleging price fixing with respect to 15 other drugs, have been consolidated for pretrial proceedings as part of a case captioned In re Generic Pharmaceuticals Pricing Antitrust Litigation, MDL No. 2724. Pursuant to the court’s schedule staging various cases in phases, we have moved to dismiss the complaints relating to Clobetasol and Econazole. At this stage, we cannot reasonably predict the outcome of the liability, if any, associated with these claims.

Securities Litigation
 
In the United States

On May 18, 2016, a shareholder filed a securities case against us and our former CEO, Joseph Papa, in the U.S. District Court for the District of New Jersey (Roofers’ Pension Fund v. Papa, et al.). The plaintiff purported to represent a class of shareholders for the period from April 21, 2015 through May 11, 2016, inclusive. The original complaint alleged violations of Securities Exchange Act sections 10(b) (and Rule 10b‑5) and 14(e) against both defendants and 20(a) control person liability against Mr. Papa. In general, the allegations concerned the actions taken by us and the former executive to defend against the unsolicited takeover bid by Mylan in the period from April 21, 2015 through November 13, 2015. The plaintiff also alleged that the defendants provided inadequate disclosure concerning alleged integration problems related to the Omega acquisition in the period from April 21, 2015 through May 11, 2016. On July 19, 2016, a different shareholder filed a securities class action against us and our former CEO, Joseph Papa, also in the District of New Jersey (Wilson v. Papa, et al.). The plaintiff purported to represent a class of persons who sold put options on our shares between April 21, 2015 and May 11, 2016. In general, the allegations and the claims were the same as those made in the original complaint filed in the Roofers' Pension Fund case described above. On December 8, 2016, the court consolidated Roofers' Pension Fund case and the Wilson case under the Roofers' Pension Fund case number. In February 2017, the court selected the lead plaintiffs for the consolidated case and the lead counsel to the putative class. In March 2017, the court entered a scheduling order.

On June 21, 2017, the court-appointed lead plaintiffs filed an amended complaint that superseded the original complaints in the Roofers’ Pension Fund case and the Wilson case. The lead plaintiffs seek to represent a class of shareholders for the period April 21, 2015 through May 3, 2017, and identifies three subclasses - shareholders who traded during the entire period on the U.S. exchanges; shareholders who traded during the entire period on the Tel Aviv exchange; and shareholders who traded during the period while the Mylan tender offer was pending (April 21, 2015 through November 13, 2015). The amended complaint names as defendants us and 11 current or former directors and officers of Perrigo (Mses. Judy Brown, Laurie Brlas, Jacqualyn Fouse, Ellen Hoffing, and Messrs. Joe Papa, Marc Coucke, Gary Cohen, Michael Jandernoa, Gerald Kunkle, Herman Morris, and Donal O’Connor). The amended complaint alleges violations of Securities Exchange Act sections 10(b) (and Rule 10b‑5) and 14(e) against all defendants and 20(a) control person liability against the 11 individuals. In general, the allegations concern the actions taken by us and the former executives to defend against the unsolicited takeover bid by Mylan in the period from April 21, 2015 through November 13, 2015 and the allegedly inadequate disclosure throughout the entire class period related to purported integration problems related to the Omega acquisition, alleges incorrect reporting of organic growth at the Company, alleges price fixing activities with respect to six generic prescription pharmaceuticals, and alleges improper accounting for the Tysabri® royalty stream. The amended complaint does not include an estimate of damages. In August 2017, the defendants filed motions to dismiss the amended complaint. The plaintiffs filed their opposition in October 2017. The defendants filed replies in support of the motions to dismiss in November 2017. The court has not indicated whether there will be oral argument of the motions or whether the court will decide the motions on the papers. We intend to defend the lawsuit vigorously.

27
Perrigo Company plc - Item 1
Note 14



On November 1, 2017, Carmignac Gestion, S.A., filed a securities lawsuit against us and three individuals (former Chairman and CEO Joseph Papa, former CFO Judy Brown, and former Executive Vice President and Board member Marc Coucke). This lawsuit is not a securities class action. The case is styled Carmignac Gestion, S.A. v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of New Jersey. The complaint asserts claims under Securities Exchange Act sections 10(b) (and Rule 10b-5), 14(e), and 18 against all defendants as well as 20(a) control person liability against the individual defendants. In general, the plaintiff’s allegations focus on events during the period from April 2015 through April 2016. Plaintiff contends that the defendants provided inadequate disclosure throughout the period concerning the valuation and integration of Omega, the financial guidance provided by us during that period, our reporting about the generic prescription pharmaceutical business and its prospects, and the activities surrounding the efforts to defeat the Mylan tender offer during 2015. Many of the allegations in this newly-filed case overlap with the allegations of the June 2017 amended complaint in the Roofers’ Pension Fund case described above. The plaintiff does not provide an estimate of damages. We intend to defend the lawsuit vigorously.   

In Israel

Because our shares are traded on the Tel Aviv exchange under a dual trading arrangement, we are subject to securities litigation in Israel. Three cases are currently pending. We are consulting Israeli counsel about our response to these allegations and we intend to defend these cases vigorously.

On May 22, 2016, shareholders filed a securities class action against us and five individual defendants: Our former CEO Mr. Papa, our former Executive Vice President and General Manager of the BCH segment Marc Coucke, our Chief Executive Officer John Hendrickson, our former Board member Gary Kunkle, Jr., and our Board member Laurie Brlas alleging violations of Israeli law in the District Court of Tel Aviv-Jaffa (Schweiger et al. v. Perrigo Company plc, et al.). On June 15, 2016, we filed a motion to stay the case pending the outcome of the securities class action pending in the New Jersey Federal Court. The plaintiffs did not oppose the motion. The Israeli court granted the motion on the same day, and the Schweiger action is stayed. We intend to defend the lawsuit vigorously when and if the stay is lifted. In October 2017, the Schweiger plaintiffs dismissed their claims without prejudice because of the pendency of another class action case filed in Israel (see discussion below of the Israel Elec. Corp. Employees’ Educ. Fund case). The court approved the voluntary dismissal. 

On March 29, 2017, plaintiff Eyal Keinan commenced an action in the District Court of Tel Aviv-Jaffa asserting securities claims against two defendants: Perrigo and its auditor Ernst & Young LLP ("EY"). The case is styled Keinan v. Perrigo Company plc, et al. The action seeks certification of a class of purchasers of Perrigo shares on the Israeli exchange beginning February 6, 2014. The proposed closing date for the class is not clear from the complaint though it appears to extend into 2017. In general, the plaintiff asserts that we improperly accounted for our stream of royalty income from two drugs: Tysabri® and Prialt. The court filings contend that the alleged improper accounting caused the audited financial results for Perrigo to be incorrect for the six month period ended December 31, 2015, and the years ended June 27, 2015 and June 28, 2014 and the other financial data released by us over those years and 2016 to also be inaccurate. The plaintiff maintains that the defendants are liable under Israeli securities law or, in the alternative, under U.S. securities law. The plaintiff indicates an initial, preliminary class damages estimate of 686.0 million NIS (approximately $192.0 million at 1 NIS = $0.28 cent). The response from the defendants is not yet due. We intend to defend the lawsuit vigorously.

On June 28, 2017, a plaintiff filed a complaint in Tel Aviv District Court styled Israel Elec. Corp. Employees’ Educ. Fund v. Perrigo Company plc, et al. The lead plaintiff seeks to represent a class of shareholders who traded in Perrigo stock on the Tel Aviv exchange during the period April 24, 2015 through May 3, 2017. The amended complaint names as defendants the Company, EY (the Company’s auditor), and 11 current or former directors and officers of Perrigo (Mses. Judy Brown, Laurie Brlas, Jacqualyn Fouse, Ellen Hoffing, and Messrs. Joe Papa, Marc Coucke, Gary Cohen, Michael Jandernoa, Gerald Kunkle, Herman Morris, and Donal O’Connor). The complaint alleges violations under U.S. securities laws of Securities Exchange Act sections 10(b) (and Rule 10b‑5) and 14(e) against all defendants and 20(a) control person liability against the 11 individuals or, in the alternative, under Israeli securities laws. In general, the allegations concern the actions taken by us and our former executives to defend against the unsolicited takeover bid by Mylan in the period from April 21, 2015 through November 13, 2015 and the allegedly inadequate disclosure concerning purported integration problems related to the Omega acquisition, alleges incorrect reporting of organic growth at the Company, alleges price fixing activities with respect to six

28
Perrigo Company plc - Item 1
Note 14


generic prescription pharmaceuticals, and alleges improper accounting for the Tysabri® royalty stream. The plaintiff indicates an initial, preliminary class damages estimate of 2.7 billion NIS (approximately $760.0 million at 1 NIS = $0.28 cent). We intend to defend the lawsuit vigorously.

On July 12, 2017, the plaintiff in the Israel Elec. Corp. Employees’ Educ. Fund v. Perrigo Company plc, et al. case filed a motion to have all three cases pending in Israel either consolidated or the other two cases dismissed so that the Israel Elec. Corp. Educ. Fund plaintiff can proceed as the sole plaintiff. That motion is pending. In October 2017, the Schweiger plaintiffs (see description above) voluntarily dismissed their securities class action without prejudice as part of their response to the motion filed by the Israel Elec. Corp. Educ. Fund plaintiff. A variety of other procedural motions are also pending at this time having to do with the timing of any response by defendants. The court has scheduled an initial conference on November 9, 2017 to address the motion filed by the Israel Elec. Corp. Educ. Fund plaintiff. The court has indicated that other procedural motions will be addressed after it has decided the Israel Elec. Corp. Educ. Fund plaintiff’s motion.

Eltroxin

During October and November 2011, nine applications to certify a class action lawsuit were filed in various courts in Israel related to Eltroxin, a prescription thyroid medication manufactured by a third party and distributed in Israel by our subsidiary, Perrigo Israel Agencies Ltd. The respondents included our subsidiaries, Perrigo Israel Pharmaceuticals Ltd. and/or Perrigo Israel Agencies Ltd., the manufacturers of the product, and various healthcare providers who provide healthcare services as part of the compulsory healthcare system in Israel.

One of the applications was dismissed and the remaining eight applications were consolidated into one application. The applications arose from the 2011 launch of a reformulated version of Eltroxin in Israel. The consolidated application generally alleges that the respondents (a) failed to timely inform patients, pharmacists and physicians about the change in the formulation; and (b) failed to inform physicians about the need to monitor patients taking the new formulation in order to confirm patients were receiving the appropriate dose of the drug. As a result, claimants allege they incurred the following damages: (a) purchases of product that otherwise would not have been made by patients had they been aware of the reformulation; (b) adverse events to some patients resulting from an imbalance of thyroid functions that could have been avoided; and (c) harm resulting from the patients' lack of informed consent prior to the use of the reformulation.

Several hearings on whether or not to certify the consolidated application took place in December 2013 and January 2014. On May 17, 2015, the District Court certified the motion against Perrigo Israel Agencies Ltd. and dismissed it against the remaining respondents, including Perrigo Israel Pharmaceuticals Ltd.

On June 16, 2015, we submitted a motion for permission to appeal the decision to certify to the Israeli Supreme Court together with a motion to stay the proceedings of the class action until the motion for permission to appeal is adjudicated. We have filed our statement of defense to the underlying proceedings. The parties are currently engaged in mediation in an attempt to settle the matter. The underlying proceedings have been stayed pending the outcome of the mediation process and, if necessary, a decision on the motion to appeal.

Tysabri® Product Liability Lawsuits

We and our collaborator Biogen are co-defendants in product liability lawsuits arising out of the occurrence of Progressive Multifocal Leukoencephalopathy, a serious brain infection, and serious adverse events, including deaths, which occurred in patients taking Tysabri®. Each co-defendant would be responsible for 50% of losses and expenses arising out of any Tysabri® product liability claims. During calendar year 2016, one case in the U.S. was settled and two others were dismissed with prejudice. In 2017, seven other cases were dismissed with prejudice. While we intend to vigorously defend the remaining lawsuits, management cannot predict how these cases will be resolved. Adverse results in one or more of these lawsuits could result in substantial judgments against us.

Claim Arising from the Omega Acquisition

On December 16, 2016, we and Perrigo Ireland 2 brought an arbitral claim ("Claim") against Alychlo NV ("Alychlo") and Holdco I BE NV ("Holdco") (together the Sellers) in accordance with clause 26.2 of the Share Purchase Agreement dated November 6, 2014 ("SPA") and the rules of the Belgian Centre for Arbitration and

29
Perrigo Company plc - Item 1
Note 14


Mediation ("CEPANI"). Our Claim relates to the accuracy and completeness of information about Omega provided by the Sellers as part of the sale process, the withholding of information by the Sellers during that process and breaches of Sellers’ warranties. We are seeking monetary damages from the Sellers. The Sellers served their respective responses to the Claim on February 20, 2017. In its response, Alychlo has asserted a counterclaim for monetary damages contending that we breached the duty of good faith in performing the SPA. There can be no assurance that our Claim will be successful, and Sellers deny liability for the Claim. We deny that Alychlo is entitled to any relief (including monetary relief) under the counterclaim. The arbitration proceedings are confidential as required by the SPA and the rules of the CEPANI.

NOTE 15 – RESTRUCTURING CHARGES

We periodically take action to reduce redundant expenses and improve operating efficiencies. The following reflects our restructuring activity (in millions):
 
Three Months Ended
 
Nine Months Ended
 
September 30,
2017
 
October 1,
2016
 
September 30,
2017
 
October 1,
2016
Beginning balance
$
39.7

 
$
12.2

 
$
19.7

 
$
20.7

Additional charges
3.8

 
6.6

 
54.7

 
17.9

Payments
(17.8
)
 
(8.6
)
 
(47.6
)
 
(33.3
)
Non-cash adjustments
0.4

 
0.1

 
(0.7
)
 
5.0

Ending balance
$
26.1

 
$
10.3

 
$
26.1

 
$
10.3


Restructuring activity includes severance, lease exit costs, and asset impairments. The charges incurred during the three and nine months ended September 30, 2017 were primarily associated with actions we took to streamline our organization as announced on February 21, 2017. During the three and nine months ended September 30, 2017, $3.8 million and $54.7 million of restructuring expenses were recorded, respectively. Of the amount recorded during the nine months ended September 30, 2017, $27.2 million was related to the CHCA segment. There were no other material restructuring programs that significantly impacted any other reportable segments. All charges are recorded in Restructuring on the Condensed Consolidated Statements of Operations. The remaining $22.4 million liability for employee severance benefits is expected to be paid within the next year, while the remaining $3.7 million liability for lease exit costs is expected to be incurred over the remaining terms of the applicable leases.

NOTE 16 – SEGMENT INFORMATION
    
Our reporting segments are as follows:

•
CHCA, comprises our U.S., Mexico and Canada consumer healthcare business (OTC, contract, infant formula and animal health categories).
•
CHCI, comprises our legacy Branded Consumer Healthcare segment and now includes our consumer focused businesses in the U.K., Australia, and Israel. This segment also includes our U.K. liquid licensed products business.
•
RX, comprises our U.S. Prescription Pharmaceuticals business.

We also have an "Other" reporting segment that consists of our legacy API business, which does not meet the quantitative threshold required to be a separately reportable segment. Effective January 1, 2017, due to the sale of the Tysabri® financial asset, all legal expenses associated with the former Specialty Sciences segment were moved to unallocated expenses. Our segments reflect the way in which our chief operating decision maker reviews our operating results and allocates resources.


30
Perrigo Company plc - Item 1
Note 16


The below tables show select financial measures by reporting segment (in millions):
 
 
Total Assets
 
 
September 30,
2017
 
December 31,
2016
CHCA
 
$
3,833.7

 
$
3,351.3

CHCI
 
5,114.2

 
4,795.2

RX
 
2,597.0

 
2,646.4

Specialty Sciences
 
—

 
2,775.8

Other
 
297.7

 
301.4

Total
 
$
11,842.6

 
$
13,870.1

 
Three Months Ended
 
September 30, 2017
 
October 1, 2016
 
Net
Sales
 
Operating Income (Loss)
 
Intangible Asset Amortization
 
Net
Sales
 
Operating Income (Loss)
 
Intangible Asset Amortization
CHCA
$
598.8

 
$
124.3

 
$
16.9

 
$
611.2

 
$
99.0

 
$
17.6

CHCI
365.4

 
4.6

 
50.2

 
377.4

 
(1,615.5
)
 
44.4

RX
250.6

 
82.1

 
21.0

 
251.9

 
74.4

 
27.2

Specialty Sciences
—

 
—

 
—

 
—

 
3.2

 
—

Other
16.5

 
(0.4
)
 
0.4

 
21.1

 
(1.5
)
 
0.5

Unallocated
—

 
(48.2
)
 
—

 
—

 
(27.9
)
 
—

Total
$
1,231.3

 
$
162.4

 
$
88.5

 
$
1,261.6

 
$
(1,468.3
)
 
$
89.7


 
Nine Months Ended
 
September 30, 2017
 
October 1, 2016
 
Net
Sales
 
Operating Income (Loss)
 
Intangible Asset Amortization
 
Net
Sales
 
Operating Income (Loss)
 
Intangible Asset Amortization
CHCA
$
1,786.4

 
$
303.6

 
$
51.1

 
$
1,880.2

 
$
316.4

 
$
53.3

CHCI
1,116.8

 
8.7

 
143.4

 
1,232.7

 
(2,011.3
)
 
130.6

RX
708.4

 
239.6

 
65.6

 
776.9

 
258.3

 
78.6

Specialty Sciences
—

 
—

 
—

 
—

 
(1.9
)
 
—

Other
51.5

 
9.4

 
1.2

 
59.5

 
2.6

 
1.4

Unallocated
—

 
(121.7
)
 
—

 
—

 
(79.2
)
 
—

Total
$
3,663.1

 
$
439.6

 
$
261.3

 
$
3,949.3

 
$
(1,515.1
)
 
$
263.9


ITEM 2.        MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

EXECUTIVE OVERVIEW

This Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the financial statements included in this Form 10-Q and our Form 10-K for the year ended December 31, 2016 (the “2016 Form 10-K”). These historical financial statements may not be indicative of our future performance. This discussion contains a number of forward-looking statements, all of which are based on our current expectations and could be affected by the uncertainties and risks referred to under “Risk Factors” in Item 1A of our 2016 Form 10-K and Part II, Item 1A of this Form 10-Q.

Perrigo Company plc was incorporated under the laws of Ireland on June 28, 2013 and became the successor registrant of Perrigo Company, a Michigan corporation, on December 18, 2013 in connection with the acquisition of Elan Corporation, plc ("Elan"). Unless the context requires otherwise, the terms "Perrigo," the "Company," "we," "our," "us," and similar pronouns used herein refer to Perrigo Company plc, its subsidiaries, and all predecessors of Perrigo Company plc and its subsidiaries.

31
Perrigo Company plc - Item 2
Executive Overview




We are a leading global healthcare company that delivers value to our customers and consumers by providing Quality Affordable Healthcare Products®. Founded in 1887 as a packager of home remedies, we have built a unique business model that is best described as the convergence of a fast-moving consumer goods company, a high-quality pharmaceutical manufacturing organization and a world-class supply chain network. We believe we are one of the world's largest manufacturers of over-the-counter (“OTC”) healthcare products and suppliers of infant formulas for the store brand market. We also are a leading provider of branded OTC products throughout Europe and the U.S., as well as a leading producer of generic standard topical products such as creams, lotions, and gels, as well as inhalants and injections ("extended topical") prescription drugs. We are headquartered in Ireland, and sell our products primarily in North America and Europe, as well as in other markets, including Australia, Israel and China.

             Our reporting segments are as follows:

•
Consumer Healthcare Americas ("CHCA"), comprises our U.S., Mexico and Canada consumer healthcare business (OTC, contract, infant formula and animal health categories).
•
Consumer Healthcare International ("CHCI"), comprises our legacy Branded Consumer Healthcare segment and now includes our consumer focused businesses in the U.K., Australia, and Israel. This segment also includes our U.K. liquid licensed products business.
•
Prescription Pharmaceuticals ("RX"), comprises our U.S. Prescription Pharmaceuticals business.

We also have an "Other" reporting segment, which comprises our legacy Active Pharmaceutical Ingredients ("API") business, which does not meet the quantitative threshold required to be a separately reportable segment. Effective January 1, 2017, due to the sale of the Tysabri® financial asset, all legal expenses associated with our former Specialty Sciences segment were moved to unallocated expenses. For results by segment, see "Segment Results" below and Item 1. Note 16.

2017 Year-to-Date Highlights

•
On March 27, 2017, we completed the sale of our Tysabri® financial asset, effective January 1, 2017, to Royalty Pharma for up to $2.85 billion, which consists of $2.2 billion in cash and up to $250.0 million and $400.0 million in milestone payments if the royalties on global net sales of Tysabri® that are received by Royalty Pharma meet specific thresholds in 2018 and 2020, respectively. As a result of this transaction, we derecognized the Tysabri® financial asset and recorded a $17.1 million gain (refer to Item 1. Note 6).

•
On April 6, 2017, we completed the sale of our India API business to Strides Shasun Limited for $22.2 million, inclusive of an estimated working capital adjustment. The sale did not have a material impact on our operations (refer to Item 1. Note 2).

•
On August 4, 2017, we signed a definitive agreement for the sale of our Israel API business to SK Capital for $110.0 million in cash, inclusive of a net debt adjustment. We expect to finalize the sale within the next three months. The sale is not expected to have a material impact on our operations (refer to Item 1. Note 9).

•
We completed $2.2 billion of debt repayments during the nine months ended September 30, 2017 (refer to Item 1. Note 10).

•
On August 25, 2017, we completed the sale of our Russian business to Alvogen Pharma LLC and Alvogen CEE Kft. for €12.7 million ($15.1 million), inclusive of an estimated working capital adjustment. The sale did not have a material impact on our operations (refer to Item 1. Note 2).



32
Perrigo Company plc - Item 2
Consolidated


RESULTS OF OPERATIONS

CONSOLIDATED

Consolidated Results
 
Three Months Ended
 
Nine Months Ended
($ in millions)
October 1,
2016
 
September 30,
2017
 
October 1,
2016
 
September 30,
2017
Net sales
$
1,261.6

 
$
1,231.3

 
$
3,949.3

 
$
3,663.1

Gross profit
$
484.5

 
$
497.8

 
$
1,564.1

 
$
1,466.7

Gross profit %
38.4
 %
 
40.4
%
 
39.6
 %
 
40.0
%
Operating expenses
$
1,952.8

 
$
335.4

 
$
3,079.2

 
$
1,027.1

Operating expenses %
154.8
 %
 
27.2
%
 
78.0
 %
 
28.0
%
Operating income (loss)
$
(1,468.3
)
 
$
162.4

 
$
(1,515.1
)
 
$
439.6

Operating income (loss) %
(116.4
)%
 
13.2
%
 
(38.4
)%
 
12.0
%
Change in financial assets
$
377.4

 
$
2.6

 
$
1,492.6

 
$
24.2

Interest and other, net
$
55.6

 
$
31.1

 
$
195.6

 
$
132.0

Loss on extinguishment of debt
$
0.7

 
$
—

 
$
1.1

 
$
135.2

Income tax expense (benefit)
$
(311.8
)
 
$
84.2

 
$
(550.7
)
 
$
101.8

Net income (loss)
$
(1,590.2
)
 
$
44.5

 
$
(2,653.7
)
 
$
46.4

cy17q110q_chart-47601a02.jpgcy17q210q_chart-39323a01.jpg

The $30.3 million decrease in consolidated net sales for the three months ended September 30, 2017 as compared to the prior year period was due to discontinued products of $6.2 million, lower sales in the CHCA segment, due primarily to the absence of $21.0 million of sales related to the U.S. Vitamins, Minerals, and Supplements ("VMS") business, lower sales in the CHCI segment due primarily to the absence of $41.7 million of sales as a result of the cancellation of certain distribution contracts, and lower sales in the RX segment driven by lower net sales of Entocort® in the amount of $10.2 million and pricing pressures across the portfolio. These decreases were partially offset by new product sales of $55.4 million and favorable foreign currency translation of $13.0 million. Consolidated operating income for the three months ended September 30, 2017 increased due primarily to the absence of asset impairment charges in the amount of $1.6 billion taken in the prior year period (refer to Item 1. Note 3).

The $286.2 million decrease in consolidated net sales for the nine months ended September 30, 2017 as compared to the prior year period was due to discontinued products of $18.4 million, lower sales in the CHCA segment due primarily to the absence of $110.1 million of sales related to the U.S. VMS business, lower sales in the CHCI segment due primarily to the absence of $118.4 million of sales as a result of the cancellation of certain distribution contracts, and lower sales in the RX segment driven by lower net sales of Entocort® in the amount of $61.4 million and pricing pressures across the portfolio. These decreases were partially offset by new product sales

33
Perrigo Company plc - Item 2
Consolidated


of $155.8 million. Consolidated operating income for the nine months ended September 30, 2017 increased due primarily to the absence of asset impairment charges in the amount of $2.0 billion taken in the prior year period (refer to Item 1. Note 3).

Further details and analysis of our financial results for the three and nine months ended September 30, 2017 are described below by reporting segment and line item. Refer to the "Unallocated Expenses," "Interest, Other and Change in financial assets (Consolidated)," and "Income Taxes (Consolidated)" sections below for discussions related to our expenses.

Restructuring

On February 21, 2017, we approved a workforce reduction plan as part of a larger cost optimization strategy across the Company. We expect to reduce our global workforce by approximately 750 employees, which includes some actions already taken and 235 employees who have elected to participate in a voluntary early retirement program. This represents a reduction of approximately 14% of our global non-production workforce. The changes to our workforce will vary by country, based on legal requirements and required consultations with works councils and other employee representatives, as appropriate.

In connection with this plan, we estimate that we will recognize total pre-tax restructuring charges of approximately $55.0 million to $65.0 million, consisting of one-time termination benefits, severance arrangements, and other termination costs. We expect to incur the majority of the remaining charges in 2017, with the balance to be recognized during the first quarter of the year ending December 31, 2018. During the three and nine months ended September 30, 2017, we recognized $3.8 million and $54.7 million, respectively, of restructuring expenses due primarily to this cost optimization strategy.

Our cost optimization strategy is expected to yield approximately $130.0 million in savings per annum by mid-2018. This is in addition to the savings that our supply chain organization continues to generate for both our North American and International segments.

CONSUMER HEALTHCARE AMERICAS

Recent Trends and Developments

•
We continue to experience a reduction in pricing expectations within our CHCA segment, primarily in the cough/cold, animal health, and analgesics categories due to various factors, including increased focus from customers to capture supply chain productivity savings and competition in specific product categories. We expect this pricing environment to continue to impact our CHCA segment for the foreseeable future.

•
We completed the sale of the animal health pet treats plant fixed assets on February 1, 2017 and received $7.7 million in proceeds (refer to Item 1. Note 2).


34
Perrigo Company plc - Item 2
CHCA


Segment Results

Three Month Comparison
cy17q110q_chart-47252a02.jpg
 

 
Three Months Ended
($ in millions)
October 1,
2016
 
September 30,
2017
Net sales
$
611.2

 
$
598.8

Gross profit
$
199.2

 
$
206.1

Gross profit %
32.6
%
 
34.4
%
Operating income
$
99.0

 
$
124.3

Operating income %
16.2
%
 
20.8
%
Three Months Ended September 30, 2017 vs. Three Months Ended October 1, 2016

Net sales decreased $12.4 million, or 2%, over the prior year period due to:

•
New product sales of $13.2 million related primarily to the launches of Esomemprazole Magnesium (store brand equivalent to Nexium®); and
•
Favorable foreign currency translation movement of $1.4 million; more than offset by
•
The absence of $21.0 million in sales attributable to the U.S. VMS business, which was sold in August 2016 (refer to Item 1. Note 2);
•
A net decrease in sales of existing products of $3.2 million due primarily to:
•
Higher sales in the gastrointestinal and animal health categories and in our Mexico business;
•
Pricing pressures in the cough/cold, and analgesics categories; and
•
Lower volumes in the nicotine replacement category; and
•
Discontinued products of $2.7 million.

Operating income increased $25.3 million, or 26%, as a result of:

•
An increase of $6.9 million in gross profit due to:
•
Favorable product mix in certain categories; and
•
Positive contributions from supply chain efficiencies; offset partially by
•
The absence of $3.4 million in gross profit as a result of the sale of the U.S. VMS business (refer to Item 1. Note 2); and
•
Pricing pressures in certain categories as discussed above.

•
A decrease of $18.4 million in operating expenses due to:
•
Decreased restructuring expense of $4.8 million related primarily to the cost reduction initiatives taken in the prior year (refer to Item 1. Note 15);
•
Decreased selling and administrative expenses of $4.8 million due primarily to timing of promotions related to our animal health category and savings related to our previously announced strategic initiatives;
•
Decreased Research and Development ("R&D") expenses of $4.5 million due to timing of clinical trials; and
•
The absence of a $3.4 million impairment charge related to held-for-sale assets associated with our animal health pet treats plant (refer to Item 1. Note 9); offset partially by
•
A $2.0 million gain related to contingent consideration (refer to Item 1. Note 6).

•
Gross profit as a percentage of net sales was 1.8% higher due primarily to favorable product mix and supply chain efficiencies as discussed above.


35
Perrigo Company plc - Item 2
CHCA


•
Operating income as a percentage of net sales was 4.6% higher due primarily to favorable product mix as discussed above and decreased operating expenses.

Nine Month Comparison
cy17q210q_chart-39117a01.jpg
 

 
Nine Months Ended
($ in millions)
October 1,
2016
 
September 30,
2017
Net sales
$
1,880.2

 
$
1,786.4

Gross profit
$
615.1

 
$
598.3

Gross profit %
32.7
%
 
33.5
%
Operating income
$
316.4

 
$
303.6

Operating income %
16.8
%
 
17.0
%
Nine Months Ended September 30, 2017 vs. Nine Months Ended October 1, 2016

Net sales decreased $93.8 million, or 5%, over the prior year period due to:

•
New product sales of $51.2 million related primarily to the launches of fluticasone nasal spray (store brand equivalent to Flonase®), smoking cessation products and Esomemprazole Magnesium (store brand equivalent to Nexium®); more than offset by
•
The absence of $110.1 million in sales attributable to the U.S. VMS business (refer to Item 1. Note 2);
•
A net decrease in sales of existing products of $22.6 million due to:
•
Higher sales in the cough/cold category and Mexico business; more than offset by
•
Lower sales in our infant nutrition and animal health categories;
•
Pricing pressures in the cough/cold, analgesics, and gastrointestinal categories; and
•
Lower volumes in the nicotine replacement category;
•
Discontinued products of $11.1 million; and
•
Unfavorable foreign currency translation movement of $1.1 million.

Operating income decreased $12.8 million, or 4%, as a result of:

•
A decrease of $16.8 million in gross profit due to:
•
Favorable product mix in certain categories; and
•
Positive contributions from supply chain efficiencies; more than offset by
•
The absence of $17.6 million in gross profit as a result of the sale of the U.S. VMS business (refer to Item 1. Note 2); and
•
Pricing pressures in certain categories as discussed above.

•
A decrease of $4.0 million in operating expenses due to:
•
Decreased selling and administrative expenses of $10.8 million due primarily to timing of promotions related to our animal health category and savings related to our cost reduction initiatives taken in the prior year;
•
The absence of a $9.6 million impairment charge related to the U.S. VMS business (refer to Item 1. Note 2) and held-for-sale assets associated with our animal health pet treats plant (refer to Item 1. Note 9); and
•
Decreased R&D expenses of $7.6 million due to timing of clinical trials, reduced spending on infant formula clinical trials and lower costs related to our cost reduction initiatives; offset partially by
•
A $2.9 million gain related to contingent consideration (refer to Item 1. Note 6);
•
Increased restructuring expenses of $21.5 million related primarily to strategic organizational enhancements (refer to Item 1. Note 15); and
•
A $4.1 million impairment charge recorded on idle property, plant and equipment.


36
Perrigo Company plc - Item 2
CHCI


CONSUMER HEALTHCARE INTERNATIONAL

Recent Trends and Developments

As part of our strategic initiatives, management continues to drive improvements and evaluate the overall cost structures within our CHCI segment in the following ways:

•
On December 8, 2016, we announced the cancellation of the unprofitable EuroGenerics NV distribution agreement in Belgium. The cancellation, combined with the exit of certain OTC distribution agreements, is expected to reduce net sales by approximately $210.0 million in 2017.

•
We continue to make progress on our previously announced restructuring plans to right-size the Omega business due to the impact of market dynamics on sales volumes. Management continues to evaluate the overall cost structure relative to current and expected market dynamics. During the three and nine months ended September 30, 2017, we recognized $3.6 million and $13.2 million of restructuring expense in the CHCI segment, respectively.

•
Management continues to evaluate the most effective business model for each country, aligning our sales infrastructure and actively integrating sales strategies with promotional programs.

•
On August 25, 2017, we completed the sale of our Russian business, which was previously classified as held-for-sale, to Alvogen Pharma LLC and Alvogen CEE Kft. The total sale price was €12.7 million ($15.1 million), inclusive of an estimated working capital adjustment, which resulted in an immaterial gain in the segment (refer to Item 1. Note 2).

The combination of these actions is expected to improve the segment's focus on higher value OTC products, reduce selling costs and improve operating margins in the segment.

Segment Results

Three Month Comparison

cy17q110q_chart-47491a02.jpg
 

 
Three Months Ended
($ in millions)
October 1,
2016
 
September 30,
2017
Net sales
$
377.4

 
$
365.4

Gross profit
$
155.2

 
$
165.9

Gross profit %
41.1
 %
 
45.4
%
Operating income (loss)
$
(1,615.5
)
 
$
4.6

Operating income (loss) %
(428.1
)%
 
1.2
%
Three Months Ended September 30, 2017 vs. Three Months Ended October 1, 2016

Net sales decreased $12.0 million, or 3%, over the prior year period due primarily to:

•
Favorable foreign currency translation movement of $11.6 million;
•
New product sales of $11.4 million; and
•
A net increase in sales of existing products of $8.9 million due to increased sales primarily in the cough/cold, allergy, analgesics, and lifestyle categories; more than offset by

37
Perrigo Company plc - Item 2
CHCI


•
The absence of $41.7 million in sales attributable to the cancellation of unprofitable distribution contracts; and
•
Discontinued products of $3.2 million.

Operating income increased $1.6 billion, as a result of:

•
An increase of $10.7 million in gross profit due primarily to:
•
Favorable foreign currency translation movement;
•
Improved product mix for sales of existing products; and
•
Operational efficiencies across the organization.

•
A decrease of $1.6 billion in operating expenses due primarily to:
•
The absence of $1.6 billion of impairment charges on certain indefinite-lived and definite-lived intangible brand category assets and goodwill impairments in the Branded Consumer Healthcare - Rest of World ("BCH-ROW") and Branded Consumer Healthcare - Belgium ("BCH-Belgium")
reporting units recorded in the prior year period (refer to Item 1. Note 3); and
•
A decrease of $4.6 million in selling and administrative expenses due to previously announced strategic initiatives to better align promotional investments with sales and cost reduction initiatives taken in the current year; offset partially by
•
Increased restructuring charges totaling $1.2 million related to strategic organizational enhancements (refer to Item 1. Note 15).

•
Gross profit as a percentage of net sales was 4.3% higher due primarily to improved product mix primarily driven by the cancellation of certain unprofitable distribution contracts, as described above.

•
Operating income as a percentage of net sales was 429.3% higher due primarily to the absence of $1.6 billion of intangible asset and goodwill impairment charges as discussed above (refer to Item 1. Note 3).

Nine Month Comparison

cy17q210q_chart-39013a01.jpg
 


 
Nine Months Ended
($ in millions)
October 1,
2016
 
September 30,
2017
Net sales
$
1,232.7

 
$
1,116.8

Gross profit
$
542.1

 
$
509.4

Gross profit %
44.0%
 
45.6
%
Operating income (loss)
$
(2,011.3
)
 
$
8.7

Operating income (loss) %
(163.2
)%
 
0.8
%

Nine Months Ended September 30, 2017 vs. Nine Months Ended October 1, 2016

Net sales decreased $115.9 million, or 9%, over the prior year period due primarily to:

•
New product sales of $50.4 million; more than offset by
•
The absence of $118.4 million in sales attributable to the cancellation of unprofitable distribution contracts;
•
Unfavorable foreign currency translation movement of $25.2 million;
•
A decrease in sales of existing products of $17.4 million primarily in the anti-parasites and vitamins categories; and
•
Discontinued products of $5.0 million.


38
Perrigo Company plc - Item 2
CHCI


Operating income increased $2.0 billion due to:

•
A decrease of $32.7 million in gross profit due primarily to:
•
Improved product mix for sales of existing products; and
•
Operational efficiencies across the organization; more than offset by
•
Lower margins in our U.K. store brand business; and
•
Unfavorable foreign currency translation movement.

•
A decrease of $2.1 billion in operating expenses due primarily to:
•
The absence of $2.0 billion of impairment charges on certain indefinite-lived and definite-lived intangible brand category assets and goodwill impairments in the BCH-ROW and BCH-Belgium
reporting units recorded in the prior year period (refer to Item 1. Note 3); and
•
A decrease in selling and administrative expenses of $48.5 million due to previously announced strategic initiatives to better align promotional investments with sales and cost reduction initiatives taken in the current year; offset partially by
•
A $4.8 million impairment charge recorded related to the Russian business (refer to Item 1. Note 2) and In-Process Research and Development ("IPR&D"); and
•
Increased restructuring expense of $2.8 million related to strategic organizational enhancements (refer to Item 1. Note 15).

•
Gross profit as a percentage of net sales was 1.6% higher due primarily to improved product mix primarily driven by the cancellation of certain unprofitable distribution contracts, as described above.

•
Operating income as a percentage of net sales was 164.0% higher due primarily to the absence of $2.0 billion of intangible asset and goodwill impairment charges as discussed above (refer to Item 1. Note 3).

PRESCRIPTION PHARMACEUTICALS

Recent Trends and Developments

•
We continue to experience a significant reduction in pricing expectations from historical levels in our RX segment due to industry and competitive pressures. This softness in pricing is attributable to various factors, including increased focus from customers to capture supply chain productivity savings, low raw material commodity pricing, competition in specific products, and consolidation of certain customers. We expect this softness to continue to impact the segment for the foreseeable future, and we are forecasting a high single digit pricing decline in this segment for the year ending December 31, 2017.

•
On November 10, 2016, we announced that as part of our portfolio review process we are conducting a comprehensive internal evaluation of the RX segment's market position, growth opportunities, and interdependencies with our manufacturing and shared service operations to determine if strategic alternatives should be explored.

•
During the three months ended December 31, 2016, the U.S. market for Entocort® (Budesonide) capsules, including both brand and authorized generic capsules, experienced significant and unexpected increased competition, which reduced our future revenue stream. We expect our net sales in the RX segment for the year ending December 31, 2017 will be negatively impacted by approximately $67.0 million.

•
During the nine months ended September 30, 2017, we sold various Abbreviated New Drug Applications ("ANDAs") for a total gain of $23.0 million.


39
Perrigo Company plc - Item 2
RX


Segment Results

Three Month Comparison
cy17q110q_chart-47343a02.jpg
 

 
Three Months Ended
($ in millions)
October 1,
2016
 
September 30,
2017
Net sales
$
251.9

 
$
250.6

Gross profit
$
120.9

 
$
116.7

Gross profit %
48.0
%
 
46.6
%
Operating income
$
74.4

 
$
82.1

Operating income %
29.5
%
 
32.8
%
Three Months Ended September 30, 2017 vs. Three Months Ended October 1, 2016

Net sales decreased $1.3 million, or 1%, due to:

•
New product sales of $30.8 million due primarily to the sale of Scopolamine and Testosterone 2% topical (store brand equivalent to Axiron®); more than offset by
•
Decreased sales of existing products of $21.5 million due primarily to pricing pressure across the portfolio; and
•
Lower Entocort® sales of $10.2 million.

Segment operating income increased $7.7 million, or 10%, as a result of:

•
A decrease of $4.2 million in gross profit due primarily to:
•
Lower Entocort® sales as discussed above; and
•
Pricing pressure as discussed above.

•
A decrease of $11.9 million in operating expenses due primarily to:
•
Decreased selling and administrative expenses of $8.4 million due primarily to the prior year specialty pharmaceuticals sales force restructuring initiative; and
•
Decreased R&D expenses of $7.3 million due to timing of clinical trials, lower legal spend, and lower ongoing costs on certain projects; offset partially by
•
A $4.0 million impairment charge on certain fixed assets in the current period.

•
Gross profit as a percentage of net sales was 1.4% lower due primarily to lower sales of Entocort® and pricing pressures.

•
Operating income as a percentage of net sales was 3.3% higher due primarily to decreased costs related to R&D spend and restructuring initiatives taken in the prior year; offset partially by lower sales of Entocort®.


40
Perrigo Company plc - Item 2
RX


Nine Month Comparison
cy17q210q_chart-38938a01.jpg
 


 
Nine Months Ended
($ in millions)
October 1,
2016
 
September 30,
2017
Net sales
$
776.9

 
$
708.4

Gross profit
$
380.2

 
$
332.1

Gross profit %
48.9
%
 
46.9
%
Operating income
$
258.3

 
$
239.6

Operating income %
33.3
%
 
33.8
%
Nine Months Ended September 30, 2017 vs. Nine Months Ended October 1, 2016

Net sales decreased $68.5 million, or 9%, due to:

•
New product sales of $53.2 million due primarily to sales of Scopolamine and Testosterone 2% topical (store brand equivalent to Axiron®); more than offset by
•
Lower Entocort® sales of $61.4 million;
•
Decreased sales of existing products of $58.0 million due to decreased sales volume of certain products and pricing pressure across the portfolio; and
•
Discontinued products of $2.3 million.

Operating income decreased $18.7 million, or 7%, as a result of:

•
A decrease of $48.1 million in gross profit due primarily to:
•
Lower Entocort® sales as noted above; and
•
Pricing pressure as discussed above.

•
A decrease of $29.4 million in operating expenses due to:
•
A $23.0 million gain on sales of certain ANDAs;
•
A $17.0 million gain related to contingent consideration (refer to Item 1. Note 6);
•
Decreased selling and administrative expenses of $18.3 million due primarily to the prior year specialty pharmaceuticals sales force restructuring initiative; and
•
Decreased R&D expenses of $14.1 million due to timing of clinical trials, lower legal spend, and lower ongoing costs on certain projects; offset partially by
•
Impairment charges related to certain definite-lived intangible assets, certain fixed assets and IPR&D of $34.8 million (refer to Item 1. Note 3); and
•
Increased restructuring expenses of $5.9 million related to strategic organizational enhancements (refer to Item 1. Note 15).

•
Gross profit as a percentage of net sales was 2.0% lower due primarily to lower sales of Entocort® as discussed above.


41
Perrigo Company plc - Item 2
Other


OTHER

Recent Trends and Developments

On April 6, 2017, we completed the sale of our India API business to Strides Shasun Limited. We received $22.2 million of proceeds, inclusive of an estimated working capital adjustment, which resulted in an immaterial gain. Prior to closing the sale, we determined that the carrying value of the India API business exceeded its fair value less the cost to sell, resulting in an impairment charge of $35.3 million, which was recorded in Impairment charges on the Consolidated Statements of Operations for the year ended December 31, 2016 (refer to Item 1. Note 2).

On August 4, 2017, we signed a definitive agreement for the sale of our Israel API business to SK Capital for $110.0 million in cash, inclusive of a net debt adjustment. We expect to finalize the sale within the next three months, and the sale is not expected to have a material impact on our operations (refer to Item 1. Note 9).

Segment Results

Three Month Comparison
cy17q110q_chart-47367a02.jpg
 
 
Three Months Ended
($ in millions)
October 1,
2016
 
September 30,
2017
Net sales
$
21.1

 
$
16.5

Gross profit
$
9.4

 
$
9.1

Gross profit %
44.5
 %
 
55.5
 %
Operating income (loss)
$
(1.5
)
 
$
(0.4
)
Operating income (loss)%
(7.4
)%
 
(2.4
)%
Three Months Ended September 30, 2017 vs. Three Months Ended October 1, 2016

Net sales decreased $4.6 million due primarily to increased competition on certain products. Operating loss decreased $1.1 million due primarily to a $1.4 million decrease in operating expenses. The decrease in operating expenses related to the absence of a $6.5 million impairment charge recorded on the India API business in the prior year; offset partially by a $3.3 million impairment charge recorded on the Israel API business in the current period (refer to Item 1. Note 9).




42
Perrigo Company plc - Item 2
Other


Nine Month Comparison

cy17q210q_chart-38723a01.jpg
 


 
Nine Months Ended
($ in millions)
October 1,
2016
 
September 30,
2017
Net sales
$
59.5

 
$
51.5

Gross profit
$
26.8

 
$
27.8

Gross profit %
45.0
%
 
54.1
%
Operating income
$
2.6

 
$
9.4

Operating income %
4.4
%
 
18.2
%
Nine Months Ended September 30, 2017 vs. Nine Months Ended October 1, 2016

Net sales decreased $8.0 million due primarily to competition on certain products. Operating income increased $6.8 million due to a $1.0 million increase in gross profit driven by favorable product mix and a $5.8 million decrease in operating expenses. The decrease in operating expenses related primarily to the absence of a $10.8 million impairment charge recorded on the India API business in the prior year; offset partially by a $3.3 million impairment charge recorded on the Israel API business in the current period (refer to Item 1. Note 9).

Unallocated Expenses

Unallocated expenses are comprised of certain corporate services not allocated to our reporting segments and are recorded above Operating income on the Condensed Consolidated Statements of Operations. Unallocated expenses were as follows (in millions):
Three Months Ended
 
Nine Months Ended
October 1,
2016
 
September 30,
2017
 
October 1,
2016
 
September 30,
2017
$
27.7

 
$
48.2

 
$
79.1

 
$
120.8


Effective January 1, 2017, due to the sale of the Tysabri® financial asset, all legal expenses associated with the former Specialty Sciences segment were moved to unallocated expenses.

The increase of $20.5 million in unallocated expenses during the three months ended September 30, 2017 compared to the prior year period was due primarily to an increase in share-based compensation expense of $4.7 million driven primarily by the resignation of certain executives, which had a favorable impact on the prior year period, and an increase of $15.6 million of administrative expenses driven by consulting fees and employee-related expenses.

The increase of $41.7 million in unallocated expenses during the nine months ended September 30, 2017 compared to the prior year period was due to an increase of $26.9 million of administrative expenses driven by consulting fees and employee-related expenses, $8.8 million in share-based compensation driven primarily by the resignation of certain executives, which had a favorable impact on the prior year period, and $5.9 million of restructuring expenses related to our cost reduction initiatives.


43
Perrigo Company plc - Item 2
Unallocated, Interest, Other, and Taxes


Interest, Other and Change in financial assets (Consolidated)
 
Three Months Ended
 
Nine Months Ended
($ in millions)
October 1,
2016
 
September 30,
2017
 
October 1,
2016
 
September 30,
2017
Change in financial assets
$
377.4

 
$
2.6

 
$
1,492.6

 
$
24.2

Interest expense, net
$
54.6

 
$
34.7

 
$
163.2

 
$
133.1

Other (income) expense, net
$
1.0

 
$
(3.6
)
 
$
32.4

 
$
(1.1
)
Loss on extinguishment of debt
$
0.7

 
$
—

 
$
1.1

 
$
135.2


Change in Financial Assets

On December 18, 2013, we acquired Elan, which had a royalty agreement with Biogen Idec Inc. ("Biogen"), whereby Biogen conveyed the right to receive royalties that are typically payable on sales revenue generated by the sale, distribution or other use of the drug Tysabri®. Pursuant to the royalty agreement, we were entitled to royalty payments from Biogen based on its Tysabri® sales in all indications and geographies. We received royalties of 12% on worldwide Biogen sales of Tysabri® from December 18, 2013 through April 30, 2014. From May 1, 2014, we received royalties of 18% on annual worldwide Biogen sales of Tysabri® up to $2.0 billion and 25% on annual sales above $2.0 billion.

We accounted for the Tysabri® royalty stream as a financial asset and elected to use the fair value option model. We made the election to account for the Tysabri® financial asset using the fair value option as we believed this method was most appropriate for an asset that did not have a par value, a stated interest stream, or a termination date. The financial asset acquired represented a single unit of accounting. The fair value of the financial asset acquired was determined by using a discounted cash flow analysis related to the expected probability weighted future cash flows to be generated by the royalty stream. The financial asset was classified as a Level 3 asset within the fair value hierarchy, as our valuation utilized significant unobservable inputs, including industry analyst estimates for global Tysabri® sales, probability weighted as to the timing and amount of future cash flows along with certain discount rate assumptions. Cash flow forecasts included the estimated effect and timing of future competition, considering patents in effect for Tysabri® through 2024 and contractual rights to receive cash flows into perpetuity. The discounted cash flows were based upon the expected royalty stream forecasted into perpetuity using a 20-year discrete period with a declining rate terminal value.

In the first quarter of 2016, a competitor's pipeline product, Ocrevus®, received breakthrough therapy designation from the U.S. Food and Drug Administration ("FDA"). Breakthrough therapy designation is granted when a drug is intended alone or in combination with one or more other drugs to treat a serious or life threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. In June 2016, the FDA granted priority review with a target action date in December 2016. A priority review is a designation when the FDA will direct overall attention and resources to the evaluation of applications for drugs that, if approved, would be significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to standard applications. The product was approved late in the first quarter of 2017. The product is expected to compete with Tysabri®, and we expected it to have a significant negative impact on the Tysabri® royalty stream. Industry analysts believe that, based on released clinical study information, Ocrevus® will compete favorably against Tysabri® in the relapsing, remitting multiple sclerosis market segment due to its high efficacy and convenient dosage form.

Given the new market information for Ocrevus®, we used industry analyst estimates to reduce our first ten year growth forecasts from an average of growth of approximately 3.4% in the fourth calendar quarter of 2015 to an average decline of approximately minus 2.0% in the third and fourth calendar quarters of 2016. In November 2016, we announced we were evaluating strategic alternatives for the Tysabri® asset. As of December 31, 2016, the financial asset was adjusted based on the strategic review and sale process. These effects, combined with the change in discount rate each quarter, led to a reduction in fair value of $204.4 million, $910.8 million, $377.4 million and $1.1 billion in the first, second, third and fourth quarters of 2016, respectively.

On March 27, 2017, we announced the completed divestment of our Tysabri® financial asset to Royalty Pharma for up to $2.85 billion, which consists of $2.2 billion in cash and up to $250.0 million and $400.0 million in

44
Perrigo Company plc - Item 2
Unallocated, Interest, Other, and Taxes


milestone payments if the royalties on global net sales of Tysabri® that are received by Royalty Pharma meet specific thresholds in 2018 and 2020, respectively. As a result of this transaction, we transferred the entire financial asset to Royalty Pharma and recorded a $17.1 million gain during the three months ended July 1, 2017. We elected to account for the contingent milestone payments using the fair value option method, and these were recorded at an estimated fair value of $143.2 million as of September 30, 2017. We chose the fair value option as we believe it will help investors understand the potential future cash flows we may receive associated with the two contingent milestones.

We valued the contingent milestone payments using a modified Black-Scholes Option Pricing Model ("BSOPM"). Key inputs in the BSOPM are the estimated volatility and rate of return of royalties on global net sales of Tysabri® that are received by Royalty Pharma over time until payment of the contingent milestone payments is completed. Volatility and the estimated fair value of the milestones have a positive relationship such that higher volatility translates to a higher estimated fair value of the contingent milestone payments. In the valuation of contingent milestone payments performed, we assumed volatility of 30.0% and a rate of return of 8.05% as of July 1, 2017 and a volatility of 30.0% and a rate of return of 8.06% as of September 30, 2017. We assess volatility and rate of return inputs quarterly by analyzing certain market volatility benchmarks and the risk associated with Royalty Pharma achieving the underlying projected royalties. During the three and nine months ended September 30, 2017, the fair value of the Royalty Pharma contingent milestone payments decreased $2.9 million and $42.1 million, respectively, as a result of the decrease in the estimated projected Tysabri® revenues due to the launch of Ocrevus® late in the first quarter of 2017 (refer to Item 1. Note 6).

Interest Expense, Net

Interest expense, net was $34.7 million and $133.1 million during the three and nine months ended September 30, 2017, respectively, compared to $54.6 million and $163.2 million for the three and nine months ended October 1, 2016, respectively. The $19.9 million and $30.1 million decreases were the result of the early debt repayments made during the nine months ended September 30, 2017 (refer to the "Borrowings and Capital Resources" section below and Item 1. Note 10).

Other (Income) Expense, Net

Other (income) expense, net was $3.6 million income for the three months ended September 30, 2017, compared to $1.0 million expense for the three months ended October 1, 2016. The $4.6 million decrease in expense was due primarily to $2.6 million of favorable changes in revaluation of monetary assets and liabilities held in foreign currencies.

Other (income) expense, net was $1.1 million income during the nine months ended September 30, 2017, compared to $32.4 million expense for the nine months ended October 1, 2016. The $33.5 million decrease in expenses was due primarily to the absence of a $22.3 million equity investment impairment (refer to Item 1. Note 7), $6.7 million of favorable changes in revaluation of monetary assets and liabilities held in foreign currencies, and a $4.2 million reduction in equity method losses, partially offset by a $5.9 million loss related to the pre-issuance hedge reclassification (refer to Item 1. Note 8).

Loss on Extinguishment of Debt

During the nine months ended September 30, 2017, we recorded a $135.2 million loss on extinguishment of debt, which consisted of tender premium on debt repayments, transaction costs, write-off of deferred financing fees, and bond discounts related to the $500.0 million 3.500% senior notes due December 2021, $500.0 million 3.500% senior notes due March 2021, $400.0 million 4.900% senior notes due 2044, $800.0 million 4.000% senior notes due 2023, and $400.0 million 5.300% senior notes due 2043 (refer to Item 1. Note 10).


45
Perrigo Company plc - Item 2
Unallocated, Interest, Other, and Taxes


Income Taxes (Consolidated)

The effective tax rates were as follows:

Three Months Ended
 
Nine Months Ended
October 1,
2016
 
September 30,
2017
 
October 1,
2016
 
September 30,
2017
16.4
%
 
65.5
%
 
17.2
%
 
68.7
%

The effective tax rate for the nine months ended September 30, 2017 was negatively impacted by non-deductible fees related to our debt cancellation, discrete tax items, and additional valuation allowances recorded against deferred tax assets.

Our tax rate is subject to adjustment over the balance of the fiscal year due to, among other things: the jurisdictions in which our profits are determined to be earned and taxed; changes in the valuation of our deferred tax assets and liabilities; adjustments to estimated taxes upon finalization of various tax returns; adjustments based on differing interpretations of the applicable transfer pricing standards; changes in available tax credits, grants and other incentives; changes in stock-based compensation expense; changes in tax laws or the interpretation of such tax laws (for example, proposals for fundamental U.S. international tax reform); changes in U.S. GAAP; and expiration of or the inability to renew tax rulings or tax holiday incentives.

On August 15, 2017, we filed a complaint in the United States District Court for the Western District of Michigan to recover $163.6 million of Federal income tax, penalties, and interest assessed and collected by the Internal Revenue Service (“IRS”), plus statutory interest thereon from the dates of payment, for the fiscal years ended June 27, 2009, June 26, 2010, June 25, 2011, and June 30, 2012 (the “2009 tax year,” “2010 tax year,” “2011 tax year,” and “2012 tax year,” respectively). The IRS audits of those years culminated in the issuances of two statutory notices of deficiency: (1) on August 27, 2014 for the 2009 and 2010 tax years and (2) on April 20, 2017 for the 2011 and 2012 tax years. The statutory notices of deficiency both included un-agreed income adjustments related principally to transfer pricing adjustments regarding the purchase, distribution, and sale of store-brand OTC pharmaceutical products in the United States. In addition, the statutory notice of deficiency for the 2011 and 2012 tax years included the capitalization of certain expenses that were deducted when paid or incurred in defending against certain patent infringement lawsuits. We fully paid the assessed amounts of tax, interest, and penalties set forth in the statutory notices and filed timely claims for refund on June 11, 2015 and June 7, 2017 for the 2009-2010 tax years and 2011-2012 tax years, respectively. Our claims for refund were disallowed by certified letters dated August 18, 2015 and July 11, 2017, for the 2009-2010 tax years and 2011-2012 tax years, respectively. The complaint was timely, based upon the refund claim denials, and seeks refunds of tax, interest, and penalties of $37.2 million for the 2009 tax year, $61.5 million for the 2010 tax year, $40.2 million for the 2011 tax year, and $24.7 million for the 2012 tax year. The amounts sought in the complaint for the 2009 and 2010 tax years were recorded as deferred charges on our balance sheet during the three months ended March 28, 2015, and the amounts sought in the complaint for the 2011 and 2012 tax years were recorded as deferred charges on our balance sheet during the three months ended July 1, 2017.

On December 22, 2016, we received a notice of proposed adjustment for the IRS audit of Athena Neurosciences, Inc. (“Athena”), a subsidiary of Elan acquired in 1996, for the years ended December 31, 2011, December 31, 2012, and December 31, 2013. Perrigo acquired Elan in December 2013. This proposed adjustment relates to the deductibility of litigation costs.

On July 11, 2017, we received a draft notice of proposed adjustment associated with transfer pricing positions for the IRS audit of Athena for the years ended December 31, 2011, December 31, 2012, and December 31, 2013.  Athena was the originator of the patents associated with Tysabri® prior to the acquisition of Athena by Elan in 1996. The amount of adjustments that may be asserted by the IRS in the final notice of proposed adjustment cannot be quantified at this time; however, based on the draft notice received, the amount to be assessed may be material. We disagree with the IRS’s position as asserted in the draft notice of proposed adjustment and intend to contest it.



46
Perrigo Company plc - Item 2
Unallocated, Interest, Other, and Taxes


We have ongoing audits in multiple other jurisdictions the resolution of which remains uncertain. These jurisdictions include, but are not limited to, the United States, Israel and France. In addition to the matters discussed above, the IRS is currently auditing our fiscal years ended June 29, 2013, June 28, 2014, and June 27, 2015. The Israel Tax Authority is currently auditing our fiscal years ended June 29, 2013 and June 28, 2014. The French Tax Authority is currently auditing the years ended December 2014, December 2015, and December 2016.


FINANCIAL CONDITION, LIQUIDITY, AND CAPITAL RESOURCES

Cash and Cash Equivalents

cy17q110q_chart-47174a02.jpg
*    Working capital represents current assets less current liabilities, excluding cash and cash equivalents, and current indebtedness.

Cash, cash equivalents, cash flows from operations, and borrowings available under our credit facilities are expected to be sufficient to finance the known and/or foreseeable liquidity and capital expenditures. Although our lenders have made commitments to make funds available to us in a timely fashion under our revolving credit agreements and overdraft facilities, if economic conditions worsen or new information becomes publicly available impacting the institutions’ credit rating or capital ratios, these lenders may be unable or unwilling to lend money pursuant to our existing credit facilities.


47
Perrigo Company plc - Item 2
Financial Condition, Liquidity and Capital Resources


Operating Activities
 
Nine Months Ended
(in millions)
October 1,
2016
 
September 30,
2017
 
Increase/(Decrease)
Cash Flows From (For) Operating Activities
 
 
 
 
 
Net income (loss)
$
(2,653.7
)
 
$
46.4

 
$
2,700.1

Non-cash adjustments
3,229.9

 
560.8

 
(2,669.1
)
Subtotal
576.2

 
607.2

 
31.0

 
 
 
 
 
 
Increase (decrease) in cash due to:
 
 
 
 
 
Accounts receivable
113.0

 
38.4

 
(74.6
)
Inventories
25.1

 
(28.3
)
 
(53.4
)
Accounts payable
(57.7
)
 
(6.0
)
 
51.7

Payroll and related taxes
(40.0
)
 
(36.7
)
 
3.3

Accrued customer programs
(73.7
)
 
(15.8
)
 
57.9

Accrued liabilities
(90.0
)
 
(18.8
)
 
71.2

Accrued income taxes
5.2

 
(61.5
)
 
(66.7
)
Other, net
(9.4
)
 
3.5

 
12.9

Subtotal
$
(127.5
)
 
$
(125.2
)
 
$
2.3

 
 
 
 
 
 
Net cash from operating activities
$
448.7

 
$
482.0


$
33.3


We generated $482.0 million of cash from operating activities during the nine months ended September 30, 2017, a $33.3 million increase over the prior year period, due to the following:

•
Increased net earnings after adjustments for items such as deferred income taxes, impairment charges, restructuring charges, changes in our financial assets, loss on extinguishment of debt, and depreciation and amortization;

•
Changes in accrued liabilities due to deferred revenue associated with BCH-Belgium distribution contracts and the absence of accruals related to the sale of our U.S. VMS business;

•
Changes in accrued customer-related programs due primarily to the pricing dynamics in the RX segment; and

•
Changes in accounts payable due primarily to changes to the Omega accounts payable structure that occurred in the prior year period; offset primarily by

•
Changes in accounts receivable due primarily to timing of receipt of payments and the absence of receivables related to the sale of our U.S. VMS business;

•
Changes in inventory due to the build up of inventory levels to support customer demands in the current period; offset by improved inventory management in the comparable prior year period; and

•
Changes in accrued income taxes due primarily to a U.S. Federal tax obligation payment made in the current year period, offset by expected tax refunds (refer to Item 1. Note 13).


48
Perrigo Company plc - Item 2
Financial Condition, Liquidity and Capital Resources


Investing Activities
 
Nine Months Ended
($ in millions)
October 1,
2016
 
September 30,
2017
 
Increase/(Decrease)
Cash Flows From (For) Investing Activities
Proceeds from royalty rights
$
259.5

 
$
86.4

 
$
(173.1
)
Acquisitions of businesses, net of cash acquired
(436.8
)
 
—

 
436.8

Asset acquisitions
(65.1
)
 
—

 
65.1

Additions to property, plant and equipment
(84.6
)
 
(55.2
)
 
29.4

Net proceeds from sale of business and other assets
58.5

 
46.7

 
(11.8
)
Proceeds from sale of the Tysabri® financial asset
—

 
2,200.0

 
2,200.0

Other investing, net
(1.0
)
 
(5.8
)
 
(4.8
)
Net cash from (for) investing activities
$
(269.5
)
 
$
2,272.1

 
$
2,541.6


Cash generated from investing activities totaled $2.3 billion for the nine months ended September 30, 2017, compared to cash used of $269.5 million in the prior year period. The inflow in the current year was due primarily to the completed divestment of our Tysabri® financial asset to Royalty Pharma, for which we received $2.2 billion in cash at closing (refer to Item 1. Note 6). The outflow in the prior year was due primarily to the acquisition of a portfolio of generic dosage forms and strengths of Retin-A® ("Tretinoin"), a topical prescription acne treatment from Mattawan Pharmaceuticals, LLC, which used $416.4 million in cash. The prior year outflow was offset partially by proceeds from royalty rights of $259.5 million. Cash used for capital expenditures totaled $55.2 million during the nine months ended September 30, 2017 compared to $84.6 million in the prior year period. The decrease in cash used for capital expenditures was due primarily to the decrease in the number of projects in the current year compared to the prior year period.

Financing Activities
 
Nine Months Ended
($ in millions)
October 1,
2016
 
September 30,
2017
 
Increase/(Decrease)
Cash Flows From (For) Financing Activities
Issuances of long-term debt
$
1,190.3

 
$
—

 
$
(1,190.3
)
Borrowings (repayments) of revolving credit agreements and other financing, net
(803.6
)
 
—

 
803.6

Payments on long-term debt
(545.8
)
 
(2,243.7
)
 
(1,697.9
)
Deferred financing fees
(2.8
)
 
(4.2
)
 
(1.4
)
Premium on early debt retirement
(0.6
)
 
(116.1
)
 
(115.5
)
Issuance of ordinary shares
8.2

 
0.5

 
(7.7
)
Repurchase of ordinary shares
—

 
(191.5
)
 
(191.5
)
Cash dividends
(62.4
)
 
(68.7
)
 
(6.3
)
Other financing
(17.4
)
 
2.7

 
20.1

Net cash (for) financing activities
$
(234.1
)
 
$
(2,621.0
)
 
$
(2,386.9
)

Cash used for financing activities totaled $2.6 billion for the nine months ended September 30, 2017, compared to $234.1 million for the comparable prior year period. In the current year period, cash used for financing included $2.2 billion of repayments on long-term debt and $116.1 million of discounts on early debt retirement related to the current year debt extinguishment and $191.5 million in share repurchases, as discussed below. In the prior year period, the cash used for financing activities was due primarily to borrowings of $1.2 billion of long-term debt, more than offset by net repayments on our revolving credit agreements and other short-term financing of $803.6 million and net repayments on our long-term debt of $545.8 million (refer to "Borrowings and Capital Resources" below and Item 1. Note 10).


49
Perrigo Company plc - Item 2
Financial Condition, Liquidity and Capital Resources


The declaration and payment of dividends, if any, is subject to the discretion of our Board of Directors and will depend on our earnings, financial condition, availability of distributable reserves, capital and surplus requirements, and other factors our Board of Directors may consider relevant.

On October 22, 2015, the Board of Directors approved a share repurchase plan of up to $2.0 billion (the "2015 Authorization"). During the three and nine months ended September 30, 2017, we repurchased 1.9 million and 2.7 million ordinary shares at an average repurchase price of $71.73 and $71.72 per share, for a total of $133.3 million and $191.5 million, respectively. As of September 30, 2017, there was $1.3 billion still available to be repurchased through December 31, 2018 under the 2015 Authorization. We did not repurchase any shares under the share repurchase plan during the nine months ended October 1, 2016.

Borrowings and Capital Resources

cy17q110q_chart-47327a02.jpg

Overdraft Facilities

We have overdraft facilities available that we use to support our cash management operations. There were no balances outstanding under the facilities at September 30, 2017 and December 31, 2016.

Accounts Receivable Factoring

We have multiple accounts receivable factoring arrangements with non-related third-party financial institutions (the “Factors”). Pursuant to the terms of the arrangements, we sell to the Factors certain of our accounts receivable balances on a non-recourse basis for credit approved accounts. An administrative fee ranging from 0.14% to 0.15% per invoice is charged on the gross amount of accounts receivables assigned to the Factors, and interest is calculated at the applicable EUR LIBOR rate plus 70 basis points. The total amount factored on a non-recourse basis and excluded from accounts receivable was $24.3 million and $50.7 million at September 30, 2017 and December 31, 2016, respectively.

Revolving Credit Agreements

On December 9, 2015, our 100% owned finance subsidiary, Perrigo Finance Unlimited Company (formerly Perrigo Finance plc) ("Perrigo Finance"), entered into a $750.0 million revolving credit agreement (the "2015 Revolver"). On March 15, 2016, we used the proceeds of the long-term debt issuance described below to repay the $750.0 million then outstanding under the 2015 Revolver and terminated the facility.

On December 5, 2014, Perrigo Finance entered into a $600.0 million revolving credit agreement, which increased to $1.0 billion on March 30, 2015 (the "2014 Revolver"). On March 15, 2016, we used the proceeds of the long-term debt issuance described below to repay the $435.0 million then outstanding under the 2014 Revolver. There were no borrowings outstanding under the 2014 Revolver as of September 30, 2017.

50
Perrigo Company plc - Item 2
Financial Condition, Liquidity and Capital Resources



Term Loans and Notes

On March 7, 2016, Perrigo Finance issued $500.0 million in aggregate principal amount of 3.500% senior notes due 2021 and $700.0 million in aggregate principal amount of 4.375% senior notes due 2026 (together, the "2016 Notes") and received net proceeds of $1.2 billion after fees and market discount, which were used to repay the amounts outstanding under the 2015 Revolver and 2014 Revolver mentioned above.

We had $3.3 billion and $5.4 billion outstanding under our notes and bonds, and $428.3 million and $420.7 million outstanding under our term loan, as of September 30, 2017 and December 31, 2016, respectively. On September 29, 2016, we repaid the 1.300% senior notes due 2016 in full.

On December 5, 2014, Perrigo Finance entered into a term loan agreement consisting of a €500.0 million ($614.3 million) tranche, with the ability to draw an additional €300.0 million ($368.6 million) tranche, maturing December 5, 2019, and we entered into a $300.0 million term loan tranche maturing December 18, 2015, which we repaid in full on June 25, 2015.

Debt Repayments

During the nine months ended September 30, 2017, we reduced our outstanding debt through a variety of transactions (in millions):
Date
 
Series
 
Transaction Type
 
Principal Retired
April 1, 2017
 
2014 term loan due December 5, 2019
 
Scheduled quarterly payment
 
$
13.3

July 1, 2017
 
2014 term loan due December 5, 2019
 
Scheduled quarterly payment
 
14.3

September 30, 2017
 
2014 term loan due December 5, 2019
 
Scheduled quarterly payment
 
14.8

May 8, 2017
 
$600.0 2.300% senior notes due 2018
 
Early redemption
 
600.0

May 23, 2017
 
€180.0 4.500% retail bonds due 2017
 
Scheduled maturity
 
201.3

June 15, 2017
 
$500.0 3.500% senior notes due 2021
 
Tender offer
 
190.4

June 15, 2017
 
$500.0 3.500% senior notes due 2021
 
Tender offer
 
219.6

June 15, 2017
 
$800.0 4.000% senior notes due 2023
 
Tender offer
 
584.4

June 15, 2017
 
$400.0 5.300% senior notes due 2043
 
Tender offer
 
309.5

June 15, 2017
 
$400.0 4.900% senior notes due 2044
 
Tender offer
 
96.1

 
 
 
 
 
 
$
2,243.7


As previously disclosed, during the three months ended April 1, 2017 we entered into amendments to the 2014 Revolver and the 2014 term loan to modify provisions of such agreements necessary as a result of the correction in accounting related to the Tysabri® financial asset, as well as waivers of any default or event of default that may have arisen from any restatement of or deficiencies in our financial statements for the periods specified in such amendments and waivers. We are in compliance with all covenants under our debt agreements as of September 30, 2017.
 
See Item 1. Note 10 for more information on all of the above debt facilities.

Credit Ratings
    
Our credit ratings on September 30, 2017 were Baa3 (stable) and BBB- (stable) by Moody's Investors Service and Standard and Poor's Global Ratings, respectively.
 
Credit rating agencies review their ratings periodically and, therefore, the credit rating assigned to us by each agency may be subject to revision at any time. Accordingly, we are not able to predict whether current credit ratings will remain as disclosed above. Factors that can affect our credit ratings include changes in operating performance, the economic environment, our financial position, and changes in business strategy. If changes in our credit ratings were to occur, they could impact, among other things, future borrowing costs, access to capital markets, and vendor financing terms.

51
Perrigo Company plc - Item 2
Financial Condition, Liquidity and Capital Resources




Contractual Obligations and Commitments

Other than the obligations related to the changes to our debt structure in relation to the repayments, as discussed in Item 1. Note 10, there were no material changes in contractual obligations as of September 30, 2017 from those provided in our 2016 Form 10-K. See below for a revised schedule of our enforceable and legally binding obligations as of September 30, 2017 related to our short and long-term debt arrangements.
 
Payment Due by Period (in millions)
 
2017(1)
 
2018 - 2019
 
2020 - 2021
 
After 2021
 
Total
Short and long-term debt(2)
$
406.5

 
$
811.5

 
$
812.5

 
$
2,859.6

 
$
4,890.1


(1)     Reflects remaining three months of 2017.
(2) 
Short and long-term debt includes interest payments, which were calculated using the effective interest rate at September 30, 2017.

ITEM 3.        QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

There have been no material changes to our quantitative or qualitative disclosures found in Item 7A, "Quantitative and Qualitative Disclosures about Market Risk," of our Annual Report on Form 10-K for the year ended December 31, 2016.

ITEM 4.        CONTROLS AND PROCEDURES

Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) or 15d-15(e) of the Exchange Act) as of September 30, 2017. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were not effective as of September 30, 2017 because of the material weaknesses in our internal control over financial reporting described below.

All systems of internal control, no matter how well designed, have inherent limitations. Therefore, even those systems deemed to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a company’s annual or interim consolidated financial statements will not be prevented or detected on a timely basis.

Evaluation of the Effectiveness of Internal Control over Financial Reporting

We conducted an evaluation of the effectiveness of our internal control over financial reporting based upon the framework established in the 2013 Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”).


52
Perrigo Company plc - Item 4
Controls and Procedures


Tysabri® Contingent Payments

We acquired the Tysabri® royalty stream in our acquisition of Elan Pharmaceuticals plc (“Elan”) in December 2013, and at the time of the acquisition, concluded that the right to receive quarterly royalty payments from Biogen Idec Inc. should be an intangible asset and such payments recognized as revenue in our financial statements. As discussed in Item 4.02 of our Form 8-K filed on April 25, 2017, during the 2016 year-end close process, and in anticipation of our potential sale of the Tysabri® royalty rights and the 2018 adoption of ASC 606 Revenue from Contracts with Customers, we re-evaluated the historical classification of the Tysabri® royalty stream as an intangible asset and concluded that it should have been reflected in the financial statements as a financial asset as of its 2013 acquisition date. As part of this evaluation, management determined that its control over the review of the application of the accounting guidance in ASC 805 Business Combinations did not operate effectively in the appropriate identification of the assets acquired and liabilities assumed in connection with the Elan acquisition in December 2013. All of our originally filed financial statements through the filing of the Form 10-Q for the quarter ended October 1, 2016, as originally filed on November 10, 2016, included the disclosure of the Elan acquisition with the Tysabri® royalty stream presented as an intangible asset. In addition, due to the fact that the asset was historically classified as an intangible asset, we did not design or implement controls around the fair value accounting for the Tysabri® royalty stream as a financial asset, so these controls were not in place at any quarter end subsequent to the acquisition, including the date of the quarterly and annual assessment of internal control. Accordingly, management concluded that these control deficiencies represent material weaknesses. As discussed in our Form 10-Q for the quarter ended July 1, 2017, the material weakness related to the fair value accounting for the Tysabri® royalty stream as a financial asset was remediated during that period. See below for our discussion of the remediation efforts related to our acquisition of the Tysabri® royalty rights.

Income Taxes

Management has determined that we did not design or maintain effective management review controls related to our (1) evaluation of non-routine transactions that impact our effective tax rate on an annual and interim basis and (2) determination of our deferred taxes in connection with business combinations.

During our quarterly and annual fiscal 2016 close processes, management determined that the design and operating effectiveness of our controls around the evaluation of non-routine events did not operate appropriately. As disclosed in our Form 10-Q for the quarterly period ended April 2, 2016, our management review controls did not operate at a sufficient level of precision to ensure interim income taxes were properly recorded and disclosed in our condensed consolidated financial statements in connection with the recording of an indefinite-lived intangible asset impairment and estimated goodwill impairment as part of the Company’s controls to evaluate non-routine events that occur during a quarterly period and the related income tax impacts. These control deficiencies resulted in a material misstatement in income taxes in the preliminary financial statements for the quarter ended April 2, 2016. Additionally, these controls remained unremediated as of September 30, 2017, as they were in February 2017 when we identified that these controls did not appropriately evaluate the need for a valuation allowance. ASC 740, Income Taxes, requires a company to record a valuation allowance to reduce a deferred tax asset to its net realizable value. Our controls related to consideration of non-routine transactions or events were not designed and did not operate appropriately and identify whether a valuation allowance was needed as they did not identify that we entered into a three year cumulative loss and did not consider the positive and negative evidence in evaluating the potential sources of taxable income in determining whether a valuation allowance was required in the consolidated financial statements.

In February 2017, management identified the existence of tax basis in certain acquired intangible assets (“tax amortization benefits”) that existed at the time of the acquisition of Omega Pharma Invest N.V. (“Omega”) on March 30, 2015. Upon evaluating the tax amortization benefits, management concluded that the purchase accounting for Omega should have included the tax basis in the intangible assets in calculating the deferred tax liability in the opening balance sheet. This omission of existing tax basis in calculating the deferred tax liability on the acquisition date indicated that management’s review over the opening balance sheet deferred income tax accounts was not designed or operating appropriately.

Accordingly, management concluded that these control deficiencies represent material weaknesses.


53
Perrigo Company plc - Item 4
Controls and Procedures


Impairment

In connection with our long-lived asset impairment testing, management determined that the controls around the identification of the relevant asset group under ASC 360, Impairment and Disposal of Long-lived Assets, did not operate effectively. In determining the level to evaluate the long-lived assets in our animal health reporting unit for impairment testing, we inappropriately grouped the assets that constituted the asset group in applying the guidance in ASC 360.

Accordingly, management concluded that this control deficiency represented a material weakness.

Remediation Plan for the Material Weaknesses

We are committed to remediating the control deficiencies that gave rise to the material weaknesses described above. Management is responsible for implementing changes and improvements to internal control over financial reporting and for remediating the control deficiencies that gave rise to the material weaknesses.

Tysabri® Contingent Payments

To remediate the material weakness related to the acquisition of the Tysabri® royalty rights, we, with oversight from the Audit committee, designed certain controls around the identification of assets acquired and liabilities assumed in our business combination process. As part of the re-design of the controls, we: (1) considered our controls around the review of the related contracts and agreements and our application of ASC 805 to identify the type of assets acquired and liabilities assumed and (2) evaluated and enhanced management review controls related to business acquisitions. Based on the evaluation of the design and changes to our business acquisition process performed during the second and third quarters of 2017 on these newly implemented controls, we have concluded that these controls have been designed and implemented appropriately. As a result, we consider this material weakness to be remediated as of September 30, 2017.

Income Taxes

To remediate the material weaknesses in internal control over financial reporting related to income taxes, we have, with oversight from the Audit Committee, completed the review of the organizational structure, resources, processes and controls in place to measure and record income taxes to enhance the effectiveness of the design and operation of those controls. In addition, we continue to:

•
Evaluate the design and operating effectiveness of our controls related to income taxes for business acquisitions and non-routine transactions on an interim and annual basis;
•
Enhance monitoring activities related to income taxes; and
•
Evaluate and enhance the level of precision in the management review controls related to income taxes.

We have begun to implement the remediation actions and expect to complete the implementation as part of our 2017 fiscal year closing process. Until the remediation actions are fully implemented and the operational effectiveness of related internal controls is validated through testing, the material weaknesses related to income taxes described above will continue to exist.

Impairment

We, with oversight from the Audit Committee, designed and initiated certain controls around the financial reporting related to the identification of asset groups as part of our impairment testing. Controls we implemented include: (1) reviewing the design and operation of our controls related to asset group determination in our impairment process on an interim and annual basis and (2) evaluating and enhancing the management review controls related to impairment. Based on the testing performed during the second and third quarters of 2017 on these newly implemented controls around the identification of asset groups as part of our impairment testing, we have concluded that these controls have been designed appropriately and are operating effectively. As a result, we consider this material weakness to be remediated as of September 30, 2017.


54
Perrigo Company plc - Item 4
Controls and Procedures


We are committed to achieving and maintaining a strong internal control environment and believe the remediation measures will strengthen our internal control over financial reporting and remediate the material weaknesses identified. We continue to review the remaining un-remediated material weaknesses and intend to add resources and improve our processes to achieve and maintain a strong control environment. We will continue to monitor the effectiveness of our remediation measures and will make any changes and take such other actions that we deem appropriate given the circumstances.

Changes in Internal Control over Financial Reporting

Other than as described above under "Remediation Plan for Material Weaknesses," there have been no changes in our internal control over financial reporting during the three months ended September 30, 2017 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II.     OTHER INFORMATION

ITEM 1.    LEGAL PROCEEDINGS

Refer to Part I, Item 1. Note 14 of the Notes to the Condensed Consolidated Financial Statements.

ITEM 1A.    RISK FACTORS

Our Annual Report on Form 10-K for the year ended December 31, 2016 includes a detailed discussion of our risk factors. At the time of this filing, there have been no material changes to the risk factors that were included in the Form 10-K, other than described below.

We identified material weaknesses in our internal controls over financial reporting; failure to remediate the material weaknesses could negatively impact our business and the price of our ordinary shares.

In connection with our review of certain material misstatements related to the characterization of the Tysabri® royalty stream acquired in the Elan transaction, as well as material misstatements related to the calculation of deferred tax liabilities that existed at the time of the acquisition of Omega, and the evaluation of long-lived assets in our animal health reporting unit for impairment testing, in each case contained in certain of our historical financial statements, we concluded that there were material weaknesses in our internal control over financial reporting that contributed to those misstatements. As a result of the material weaknesses, which existed at December 31, 2016 and some of which remained at September 30, 2017, we have concluded that we did not maintain, in all material respects, effective internal control over financial reporting as of December 31, 2016, April 1, 2017, July 1, 2017 or September 30, 2017, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). The failure to maintain effective control over financial reporting in turn resulted in material deficiencies in our disclosure controls and procedures.

We have identified and begun the implementation of actions, and continue to identify and implement, actions to improve the effectiveness of our internal control over financial reporting and disclosure controls and procedures, but there can be no assurance that such remediation efforts will be successful. We have also incurred and will continue to incur substantial accounting, legal, consulting, and other costs in connection with identifying and remediating the material weaknesses. Failure to remediate the material weaknesses could have a negative impact on our business and the market for our ordinary shares. For more information on our material weaknesses and the status of our remediation efforts, See Part I, Item 4 - Controls and Procedures.

We are currently involved in a search for a new Chief Executive Officer and a subsequent search for a permanent Chief Financial Officer. If these searches are delayed, our business could be negatively impacted.

On June 5, 2017, we announced the forthcoming retirement of John T. Hendrickson as our Chief Executive Officer. Mr. Hendrickson will continue to serve as our Chief Executive Officer and a member of our Board until such time as a successor has been appointed. Our Board of Directors has initiated a Chief Executive Officer search process and has retained an executive search and leadership advisory firm to assist with the process of identifying and evaluating candidates.

55
Perrigo Company plc - Item 1A
Risk Factors





In addition, on February 21, 2017, we announced the resignation of Judy L. Brown as our Executive Vice President, Business Operations and Chief Financial Officer, effective February 27, 2017. Since that time, Ronald L. Winowiecki has served as our acting Chief Financial Officer. Although Mr. Winowiecki remains a key candidate for our permanent Chief Financial Officer, our Board of Directors has suspended its Chief Financial Officer search during its search for Mr. Hendrickson’s successor as Chief Executive Officer. There are no assurances concerning the timing or outcome of our search for a new Chief Executive Officer or subsequent search for a permanent Chief Financial Officer. If there are any delays in this process, or if any transition is not successful, our business could be negatively impacted.

The resolution of uncertain tax positions could be unfavorable, which could have an adverse effect on our business.

Although we believe that our tax estimates are reasonable and that our tax filings are prepared in accordance with all applicable tax laws, the final determination with respect to any tax audit and any related litigation could be materially different from our estimates or from our historical income tax provisions and accruals. The results of an audit or litigation could have a material effect on operating results or cash flows in the periods for which that determination is made. In addition, future period earnings may be adversely impacted by litigation costs, settlements, penalties or interest assessments.

•
On August 15, 2017, we filed a complaint in the United States District Court for the Western District of Michigan to recover $163.6 million of Federal income tax, penalties, and interest assessed and collected by the Internal Revenue Service (“IRS”), plus statutory interest thereon from the dates of payment, for the fiscal years ended June 27, 2009, June 26, 2010, June 25, 2011, and June 30, 2012 (the “2009 tax year,” “2010 tax year,” “2011 tax year,” and “2012 tax year,” respectively). The IRS audits of those years culminated in the issuances of two statutory notices of deficiency: (1) on August 27, 2014 for the 2009 and 2010 tax years and (2) on April 20, 2017 for the 2011 and 2012 tax years. The statutory notices of deficiency both included un-agreed income adjustments related principally to transfer pricing adjustments regarding the purchase, distribution, and sale of store-brand OTC pharmaceutical products in the United States. In addition, the statutory notice of deficiency for the 2011 and 2012 tax years included the capitalization of certain expenses that were deducted when paid or incurred in defending against certain patent infringement lawsuits. We fully paid the assessed amounts of tax, interest, and penalties set forth in the statutory notices and filed timely claims for refund on June 11, 2015 and June 7, 2017 for the 2009-2010 tax years and 2011-2012 tax years, respectively. Our claims for refund were disallowed by certified letters dated August 18, 2015 and July 11, 2017, for the 2009-2010 tax years and 2011-2012 tax years, respectively. The complaint was timely, based upon the refund claim denials, and seeks refunds of tax, interest, and penalties of $37.2 million for the 2009 tax year, $61.5 million for the 2010 tax year, $40.2 million for the 2011 tax year and $24.7 million for the 2012 tax year. The amounts sought in the complaint for the 2009 and 2010 tax years were recorded as deferred charges on our balance sheet during the three months ended March 28, 2015, and the amounts sought in the complaint for the 2011 and 2012 tax years were recorded as deferred charges on our balance sheet in the second quarter of the year ending December 31, 2017.

•
On December 22, 2016, we received a notice of proposed adjustment for the IRS audit of Athena Neurosciences, Inc. (“Athena”), a subsidiary of Elan Corporation plc (“Elan”) acquired in 1996, for the years ended December 31, 2011, December 31, 2012 and December 31, 2013. We acquired Elan in December 2013. This proposed amendment relates to the deductibility of litigation costs. We disagree with the IRS’s position asserted in the notice of proposed adjustment and intend to contest it.

On July 11, 2017, we received a draft notice of proposed adjustment associated with transfer pricing positions for the IRS audit of Athena for the years ended December 31, 2011, December 31, 2012 and December 31, 2013. Athena was the originator of the patents associated with Tysabri® prior to the acquisition of Athena by Elan in 1996. The amount of adjustments that may be asserted by the IRS in the final notice of proposed adjustment cannot be quantified at this time; however, based on the draft notice received, the amount to be assessed may be material. We disagree with the IRS’s position as asserted in the draft notice of proposed adjustment and intend to contest it.


56
Perrigo Company plc - Item 1A
Risk Factors




There are numerous other income tax jurisdictions for which tax returns are not yet settled, none of which are individually significant. At this time, we cannot predict the outcome of any audit or related litigation. Unfavorable resolutions of the audit matters discussed above could have a material impact on our consolidated financial statements in future periods.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Share repurchase activity during the three months ended September 30, 2017 was as follows:

 
Total Number of Shares Purchased
 
Average Price Paid per Share
 
Total Number of Shares Purchased as Part of Publicly Announced Plans
 
Value of Shares Available for Purchase(1)
July 2 - July 31, 2017
484,860

 
$
72.27

 
484,860

 
 
August 1 - August 31, 2017
1,354,721

 
$
71.46

 
1,354,721

 
 
September 1 - September 30, 2017
19,124

 
$
77.50

 
19,124

 
 
Total
1,858,705

 
 
 
 
 
$
1.30
 billion

(1) The remaining $1.30 billion in the table represents the amount available to be repurchased under our 2015 Authorization as of September 30, 2017.

ITEM 5. OTHER INFORMATION
Our Board of Directors has established May 4, 2018 as the date of our 2018 Annual General Meeting of Shareholders (the “2018 Annual Meeting”). Because the date of the 2018 Annual Meeting will be more than 30 days before the anniversary of our 2017 Annual General Meeting of Shareholders, we are informing shareholders of the change in accordance with Rule 14a-5(f) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

For shareholders who wish to present a proposal to be considered for inclusion in our proxy materials for the 2018 Annual Meeting, we have set a new deadline for the receipt of those proposals in accordance with Rule 14a-8 under the Exchange Act. To be considered timely, shareholders must submit their proposals, in writing, to our Company Secretary at our principal executive offices located at Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland by December 19, 2017, which we have determined to be a reasonable time before we expect to begin to print and mail our proxy materials. Shareholder proposals must also comply with all applicable requirements of Rule 14a-8.

Because the 2018 Annual Meeting will be more than 30 days before the anniversary of the 2017 Annual General Meeting of Shareholders, our Articles of Association (the “Articles”) provide that shareholders who wish to bring a proposal or nominate a director at the 2018 Annual Meeting, but who are not requesting that the proposal or nomination be included in our proxy materials, must notify our Company Secretary, in writing, not earlier than the close of business on February 3, 2018 and not later than the close of business on February 23, 2018. Shareholders are advised to review the Articles, which contain additional requirements about advance notice of shareholder proposals and director nominations.


57
Perrigo Company plc - Part II - Item 6
Exhibits


ITEM 6.    EXHIBITS

Exhibit
Number
 
Description
 
 
 
3.1
 
 
 
 
3.2
 
 
 
 
10.1
 
 
 
 
10.2
 
 
 
 
10.3
 
 
 
 
10.4
 
 
 
 
10.5
 
 
 
 
31.1
 
 
 
 
31.2
 
 
 
 
32
 
 
 
 
101.INS
 
XBRL Instance Document.
 
 
 
101.SCH
 
XBRL Taxonomy Extension Schema Document.
 
 
 
101.CAL
 
XBRL Taxonomy Extension Calculation Linkbase Document.
 
 
 
101.DEF
 
XBRL Taxonomy Extension Definition Linkbase Document.
 
 
 
101.LAB
 
XBRL Taxonomy Extension Label Linkbase Document.
 
 
 
101.PRE
 
XBRL Taxonomy Extension Presentation Linkbase Document.

58

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
 
 
PERRIGO COMPANY PLC
 
 
 
(Registrant)
 
 
 
 
Date:
November 9, 2017
 
By: /s/ John T. Hendrickson
 
 
 
John T. Hendrickson
 
 
 
Chief Executive Officer
 
 
 
(Principal Executive Officer)
 
 
 
 
Date:
November 9, 2017
 
By: /s/ Ronald L. Winowiecki
 
 
 
Ronald L. Winowiecki
 
 
 
Acting Chief Financial Officer
 
 
 
(Principal Accounting and Financial Officer)


59
 EX-10.2 2 cy17q310qex102.htm EXHIBIT 10.2 Exhibit
Exhibit 10.2

AMENDMENT NO. 3
TO THE
PERRIGO COMPANY
2013 LONG-TERM INCENTIVE PLAN
WHEREAS, Perrigo Company plc (the “Company”) sponsors the Perrigo Company 2013 Long-Term Incentive Plan (the “Plan”);
WHEREAS, the Company desires to amend the Plan to impose a one-year minimum vesting period on awards granted under the Plan.
NOW, THEREFORE, by virtue and in exercise of the amending authority reserved by the Plan sponsor pursuant to Section 15(a) of the Plan, effective as of the date hereof, the Plan is amended by adding the following subsection to the end of Section 3 (“Administration”):
(c)    MINIMUM VESTING REQUIREMENTS. No Award granted under the Plan on or after November 3, 2017 may vest, in whole or in part, prior to the one-year anniversary of the date of grant of the Award. Notwithstanding the foregoing, a Participant’s Award Agreement may provide for accelerated vesting if the Participant’s Termination Date occurs due to the Participant’s death, Disability or Retirement, upon a Change in Control, or upon the Participant’s termination without Cause or separation for good reason within a specified period following a Change in Control. The forgoing one-year minimum vesting period shall not apply to any Award granted in substitution for an Award pursuant to Section 4(e) that does not reduce the vesting period of the Award being substituted.
*    *    *
IN WITNESS WHEREOF, Perrigo Company plc has caused this Amendment No. 3 to be executed by its duly authorized officer this 3rd day of November, 2017.

PERRIGO COMPANY PLC
 
 
By:
/s/ Ronald L. Winowiecki
 
 
Title:
SVP, Acting CFO
 
 



 EX-10.3 3 cy17q310qex103.htm EXHIBIT 10.3 Exhibit
Exhibit 10.3

PERRIGO COMPANY PLC
RESTRICTED STOCK UNIT AWARD AGREEMENT FOR NON-U.S. PARTICIPANTS
(SERVICE-BASED)
(Under the Perrigo Company plc 2013 Long-Term Incentive Plan)
TO:        Participant Name

RE:        Notice of Restricted Stock Unit Award (Service-Based)
This is to notify you that Perrigo Company plc (the “Company”) has granted you an Award for non-U.S. participants under the Perrigo Company plc 2013 Long-Term Incentive Plan (the “Plan”), effective as of Grant Date (the “Grant Date”). This Award consists of service-based restricted stock units. The terms and conditions of this incentive are set forth in the remainder of this agreement (including any special terms and conditions set forth in any appendix for your country (“Appendix”)) (collectively, the “Agreement”). The capitalized terms that are not otherwise defined in this Agreement shall have the meanings ascribed to such terms under the Plan.
SECTION 1
Restricted Stock Units – Service-Based Vesting
1.1    Grant. As of the Grant Date, and subject to the terms and conditions of this Agreement and the Plan, the Company grants you Number of Awards Granted (“Restricted Stock Units” or “RSUs”). Each Restricted Stock Unit shall entitle you to one ordinary share of the Company, nominal value €0.001 per share (“Ordinary Share”) on the applicable RSU Vesting Date, provided the vesting conditions described in Section 1.2 are satisfied.
1.2    Vesting. Except as provided in Section 1.3, the Restricted Stock Units awarded in Section 1.1 shall vest on the third anniversary of the Grant Date (“RSU Vesting Date”) provided that you continue in the service of the Company from the Grant Date through the applicable RSU Vesting Date.
Except as provided in Section 1.3, if your Termination Date occurs prior to the RSU Vesting Date, any Restricted Stock Units awarded under Section 1.1 that have not previously vested as of such Termination Date shall be permanently forfeited on your Termination Date.
1.3    Special Vesting Rules. Notwithstanding Section 1.2 above:
(a)    If your Termination Date occurs by reason of death, Disability or Retirement with the Company’s consent, any Restricted Stock Units awarded under Section 1.1 that have not vested prior to such Termination Date shall become fully vested.
(b)    If your Termination Date occurs by reason of an Involuntary Termination for Economic Reasons, any Restricted Stock Units awarded under Section 1.1 that would otherwise be scheduled to vest under Section 1.2 in the 24-month period following such

    

Termination Date shall continue to vest during such 24-month period according to the vesting schedule in effect prior to such Termination Date; provided, however, that if your Termination Date occurs for a reason that is both described in this subsection (b) and in subsection (c) below, the special vesting rules described in subsection (c) shall apply in lieu of the vesting rules described in this subsection (b). Any Restricted Stock Units that are not scheduled to vest during such 24-month period will be permanently forfeited on the Termination Date.
(c)    If your Termination Date occurs by reason of a Termination without Cause or a Separation for Good Reason on or after a Change in Control (as defined in the Plan and as such definition may be amended hereafter) and prior to the two (2) year anniversary of the Change in Control, all Restricted Stock Units awarded under Section 1.1 that have not vested or been forfeited prior to such Termination Date shall become fully vested.
(d)    As used in this Section 1.3, the following terms shall have the meanings set forth below:
(1)    “Separation for Good Reason” means your voluntary resignation (or any legal act having the same consequence, such as amicable termination or constructive dismissal) from the Company on the ground of one or more of the following conditions that arose without your consent: (i) a material change in the geographic location at which you are required to perform services, such that your commute between home and your primary job site increases by more than 30 miles, or (ii) a material diminution in your authority, duties or responsibilities or a material diminution in your base compensation or incentive compensation opportunities; provided, however, that a voluntary resignation from the Company (or any legal act having the same consequence, such as a constructive dismissal) shall not be considered a Separation for Good Reason unless you provide the Company with notice, in writing, of your voluntary resignation and the existence of the condition(s) giving rise to the separation within 90 days of its initial existence. The Company will then have 30 days to remedy the condition, in which case you will not be deemed to have incurred a Separation for Good Reason. In the event the Company fails to cure the condition within the 30 day period, your Termination Date shall occur on the 31st day following the Company’s receipt of such written notice.
(2)    “Termination without Cause” means the involuntary termination of your employment or contractual relationship by the Company without Cause, including, but not limited to, (i) a termination effective when you exhaust an approved leave of absence, and (ii) a situation where you are on an approved leave of absence during which your position is protected under applicable leave law, you return from such leave, and you cannot be placed in employment or other form of contractual relationship with the Company.
1.4    Settlement of Restricted Stock Units. As soon as practicable after the RSU Vesting Date, the Company shall transfer to you one Ordinary Share for each Restricted Stock Unit becoming vested on such date (the date of any such transfer shall be the “settlement date” for purposes of this Agreement); provided, however, the Company may withhold shares otherwise transferable to you to the extent necessary to satisfy withholding taxes due by reason of the vesting of the Restricted Stock Units, in accordance with Section 2.7. You shall have no rights as a stockholder with respect to the Restricted Stock Units awarded hereunder prior to the

    


date of issuance to you of a certificate or certificates for such shares. Notwithstanding the foregoing, the Committee, in its sole discretion, may elect to settle Restricted Stock Units in cash based on the fair market value of the Ordinary Shares on the RSU Vesting Date.
1.5    Dividend Equivalents. The Restricted Stock Units awarded under Section 1.1 shall be eligible to receive dividend equivalents in accordance with the following:
(a)    An “Account” will be established in your name. Such Account shall be for recordkeeping purposes only, and no assets or other amounts shall be set aside from the Company’s general assets with respect to such Account.
(b)    On each date that a cash dividend is paid with respect to Ordinary Shares, the Company shall credit your Account with the dollar amount of dividends you would have received if each Restricted Stock Unit held by you on the record date for such dividend payment had been an Ordinary Share. No interest or other earnings shall accrue on such Account.
(c)    As of each RSU Vesting Date, you shall receive a payment equal to the amount of dividends that would have been paid on the Restricted Stock Units vesting on such date had they been Ordinary Shares during the period beginning on the Grant Date and ending on the RSU Vesting Date, and the Account shall be debited appropriately. If you forfeit Restricted Stock Units, any amounts in the Account attributable to such Restricted Stock Units shall also be forfeited.
(d)    If dividends are paid in the form of Ordinary Shares rather than cash, then you will be credited with one additional Restricted Stock Unit for each Ordinary Share that would have been received as a dividend had your outstanding Restricted Stock Units been Ordinary Shares. Such additional Restricted Stock Units shall vest or be forfeited at the same time as the Restricted Stock Unit to which they relate.

SECTION 2
General Terms and Conditions
2.1    Nontransferability. The Award under this Agreement shall not be transferable other than by will or by the laws of descent and distribution.
2.2    No Rights as a Stockholder. You shall not have any rights as a stockholder with respect to any Ordinary Shares subject to the RSU awarded under this Agreement prior to the date of issuance to you of a certificate or certificates for such shares.
2.3    Cause Termination. If your Termination Date occurs for reasons of Cause, all of your rights under this Agreement, whether or not vested, shall terminate immediately.
2.4    Award Subject to Plan. The granting of the Award under this Agreement is being made pursuant to the Plan and the Award shall be payable only in accordance with the applicable

    


terms of the Plan. The Plan contains certain definitions, restrictions, limitations and other terms and conditions all of which shall be applicable to this Agreement. ALL THE PROVISIONS OF THE PLAN ARE INCORPORATED HEREIN BY REFERENCE AND ARE MADE A PART OF THIS AGREEMENT IN THE SAME MANNER AS IF EACH AND EVERY SUCH PROVISION WERE FULLY WRITTEN INTO THIS AGREEMENT. Should the Plan become void or unenforceable by operation of law or judicial decision, this Agreement shall have no force or effect. Nothing set forth in this Agreement is intended, nor shall any of its provisions be construed, to limit or exclude any definition, restriction, limitation or other term or condition of the Plan as is relevant to this Agreement and as may be specifically applied to it by the Committee. In the event of a conflict in the provisions of this Agreement and the Plan, as a rule of construction the terms of the Plan shall be deemed superior and apply.
2.5    Adjustments in Event of Change in Ordinary Shares. In the event of a stock split, stock dividend, recapitalization, reclassification or combination of shares, merger, sale of assets or similar event, the number and kind of shares subject to the Award under this Agreement will be appropriately adjusted in an equitable manner to prevent dilution or enlargement of the rights granted to or available for you.
2.6    Acknowledgement. The Company and you agree that the RSUs are granted under and governed by the Notice of Grant, this Agreement (including the Appendix) and by the provisions of the Plan (incorporated herein by reference). You: (i) acknowledge receipt of a copy of each of the foregoing documents, (ii) represent that you have carefully read and are familiar with their provisions, and (iii) hereby accept the RSUs subject to all of the terms and conditions set forth herein and those set forth in the Plan and the Notice of Grant.
2.7    Responsibility for Taxes. Regardless of any action the Company or, if different, the Affiliate employing or retaining you takes with respect to any or all income tax, social insurance, payroll tax, payment on account or other tax-related items related to your participation in the Plan and legally applicable to you (“Tax-Related Items”), you acknowledge that the ultimate liability for all Tax-Related Items is and remains your responsibility and may exceed the amount actually withheld by the Company or the Affiliate employing or retaining you. You further acknowledge that the Company and/or the Affiliate employing or retaining you (1) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the RSUs, including, but not limited to, the grant, vesting or settlement of the RSUs, the subsequent sale of Ordinary Shares acquired pursuant to such settlement and the receipt of any dividends; and (2) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the RSUs to reduce or eliminate your liability for Tax-Related Items or achieve any particular tax result. Further, if you have become subject to tax in more than one jurisdiction between the RSU Grant Date and the date of any relevant taxable event, as applicable, you acknowledge that the Company and/or the Affiliate employing or retaining you (or formerly employing or retaining you, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.
(a)     Prior to any relevant taxable or tax withholding event, as applicable, you will pay or make adequate arrangements satisfactory to the Company and/or the Affiliate

    


employing or retaining you to satisfy all Tax-Related Items. In this regard, you authorize the Company and/or the Affiliate employing or retaining you, or their respective agents, at their discretion, to satisfy the obligations with regard to all Tax-Related Items by one or a combination of the following:
(1)    withholding from your wages or other cash compensation paid to you by the Company and/or the Affiliate employing or retaining you; or
(2)    withholding from proceeds of the sale of Ordinary Shares acquired upon settlement of the RSUs either through a voluntary sale or through a mandatory sale arranged by the Company (on your behalf pursuant to this authorization); or
(3)    withholding in Ordinary Shares to be issued upon settlement of the RSUs.
(b)    To avoid negative accounting treatment, the Company may withhold or account for Tax-Related Items by considering applicable minimum statutory withholding amounts or other applicable withholding rates. If the obligation for Tax-Related Items is satisfied by withholding in Ordinary Shares, for tax purposes, you are deemed to have been issued the full number of Ordinary Shares subject to the vested RSUs, notwithstanding that a number of the Ordinary Shares are held back solely for the purpose of paying the Tax-Related Items.
(c)    Finally, you shall pay to the Company or the Affiliate employing or retaining you any amount of Tax-Related Items that the Company or the Affiliate employing or retaining you may be required to withhold or account for as a result of your participation in the Plan that cannot be satisfied by the means previously described. The Company may refuse to issue or deliver the Ordinary Sharse or the proceeds of the sale of Ordinary Shares, if you fail to comply with your obligations in connection with the Tax-Related Items.
2.8    Compliance with Applicable Law. The issuance of Ordinary Shares will be subject to and conditioned upon compliance by the Company and you, including any written representations, warranties and agreements as the Administrator may request of you for compliance with all (i) applicable U.S. state and federal laws and regulations, (ii) applicable laws of the country where you reside pertaining to the issuance or sale of Ordinary Shares, and (iii) applicable requirements of any stock exchange or automated quotation system on which the Company’s Ordinary Shares may be listed or quoted at the time of such issuance or transfer.
2.9    Code Section 409A (Only Applicable to Individuals Subject to U.S. Federal Tax Laws).
(a)    Restricted Stock Units other than Restricted Stock Units that continue to vest by reason of your Involuntary Termination for Economic Reasons and dividend equivalents payable under this Agreement are intended to be exempt from Code Section 409A under the exemption for short-term deferrals. Accordingly, Restricted Stock Units (other than Restricted Stock Units that continue to vest by reason of your Involuntary Termination for Economic

    


Reasons) will be settled and dividend equivalents will be paid no later than the 15th day of the third month following the later of (i) the end of your taxable year in which the RSU Vesting Date occurs, or (ii) the end of the fiscal year of the Company in which the RSU Vesting Date occurs.
(b)    Restricted Stock Units that continue to vest by reason of your Involuntary Termination for Economic Reasons are subject to the provisions of this subsection (b). Any distribution in settlement of such Restricted Stock Units will occur provided your Involuntary Termination for Economic Reasons constitutes a “separation from service” as defined in Treasury Regulation §1.409A-1(h). If the Company determines that you are a “specified employee” as defined in Code Section 409A (i.e., an officer with annual compensation above $130,000 (as adjusted for inflation), a five-percent owner of the Company or a one-percent owner with annual compensation in excess of $150,000), distribution in settlement of any such Restricted Stock Units that would be payable within six months of your separation from service shall be delayed to the first business day following the six-month anniversary of your separation from service. Any distribution in settlement of such Restricted Stock Units that would be made more than six months after your separation from service (without application of the six-month delay) shall not be subject to the six-month delay described in this subsection.
2.10    Data Privacy.
(a)    By entering into this Agreement and accepting this Award, you hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Agreement and any other RSU grant materials by and among, as applicable, the Affiliate employing or retaining you, the Company and its Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.
(b)    You understand that the Company and the Affiliate employing or retaining you may hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all RSUs or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the exclusive purpose of implementing, administering and managing the Plan (“Data”).
(c)    You understand that Data will be transferred to legal counsel or a broker or such other stock plan service provider as may be selected by the Company in the future, which is assisting the Company with the implementation, administration and management of the Plan. You understand that the recipients of the Data may be located in the United States or elsewhere, and that the recipients’ country (e.g., the United States) may have different data privacy laws and protections than your country. You understand that if you reside outside the United States, you may request a list with the names and addresses of any potential recipients of the Data by contacting your local or Company human resources representative. You authorize the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole

    


purpose of implementing, administering and managing your participation in the Plan. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan. You understand that if you reside outside the United States, you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local or Company human resources representative. You understand, however, that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local or Company human resources representative.
2.11     Nature of Grant. In accepting the grant, you acknowledge, understand and agree that:
(a)    the Plan is established voluntarily by the Company, it is discretionary in nature and it may be modified, amended, suspended or terminated by the Company at any time, except as otherwise provided in the Plan;
(b)    the grant of the RSUs is voluntary and occasional and does not create any contractual or other right to receive future grants of RSUs, or benefits in lieu of RSUs, even if RSUs have been granted repeatedly in the past;
(c)    all decisions with respect to future RSU grants, if any, will be at the sole discretion of the Company;
(d)    you are voluntarily participating in the Plan;
(e)    the RSUs and the Ordinary Shares subject to the RSUs are an extraordinary item and which is outside the scope of your employment or service contract, if any;
(f)    the RSUs and the Ordinary Shares subject to the RSUs are not intended to replace any pension rights or compensation;
(g)    the RSUs and the Ordinary Shares subject to the RSUs are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments and in no event should be considered as compensation for, or relating in any way to, past services for the Company, the Affiliate employing or retaining you or any other Affiliate;
(h)    the grant and your participation in the Plan will not be interpreted to form an employment or service contract with the Company or any Affiliate;
(i)    the future value of the underlying Ordinary Shares is unknown, indeterminable and cannot be predicted with certainty;

    


(j)    no claim or entitlement to compensation or damages shall arise from forfeiture of the RSUs resulting from your Termination Date (for any reason whatsoever, whether or not later found to be invalid and whether or not in breach of employment laws in the jurisdiction where you are employed or rendering services, or the terms of your employment agreement, if any), and in consideration of the grant of the RSUs to which you are otherwise not entitled, you irrevocably agree never to institute any claim against the Company or the Affiliate employing or retaining you, waive your ability, if any, to bring any such claim, and release the Company and the Affiliate employing or retaining you from any such claim; if, notwithstanding the foregoing, any such claim is allowed by a court of competent jurisdiction, then, by participating in the Plan, you shall be deemed irrevocably to have agreed not to pursue such claim and agree to execute any and all documents necessary to request dismissal or withdrawal of such claim; and
(k)    you acknowledge and agree that neither the Company, the Affiliate employing or retaining you nor any other Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the United States Dollar that may affect the value of the RSUs or of any amounts due to you pursuant to the settlement of the RSUs or the subsequent sale of any Ordinary Shares acquired upon settlement.
2.12    Successors and Assigns. This Agreement shall be binding upon any or all successors and assigns of the Company.
2.13    Applicable Law. This Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of Michigan, U.S.A., without regard to principals of conflict of laws. Any proceeding related to or arising out of this Agreement shall be commenced, prosecuted or continued in the Circuit Court in Kent County, Michigan located in Grand Rapids, Michigan or in the United Stated District Court for the Western District of Michigan, and in any appellate court thereof.
2.14 Forfeiture of RSUs. If the Company, as a result of misconduct, is required to prepare an accounting restatement due to material noncompliance with any financial reporting requirement under the securities laws, then (a) if your incentive or equity-based compensation is subject to automatic forfeiture due to such misconduct and restatement under Section 304 of the Sarbanes-Oxley Act of 2002, or (b) the Committee determines you either knowingly engaged in or failed to prevent the misconduct, or your actions or inactions with respect to the misconduct and restatement constituted gross negligence, you shall (i) be required to reimburse the Company the amount of any payment (including dividend equivalents) relating to any RSUs earned or accrued during the twelve month period following the first public issuance or filing with the SEC (whichever first occurred) of the financial document embodying such financial reporting requirement, and (ii) all outstanding RSUs (including related dividend equivalents) that have not yet been settled shall be immediately forfeited. In addition, Ordinary Shares acquired under this Agreement, and any gains or profits on the sale of such Ordinary Shares, shall be subject to any “clawback” or recoupment policy later adopted by the Company.
2.15    Appendix. Notwithstanding any provisions in this Agreement, the RSU grant shall be subject to any special terms and conditions set forth in any Appendix to this Agreement

    


for your country. Moreover, if you relocate to one of the countries included in the Appendix, the special terms and conditions for such country will apply to you, to the extent the Company determines that the application of such provisions is necessary or advisable in order to comply with laws of the country where you reside or to facilitate the administration of the Plan. The Appendix constitutes part of this Agreement.
2.16    Imposition of Other Requirements. The Company reserves the right to impose other requirements on your participation in the Plan, on the RSUs and on any Ordinary Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable in order to comply with laws of the country where you reside or to facilitate the administration of the Plan, and to require you to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.
****
We look forward to your continuing contribution to the growth of the Company. Please acknowledge your receipt of the Plan and this Award.
Very truly yours,



Print Name: ___________________________
Title:_________________________________

    


APPENDIX

PERRIGO COMPANY PLC
Additional Terms and Provisions to
Restricted Stock Unit Award Agreement (Service-Based)

Terms and Conditions
This Appendix (the “Appendix”) includes additional terms and conditions that govern the restricted stock units (“RSUs” or “Award”) granted to you under the Plan if you reside in one of the countries listed below. Certain capitalized terms used but not defined in this Appendix have the meanings set forth in the Plan and/or the Agreement.
In addition, please note that the Award is exceptional in nature as it relates to the specific cicumstances of acquisition of the shares of Omega Pharma. Perrigo considers it to be a useful incentive for the combined portfolio to be successful. Therefore, it will not create any entitlement to receive any similar benefit in the future.
Notifications
This Appendix also includes country-specific information of which you should be aware with respect to your participation in the Plan. The information is based on the securities, exchange control and other laws in effect in the respective countries as of December 2014. Such laws are often complex and change frequently. As a result, the Company strongly recommends that you do not rely on the information noted herein as the only source of information relating to the consequences of your participation in the Plan because the information may be out of date at the time that you vest in the RSUs and Ordinary Shares are issued to you or the shares issued upon vesting of the RSUs are sold.
In addition, the information is general in nature and may not apply to your particular situation, and the Company is not in a position to assure you of any particular result. Accordingly, you are advised to seek appropriate professional advice as to how the relevant laws in your country may apply to your particular situation. Finally, please note that if you are a citizen or resident of a country other than the country in which you are currently working, or transfers employment after grant, the information contained in the Appendix may not be applicable.



    


Argentina
Notifications
Securities Law Information. Neither the Award nor the issuance of the shares are publicly offered or listed on any stock exchange in Argentina. The offer is private and not subject to the supervision of any Argentine governmental authority.
Exchange Control Information. In the event that you transfer sales proceeds in excess of US$50,000 from the sale of shares into Argentina in a single month, you will be subject to certain exchange control reporting requirements. In addition, you may be subject to a mandatory 30% restriction on holding of funds brought into Argentina. Please note that exchange control regulations in Argentina are subject to frequent change. You should consult with your personal legal advisor regarding any exchange control obligations that you may have.
Australia
Terms and Conditions
RSUs Settled in Shares Only. Notwithstanding any discretion contained in the Plan, or any provision in the Agreement to the contrary, RSUs granted to employees in Australia shall be settled in shares only and do not provide any right for you to receive a cash payment under this Award.
Notifications
Securities Information. If you acquire shares pursuant to the Award and you offer the shares for sale to a person or entity resident in Australia, then the offer may be subject to disclosure requirements under Australian law. You should obtain legal advice on your disclosure obligations prior to making any such offer.
Exchange Control Information. Exchange control reporting is required for cash transactions exceeding AUD10,000 and for international fund transfers. The Australian bank assisting with the transaction will file the report for you. If there is no Australian bank involved in the transfer, you will have to file the report.
Austria
Notifications
Exchange Control Information. If you hold shares of Company stock outside of Austria, you must submit a report to the Austrian National Bank. An exemption applies if the value of the shares as of any given quarter does not exceed €30,000,000 or as of December 31 does not exceed €5,000,000. If the former threshold is exceeded, quarterly obligations are imposed, whereas if the latter threshold is exceeded, annual reports must be given. The annual reporting date is as of December 31 and the deadline for filing the annual report is March 31 of the following year.
When shares are sold, there may be exchange control obligations if the cash received is held outside Austria. If the transaction volume of all your accounts abroad exceeds €3,000,000, the

    


movements and balances of all accounts must be reported monthly, as of the last day of the month, on or before the fifteenth day of the following month.
Belgium
No country specific provisions.
Czech Republic
Notifications
Exchange Control Information. The Czech National Bank may require you to report the RSUs and or Ordinary Shares received and the opening and maintenance of a foreign account. However, because exchange control regulations change frequently and without notice, you should consult your personal legal advisor prior to the vesting of the RSUs to ensure your compliance with current regulations. It is your responsibility to comply with applicable Czech exchange control laws.
Denmark
Notifications
Exchange Control Information. If you establish an account holding shares pursuant to the Award or an account holding cash outside Denmark, you must report the account to the Danish Tax Administration. The form which should be used in this respect can be obtained from a local bank. (Please note that these obligations are separate from and in addition to the obligations described below.)
Securities/Tax Reporting Information. If you hold shares acquired under the Plan in a brokerage account with a broker or bank outside Denmark, you are required to inform the Danish Tax Administration about the account. For this purpose, you must file a Form V (Erklaering V) with the Danish Tax Administration. The Form V must be signed both by you and by the applicable broker or bank where the account is held. By signing the Form V, the broker or bank undertakes to forward information to the Danish Tax Administration concerning the shares in the account without further request each year. By signing the Form V, you authorize the Danish Tax Administration to examine the account. A sample of the Form V can be found at the following website: www.skat.dk.
In addition, if you open a brokerage account (or a deposit account with a U.S. bank) for the purpose of holding cash outside Denmark, you are also required to inform the Danish Tax Administration about this account. To do so, you must also file a Form K (Erklaering K) with the Danish Tax Administration. The Form K must be signed both by you and by the applicable broker or bank where the account is held. By signing the Form K, the broker/bank undertakes an obligation, without further request each year, to forward information to the Danish Tax Administration concerning the content of the account. By signing the Form K, you authorize the Danish Tax Administration to examine the account. A sample of Form K can be found at the following website: www.skat.dk.


    


Finland
There are no country specific provisions.
France
Terms and Conditions
Consent to Receive Information in English. By accepting the Award, you confirm having read and understood the Plan and the Agreement, which were provided in the English language. You accept the terms of those documents accordingly.
En acceptant cette attribution gratuite d'actions, vous confirmez avoir lu et comprenez le Plan et ce Contrat, incluant tous leurs termes et conditions, qui ont été transmis en langue anglaise. Vous acceptez les dispositions de ces documents en connaissance de cause.
Notifications
Exchange Control Information. If you hold Ordinary Shares outside of France or maintain a foreign bank account, you are required to report such to the French tax authorities when you file your annual tax return.
Germany
Notifications
Exchange Control Information. Cross-border payments in excess of €12,500 must be reported monthly to the German Federal Bank. If you use a German bank to transfer a cross-border payment in excess of €12,500 in connection with the sale of shares acquired under the Plan, the bank will make the report for you. In addition, you must report any receivables, payables, or debts in foreign currency exceeding an amount of €5,000,000 on a monthly basis.
Greece
Notifications
Exchange Control Information. Pursuant to your Award, if you withdraw funds in excess of €15,000 from a bank in Greece and remit those funds out of Greece, you may be required to submit certain documentation/ information to the Greek bank to ensure that the transfer is not in violation of Greek anti-money laundering rules.
Hungary
No country specific provisions.


    


India
Notifications
Exchange Control Notification. You must repatriate all proceeds received from the sale of the shares to India within 90 days after sale. You will receive a foreign inward remittance certificate (“FIRC”) from the bank where you deposit the foreign currency. You should maintain the FIRC as evidence of the repatriation of funds in the event that the Reserve Bank of India or the employer requests proof of repatriation.
Tax Information. The amount subject to tax at vesting will partially be dependent upon a valuation that the Company or your employer will obtain from a Merchant Banker in India. Neither the Company nor your employer has any responsibility or obligation to obtain the most favorable valuation possible, nor obtain valuations more frequently than required under Indian tax law.
Ireland
Notifications
Director Notification Obligation. If you are a director, shadow director or secretary of the Company or an Irish Subsidiary or Affiliate of the Company, and you acquire or dispose of an interest under this Agreement comprising more than 1% of the share capital in the Company, you must notify the entity in which you hold that office (whether the Company itself or an Irish Subsidiary or Affiliate of the Company) in writing within five business days of receiving or disposing of an interest in the Company, or within five business days of becoming aware of the event giving rise to the notification requirement or within five days of becoming a director or secretary if such an interest exists at the time. This notification requirement also applies with respect to the interests of a spouse or children under the age of 18 (whose interests will be attributed to the director, shadow director or secretary).
Italy
Terms and Conditions
Data Privacy Notice. The following provision supplements the terms in the Agreement:
You understand that your employer and/or the Company may hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social security number (or any other social or national identification number), salary, nationality, job title, number of Ordinary Shares held and the details of all RSUs or any other entitlement to Ordinary Shares awarded, cancelled, exercised, vested, unvested or outstanding (the “Data”) for the purpose of implementing, administering and managing your participation in the Plan. You are aware that providing the Company with the Data is necessary for the performance of this Agreement and that your refusal to provide such Data would make it impossible for the Company to perform its contractual obligations and may affect your ability to participate in the Plan.
The "Controller" of personal data processing is Perrigo Company, plc, with registered offices at Allegan, Michigan, USA, and, pursuant to D.lgs 196/2003, its representative is David A. McConnell. You understand that the Data may be transferred to the Company or any of its subsidiaries or

    


affiliates, or to any third parties assisting in the implementation, administration and management of the Plan, including any transfer required to a broker or other third party with whom Ordinary Shares acquired pursuant to the vesting of the RSUs or cash from the sale of Ordinary Shares acquired pursuant to the Plan may be deposited. Furthermore, the recipients that may receive, possess, use, retain and transfer such Data for the above mentioned purposes may be located in Italy or elsewhere, including outside of the European Union and that the recipients’ country (e.g., the United States) may have different data privacy laws and protections than Italy. The processing activity, including the transfer of your personal data abroad, outside of the European Union, as herein specified and pursuant to applicable laws and regulations, does not require your consent thereto as the processing is necessary for the performance of contractual obligations related to the implementation, administration and management of the Plan. You understand that Data processing relating to the purposes above specified shall take place under automated or non-automated conditions, anonymously when possible, that comply with the purposes for which Data are collected and with confidentiality and security provisions as set forth by applicable laws and regulations, with specific reference to D.lgs. 196/2003.
You understand that Data will be held only as long as is required by law or as necessary to implement, administer and manage your participation in the Plan. You understand that pursuant to art.7 of D.lgs 196/2003, you have the right, including but not limited to, access, delete, update, request the rectification of your personal Data and cease, for legitimate reasons, the Data processing. Furthermore, you are aware that your Data will not be used for direct marketing purposes.
Plan Document Acknowledgment. In accepting the RSUs, you acknowledge that you have received a copy of the Plan and the Agreement and have reviewed the Plan and the Agreement, including this Appendix, in their entirety and fully understand and accept all provisions of the Plan and the Agreement, including this Appendix.
Notifications
Tax/Exchange Control Information. You are required to report on your annual tax return: (a) any transfers of cash or Ordinary Shares to or from Italy exceeding €10,000 or the equivalent amount in U.S. dollars; (b) any foreign investments or investments (including the Ordinary Shares issued at vesting of the RSUs, cash or proceeds from the sale of Ordinary Shares acquired under the Plan) held outside of Italy exceeding €10,000 or the equivalent amount in U.S. dollars, if the investment may give rise to income in Italy (this will include reporting the Ordinary Shares issued at vesting of the RSUs if the fair market value of such Ordinary Shares combined with other foreign assets exceed €10,000); and (c) the amount of the transfers to and from abroad which have had an impact during the calendar year on your foreign investments or investments held outside of Italy. You are exempt from the formalities in (a) if the investments are made through an authorized broker resident in Italy, as the broker will comply with the reporting obligation on your behalf.
Kazakhstan
Notifications
Exchange Control Information. Although Kazakh residents are no longer required to obtain a license from the National Bank of Kazakhstan in advance of obtaining securities in foreign companies, you are nevertheless required to notify the National Bank of Kazakhstan when you acquire shares under the Plan.

    


Latvia
No country specific provisions.
Luxembourg
Notifications
Exchange Control Information. You are required to report any inward remittances of funds to the Banque Central de Luxembourg and/or the Service Central de La Statistique et des Etudes Economiques within 15 working days following the month during the transaction occurred. If a Luxembourg financial institution is involved in the transaction, it generally will fulfill the reporting obligation on your behalf.
Mexico
Terms and Conditions
Modification. By accepting the RSUs, you understand and agree that any modification of the Plan or the Agreement or its termination shall not constitute a change or impairment of the terms and conditions of employment.
Policy Statement. The award of the RSUs the Company is making under the Plan is unilateral and discretionary and, therefore, the Company reserves the absolute right to amend it and discontinue it at any time without any liability.
The Company, with registered offices in the U.S., is solely responsible for the administration of the Plan and participation in the Plan and the acquisition of shares does not, in any way, establish an employment relationship between you and the Company since you are participating in the Plan on a wholly commercial basis and the sole employer is as applicable, nor does it establish any rights between you and the Employer.
Plan Document Acknowledgment. By accepting the award of the RSUs, you acknowledge that you have received copies of the Plan, have reviewed the Plan and the Agreement in their entirety and fully understand and accept all provisions of the Plan and the Agreement.
In addition, by signing the Agreement, you further acknowledge that you have read and specifically and expressly approve the terms and conditions in the Agreement, in which the following is clearly described and established: (i) participation in the Plan does not constitute an acquired right; (ii) the Plan and participation in the Plan is offered by the Company on a wholly discretionary basis; (iii) participation in the Plan is voluntary; and (iv) the Company and any Parent, Subsidiary or Affiliates are not responsible for any decrease in the value of the shares.
Finally, you hereby declare that you do not reserve any action or right to bring any claim against the Company for any compensation or damages as a result of your participation in the Plan and therefore grant a full and broad release to the Employer, the Company and any Parent, Subsidiary or Affiliates with respect to any claim that may arise under the Plan.


    


Spanish Translation
Modification. Al aceptar las Unidades de Accion Restringida, usted reconoce y acuerda que cualquier modification del Plan o su terminacion no constituye un cambio o desmejora de los terminos y condiciones de empleo.
Declaracion de Politica. El Otorgarmiento de Unidades de Accion Restringida de la Compañia en virtud del Plan es unilateral y discrecional y, por lo tanto, la Compañia se reserva el derecho absoluto de modificar y discontinuar el mismo en cualquier tiempo, sin responsabilidad alguna.
La Compañia, con oficinas registradas ubicadas en the U.S., es la unica responsable de la administración del Plan y de la participación en el mismo y la adquisición de Acciones no establece de forma alguna una relación de trabajo entre usted y la Compañia, ya que su participación en el Plan es completamente comercial y el unico empleador es en caso de ser aplicable, asi como tampoco establece ningun derecho entre la persona que tenga el derecho a optar y el Empleador.
Reconocimiento del Documento del Plan. Al aceptar el Otorgamiento de las Unidades de Acciόn Restringida, usted reconoce que ha recibido copias del Plan, ha revisado el mismo, al igual que la totalidad del Acuerdo y, que ha entendido y aceptado completamente todas las disposiciones contenidas en el Plan y en el Acuerdo.
Adicionalmente, al firmar el Acuerdo, reconoce que ha leido, y que aprueba especifica y expresamente los términos y condiciones contenidos en la Renuncia de Derecho o Reclamo por Compensación del Acuerdo, en el cual se encuentra claramente descrito y establecido lo siguiente: (i) la participación en el Plan no constituye un derecho adquirido; (ii) el plan y la participación en el mismo es ofrecida por la Compañia de forma enteramente discrecional; (iii) la participación en el Plan es voluntaria; y (iv) la Compañia, asi como su Sociedad controlante, Subsidiaria o Filiales no son responsables por cualquier disminución en el valor de las Acciones.
Finalmente, declara que no se reserva ninguna acciόn o derecho para interponer una demanda en contra de la Compañia por compensación, dano o perjuicio alguno como resultado de su participación en el Plan y, en consecuencia, otorga el más amplio finiquito al Empleador, asi como a la Compañia, a su Sociedad controlante, Subsidiaria o Filiales con respecto a cualquier demanda que pudiera originarse en virtud del Plan.
Netherlands
Notifications
Insider-Trading Notification. You should be aware of the Dutch insider-trading rules which may prohibit you from effectuating certain transactions involving shares if you have inside information about the Company. If you are uncertain whether the insider-trading rules apply to you, you should consult your personal legal advisor.
Norway
No country specific provisions.

    


Poland
Terms and Conditions
Consent to Receive Information in English. By accepting the Award, you confirm having read and understood the Plan and the Agreement, which were provided in the English language. You accept the terms of those documents accordingly.
Section 2.11 item (h) of the Award Agreement shall be also understood as that the grant and your participation in the Plan will not be interpreted to form or be part of terms and conditions of your employment or service with any Subsidiary or affiliate of the Company.
Notifications
Exchange Control Information. If you hold foreign securities (including shares pursuant to the Award) and maintain accounts abroad, you may be required to file certain reports with the National Bank of Poland. Specifically, if the value of securities and cash held in such foreign accounts exceeds PLN 7,000,000 at the end of the year, you must file reports on the transactions and balances of the accounts on a quarterly basis by the 20th day of the month following the end of each quarter and an annual report by no later than January 30 of the following calendar year. Such reports are filed on special forms available on the website of the National Bank of Poland. Additionally, if you are a Polish citizen and you transfer funds abroad in excess of the PLN equivalent of €15,000, the transfer must be made through an authorized bank, a payment institution or an electronic money institution authorized to render payment services.
Portugal
Notifications
Exchange Control Information. If you receive shares pursuant to the Award, the acquisition of the shares should be reported to the Banco de Portugal for statistical purposes. If the shares are deposited with a commercial bank or financial intermediary in Portugal, such bank or financial intermediary will submit the report on your behalf. If the shares are not deposited with a commercial bank or financial intermediary in Portugal, you are responsible for submitting the report to the Banco de Portugal.
Romania
Notifications
Exchange Control Information. Payments by Romanian citizens to or from non-residents in excess of €50,000 should be reported to the National Bank of Romania (“NBR”) for statistical purposes. If you deposit the proceeds from the sale of shares issued to you at vesting in a bank account in Romania, you may be required to provide the Romanian bank with appropriate documentation explaining the source of the funds. You should consult your personal advisor to determine whether you will be required to submit such documentation to the Romanian bank.

    


Insider-Trading Notification. You should be aware of the Romanian insider-trading rules which may prohibit you from effectuating certain transactions involving shares if you have inside information about the Company. If you are uncertain whether the insider-trading rules apply to you, you should consult your personal legal advisor.
Russia
Terms and Conditions
(i)U.S. Transaction. You understand that the RSUs shall be valid and this Agreement shall be concluded and become effective only when the Agreement is electronically received by the Company in the United States. Upon vesting, any shares to be issued to you shall be delivered to you through a bank or brokerage account in the United States. You are not permitted to sell the shares directly to other Russian legal entities or individuals.
Notifications
(ii)Exchange Control Information. Under current exchange control regulations, within a reasonably short time after sale of the shares issued at vesting, you must repatriate the sale proceeds to Russia. Such sale proceeds must be initially credited to you through a foreign currency account at an authorized bank in Russia. After the sale proceeds are initially received in Russia, they may be further remitted to foreign banks in accordance with Russian exchange control laws.
(iii)You are encouraged to contact your personal advisor before remitting your sale proceeds to Russia as exchange control requirements may change.
Securities Law Notification. This Appendix, the Agreement, the Plan and all other materials that you may receive regarding participation in the Plan do not constitute advertising or an offering of securities in Russia. Absent any requirement under local law, the issuance of securities pursuant to the Plan has not and will not be registered in Russia; hence, the securities described in any Plan-related documents may not be used for offering or public circulation in Russia.
Serbia
No country specific provisions.
Slovakia
No country specific provisions.

    


Slovenia
No country specific provisions.
South Africa
Terms and Conditions
Taxes. By accepting the RSUs, you agree that, immediately upon vesting of the RSUs, you will notify your employer of the amount of any gain realized. If you fail to advise your employer of the gain realized upon vesting, you may be liable for a fine. You will be solely responsible for paying any difference between the actual tax liability and the amount withheld by your employer.
Notifications
Exchange Control Information. Because no transfer of funds from South Africa is required under the RSUs, no filing or reporting requirements should apply when the award is granted nor when Ordinary Shares are issued upon vesting of the RSUs. However, because the exchange control regulations are subject to change, you should consult your personal advisor prior to vesting and settlement of the award to ensure compliance with current regulations.
Spain
Terms and Conditions
No Entitlement for Claims or Compensation. By accepting the award of RSUs, you consent to participation in the Plan, and acknowledge that you have received a copy of the Plan document. You understand that the Company has unilaterally, gratuitously and in its sole discretion decided to make awards of RSUs under the Plan to individuals who may be employees, consultants and directors throughout the world. The decision is limited and entered into based upon the express assumption and condition that any RSUs will not economically or otherwise bind the Company or any Parent, Subsidiary or Affiliate, including your employer, on an ongoing basis, other than as expressly set forth in the Agreement. Consequently, you understand that the Award is given on the assumption and condition that the RSUs shall not become part of any employment contract (whether with the Company or any Parent, Subsidiary or Affiliate, including your employer) and shall not be considered a mandatory benefit, salary for any purpose (including severance compensation) or any other right whatsoever. Furthermore, you understand and freely accept that there is no guarantee that any benefit whatsoever shall arise from the award, which is gratuitous and discretionary, since the future value of the RSUs and the underlying shares is unknown and unpredictable. You also understand that this Award would not be made but for the assumptions and conditions set forth hereinabove; thus, you understand, acknowledge and freely accept that, should any or all of the assumptions be mistaken or any of the conditions not be met for any reason, the Award, the RSUs and any right to the underlying shares shall be null and void.
Notifications
Exchange Control Information. You must declare the acquisition of Ordinary Shares to the Dirección General de Politica Comercial e Inversiones Exteriores ("DGPCIE") of the Ministerio de

    


Economia for statistical purposes. You must also declare the ownership of any Ordinary Shares with the Directorate of Foreign Transactions each January while the shares are owned. In addition, you wish to import the share certificates into Spain, you must declare the importation of such securities to the DGPCIE.
When receiving foreign currency payments derived from the ownership of Ordinary Shares (i.e., dividends or sale proceeds), you must inform the financial institution receiving the payment of the basis upon which such payment is made. You will need to provide the following information: (i) your name, address, and fiscal identification number; (ii) the name and corporate domicile of the Company; (iii) the amount of the payment and the currency used; (iv) the country of origin; (v) the reasons for the payment; and (vi) further information that may be required.
Tax Information. If you hold assets or rights outside of Spain (including shares acquired under the Plan), you may have to file an informational tax report with the tax authorities declaring such ownership. Generally, if the value of your foreign investments exceeds €50,000, you may have to file this informational return. Please note that reporting requirements are based on what you have previously disclosed and the increase in value of such and the total value of certain groups of foreign assets. Also, the thresholds for annual filing requirements may change each year. Therefore, you should consult your personal advisor regarding whether you will be required to file an informational tax report for asset and rights that you hold abroad.
Sweden
Terms and Conditions
The following shall apply in addition to what is set out under section 2.14 of the Award Agreement:
Forfeiture of entitlements under the Plan in case of termination shall apply in case of termination of employment regardless of whether such termination of employment may be justified under Swedish employment protection legislation, and regardless of whether such termination may be challenged by you, and regardless of whether such termination is invalidated by verdict or a court order.
Switzerland
Notifications
Securities Law Notification The award is considered a private offering in Switzerland; therefore, it is not subject to registration in Switzerland.
Turkey
No country specific provisions.
Ukraine
Notifications

    


Exchange Control Information. Exchange control rules change frequently and you should consult your personal advisor to determine whether you are required to obtain a license for obtaining shares of a foreign company from the National Bank of Ukraine (NBU).
Terms and Conditions
The Award will be outside the scope of your employment or service contract (if any) and as such will not constitute a part of your compensation package under the respective employment or service contract.
United Kingdom
Terms and Conditions
Income Tax and National Insurance Contribution Withholding. The following provision supplements the terms in the Agreement:
If payment or withholding of the income tax due in connection with the RSUs is not made within ninety (90) days of the end of the U.K. tax year in which the event giving rise to the income tax liability or such other period specified in Section 222(1)(c) of the U.K. Income Tax (Earnings and Pensions) Act 2003 occurred (the “Due Date”), the amount of any uncollected income tax shall constitute a loan owed by you to your employer, effective as of the Due Date. You agree that the loan will bear interest at the then-current official rate of Her Majesty’s Revenue & Customs (“HMRC”), it shall be immediately due and repayable, and the Company or your employer may recover it at any time thereafter by any of the means referred to in Section 2.7 of the Agreement. Notwithstanding the foregoing, if you are a director or executive officer of the Company (within the meaning of Section 13(k) of the U.S. Securities and Exchange Act of 1934, as amended), you will not be eligible for a loan from the Company or your employer to cover the income tax liability. In the event that you are a director or executive officer and the income tax is not collected from or paid by the Due Date, the amount of any uncollected income tax will constitute a benefit to you on which additional income tax and national insurance contributions (“NICs”) will be payable. You will be responsible for reporting any income tax for reimbursing the Company or your employer the value of any employee NICs due on this additional benefit.
* * * * *









België

    


PERRIGO COMPANY PLC

    


PERRIGO COMPANY PLC
RESTRICTED STOCK UNIT AWARD AGREEMENT
(SERVICE-BASED)
(Under the Perrigo Company plc 2013 Long-Term Incentive Plan)
TO:        «First_Name» «Last_Name»
RE:        Notice of Restricted Stock Unit Award (Service-Based)
This is to notify you that Perrigo Company plc (the “Company”) has granted you an Award under the Perrigo Company plc 2013 Long-Term Incentive Plan (the “Plan”), effective as of ______________________ (the “Grant Date”). This Award consists of service-based restricted stock units. The terms and conditions of this incentive are set forth in the remainder of this agreement (the “Agreement”). The capitalized terms that are not otherwise defined in this Agreement shall have the meanings ascribed to such terms under the Plan.
SECTION 1
Restricted Stock Units – Service-Based Vesting
1.1    Grant. As of the Grant Date, and subject to the terms and conditions of this Agreement and the Plan, the Company grants you «Number_of_restricted_stock units» (“Restricted Stock Units” or “RSUs”). Each Restricted Stock Unit shall entitle you to one Share on the applicable RSU Vesting Date, provided the vesting conditions described in Section 1.2 are satisfied.
1.2    Vesting. Except as provided in Section 1.3, the Restricted Stock Units awarded hereunder shall fully vest on the first anniversary of the Grant Date (the “RSU Vesting Date”) provided that you have continuously provided services to the Company from the Grant Date through the RSU Vesting Date.
Except as provided in Section 1.3, if your Termination Date occurs prior to the RSU Vesting Date, any Restricted Stock Units awarded under this Agreement that have not previously vested as of such Termination Date shall be permanently forfeited on your Termination Date.
1.3    Special Vesting Rules. Notwithstanding Section 1.2 above:
(a)    If your Termination Date occurs by reason of death, Disability or Retirement, with the Company’s consent, any Restricted Stock Units awarded under this Agreement that have not vested prior to such Termination Date shall become fully vested.
(b)    If your Termination Date occurs by reason of the involuntary termination of your directorship by the Company without Cause on or after a Change in Control (as defined in the Plan and as such definition may be amended hereafter) and prior to the one (1) year

    


anniversary of the Change in Control, all RSUs awarded under this Agreement that have not vested or been forfeited prior to such Termination Date shall become fully vested.
1.4    Settlement of Restricted Stock Units. As soon as practicable after the RSU Vesting Date, the Company shall transfer to you one Share for each Restricted Stock Unit becoming vested on such date (the date of any such transfer shall be the “settlement date” for purposes of this Agreement); provided, however, the Company may withhold Shares otherwise transferable to the extent necessary to satisfy withholding taxes due by reason of the vesting of the Restricted Stock Units, in accordance with Section 2.6. You shall have no rights as a stockholder with respect to the Restricted Stock Units awarded hereunder prior to the date of issuance to you of a certificate or certificates for such Shares. Notwithstanding the foregoing, the Committee, in its sole discretion, may elect to settle Restricted Stock Units in cash based on the fair market value of Shares on the RSU Vesting Date.
1.5    Dividend Equivalents. The Restricted Stock Units awarded under Section 1.1 shall be eligible to receive dividend equivalents in accordance with the following:
(a)    An “Account” will be established in your name. Such Account shall be for recordkeeping purposes only, and no assets or other amounts shall be set aside from the Company’s general assets with respect to such Account.
(b)    On each date that a cash dividend is paid with respect to Shares, the Company shall credit the Account with the dollar amount of dividends you would have received if each Restricted Stock Unit held by you on the record date for such dividend payment had been a Share. No interest or other earnings shall accrue on such Account.
(c)    As of the RSU Vesting Date, you shall receive a payment equal to the amount of dividends that would have been paid on the Restricted Stock Units vesting on such date had they been Shares during the period beginning on the Grant Date and ending on the RSU Vesting Date, and the Account shall be debited appropriately. If you forfeit Restricted Stock Units, any amounts in the Account attributable to such Restricted Stock Units shall also be forfeited.
(d)    If dividends are paid in the form of Shares rather than cash, you will be credited with one additional Restricted Stock Unit for each Share that would have been received as a dividend had your outstanding Restricted Stock Units been Shares. Such additional Restricted Stock Units shall vest or be forfeited at the same time as the Restricted Stock Unit to which they relate.
SECTION 2
General Terms And Conditions
2.1    Nontransferability. The Award under this Agreement shall not be transferable other than by will or by the laws of descent and distribution.

    


2.2    No Rights as a Stockholder. You shall not have any rights as a stockholder with respect to any Shares subject to the RSU awarded under this Agreement prior to the date of issuance to you of a certificate or certificates for such Shares.
2.3    Cause Termination. If your Termination Date occurs for reasons of Cause, all of your rights under this Agreement, whether or not vested, shall terminate immediately.
2.4    Award Subject to Plan. The granting of the Award under this Agreement is being made pursuant to the Plan and the Award shall be payable only in accordance with the applicable terms of the Plan. The Plan contains certain definitions, restrictions, limitations and other terms and conditions all of which shall be applicable to this Agreement. ALL THE PROVISIONS OF THE PLAN ARE INCORPORATED HEREIN BY REFERENCE AND ARE MADE A PART OF THIS AGREEMENT IN THE SAME MANNER AS IF EACH AND EVERY SUCH PROVISION WERE FULLY WRITTEN INTO THIS AGREEMENT. Should the Plan become void or unenforceable by operation of law or judicial decision, this Agreement shall have no force or effect. Nothing set forth in this Agreement is intended, nor shall any of its provisions be construed, to limit or exclude any definition, restriction, limitation or other term or condition of the Plan as is relevant to this Agreement and as may be specifically applied to it by the Committee. In the event of a conflict in the provisions of this Agreement and the Plan, as a rule of construction the terms of the Plan shall be deemed superior and apply.
2.5    Adjustments in Event of Change in Shares. In the event of a stock split, stock dividend, recapitalization, reclassification or combination of shares, merger, sale of assets or similar event, the number and kind of shares subject to the Award under this Agreement will be appropriately adjusted in an equitable manner to prevent dilution or enlargement of the rights granted to or available for you.
2.6    Withholding. This Award is subject to the withholding of all applicable taxes. The Company may withhold, or permit you to remit to the Company, any Federal, state or local taxes applicable to the grant, vesting or other event giving rise to tax liability with respect to this Award. If you have not remitted the full amount of applicable withholding taxes to the Company by the date the Company is required to pay such withholding to the appropriate taxing authority (or such earlier date that the Company may specify to assist it in timely meeting its withholding obligations), the Company shall have the unilateral right to withhold Shares relating to this Award in the amount it determines is sufficient to satisfy the tax withholding required by law. State taxes will be withheld at the appropriate rate set by the state in which you are employed or were last employed by the Company. In no event may the number of Shares withheld exceed the number necessary to satisfy the maximum Federal, state and local income and employment tax withholding requirements. You may elect to surrender previously acquired Shares or to have the Company withhold Shares relating to this Award in an amount sufficient to satisfy all or a portion of the tax withholding required by law.
2.7    Compliance with Applicable Law. Notwithstanding any other provision of this Agreement, the Company shall have no obligation to issue any Shares under this Agreement if such issuance would violate any applicable law or any applicable regulation or requirement of any securities exchange or similar entity.

    


2.8    Code Section 409A. Restricted Stock Units and dividend equivalents payable under this Agreement are intended to be exempt from Code Section 409A under the exemption for short-term deferrals. Accordingly, Restricted Stock Units will be settled and dividend equivalents will be paid no later than the 15th day of the third month following the later of (i) the end of your taxable year in which the RSU Vesting Date occurs, or (ii) the end of the fiscal year of the Company in which the RSU Vesting Date occurs.
2.9    Data Privacy. By entering into this Agreement and accepting this Award, you (a) explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of any of your personal data that is necessary to facilitate the implementation, administration and management of the Award and the Plan, (b) understand that the Company may, for the purpose of implementing, administering and managing the Plan, hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, and details of all awards or entitlements to Shares granted to you under the Plan or otherwise (“Data”), (c) understand that Data may be transferred to any third parties assisting in the implementation, administration and management of the Plan, including any broker with whom the Shares issued upon vesting of the Award may be deposited, and that these recipients may be located in your country or elsewhere, and that the recipient’s country may have different data privacy laws and protections than your country, (d) waive any data privacy rights you may have with respect to the data, and (e) authorize the Company, its subsidiaries and its agents, to store and transmit such information in electronic form.
2.10    Successors and Assigns. This Agreement shall be binding upon any or all successors and assigns of the Company.
2.11    Applicable Law. This Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of Michigan without regard to principals of conflict of laws. Any proceeding related to or arising out of this Agreement shall be commenced, prosecuted or continued in the Circuit Court in Kent County, Michigan located in Grand Rapids, Michigan or in the United States District Court for the Western District of Michigan, and in any appellate court thereof.
****
We look forward to your continuing contribution to the growth of the Company. Please acknowledge your receipt of the Plan and this Award.
Very truly yours,




Print Name: ___________________________
Title:_________________________________

    


English
PERRIGO COMPANY PLC
RESTRICTED STOCK UNIT AWARD AGREEMENT FOR NON-U.S. PARTICIPANTS
(SERVICE-BASED)
(Under the Perrigo Company plc 2013 Long-Term Incentive Plan)
TO:        Participant Name

RE:        Notice of Restricted Stock Unit Award (Service-Based)
This is to notify you that Perrigo Company plc (the “Company”) has granted you an Award for non-U.S. participants under the Perrigo Company plc 2013 Long-Term Incentive Plan (the “Plan”), effective as of Grant Date (the “Grant Date”). This Award consists of service-based restricted stock units. The terms and conditions of this incentive are set forth in the remainder of this agreement (including any special terms and conditions set forth in any appendix for your country (“Appendix”)) (collectively, the “Agreement”). The capitalized terms that are not otherwise defined in this Agreement shall have the meanings ascribed to such terms under the Plan.
SECTION 1
Restricted Stock Units – Service-Based Vesting
1.1    Grant. As of the Grant Date, and subject to the terms and conditions of this Agreement and the Plan, the Company grants you Number of Awards Granted (“Restricted Stock Units” or “RSUs”). Each Restricted Stock Unit shall entitle you to one ordinary share of the Company, nominal value €0.001 per share (“Ordinary Share”) on the applicable RSU Vesting Date, provided the vesting conditions described in Section 1.2 are satisfied.
1.2    Vesting. Except as provided in Section 1.3, the Restricted Stock Units awarded in Section 1.1 shall vest on the third anniversary of the Grant Date (“RSU Vesting Date”) provided that you continue in the service of the Company from the Grant Date through the applicable RSU Vesting Date.
Except as provided in Section 1.3, if your Termination Date occurs prior to the RSU Vesting Date, any Restricted Stock Units awarded under Section 1.1 that have not previously vested as of such Termination Date shall be permanently forfeited on your Termination Date.
1.3    Special Vesting Rules. Notwithstanding Section 1.2 above:
(a)    If your Termination Date occurs by reason of death, Disability or Retirement with the Company’s consent, any Restricted Stock Units awarded under Section 1.1 that have not vested prior to such Termination Date shall become fully vested.
(b)    If your Termination Date occurs by reason of an Involuntary Termination for Economic Reasons, any Restricted Stock Units awarded under Section 1.1 that would otherwise be scheduled to vest under Section 1.2 in the 24-month period following such

    


Termination Date shall continue to vest during such 24-month period according to the vesting schedule in effect prior to such Termination Date; provided, however, that if your Termination Date occurs for a reason that is both described in this subsection (b) and in subsection (c) below, the special vesting rules described in subsection (c) shall apply in lieu of the vesting rules described in this subsection (b). Any Restricted Stock Units that are not scheduled to vest during such 24-month period will be permanently forfeited on the Termination Date.
(c)    If your Termination Date occurs by reason of a Termination without Cause or a Separation for Good Reason on or after a Change in Control (as defined in the Plan and as such definition may be amended hereafter) and prior to the two (2) year anniversary of the Change in Control, all Restricted Stock Units awarded under Section 1.1 that have not vested or been forfeited prior to such Termination Date shall become fully vested.
(d)    As used in this Section 1.3, the following terms shall have the meanings set forth below:
(1)    “Separation for Good Reason” means your voluntary resignation from the Company and the existence of one or more of the following conditions that arose without your consent: (i) a material change in the geographic location at which you are required to perform services, such that your commute between home and your primary job site increases by more than 30 miles, or (ii) a material diminution in your authority, duties or responsibilities or a material diminution in your base compensation or incentive compensation opportunities; provided, however, that a voluntary resignation from the Company shall not be considered a Separation for Good Reason unless you provide the Company with notice, in writing, of your voluntary resignation and the existence of the condition(s) giving rise to the separation within 90 days of its initial existence. The Company will then have 30 days to remedy the condition, in which case you will not be deemed to have incurred a Separation for Good Reason. In the event the Company fails to cure the condition within the 30 day period, your Termination Date shall occur on the 31st day following the Company’s receipt of such written notice.
(2)    “Termination without Cause” means the involuntary termination of your employment or contractual relationship by the Company without Cause, including, but not limited to, (i) a termination effective when you exhaust an approved leave of absence, and (ii) a situation where you are on an approved leave of absence during which your position is protected under applicable leave law, you return from such leave, and you cannot be placed in employment or other form of contractual relationship with the Company.
1.4    Settlement of Restricted Stock Units. As soon as practicable after the RSU Vesting Date, the Company shall transfer to you one Ordinary Share for each Restricted Stock Unit becoming vested on such date (the date of any such transfer shall be the “settlement date” for purposes of this Agreement); provided, however, the Company may withhold shares otherwise transferable to you to the extent necessary to satisfy withholding taxes due by reason of the vesting of the Restricted Stock Units, in accordance with Section 2.7. You shall have no rights as a stockholder with respect to the Restricted Stock Units awarded hereunder prior to the date of issuance to you of a certificate or certificates for such shares. Notwithstanding the

    


foregoing, the Committee, in its sole discretion, may elect to settle Restricted Stock Units in cash based on the fair market value of the Ordinary Shares on the RSU Vesting Date.
1.5    Dividend Equivalents. The Restricted Stock Units awarded under Section 1.1 shall be eligible to receive dividend equivalents in accordance with the following:
(a)    An “Account” will be established in your name. Such Account shall be for recordkeeping purposes only, and no assets or other amounts shall be set aside from the Company’s general assets with respect to such Account.
(b)    On each date that a cash dividend is paid with respect to Ordinary Shares, the Company shall credit your Account with the dollar amount of dividends you would have received if each Restricted Stock Unit held by you on the record date for such dividend payment had been an Ordinary Share. No interest or other earnings shall accrue on such Account.
(c)    As of each RSU Vesting Date, you shall receive a payment equal to the amount of dividends that would have been paid on the Restricted Stock Units vesting on such date had they been Ordinary Shares during the period beginning on the Grant Date and ending on the RSU Vesting Date, and the Account shall be debited appropriately. If you forfeit Restricted Stock Units, any amounts in the Account attributable to such Restricted Stock Units shall also be forfeited.
(d)    If dividends are paid in the form of Ordinary Shares rather than cash, then you will be credited with one additional Restricted Stock Unit for each Ordinary Share that would have been received as a dividend had your outstanding Restricted Stock Units been Ordinary Shares. Such additional Restricted Stock Units shall vest or be forfeited at the same time as the Restricted Stock Unit to which they relate.
SECTION 2
General Terms and Conditions
2.1    Nontransferability. The Award under this Agreement shall not be transferable other than by will or by the laws of descent and distribution.
2.2    No Rights as a Stockholder. You shall not have any rights as a stockholder with respect to any Ordinary Shares subject to the RSU awarded under this Agreement prior to the date of issuance to you of a certificate or certificates for such shares.
2.3    Cause Termination. If your Termination Date occurs for reasons of Cause, all of your rights under this Agreement, whether or not vested, shall terminate immediately.
2.4    Award Subject to Plan. The granting of the Award under this Agreement is being made pursuant to the Plan and the Award shall be payable only in accordance with the applicable terms of the Plan. The Plan contains certain definitions, restrictions, limitations and other terms and conditions all of which shall be applicable to this Agreement. ALL THE PROVISIONS OF THE PLAN ARE INCORPORATED HEREIN BY REFERENCE AND ARE MADE A

    


PART OF THIS AGREEMENT IN THE SAME MANNER AS IF EACH AND EVERY SUCH PROVISION WERE FULLY WRITTEN INTO THIS AGREEMENT. Should the Plan become void or unenforceable by operation of law or judicial decision, this Agreement shall have no force or effect. Nothing set forth in this Agreement is intended, nor shall any of its provisions be construed, to limit or exclude any definition, restriction, limitation or other term or condition of the Plan as is relevant to this Agreement and as may be specifically applied to it by the Committee. In the event of a conflict in the provisions of this Agreement and the Plan, as a rule of construction the terms of the Plan shall be deemed superior and apply.
2.5    Adjustments in Event of Change in Ordinary Shares. In the event of a stock split, stock dividend, recapitalization, reclassification or combination of shares, merger, sale of assets or similar event, the number and kind of shares subject to the Award under this Agreement will be appropriately adjusted in an equitable manner to prevent dilution or enlargement of the rights granted to or available for you.
2.6    Acknowledgement. The Company and you agree that the RSUs are granted under and governed by the Notice of Grant, this Agreement (including the Appendix) and by the provisions of the Plan (incorporated herein by reference). You: (i) acknowledge receipt of a copy of each of the foregoing documents, (ii) represent that you have carefully read and are familiar with their provisions, and (iii) hereby accept the RSUs subject to all of the terms and conditions set forth herein and those set forth in the Plan and the Notice of Grant.
2.7    Responsibility for Taxes. Regardless of any action the Company or, if different, the Affiliate employing or retaining you takes with respect to any or all income tax, social insurance, payroll tax, payment on account or other tax-related items related to your participation in the Plan and legally applicable to you (“Tax-Related Items”), you acknowledge that the ultimate liability for all Tax-Related Items is and remains your responsibility and may exceed the amount actually withheld by the Company or the Affiliate employing or retaining you. You further acknowledge that the Company and/or the Affiliate employing or retaining you (1) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the RSUs, including, but not limited to, the grant, vesting or settlement of the RSUs, the subsequent sale of Ordinary Shares acquired pursuant to such settlement and the receipt of any dividends; and (2) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the RSUs to reduce or eliminate your liability for Tax-Related Items or achieve any particular tax result. Further, if you have become subject to tax in more than one jurisdiction between the RSU Grant Date and the date of any relevant taxable event, as applicable, you acknowledge that the Company and/or the Affiliate employing or retaining you (or formerly employing or retaining you, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.
(a)     Prior to any relevant taxable or tax withholding event, as applicable, you will pay or make adequate arrangements satisfactory to the Company and/or the Affiliate employing or retaining you to satisfy all Tax-Related Items. In this regard, you authorize the Company and/or the Affiliate employing or retaining you, or their respective agents, at their

    


discretion, to satisfy the obligations with regard to all Tax-Related Items by one or a combination of the following:
(1)    withholding from your wages or other cash compensation paid to you by the Company and/or the Affiliate employing or retaining you; or
(2)    withholding from proceeds of the sale of Ordinary Shares acquired upon settlement of the RSUs either through a voluntary sale or through a mandatory sale arranged by the Company (on your behalf pursuant to this authorization); or
(3)    withholding in Ordinary Shares to be issued upon settlement of the RSUs.
(b)    To avoid negative accounting treatment, the Company may withhold or account for Tax-Related Items by considering applicable minimum statutory withholding amounts or other applicable withholding rates. If the obligation for Tax-Related Items is satisfied by withholding in Ordinary Shares, for tax purposes, you are deemed to have been issued the full number of Ordinary Shares subject to the vested RSUs, notwithstanding that a number of the Ordinary Shares are held back solely for the purpose of paying the Tax-Related Items.
(c)    Finally, you shall pay to the Company or the Affiliate employing or retaining you any amount of Tax-Related Items that the Company or the Affiliate employing or retaining you may be required to withhold or account for as a result of your participation in the Plan that cannot be satisfied by the means previously described. The Company may refuse to issue or deliver the Ordinary Sharse or the proceeds of the sale of Ordinary Shares, if you fail to comply with your obligations in connection with the Tax-Related Items.
2.8    Compliance with Applicable Law. The issuance of Ordinary Shares will be subject to and conditioned upon compliance by the Company and you, including any written representations, warranties and agreements as the Administrator may request of you for compliance with all (i) applicable U.S. state and federal laws and regulations, (ii) applicable laws of the country where you reside pertaining to the issuance or sale of Ordinary Shares, and (iii) applicable requirements of any stock exchange or automated quotation system on which the Company’s Ordinary Shares may be listed or quoted at the time of such issuance or transfer.
2.9    Code Section 409A (Only Applicable to Individuals Subject to U.S. Federal Tax Laws).
(a)    Restricted Stock Units other than Restricted Stock Units that continue to vest by reason of your Involuntary Termination for Economic Reasons and dividend equivalents payable under this Agreement are intended to be exempt from Code Section 409A under the exemption for short-term deferrals. Accordingly, Restricted Stock Units (other than Restricted Stock Units that continue to vest by reason of your Involuntary Termination for Economic Reasons) will be settled and dividend equivalents will be paid no later than the 15th day of the

    


third month following the later of (i) the end of your taxable year in which the RSU Vesting Date occurs, or (ii) the end of the fiscal year of the Company in which the RSU Vesting Date occurs.
(b)    Restricted Stock Units that continue to vest by reason of your Involuntary Termination for Economic Reasons are subject to the provisions of this subsection (b). Any distribution in settlement of such Restricted Stock Units will occur provided your Involuntary Termination for Economic Reasons constitutes a “separation from service” as defined in Treasury Regulation §1.409A-1(h). If the Company determines that you are a “specified employee” as defined in Code Section 409A (i.e., an officer with annual compensation above $130,000 (as adjusted for inflation), a five-percent owner of the Company or a one-percent owner with annual compensation in excess of $150,000), distribution in settlement of any such Restricted Stock Units that would be payable within six months of your separation from service shall be delayed to the first business day following the six-month anniversary of your separation from service. Any distribution in settlement of such Restricted Stock Units that would be made more than six months after your separation from service (without application of the six-month delay) shall not be subject to the six-month delay described in this subsection.
2.10    Data Privacy.
(a)    By entering into this Agreement and accepting this Award, you hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Agreement and any other RSU grant materials by and among, as applicable, the Affiliate employing or retaining you, the Company and its Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.
(b)    You understand that the Company and the Affiliate employing or retaining you may hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all RSUs or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the exclusive purpose of implementing, administering and managing the Plan (“Data”).
(c)    You understand that Data will be transferred to legal counsel or a broker or such other stock plan service provider as may be selected by the Company in the future, which is assisting the Company with the implementation, administration and management of the Plan. You understand that the recipients of the Data may be located in the United States or elsewhere, and that the recipients’ country (e.g., the United States) may have different data privacy laws and protections than your country. You understand that if you reside outside the United States, you may request a list with the names and addresses of any potential recipients of the Data by contacting your local or Company human resources representative. You authorize the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing your participation in the Plan. You

    


understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan. You understand that if you reside outside the United States, you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local or Company human resources representative. You understand, however, that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local or Company human resources representative.
2.11     Nature of Grant. In accepting the grant, you acknowledge, understand and agree that:
(a)    the Plan is established voluntarily by the Company, it is discretionary in nature and it may be modified, amended, suspended or terminated by the Company at any time, except as otherwise provided in the Plan;
(b)    the grant of the RSUs is voluntary and occasional and does not create any contractual or other right to receive future grants of RSUs, or benefits in lieu of RSUs, even if RSUs have been granted repeatedly in the past;
(c)    all decisions with respect to future RSU grants, if any, will be at the sole discretion of the Company;
(d)    you are voluntarily participating in the Plan;
(e)    the RSUs and the Ordinary Shares subject to the RSUs are an extraordinary item and which is outside the scope of your employment or service contract, if any;
(f)    the RSUs and the Ordinary Shares subject to the RSUs are not intended to replace any pension rights or compensation;
(g)    the RSUs and the Ordinary Shares subject to the RSUs are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments and in no event should be considered as compensation for, or relating in any way to, past services for the Company, the Affiliate employing or retaining you or any other Affiliate;
(h)    the grant and your participation in the Plan will not be interpreted to form an employment or service contract with the Company or any Affiliate;
(i)    the future value of the underlying Ordinary Shares is unknown, indeterminable and cannot be predicted with certainty;
(j)    no claim or entitlement to compensation or damages shall arise from forfeiture of the RSUs resulting from your Termination Date (for any reason whatsoever, whether

    


or not later found to be invalid and whether or not in breach of employment laws in the jurisdiction where you are employed or rendering services, or the terms of your employment agreement, if any), and in consideration of the grant of the RSUs to which you are otherwise not entitled, you irrevocably agree never to institute any claim against the Company or the Affiliate employing or retaining you, waive your ability, if any, to bring any such claim, and release the Company and the Affiliate employing or retaining you from any such claim; if, notwithstanding the foregoing, any such claim is allowed by a court of competent jurisdiction, then, by participating in the Plan, you shall be deemed irrevocably to have agreed not to pursue such claim and agree to execute any and all documents necessary to request dismissal or withdrawal of such claim; and
(k)    you acknowledge and agree that neither the Company, the Affiliate employing or retaining you nor any other Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the United States Dollar that may affect the value of the RSUs or of any amounts due to you pursuant to the settlement of the RSUs or the subsequent sale of any Ordinary Shares acquired upon settlement.
2.12    Successors and Assigns. This Agreement shall be binding upon any or all successors and assigns of the Company.
2.13    Applicable Law. This Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of Michigan, U.S.A., without regard to principals of conflict of laws. Any proceeding related to or arising out of this Agreement shall be commenced, prosecuted or continued in the Circuit Court in Kent County, Michigan located in Grand Rapids, Michigan or in the United Stated District Court for the Western District of Michigan, and in any appellate court thereof.
2.14 Forfeiture of RSUs. If the Company, as a result of misconduct, is required to prepare an accounting restatement due to material noncompliance with any financial reporting requirement under the securities laws, then (a) if your incentive or equity-based compensation is subject to automatic forfeiture due to such misconduct and restatement under Section 304 of the Sarbanes-Oxley Act of 2002, or (b) the Committee determines you either knowingly engaged in or failed to prevent the misconduct, or your actions or inactions with respect to the misconduct and restatement constituted gross negligence, you shall (i) be required to reimburse the Company the amount of any payment (including dividend equivalents) relating to any RSUs earned or accrued during the twelve month period following the first public issuance or filing with the SEC (whichever first occurred) of the financial document embodying such financial reporting requirement, and (ii) all outstanding RSUs (including related dividend equivalents) that have not yet been settled shall be immediately forfeited. In addition, Ordinary Shares acquired under this Agreement, and any gains or profits on the sale of such Ordinary Shares, shall be subject to any “clawback” or recoupment policy later adopted by the Company.
2.15    Appendix. Notwithstanding any provisions in this Agreement, the RSU grant shall be subject to any special terms and conditions set forth in any Appendix to this Agreement for your country. Moreover, if you relocate to one of the countries included in the Appendix, the special terms and conditions for such country will apply to you, to the extent the Company

    


determines that the application of such provisions is necessary or advisable in order to comply with laws of the country where you reside or to facilitate the administration of the Plan. The Appendix constitutes part of this Agreement.
2.16    Imposition of Other Requirements. The Company reserves the right to impose other requirements on your participation in the Plan, on the RSUs and on any Ordinary Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable in order to comply with laws of the country where you reside or to facilitate the administration of the Plan, and to require you to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.
****
We look forward to your continuing contribution to the growth of the Company. Please acknowledge your receipt of the Plan and this Award.
Very truly yours,




Print Name: ___________________________
Title:_________________________________

    



APPENDIX

PERRIGO COMPANY PLC
Additional Terms and Provisions to
Restricted Stock Unit Award Agreement (Service-Based)

Terms and Conditions
This Appendix (the “Appendix”) includes additional terms and conditions that govern the restricted stock units (“RSUs” or “Award”) granted to you under the Plan if you reside in one of the countries listed below. Certain capitalized terms used but not defined in this Appendix have the meanings set forth in the Plan and/or the Agreement.
In addition, please note that the Award is exceptional in nature as it relates to the specific cicumstances of acquisition of the shares of Omega Pharma. Perrigo considers it to be a useful incentive for the combined portfolio to be successful. Therefore, it will not create any entitlement to receive any similar benefit in the future.
Notifications
This Appendix also includes country-specific information of which you should be aware with respect to your participation in the Plan. The information is based on the securities, exchange control and other laws in effect in the respective countries as of December 2014. Such laws are often complex and change frequently. As a result, the Company strongly recommends that you do not rely on the information noted herein as the only source of information relating to the consequences of your participation in the Plan because the information may be out of date at the time that you vest in the RSUs and Ordinary Shares are issued to you or the shares issued upon vesting of the RSUs are sold.
In addition, the information is general in nature and may not apply to your particular situation, and the Company is not in a position to assure you of any particular result. Accordingly, you are advised to seek appropriate professional advice as to how the relevant laws in your country may apply to your particular situation. Finally, please note that if you are a citizen or resident of a country other than the country in which you are currently working, or transfers employment after grant, the information contained in the Appendix may not be applicable.



    


Argentina
Notifications
Securities Law Information. Neither the Award nor the issuance of the shares are publicly offered or listed on any stock exchange in Argentina. The offer is private and not subject to the supervision of any Argentine governmental authority.
Exchange Control Information. In the event that you transfer sales proceeds in excess of US$50,000 from the sale of shares into Argentina in a single month, you will be subject to certain exchange control reporting requirements. In addition, you may be subject to a mandatory 30% restriction on holding of funds brought into Argentina. Please note that exchange control regulations in Argentina are subject to frequent change. You should consult with your personal legal advisor regarding any exchange control obligations that you may have.
Australia
Terms and Conditions
RSUs Settled in Shares Only. Notwithstanding any discretion contained in the Plan, or any provision in the Agreement to the contrary, RSUs granted to employees in Australia shall be settled in shares only and do not provide any right for you to receive a cash payment under this Award.
Notifications
Securities Information. If you acquire shares pursuant to the Award and you offer the shares for sale to a person or entity resident in Australia, then the offer may be subject to disclosure requirements under Australian law. You should obtain legal advice on your disclosure obligations prior to making any such offer.
Exchange Control Information. Exchange control reporting is required for cash transactions exceeding AUD10,000 and for international fund transfers. The Australian bank assisting with the transaction will file the report for you. If there is no Australian bank involved in the transfer, you will have to file the report.
Austria
Notifications
Exchange Control Information. If you hold shares of Company stock outside of Austria, you must submit a report to the Austrian National Bank. An exemption applies if the value of the shares as of any given quarter does not exceed €30,000,000 or as of December 31 does not exceed €5,000,000. If the former threshold is exceeded, quarterly obligations are imposed, whereas if the latter threshold is exceeded, annual reports must be given. The annual reporting date is as of December 31 and the deadline for filing the annual report is March 31 of the following year.
When shares are sold, there may be exchange control obligations if the cash received is held outside Austria. If the transaction volume of all your accounts abroad exceeds €3,000,000, the

    


movements and balances of all accounts must be reported monthly, as of the last day of the month, on or before the fifteenth day of the following month.
Belgium
No country specific provisions.
Czech Republic
Notifications
Exchange Control Information. The Czech National Bank may require you to report the RSUs and or Ordinary Shares received and the opening and maintenance of a foreign account. However, because exchange control regulations change frequently and without notice, you should consult your personal legal advisor prior to the vesting of the RSUs to ensure your compliance with current regulations. It is your responsibility to comply with applicable Czech exchange control laws.
Denmark
Notifications
Exchange Control Information. If you establish an account holding shares pursuant to the Award or an account holding cash outside Denmark, you must report the account to the Danish Tax Administration. The form which should be used in this respect can be obtained from a local bank. (Please note that these obligations are separate from and in addition to the obligations described below.)
Securities/Tax Reporting Information. If you hold shares acquired under the Plan in a brokerage account with a broker or bank outside Denmark, you are required to inform the Danish Tax Administration about the account. For this purpose, you must file a Form V (Erklaering V) with the Danish Tax Administration. The Form V must be signed both by you and by the applicable broker or bank where the account is held. By signing the Form V, the broker or bank undertakes to forward information to the Danish Tax Administration concerning the shares in the account without further request each year. By signing the Form V, you authorize the Danish Tax Administration to examine the account. A sample of the Form V can be found at the following website: www.skat.dk.
In addition, if you open a brokerage account (or a deposit account with a U.S. bank) for the purpose of holding cash outside Denmark, you are also required to inform the Danish Tax Administration about this account. To do so, you must also file a Form K (Erklaering K) with the Danish Tax Administration. The Form K must be signed both by you and by the applicable broker or bank where the account is held. By signing the Form K, the broker/bank undertakes an obligation, without further request each year, to forward information to the Danish Tax Administration concerning the content of the account. By signing the Form K, you authorize the Danish Tax Administration to examine the account. A sample of Form K can be found at the following website: www.skat.dk.

    


Finland
There are no country specific provisions.
France
Terms and Conditions
Consent to Receive Information in English. By accepting the Award, you confirm having read and understood the Plan and the Agreement, which were provided in the English language. You accept the terms of those documents accordingly.
En acceptant cette attribution gratuite d'actions, vous confirmez avoir lu et comprenez le Plan et ce Contrat, incluant tous leurs termes et conditions, qui ont été transmis en langue anglaise. Vous acceptez les dispositions de ces documents en connaissance de cause.
Notifications
Exchange Control Information. If you hold Ordinary Shares outside of France or maintain a foreign bank account, you are required to report such to the French tax authorities when you file your annual tax return.
Germany
Notifications
Exchange Control Information. Cross-border payments in excess of €12,500 must be reported monthly to the German Federal Bank. If you use a German bank to transfer a cross-border payment in excess of €12,500 in connection with the sale of shares acquired under the Plan, the bank will make the report for you. In addition, you must report any receivables, payables, or debts in foreign currency exceeding an amount of €5,000,000 on a monthly basis.
Greece
Notifications
Exchange Control Information. Pursuant to your Award, if you withdraw funds in excess of €15,000 from a bank in Greece and remit those funds out of Greece, you may be required to submit certain documentation/ information to the Greek bank to ensure that the transfer is not in violation of Greek anti-money laundering rules.
Hungary
No country specific provisions.


    


India
Notifications
Exchange Control Notification. You must repatriate all proceeds received from the sale of the shares to India within 90 days after sale. You will receive a foreign inward remittance certificate (“FIRC”) from the bank where you deposit the foreign currency. You should maintain the FIRC as evidence of the repatriation of funds in the event that the Reserve Bank of India or the employer requests proof of repatriation.
Tax Information. The amount subject to tax at vesting will partially be dependent upon a valuation that the Company or your employer will obtain from a Merchant Banker in India. Neither the Company nor your employer has any responsibility or obligation to obtain the most favorable valuation possible, nor obtain valuations more frequently than required under Indian tax law.
Ireland
Notifications
Director Notification Obligation. If you are a director, shadow director or secretary of the Company or an Irish Subsidiary or Affiliate of the Company, and you acquire or dispose of an interest under this Agreement comprising more than 1% of the share capital in the Company, you must notify the entity in which you hold that office (whether the Company itself or an Irish Subsidiary or Affiliate of the Company) in writing within five business days of receiving or disposing of an interest in the Company, or within five business days of becoming aware of the event giving rise to the notification requirement or within five days of becoming a director or secretary if such an interest exists at the time. This notification requirement also applies with respect to the interests of a spouse or children under the age of 18 (whose interests will be attributed to the director, shadow director or secretary).
Italy
Terms and Conditions
Data Privacy Notice. The following provision supplements the terms in the Agreement:
You understand that your employer and/or the Company may hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social security number (or any other social or national identification number), salary, nationality, job title, number of Ordinary Shares held and the details of all RSUs or any other entitlement to Ordinary Shares awarded, cancelled, exercised, vested, unvested or outstanding (the “Data”) for the purpose of implementing, administering and managing your participation in the Plan. You are aware that providing the Company with the Data is necessary for the performance of this Agreement and that your refusal to provide such Data would make it impossible for the Company to perform its contractual obligations and may affect your ability to participate in the Plan.
The "Controller" of personal data processing is Perrigo Company, plc, with registered offices at Allegan, Michigan, USA, and, pursuant to D.lgs 196/2003, its representative is David A. McConnell. You understand that the Data may be transferred to the Company or any of its subsidiaries or

    


affiliates, or to any third parties assisting in the implementation, administration and management of the Plan, including any transfer required to a broker or other third party with whom Ordinary Shares acquired pursuant to the vesting of the RSUs or cash from the sale of Ordinary Shares acquired pursuant to the Plan may be deposited. Furthermore, the recipients that may receive, possess, use, retain and transfer such Data for the above mentioned purposes may be located in Italy or elsewhere, including outside of the European Union and that the recipients’ country (e.g., the United States) may have different data privacy laws and protections than Italy. The processing activity, including the transfer of your personal data abroad, outside of the European Union, as herein specified and pursuant to applicable laws and regulations, does not require your consent thereto as the processing is necessary for the performance of contractual obligations related to the implementation, administration and management of the Plan. You understand that Data processing relating to the purposes above specified shall take place under automated or non-automated conditions, anonymously when possible, that comply with the purposes for which Data are collected and with confidentiality and security provisions as set forth by applicable laws and regulations, with specific reference to D.lgs. 196/2003.
You understand that Data will be held only as long as is required by law or as necessary to implement, administer and manage your participation in the Plan. You understand that pursuant to art.7 of D.lgs 196/2003, you have the right, including but not limited to, access, delete, update, request the rectification of your personal Data and cease, for legitimate reasons, the Data processing. Furthermore, you are aware that your Data will not be used for direct marketing purposes.
Plan Document Acknowledgment. In accepting the RSUs, you acknowledge that you have received a copy of the Plan and the Agreement and have reviewed the Plan and the Agreement, including this Appendix, in their entirety and fully understand and accept all provisions of the Plan and the Agreement, including this Appendix.
Notifications
Tax/Exchange Control Information. You are required to report on your annual tax return: (a) any transfers of cash or Ordinary Shares to or from Italy exceeding €10,000 or the equivalent amount in U.S. dollars; (b) any foreign investments or investments (including the Ordinary Shares issued at vesting of the RSUs, cash or proceeds from the sale of Ordinary Shares acquired under the Plan) held outside of Italy exceeding €10,000 or the equivalent amount in U.S. dollars, if the investment may give rise to income in Italy (this will include reporting the Ordinary Shares issued at vesting of the RSUs if the fair market value of such Ordinary Shares combined with other foreign assets exceed €10,000); and (c) the amount of the transfers to and from abroad which have had an impact during the calendar year on your foreign investments or investments held outside of Italy. You are exempt from the formalities in (a) if the investments are made through an authorized broker resident in Italy, as the broker will comply with the reporting obligation on your behalf.
Kazakhstan
Notifications
Exchange Control Information. Although Kazakh residents are no longer required to obtain a license from the National Bank of Kazakhstan in advance of obtaining securities in foreign companies, you are nevertheless required to notify the National Bank of Kazakhstan when you acquire shares under the Plan.

    


Latvia
No country specific provisions.
Luxembourg
Notifications
Exchange Control Information. You are required to report any inward remittances of funds to the Banque Central de Luxembourg and/or the Service Central de La Statistique et des Etudes Economiques within 15 working days following the month during the transaction occurred. If a Luxembourg financial institution is involved in the transaction, it generally will fulfill the reporting obligation on your behalf.
Mexico
Terms and Conditions
Modification. By accepting the RSUs, you understand and agree that any modification of the Plan or the Agreement or its termination shall not constitute a change or impairment of the terms and conditions of employment.
Policy Statement. The award of the RSUs the Company is making under the Plan is unilateral and discretionary and, therefore, the Company reserves the absolute right to amend it and discontinue it at any time without any liability.
The Company, with registered offices in the U.S., is solely responsible for the administration of the Plan and participation in the Plan and the acquisition of shares does not, in any way, establish an employment relationship between you and the Company since you are participating in the Plan on a wholly commercial basis and the sole employer is as applicable, nor does it establish any rights between you and the Employer.
Plan Document Acknowledgment. By accepting the award of the RSUs, you acknowledge that you have received copies of the Plan, have reviewed the Plan and the Agreement in their entirety and fully understand and accept all provisions of the Plan and the Agreement.
In addition, by signing the Agreement, you further acknowledge that you have read and specifically and expressly approve the terms and conditions in the Agreement, in which the following is clearly described and established: (i) participation in the Plan does not constitute an acquired right; (ii) the Plan and participation in the Plan is offered by the Company on a wholly discretionary basis; (iii) participation in the Plan is voluntary; and (iv) the Company and any Parent, Subsidiary or Affiliates are not responsible for any decrease in the value of the shares.
Finally, you hereby declare that you do not reserve any action or right to bring any claim against the Company for any compensation or damages as a result of your participation in the Plan and therefore grant a full and broad release to the Employer, the Company and any Parent, Subsidiary or Affiliates with respect to any claim that may arise under the Plan.


    


Spanish Translation
Modification. Al aceptar las Unidades de Accion Restringida, usted reconoce y acuerda que cualquier modification del Plan o su terminacion no constituye un cambio o desmejora de los terminos y condiciones de empleo.
Declaracion de Politica. El Otorgarmiento de Unidades de Accion Restringida de la Compañia en virtud del Plan es unilateral y discrecional y, por lo tanto, la Compañia se reserva el derecho absoluto de modificar y discontinuar el mismo en cualquier tiempo, sin responsabilidad alguna.
La Compañia, con oficinas registradas ubicadas en the U.S., es la unica responsable de la administración del Plan y de la participación en el mismo y la adquisición de Acciones no establece de forma alguna una relación de trabajo entre usted y la Compañia, ya que su participación en el Plan es completamente comercial y el unico empleador es en caso de ser aplicable, asi como tampoco establece ningun derecho entre la persona que tenga el derecho a optar y el Empleador.
Reconocimiento del Documento del Plan. Al aceptar el Otorgamiento de las Unidades de Acciόn Restringida, usted reconoce que ha recibido copias del Plan, ha revisado el mismo, al igual que la totalidad del Acuerdo y, que ha entendido y aceptado completamente todas las disposiciones contenidas en el Plan y en el Acuerdo.
Adicionalmente, al firmar el Acuerdo, reconoce que ha leido, y que aprueba especifica y expresamente los términos y condiciones contenidos en la Renuncia de Derecho o Reclamo por Compensación del Acuerdo, en el cual se encuentra claramente descrito y establecido lo siguiente: (i) la participación en el Plan no constituye un derecho adquirido; (ii) el plan y la participación en el mismo es ofrecida por la Compañia de forma enteramente discrecional; (iii) la participación en el Plan es voluntaria; y (iv) la Compañia, asi como su Sociedad controlante, Subsidiaria o Filiales no son responsables por cualquier disminución en el valor de las Acciones.
Finalmente, declara que no se reserva ninguna acciόn o derecho para interponer una demanda en contra de la Compañia por compensación, dano o perjuicio alguno como resultado de su participación en el Plan y, en consecuencia, otorga el más amplio finiquito al Empleador, asi como a la Compañia, a su Sociedad controlante, Subsidiaria o Filiales con respecto a cualquier demanda que pudiera originarse en virtud del Plan.
Netherlands
Notifications
Insider-Trading Notification. You should be aware of the Dutch insider-trading rules which may prohibit you from effectuating certain transactions involving shares if you have inside information about the Company. If you are uncertain whether the insider-trading rules apply to you, you should consult your personal legal advisor.
Norway
No country specific provisions.

    


Poland
Terms and Conditions
Consent to Receive Information in English. By accepting the Award, you confirm having read and understood the Plan and the Agreement, which were provided in the English language. You accept the terms of those documents accordingly.
Section 2.11 item (h) of the Award Agreement shall be also understood as that the grant and your participation in the Plan will not be interpreted to form or be part of terms and conditions of your employment or service with any Subsidiary or affiliate of the Company.
Notifications
Exchange Control Information. If you hold foreign securities (including shares pursuant to the Award) and maintain accounts abroad, you may be required to file certain reports with the National Bank of Poland. Specifically, if the value of securities and cash held in such foreign accounts exceeds PLN 7,000,000 at the end of the year, you must file reports on the transactions and balances of the accounts on a quarterly basis by the 20th day of the month following the end of each quarter and an annual report by no later than January 30 of the following calendar year. Such reports are filed on special forms available on the website of the National Bank of Poland. Additionally, if you are a Polish citizen and you transfer funds abroad in excess of the PLN equivalent of €15,000, the transfer must be made through an authorized bank, a payment institution or an electronic money institution authorized to render payment services.
Portugal
Notifications
Exchange Control Information. If you receive shares pursuant to the Award, the acquisition of the shares should be reported to the Banco de Portugal for statistical purposes. If the shares are deposited with a commercial bank or financial intermediary in Portugal, such bank or financial intermediary will submit the report on your behalf. If the shares are not deposited with a commercial bank or financial intermediary in Portugal, you are responsible for submitting the report to the Banco de Portugal.
Romania
Notifications
Exchange Control Information. Payments by Romanian citizens to or from non-residents in excess of €50,000 should be reported to the National Bank of Romania (“NBR”) for statistical purposes. If you deposit the proceeds from the sale of shares issued to you at vesting in a bank account in Romania, you may be required to provide the Romanian bank with appropriate documentation explaining the source of the funds. You should consult your personal advisor to determine whether you will be required to submit such documentation to the Romanian bank.

    


Insider-Trading Notification. You should be aware of the Romanian insider-trading rules which may prohibit you from effectuating certain transactions involving shares if you have inside information about the Company. If you are uncertain whether the insider-trading rules apply to you, you should consult your personal legal advisor.
Russia
Terms and Conditions
(iv)U.S. Transaction. You understand that the RSUs shall be valid and this Agreement shall be concluded and become effective only when the Agreement is electronically received by the Company in the United States. Upon vesting, any shares to be issued to you shall be delivered to you through a bank or brokerage account in the United States. You are not permitted to sell the shares directly to other Russian legal entities or individuals.
Notifications
(v)Exchange Control Information. Under current exchange control regulations, within a reasonably short time after sale of the shares issued at vesting, you must repatriate the sale proceeds to Russia. Such sale proceeds must be initially credited to you through a foreign currency account at an authorized bank in Russia. After the sale proceeds are initially received in Russia, they may be further remitted to foreign banks in accordance with Russian exchange control laws.
(vi)You are encouraged to contact your personal advisor before remitting your sale proceeds to Russia as exchange control requirements may change.
Securities Law Notification. This Appendix, the Agreement, the Plan and all other materials that you may receive regarding participation in the Plan do not constitute advertising or an offering of securities in Russia. Absent any requirement under local law, the issuance of securities pursuant to the Plan has not and will not be registered in Russia; hence, the securities described in any Plan-related documents may not be used for offering or public circulation in Russia.
Serbia
No country specific provisions.
Slovakia
No country specific provisions.

    


Slovenia
No country specific provisions.
South Africa
Terms and Conditions
Taxes. By accepting the RSUs, you agree that, immediately upon vesting of the RSUs, you will notify your employer of the amount of any gain realized. If you fail to advise your employer of the gain realized upon vesting, you may be liable for a fine. You will be solely responsible for paying any difference between the actual tax liability and the amount withheld by your employer.
Notifications
Exchange Control Information. Because no transfer of funds from South Africa is required under the RSUs, no filing or reporting requirements should apply when the award is granted nor when Ordinary Shares are issued upon vesting of the RSUs. However, because the exchange control regulations are subject to change, you should consult your personal advisor prior to vesting and settlement of the award to ensure compliance with current regulations.
Spain
Terms and Conditions
No Entitlement for Claims or Compensation. By accepting the award of RSUs, you consent to participation in the Plan, and acknowledge that you have received a copy of the Plan document. You understand that the Company has unilaterally, gratuitously and in its sole discretion decided to make awards of RSUs under the Plan to individuals who may be employees, consultants and directors throughout the world. The decision is limited and entered into based upon the express assumption and condition that any RSUs will not economically or otherwise bind the Company or any Parent, Subsidiary or Affiliate, including your employer, on an ongoing basis, other than as expressly set forth in the Agreement. Consequently, you understand that the Award is given on the assumption and condition that the RSUs shall not become part of any employment contract (whether with the Company or any Parent, Subsidiary or Affiliate, including your employer) and shall not be considered a mandatory benefit, salary for any purpose (including severance compensation) or any other right whatsoever. Furthermore, you understand and freely accept that there is no guarantee that any benefit whatsoever shall arise from the award, which is gratuitous and discretionary, since the future value of the RSUs and the underlying shares is unknown and unpredictable. You also understand that this Award would not be made but for the assumptions and conditions set forth hereinabove; thus, you understand, acknowledge and freely accept that, should any or all of the assumptions be mistaken or any of the conditions not be met for any reason, the Award, the RSUs and any right to the underlying shares shall be null and void.
Notifications
Exchange Control Information. You must declare the acquisition of Ordinary Shares to the Dirección General de Politica Comercial e Inversiones Exteriores ("DGPCIE") of the Ministerio de

    


Economia for statistical purposes. You must also declare the ownership of any Ordinary Shares with the Directorate of Foreign Transactions each January while the shares are owned. In addition, you wish to import the share certificates into Spain, you must declare the importation of such securities to the DGPCIE.
When receiving foreign currency payments derived from the ownership of Ordinary Shares (i.e., dividends or sale proceeds), you must inform the financial institution receiving the payment of the basis upon which such payment is made. You will need to provide the following information: (i) your name, address, and fiscal identification number; (ii) the name and corporate domicile of the Company; (iii) the amount of the payment and the currency used; (iv) the country of origin; (v) the reasons for the payment; and (vi) further information that may be required.
Tax Information. If you hold assets or rights outside of Spain (including shares acquired under the Plan), you may have to file an informational tax report with the tax authorities declaring such ownership. Generally, if the value of your foreign investments exceeds €50,000, you may have to file this informational return. Please note that reporting requirements are based on what you have previously disclosed and the increase in value of such and the total value of certain groups of foreign assets. Also, the thresholds for annual filing requirements may change each year. Therefore, you should consult your personal advisor regarding whether you will be required to file an informational tax report for asset and rights that you hold abroad.
Sweden
Terms and Conditions
The following shall apply in addition to what is set out under section 2.14 of the Award Agreement:
Forfeiture of entitlements under the Plan in case of termination shall apply in case of termination of employment regardless of whether such termination of employment may be justified under Swedish employment protection legislation, and regardless of whether such termination may be challenged by you, and regardless of whether such termination is invalidated by verdict or a court order.
Switzerland
Notifications
Securities Law Notification The award is considered a private offering in Switzerland; therefore, it is not subject to registration in Switzerland.
Turkey
No country specific provisions.
Ukraine
Notifications

    


Exchange Control Information. Exchange control rules change frequently and you should consult your personal advisor to determine whether you are required to obtain a license for obtaining shares of a foreign company from the National Bank of Ukraine (NBU).
Terms and Conditions
The Award will be outside the scope of your employment or service contract (if any) and as such will not constitute a part of your compensation package under the respective employment or service contract.
United Kingdom
Terms and Conditions
Income Tax and National Insurance Contribution Withholding. The following provision supplements the terms in the Agreement:
If payment or withholding of the income tax due in connection with the RSUs is not made within ninety (90) days of the end of the U.K. tax year in which the event giving rise to the income tax liability or such other period specified in Section 222(1)(c) of the U.K. Income Tax (Earnings and Pensions) Act 2003 occurred (the “Due Date”), the amount of any uncollected income tax shall constitute a loan owed by you to your employer, effective as of the Due Date. You agree that the loan will bear interest at the then-current official rate of Her Majesty’s Revenue & Customs (“HMRC”), it shall be immediately due and repayable, and the Company or your employer may recover it at any time thereafter by any of the means referred to in Section 2.7 of the Agreement. Notwithstanding the foregoing, if you are a director or executive officer of the Company (within the meaning of Section 13(k) of the U.S. Securities and Exchange Act of 1934, as amended), you will not be eligible for a loan from the Company or your employer to cover the income tax liability. In the event that you are a director or executive officer and the income tax is not collected from or paid by the Due Date, the amount of any uncollected income tax will constitute a benefit to you on which additional income tax and national insurance contributions (“NICs”) will be payable. You will be responsible for reporting any income tax for reimbursing the Company or your employer the value of any employee NICs due on this additional benefit.
* * * * *












    




Bel
PERRIGO COMPANY PLC

    



PERRIGO COMPANY PLC
RESTRICTED STOCK UNIT AWARD AGREEMENT
(SERVICE-BASED)
(Under the Perrigo Company plc 2013 Long-Term Incentive Plan)
TO:        «First_Name» «Last_Name»
RE:        Notice of Restricted Stock Unit Award (Service-Based)
This is to notify you that Perrigo Company plc (the “Company”) has granted you an Award under the Perrigo Company plc 2013 Long-Term Incentive Plan (the “Plan”), effective as of ______________________ (the “Grant Date”). This Award consists of service-based restricted stock units. The terms and conditions of this incentive are set forth in the remainder of this agreement (the “Agreement”). The capitalized terms that are not otherwise defined in this Agreement shall have the meanings ascribed to such terms under the Plan.
SECTION 1
Restricted Stock Units – Service-Based Vesting
1.1    Grant. As of the Grant Date, and subject to the terms and conditions of this Agreement and the Plan, the Company grants you «Number_of_restricted_stock units» (“RSUs”). Each RSU entitles you to one ordinary share of the Company, nominal value €0.001 per share (“Ordinary Share”) on the applicable RSU Vesting Date, provided the vesting conditions described in Section 1.2 are satisfied.
1.2    Vesting. Except as provided in Section 1.3, the RSUs awarded in Section 1.1 shall fully vest on the first anniversary of the Grant Date (the “RSU Vesting Date”) provided that you continue in the service of the Company from the Grant Date through the applicable RSU Vesting Date.
Except as provided in Section 1.3, if your Termination Date occurs prior to the RSU Vesting Date, any RSUs awarded under Section 1.1 that have not previously vested as of such Termination Date shall be permanently forfeited on your Termination Date.
1.3    Special Vesting Rules. Notwithstanding Section 1.2 above:
(a)    If your Termination Date occurs by reason of death, Disability or Retirement with the Company’s consent, any RSUs awarded under Section 1.1 that have not vested prior to such Termination Date shall become fully vested.
(b)    If your Termination Date occurs by reason of an Involuntary Termination for Economic Reasons, any RSUs awarded under Section 1.1 that would otherwise be scheduled to vest under Section 1.2 in the 24-month period following such Termination Date shall continue to vest during such 24-month period according to the vesting schedule in effect prior to such

    


Termination Date; provided, however, that if your Termination Date occurs for a reason that is both described in this subsection (b) and in subsection (c) below, the special vesting rules described in subsection (c) shall apply in lieu of the vesting rules described in this subsection (b). Any RSUs that are not scheduled to vest during such 24-month period will be permanently forfeited on the Termination Date.
(c)    If your Termination Date occurs by reason of a Termination without Cause or a Separation for Good Reason on or after a Change in Control (as defined in the Plan and as such definition may be amended hereafter) and prior to the two (2) year anniversary of the Change in Control, all RSUs awarded under Section 1.1 that have not vested or been forfeited prior to such Termination Date shall become fully vested.
(d)    As used in this Section 1.3, the following terms shall have the meanings set forth below:
(1)    “Separation for Good Reason” means your voluntary resignation from the Company and the existence of one or more of the following conditions that arose without your consent: (i) a material change in the geographic location at which you are required to perform services, such that your commute between home and your primary job site increases by more than 30 miles, or (ii) a material diminution in your authority, duties or responsibilities or a material diminution in your base compensation or incentive compensation opportunities; provided, however, that a voluntary resignation from the Company shall not be considered a Separation for Good Reason unless you provide the Company with notice, in writing, of your voluntary resignation and the existence of the condition(s) giving rise to the separation within 90 days of its initial existence. The Company will then have 30 days to remedy the condition, in which case you will not be deemed to have incurred a Separation for Good Reason. In the event the Company fails to cure the condition within the 30 day period, your Termination Date shall occur on the 31st day following the Company’s receipt of such written notice.
(2)     “Termination without Cause” means the involuntary termination of your employment or contractual relationship by the Company without Cause, including, but not limited to, (i) a termination effective when you exhaust a leave of absence during, or at the end of, a notice period under the Worker Adjustment and Retraining Notification Act (“WARN”), and (ii) a situation where you are on an approved leave of absence during which your position is protected under applicable law (e.g., a leave under the Family Medical Leave Act), you return from such leave, and you cannot be placed in employment or other form of contractual relationship with the Company.
1.4    Settlement of RSUs. As soon as practicable after the RSU Vesting Date, the Company shall transfer to you one Ordinary Share for each RSU becoming vested on such date (the date of any such transfer shall be the “settlement date” for purposes of this Agreement); provided, however, the Company may withhold shares otherwise transferable to you to the extent necessary to satisfy withholding taxes due by reason of the vesting of the RSUs, in accordance with Section 2.6. You shall have no rights as a stockholder with respect to the RSUs awarded hereunder prior to the date of issuance to you of a certificate or certificates for such shares. Notwithstanding the foregoing,

    


the Committee, in its sole discretion, may elect to settle RSUs in cash based on the fair market value of the Ordinary Shares on the RSU Vesting Date.
1.5    Dividend Equivalents. The RSUs awarded under Section 1.1 shall be eligible to receive dividend equivalents in accordance with the following:
(a)    An “Account” will be established in your name. Such Account shall be for recordkeeping purposes only, and no assets or other amounts shall be set aside from the Company’s general assets with respect to such Account.
(b)    On each date that a cash dividend is paid with respect to Ordinary Shares, the Company shall credit your Account with the dollar amount of dividends you would have received if each RSU held by you on the record date for such dividend payment had been an Ordinary Share. No interest or other earnings shall accrue on such Account.
(c)    As of each RSU Vesting Date, you shall receive a payment equal to the amount of dividends that would have been paid on the RSUs vesting on such date had they been Ordinary Shares during the period beginning on the Grant Date and ending on the RSU Vesting Date, and the Account shall be debited appropriately. If you forfeit RSUs, any amounts in the Account attributable to such RSUs shall also be forfeited.
(d)    If dividends are paid in the form of Ordinary Shares rather than cash, then you will be credited with one additional RSU for each Ordinary Share that would have been received as a dividend had your outstanding RSUs been Ordinary Shares. Such additional RSUs shall vest or be forfeited at the same time as the RSUs to which they relate.
SECTION 2
General Terms and Conditions
2.1    Nontransferability. The Award under this Agreement shall not be transferable other than by will or by the laws of descent and distribution.
2.2    No Rights as a Stockholder. You shall not have any rights as a stockholder with respect to any Ordinary Shares subject to the RSU awarded under this Agreement prior to the date of issuance to you of a certificate or certificates for such shares.
2.3    Cause Termination. If your Termination Date occurs for reasons of Cause, all of your rights under this Agreement, whether or not vested, shall terminate immediately.
2.4    Award Subject to Plan. The granting of the Award under this Agreement is being made pursuant to the Plan and the Award shall be payable only in accordance with the applicable terms of the Plan. The Plan contains certain definitions, restrictions, limitations and other terms and conditions all of which shall be applicable to this Agreement. ALL THE PROVISIONS OF THE PLAN ARE INCORPORATED HEREIN BY REFERENCE AND ARE MADE A PART OF THIS AGREEMENT IN THE SAME MANNER AS IF EACH AND EVERY SUCH PROVISION WERE FULLY WRITTEN INTO THIS AGREEMENT. Should the Plan become

    


void or unenforceable by operation of law or judicial decision, this Agreement shall have no force or effect. Nothing set forth in this Agreement is intended, nor shall any of its provisions be construed, to limit or exclude any definition, restriction, limitation or other term or condition of the Plan as is relevant to this Agreement and as may be specifically applied to it by the Committee. In the event of a conflict in the provisions of this Agreement and the Plan, as a rule of construction the terms of the Plan shall be deemed superior and apply.
2.5    Adjustments in Event of Change in Ordinary Shares. In the event of a stock split, stock dividend, recapitalization, reclassification or combination of shares, merger, sale of assets or similar event, the number and kind of shares subject to Award under this Agreement will be appropriately adjusted in an equitable manner to prevent dilution or enlargement of the rights granted to or available for you.
2.6    Withholding. This Award is subject to the withholding of all applicable taxes. The Company may withhold, or permit you to remit to the Company, any Federal, state or local taxes applicable to the grant, vesting or other event giving rise to tax liability with respect to this Award. If you have not remitted the full amount of applicable withholding taxes to the Company by the date the Company is required to pay such withholding to the appropriate taxing authority (or such earlier date that the Company may specify to assist it in timely meeting its withholding obligations), the Company shall have the unilateral right to withhold Ordinary Shares relating to this Award in the amount it determines is sufficient to satisfy the tax withholding required by law. State taxes will be withheld at the appropriate rate set by the state in which you are employed or were last employed by the Company. In no event may the number of shares withheld exceed the number necessary to satisfy the maximum Federal, state and local income and employment tax withholding requirements. You may elect to surrender previously acquired Ordinary Shares or to have the Company withhold Ordinary Shares relating to this Award in an amount sufficient to satisfy all or a portion of the tax withholding required by law.
2.7    Compliance with Applicable Law. Notwithstanding any other provision of this Agreement, the Company shall have no obligation to issue any Ordinary Shares under this Agreement if such issuance would violate any applicable law or any applicable regulation or requirement of any securities exchange or similar entity.
2.8    Code Section 409A.
(a)    RSUs other than RSUs that continue to vest by reason of your Involuntary Termination for Economic Reasons and dividend equivalents payable under this Agreement are intended to be exempt from Code Section 409A under the exemption for short-term deferrals. Accordingly, RSUs (other than RSUs that continue to vest by reason of your Involuntary Termination for Economic Reasons) will be settled and dividend equivalents will be paid no later than the 15th day of the third month following the later of (i) the end of your taxable year in which the RSU Vesting Date occurs, or (ii) the end of the fiscal year of the Company in which the RSU Vesting Date occurs.
(b)    RSUs that continue to vest by reason of your Involuntary Termination for Economic Reasons are subject to the provisions of this subsection (b). Any distribution in settlement

    


of such RSUs will occur provided your Involuntary Termination for Economic Reasons constitutes a “separation from service” as defined in Treasury Regulation §1.409A-1(h). If the Company determines that you are a “specified employee” as defined in Code Section 409A (i.e., an officer with annual compensation above $130,000 (as adjusted for inflation), a five-percent owner of the Company or a one-percent owner with annual compensation in excess of $150,000), distribution in settlement of any such RSUs that would be payable within six months of your separation from service shall be delayed to the first business day following the six-month anniversary of your separation from service. Any distribution in settlement of such RSUs that would be made more than six months after your separation from service (without application of the six-month delay) shall not be subject to the six-month delay described in this subsection.
2.9    Data Privacy. By entering into this Agreement and accepting this Award, you (a) explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of any of your personal data that is necessary to facilitate the implementation, administration and management of the Award and the Plan, (b) understand that the Company may, for the purpose of implementing, administering and managing the Plan, hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, and details of all awards or entitlements to Shares granted to you under the Plan or otherwise (“Data”), (c) understand that Data may be transferred to any third parties assisting in the implementation, administration and management of the Plan, including any broker with whom the Shares issued upon vesting of the Award may be deposited, and that these recipients may be located in your country or elsewhere, and that the recipient’s country may have different data privacy laws and protections than your country, (d) waive any data privacy rights you may have with respect to the data, and (e) authorize the Company, its subsidiaries and its agents, to store and transmit such information in electronic form.
2.10    Successors and Assigns. This Agreement shall be binding upon any or all successors and assigns of the Company.
2.11    Applicable Law. This Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of Michigan without regard to principals of conflict of laws. Any proceeding related to or arising out of this Agreement shall be commenced, prosecuted or continued in the Circuit Court in Kent County, Michigan located in Grand Rapids, Michigan or in the United Stated District Court for the Western District of Michigan, and in any appellate court thereof.
2.12    Forfeiture of RSUs. If the Company, as a result of misconduct, is required to prepare an accounting restatement due to material noncompliance with any financial reporting requirement under the securities laws, then (a) if your incentive or equity-based compensation is subject to automatic forfeiture due to such misconduct and restatement under Section 304 of the Sarbanes-Oxley Act of 2002, or (b) the Committee determines you either knowingly engaged in or failed to prevent the misconduct, or your actions or inactions with respect to the misconduct and restatement constituted gross negligence, you shall (i) be required to reimburse the Company the amount of any payment (including dividend equivalents) relating to any RSUs earned or accrued during the twelve

    


month period following the first public issuance or filing with the SEC (whichever first occurred) of the financial document embodying such financial reporting requirement, and (ii) all outstanding RSUs (including related dividend equivalents) that have not yet been settled shall be immediately forfeited. In addition, Ordinary Shares acquired under this Agreement, and any gains or profits on the sale of such Ordinary Shares, shall be subject to any “clawback” or recoupment policy later adopted by the Company.
****
We look forward to your continuing contribution to the growth of the Company. Please acknowledge your receipt of the Plan and this Award.
Very truly yours,




Print Name: ___________________________
Title:_________________________________

    



PERRIGO COMPANY PLC
RESTRICTED STOCK UNIT AWARD AGREEMENT
(SERVICE-BASED)
(Under the Perrigo Company plc 2013 Long-Term Incentive Plan)
TO:        «First_Name» «Last_Name»
RE:        Notice of Restricted Stock Unit Award (Service-Based)
This is to notify you that Perrigo Company plc (the “Company”) has granted you an Award under the Perrigo Company plc 2013 Long-Term Incentive Plan (the “Plan”), effective as of ______________________ (the “Grant Date”). This Award consists of service-based restricted stock units. The terms and conditions of this incentive are set forth in the remainder of this agreement (the “Agreement”). The capitalized terms that are not otherwise defined in this Agreement shall have the meanings ascribed to such terms under the Plan.
SECTION 1
Restricted Stock Units – Service-Based Vesting
1.1    Grant. As of the Grant Date, and subject to the terms and conditions of this Agreement and the Plan, the Company grants you «Number_of_restricted_stock units» (“RSUs”). Each RSU entitles you to one ordinary share of the Company, nominal value €0.001 per share (“Ordinary Share”) on the applicable RSU Vesting Date, provided the vesting conditions described in Section 1.2 are satisfied.
1.2    Vesting. Except as provided in Section 1.3, the RSUs awarded in Section 1.1 shall vest with respect to one-third of the Shares awarded in Section 1.1 on the first, second and third anniversaries of the Grant Date (each, an “RSU Vesting Date”) provided that you continue in the service of the Company from the Grant Date through the applicable RSU Vesting Date.
Except as provided in Section 1.3, if your Termination Date occurs prior to the RSU Vesting Date, any RSUs awarded under Section 1.1 that have not previously vested as of such Termination Date shall be permanently forfeited on your Termination Date.
1.3    Special Vesting Rules. Notwithstanding Section 1.2 above:
(a)    If your Termination Date occurs by reason of death, Disability or Retirement with the Company’s consent, any RSUs awarded under Section 1.1 that have not vested prior to such Termination Date shall become fully vested.
(b)    If your Termination Date occurs by reason of an Involuntary Termination for Economic Reasons, any RSUs awarded under Section 1.1 that would otherwise be scheduled to vest under Section 1.2 in the 24-month period following such Termination Date shall continue to vest during such 24-month period according to the vesting schedule in effect prior to such

    


Termination Date; provided, however, that if your Termination Date occurs for a reason that is both described in this subsection (b) and in subsection (c) below, the special vesting rules described in subsection (c) shall apply in lieu of the vesting rules described in this subsection (b). Any RSUs that are not scheduled to vest during such 24-month period will be permanently forfeited on the Termination Date.
(c)    If your Termination Date occurs by reason of a Termination without Cause or a Separation for Good Reason on or after a Change in Control (as defined in the Plan and as such definition may be amended hereafter) and prior to the two (2) year anniversary of the Change in Control, all RSUs awarded under Section 1.1 that have not vested or been forfeited prior to such Termination Date shall become fully vested.
(d)    As used in this Section 1.3, the following terms shall have the meanings set forth below:
(1)    “Separation for Good Reason” means your voluntary resignation from the Company and the existence of one or more of the following conditions that arose without your consent: (i) a material change in the geographic location at which you are required to perform services, such that your commute between home and your primary job site increases by more than 30 miles, or (ii) a material diminution in your authority, duties or responsibilities or a material diminution in your base compensation or incentive compensation opportunities; provided, however, that a voluntary resignation from the Company shall not be considered a Separation for Good Reason unless you provide the Company with notice, in writing, of your voluntary resignation and the existence of the condition(s) giving rise to the separation within 90 days of its initial existence. The Company will then have 30 days to remedy the condition, in which case you will not be deemed to have incurred a Separation for Good Reason. In the event the Company fails to cure the condition within the 30 day period, your Termination Date shall occur on the 31st day following the Company’s receipt of such written notice.
(2)    “Termination without Cause” means the involuntary termination of your employment or contractual relationship by the Company without Cause, including, but not limited to, (i) a termination effective when you exhaust a leave of absence during, or at the end of, a notice period under the Worker Adjustment and Retraining Notification Act (“WARN”), and (ii) a situation where you are on an approved leave of absence during which your position is protected under applicable law (e.g., a leave under the Family Medical Leave Act), you return from such leave, and you cannot be placed in employment or other form of contractual relationship with the Company.
1.4    Settlement of RSUs. As soon as practicable after the RSU Vesting Date, the Company shall transfer to you one Ordinary Share for each RSU becoming vested on such date (the date of any such transfer shall be the “settlement date” for purposes of this Agreement); provided, however, the Company may withhold shares otherwise transferable to you to the extent necessary to satisfy withholding taxes due by reason of the vesting of the RSUs, in accordance with Section 2.6. You shall have no rights as a stockholder with respect to the RSUs awarded hereunder prior to the date of issuance to you of a certificate or certificates for such shares. Notwithstanding the foregoing,

    


the Committee, in its sole discretion, may elect to settle RSUs in cash based on the fair market value of the Ordinary Shares on the RSU Vesting Date.
1.5    Dividend Equivalents. The RSUs awarded under Section 1.1 shall be eligible to receive dividend equivalents in accordance with the following:
(a)    An “Account” will be established in your name. Such Account shall be for recordkeeping purposes only, and no assets or other amounts shall be set aside from the Company’s general assets with respect to such Account.
(b)    On each date that a cash dividend is paid with respect to Ordinary Shares, the Company shall credit your Account with the dollar amount of dividends you would have received if each RSU held by you on the record date for such dividend payment had been an Ordinary Share. No interest or other earnings shall accrue on such Account.
(c)    As of each RSU Vesting Date, you shall receive a payment equal to the amount of dividends that would have been paid on the RSUs vesting on such date had they been Ordinary Shares during the period beginning on the Grant Date and ending on the RSU Vesting Date, and the Account shall be debited appropriately. If you forfeit RSUs, any amounts in the Account attributable to such RSUs shall also be forfeited.
(d)    If dividends are paid in the form of Ordinary Shares rather than cash, then you will be credited with one additional RSU for each Ordinary Share that would have been received as a dividend had your outstanding RSUs been Ordinary Shares. Such additional RSUs shall vest or be forfeited at the same time as the RSUs to which they relate.
SECTION 2
General Terms and Conditions
2.1    Nontransferability. The Award under this Agreement shall not be transferable other than by will or by the laws of descent and distribution.
2.2    No Rights as a Stockholder. You shall not have any rights as a stockholder with respect to any Ordinary Shares subject to the RSU awarded under this Agreement prior to the date of issuance to you of a certificate or certificates for such shares.
2.3    Cause Termination. If your Termination Date occurs for reasons of Cause, all of your rights under this Agreement, whether or not vested, shall terminate immediately.
2.4    Award Subject to Plan. The granting of the Award under this Agreement is being made pursuant to the Plan and the Award shall be payable only in accordance with the applicable terms of the Plan. The Plan contains certain definitions, restrictions, limitations and other terms and conditions all of which shall be applicable to this Agreement. ALL THE PROVISIONS OF THE PLAN ARE INCORPORATED HEREIN BY REFERENCE AND ARE MADE A PART OF THIS AGREEMENT IN THE SAME MANNER AS IF EACH AND EVERY SUCH PROVISION WERE FULLY WRITTEN INTO THIS AGREEMENT. Should the Plan become

    


void or unenforceable by operation of law or judicial decision, this Agreement shall have no force or effect. Nothing set forth in this Agreement is intended, nor shall any of its provisions be construed, to limit or exclude any definition, restriction, limitation or other term or condition of the Plan as is relevant to this Agreement and as may be specifically applied to it by the Committee. In the event of a conflict in the provisions of this Agreement and the Plan, as a rule of construction the terms of the Plan shall be deemed superior and apply.
2.5    Adjustments in Event of Change in Ordinary Shares. In the event of a stock split, stock dividend, recapitalization, reclassification or combination of shares, merger, sale of assets or similar event, the number and kind of shares subject to Award under this Agreement will be appropriately adjusted in an equitable manner to prevent dilution or enlargement of the rights granted to or available for you.
2.6    Withholding. This Award is subject to the withholding of all applicable taxes. The Company may withhold, or permit you to remit to the Company, any Federal, state or local taxes applicable to the grant, vesting or other event giving rise to tax liability with respect to this Award. If you have not remitted the full amount of applicable withholding taxes to the Company by the date the Company is required to pay such withholding to the appropriate taxing authority (or such earlier date that the Company may specify to assist it in timely meeting its withholding obligations), the Company shall have the unilateral right to withhold Ordinary Shares relating to this Award in the amount it determines is sufficient to satisfy the tax withholding required by law. State taxes will be withheld at the appropriate rate set by the state in which you are employed or were last employed by the Company. In no event may the number of shares withheld exceed the number necessary to satisfy the maximum Federal, state and local income and employment tax withholding requirements. You may elect to surrender previously acquired Ordinary Shares or to have the Company withhold Ordinary Shares relating to this Award in an amount sufficient to satisfy all or a portion of the tax withholding required by law.
2.7    Compliance with Applicable Law. Notwithstanding any other provision of this Agreement, the Company shall have no obligation to issue any Ordinary Shares under this Agreement if such issuance would violate any applicable law or any applicable regulation or requirement of any securities exchange or similar entity.
2.8    Code Section 409A.
(a)    RSUs other than RSUs that continue to vest by reason of your Involuntary Termination for Economic Reasons and dividend equivalents payable under this Agreement are intended to be exempt from Code Section 409A under the exemption for short-term deferrals. Accordingly, RSUs (other than RSUs that continue to vest by reason of your Involuntary Termination for Economic Reasons) will be settled and dividend equivalents will be paid no later than the 15th day of the third month following the later of (i) the end of your taxable year in which the RSU Vesting Date occurs, or (ii) the end of the fiscal year of the Company in which the RSU Vesting Date occurs.
(b)    RSUs that continue to vest by reason of your Involuntary Termination for Economic Reasons are subject to the provisions of this subsection (b). Any distribution in settlement

    


of such RSUs will occur provided your Involuntary Termination for Economic Reasons constitutes a “separation from service” as defined in Treasury Regulation §1.409A-1(h). If the Company determines that you are a “specified employee” as defined in Code Section 409A (i.e., an officer with annual compensation above $130,000 (as adjusted for inflation), a five-percent owner of the Company or a one-percent owner with annual compensation in excess of $150,000), distribution in settlement of any such RSUs that would be payable within six months of your separation from service shall be delayed to the first business day following the six-month anniversary of your separation from service. Any distribution in settlement of such RSUs that would be made more than six months after your separation from service (without application of the six-month delay) shall not be subject to the six-month delay described in this subsection.
2.9    Data Privacy. By entering into this Agreement and accepting this Award, you (a) explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of any of your personal data that is necessary to facilitate the implementation, administration and management of the Award and the Plan, (b) understand that the Company may, for the purpose of implementing, administering and managing the Plan, hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, and details of all awards or entitlements to Shares granted to you under the Plan or otherwise (“Data”), (c) understand that Data may be transferred to any third parties assisting in the implementation, administration and management of the Plan, including any broker with whom the Shares issued upon vesting of the Award may be deposited, and that these recipients may be located in your country or elsewhere, and that the recipient’s country may have different data privacy laws and protections than your country, (d) waive any data privacy rights you may have with respect to the data, and (e) authorize the Company, its subsidiaries and its agents, to store and transmit such information in electronic form.
2.10    Successors and Assigns. This Agreement shall be binding upon any or all successors and assigns of the Company.
2.11    Applicable Law. This Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of Michigan without regard to principals of conflict of laws. Any proceeding related to or arising out of this Agreement shall be commenced, prosecuted or continued in the Circuit Court in Kent County, Michigan located in Grand Rapids, Michigan or in the United Stated District Court for the Western District of Michigan, and in any appellate court thereof.
2.12    Forfeiture of RSUs. If the Company, as a result of misconduct, is required to prepare an accounting restatement due to material noncompliance with any financial reporting requirement under the securities laws, then (a) if your incentive or equity-based compensation is subject to automatic forfeiture due to such misconduct and restatement under Section 304 of the Sarbanes-Oxley Act of 2002, or (b) the Committee determines you either knowingly engaged in or failed to prevent the misconduct, or your actions or inactions with respect to the misconduct and restatement constituted gross negligence, you shall (i) be required to reimburse the Company the amount of any payment (including dividend equivalents) relating to any RSUs earned or accrued during the twelve

    


month period following the first public issuance or filing with the SEC (whichever first occurred) of the financial document embodying such financial reporting requirement, and (ii) all outstanding RSUs (including related dividend equivalents) that have not yet been settled shall be immediately forfeited. In addition, Ordinary Shares acquired under this Agreement, and any gains or profits on the sale of such Ordinary Shares, shall be subject to any “clawback” or recoupment policy later adopted by the Company.
****
We look forward to your continuing contribution to the growth of the Company. Please acknowledge your receipt of the Plan and this Award.
Very truly yours,




Print Name: ___________________________
Title:_________________________________


    



PERRIGO COMPANY PLC
RESTRICTED STOCK UNIT AWARD AGREEMENT
(SERVICE-BASED)
(Under the Perrigo Company plc 2013 Long-Term Incentive Plan)
TO:        Participant Name
RE:        Notice of Restricted Stock Unit Award (Service-Based)
This is to notify you that Perrigo Company plc (the “Company”) has granted you an Award under the Perrigo Company plc 2013 Long-Term Incentive Plan (the “Plan”), effective as of Grant Date (the “Grant Date”). This Award consists of service-based restricted stock units. The terms and conditions of this incentive are set forth in the remainder of this agreement (the “Agreement”). The capitalized terms that are not otherwise defined in this Agreement shall have the meanings ascribed to such terms under the Plan.
SECTION 1
Restricted Stock Units – Service-Based Vesting
1.1    Grant. As of the Grant Date, and subject to the terms and conditions of this Agreement and the Plan, the Company grants you Number of Awards Granted (“Restricted Stock Units” or “RSUs”). Each Restricted Stock Unit shall entitle you to one ordinary share of the Company, nominal value €0.001 per share (“Ordinary Share”) on the applicable RSU Vesting Date, provided the vesting conditions described in Section 1.2 are satisfied.
1.2    Vesting. Except as provided in Section 1.3, the Restricted Stock Units awarded in Section 1.1 shall vest on the third anniversary of the Grant Date (“RSU Vesting Date”) provided that you continue in the service of the Company from the Grant Date through the applicable RSU Vesting Date.
Except as provided in Section 1.3, if your Termination Date occurs prior to the RSU Vesting Date, any Restricted Stock Units awarded under Section 1.1 that have not previously vested as of such Termination Date shall be permanently forfeited on your Termination Date.
1.3    Special Vesting Rules. Notwithstanding Section 1.2 above:
(a)    If your Termination Date occurs by reason of death, Disability or Retirement with the Company’s consent, any Restricted Stock Units awarded under Section 1.1 that have not vested prior to such Termination Date shall become fully vested.
(b)    If your Termination Date occurs by reason of an Involuntary Termination for Economic Reasons, any Restricted Stock Units awarded under Section 1.1 that would otherwise be scheduled to vest under Section 1.2 in the 24-month period following such Termination Date shall continue to vest during such 24-month period according to the vesting

    


schedule in effect prior to such Termination Date; provided, however, that if your Termination Date occurs for a reason that is both described in this subsection (b) and in subsection (c) below, the special vesting rules described in subsection (c) shall apply in lieu of the vesting rules described in this subsection (b). Any Restricted Stock Units that are not scheduled to vest during such 24-month period will be permanently forfeited on the Termination Date.
(c)    If your Termination Date occurs by reason of a Termination without Cause or a Separation for Good Reason on or after a Change in Control (as defined in the Plan and as such definition may be amended hereafter) and prior to the two (2) year anniversary of the Change in Control, all Restricted Stock Units awarded under Section 1.1 that have not vested or been forfeited prior to such Termination Date shall become fully vested.
(d)    As used in this Section 1.3, the following terms shall have the meanings set forth below:
(1)    “Separation for Good Reason” means your voluntary resignation from the Company and the existence of one or more of the following conditions that arose without your consent: (i) a material change in the geographic location at which you are required to perform services, such that your commute between home and your primary job site increases by more than 30 miles, or (ii) a material diminution in your authority, duties or responsibilities or a material diminution in your base compensation or incentive compensation opportunities; provided, however, that a voluntary resignation from the Company shall not be considered a Separation for Good Reason unless you provide the Company with notice, in writing, of your voluntary resignation and the existence of the condition(s) giving rise to the separation within 90 days of its initial existence. The Company will then have 30 days to remedy the condition, in which case you will not be deemed to have incurred a Separation for Good Reason. In the event the Company fails to cure the condition within the 30 day period, your Termination Date shall occur on the 31st day following the Company’s receipt of such written notice.
(2)    “Termination without Cause” means the involuntary termination of your employment or contractual relationship by the Company without Cause, including, but not limited to, (i) a termination effective when you exhaust a leave of absence during, or at the end of, a notice period under the Worker Adjustment and Retraining Notification Act (“WARN”), and (ii) a situation where you are on an approved leave of absence during which your position is protected under applicable law (e.g., a leave under the Family Medical Leave Act), you return from such leave, and you cannot be placed in employment or other form of contractual relationship with the Company.
1.4    Settlement of Restricted Stock Units. As soon as practicable after the RSU Vesting Date, the Company shall transfer to you one Ordinary Share for each Restricted Stock Unit becoming vested on such date (the date of any such transfer shall be the “settlement date” for purposes of this Agreement); provided, however, the Company may withhold shares otherwise transferable to you to the extent necessary to satisfy withholding taxes due by reason of the vesting of the Restricted Stock Units, in accordance with Section 2.6. You shall have no rights as a stockholder with respect to the Restricted Stock Units awarded hereunder prior to the date of issuance to you of a certificate or certificates for such shares. Notwithstanding the

    


foregoing, the Committee, in its sole discretion, may elect to settle Restricted Stock Units in cash based on the fair market value of the Ordinary Shares on the RSU Vesting Date.
1.5    Dividend Equivalents. The Restricted Stock Units awarded under Section 1.1 shall be eligible to receive dividend equivalents in accordance with the following:
(a)    An “Account” will be established in your name. Such Account shall be for recordkeeping purposes only, and no assets or other amounts shall be set aside from the Company’s general assets with respect to such Account.
(b)    On each date that a cash dividend is paid with respect to Ordinary Shares, the Company shall credit your Account with the dollar amount of dividends you would have received if each Restricted Stock Unit held by you on the record date for such dividend payment had been an Ordinary Share. No interest or other earnings shall accrue on such Account.
(c)    As of each RSU Vesting Date, you shall receive a payment equal to the amount of dividends that would have been paid on the Restricted Stock Units vesting on such date had they been Ordinary Shares during the period beginning on the Grant Date and ending on the RSU Vesting Date, and the Account shall be debited appropriately. If you forfeit Restricted Stock Units, any amounts in the Account attributable to such Restricted Stock Units shall also be forfeited.
(d)    If dividends are paid in the form of Ordinary Shares rather than cash, then you will be credited with one additional Restricted Stock Unit for each Ordinary Share that would have been received as a dividend had your outstanding Restricted Stock Units been Ordinary Shares. Such additional Restricted Stock Units shall vest or be forfeited at the same time as the Restricted Stock Unit to which they relate.
SECTION 2
General Terms and Conditions
2.1    Nontransferability. The Award under this Agreement shall not be transferable other than by will or by the laws of descent and distribution.
2.2    No Rights as a Stockholder. You shall not have any rights as a stockholder with respect to any Ordinary Shares subject to the RSU awarded under this Agreement prior to the date of issuance to you of a certificate or certificates for such shares.
2.3    Cause Termination. If your Termination Date occurs for reasons of Cause, all of your rights under this Agreement, whether or not vested, shall terminate immediately.
2.4    Award Subject to Plan. The granting of the Award under this Agreement is being made pursuant to the Plan and the Award shall be payable only in accordance with the applicable terms of the Plan. The Plan contains certain definitions, restrictions, limitations and other terms and conditions all of which shall be applicable to this Agreement. ALL THE PROVISIONS OF THE PLAN ARE INCORPORATED HEREIN BY REFERENCE AND ARE MADE A

    


PART OF THIS AGREEMENT IN THE SAME MANNER AS IF EACH AND EVERY SUCH PROVISION WERE FULLY WRITTEN INTO THIS AGREEMENT. Should the Plan become void or unenforceable by operation of law or judicial decision, this Agreement shall have no force or effect. Nothing set forth in this Agreement is intended, nor shall any of its provisions be construed, to limit or exclude any definition, restriction, limitation or other term or condition of the Plan as is relevant to this Agreement and as may be specifically applied to it by the Committee. In the event of a conflict in the provisions of this Agreement and the Plan, as a rule of construction the terms of the Plan shall be deemed superior and apply.
2.5    Adjustments in Event of Change in Ordinary Shares. In the event of a stock split, stock dividend, recapitalization, reclassification or combination of shares, merger, sale of assets or similar event, the number and kind of shares subject to Award under this Agreement will be appropriately adjusted in an equitable manner to prevent dilution or enlargement of the rights granted to or available for you.
2.6    Withholding. This Award is subject to the withholding of all applicable taxes. The Company may withhold, or permit you to remit to the Company, any Federal, state or local taxes applicable to the grant, vesting or other event giving rise to tax liability with respect to this Award. If you have not remitted the full amount of applicable withholding taxes to the Company by the date the Company is required to pay such withholding to the appropriate taxing authority (or such earlier date that the Company may specify to assist it in timely meeting its withholding obligations), the Company shall have the unilateral right to withhold Ordinary Shares relating to this Award in the amount it determines is sufficient to satisfy the tax withholding required by law. State taxes will be withheld at the appropriate rate set by the state in which you are employed or were last employed by the Company. In no event may the number of shares withheld exceed the number necessary to satisfy the maximum Federal, state and local income and employment tax withholding requirements. You may elect to surrender previously acquired Ordinary Shares or to have the Company withhold Ordinary Shares relating to this Award in an amount sufficient to satisfy all or a portion of the tax withholding required by law.
2.7    Compliance with Applicable Law. Notwithstanding any other provision of this Agreement, the Company shall have no obligation to issue any Ordinary Shares under this Agreement if such issuance would violate any applicable law or any applicable regulation or requirement of any securities exchange or similar entity.
2.8    Code Section 409A.
(a)    Restricted Stock Units other than Restricted Stock Units that continue to vest by reason of your Involuntary Termination for Economic Reasons and dividend equivalents payable under this Agreement are intended to be exempt from Code Section 409A under the exemption for short-term deferrals. Accordingly, Restricted Stock Units (other than Restricted Stock Units that continue to vest by reason of your Involuntary Termination for Economic Reasons) will be settled and dividend equivalents will be paid no later than the 15th day of the third month following the later of (i) the end of your taxable year in which the RSU Vesting Date occurs, or (ii) the end of the fiscal year of the Company in which the RSU Vesting Date occurs.

    


(b)    Restricted Stock Units that continue to vest by reason of your Involuntary Termination for Economic Reasons are subject to the provisions of this subsection (b). Any distribution in settlement of such Restricted Stock Units will occur provided your Involuntary Termination for Economic Reasons constitutes a “separation from service” as defined in Treasury Regulation §1.409A-1(h). If the Company determines that you are a “specified employee” as defined in Code Section 409A (i.e., an officer with annual compensation above $130,000 (as adjusted for inflation), a five-percent owner of the Company or a one-percent owner with annual compensation in excess of $150,000), distribution in settlement of any such Restricted Stock Units that would be payable within six months of your separation from service shall be delayed to the first business day following the six-month anniversary of your separation from service. Any distribution in settlement of such Restricted Stock Units that would be made more than six months after your separation from service (without application of the six-month delay) shall not be subject to the six-month delay described in this subsection.
2.9    Data Privacy. By entering into this Agreement and accepting this Award, you (a) explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of any of your personal data that is necessary to facilitate the implementation, administration and management of the Award and the Plan, (b) understand that the Company may, for the purpose of implementing, administering and managing the Plan, hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, and details of all awards or entitlements to Shares granted to you under the Plan or otherwise (“Data”), (c) understand that Data may be transferred to any third parties assisting in the implementation, administration and management of the Plan, including any broker with whom the Shares issued upon vesting of the Award may be deposited, and that these recipients may be located in your country or elsewhere, and that the recipient’s country may have different data privacy laws and protections than your country, (d) waive any data privacy rights you may have with respect to the data, and (e) authorize the Company, its subsidiaries and its agents, to store and transmit such information in electronic form.
2.10    Successors and Assigns. This Agreement shall be binding upon any or all successors and assigns of the Company.
2.11    Applicable Law. This Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of Michigan without regard to principals of conflict of laws. Any proceeding related to or arising out of this Agreement shall be commenced, prosecuted or continued in the Circuit Court in Kent County, Michigan located in Grand Rapids, Michigan or in the United Stated District Court for the Western District of Michigan, and in any appellate court thereof.
2.12 Forfeiture of RSUs. If the Company, as a result of misconduct, is required to prepare an accounting restatement due to material noncompliance with any financial reporting requirement under the securities laws, then (a) if your incentive or equity-based compensation is subject to automatic forfeiture due to such misconduct and restatement under Section 304 of the Sarbanes-Oxley Act of 2002, or (b) the Committee determines you either knowingly engaged in

    


or failed to prevent the misconduct, or your actions or inactions with respect to the misconduct and restatement constituted gross negligence, you shall (i) be required to reimburse the Company the amount of any payment (including dividend equivalents) relating to any RSUs earned or accrued during the twelve month period following the first public issuance or filing with the SEC (whichever first occurred) of the financial document embodying such financial reporting requirement, and (ii) all outstanding RSUs (including related dividend equivalents) that have not yet been settled shall be immediately forfeited. In addition, Ordinary Shares acquired under this Agreement, and any gains or profits on the sale of such Ordinary Shares, shall be subject to any “clawback” or recoupment policy later adopted by the Company.
****
We look forward to your continuing contribution to the growth of the Company. Please acknowledge your receipt of the Plan and this Award.
Very truly yours,




Print Name: ___________________________
Title:_________________________________




    

 EX-10.4 4 cy17q310qex104.htm EXHIBIT 10.4 Exhibit
Exhibit 10.4

PERRIGO COMPANY PLC
RESTRICTED STOCK UNIT AWARD AGREEMENT FOR NON-U.S. PARTICIPANTS
(PERFORMANCE-BASED)
(Under the Perrigo Company plc 2013 Long-Term Incentive Plan)
TO:        Participant Name

RE:        Notice of Restricted Stock Unit Award (Performance-Based)
This is to notify you that Perrigo Company plc (the “Company”) has granted you an Award for non-U.S. participants under the Perrigo Company plc 2013 Long-Term Incentive Plan (the “Plan”), effective as of Grant Date (the “Grant Date”). This Award consists of performance-based restricted stock units. The terms and conditions of this incentive are set forth in the remainder of this agreement (including any special terms and conditions set forth in any appendix for your country (“Appendix”)) (collectively, the “Agreement”). The capitalized terms that are not otherwise defined in this Agreement shall have the meanings ascribed to such terms under the Plan.
SECTION 1
Restricted Stock Units – Performance-Based Vesting
1.1    Grant. As of the Grant Date, the Company grants to you Number of Awards Granted restricted stock units (“Performance Restricted Stock Units” or “PRSUs”), subject to the terms and conditions set forth in this Agreement. The number of Performance Restricted Stock Units awarded in this Section 1.1 is referred to as the “Target Award.” The Target Award may be increased or decreased depending on the level of attainment of Performance Goals for designated Performance Measures as described in Section 1.2. Each Performance Restricted Stock Unit shall entitle you to one ordinary share of the Company, nominal value €0.001 per share (“Ordinary Share”) on the PRSU Vesting Date set forth in Section 1.2, provided the applicable Performance Goals for each Performance Measure are satisfied.
1.2    Vesting. The number of Performance Restricted Stock Units awarded in Section 1.1 vesting, if any, shall be determined as of the PRSU Vesting Date. That number will be determined based on the average level of attainment of annual Performance Measure(s) for each fiscal year in the Performance Period, in accordance with the schedule determined by the Committee at the time the Performance Measures and applicable Performance Goals are established by the Committee.
The Committee shall establish annually one or more Performance Measures and the Performance Goals with respect to each Performance Measure that must be attained for Threshold, Target and Maximum performance for a fiscal year. The Performance Measure and Performance Goals for each fiscal year will be provided to you.


Following the end of each fiscal year in the Performance Period, the Committee will determine the percentage of Target Award PRSUs that would be payable for such fiscal year, based on the attainment of the Performance Goals for each Performance Measure(s) established by the Committee for that fiscal year. The percentage of the Target Award that would be payable under the schedule shall be adjusted, pro rata, to reflect attained performance between Threshold and Target, and Target and Maximum.
At the end of the Performance Period, the percentage payout for each fiscal year in the Performance Period will be averaged to determine the actual percentage of Target Award PRSUs that will vest and be payable on the PRSU Vesting Date. In no event will the calculation of a positive payout percentage for any fiscal year be construed to guarantee that any PRSUs will vest on the PRSU Vesting Date. Payout percentages for the individual fiscal years are determined solely for purposes of determining the average annual payout percentage for the three-year Performance Period.
Except as provided in Section 1.4, the PRSUs will be permanently forfeited if your Termination Date occurs prior to the PRSU Vesting Date. If the average annual performance payout for the Performance Period is less than the Threshold performance level established by the Committee, all PRSUs that have not previously been forfeited shall be forfeited as of the PRSU Vesting Date. If the average annual performance payout for the Performance Period exceeds the Maximum performance level established by the Committee, then in no event will the number of PRSUs vesting exceed 200% of the Target Award.
1.3    Definitions. The following terms shall have the following meanings under this Section 1.
(a)    “Performance Goal” means the level of performance that must be attained with respect to a Performance Measure for a fiscal year for Minimum, Target and Maximum payout.
(b)    “Performance Measure” for any fiscal year means one or more financial measures, as determined by the Committee. The Committee shall provide how the Performance Measure will be adjusted, if at all, as a result of extraordinary events or circumstances, as determined by the Committee, or to exclude the effects of extraordinary, unusual, or non-recurring items; changes in applicable laws, regulations, or accounting principles; currency fluctuations; discontinued operations; non-cash items, such as amortization, depreciation, or reserves; asset impairment; or any recapitalization, restructuring, reorganization, merger, acquisition, divestiture, consolidation, spin-off, split-up, combination, liquidation, dissolution, sale of assets, or other similar corporation transaction.
(c)    “Performance Period” means a period of three consecutive fiscal years of the Company, beginning with the first day of the fiscal year of the Company in which the Grant Date occurs and ending on the last day of the third fiscal year in the 3-year period.
(d)    “PRSU Vesting Date” means the last day of the Performance Period.


(e)    “Separation for Good Reason” means your voluntary resignation (or any legal act having the same consequence, such as amicable termination or constructive dismissal) from the Company on the ground of one or more of the following conditions that arose without your consent: (i) a material change in the geographic location at which you are required to perform services, such that your commute between home and your primary job site increases by more than 30 miles, or (ii) a material diminution in your authority, duties or responsibilities or a material diminution in your base compensation or incentive compensation opportunities; provided, however, that a voluntary resignation from the Company (or any legal act having the same consequence, such as a constructive dismissal) shall not be considered a Separation for Good Reason unless you provide the Company with notice, in writing, of your voluntary resignation and the existence of the condition(s) giving rise to the separation within 90 days of its initial existence. The Company will then have 30 days to remedy the condition, in which case you will not be deemed to have incurred a Separation for Good Reason. In the event the Company fails to cure the condition within the 30 day period, your Termination Date shall occur on the 31st day following the Company’s receipt of such written notice.
(f)    “Termination without Cause” means the involuntary termination of your employment or contractual relationship by the Company without Cause, including, but not limited to, (i) a termination effective when you exhaust an approved leave of absence, and (ii) a situation where you are on an approved leave of absence during which your position is protected under applicable leave law, you return from such leave, and you cannot be placed in employment or other form of contractual relationship with the Company.
1.4    Special Vesting Rules. Notwithstanding Section 1.2 above, if your Termination Date occurs by reason of a Termination without Cause or a Separation for Good Reason on or after a Change in Control (as defined in the Plan and as such definition may be amended hereafter) and prior to the two (2) year anniversary of the Change in Control, all of the Performance Restricted Stock Units awarded under Section 1.1 that have not previously been forfeited shall become fully vested as if Target performance had been obtained for the Performance Period effective as of your Termination Date. If your Termination Date occurs because of death, Disability, or Retirement, the Performance Restricted Stock Units shall vest or be forfeited as of the PRSU Vesting Date set forth in Section 1.2, based on the attainment of the performance goals. If your Termination Date occurs because of an Involuntary Termination for Economic Reasons, the Company’s Chief Executive Officer (or the Committee, if you are subject to Section 16 of the Exchange Act), in his or her sole and absolute discretion, may permit all or part of the Performance Restricted Stock Units awarded hereunder to remain outstanding and vest or be forfeited as of the date set forth in Section 1.2, depending on the attainment of Performance Goals; provided, however, that if your Termination Date occurs for a reason that is both described in this sentence and in the first sentence of this Section 1.4, the special vesting rules described in the first sentence of this Section 1.4 shall apply in lieu of the vesting rules described in this sentence. To the extent that the Chief Executive Officer (or Committee, if applicable) does not exercise discretionary authority to allow Performance Restricted Stock Units to remain outstanding on the date of your Involuntary Termination for Economic Reasons, such Restricted Stock Units shall be permanently forfeited.


1.5    Settlement of Performance Restricted Stock Units. As soon as practicable following the date of the Committee’s first regularly scheduled meeting following the last day of the Performance Period at which the Committee certifies the average payout for each of the three years in the Performance Period, the Company shall transfer to you one Ordinary Share for each Performance Restricted Stock Unit, if any, that becomes vested pursuant to Section 1.2 or 1.4 of this Agreement (the date of any such transfer shall be the “settlement date” for purposes of this Agreement); provided, however, the Company in its discretion may settle Performance Restricted Stock Units in cash, based on the fair market value of the shares on the PRSU Vesting Date. No fractional shares shall be transferred. Any fractional share shall be rounded to the nearest whole share. The income attributable to the vesting of PRSUs and the amount of any required tax withholding will be determined based on the value of the shares on the settlement date. Performance Restricted Stock Units are not eligible for dividend equivalents.
SECTION 2
General Terms and Conditions
2.1    Nontransferability. The Award under this Agreement shall not be transferable other than by will or by the laws of descent and distribution.
2.2    No Rights as a Stockholder. You shall not have any rights as a stockholder with respect to any Ordinary Shares subject to the PRSUs awarded under this Agreement prior to the date of issuance to you of a certificate or certificates for such shares.
2.3    Cause Termination. If your Termination Date occurs for reasons of Cause, all of your rights under this Agreement, whether or not vested, shall terminate immediately.
2.4    Award Subject to Plan. The granting of the Award under this Agreement is being made pursuant to the Plan and the Award shall be payable only in accordance with the applicable terms of the Plan. The Plan contains certain definitions, restrictions, limitations and other terms and conditions all of which shall be applicable to this Agreement. ALL THE PROVISIONS OF THE PLAN ARE INCORPORATED HEREIN BY REFERENCE AND ARE MADE A PART OF THIS AGREEMENT IN THE SAME MANNER AS IF EACH AND EVERY SUCH PROVISION WERE FULLY WRITTEN INTO THIS AGREEMENT. Should the Plan become void or unenforceable by operation of law or judicial decision, this Agreement shall have no force or effect. Nothing set forth in this Agreement is intended, nor shall any of its provisions be construed, to limit or exclude any definition, restriction, limitation or other term or condition of the Plan as is relevant to this Agreement and as may be specifically applied to it by the Committee. In the event of a conflict in the provisions of this Agreement and the Plan, as a rule of construction the terms of the Plan shall be deemed superior and apply.
2.5    Adjustments in Event of Change in Ordinary Shares. In the event of a stock split, stock dividend, recapitalization, reclassification or combination of shares, merger, sale of assets or similar event, the number and kind of shares subject to Award under this Agreement will be appropriately adjusted in an equitable manner to prevent dilution or enlargement of the rights granted to or available for you.


2.6    Acknowledgement. The Company and you agree that the PRSUs are granted under and governed by the Notice of Grant, this Agreement (including the Appendix) and by the provisions of the Plan (incorporated herein by reference). You: (i) acknowledge receipt of a copy of each of the foregoing documents, (ii) represent that you have carefully read and are familiar with their provisions, and (iii) hereby accept the PRSUs subject to all of the terms and conditions set forth herein and those set forth in the Plan and the Notice of Grant.
2.7    Responsibility for Taxes. Regardless of any action the Company or, if different, the Affiliate employing or retaining you takes with respect to any or all income tax, social insurance, payroll tax, payment on account or other tax-related items related to your participation in the Plan and legally applicable to you (“Tax-Related Items”), you acknowledge that the ultimate liability for all Tax-Related Items is and remains your responsibility and may exceed the amount actually withheld by the Company or the Affiliate employing or retaining you. You further acknowledge that the Company and/or the Affiliate employing or retaining you (1) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the PRSUs, including, but not limited to, the grant, vesting or settlement of the PRSUs, the subsequent sale of Ordinary Shares acquired pursuant to such settlement and the receipt of any dividends; and (2) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the PRSUs to reduce or eliminate your liability for Tax-Related Items or achieve any particular tax result. Further, if you have become subject to tax in more than one jurisdiction between the PRSU Grant Date and the date of any relevant taxable event, as applicable, you acknowledge that the Company and/or the Affiliate employing or retaining you (or formerly employing or retaining you, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.
(a)     Prior to any relevant taxable or tax withholding event, as applicable, you will pay or make adequate arrangements satisfactory to the Company and/or the Affiliate employing or retaining you to satisfy all Tax-Related Items. In this regard, you authorize the Company and/or the Affiliate employing or retaining you, or their respective agents, at their discretion, to satisfy the obligations with regard to all Tax-Related Items by one or a combination of the following:
(1)    withholding from your wages or other cash compensation paid to you by the Company and/or the Affiliate employing or retaining you; or
(2)    withholding from proceeds of the sale of Ordinary Shares acquired upon settlement of the PRSUs either through a voluntary sale or through a mandatory sale arranged by the Company (on your behalf pursuant to this authorization); or
(3)    withholding in Ordinary Shares to be issued upon settlement of the PRSUs.
(b)    To avoid negative accounting treatment, the Company may withhold or account for Tax-Related Items by considering applicable minimum statutory withholding amounts or other applicable withholding rates. If the obligation for Tax-Related Items is satisfied by withholding in Ordinary Shares, for tax purposes, you are deemed to have been


issued the full number of Ordinary Shares subject to the vested PRSUs, notwithstanding that a number of the Ordinary Shares are held back solely for the purpose of paying the Tax-Related Items.
(c)    Finally, you shall pay to the Company or the Affiliate employing or retaining you any amount of Tax-Related Items that the Company or the Affiliate employing or retaining you may be required to withhold or account for as a result of your participation in the Plan that cannot be satisfied by the means previously described. The Company may refuse to issue or deliver the Ordinary Sharse or the proceeds of the sale of Ordinary Shares, if you fail to comply with your obligations in connection with the Tax-Related Items.
2.8    Compliance with Applicable Law. The issuance of Ordinary Shares will be subject to and conditioned upon compliance by the Company and you, including any written representations, warranties and agreements as the Administrator may request of you for compliance with all (i) applicable U.S. state and federal laws and regulations, (ii) applicable laws of the country where you reside pertaining to the issuance or sale of Ordinary Shares, and (iii) applicable requirements of any stock exchange or automated quotation system on which the Company’s Ordinary Shares may be listed or quoted at the time of such issuance or transfer.
2.9    Short Term Deferral. Performance Restricted Stock Units payable under this Agreement are intended to be exempt from Code Section 409A under the exemption for short-term deferrals. Accordingly, Performance Restricted Stock Units will be settled no later than the 15th day of the third month following the later of (i) the end of the Employee’s taxable year in which the PRSU Vesting Date occurs, or (ii) the end of the fiscal year of the Company in which the PRSU Vesting Date occurs.
2.10    Data Privacy.
(a)    By entering into this Agreement and accepting this Award, you hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Agreement and any other PRSU grant materials by and among, as applicable, the Affiliate employing or retaining you, the Company and its Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.
(b)    You understand that the Company and the Affiliate employing or retaining you may hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all PRSUs or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the exclusive purpose of implementing, administering and managing the Plan (“Data”).
(c)    You understand that Data will be transferred to legal counsel or a broker or such other stock plan service provider as may be selected by the Company in the future,


which is assisting the Company with the implementation, administration and management of the Plan. You understand that the recipients of the Data may be located in the United States or elsewhere, and that the recipients’ country (e.g., the United States) may have different data privacy laws and protections than your country. You understand that if you reside outside the United States, you may request a list with the names and addresses of any potential recipients of the Data by contacting your local or Company human resources representative. You authorize the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing your participation in the Plan. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan. You understand that if you reside outside the United States, you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local or Company human resources representative. You understand, however, that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local or Company human resources representative.
2.11     Nature of Grant. In accepting the grant, you acknowledge, understand and agree that:
(a)    the Plan is established voluntarily by the Company, it is discretionary in nature and it may be modified, amended, suspended or terminated by the Company at any time, except as otherwise provided in the Plan;
(b)    the grant of the PRSUs is voluntary and occasional and does not create any contractual or other right to receive future grants of PRSUs, or benefits in lieu of PRSUs, even if PRSUs have been granted repeatedly in the past;
(c)    all decisions with respect to future PRSU grants, if any, will be at the sole discretion of the Company;
(d)    you are voluntarily participating in the Plan;
(e)    the PRSUs and the Ordinary Shares subject to the PRSUs are an extraordinary item which is outside the scope of your employment or service contract, if any;
(f)    the PRSUs and the Ordinary Shares subject to the PRSUs are not intended to replace any pension rights or compensation;
(g)    the PRSUs and the Ordinary Shares subject to the PRSUs are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments and in no event should be


considered as compensation for, or relating in any way to, past services for the Company, the Affiliate employing or retaining you or any other Affiliate;
(h)    the grant and your participation in the Plan will not be interpreted to form an employment or service contract with the Company or any Affiliate;
(i)    the future value of the underlying Ordinary Shares is unknown, indeterminable and cannot be predicted with certainty;
(j)    no claim or entitlement to compensation or damages shall arise from forfeiture of the PRSUs resulting from your Termination Date (for any reason whatsoever, whether or not later found to be invalid and whether or not in breach of employment laws in the jurisdiction where you are employed or rendering services, or the terms of your employment agreement, if any), and in consideration of the grant of the PRSUs to which you are otherwise not entitled, you irrevocably agree never to institute any claim against the Company or the Affiliate employing or retaining you, waive your ability, if any, to bring any such claim, and release the Company and the Affiliate employing or retaining you from any such claim; if, notwithstanding the foregoing, any such claim is allowed by a court of competent jurisdiction, then, by participating in the Plan, you shall be deemed irrevocably to have agreed not to pursue such claim and agree to execute any and all documents necessary to request dismissal or withdrawal of such claim; and
(k)    you acknowledge and agree that neither the Company, the Affiliate employing or retaining you nor any other Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the United States Dollar that may affect the value of the PRSUs or of any amounts due to you pursuant to the settlement of the PRSUs or the subsequent sale of any Ordinary Shares acquired upon settlement.
2.12    Successors and Assigns. This Agreement shall be binding upon any or all successors and assigns of the Company.
2.13    Applicable Law. This Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of Michigan, U.S.A., without regard to principals of conflict of laws. Any proceeding related to or arising out of this Agreement shall be commenced, prosecuted or continued in the Circuit Court in Kent County, Michigan located in Grand Rapids, Michigan or in the United Stated District Court for the Western District of Michigan, and in any appellate court thereof.
2.14    Forfeiture of PRSUs. If the Company, as a result of misconduct, is required to prepare an accounting restatement due to material noncompliance with any financial reporting requirement under the securities laws, then (a) if your incentive or equity-based compensation is subject to automatic forfeiture due to such misconduct and restatement under Section 304 of the Sarbanes-Oxley Act of 2002, or (b) the Committee determines you either knowingly engaged in or failed to prevent the misconduct, or your actions or inactions with respect to the misconduct and restatement constituted gross negligence, you shall (i) be required to reimburse the Company the amount of any payment relating to any PRSUs earned or accrued during the twelve month


period following the first public issuance or filing with the SEC (whichever first occurred) of the financial document embodying such financial reporting requirement, and (ii) all outstanding PRSUs (including related dividend equivalents) that have not yet been settled shall be immediately forfeited. In addition, Ordinary Shares acquired under this Agreement, and any gains or profits on the sale of such Ordinary Shares, shall be subject to any “clawback” or recoupment policy later adopted by the Company.
2.15    Appendix. Notwithstanding any provisions in this Agreement, the PRSU grant shall be subject to any special terms and conditions set forth in any Appendix to this Agreement for your country. Moreover, if you relocate to one of the countries included in the Appendix, the special terms and conditions for such country will apply to you, to the extent the Company determines that the application of such provisions is necessary or advisable in order to comply with laws of the country where you reside or to facilitate the administration of the Plan. The Appendix constitutes part of this Agreement.
2.16    Imposition of Other Requirements. The Company reserves the right to impose other requirements on your participation in the Plan, on the PRSUs and on any Ordinary Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable in order to comply with laws of the country where you reside or to facilitate the administration of the Plan, and to require you to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.
****
We look forward to your continuing contribution to the growth of the Company. Please acknowledge your receipt of the Plan and this Award.
Very truly yours,




Print Name: ___________________________
Title:_________________________________



APPENDIX

PERRIGO COMPANY PLC
Additional Terms and Provisions to
Restricted Stock Unit Award Agreement (Performance-Based)

Terms and Conditions
This Appendix (the “Appendix”) includes additional terms and conditions that govern the restricted stock units (Performance-Based) (“PRSUs” or “Award”) granted to you under the Plan if you reside in one of the countries listed below. Certain capitalized terms used but not defined in this Appendix have the meanings set forth in the Plan and/or the Agreement.
In addition, please note that the Award is exceptional in nature as it relates to the specific cicumstances of acquisition of the shares of Omega Pharma. Perrigo considers it to be a useful incentive for the combined portfolio to be successful. Therefore, it will not create any entitlement to receive any similar benefit in the future.
Notifications
This Appendix also includes country-specific information of which you should be aware with respect to your participation in the Plan. The information is based on the securities, exchange control and other laws in effect in the respective countries as of December 2014. Such laws are often complex and change frequently. As a result, the Company strongly recommends that you do not rely on the information noted herein as the only source of information relating to the consequences of your participation in the Plan because the information may be out of date at the time that you vest in the PRSUs and shares of the Company, nominal value €0.001 per share (“shares”) are issued to you or the shares issued upon vesting of the PRSUs are sold.
In addition, the information is general in nature and may not apply to your particular situation, and the Company is not in a position to assure you of any particular result. Accordingly, you are advised to seek appropriate professional advice as to how the relevant laws in your country may apply to your particular situation. Finally, please note that if you are a citizen or resident of a country other than the country in which you are currently working, or transfers employment after grant, the information contained in the Appendix may not be applicable.



Argentina
Notifications
Securities Law Information. Neither the Award nor the issuance of the shares are publicly offered or listed on any stock exchange in Argentina. The offer is private and not subject to the supervision of any Argentine governmental authority.
Exchange Control Information. In the event that you transfer sales proceeds in excess of US$50,000 from the sale of shares into Argentina in a single month, you will be subject to certain exchange control reporting requirements. In addition, you may be subject to a mandatory 30% restriction on holding of funds brought into Argentina. Please note that exchange control regulations in Argentina are subject to frequent change. You should consult with your personal legal advisor regarding any exchange control obligations that you may have.
Australia
Terms and Conditions
PRSUs Settled in Shares Only. Notwithstanding any discretion contained in the Plan, or any provision in the Agreement to the contrary, PRSUs granted to employees in Australia shall be settled in shares only and do not provide any right for you to receive a cash payment under this Award.
Notifications
Securities Information. If you acquire shares pursuant to the Award and you offer the shares for sale to a person or entity resident in Australia, then the offer may be subject to disclosure requirements under Australian law. You should obtain legal advice on your disclosure obligations prior to making any such offer.
Exchange Control Information. Exchange control reporting is required for cash transactions exceeding AUD10,000 and for international fund transfers. The Australian bank assisting with the transaction will file the report for you. If there is no Australian bank involved in the transfer, you will have to file the report.
Austria
Notifications
Exchange Control Information. If you hold shares of Company stock outside of Austria, you must submit a report to the Austrian National Bank. An exemption applies if the value of the shares as of any given quarter does not exceed €30,000,000 or as of December 31 does not exceed €5,000,000. If the former threshold is exceeded, quarterly obligations are imposed, whereas if the latter threshold is exceeded, annual reports must be given. The annual reporting date is as of December 31 and the deadline for filing the annual report is March 31 of the following year.
When shares are sold, there may be exchange control obligations if the cash received is held outside Austria. If the transaction volume of all your accounts abroad exceeds €3,000,000, the


movements and balances of all accounts must be reported monthly, as of the last day of the month, on or before the fifteenth day of the following month.
Belgium
No country specific provisions.
Czech Republic
Notifications
Exchange Control Information. The Czech National Bank may require you to report the PRSUs and or Ordinary Shares received and the opening and maintenance of a foreign account. However, because exchange control regulations change frequently and without notice, you should consult your personal legal advisor prior to the vesting of the PRSUs to ensure your compliance with current regulations. It is your responsibility to comply with applicable Czech exchange control laws.
Denmark
Notifications
Exchange Control Information. If you establish an account holding shares pursuant to the Award or an account holding cash outside Denmark, you must report the account to the Danish Tax Administration. The form which should be used in this respect can be obtained from a local bank. (Please note that these obligations are separate from and in addition to the obligations described below.)
Securities/Tax Reporting Information. If you hold shares acquired under the Plan in a brokerage account with a broker or bank outside Denmark, you are required to inform the Danish Tax Administration about the account. For this purpose, you must file a Form V (Erklaering V) with the Danish Tax Administration. The Form V must be signed both by you and by the applicable broker or bank where the account is held. By signing the Form V, the broker or bank undertakes to forward information to the Danish Tax Administration concerning the shares in the account without further request each year. By signing the Form V, you authorize the Danish Tax Administration to examine the account. A sample of the Form V can be found at the following website: www.skat.dk.
In addition, if you open a brokerage account (or a deposit account with a U.S. bank) for the purpose of holding cash outside Denmark, you are also required to inform the Danish Tax Administration about this account. To do so, you must also file a Form K (Erklaering K) with the Danish Tax Administration. The Form K must be signed both by you and by the applicable broker or bank where the account is held. By signing the Form K, the broker/bank undertakes an obligation, without further request each year, to forward information to the Danish Tax Administration concerning the content of the account. By signing the Form K, you authorize the Danish Tax Administration to examine the account. A sample of Form K can be found at the following website: www.skat.dk.
Finland


There are no country specific provisions.
France
Terms and Conditions
Consent to Receive Information in English. By accepting the Award, you confirm having read and understood the Plan and the Agreement, which were provided in the English language. You accept the terms of those documents accordingly.
En acceptant cette attribution gratuite d'actions, vous confirmez avoir lu et comprenez le Plan et ce Contrat, incluant tous leurs termes et conditions, qui ont été transmis en langue anglaise. Vous acceptez les dispositions de ces documents en connaissance de cause.
Notifications
Exchange Control Information. If you hold Ordinary Shares outside of France or maintain a foreign bank account, you are required to report such to the French tax authorities when you file your annual tax return.
Germany
Notifications
Exchange Control Information. Cross-border payments in excess of €12,500 must be reported monthly to the German Federal Bank. If you use a German bank to transfer a cross-border payment in excess of €12,500 in connection with the sale of shares acquired under the Plan, the bank will make the report for you. In addition, you must report any receivables, payables, or debts in foreign currency exceeding an amount of €5,000,000 on a monthly basis.
Greece
Notifications
Exchange Control Information. Pursuant to your Award, if you withdraw funds in excess of €15,000 from a bank in Greece and remit those funds out of Greece, you may be required to submit certain documentation/ information to the Greek bank to ensure that the transfer is not in violation of Greek anti-money laundering rules.
Hungary
No country specific provisions.



India
Notifications
Exchange Control Notification. You must repatriate all proceeds received from the sale of the shares to India within 90 days after sale. You will receive a foreign inward remittance certificate (“FIRC”) from the bank where you deposit the foreign currency. You should maintain the FIRC as evidence of the repatriation of funds in the event that the Reserve Bank of India or the employer requests proof of repatriation.
Tax Information. The amount subject to tax at vesting will partially be dependent upon a valuation that the Company or your employer will obtain from a Merchant Banker in India. Neither the Company nor your employer has any responsibility or obligation to obtain the most favorable valuation possible, nor obtain valuations more frequently than required under Indian tax law.
Ireland
Notifications
Director Notification Obligation. If you are a director, shadow director or secretary of the Company or an Irish Subsidiary or Affiliate of the Company, and you acquire or dispose of an interest under this Agreement comprising more than 1% of the share capital in the Company, you must notify the entity in which you hold that office (whether the Company itself or an Irish Subsidiary or Affiliate of the Company) in writing within five business days of receiving or disposing of an interest in the Company, or within five business days of becoming aware of the event giving rise to the notification requirement or within five days of becoming a director or secretary if such an interest exists at the time. This notification requirement also applies with respect to the interests of a spouse or children under the age of 18 (whose interests will be attributed to the director, shadow director or secretary).
Italy
Terms and Conditions
Data Privacy Notice. The following provision supplements the terms in the Agreement:
You understand that your employer and/or the Company may hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social security number (or any other social or national identification number), salary, nationality, job title, number of Ordinary Shares held and the details of all PRSUs or any other entitlement to Ordinary Shares awarded, cancelled, exercised, vested, unvested or outstanding (the “Data”) for the purpose of implementing, administering and managing your participation in the Plan. You are aware that providing the Company with the Data is necessary for the performance of this Agreement and that your refusal to provide such Data would make it impossible for the Company to perform its contractual obligations and may affect your ability to participate in the Plan.
The "Controller" of personal data processing is Perrigo Company, plc, with registered offices at Allegan, Michigan, USA, and, pursuant to D.lgs 196/2003, its representative David A. McConnell. You understand that the Data may be transferred to the Company or any of its subsidiaries or


affiliates, or to any third parties assisting in the implementation, administration and management of the Plan, including any transfer required to a broker or other third party with whom Ordinary Shares acquired pursuant to the vesting of the PRSUs or cash from the sale of Ordinary Shares acquired pursuant to the Plan may be deposited. Furthermore, the recipients that may receive, possess, use, retain and transfer such Data for the above mentioned purposes may be located in Italy or elsewhere, including outside of the European Union and that the recipients’ country (e.g., the United States) may have different data privacy laws and protections than Italy. The processing activity, including the transfer of your personal data abroad, outside of the European Union, as herein specified and pursuant to applicable laws and regulations, does not require your consent thereto as the processing is necessary for the performance of contractual obligations related to the implementation, administration and management of the Plan. You understand that Data processing relating to the purposes above specified shall take place under automated or non-automated conditions, anonymously when possible, that comply with the purposes for which Data are collected and with confidentiality and security provisions as set forth by applicable laws and regulations, with specific reference to D.lgs. 196/2003.
You understand that Data will be held only as long as is required by law or as necessary to implement, administer and manage your participation in the Plan. You understand that pursuant to art.7 of D.lgs 196/2003, you have the right, including but not limited to, access, delete, update, request the rectification of your personal Data and cease, for legitimate reasons, the Data processing. Furthermore, you are aware that your Data will not be used for direct marketing purposes.
Plan Document Acknowledgment. In accepting the PRSUs, you acknowledge that you have received a copy of the Plan and the Agreement and have reviewed the Plan and the Agreement, including this Appendix, in their entirety and fully understand and accept all provisions of the Plan and the Agreement, including this Appendix.
Notifications
Tax/Exchange Control Information. You are required to report on your annual tax return: (a) any transfers of cash or Ordinary Shares to or from Italy exceeding €10,000 or the equivalent amount in U.S. dollars; (b) any foreign investments or investments (including the Ordinary Shares issued at vesting of the PRSUs, cash or proceeds from the sale of Ordinary Shares acquired under the Plan) held outside of Italy exceeding €10,000 or the equivalent amount in U.S. dollars, if the investment may give rise to income in Italy (this will include reporting the Ordinary Shares issued at vesting of the PRSUs if the fair market value of such Ordinary Shares combined with other foreign assets exceed €10,000); and (c) the amount of the transfers to and from abroad which have had an impact during the calendar year on your foreign investments or investments held outside of Italy. You are exempt from the formalities in (a) if the investments are made through an authorized broker resident in Italy, as the broker will comply with the reporting obligation on your behalf.
Kazakhstan
Notifications
Exchange Control Information. Although Kazakh residents are no longer required to obtain a license from the National Bank of Kazakhstan in advance of obtaining securities in foreign


companies, you are nevertheless required to notify the National Bank of Kazakhstan when you acquire shares under the Plan.
Latvia
No country specific provisions.
Luxembourg
Notifications
Exchange Control Information. You are required to report any inward remittances of funds to the Banque Central de Luxembourg and/or the Service Central de La Statistique et des Etudes Economiques within 15 working days following the month during the transaction occurred. If a Luxembourg financial institution is involved in the transaction, it generally will fulfill the reporting obligation on your behalf.
Mexico
Modification. By accepting the PRSUs, you understand and agree that any modification of the Plan or the Agreement or its termination shall not constitute a change or impairment of the terms and conditions of employment.
Policy Statement. The award of the PRSUs the Company is making under the Plan is unilateral and discretionary and, therefore, the Company reserves the absolute right to amend it and discontinue it at any time without any liability.
The Company, with registered offices in the U.S., is solely responsible for the administration of the Plan and participation in the Plan and the acquisition of shares does not, in any way, establish an employment relationship between you and the Company since you are participating in the Plan on a wholly commercial basis and the sole employer is as applicable, nor does it establish any rights between you and the Employer.
Plan Document Acknowledgment. By accepting the award of the PRSUs, you acknowledge that you have received copies of the Plan, have reviewed the Plan and the Agreement in their entirety and fully understand and accept all provisions of the Plan and the Agreement.
In addition, by signing the Agreement, you further acknowledge that you have read and specifically and expressly approve the terms and conditions in the Agreement, in which the following is clearly described and established: (i) participation in the Plan does not constitute an acquired right; (ii) the Plan and participation in the Plan is offered by the Company on a wholly discretionary basis; (iii) participation in the Plan is voluntary; and (iv) the Company and any Parent, Subsidiary or Affiliates are not responsible for any decrease in the value of the shares.
Finally, you hereby declare that you do not reserve any action or right to bring any claim against the Company for any compensation or damages as a result of your participation in the Plan and therefore grant a full and broad release to the Employer, the Company and any Parent, Subsidiary or Affiliates with respect to any claim that may arise under the Plan.


Spanish Translation
Modification. Al aceptar las Unidades de Accion Restringida, usted reconoce y acuerda que cualquier modification del Plan o su terminacion no constituye un cambio o desmejora de los terminos y condiciones de empleo.
Declaracion de Politica. El Otorgarmiento de Unidades de Accion Restringida de la Compañia en virtud del Plan es unilateral y discrecional y, por lo tanto, la Compañia se reserva el derecho absoluto de modificar y discontinuar el mismo en cualquier tiempo, sin responsabilidad alguna.
La Compañia, con oficinas registradas ubicadas en the U.S., es la unica responsable de la administración del Plan y de la participación en el mismo y la adquisición de Acciones no establece de forma alguna una relación de trabajo entre usted y la Compañia, ya que su participación en el Plan es completamente comercial y el unico empleador es en caso de ser aplicable, asi como tampoco establece ningun derecho entre la persona que tenga el derecho a optar y el Empleador.
Reconocimiento del Documento del Plan. Al aceptar el Otorgamiento de las Unidades de Acciόn Restringida, usted reconoce que ha recibido copias del Plan, ha revisado el mismo, al igual que la totalidad del Acuerdo y, que ha entendido y aceptado completamente todas las disposiciones contenidas en el Plan y en el Acuerdo.
Adicionalmente, al firmar el Acuerdo, reconoce que ha leido, y que aprueba especifica y expresamente los términos y condiciones contenidos en la Renuncia de Derecho o Reclamo por Compensación del Acuerdo, en el cual se encuentra claramente descrito y establecido lo siguiente: (i) la participación en el Plan no constituye un derecho adquirido; (ii) el plan y la participación en el mismo es ofrecida por la Compañia de forma enteramente discrecional; (iii) la participación en el Plan es voluntaria; y (iv) la Compañia, asi como su Sociedad controlante, Subsidiaria o Filiales no son responsables por cualquier disminución en el valor de las Acciones.
Finalmente, declara que no se reserva ninguna acciόn o derecho para interponer una demanda en contra de la Compañia por compensación, dano o perjuicio alguno como resultado de su participación en el Plan y, en consecuencia, otorga el más amplio finiquito al Empleador, asi como a la Compañia, a su Sociedad controlante, Subsidiaria o Filiales con respecto a cualquier demanda que pudiera originarse en virtud del Plan.
Netherlands
Notifications
Insider-Trading Notification. You should be aware of the Dutch insider-trading rules which may prohibit you from effectuating certain transactions involving shares if you have inside information about the Company. If you are uncertain whether the insider-trading rules apply to you, you should consult your personal legal advisor.
Norway
No country specific provisions.


Poland
Terms and Conditions
Consent to Receive Information in English. By accepting the Award, you confirm having read and understood the Plan and the Agreement, which were provided in the English language. You accept the terms of those documents accordingly.
Section 2.11 item (h) of the Award Agreement shall be also understood as that the grant and your participation in the Plan will not be interpreted to form or be part of terms and conditions of your employment or service with any Subsidiary or affiliate of the Company.
Notifications
Exchange Control Information. If you hold foreign securities (including shares pursuant to the Award) and maintain accounts abroad, you may be required to file certain reports with the National Bank of Poland. Specifically, if the value of securities and cash held in such foreign accounts exceeds PLN 7,000,000 at the end of the year, you must file reports on the transactions and balances of the accounts on a quarterly basis by the 20th day of the month following the end of each quarter and an annual report by no later than January 30 of the following calendar year. Such reports are filed on special forms available on the website of the National Bank of Poland. Additionally, if you are a Polish citizen and you transfer funds abroad in excess of the PLN equivalent of €15,000, the transfer must be made through an authorized bank, a payment institution or an electronic money institution authorized to render payment services.
Portugal
Notifications
Exchange Control Information. If you receive shares pursuant to the Award, the acquisition of the shares should be reported to the Banco de Portugal for statistical purposes. If the shares are deposited with a commercial bank or financial intermediary in Portugal, such bank or financial intermediary will submit the report on your behalf. If the shares are not deposited with a commercial bank or financial intermediary in Portugal, you are responsible for submitting the report to the Banco de Portugal.
Romania
Notifications
Exchange Control Information. Payments by Romanian citizens to or from non-residents in excess of €50,000 should be reported to the National Bank of Romania (“NBR”) for statistical purposes. If you deposit the proceeds from the sale of shares issued to you at vesting in a bank account in Romania, you may be required to provide the Romanian bank with appropriate documentation explaining the source of the funds. You should consult your personal advisor to determine whether you will be required to submit such documentation to the Romanian bank.


Insider-Trading Notification. You should be aware of the Romanian insider-trading rules which may prohibit you from effectuating certain transactions involving shares if you have inside information about the Company. If you are uncertain whether the insider-trading rules apply to you, you should consult your personal legal advisor.
Russia
Terms and Conditions
(i)U.S. Transaction. You understand that the PRSUs shall be valid and this Agreement shall be concluded and become effective only when the Agreement is electronically received by the Company in the United States. Upon vesting, any shares to be issued to you shall be delivered to you through a bank or brokerage account in the United States. You are not permitted to sell the shares directly to other Russian legal entities or individuals.
Notifications
(ii)Exchange Control Information. Under current exchange control regulations, within a reasonably short time after sale of the shares issued at vesting, you must repatriate the sale proceeds to Russia. Such sale proceeds must be initially credited to you through a foreign currency account at an authorized bank in Russia. After the sale proceeds are initially received in Russia, they may be further remitted to foreign banks in accordance with Russian exchange control laws.
(iii)You are encouraged to contact your personal advisor before remitting your sale proceeds to Russia as exchange control requirements may change.
Securities Law Notification. This Appendix, the Agreement, the Plan and all other materials that you may receive regarding participation in the Plan do not constitute advertising or an offering of securities in Russia. Absent any requirement under local law, the issuance of securities pursuant to the Plan has not and will not be registered in Russia; hence, the securities described in any Plan-related documents may not be used for offering or public circulation in Russia.
Serbia
No country specific provisions.
Slovakia
No country specific provisions.


Slovenia
No country specific provisions.
South Africa
Terms and Conditions
Taxes. By accepting the PRSUs, you agree that, immediately upon vesting of the PRSUs, you will notify your employer of the amount of any gain realized. If you fail to advise your employer of the gain realized upon vesting, you may be liable for a fine. You will be solely responsible for paying any difference between the actual tax liability and the amount withheld by your employer.
Notifications
Exchange Control Information. Because no transfer of funds from South Africa is required under the PRSUs, no filing or reporting requirements should apply when the award is granted nor when Ordinary Shares are issued upon vesting of the PRSUs. However, because the exchange control regulations are subject to change, you should consult your personal advisor prior to vesting and settlement of the award to ensure compliance with current regulations.
Spain
Terms and Conditions
No Entitlement for Claims or Compensation. By accepting the award of PRSUs, you consent to participation in the Plan, and acknowledge that you have received a copy of the Plan document. You understand that the Company has unilaterally, gratuitously and in its sole discretion decided to make awards of PRSUs under the Plan to individuals who may be employees, consultants and directors throughout the world. The decision is limited and entered into based upon the express assumption and condition that any PRSUs will not economically or otherwise bind the Company or any Parent, Subsidiary or Affiliate, including your employer, on an ongoing basis, other than as expressly set forth in the Agreement. Consequently, you understand that the Award is given on the assumption and condition that the PRSUs shall not become part of any employment contract (whether with the Company or any Parent, Subsidiary or Affiliate, including your employer) and shall not be considered a mandatory benefit, salary for any purpose (including severance compensation) or any other right whatsoever. Furthermore, you understand and freely accept that there is no guarantee that any benefit whatsoever shall arise from the award, which is gratuitous and discretionary, since the future value of the PRSUs and the underlying shares is unknown and unpredictable. You also understand that this Award would not be made but for the assumptions and conditions set forth hereinabove; thus, you understand, acknowledge and freely accept that, should any or all of the assumptions be mistaken or any of the conditions not be met for any reason, the Award, the PRSUs and any right to the underlying shares shall be null and void.
Notifications
Exchange Control Information. You must declare the acquisition of Ordinary Shares to the Dirección General de Politica Comercial e Inversiones Exteriores ("DGPCIE") of the Ministerio de


Economia for statistical purposes. You must also declare the ownership of any Ordinary Shares with the Directorate of Foreign Transactions each January while the shares are owned. In addition, you wish to import the share certificates into Spain, you must declare the importation of such securities to the DGPCIE.
When receiving foreign currency payments derived from the ownership of Ordinary Shares (i.e., dividends or sale proceeds), you must inform the financial institution receiving the payment of the basis upon which such payment is made. You will need to provide the following information: (i) your name, address, and fiscal identification number; (ii) the name and corporate domicile of the Company; (iii) the amount of the payment and the currency used; (iv) the country of origin; (v) the reasons for the payment; and (vi) further information that may be required.
Tax Information. If you hold assets or rights outside of Spain (including shares acquired under the Plan), you may have to file an informational tax report with the tax authorities declaring such ownership. Generally, if the value of your foreign investments exceeds €50,000, you may have to file this informational return. Please note that reporting requirements are based on what you have previously disclosed and the increase in value of such and the total value of certain groups of foreign assets. Also, the thresholds for annual filing requirements may change each year. Therefore, you should consult your personal advisor regarding whether you will be required to file an informational tax report for asset and rights that you hold abroad.
Sweden
Terms and Conditions
The following shall apply in addition to what is set out under section 2.14 of the Award Agreement:
Forfeiture of entitlements under the Plan in case of termination shall apply in case of termination of employment regardless of whether such termination of employment may be justified under Swedish employment protection legislation, and regardless of whether such termination may be challenged by you, and regardless of whether such termination is invalidated by verdict or a court order.
Switzerland
Notifications
Securities Law Notification The award is considered a private offering in Switzerland; therefore, it is not subject to registration in Switzerland.
Turkey
No country specific provisions.
Ukraine
Notifications


Exchange Control Information. Exchange control rules change frequently and you should consult your personal advisor to determine whether you are required to obtain a license for obtaining shares of a foreign company from the National Bank of Ukraine (NBU).
Terms and Conditions
The Award will be outside the scope of your employment or service contract (if any) and as such will not constitute a part of your compensation package under the respective employment or service contract.
United Kingdom
Terms and Conditions
Income Tax and National Insurance Contribution Withholding. The following provision supplements the terms in the Agreement:
If payment or withholding of the income tax due in connection with the PRSUs is not made within ninety (90) days of the end of the U.K. tax year in which the event giving rise to the income tax liability or such other period specified in Section 222(1)(c) of the U.K. Income Tax (Earnings and Pensions) Act 2003 occurred (the “Due Date”), the amount of any uncollected income tax shall constitute a loan owed by you to your employer, effective as of the Due Date. You agree that the loan will bear interest at the then-current official rate of Her Majesty’s Revenue & Customs (“HMRC”), it shall be immediately due and repayable, and the Company or your employer may recover it at any time thereafter by any of the means referred to in Section 2.7 of the Agreement. Notwithstanding the foregoing, if you are a director or executive officer of the Company (within the meaning of Section 13(k) of the U.S. Securities and Exchange Act of 1934, as amended), you will not be eligible for a loan from the Company or your employer to cover the income tax liability. In the event that you are a director or executive officer and the income tax is not collected from or paid by the Due Date, the amount of any uncollected income tax will constitute a benefit to you on which additional income tax and national insurance contributions (“NICs”) will be payable. You will be responsible for reporting any income tax for reimbursing the Company or your employer the value of any employee NICs due on this additional benefit.
* * * * *




PERRIGO COMPANY PLC
RESTRICTED STOCK UNIT AWARD AGREEMENT FOR NON-U.S. PARTICIPANTS
(PERFORMANCE-BASED)
(Under the Perrigo Company plc 2013 Long-Term Incentive Plan)
TO:        Participant Name

RE:        Notice of Restricted Stock Unit Award (Performance-Based)
This is to notify you that Perrigo Company plc (the “Company”) has granted you an Award for non-U.S. participants under the Perrigo Company plc 2013 Long-Term Incentive Plan (the “Plan”), effective as of Grant Date (the “Grant Date”). This Award consists of performance-based restricted stock units. The terms and conditions of this incentive are set forth in the remainder of this agreement (including any special terms and conditions set forth in any appendix for your country (“Appendix”)) (collectively, the “Agreement”). The capitalized terms that are not otherwise defined in this Agreement shall have the meanings ascribed to such terms under the Plan.
SECTION 1
Restricted Stock Units – Performance-Based Vesting
1.1    Grant. As of the Grant Date, the Company grants to you Number of Awards Granted restricted stock units (“Performance Restricted Stock Units” or “PRSUs”), subject to the terms and conditions set forth in this Agreement. The number of Performance Restricted Stock Units awarded in this Section 1.1 is referred to as the “Target Award.” The Target Award may be increased or decreased depending on the level of attainment of Performance Goals for designated Performance Measures as described in Section 1.2. Each Performance Restricted Stock Unit shall entitle you to one ordinary share of the Company, nominal value €0.001 per share (“Ordinary Share”) on the PRSU Vesting Date set forth in Section 1.2, provided the applicable Performance Goals for each Performance Measure are satisfied.
1.2    Vesting. The number of Performance Restricted Stock Units awarded in Section 1.1 vesting, if any, shall be determined as of the PRSU Vesting Date. That number will be determined based on the average level of attainment of annual Performance Measure(s) for each fiscal year in the Performance Period, in accordance with the schedule determined by the Committee at the time the Performance Measures and applicable Performance Goals are established by the Committee.
The Committee shall establish annually one or more Performance Measures and the Performance Goals with respect to each Performance Measure that must be attained for Threshold, Target and Maximum performance for a fiscal year. The Performance Measure and Performance Goals for each fiscal year will be provided to you.


Following the end of each fiscal year in the Performance Period, the Committee will determine the percentage of Target Award PRSUs that would be payable for such fiscal year, based on the attainment of the Performance Goals for each Performance Measure(s) established by the Committee for that fiscal year. The percentage of the Target Award that would be payable under the schedule shall be adjusted, pro rata, to reflect attained performance between Threshold and Target, and Target and Maximum.
At the end of the Performance Period, the percentage payout for each fiscal year in the Performance Period will be averaged to determine the actual percentage of Target Award PRSUs that will vest and be payable on the PRSU Vesting Date. In no event will the calculation of a positive payout percentage for any fiscal year be construed to guarantee that any PRSUs will vest on the PRSU Vesting Date. Payout percentages for the individual fiscal years are determined solely for purposes of determining the average annual payout percentage for the three-year Performance Period.
Except as provided in Section 1.4, the PRSUs will be permanently forfeited if your Termination Date occurs prior to the PRSU Vesting Date. If the average annual performance payout for the Performance Period is less than the Threshold performance level established by the Committee, all PRSUs that have not previously been forfeited shall be forfeited as of the PRSU Vesting Date. If the average annual performance payout for the Performance Period exceeds the Maximum performance level established by the Committee, then in no event will the number of PRSUs vesting exceed 200% of the Target Award.
1.3    Definitions. The following terms shall have the following meanings under this Section 1.
(a)    “Performance Goal” means the level of performance that must be attained with respect to a Performance Measure for a fiscal year for Minimum, Target and Maximum payout.
(b)    “Performance Measure” for any fiscal year means one or more financial measures, as determined by the Committee. The Committee shall provide how the Performance Measure will be adjusted, if at all, as a result of extraordinary events or circumstances, as determined by the Committee, or to exclude the effects of extraordinary, unusual, or non-recurring items; changes in applicable laws, regulations, or accounting principles; currency fluctuations; discontinued operations; non-cash items, such as amortization, depreciation, or reserves; asset impairment; or any recapitalization, restructuring, reorganization, merger, acquisition, divestiture, consolidation, spin-off, split-up, combination, liquidation, dissolution, sale of assets, or other similar corporation transaction.
(c)    “Performance Period” means a period of three consecutive fiscal years of the Company, beginning with the first day of the fiscal year of the Company in which the Grant Date occurs and ending on the last day of the third fiscal year in the 3-year period.
(d)    “PRSU Vesting Date” means the last day of the Performance Period.


(e)    “Separation for Good Reason” means your voluntary resignation from the Company and the existence of one or more of the following conditions that arose without your consent: (i) a material change in the geographic location at which you are required to perform services, such that your commute between home and your primary job site increases by more than 30 miles, or (ii) a material diminution in your authority, duties or responsibilities or a material diminution in your base compensation or incentive compensation opportunities; provided, however, that a voluntary resignation from the Company shall not be considered a Separation for Good Reason unless you provide the Company with notice, in writing, of your voluntary resignation and the existence of the condition(s) giving rise to the separation within 90 days of its initial existence. The Company will then have 30 days to remedy the condition, in which case you will not be deemed to have incurred a Separation for Good Reason. In the event the Company fails to cure the condition within the 30 day period, your Termination Date shall occur on the 31st day following the Company’s receipt of such written notice.
(f)    “Termination without Cause” means the involuntary termination of your employment or contractual relationship by the Company without Cause, including, but not limited to, (i) a termination effective when you exhaust an approved leave of absence, and (ii) a situation where you are on an approved leave of absence during which your position is protected under applicable leave law, you return from such leave, and you cannot be placed in employment or other form of contractual relationship with the Company.
1.4    Special Vesting Rules. Notwithstanding Section 1.2 above, if your Termination Date occurs by reason of a Termination without Cause or a Separation for Good Reason on or after a Change in Control (as defined in the Plan and as such definition may be amended hereafter) and prior to the two (2) year anniversary of the Change in Control, all of the Performance Restricted Stock Units awarded under Section 1.1 that have not previously been forfeited shall become fully vested as if Target performance had been obtained for the Performance Period effective as of your Termination Date. If your Termination Date occurs because of death, Disability, or Retirement, the Performance Restricted Stock Units shall vest or be forfeited as of the PRSU Vesting Date set forth in Section 1.2, based on the attainment of the performance goals. If your Termination Date occurs because of an Involuntary Termination for Economic Reasons, the Company’s Chief Executive Officer (or the Committee, if you are subject to Section 16 of the Exchange Act), in his or her sole and absolute discretion, may permit all or part of the Performance Restricted Stock Units awarded hereunder to remain outstanding and vest or be forfeited as of the date set forth in Section 1.2, depending on the attainment of Performance Goals; provided, however, that if your Termination Date occurs for a reason that is both described in this sentence and in the first sentence of this Section 1.4, the special vesting rules described in the first sentence of this Section 1.4 shall apply in lieu of the vesting rules described in this sentence. To the extent that the Chief Executive Officer (or Committee, if applicable) does not exercise discretionary authority to allow Performance Restricted Stock Units to remain outstanding on the date of your Involuntary Termination for Economic Reasons, such Restricted Stock Units shall be permanently forfeited.
1.5    Settlement of Performance Restricted Stock Units. As soon as practicable following the date of the Committee’s first regularly scheduled meeting following the last day of


the Performance Period at which the Committee certifies the average payout for each of the three years in the Performance Period, the Company shall transfer to you one Ordinary Share for each Performance Restricted Stock Unit, if any, that becomes vested pursuant to Section 1.2 or 1.4 of this Agreement (the date of any such transfer shall be the “settlement date” for purposes of this Agreement); provided, however, the Company in its discretion may settle Performance Restricted Stock Units in cash, based on the fair market value of the shares on the PRSU Vesting Date. No fractional shares shall be transferred. Any fractional share shall be rounded to the nearest whole share. The income attributable to the vesting of PRSUs and the amount of any required tax withholding will be determined based on the value of the shares on the settlement date. Performance Restricted Stock Units are not eligible for dividend equivalents.
SECTION 2
General Terms and Conditions
2.1    Nontransferability. The Award under this Agreement shall not be transferable other than by will or by the laws of descent and distribution.
2.2    No Rights as a Stockholder. You shall not have any rights as a stockholder with respect to any Ordinary Shares subject to the PRSUs awarded under this Agreement prior to the date of issuance to you of a certificate or certificates for such shares.
2.3    Cause Termination. If your Termination Date occurs for reasons of Cause, all of your rights under this Agreement, whether or not vested, shall terminate immediately.
2.4    Award Subject to Plan. The granting of the Award under this Agreement is being made pursuant to the Plan and the Award shall be payable only in accordance with the applicable terms of the Plan. The Plan contains certain definitions, restrictions, limitations and other terms and conditions all of which shall be applicable to this Agreement. ALL THE PROVISIONS OF THE PLAN ARE INCORPORATED HEREIN BY REFERENCE AND ARE MADE A PART OF THIS AGREEMENT IN THE SAME MANNER AS IF EACH AND EVERY SUCH PROVISION WERE FULLY WRITTEN INTO THIS AGREEMENT. Should the Plan become void or unenforceable by operation of law or judicial decision, this Agreement shall have no force or effect. Nothing set forth in this Agreement is intended, nor shall any of its provisions be construed, to limit or exclude any definition, restriction, limitation or other term or condition of the Plan as is relevant to this Agreement and as may be specifically applied to it by the Committee. In the event of a conflict in the provisions of this Agreement and the Plan, as a rule of construction the terms of the Plan shall be deemed superior and apply.
2.5    Adjustments in Event of Change in Ordinary Shares. In the event of a stock split, stock dividend, recapitalization, reclassification or combination of shares, merger, sale of assets or similar event, the number and kind of shares subject to Award under this Agreement will be appropriately adjusted in an equitable manner to prevent dilution or enlargement of the rights granted to or available for you.


2.6    Acknowledgement. The Company and you agree that the PRSUs are granted under and governed by the Notice of Grant, this Agreement (including the Appendix) and by the provisions of the Plan (incorporated herein by reference). You: (i) acknowledge receipt of a copy of each of the foregoing documents, (ii) represent that you have carefully read and are familiar with their provisions, and (iii) hereby accept the PRSUs subject to all of the terms and conditions set forth herein and those set forth in the Plan and the Notice of Grant.
2.7    Responsibility for Taxes. Regardless of any action the Company or, if different, the Affiliate employing or retaining you takes with respect to any or all income tax, social insurance, payroll tax, payment on account or other tax-related items related to your participation in the Plan and legally applicable to you (“Tax-Related Items”), you acknowledge that the ultimate liability for all Tax-Related Items is and remains your responsibility and may exceed the amount actually withheld by the Company or the Affiliate employing or retaining you. You further acknowledge that the Company and/or the Affiliate employing or retaining you (1) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the PRSUs, including, but not limited to, the grant, vesting or settlement of the PRSUs, the subsequent sale of Ordinary Shares acquired pursuant to such settlement and the receipt of any dividends; and (2) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the PRSUs to reduce or eliminate your liability for Tax-Related Items or achieve any particular tax result. Further, if you have become subject to tax in more than one jurisdiction between the PRSU Grant Date and the date of any relevant taxable event, as applicable, you acknowledge that the Company and/or the Affiliate employing or retaining you (or formerly employing or retaining you, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.
(a)     Prior to any relevant taxable or tax withholding event, as applicable, you will pay or make adequate arrangements satisfactory to the Company and/or the Affiliate employing or retaining you to satisfy all Tax-Related Items. In this regard, you authorize the Company and/or the Affiliate employing or retaining you, or their respective agents, at their discretion, to satisfy the obligations with regard to all Tax-Related Items by one or a combination of the following:
(1)    withholding from your wages or other cash compensation paid to you by the Company and/or the Affiliate employing or retaining you; or
(2)    withholding from proceeds of the sale of Ordinary Shares acquired upon settlement of the PRSUs either through a voluntary sale or through a mandatory sale arranged by the Company (on your behalf pursuant to this authorization); or
(3)    withholding in Ordinary Shares to be issued upon settlement of the PRSUs.
(b)    To avoid negative accounting treatment, the Company may withhold or account for Tax-Related Items by considering applicable minimum statutory withholding amounts or other applicable withholding rates. If the obligation for Tax-Related Items is satisfied by withholding in Ordinary Shares, for tax purposes, you are deemed to have been


issued the full number of Ordinary Shares subject to the vested PRSUs, notwithstanding that a number of the Ordinary Shares are held back solely for the purpose of paying the Tax-Related Items.
(c)    Finally, you shall pay to the Company or the Affiliate employing or retaining you any amount of Tax-Related Items that the Company or the Affiliate employing or retaining you may be required to withhold or account for as a result of your participation in the Plan that cannot be satisfied by the means previously described. The Company may refuse to issue or deliver the Ordinary Sharse or the proceeds of the sale of Ordinary Shares, if you fail to comply with your obligations in connection with the Tax-Related Items.
2.8    Compliance with Applicable Law. The issuance of Ordinary Shares will be subject to and conditioned upon compliance by the Company and you, including any written representations, warranties and agreements as the Administrator may request of you for compliance with all (i) applicable U.S. state and federal laws and regulations, (ii) applicable laws of the country where you reside pertaining to the issuance or sale of Ordinary Shares, and (iii) applicable requirements of any stock exchange or automated quotation system on which the Company’s Ordinary Shares may be listed or quoted at the time of such issuance or transfer.
2.9    Short Term Deferral. Performance Restricted Stock Units payable under this Agreement are intended to be exempt from Code Section 409A under the exemption for short-term deferrals. Accordingly, Performance Restricted Stock Units will be settled no later than the 15th day of the third month following the later of (i) the end of the Employee’s taxable year in which the PRSU Vesting Date occurs, or (ii) the end of the fiscal year of the Company in which the PRSU Vesting Date occurs.
2.10    Data Privacy.
(a)    By entering into this Agreement and accepting this Award, you hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Agreement and any other PRSU grant materials by and among, as applicable, the Affiliate employing or retaining you, the Company and its Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.
(b)    You understand that the Company and the Affiliate employing or retaining you may hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all PRSUs or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the exclusive purpose of implementing, administering and managing the Plan (“Data”).
(c)    You understand that Data will be transferred to legal counsel or a broker or such other stock plan service provider as may be selected by the Company in the future,


which is assisting the Company with the implementation, administration and management of the Plan. You understand that the recipients of the Data may be located in the United States or elsewhere, and that the recipients’ country (e.g., the United States) may have different data privacy laws and protections than your country. You understand that if you reside outside the United States, you may request a list with the names and addresses of any potential recipients of the Data by contacting your local or Company human resources representative. You authorize the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing your participation in the Plan. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan. You understand that if you reside outside the United States, you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local or Company human resources representative. You understand, however, that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local or Company human resources representative.
2.11     Nature of Grant. In accepting the grant, you acknowledge, understand and agree that:
(a)    the Plan is established voluntarily by the Company, it is discretionary in nature and it may be modified, amended, suspended or terminated by the Company at any time, except as otherwise provided in the Plan;
(b)    the grant of the PRSUs is voluntary and occasional and does not create any contractual or other right to receive future grants of PRSUs, or benefits in lieu of PRSUs, even if PRSUs have been granted repeatedly in the past;
(c)    all decisions with respect to future PRSU grants, if any, will be at the sole discretion of the Company;
(d)    you are voluntarily participating in the Plan;
(e)    the PRSUs and the Ordinary Shares subject to the PRSUs are an extraordinary item which is outside the scope of your employment or service contract, if any;
(f)    the PRSUs and the Ordinary Shares subject to the PRSUs are not intended to replace any pension rights or compensation;
(g)    the PRSUs and the Ordinary Shares subject to the PRSUs are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments and in no event should be


considered as compensation for, or relating in any way to, past services for the Company, the Affiliate employing or retaining you or any other Affiliate;
(h)    the grant and your participation in the Plan will not be interpreted to form an employment or service contract with the Company or any Affiliate;
(i)    the future value of the underlying Ordinary Shares is unknown, indeterminable and cannot be predicted with certainty;
(j)    no claim or entitlement to compensation or damages shall arise from forfeiture of the PRSUs resulting from your Termination Date (for any reason whatsoever, whether or not later found to be invalid and whether or not in breach of employment laws in the jurisdiction where you are employed or rendering services, or the terms of your employment agreement, if any), and in consideration of the grant of the PRSUs to which you are otherwise not entitled, you irrevocably agree never to institute any claim against the Company or the Affiliate employing or retaining you, waive your ability, if any, to bring any such claim, and release the Company and the Affiliate employing or retaining you from any such claim; if, notwithstanding the foregoing, any such claim is allowed by a court of competent jurisdiction, then, by participating in the Plan, you shall be deemed irrevocably to have agreed not to pursue such claim and agree to execute any and all documents necessary to request dismissal or withdrawal of such claim; and
(k)    you acknowledge and agree that neither the Company, the Affiliate employing or retaining you nor any other Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the United States Dollar that may affect the value of the PRSUs or of any amounts due to you pursuant to the settlement of the PRSUs or the subsequent sale of any Ordinary Shares acquired upon settlement.
2.12    Successors and Assigns. This Agreement shall be binding upon any or all successors and assigns of the Company.
2.13    Applicable Law. This Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of Michigan, U.S.A., without regard to principals of conflict of laws. Any proceeding related to or arising out of this Agreement shall be commenced, prosecuted or continued in the Circuit Court in Kent County, Michigan located in Grand Rapids, Michigan or in the United Stated District Court for the Western District of Michigan, and in any appellate court thereof.
2.14    Forfeiture of PRSUs. If the Company, as a result of misconduct, is required to prepare an accounting restatement due to material noncompliance with any financial reporting requirement under the securities laws, then (a) if your incentive or equity-based compensation is subject to automatic forfeiture due to such misconduct and restatement under Section 304 of the Sarbanes-Oxley Act of 2002, or (b) the Committee determines you either knowingly engaged in or failed to prevent the misconduct, or your actions or inactions with respect to the misconduct and restatement constituted gross negligence, you shall (i) be required to reimburse the Company the amount of any payment relating to any PRSUs earned or accrued during the twelve month


period following the first public issuance or filing with the SEC (whichever first occurred) of the financial document embodying such financial reporting requirement, and (ii) all outstanding PRSUs (including related dividend equivalents) that have not yet been settled shall be immediately forfeited. In addition, Ordinary Shares acquired under this Agreement, and any gains or profits on the sale of such Ordinary Shares, shall be subject to any “clawback” or recoupment policy later adopted by the Company.
2.15    Appendix. Notwithstanding any provisions in this Agreement, the PRSU grant shall be subject to any special terms and conditions set forth in any Appendix to this Agreement for your country. Moreover, if you relocate to one of the countries included in the Appendix, the special terms and conditions for such country will apply to you, to the extent the Company determines that the application of such provisions is necessary or advisable in order to comply with laws of the country where you reside or to facilitate the administration of the Plan. The Appendix constitutes part of this Agreement.
2.16    Imposition of Other Requirements. The Company reserves the right to impose other requirements on your participation in the Plan, on the PRSUs and on any Ordinary Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable in order to comply with laws of the country where you reside or to facilitate the administration of the Plan, and to require you to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.
****
We look forward to your continuing contribution to the growth of the Company. Please acknowledge your receipt of the Plan and this Award.
Very truly yours,




Print Name: ___________________________
Title:_________________________________



APPENDIX

PERRIGO COMPANY PLC
Additional Terms and Provisions to
Restricted Stock Unit Award Agreement (Performance-Based)

Terms and Conditions
This Appendix (the “Appendix”) includes additional terms and conditions that govern the restricted stock units (Performance-Based) (“PRSUs” or “Award”) granted to you under the Plan if you reside in one of the countries listed below. Certain capitalized terms used but not defined in this Appendix have the meanings set forth in the Plan and/or the Agreement.
In addition, please note that the Award is exceptional in nature as it relates to the specific cicumstances of acquisition of the shares of Omega Pharma. Perrigo considers it to be a useful incentive for the combined portfolio to be successful. Therefore, it will not create any entitlement to receive any similar benefit in the future.
Notifications
This Appendix also includes country-specific information of which you should be aware with respect to your participation in the Plan. The information is based on the securities, exchange control and other laws in effect in the respective countries as of December 2014. Such laws are often complex and change frequently. As a result, the Company strongly recommends that you do not rely on the information noted herein as the only source of information relating to the consequences of your participation in the Plan because the information may be out of date at the time that you vest in the PRSUs and shares of the Company, nominal value €0.001 per share (“shares”) are issued to you or the shares issued upon vesting of the PRSUs are sold.
In addition, the information is general in nature and may not apply to your particular situation, and the Company is not in a position to assure you of any particular result. Accordingly, you are advised to seek appropriate professional advice as to how the relevant laws in your country may apply to your particular situation. Finally, please note that if you are a citizen or resident of a country other than the country in which you are currently working, or transfers employment after grant, the information contained in the Appendix may not be applicable.



Argentina
Notifications
Securities Law Information. Neither the Award nor the issuance of the shares are publicly offered or listed on any stock exchange in Argentina. The offer is private and not subject to the supervision of any Argentine governmental authority.
Exchange Control Information. In the event that you transfer sales proceeds in excess of US$50,000 from the sale of shares into Argentina in a single month, you will be subject to certain exchange control reporting requirements. In addition, you may be subject to a mandatory 30% restriction on holding of funds brought into Argentina. Please note that exchange control regulations in Argentina are subject to frequent change. You should consult with your personal legal advisor regarding any exchange control obligations that you may have.
Australia
Terms and Conditions
PRSUs Settled in Shares Only. Notwithstanding any discretion contained in the Plan, or any provision in the Agreement to the contrary, PRSUs granted to employees in Australia shall be settled in shares only and do not provide any right for you to receive a cash payment under this Award.
Notifications
Securities Information. If you acquire shares pursuant to the Award and you offer the shares for sale to a person or entity resident in Australia, then the offer may be subject to disclosure requirements under Australian law. You should obtain legal advice on your disclosure obligations prior to making any such offer.
Exchange Control Information. Exchange control reporting is required for cash transactions exceeding AUD10,000 and for international fund transfers. The Australian bank assisting with the transaction will file the report for you. If there is no Australian bank involved in the transfer, you will have to file the report.
Austria
Notifications
Exchange Control Information. If you hold shares of Company stock outside of Austria, you must submit a report to the Austrian National Bank. An exemption applies if the value of the shares as of any given quarter does not exceed €30,000,000 or as of December 31 does not exceed €5,000,000. If the former threshold is exceeded, quarterly obligations are imposed, whereas if the latter threshold is exceeded, annual reports must be given. The annual reporting date is as of December 31 and the deadline for filing the annual report is March 31 of the following year.
When shares are sold, there may be exchange control obligations if the cash received is held outside Austria. If the transaction volume of all your accounts abroad exceeds €3,000,000, the


movements and balances of all accounts must be reported monthly, as of the last day of the month, on or before the fifteenth day of the following month.
Belgium
No country specific provisions.
Czech Republic
Notifications
Exchange Control Information. The Czech National Bank may require you to report the PRSUs and or Ordinary Shares received and the opening and maintenance of a foreign account. However, because exchange control regulations change frequently and without notice, you should consult your personal legal advisor prior to the vesting of the PRSUs to ensure your compliance with current regulations. It is your responsibility to comply with applicable Czech exchange control laws.
Denmark
Notifications
Exchange Control Information. If you establish an account holding shares pursuant to the Award or an account holding cash outside Denmark, you must report the account to the Danish Tax Administration. The form which should be used in this respect can be obtained from a local bank. (Please note that these obligations are separate from and in addition to the obligations described below.)
Securities/Tax Reporting Information. If you hold shares acquired under the Plan in a brokerage account with a broker or bank outside Denmark, you are required to inform the Danish Tax Administration about the account. For this purpose, you must file a Form V (Erklaering V) with the Danish Tax Administration. The Form V must be signed both by you and by the applicable broker or bank where the account is held. By signing the Form V, the broker or bank undertakes to forward information to the Danish Tax Administration concerning the shares in the account without further request each year. By signing the Form V, you authorize the Danish Tax Administration to examine the account. A sample of the Form V can be found at the following website: www.skat.dk.
In addition, if you open a brokerage account (or a deposit account with a U.S. bank) for the purpose of holding cash outside Denmark, you are also required to inform the Danish Tax Administration about this account. To do so, you must also file a Form K (Erklaering K) with the Danish Tax Administration. The Form K must be signed both by you and by the applicable broker or bank where the account is held. By signing the Form K, the broker/bank undertakes an obligation, without further request each year, to forward information to the Danish Tax Administration concerning the content of the account. By signing the Form K, you authorize the Danish Tax Administration to examine the account. A sample of Form K can be found at the following website: www.skat.dk.



Finland
There are no country specific provisions.
France
Terms and Conditions
Consent to Receive Information in English. By accepting the Award, you confirm having read and understood the Plan and the Agreement, which were provided in the English language. You accept the terms of those documents accordingly.
En acceptant cette attribution gratuite d'actions, vous confirmez avoir lu et comprenez le Plan et ce Contrat, incluant tous leurs termes et conditions, qui ont été transmis en langue anglaise. Vous acceptez les dispositions de ces documents en connaissance de cause.
Notifications
Exchange Control Information. If you hold Ordinary Shares outside of France or maintain a foreign bank account, you are required to report such to the French tax authorities when you file your annual tax return.
Germany
Notifications
Exchange Control Information. Cross-border payments in excess of €12,500 must be reported monthly to the German Federal Bank. If you use a German bank to transfer a cross-border payment in excess of €12,500 in connection with the sale of shares acquired under the Plan, the bank will make the report for you. In addition, you must report any receivables, payables, or debts in foreign currency exceeding an amount of €5,000,000 on a monthly basis.
Greece
Notifications
Exchange Control Information. Pursuant to your Award, if you withdraw funds in excess of €15,000 from a bank in Greece and remit those funds out of Greece, you may be required to submit certain documentation/ information to the Greek bank to ensure that the transfer is not in violation of Greek anti-money laundering rules.
Hungary
No country specific provisions.



India
Notifications
Exchange Control Notification. You must repatriate all proceeds received from the sale of the shares to India within 90 days after sale. You will receive a foreign inward remittance certificate (“FIRC”) from the bank where you deposit the foreign currency. You should maintain the FIRC as evidence of the repatriation of funds in the event that the Reserve Bank of India or the employer requests proof of repatriation.
Tax Information. The amount subject to tax at vesting will partially be dependent upon a valuation that the Company or your employer will obtain from a Merchant Banker in India. Neither the Company nor your employer has any responsibility or obligation to obtain the most favorable valuation possible, nor obtain valuations more frequently than required under Indian tax law.
Ireland
Notifications
Director Notification Obligation. If you are a director, shadow director or secretary of the Company or an Irish Subsidiary or Affiliate of the Company, and you acquire or dispose of an interest under this Agreement comprising more than 1% of the share capital in the Company, you must notify the entity in which you hold that office (whether the Company itself or an Irish Subsidiary or Affiliate of the Company) in writing within five business days of receiving or disposing of an interest in the Company, or within five business days of becoming aware of the event giving rise to the notification requirement or within five days of becoming a director or secretary if such an interest exists at the time. This notification requirement also applies with respect to the interests of a spouse or children under the age of 18 (whose interests will be attributed to the director, shadow director or secretary).
Italy
Terms and Conditions
Data Privacy Notice. The following provision supplements the terms in the Agreement:
You understand that your employer and/or the Company may hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social security number (or any other social or national identification number), salary, nationality, job title, number of Ordinary Shares held and the details of all PRSUs or any other entitlement to Ordinary Shares awarded, cancelled, exercised, vested, unvested or outstanding (the “Data”) for the purpose of implementing, administering and managing your participation in the Plan. You are aware that providing the Company with the Data is necessary for the performance of this Agreement and that your refusal to provide such Data would make it impossible for the Company to perform its contractual obligations and may affect your ability to participate in the Plan.
The "Controller" of personal data processing is Perrigo Company, plc, with registered offices at Allegan, Michigan, USA, and, pursuant to D.lgs 196/2003, its representative David A. McConnell. You understand that the Data may be transferred to the Company or any of its subsidiaries or


affiliates, or to any third parties assisting in the implementation, administration and management of the Plan, including any transfer required to a broker or other third party with whom Ordinary Shares acquired pursuant to the vesting of the PRSUs or cash from the sale of Ordinary Shares acquired pursuant to the Plan may be deposited. Furthermore, the recipients that may receive, possess, use, retain and transfer such Data for the above mentioned purposes may be located in Italy or elsewhere, including outside of the European Union and that the recipients’ country (e.g., the United States) may have different data privacy laws and protections than Italy. The processing activity, including the transfer of your personal data abroad, outside of the European Union, as herein specified and pursuant to applicable laws and regulations, does not require your consent thereto as the processing is necessary for the performance of contractual obligations related to the implementation, administration and management of the Plan. You understand that Data processing relating to the purposes above specified shall take place under automated or non-automated conditions, anonymously when possible, that comply with the purposes for which Data are collected and with confidentiality and security provisions as set forth by applicable laws and regulations, with specific reference to D.lgs. 196/2003.
You understand that Data will be held only as long as is required by law or as necessary to implement, administer and manage your participation in the Plan. You understand that pursuant to art.7 of D.lgs 196/2003, you have the right, including but not limited to, access, delete, update, request the rectification of your personal Data and cease, for legitimate reasons, the Data processing. Furthermore, you are aware that your Data will not be used for direct marketing purposes.
Plan Document Acknowledgment. In accepting the PRSUs, you acknowledge that you have received a copy of the Plan and the Agreement and have reviewed the Plan and the Agreement, including this Appendix, in their entirety and fully understand and accept all provisions of the Plan and the Agreement, including this Appendix.
Notifications
Tax/Exchange Control Information. You are required to report on your annual tax return: (a) any transfers of cash or Ordinary Shares to or from Italy exceeding €10,000 or the equivalent amount in U.S. dollars; (b) any foreign investments or investments (including the Ordinary Shares issued at vesting of the PRSUs, cash or proceeds from the sale of Ordinary Shares acquired under the Plan) held outside of Italy exceeding €10,000 or the equivalent amount in U.S. dollars, if the investment may give rise to income in Italy (this will include reporting the Ordinary Shares issued at vesting of the PRSUs if the fair market value of such Ordinary Shares combined with other foreign assets exceed €10,000); and (c) the amount of the transfers to and from abroad which have had an impact during the calendar year on your foreign investments or investments held outside of Italy. You are exempt from the formalities in (a) if the investments are made through an authorized broker resident in Italy, as the broker will comply with the reporting obligation on your behalf.
Kazakhstan
Notifications
Exchange Control Information. Although Kazakh residents are no longer required to obtain a license from the National Bank of Kazakhstan in advance of obtaining securities in foreign


companies, you are nevertheless required to notify the National Bank of Kazakhstan when you acquire shares under the Plan.
Latvia
No country specific provisions.
Luxembourg
Notifications
Exchange Control Information. You are required to report any inward remittances of funds to the Banque Central de Luxembourg and/or the Service Central de La Statistique et des Etudes Economiques within 15 working days following the month during the transaction occurred. If a Luxembourg financial institution is involved in the transaction, it generally will fulfill the reporting obligation on your behalf.
Mexico
Modification. By accepting the PRSUs, you understand and agree that any modification of the Plan or the Agreement or its termination shall not constitute a change or impairment of the terms and conditions of employment.
Policy Statement. The award of the PRSUs the Company is making under the Plan is unilateral and discretionary and, therefore, the Company reserves the absolute right to amend it and discontinue it at any time without any liability.
The Company, with registered offices in the U.S., is solely responsible for the administration of the Plan and participation in the Plan and the acquisition of shares does not, in any way, establish an employment relationship between you and the Company since you are participating in the Plan on a wholly commercial basis and the sole employer is as applicable, nor does it establish any rights between you and the Employer.
Plan Document Acknowledgment. By accepting the award of the PRSUs, you acknowledge that you have received copies of the Plan, have reviewed the Plan and the Agreement in their entirety and fully understand and accept all provisions of the Plan and the Agreement.
In addition, by signing the Agreement, you further acknowledge that you have read and specifically and expressly approve the terms and conditions in the Agreement, in which the following is clearly described and established: (i) participation in the Plan does not constitute an acquired right; (ii) the Plan and participation in the Plan is offered by the Company on a wholly discretionary basis; (iii) participation in the Plan is voluntary; and (iv) the Company and any Parent, Subsidiary or Affiliates are not responsible for any decrease in the value of the shares.
Finally, you hereby declare that you do not reserve any action or right to bring any claim against the Company for any compensation or damages as a result of your participation in the Plan and therefore grant a full and broad release to the Employer, the Company and any Parent, Subsidiary or Affiliates with respect to any claim that may arise under the Plan.


Spanish Translation
Modification. Al aceptar las Unidades de Accion Restringida, usted reconoce y acuerda que cualquier modification del Plan o su terminacion no constituye un cambio o desmejora de los terminos y condiciones de empleo.
Declaracion de Politica. El Otorgarmiento de Unidades de Accion Restringida de la Compañia en virtud del Plan es unilateral y discrecional y, por lo tanto, la Compañia se reserva el derecho absoluto de modificar y discontinuar el mismo en cualquier tiempo, sin responsabilidad alguna.
La Compañia, con oficinas registradas ubicadas en the U.S., es la unica responsable de la administración del Plan y de la participación en el mismo y la adquisición de Acciones no establece de forma alguna una relación de trabajo entre usted y la Compañia, ya que su participación en el Plan es completamente comercial y el unico empleador es en caso de ser aplicable, asi como tampoco establece ningun derecho entre la persona que tenga el derecho a optar y el Empleador.
Reconocimiento del Documento del Plan. Al aceptar el Otorgamiento de las Unidades de Acciόn Restringida, usted reconoce que ha recibido copias del Plan, ha revisado el mismo, al igual que la totalidad del Acuerdo y, que ha entendido y aceptado completamente todas las disposiciones contenidas en el Plan y en el Acuerdo.
Adicionalmente, al firmar el Acuerdo, reconoce que ha leido, y que aprueba especifica y expresamente los términos y condiciones contenidos en la Renuncia de Derecho o Reclamo por Compensación del Acuerdo, en el cual se encuentra claramente descrito y establecido lo siguiente: (i) la participación en el Plan no constituye un derecho adquirido; (ii) el plan y la participación en el mismo es ofrecida por la Compañia de forma enteramente discrecional; (iii) la participación en el Plan es voluntaria; y (iv) la Compañia, asi como su Sociedad controlante, Subsidiaria o Filiales no son responsables por cualquier disminución en el valor de las Acciones.
Finalmente, declara que no se reserva ninguna acciόn o derecho para interponer una demanda en contra de la Compañia por compensación, dano o perjuicio alguno como resultado de su participación en el Plan y, en consecuencia, otorga el más amplio finiquito al Empleador, asi como a la Compañia, a su Sociedad controlante, Subsidiaria o Filiales con respecto a cualquier demanda que pudiera originarse en virtud del Plan.
Netherlands
Notifications
Insider-Trading Notification. You should be aware of the Dutch insider-trading rules which may prohibit you from effectuating certain transactions involving shares if you have inside information about the Company. If you are uncertain whether the insider-trading rules apply to you, you should consult your personal legal advisor.
Norway
No country specific provisions.


Poland
Terms and Conditions
Consent to Receive Information in English. By accepting the Award, you confirm having read and understood the Plan and the Agreement, which were provided in the English language. You accept the terms of those documents accordingly.
Section 2.11 item (h) of the Award Agreement shall be also understood as that the grant and your participation in the Plan will not be interpreted to form or be part of terms and conditions of your employment or service with any Subsidiary or affiliate of the Company.
Notifications
Exchange Control Information. If you hold foreign securities (including shares pursuant to the Award) and maintain accounts abroad, you may be required to file certain reports with the National Bank of Poland. Specifically, if the value of securities and cash held in such foreign accounts exceeds PLN 7,000,000 at the end of the year, you must file reports on the transactions and balances of the accounts on a quarterly basis by the 20th day of the month following the end of each quarter and an annual report by no later than January 30 of the following calendar year. Such reports are filed on special forms available on the website of the National Bank of Poland. Additionally, if you are a Polish citizen and you transfer funds abroad in excess of the PLN equivalent of €15,000, the transfer must be made through an authorized bank, a payment institution or an electronic money institution authorized to render payment services.
Portugal
Notifications
Exchange Control Information. If you receive shares pursuant to the Award, the acquisition of the shares should be reported to the Banco de Portugal for statistical purposes. If the shares are deposited with a commercial bank or financial intermediary in Portugal, such bank or financial intermediary will submit the report on your behalf. If the shares are not deposited with a commercial bank or financial intermediary in Portugal, you are responsible for submitting the report to the Banco de Portugal.
Romania
Notifications
Exchange Control Information. Payments by Romanian citizens to or from non-residents in excess of €50,000 should be reported to the National Bank of Romania (“NBR”) for statistical purposes. If you deposit the proceeds from the sale of shares issued to you at vesting in a bank account in Romania, you may be required to provide the Romanian bank with appropriate documentation explaining the source of the funds. You should consult your personal advisor to determine whether you will be required to submit such documentation to the Romanian bank.


Insider-Trading Notification. You should be aware of the Romanian insider-trading rules which may prohibit you from effectuating certain transactions involving shares if you have inside information about the Company. If you are uncertain whether the insider-trading rules apply to you, you should consult your personal legal advisor.
Russia
Terms and Conditions
(iv)U.S. Transaction. You understand that the PRSUs shall be valid and this Agreement shall be concluded and become effective only when the Agreement is electronically received by the Company in the United States. Upon vesting, any shares to be issued to you shall be delivered to you through a bank or brokerage account in the United States. You are not permitted to sell the shares directly to other Russian legal entities or individuals.
Notifications
(v)Exchange Control Information. Under current exchange control regulations, within a reasonably short time after sale of the shares issued at vesting, you must repatriate the sale proceeds to Russia. Such sale proceeds must be initially credited to you through a foreign currency account at an authorized bank in Russia. After the sale proceeds are initially received in Russia, they may be further remitted to foreign banks in accordance with Russian exchange control laws.
(vi)You are encouraged to contact your personal advisor before remitting your sale proceeds to Russia as exchange control requirements may change.
Securities Law Notification. This Appendix, the Agreement, the Plan and all other materials that you may receive regarding participation in the Plan do not constitute advertising or an offering of securities in Russia. Absent any requirement under local law, the issuance of securities pursuant to the Plan has not and will not be registered in Russia; hence, the securities described in any Plan-related documents may not be used for offering or public circulation in Russia.
Serbia
No country specific provisions.
Slovakia
No country specific provisions.


Slovenia
No country specific provisions.
South Africa
Terms and Conditions
Taxes. By accepting the PRSUs, you agree that, immediately upon vesting of the PRSUs, you will notify your employer of the amount of any gain realized. If you fail to advise your employer of the gain realized upon vesting, you may be liable for a fine. You will be solely responsible for paying any difference between the actual tax liability and the amount withheld by your employer.
Notifications
Exchange Control Information. Because no transfer of funds from South Africa is required under the PRSUs, no filing or reporting requirements should apply when the award is granted nor when Ordinary Shares are issued upon vesting of the PRSUs. However, because the exchange control regulations are subject to change, you should consult your personal advisor prior to vesting and settlement of the award to ensure compliance with current regulations.
Spain
Terms and Conditions
No Entitlement for Claims or Compensation. By accepting the award of PRSUs, you consent to participation in the Plan, and acknowledge that you have received a copy of the Plan document. You understand that the Company has unilaterally, gratuitously and in its sole discretion decided to make awards of PRSUs under the Plan to individuals who may be employees, consultants and directors throughout the world. The decision is limited and entered into based upon the express assumption and condition that any PRSUs will not economically or otherwise bind the Company or any Parent, Subsidiary or Affiliate, including your employer, on an ongoing basis, other than as expressly set forth in the Agreement. Consequently, you understand that the Award is given on the assumption and condition that the PRSUs shall not become part of any employment contract (whether with the Company or any Parent, Subsidiary or Affiliate, including your employer) and shall not be considered a mandatory benefit, salary for any purpose (including severance compensation) or any other right whatsoever. Furthermore, you understand and freely accept that there is no guarantee that any benefit whatsoever shall arise from the award, which is gratuitous and discretionary, since the future value of the PRSUs and the underlying shares is unknown and unpredictable. You also understand that this Award would not be made but for the assumptions and conditions set forth hereinabove; thus, you understand, acknowledge and freely accept that, should any or all of the assumptions be mistaken or any of the conditions not be met for any reason, the Award, the PRSUs and any right to the underlying shares shall be null and void.
Notifications
Exchange Control Information. You must declare the acquisition of Ordinary Shares to the Dirección General de Politica Comercial e Inversiones Exteriores ("DGPCIE") of the Ministerio de


Economia for statistical purposes. You must also declare the ownership of any Ordinary Shares with the Directorate of Foreign Transactions each January while the shares are owned. In addition, you wish to import the share certificates into Spain, you must declare the importation of such securities to the DGPCIE.
When receiving foreign currency payments derived from the ownership of Ordinary Shares (i.e., dividends or sale proceeds), you must inform the financial institution receiving the payment of the basis upon which such payment is made. You will need to provide the following information: (i) your name, address, and fiscal identification number; (ii) the name and corporate domicile of the Company; (iii) the amount of the payment and the currency used; (iv) the country of origin; (v) the reasons for the payment; and (vi) further information that may be required.
Tax Information. If you hold assets or rights outside of Spain (including shares acquired under the Plan), you may have to file an informational tax report with the tax authorities declaring such ownership. Generally, if the value of your foreign investments exceeds €50,000, you may have to file this informational return. Please note that reporting requirements are based on what you have previously disclosed and the increase in value of such and the total value of certain groups of foreign assets. Also, the thresholds for annual filing requirements may change each year. Therefore, you should consult your personal advisor regarding whether you will be required to file an informational tax report for asset and rights that you hold abroad.
Sweden
Terms and Conditions
The following shall apply in addition to what is set out under section 2.14 of the Award Agreement:
Forfeiture of entitlements under the Plan in case of termination shall apply in case of termination of employment regardless of whether such termination of employment may be justified under Swedish employment protection legislation, and regardless of whether such termination may be challenged by you, and regardless of whether such termination is invalidated by verdict or a court order.
Switzerland
Notifications
Securities Law Notification The award is considered a private offering in Switzerland; therefore, it is not subject to registration in Switzerland.
Turkey
No country specific provisions.
Ukraine
Notifications


Exchange Control Information. Exchange control rules change frequently and you should consult your personal advisor to determine whether you are required to obtain a license for obtaining shares of a foreign company from the National Bank of Ukraine (NBU).
Terms and Conditions
The Award will be outside the scope of your employment or service contract (if any) and as such will not constitute a part of your compensation package under the respective employment or service contract.
United Kingdom
Terms and Conditions
Income Tax and National Insurance Contribution Withholding. The following provision supplements the terms in the Agreement:
If payment or withholding of the income tax due in connection with the PRSUs is not made within ninety (90) days of the end of the U.K. tax year in which the event giving rise to the income tax liability or such other period specified in Section 222(1)(c) of the U.K. Income Tax (Earnings and Pensions) Act 2003 occurred (the “Due Date”), the amount of any uncollected income tax shall constitute a loan owed by you to your employer, effective as of the Due Date. You agree that the loan will bear interest at the then-current official rate of Her Majesty’s Revenue & Customs (“HMRC”), it shall be immediately due and repayable, and the Company or your employer may recover it at any time thereafter by any of the means referred to in Section 2.7 of the Agreement. Notwithstanding the foregoing, if you are a director or executive officer of the Company (within the meaning of Section 13(k) of the U.S. Securities and Exchange Act of 1934, as amended), you will not be eligible for a loan from the Company or your employer to cover the income tax liability. In the event that you are a director or executive officer and the income tax is not collected from or paid by the Due Date, the amount of any uncollected income tax will constitute a benefit to you on which additional income tax and national insurance contributions (“NICs”) will be payable. You will be responsible for reporting any income tax for reimbursing the Company or your employer the value of any employee NICs due on this additional benefit.
* * * * *



PERRIGO COMPANY PLC
RESTRICTED STOCK UNIT AWARD AGREEMENT
(PERFORMANCE-BASED)
(Under the Perrigo Company plc 2013 Long-Term Incentive Plan)
TO:        Participant Name
RE:        Notice of Restricted Stock Unit Award (Performance-Based)
This is to notify you that Perrigo Company plc (the “Company”) has granted you an Award under the Perrigo Company plc 2013 Long-Term Incentive Plan (the “Plan”), effective as of Grant Date (the “Grant Date”). This Award consists of performance-based restricted stock units. The terms and conditions of this incentive are set forth in the remainder of this agreement (the “Agreement”). The capitalized terms that are not otherwise defined in this Agreement shall have the meanings ascribed to such terms under the Plan.
SECTION 1
Restricted Stock Units – Performance-Based Vesting
1.1    Grant. As of the Grant Date, the Company grants to you Number of Awards Granted restricted stock units (“Performance Restricted Stock Units” or “PRSUs”), subject to the terms and conditions set forth in this Agreement. The number of Performance Restricted Stock Units awarded in this Section 1.1 is referred to as the “Target Award.” The Target Award may be increased or decreased depending on the level of attainment of Performance Goals for designated Performance Measures as described in Section 1.2. Each Performance Restricted Stock Unit shall entitle you to one ordinary share of the Company, nominal value €0.001 per share (“Ordinary Share”) on the PRSU Vesting Date set forth in Section 1.2, provided the applicable Performance Goals for each Performance Measure are satisfied.
1.2    Vesting. The number of Performance Restricted Stock Units awarded in Section 1.1 vesting, if any, shall be determined as of the PRSU Vesting Date. That number will be determined based on the average level of attainment of annual Performance Measure(s) for each fiscal year in the Performance Period, in accordance with the schedule determined by the Committee at the time the Performance Measures and applicable Performance Goals are established by the Committee.
The Committee shall establish annually one or more Performance Measures and the Performance Goals with respect to each Performance Measure that must be attained for Threshold, Target and Maximum performance for a fiscal year. The Performance Measure and Performance Goals for each fiscal year will be provided to you.
Following the end of each fiscal year in the Performance Period, the Committee will determine the percentage of Target Award PRSUs that would be payable for such fiscal year,


based on the attainment of the Performance Goals for each Performance Measure(s) established by the Committee for that fiscal year. The percentage of the Target Award that would be payable under the schedule shall be adjusted, pro rata, to reflect attained performance between Threshold and Target, and Target and Maximum.
At the end of the Performance Period, the percentage payout for each fiscal year in the Performance Period will be averaged to determine the actual percentage of Target Award PRSUs that will vest and be payable on the PRSU Vesting Date. In no event will the calculation of a positive payout percentage for any fiscal year be construed to guarantee that any PRSUs will vest on the PRSU Vesting Date. Payout percentages for the individual fiscal years are determined solely for purposes of determining the average annual payout percentage for the three-year Performance Period.
Except as provided in Section 1.4, the PRSUs will be permanently forfeited if your Termination Date occurs prior to the PRSU Vesting Date. If the average annual performance payout for the Performance Period is less than the Threshold performance level established by the Committee, all PRSUs that have not previously been forfeited shall be forfeited as of the PRSU Vesting Date. If the average annual performance payout for the Performance Period exceeds the Maximum performance level established by the Committee, in no event will the number of PRSUs vesting exceed 200% of the Target Award.
1.3    Definitions. The following terms shall have the following meanings under this Section 1.
(a)    “Performance Goal” means the level of performance that must be attained with respect to a Performance Measure for a fiscal year for Minimum, Target and Maximum payout.
(b)    “Performance Measure” for any fiscal year means one or more financial measures, as determined by the Committee. The Committee shall provide how the Performance Measure will be adjusted, if at all, as a result of extraordinary events or circumstances, as determined by the Committee, or to exclude the effects of extraordinary, unusual, or non-recurring items; changes in applicable laws, regulations, or accounting principles; currency fluctuations; discontinued operations; non-cash items, such as amortization, depreciation, or reserves; asset impairment; or any recapitalization, restructuring, reorganization, merger, acquisition, divestiture, consolidation, spin-off, split-up, combination, liquidation, dissolution, sale of assets, or other similar corporation transaction.
(c)    “Performance Period” means a period of three consecutive fiscal years of the Company, beginning with the first day of the fiscal year of the Company in which the Grant Date occurs and ending on the last day of the third fiscal year in the 3-year period.
(d)    “PRSU Vesting Date” means the last day of the Performance Period.
(e)    “Separation for Good Reason” means your voluntary resignation from the Company and the existence of one or more of the following conditions that arose without your


consent: (i) a material change in the geographic location at which you are required to perform services, such that your commute between home and your primary job site increases by more than 30 miles, or (ii) a material diminution in your authority, duties or responsibilities or a material diminution in your base compensation or incentive compensation opportunities; provided, however, that a voluntary resignation from the Company shall not be considered a Separation for Good Reason unless you provide the Company with notice, in writing, of your voluntary resignation and the existence of the condition(s) giving rise to the separation within 90 days of its initial existence. The Company will then have 30 days to remedy the condition, in which case you will not be deemed to have incurred a Separation for Good Reason. In the event the Company fails to cure the condition within the 30 day period, your Termination Date shall occur on the 31st day following the Company’s receipt of such written notice.
(f)    “Termination without Cause” means the involuntary termination of your employment or contractual relationship by the Company without Cause, including, but not limited to, (i) a termination effective when you exhaust a leave of absence during, or at the end of, a notice period under the Worker Adjustment and Retraining Notification Act (“WARN”), and (ii) a situation where you are on an approved leave of absence during which your position is protected under applicable law (e.g., a leave under the Family Medical Leave Act), you return from such leave, and you cannot be placed in employment or other form of contractual relationship with the Company.
1.4    Special Vesting Rules. Notwithstanding Section 1.2 above, if your Termination Date occurs by reason of a Termination without Cause or a Separation for Good Reason on or after a Change in Control (as defined in the Plan and as such definition may be amended hereafter) and prior to the two (2) year anniversary of the Change in Control, all of the Performance Restricted Stock Units awarded under Section 1.1 that have not previously been forfeited shall become fully vested as if Target performance had been obtained for the Performance Period effective as of your Termination Date. If your Termination Date occurs because of death, Disability, or Retirement, the Performance Restricted Stock Units shall vest or be forfeited as of the PRSU Vesting Date set forth in Section 1.2, based on the attainment of the performance goals. If your Termination Date occurs because of an Involuntary Termination for Economic Reasons, the Company’s Chief Executive Officer (or the Committee, if you are subject to Section 16 of the Exchange Act), in his or her sole and absolute discretion, may permit all or part of the Performance Restricted Stock Units awarded hereunder to remain outstanding and vest or be forfeited as of the date set forth in Section 1.2, depending on the attainment of Performance Goals; provided, however, that if your Termination Date occurs for a reason that is both described in this sentence and in the first sentence of this Section 1.4, the special vesting rules described in the first sentence of this Section 1.4 shall apply in lieu of the vesting rules described in this sentence. To the extent that the Chief Executive Officer (or Committee, if applicable) does not exercise discretionary authority to allow Performance Restricted Stock Units to remain outstanding on the date of your Involuntary Termination for Economic Reasons, such Restricted Stock Units shall be permanently forfeited.
1.5    Settlement of PRSUs. As soon as practicable following the date of the Committee’s first regularly scheduled meeting following the last day of the Performance Period


at which the Committee certifies the average payout for each of the three years in the Performance Period, the Company shall transfer to you one Ordinary Share for each PRSU, if any, that becomes vested pursuant to Section 1.2 or 1.4 of this Agreement (the date of any such transfer shall be the “settlement date” for purposes of this Agreement); provided, however, the Company in its discretion may settle PRSUs in cash, based on the fair market value of the shares on the PRSU Vesting Date. No fractional shares shall be transferred. Any fractional share shall be rounded to the nearest whole share. The income attributable to the vesting of PRSUs and the amount of any required tax withholding will be determined based on the value of the shares on the settlement date. PRSUs are not eligible for dividend equivalents.
SECTION 2
General Terms and Conditions
2.1    Nontransferability. The Award under this Agreement shall not be transferable other than by will or by the laws of descent and distribution.
2.2    No Rights as a Stockholder. You shall not have any rights as a stockholder with respect to any Ordinary Shares subject to the PRSU awarded under this Agreement prior to the date of issuance to you of a certificate or certificates for such shares.
2.3    Cause Termination. If your Termination Date occurs for reasons of Cause, all of your rights under this Agreement, whether or not vested, shall terminate immediately.
2.4    Award Subject to Plan. The granting of the Award under this Agreement is being made pursuant to the Plan and the Award shall be payable only in accordance with the applicable terms of the Plan. The Plan contains certain definitions, restrictions, limitations and other terms and conditions all of which shall be applicable to this Agreement. ALL THE PROVISIONS OF THE PLAN ARE INCORPORATED HEREIN BY REFERENCE AND ARE MADE A PART OF THIS AGREEMENT IN THE SAME MANNER AS IF EACH AND EVERY SUCH PROVISION WERE FULLY WRITTEN INTO THIS AGREEMENT. Should the Plan become void or unenforceable by operation of law or judicial decision, this Agreement shall have no force or effect. Nothing set forth in this Agreement is intended, nor shall any of its provisions be construed, to limit or exclude any definition, restriction, limitation or other term or condition of the Plan as is relevant to this Agreement and as may be specifically applied to it by the Committee. In the event of a conflict in the provisions of this Agreement and the Plan, as a rule of construction the terms of the Plan shall be deemed superior and apply.
2.5    Adjustments in Event of Change in Ordinary Shares. In the event of a stock split, stock dividend, recapitalization, reclassification or combination of shares, merger, sale of assets or similar event, the number and kind of shares subject to Award under this Agreement will be appropriately adjusted in an equitable manner to prevent dilution or enlargement of the rights granted to or available for you.
2.6    Withholding. This Award is subject to the withholding of all applicable taxes. The Company may withhold, or permit you to remit to the Company, any Federal, state or local


taxes applicable to the grant, vesting or other event giving rise to tax liability with respect to this Award. If you have not remitted the full amount of applicable withholding taxes to the Company by the date the Company is required to pay such withholding to the appropriate taxing authority (or such earlier date that the Company may specify to assist it in timely meeting its withholding obligations), the Company shall have the unilateral right to withhold Ordinary Shares relating to this Award in the amount it determines is sufficient to satisfy the tax withholding required by law. State taxes will be withheld at the appropriate rate set by the state in which you are employed or were last employed by the Company. In no event may the number of shares withheld exceed the number necessary to satisfy the maximum Federal, state and local income and employment tax withholding requirements. You may elect to surrender previously acquired Ordinary Shares or to have the Company withhold Ordinary Shares relating to this Award in an amount sufficient to satisfy all or a portion of the tax withholding required by law.
2.7    Compliance with Applicable Law. Notwithstanding any other provision of this Agreement, the Company shall have no obligation to issue any Ordinary Shares under this Agreement if such issuance would violate any applicable law or any applicable regulation or requirement of any securities exchange or similar entity.
2.8    Short Term Deferral. Performance Restricted Stock Units payable under this Agreement are intended to be exempt from Code Section 409A under the exemption for short-term deferrals. Accordingly, Performance Restricted Stock Units will be settled no later than the 15th day of the third month following the later of (i) the end of the Employee’s taxable year in which the PRSU Vesting Date occurs, or (ii) the end of the fiscal year of the Company in which the PRSU Vesting Date occurs.
2.9    Data Privacy. By entering into this Agreement and accepting this Award, you (a) explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of any of your personal data that is necessary to facilitate the implementation, administration and management of the Award and the Plan, (b) understand that the Company may, for the purpose of implementing, administering and managing the Plan, hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, and details of all awards or entitlements to Shares granted to you under the Plan or otherwise (“Data”), (c) understand that Data may be transferred to any third parties assisting in the implementation, administration and management of the Plan, including any broker with whom the Shares issued upon vesting of the Award may be deposited, and that these recipients may be located in your country or elsewhere, and that the recipient’s country may have different data privacy laws and protections than your country, (d) waive any data privacy rights you may have with respect to the data, and (e) authorize the Company, its subsidiaries and its agents, to store and transmit such information in electronic form.
2.10    Successors and Assigns. This Agreement shall be binding upon any or all successors and assigns of the Company.
2.11    Applicable Law. This Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of Michigan without regard to


principals of conflict of laws. Any proceeding related to or arising out of this Agreement shall be commenced, prosecuted or continued in the Circuit Court in Kent County, Michigan located in Grand Rapids, Michigan or in the United Stated District Court for the Western District of Michigan, and in any appellate court thereof.
2.12    Forfeiture of PRSUs. If the Company, as a result of misconduct, is required to prepare an accounting restatement due to material noncompliance with any financial reporting requirement under the securities laws, then (a) if your incentive or equity-based compensation is subject to automatic forfeiture due to such misconduct and restatement under Section 304 of the Sarbanes-Oxley Act of 2002, or (b) the Committee determines you either knowingly engaged in or failed to prevent the misconduct, or your actions or inactions with respect to the misconduct and restatement constituted gross negligence, you shall (i) be required to reimburse the Company the amount of any payment relating to any PRSUs earned or accrued during the twelve month period following the first public issuance or filing with the SEC (whichever first occurred) of the financial document embodying such financial reporting requirement, and (ii) all outstanding PRSUs (including related dividend equivalents) that have not yet been settled shall be immediately forfeited. In addition, Ordinary Shares acquired under this Agreement, and any gains or profits on the sale of such Ordinary Shares, shall be subject to any “clawback” or recoupment policy later adopted by the Company.
****
We look forward to your continuing contribution to the growth of the Company. Please acknowledge your receipt of the Plan and this Award.
Very truly yours,




Print Name: ___________________________
Title:_________________________________




PERRIGO COMPANY PLC
RESTRICTED STOCK UNIT AWARD AGREEMENT
(PERFORMANCE-BASED)
(Under the Perrigo Company plc 2013 Long-Term Incentive Plan)
TO:        «First_Name» «Last_Name»
RE:        Notice of Restricted Stock Unit Award (Performance-Based)
This is to notify you that Perrigo Company plc (the “Company”) has granted you an Award under the Perrigo Company plc 2013 Long-Term Incentive Plan (the “Plan”), effective as of ______________________ (the “Grant Date”). This Award consists of performance-based restricted stock units. The terms and conditions of this incentive are set forth in the remainder of this agreement (the “Agreement”). The capitalized terms that are not otherwise defined in this Agreement shall have the meanings ascribed to such terms under the Plan.
SECTION 1
Restricted Stock Units – Performance-Based Vesting
1.1    Grant. As of the Grant Date, the Company grants to you «Target_Number_of_Performance_Based_Restr» restricted stock units (“PRSUs”), subject to the terms and conditions set forth in this Agreement. The number of PRSUs awarded in this Section 1.1 is referred to as the “Target Award.” The Target Award may be increased or decreased depending on the level of attainment of the Performance Goals described in Section 1.2. Each PRSU entitles you to one ordinary share of the Company, nominal value €0.001 per share (“Ordinary Share”) on the PRSU Vesting Date set forth in Section 1.2, provided the applicable Performance Goals for the Performance Measure are satisfied.
1.2    Vesting. The number of PRSUs awarded in Section 1.1 vesting, if any, shall be determined as of the PRSU Vesting Date. That number will be determined based on the level of attainment of the Performance Goals for the Performance Period, in accordance with the schedule determined by the Committee at the time the Performance Goals for the Performance Measure are established by the Committee.
At the beginning of a Performance Period, the Committee shall establish one or more Performance Goals for the Performance Measure that must be attained for Threshold, Target and Maximum performance for that Performance Period. The Performance Goal(s) will be provided to you.
Following the end of the Performance Period, the Committee will determine the percentage of Target Award PRSUs that would be payable for the Performance Period based on the attainment of the Performance Goals established for that Performance Period. The percentage of the Target


Award that would be payable under the schedule shall be adjusted, pro rata, to reflect the attained performance between Threshold and Target, and Target and Maximum.
Except as provided in Section 1.4, the PRSUs will be permanently forfeited if your Termination Date occurs prior to the PRSU Vesting Date.
1.3    Definitions. The following terms shall have the following meanings under this Section 1.
(a)    “Applicable Index” for the Performance Period means the applicable index or the comparison group of peer companies selected by the Committee.
(b)    “Performance Goal” means the level of performance that must be attained with respect to the Performance Measure for the Performance Period for Minimum, Target and Maximum payout.
(c)    “Performance Measure” means relative total shareholder return (“rTSR”) which shall be based on (i) the 30-day trading price average of Ordinary Shares (as adjusted for dividends) at the end of the Performance Period (“Ending Average”) over the 30-day trading price average of Ordinary Shares (as adjusted for dividends) at the beginning of the Performance Period (“Beginning Average”), and (ii) the extent to which the Ending Average of the Applicable Index exceeds the Beginning Average of the Applicable Index.
The Committee shall provide how the Performance Measure will be adjusted, if at all, as a result of extraordinary events or circumstances, as determined by the Committee, or to exclude the effects of extraordinary, unusual, or non-recurring items; changes in applicable laws, regulations, or accounting principles; currency fluctuations; discontinued operations; non-cash items, such as amortization, depreciation, or reserves; asset impairment; or any recapitalization, restructuring, reorganization, merger, acquisition, divestiture, consolidation, spin-off, split-up, combination, liquidation, dissolution, sale of assets, or other similar corporation transaction.
(d)    “Performance Period” means the three-consecutive fiscal year period of the Company beginning on January 1 of the year in which the Grant Date occurs and ending on December 31 of the third year in the three-year period.
(e)    “PRSU Vesting Date” means the last day of the Performance Period.
(f)    “Separation for Good Reason” means your voluntary resignation from the Company and the existence of one or more of the following conditions that arose without your consent: (i) a material change in the geographic location at which you are required to perform services, such that your commute between home and your primary job site increases by more than 30 miles, or (ii) a material diminution in your authority, duties or responsibilities or a material diminution in your base compensation or incentive compensation opportunities; provided, however, that a voluntary resignation from the Company shall not be considered a Separation for Good Reason unless you provide the Company with notice, in writing, of your voluntary resignation and the existence of the condition(s) giving rise to the separation within 90 days of its initial existence. The


Company will then have 30 days to remedy the condition, in which case you will not be deemed to have incurred a Separation for Good Reason. In the event the Company fails to cure the condition within the 30 day period, your Termination Date shall occur on the 31st day following the Company’s receipt of such written notice.
(g)    “Termination without Cause” means the involuntary termination of your employment or contractual relationship by the Company without Cause, including, but not limited to, (i) a termination effective when you exhaust a leave of absence during, or at the end of, a notice period under the Worker Adjustment and Retraining Notification Act (“WARN”), and (ii) a situation where you are on an approved leave of absence during which your position is protected under applicable law (e.g., a leave under the Family Medical Leave Act), you return from such leave, and you cannot be placed in employment or other form of contractual relationship with the Company.
1.4    Special Vesting Rules. Notwithstanding Section 1.2 above, if your Termination Date occurs by reason of a Termination without Cause or a Separation for Good Reason on or after a Change in Control (as defined in the Plan and as such definition may be amended hereafter) and prior to the two (2) year anniversary of the Change in Control, all of the PRSUs awarded under Section 1.1 that have not previously been forfeited shall become fully vested as if Target performance had been obtained for the Performance Period effective as of your Termination Date. If your Termination Date occurs because of death, Disability, or Retirement, the PRSUs shall vest or be forfeited as of the PRSU Vesting Date set forth in Section 1.2, based on the attainment of the performance goals. If your Termination Date occurs because of an Involuntary Termination for Economic Reasons, the Committee, in its sole and absolute discretion, may permit all or part of the PRSUs awarded hereunder to remain outstanding and vest or be forfeited as of the date set forth in Section 1.2, depending on the attainment of Performance Goals; provided, however, that if your Termination Date occurs for a reason that is both described in this sentence and in the first sentence of this Section 1.4, the special vesting rules described in the first sentence of this Section 1.4 shall apply in lieu of the vesting rules described in this sentence. To the extent that the Committee does not exercise discretionary authority to allow PRSUs to remain outstanding on the date of your Involuntary Termination for Economic Reasons, such PRSUs shall be permanently forfeited.
1.5    Settlement of PRSUs. As soon as practicable following the date of the Committee’s first regularly scheduled meeting following the last day of the Performance Period at which the Committee certifies the attainment of the performance goals for the Performance Period, the Company shall transfer to you one Ordinary Share for each PRSU, if any, that becomes vested pursuant to Section 1.2 or 1.4 of this Agreement (the date of any such transfer shall be the “settlement date” for purposes of this Agreement); provided, however, the Company may settle PRSUs in cash, based on the fair market value of the shares on the PRSU Vesting Date. No fractional shares shall be transferred. Any fractional share shall be rounded to the nearest whole share. The income attributable to the vesting of PRSUs and the amount of any required tax withholding will be determined based on the value of the shares on the settlement date. PRSUs are not eligible for dividend equivalents.
SECTION 2
General Terms and Conditions


2.1    Nontransferability. The Award under this Agreement shall not be transferable other than by will or by the laws of descent and distribution.
2.2    No Rights as a Stockholder. You shall not have any rights as a stockholder with respect to any Ordinary Shares subject to the PRSU awarded under this Agreement prior to the date of issuance to you of a certificate or certificates for such shares.
2.3    Cause Termination. If your Termination Date occurs for reasons of Cause, all of your rights under this Agreement, whether or not vested, shall terminate immediately.
2.4    Award Subject to Plan. The granting of the Award under this Agreement is being made pursuant to the Plan and the Award shall be payable only in accordance with the applicable terms of the Plan. The Plan contains certain definitions, restrictions, limitations and other terms and conditions all of which shall be applicable to this Agreement. ALL THE PROVISIONS OF THE PLAN ARE INCORPORATED HEREIN BY REFERENCE AND ARE MADE A PART OF THIS AGREEMENT IN THE SAME MANNER AS IF EACH AND EVERY SUCH PROVISION WERE FULLY WRITTEN INTO THIS AGREEMENT. Should the Plan become void or unenforceable by operation of law or judicial decision, this Agreement shall have no force or effect. Nothing set forth in this Agreement is intended, nor shall any of its provisions be construed, to limit or exclude any definition, restriction, limitation or other term or condition of the Plan as is relevant to this Agreement and as may be specifically applied to it by the Committee. In the event of a conflict in the provisions of this Agreement and the Plan, as a rule of construction the terms of the Plan shall be deemed superior and apply.
2.5    Adjustments in Event of Change in Ordinary Shares. In the event of a stock split, stock dividend, recapitalization, reclassification or combination of shares, merger, sale of assets or similar event, the number and kind of shares subject to Award under this Agreement will be appropriately adjusted in an equitable manner to prevent dilution or enlargement of the rights granted to or available for you.
2.6    Withholding. This Award is subject to the withholding of all applicable taxes. The Company may withhold, or permit you to remit to the Company, any Federal, state or local taxes applicable to the grant, vesting or other event giving rise to tax liability with respect to this Award. If you have not remitted the full amount of applicable withholding taxes to the Company by the date the Company is required to pay such withholding to the appropriate taxing authority (or such earlier date that the Company may specify to assist it in timely meeting its withholding obligations), the Company shall have the unilateral right to withhold Ordinary Shares relating to this Award in the amount it determines is sufficient to satisfy the tax withholding required by law. State taxes will be withheld at the appropriate rate set by the state in which you are employed or were last employed by the Company. In no event may the number of shares withheld exceed the number necessary to satisfy the maximum Federal, state and local income and employment tax withholding requirements. You may elect to surrender previously acquired Ordinary Shares or to have the Company withhold Ordinary Shares relating to this Award in an amount sufficient to satisfy all or a portion of the tax withholding required by law.


2.7    Compliance with Applicable Law. Notwithstanding any other provision of this Agreement, the Company shall have no obligation to issue any Ordinary Shares under this Agreement if such issuance would violate any applicable law or any applicable regulation or requirement of any securities exchange or similar entity.
2.8    Short Term Deferral. PRSUs payable under this Agreement are intended to be exempt from Code Section 409A under the exemption for short-term deferrals. Accordingly, PRSUs will be settled no later than the 15th day of the third month following the later of (i) the end of the Employee’s taxable year in which the PRSU Vesting Date occurs, or (ii) the end of the fiscal year of the Company in which the PRSU Vesting Date occurs.
2.9    Data Privacy. By entering into this Agreement and accepting this Award, you (a) explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of any of your personal data that is necessary to facilitate the implementation, administration and management of the Award and the Plan, (b) understand that the Company may, for the purpose of implementing, administering and managing the Plan, hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, and details of all awards or entitlements to Shares granted to you under the Plan or otherwise (“Data”), (c) understand that Data may be transferred to any third parties assisting in the implementation, administration and management of the Plan, including any broker with whom the Shares issued upon vesting of the Award may be deposited, and that these recipients may be located in your country or elsewhere, and that the recipient’s country may have different data privacy laws and protections than your country, (d) waive any data privacy rights you may have with respect to the data, and (e) authorize the Company, its subsidiaries and its agents, to store and transmit such information in electronic form.
2.10    Successors and Assigns. This Agreement shall be binding upon any or all successors and assigns of the Company.
2.11    Applicable Law. This Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of Michigan without regard to principals of conflict of laws. Any proceeding related to or arising out of this Agreement shall be commenced, prosecuted or continued in the Circuit Court in Kent County, Michigan located in Grand Rapids, Michigan or in the United Stated District Court for the Western District of Michigan, and in any appellate court thereof.
2.12    Forfeiture of PRSUs. If the Company, as a result of misconduct, is required to prepare an accounting restatement due to material noncompliance with any financial reporting requirement under the securities laws, then (a) if your incentive or equity-based compensation is subject to automatic forfeiture due to such misconduct and restatement under Section 304 of the Sarbanes-Oxley Act of 2002, or (b) the Committee determines you either knowingly engaged in or failed to prevent the misconduct, or your actions or inactions with respect to the misconduct and restatement constituted gross negligence, you shall (i) be required to reimburse the Company the amount of any payment relating to any PRSUs earned or accrued during the twelve month period following the first public issuance or filing with the SEC (whichever first occurred) of the financial document


embodying such financial reporting requirement, and (ii) all outstanding PRSUs that have not yet been settled shall be immediately forfeited. In addition, Ordinary Shares acquired under this Agreement, and any gains or profits on the sale of such Ordinary Shares, shall be subject to any “clawback” or recoupment policy later adopted by the Company.
****
We look forward to your continuing contribution to the growth of the Company. Please acknowledge your receipt of the Plan and this Award.
Very truly yours,




Print Name: ___________________________
Title:_________________________________

 EX-10.5 5 cy17q310qex105.htm EXHIBIT 10.5 Exhibit

Exhibit 10.5



België PERRIGO COMPANY PLC
NONQUALIFIED STOCK OPTION AGREEMENT FOR NON-U.S. PARTICIPANTS
(Under the Perrigo Company plc 2013 Long-Term Incentive Plan)
TO:        Participant Name
RE:        Notice of Nonqualified Stock Option
This is to notify you that Perrigo Company plc (the “Company”) has granted you an Award for non-U.S. participants under the Perrigo Company plc 2013 Long-Term Incentive Plan (the “Plan”), effective as of Grant Date (the “Grant Date”). This Award consists of a nonqualified stock option. The terms and conditions of this incentive are set forth in the remainder of this agreement (including any special terms and conditions set forth in any appendix for your country (“Appendix”)) (collectively, the “Agreement”). The capitalized terms that are not otherwise defined in this Agreement shall have the meanings ascribed to such terms under the Plan.
SECTION 1
Nonqualified Stock Option
1.1    Grant of Option. As of the Grant Date, and subject to the terms and conditions of this Agreement and the Plan, the Company grants you a nonqualified stock option (the “Option”) to purchase Number of Awards Granted ordinary shares of the Company, nominal value €0.001 per share (“Ordinary Shares”), at a per share price of $Grant Date FMV (the “Option Price”), which is equal to the Fair Market Value of such Ordinary Shares as of the Grant Date.
1.2    Timing and Duration of Exercise.
(a)    The Option shall vest with respect to one-third of the Shares awarded in Section 1.1 on each of the first, second and third anniversaries of the Grant Date (each a “Vesting Date”), with the vesting of any fractional shares frontloaded to the first such Vesting Date. Subject to the requirements of subsection (b) below, vested Shares may be exercised after the applicable Vesting Date. Notwithstanding the foregoing, any portion of the Option that has not vested or been forfeited previously shall immediately vest in full upon, and, subject to subsection (b) below, may be exercised in whole or in part after (1) your Termination Date if your Termination Date occurs by reason of a Termination without Cause or a Separation for Good Reason on or after a Change in Control (as defined in the Plan and as such definition may be amended hereafter) and prior to the two (2) year anniversary of the Change in Control, or (2) your death, Disability, or Retirement.
(b)    Except as provided below, the vested Option must be exercised by you, if at all, while you are providing service to the Company or one of its Affiliates or within three months following your Termination Date, but in no event after Expiration Date (the “Expiration

 

Date”). If your Termination Date occurs by reason of your Retirement, death or Disability, the Option may thereafter be exercised by you, or in the event of your death, by your estate or your designated beneficiary, or in the event of your Disability, by you or your legal representative, at any time prior to the Expiration Date. If you die after your Termination Date and during the period in which the Option is exercisable, the right to exercise the Option during such period will be governed by Plan Section 12(d)(4). If your Termination Date occurs because of an Involuntary Termination for Economic Reasons as determined by the Chief Executive Officer (or the Committee in the case of an Employee subject to Section 16 of the Exchange Act), the terms of Plan Section 12(b)(2) shall apply; provided, however, that if your Termination Date occurs for a reason that is both described in this sentence and in subsection (a) above, the special vesting rules described in subsection (a) shall apply in lieu of the vesting rules described in Plan Section 12(b)(2).
Any portion of the Option that is not vested pursuant to this Section 1.2 as of your employment Termination Date will be forfeited immediately. If the Option is not exercised as to all of the vested shares covered by the Option within the applicable time period and in the manner provided herein, the Option will terminate and will not be exercisable thereafter. In no event may the Option be exercised after the Expiration Date.
(c)    As used in this Section 1.2, the following terms shall have the meanings set forth below:
(1)    “Separation for Good Reason” means your voluntary resignation (or any legal act having the same consequence such as amicable termination or constructive dismissal) from the Company on the ground of one or more of the following conditions that arose without your consent: (i) a material change in the geographic location at which you are required to perform services, such that your commute between home and your primary job site increases by more than 30 miles, or (ii) a material diminution in your authority, duties or responsibilities or a material diminution in your base compensation or incentive compensation opportunities; provided, however, that a voluntary resignation from the Company (or any legal act having the same consequence, such as a constructive dismissal) shall not be considered a Separation for Good Reason unless you provide the Company with notice, in writing, of your voluntary resignation and the existence of the condition(s) giving rise to the separation within 90 days of its initial existence. The Company will then have 30 days to remedy the condition, in which case you will not be deemed to have incurred a Separation for Good Reason. In the event the Company fails to cure the condition within the 30 day period, your Termination Date shall occur on the 31st day following the Company’s receipt of such written notice.
(2)    “Termination without Cause” means the involuntary termination of your employment or contractual relationship by the Company without Cause, including, but not limited to, (i) a termination effective when you exhaust an approved leave of absence, and (ii) a situation where you are on an approved leave of absence during which your position is protected under applicable leave law, you return from such leave, and you cannot be placed in employment or other form of contractual relationship with the Company.
1.3    Method of Exercise. The vested Option, or any part of it, shall be exercised by written notice directed to the President, Chief Financial Officer or Secretary of the Company at

 

the Company’s principal office in Allegan, Michigan, U.S.A., or by using other notification permitted by the Company. Such notice must satisfy the following requirements:
(a)    The notice must state the Grant Date, the number of Ordinary Shares subject to the Option, the number of Ordinary Shares with respect to which Option is being exercised, the person in whose name the stock certificate or certificates for such Ordinary Shares is to be registered and the person’s address and Social Security number (or if more than one person, the names, addresses and Social Security numbers of such persons).
(b)    The notice shall be accompanied by check, bank draft, money order or other cash payment, all in U.S. dollars, or by delivery of a certificate or certificates, properly endorsed, for Ordinary Shares that you have held for at least six months and that are equivalent in Fair Market Value on the date of exercise to the Option Price (or any combination of cash and shares), in full payment of the Option Price for the number of shares specified in the notice.
(c)    The notice must be signed by the person or persons entitled to exercise the Option and, if the Option is being exercised by any person or persons other than you, be accompanied by proof, satisfactory to the Committee, of the right of such person or persons to exercise the Option.
(d)    The Company may implement procedures for the electronic exercise of this Option, in which case the vested portion of this Option shall be exercisable in accordance with such procedures.
SECTION 2
General Terms and Conditions
2.1    Nontransferability. The Award under this Agreement shall not be transferable other than by will or by the laws of descent and distribution. During your lifetime, the Option granted under this Agreement shall be exercisable only by you or by your guardian or legal representative in the event of your Disability.
2.2    No Rights as a Stockholder. You shall not have any rights as a stockholder with respect to any Ordinary Shares subject to the Option prior to the date of issuance to you of a certificate or certificates for such shares.
2.3    Cause Termination. If your Termination Date occurs for reasons of Cause, all of your rights under this Agreement, whether or not vested, shall terminate immediately.
2.4    Awards Subject to Plan. The granting of the Award under this Agreement is being made pursuant to the Plan and the Award shall be exercisable only in accordance with the applicable terms of the Plan. The Plan contains certain definitions, restrictions, limitations and other terms and conditions all of which shall be applicable to this Agreement. ALL THE PROVISIONS OF THE PLAN ARE INCORPORATED HEREIN BY REFERENCE AND ARE MADE A PART OF THIS AGREEMENT IN THE SAME MANNER AS IF EACH AND EVERY SUCH PROVISION WERE FULLY WRITTEN INTO THIS

 

AGREEMENT. Should the Plan become void or unenforceable by operation of law or judicial decision, this Agreement shall have no force or effect. Nothing set forth in this Agreement is intended, nor shall any of its provisions be construed, to limit or exclude any definition, restriction, limitation or other term or condition of the Plan as is relevant to this Agreement and as may be specifically applied to it by the Committee. In the event of a conflict in the provisions of this Agreement and the Plan, as a rule of construction the terms of the Plan shall be deemed superior and apply.
2.5    Adjustments in Event of Change in Ordinary Shares. In the event of a stock split, stock dividend, recapitalization, reclassification or combination of shares, merger, sale of assets or similar event, the number and kind of shares subject to the Award under this Agreement, and the exercise price thereof, will be appropriately adjusted in an equitable manner to prevent dilution or enlargement of the rights granted to or available for you.
2.6     Acknowledgement. The Company and you agree that the Option is granted under and governed by the Notice of Grant, this Agreement (including the Appendix) and by the provisions of the Plan (incorporated herein by reference). You: (i) acknowledge receipt of a copy of each of the foregoing documents, (ii) represent that you have carefully read and are familiar with their provisions, and (iii) hereby accept the Option subject to all of the terms and conditions set forth herein and those set forth in the Plan and the Notice of Grant.
2.7    Responsibility for Taxes. Regardless of any action the Company or, if different, the Affiliate employing or retaining you takes with respect to any or all income tax, social insurance, payroll tax, payment on account or other tax-related items related to your participation in the Plan and legally applicable to you (“Tax-Related Items”), you acknowledge that the ultimate liability for all Tax-Related Items is and remains your responsibility and may exceed the amount actually withheld by the Company or the Affiliate employing or retaining you. You further acknowledge that the Company and/or the Affiliate employing or retaining you (1) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Option, including, but not limited to, the grant, vesting or exercise of the Option, the subsequent sale of Ordinary Shares acquired pursuant to such exercise and the receipt of any dividends; and (2) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Option to reduce or eliminate your liability for Tax-Related Items or achieve any particular tax result. Further, if you have become subject to tax in more than one jurisdiction between the Grant Date and the date of any relevant taxable event, as applicable, you acknowledge that the Company and/or the Affiliate employing or retaining you (or formerly employing or retaining you, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.
(a)     Prior to any relevant taxable or tax withholding event, as applicable, you will pay or make adequate arrangements satisfactory to the Company and/or the Affiliate employing or retaining you to satisfy all Tax-Related Items. In this regard, you authorize the Company and/or the Affiliate employing or retaining you, or their respective agents, at their discretion, to satisfy the obligations with regard to all Tax-Related Items by one or a combination of the following:

 

(1)    withholding from your wages or other cash compensation paid to you by the Company and/or the Affiliate employing or retaining you; or
(2)    withholding from proceeds of the sale of Ordinary Shares acquired upon exercise of the Option either through a voluntary sale or through a mandatory sale arranged by the Company (on your behalf pursuant to this authorization); or
(3)    withholding in Ordinary Shares to be issued upon exercise of the Option.
(b)    To avoid negative accounting treatment, the Company may withhold or account for Tax-Related Items by considering applicable minimum statutory withholding amounts or other applicable withholding rates. If the obligation for Tax-Related Items is satisfied by withholding in Ordinary Shares, for tax purposes, you are deemed to have been issued the full number of Ordinary Shares subject to the exercised Option, notwithstanding that a number of the Ordinary Shares are held back solely for the purpose of paying the Tax-Related Items.
(c)    Finally, you shall pay to the Company or the Affiliate employing or retaining you any amount of Tax-Related Items that the Company or the Affiliate employing or retaining you may be required to withhold or account for as a result of your participation in the Plan that cannot be satisfied by the means previously described. The Company may refuse to issue or deliver the Ordinary Shares or the proceeds of the sale of Ordinary Shares, if you fail to comply with your obligations in connection with the Tax-Related Items.
2.8    Compliance with Applicable Law. The issuance of Ordinary Shares will be subject to and conditioned upon compliance by the Company and you, including any written representations, warranties and agreements as the Administrator may request of you for compliance with all (i) applicable U.S. state and federal laws and regulations, (ii) applicable laws of the country where you reside pertaining to the issuance or sale of Ordinary Shares, and (iii) applicable requirements of any stock exchange or automated quotation system on which the Company’s Ordinary Shares may be listed or quoted at the time of such issuance or transfer.
2.9    Data Privacy.
(a)    By entering into this Agreement and accepting this Award, you hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Agreement and any other Option grant materials by and among, as applicable, the Affiliate employing or retaining you, the Company and its Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.
(b)    You understand that the Company and the Affiliate employing or retaining you may hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of Option or any other entitlement to shares of Stock awarded,

 

canceled, exercised, vested, unvested or outstanding in your favor, for the exclusive purpose of implementing, administering and managing the Plan (“Data”).
(c)    You understand that Data will be transferred to legal counsel or a broker or such other stock plan service provider as may be selected by the Company in the future, which is assisting the Company with the implementation, administration and management of the Plan. You understand that the recipients of the Data may be located in the United States or elsewhere, and that the recipients’ country (e.g., the United States) may have different data privacy laws and protections than your country. You understand that if you reside outside the United States, you may request a list with the names and addresses of any potential recipients of the Data by contacting your local or Company human resources representative. You authorize the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing your participation in the Plan. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan. You understand that if you reside outside the United States, you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local or Company human resources representative. You understand, however, that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local or Company human resources representative.
2.10     Nature of Grant. In accepting the grant, you acknowledge, understand and agree that:
(a)    the Plan is established voluntarily by the Company, it is discretionary in nature and it may be modified, amended, suspended or terminated by the Company at any time, except as otherwise provided in the Plan.
(b)    the grant of the Option is voluntary and occasional and does not create any contractual or other right to receive future Option grants, or benefits in lieu of the Option, even if the Option has been granted repeatedly in the past;
(c)    all decisions with respect to future Option grants, if any, will be at the sole discretion of the Company;
(d)    you are voluntarily participating in the Plan;
(e)    the Option and the Ordinary Shares subject to the Option are an extraordinary item and which is outside the scope of your employment or service contract, if any;
(f)    the Option and the Ordinary Shares subject to the Option are not intended to replace any pension rights or compensation;

 

(g)    the Option and the Ordinary Shares subject to the Option are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments and in no event should be considered as compensation for, or relating in any way to, past services for the Company, the Affiliate employing or retaining you or any other Affiliate;
(h)    the grant and your participation in the Plan will not be interpreted to form an employment or service contract with the Company or any Affiliate;
(i)    the future value of the underlying Ordinary Shares is unknown, indeterminable and cannot be predicted with certainty;
(j)    no claim or entitlement to compensation or damages shall arise from forfeiture of the Option resulting from your Termination Date (for any reason whatsoever, whether or not later found to be invalid and whether or not in breach of employment laws in the jurisdiction where you are employed or rendering services, or the terms of your employment agreement, if any), and in consideration of the grant of the Option to which you are otherwise not entitled, you irrevocably agree never to institute any claim against the Company or the Affiliate employing or retaining you, waive your ability, if any, to bring any such claim, and release the Company and the Affiliate employing or retaining you from any such claim; if, notwithstanding the foregoing, any such claim is allowed by a court of competent jurisdiction, then, by participating in the Plan, you shall be deemed irrevocably to have agreed not to pursue such claim and agree to execute any and all documents necessary to request dismissal or withdrawal of such claim; and
(k)    you acknowledge and agree that neither the Company, the Affiliate employing or retaining you nor any other Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the United States Dollar that may affect the value of the Option or of any amounts due to you pursuant to the settlement of the Option or the subsequent sale of any Ordinary Shares acquired upon settlement.
2.11    Successors and Assigns. This Agreement shall be binding upon any or all successors and assigns of the Company.
2.12    Applicable Law. This Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of Michigan, U.S.A., without regard to principals of conflict of laws. Any proceeding related to or arising out of this Agreement shall be commenced, prosecuted or continued in the Circuit Court in Kent County, Michigan located in Grand Rapids, Michigan or in the United Stated District Court for the Western District of Michigan, and in any appellate court thereof.
2.13 Repayment of Option Gain/Forfeiture of Options. If the Company, as a result of misconduct, is required to prepare an accounting restatement due to material noncompliance with any financial reporting requirement under the securities laws, then (a) if your equity compensation is subject to automatic forfeiture due to such misconduct and restatement under Section 304 of the Sarbanes-Oxley Act of 2002, or (b) the Committee determines you either

 

knowingly engaged in or failed to prevent the misconduct, or your actions or inactions with respect to the misconduct and restatement constituted gross negligence, you shall (i) be required to reimburse the Company for any gain associated with any Option exercised during the twelve month period following the first public issuance or filing with the SEC (whichever first occurred) of the financial document embodying such financial reporting requirement, and (ii) any outstanding Options shall be immediately forfeited.
2.14    Appendix. Notwithstanding any provisions in this Agreement, the Option grant shall be subject to any special terms and conditions set forth in any Appendix to this Agreement for your country. Moreover, if you relocate to one of the countries included in the Appendix, the special terms and conditions for such country will apply to you, to the extent the Company determines that the application of such provisions is necessary or advisable in order to comply with laws of the country where you reside or to facilitate the administration of the Plan. The Appendix constitutes part of this Agreement.
2.16    Imposition of Other Requirements. The Company reserves the right to impose other requirements on your participation in the Plan, on the Option and on any Ordinary Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable in order to comply with laws of the country where you reside or to facilitate the administration of the Plan, and to require you to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.
****
We look forward to your continuing contribution to the growth of the Company. Please acknowledge your receipt of the Plan and this Award.
Very truly yours,




Print Name: ___________________________
Title:_________________________________



 


APPENDIX

PERRIGO COMPANY PLC
Additional Terms and Provisions to
Nonqualified Stock Option Agreement

Terms and Conditions
This Appendix (the “Appendix”) includes additional terms and conditions that govern the nonqualified stock option (“Option”) granted to you under the Plan if you reside in one of the countries listed below. Certain capitalized terms used but not defined in this Appendix have the meanings set forth in the Plan and/or the Agreement.
Notifications
This Appendix also includes country-specific information of which you should be aware with respect to your participation in the Plan. The information is based on the securities, exchange control and other laws in effect in the respective countries as of January 2015. Such laws are often complex and change frequently. As a result, the Company strongly recommends that you do not rely on the information noted herein as the only source of information relating to the consequences of your participation in the Plan because the information may be out of date at the time that your stock options vest, or are exercised and Ordinary Shares are issued to you or when you sell Ordinary Shares acquired under the plan.
In addition, the information is general in nature and may not apply to your particular situation, and the Company is not in a position to assure you of any particular result. Accordingly, you are advised to seek appropriate professional advice as to how the relevant laws in your country may apply to your particular situation. Finally, please note that if you are a citizen or resident of a country other than the country in which you are currently working, or transfers employment after grant, the information contained in the Appendix may not be applicable.


Argentina
Notifications
Securities Law Information. Neither the Option nor the issuance of the Ordinary Shares are publicly offered or listed on any stock exchange in Argentina. The offer is private and not subject to the supervision of any Argentine governmental authority.
Exchange Control Information. You will not be able to engage in a cash exercise unless you have U.S. dollars held outside Argentina and use those funds to purchase Ordinary Shares at exercise. Otherwise, you will only be able to engage in a cashless

 

exercise pursuant to which Ordinary Shares will be sold at exercise to pay the purchase price. In the event that you transfer sales proceeds in excess of US$50,000 from the sale of shares into Argentina in a single month, you will be subject to certain exchange control reporting requirements. In addition, you may be subject to a mandatory 30% restriction on holding of funds brought into Argentina. Please note that exchange control regulations in Argentina are subject to frequent change. You should consult with your personal legal advisor regarding any exchange control obligations that you may have.
Australia
Notifications
Securities Information. If you acquire shares pursuant to the Option and you offer the shares for sale to a person or entity resident in Australia, then the offer may be subject to disclosure requirements under Australian law. You should obtain legal advice on your disclosure obligations prior to making any such offer.
Exchange Control Information. Exchange control reporting is required for cash transactions exceeding AUD10,000 and for international fund transfers. The Australian bank assisting with the transaction will file the report for you. If there is no Australian bank involved in the transfer, you will have to file the report.
Austria
Notifications
Exchange Control Information. If you hold shares of Company stock outside of Austria, you must submit a report to the Austrian National Bank. An exemption applies if the value of the shares as of any given quarter does not exceed €30,000,000 or as of December 31 does not exceed €5,000,000. If the former threshold is exceeded, quarterly obligations are imposed, whereas if the latter threshold is exceeded, annual reports must be given. The annual reporting date is as of December 31 and the deadline for filing the annual report is March 31 of the following year.
When shares are sold, there may be exchange control obligations if the cash received is held outside Austria. If the transaction volume of all your accounts abroad exceeds €3,000,000, the movements and balances of all accounts must be reported monthly, as of the last day of the month, on or before the fifteenth day of the following month.
Belgium
Notifications
Tax Information. If you accept this Agreement within sixty (60) days of the date that the material terms of the grant are communicated to you in writing (“Offer Date”), you will be subject to tax on the Offer Date. If you accept this Agreement later than sixty (60) days after the Offer Date, you will be subject to tax when you exercise your Option.
Czech Republic
Notifications

 

Exchange Control Information. The Czech National Bank may require you to report the Option and or Ordinary Shares received and the opening and maintenance of a foreign account. However, because exchange control regulations change frequently and without notice, you should consult your personal legal advisor prior to the exercise of the Option to ensure your compliance with current regulations. It is your responsibility to comply with applicable Czech exchange control laws.
Denmark
Notifications
Exchange Control Information. If you establish an account holding shares or an account holding cash outside Denmark, you must report the account to the Danish Tax Administration. The form which should be used in this respect can be obtained from a local bank. (Please note that these obligations are separate from and in addition to the obligations described below.)
Securities/Tax Reporting Information. If you hold shares acquired under the Plan in a brokerage account with a broker or bank outside Denmark, you are required to inform the Danish Tax Administration about the account. For this purpose, you must file a Form V (Erklaering V) with the Danish Tax Administration. The Form V must be signed both by you and by the applicable broker or bank where the account is held. By signing the Form V, the broker or bank undertakes to forward information to the Danish Tax Administration concerning the shares in the account without further request each year. By signing the Form V, you authorize the Danish Tax Administration to examine the account. A sample of the Form V can be found at the following website: www.skat.dk.
In addition, if you open a brokerage account (or a deposit account with a U.S. bank) for the purpose of holding cash outside Denmark, you are also required to inform the Danish Tax Administration about this account. To do so, you must also file a Form K (Erklaering K) with the Danish Tax Administration. The Form K must be signed both by you and by the applicable broker or bank where the account is held. By signing the Form K, the broker/bank undertakes an obligation, without further request each year, to forward information to the Danish Tax Administration concerning the content of the account. By signing the Form K, you authorize the Danish Tax Administration to examine the account. A sample of Form K can be found at the following website: www.skat.dk.
Finland
There are no country specific provisions.
France
Terms and Conditions
Consent to Receive Information in English. By accepting the Option, you confirm having read and understood the Plan and the Agreement, which were provided in the English language. You accept the terms of those documents accordingly.
En acceptant cette attribution gratuite d'actions, vous confirmez avoir lu et comprenez le Plan et ce Contrat, incluant tous leurs termes et conditions, qui ont été transmis en langue anglaise. Vous acceptez les dispositions de ces documents en connaissance de cause.
Notifications

 

Exchange Control Information. If you hold Ordinary Shares outside of France or maintain a foreign bank account, you are required to report such to the French tax authorities when you file your annual tax return.
Germany
Notifications
Exchange Control Information. Cross-border payments in excess of €12,500 must be reported monthly to the German Federal Bank. If you use a German bank to transfer a cross-border payment in excess of €12,500 in connection with the sale of shares acquired under the Plan, the bank will make the report for you. In addition, you must report any receivables, payables, or debts in foreign currency exceeding an amount of €5,000,000 on a monthly basis.
Greece
Notifications
Exchange Control Information. If you withdraw funds in excess of €15,000 from a bank in Greece to exercise your Option and remit those funds out of Greece, you may be required to submit certain documentation/ information to the Greek bank to ensure that the transfer is not in violation of Greek anti-money laundering rules.
Hungary
No country specific provisions.

India
Notifications
Exchange Control Notification. You must repatriate all proceeds received from the sale of the shares to India within 90 days after sale. You will receive a foreign inward remittance certificate (“FIRC”) from the bank where you deposit the foreign currency. You should maintain the FIRC as evidence of the repatriation of funds in the event that the Reserve Bank of India or the employer requests proof of repatriation.
Tax Information. The amount subject to tax at exercise will partially be dependent upon a valuation that the Company or your employer will obtain from a Merchant Banker in India. Neither the Company nor your employer has any responsibility or obligation to obtain the most favorable valuation possible, nor obtain valuations more frequently than required under Indian tax law.
Ireland
Notifications
Director Notification Obligation. If you are a director, shadow director or secretary of the Company or an Irish Subsidiary or Affiliate of the Company, and you acquire or dispose of an interest under

 

this Agreement comprising more than 1% of the share capital in the Company, you must notify the entity in which you hold that office (whether the Company itself or an Irish Subsidiary or Affiliate of the Company) in writing within five business days of receiving or disposing of an interest in the Company, or within five business days of becoming aware of the event giving rise to the notification requirement or within five days of becoming a director or secretary if such an interest exists at the time. This notification requirement also applies with respect to the interests of a spouse or children under the age of 18 (whose interests will be attributed to the director, shadow director or secretary).
Italy
Terms and Conditions
Data Privacy Notice. The following provision supplements the terms in the Agreement:
You understand that your employer and/or the Company may hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social security number (or any other social or national identification number), salary, nationality, job title, number of shares held and the details of all Options or any other entitlement to shares awarded, cancelled, exercised, vested, unvested or outstanding (the “Data”) for the purpose of implementing, administering and managing your participation in the Plan. You are aware that providing the Company with the Data is necessary for the performance of this Agreement and that your refusal to provide such Data would make it impossible for the Company to perform its contractual obligations and may affect your ability to participate in the Plan.
The "Controller" of personal data processing is Perrigo Company, plc, with registered offices at Allegan, Michigan USA, and, pursuant to D.lgs 196/2003, its Stock Plan Administrator, David A. McConnell. You understand that the Data may be transferred to the Company or any of its subsidiaries or affiliates, or to any third parties assisting in the implementation, administration and management of the Plan, including any transfer required to a broker or other third party with whom shares acquired pursuant to the exercise of the Option or cash from the sale of shares acquired pursuant to the Plan may be deposited. Furthermore, the recipients that may receive, possess, use, retain and transfer such Data for the above mentioned purposes may be located in Italy or elsewhere, including outside of the European Union and that the recipients’ country (e.g., the United States) may have different data privacy laws and protections than Italy. The processing activity, including the transfer of your personal data abroad, outside of the European Union, as herein specified and pursuant to applicable laws and regulations, does not require your consent thereto as the processing is necessary for the performance of contractual obligations related to the implementation, administration and management of the Plan. You understand that Data processing relating to the purposes above specified shall take place under automated or non-automated conditions, anonymously when possible, that comply with the purposes for which Data are collected and with confidentiality and security provisions as set forth by applicable laws and regulations, with specific reference to D.lgs. 196/2003.
You understand that Data will be held only as long as is required by law or as necessary to implement, administer and manage your participation in the Plan. You understand

 

that pursuant to art.7 of D.lgs 196/2003, you have the right, including but not limited to, access, delete, update, request the rectification of your personal Data and cease, for legitimate reasons, the Data processing. Furthermore, you are aware that your Data will not be used for direct marketing purposes.
Plan Document Acknowledgment. In accepting the Option, you acknowledge that you have received a copy of the Plan and the Agreement and have reviewed the Plan and the Agreement, including this Appendix, in their entirety and fully understand and accept all provisions of the Plan and the Agreement, including this Appendix.
Notifications
Tax/Exchange Control Information. You are required to report on your annual tax return: (a) any transfers of cash or shares to or from Italy exceeding €10,000 or the equivalent amount in U.S. dollars; (b) any foreign investments or investments (including the Ordinary Shares issued at exercise of the Option, cash or proceeds from the sale of shares acquired under the Plan) held outside of Italy exceeding €10,000 or the equivalent amount in U.S. dollars, if the investment may give rise to income in Italy (this will include reporting the Ordinary Shares issued at exercise of the Option if the fair market value of such Ordinary Shares combined with other foreign assets exceed €10,000); and (c) the amount of the transfers to and from abroad which have had an impact during the calendar year on your foreign investments or investments held outside of Italy. You are exempt from the formalities in (a) if the investments are made through an authorized broker resident in Italy, as the broker will comply with the reporting obligation on your behalf.
Kazakhstan
Notifications
Exchange Control Information. Although Kazakh residents are no longer required to obtain a license from the National Bank of Kazakhstan in advance of obtaining securities in foreign companies, you are nevertheless required to notify the National Bank of Kazakhstan when you acquire shares under the Plan.
Latvia
No country specific provisions.
Luxembourg
Notifications
Exchange Control Information. You are required to report any inward remittances of funds to the Banque Central de Luxembourg and/or the Service Central de La Statistique et des Etudes Economiques within 15 working days following the month during the transaction occurred. If a Luxembourg financial institution is involved in the transaction, it generally will fulfill the reporting obligation on your behalf.
Mexico
Terms and Conditions

 

Modification. By accepting the Option, you understand and agree that any modification of the Plan or the Agreement or its termination shall not constitute a change or impairment of the terms and conditions of employment.
Policy Statement. The award of the Option the Company is making under the Plan is unilateral and discretionary and, therefore, the Company reserves the absolute right to amend it and discontinue it at any time without any liability.
The Company, with registered offices in the U.S., is solely responsible for the administration of the Plan and participation in the Plan and the acquisition of shares does not, in any way, establish an employment relationship between you and the Company since you are participating in the Plan on a wholly commercial basis and the sole employer is as applicable, nor does it establish any rights between you and the Employer.
Plan Document Acknowledgment. By accepting the award of the Option, you acknowledge that you have received copies of the Plan, have reviewed the Plan and the Agreement in their entirety and fully understand and accept all provisions of the Plan and the Agreement.
In addition, by signing the Agreement, you further acknowledge that you have read and specifically and expressly approve the terms and conditions in the Agreement, in which the following is clearly described and established: (i) participation in the Plan does not constitute an acquired right; (ii) the Plan and participation in the Plan is offered by the Company on a wholly discretionary basis; (iii) participation in the Plan is voluntary; and (iv) the Company and any Parent, Subsidiary or Affiliates are not responsible for any decrease in the value of the shares underlying the options.
Finally, you hereby declare that you do not reserve any action or right to bring any claim against the Company for any compensation or damages as a result of your participation in the Plan and therefore grant a full and broad release to the Employer, the Company and any Parent, Subsidiary or Affiliates with respect to any claim that may arise under the Plan.
Spanish Translation
Modification. Al aceptar las Unidades de Accion Restringida, usted reconoce y acuerda que cualquier modification del Plan o su terminacion no constituye un cambio o desmejora de los terminos y condiciones de empleo.
Declaracion de Politica. El Otorgarmiento de Unidades de Accion Restringida de la Compañia en virtud del Plan es unilateral y discrecional y, por lo tanto, la Compañia se reserva el derecho absoluto de modificar y discontinuar el mismo en cualquier tiempo, sin responsabilidad alguna.
La Compañia, con oficinas registradas ubicadas en the U.S. es la unica responsable de la administración del Plan y de la participación en el mismo y la adquisición de Acciones no establece de forma alguna una relación de trabajo entre usted y la Compañia, ya que su participación en el Plan es completamente comercial y el unico empleador es en caso de ser aplicable, asi como tampoco establece ningun derecho entre la persona que tenga el derecho a optar y el Empleador.
Reconocimiento del Documento del Plan. Al aceptar el Otorgamiento de las Unidades de Acciόn Restringida, usted reconoce que ha recibido copias del Plan, ha revisado el mismo, al igual que la totalidad del Acuerdo y, que ha entendido y aceptado completamente todas las disposiciones contenidas en el Plan y en el Acuerdo.

 

Adicionalmente, al firmar el Acuerdo, reconoce que ha leido, y que aprueba especifica y expresamente los términos y condiciones contenidos en la Renuncia de Derecho o Reclamo por Compensación del Acuerdo, en el cual se encuentra claramente descrito y establecido lo siguiente: (i) la participación en el Plan no constituye un derecho adquirido; (ii) el plan y la participación en el mismo es ofrecida por la Compañia de forma enteramente discrecional; (iii) la participación en el Plan es voluntaria; y (iv) la Compañia, asi como su Sociedad controlante, Subsidiaria o Filiales no son responsables por cualquier disminución en el valor de las Acciones en relación a las Unidades de Acciόn Restringida.
Finalmente, declara que no se reserva ninguna acciόn o derecho para interponer una demanda en contra de la Compañia por compensación, dano o perjuicio alguno como resultado de su participación en el Plan y, en consecuencia, otorga el más amplio finiquito al Empleador, asi como a la Compañia, a su Sociedad controlante, Subsidiaria o Filiales con respecto a cualquier demanda que pudiera originarse en virtud del Plan.
Netherlands
Notifications
Insider-Trading Notification. You should be aware of the Dutch insider-trading rules which may prohibit you from effectuating certain transactions involving shares if you have inside information about the Company. If you are uncertain whether the insider-trading rules apply to you, you should consult your personal legal advisor.
Norway
No country specific provisions.
Poland
Terms and Conditions
Consent to Receive Information in English. By accepting the Option, you confirm having read and understood the Plan and the Agreement, which were provided in the English language. You accept the terms of those documents accordingly.
Notifications
Exchange Control Information. If you hold foreign securities (including shares) and maintain accounts abroad, you may be required to file certain reports with the National Bank of Poland. Specifically, if the value of securities and cash held in such foreign accounts exceeds PLN 7,000,000 at the end of the year, you must file reports on the transactions and balances of the accounts on a quarterly basis by the 20th day of the month following the end of each quarter and an annual report by no later than January 30 of the following calendar year. Such reports are filed on special forms available on the website of the National Bank of Poland. Additionally, if you are a Polish citizen and you transfer funds abroad in excess of the PLN equivalent of €15,000, the transfer must be made through an authorized bank, a payment institution or an electronic money institution authorized to render payment services.



 

Portugal

Notifications
Exchange Control Information. If you receive shares upon exercise, the acquisition of the shares should be reported to the Banco de Portugal for statistical purposes. If the shares are deposited with a commercial bank or financial intermediary in Portugal, such bank or financial intermediary will submit the report on your behalf. If the shares are not deposited with a commercial bank or financial intermediary in Portugal, you are responsible for submitting the report to the Banco de Portugal.


Romania
Notifications
Exchange Control Information. Payments by Romanian citizens to or from non-residents in excess of €50,000 should be reported to the National Bank of Romania (“NBR”) for statistical purposes. If you deposit the proceeds from the sale of shares issued to you at exercise in a bank account in Romania, you may be required to provide the Romanian bank with appropriate documentation explaining the source of the funds. You should consult your personal advisor to determine whether you will be required to submit such documentation to the Romanian bank.
Insider-Trading Notification. You should be aware of the Romanian insider-trading rules which may prohibit you from effectuating certain transactions involving shares if you have inside information about the Company. If you are uncertain whether the insider-trading rules apply to you, you should consult your personal legal advisor.

Russia
Terms and Conditions
U.S. Transaction. You understand that the Option shall be valid and this Agreement shall be concluded and become effective only when the Agreement is electronically received by the Company in the United States. Upon exercise, any shares to be issued to you shall be delivered to you through a bank or brokerage account in the United States. You are not permitted to sell the shares directly to other Russian legal entities or individuals.
Notifications
Exchange Control Information. Under current exchange control regulations, within a reasonably short time after sale of the shares issued at exercise, you must repatriate the sale proceeds to Russia. Such sale proceeds must be initially credited to you through a foreign currency account at an authorized bank in Russia. After the sale proceeds are initially received in Russia, they may be further remitted to foreign banks in accordance with Russian exchange control laws.

 

You are encouraged to contact your personal advisor before remitting your sale proceeds to Russia as exchange control requirements may change.
Securities Law Notification. This Appendix, the Agreement, the Plan and all other materials that you may receive regarding participation in the Plan do not constitute advertising or an offering of securities in Russia. Absent any requirement under local law, the issuance of securities pursuant to the Plan has not and will not be registered in Russia; hence, the securities described in any Plan-related documents may not be used for offering or public circulation in Russia.
Serbia
No country specific provisions.
Slovakia
No country specific provisions.
Slovenia
No country specific provisions.
South Africa
Terms and Conditions
Taxes. By accepting the Option, you agree that, immediately upon exercise of the Option, you will notify your employer of the amount of any gain realized. If you fail to advise your employer of the gain realized upon exercise, you may be liable for a fine. You will be solely responsible for paying any difference between the actual tax liability and the amount withheld by your employer.
Notifications
Exchange Control Information. You are required to obtain approval from the exchange control authorities to participate in the Plan. You are strongly advised to consult your personal advisor prior to exercising your Option to ensure compliance with current regulations.
Spain
Terms and Conditions
No Entitlement for Claims or Compensation. By accepting the Option, you consent to participation in the Plan, and acknowledge that you have received a copy of the Plan document. You understand that the Company has unilaterally, gratuitously and in its sole discretion decided to make awards of Options under the Plan to individuals who may be employees, consultants and directors throughout the world. The decision is limited and entered into based upon the express assumption and condition that any Option will not economically or otherwise bind the Company or any Parent, Subsidiary or Affiliate, including your employer, on an ongoing basis, other than as expressly set forth in the Agreement. Consequently, you understand that the Award is given on the assumption and condition that the Option shall not become part of any employment contract (whether with the Company or any Parent, Subsidiary or Affiliate, including your employer) and shall not be considered a mandatory benefit, salary for any purpose (including severance compensation) or any other right whatsoever. Furthermore, you understand and freely accept that there is no guarantee that any benefit whatsoever shall arise from the award, which is gratuitous and discretionary, since the future value of the Option and the underlying shares is unknown and

 

unpredictable. You also understand that this Award would not be made but for the assumptions and conditions set forth hereinabove; thus, you understand, acknowledge and freely accept that, should any or all of the assumptions be mistaken or any of the conditions not be met for any reason, the Award, the Option and any right to the underlying shares shall be null and void.
Notifications
Exchange Control Information. You must declare the acquisition of Ordinary Shares to the Dirección General de Politica Comercial e Inversiones Exteriores ("DGPCIE") of the Ministerio de Economia for statistical purposes. You must also declare the ownership of any Ordinary Shares with the Directorate of Foreign Transactions each January while the shares are owned. In addition, you wish to import the share certificates into Spain, you must declare the importation of such securities to the DGPCIE.
When receiving foreign currency payments derived from the ownership of Ordinary Shares (i.e., dividends or sale proceeds), you must inform the financial institution receiving the payment of the basis upon which such payment is made. You will need to provide the following information: (i) your name, address, and fiscal identification number; (ii) the name and corporate domicile of the Company; (iii) the amount of the payment and the currency used; (iv) the country of origin; (v) the reasons for the payment; and (vi) further information that may be required.
Tax Information. If you hold assets or rights outside of Spain (including shares), you may have to file an informational tax report with the tax authorities declaring such ownership. Generally, if the value of your foreign investments exceeds €50,000, you may have to file this informational return. Please note that reporting requirements are based on what you have previously disclosed and the increase in value of such and the total value of certain groups of foreign assets. Also, the thresholds for annual filing requirements may change each year. Therefore, you should consult your personal advisor regarding whether you will be required to file an informational tax report for asset and rights that you hold abroad.
Sweden
No country specific provisions.
Switzerland
Notifications
Securities Law Notification The award is considered a private offering in Switzerland; therefore, it is not subject to registration in Switzerland.
Turkey
No country specific provisions.
Ukraine
Notifications
Exchange Control Information. You may be required to obtain a license for obtaining shares of a foreign company from the National Bank of Ukraine (NBU). You are strongly encouraged to consult a personal advisor to ensure compliance with the exchange control restrictions prior to exercising your Option.

 

United Kingdom
Terms and Conditions
Income Tax and National Insurance Contribution Withholding. The following provision supplements the terms in the Agreement:
If payment or withholding of the income tax due in connection with the Option is not made within ninety (90) days of the end of the U.K. tax year in which the event giving rise to the income tax liability or such other period specified in Section 222(1)(c) of the U.K. Income Tax (Earnings and Pensions) Act 2003 occurred (the “Due Date”), the amount of any uncollected income tax shall constitute a loan owed by you to your employer, effective as of the Due Date. You agree that the loan will bear interest at the then-current official rate of Her Majesty’s Revenue & Customs (“HMRC”), it shall be immediately due and repayable, and the Company or your employer may recover it at any time thereafter by any of the means referred to in Section 2.7 of the Agreement. Notwithstanding the foregoing, if you are a director or executive officer of the Company (within the meaning of Section 13(k) of the U.S. Securities and Exchange Act of 1934, as amended), you will not be eligible for a loan from the Company or your employer to cover the income tax liability. In the event that you are a director or executive officer and the income tax is not collected from or paid by the Due Date, the amount of any uncollected income tax will constitute a benefit to you on which additional income tax and national insurance contributions (“NICs”) will be payable. You will be responsible for reporting any income tax for reimbursing the Company or your employer the value of any employee NICs due on this additional benefit.
* * * * *


 


ex105formsofnqsoagree_image1.jpg


Long-Term Incentive Plan
NQ Stock Options
























 


English
België PERRIGO COMPANY PLC
NONQUALIFIED STOCK OPTION AGREEMENT FOR NON-U.S. PARTICIPANTS
(Under the Perrigo Company plc 2013 Long-Term Incentive Plan)
TO:        Participant Name
RE:        Notice of Nonqualified Stock Option
This is to notify you that Perrigo Company plc (the “Company”) has granted you an Award for non-U.S. participants under the Perrigo Company plc 2013 Long-Term Incentive Plan (the “Plan”), effective as of Grant Date (the “Grant Date”). This Award consists of a nonqualified stock option. The terms and conditions of this incentive are set forth in the remainder of this agreement (including any special terms and conditions set forth in any appendix for your country (“Appendix”)) (collectively, the “Agreement”). The capitalized terms that are not otherwise defined in this Agreement shall have the meanings ascribed to such terms under the Plan.
SECTION 1
Nonqualified Stock Option
1.1    Grant of Option. As of the Grant Date, and subject to the terms and conditions of this Agreement and the Plan, the Company grants you a nonqualified stock option (the “Option”) to purchase Number of Awards Granted ordinary shares of the Company, nominal value €0.001 per share (“Ordinary Shares”), at a per share price of $Grant Date FMV (the “Option Price”), which is equal to the Fair Market Value of such Ordinary Shares as of the Grant Date.
1.2    Timing and Duration of Exercise.
(a)    The Option shall vest with respect to one-third of the Shares awarded in Section 1.1 on each of the first, second and third anniversaries of the Grant Date (each a “Vesting Date”), with the vesting of any fractional shares frontloaded to the first such Vesting Date. Subject to the requirements of subsection (b) below, vested Shares may be exercised after the applicable Vesting Date. Notwithstanding the foregoing, any portion of the Option that has not vested or been forfeited previously shall immediately vest in full upon, and, subject to subsection (b) below, may be exercised in whole or in part after (1) your Termination Date if your Termination Date occurs by reason of a Termination without Cause or a Separation for Good Reason on or after a Change in Control (as defined in the Plan and as such definition may be amended hereafter) and prior to the two (2) year anniversary of the Change in Control, or (2) your death, Disability, or Retirement.
(b)    Except as provided below, the vested Option must be exercised by you, if at all, while you are providing service to the Company or one of its Affiliates or within three

 

months following your Termination Date, but in no event after Expiration Date (the “Expiration Date”). If your Termination Date occurs by reason of your Retirement, death or Disability, the Option may thereafter be exercised by you, or in the event of your death, by your estate or your designated beneficiary, or in the event of your Disability, by you or your legal representative, at any time prior to the Expiration Date. If you die after your Termination Date and during the period in which the Option is exercisable, the right to exercise the Option during such period will be governed by Plan Section 12(d)(4). If your Termination Date occurs because of an Involuntary Termination for Economic Reasons as determined by the Chief Executive Officer (or the Committee in the case of an Employee subject to Section 16 of the Exchange Act), the terms of Plan Section 12(b)(2) shall apply; provided, however, that if your Termination Date occurs for a reason that is both described in this sentence and in subsection (a) above, the special vesting rules described in subsection (a) shall apply in lieu of the vesting rules described in Plan Section 12(b)(2).
Any portion of the Option that is not vested pursuant to this Section 1.2 as of your employment Termination Date will be forfeited immediately. If the Option is not exercised as to all of the vested shares covered by the Option within the applicable time period and in the manner provided herein, the Option will terminate and will not be exercisable thereafter. In no event may the Option be exercised after the Expiration Date.
(c)    As used in this Section 1.2, the following terms shall have the meanings set forth below:
(1)    “Separation for Good Reason” means your voluntary resignation from the Company and the existence of one or more of the following conditions that arose without your consent: (i) a material change in the geographic location at which you are required to perform services, such that your commute between home and your primary job site increases by more than 30 miles, or (ii) a material diminution in your authority, duties or responsibilities or a material diminution in your base compensation or incentive compensation opportunities; provided, however, that a voluntary resignation from the Company shall not be considered a Separation for Good Reason unless you provide the Company with notice, in writing, of your voluntary resignation and the existence of the condition(s) giving rise to the separation within 90 days of its initial existence. The Company will then have 30 days to remedy the condition, in which case you will not be deemed to have incurred a Separation for Good Reason. In the event the Company fails to cure the condition within the 30 day period, your Termination Date shall occur on the 31st day following the Company’s receipt of such written notice.
(2)    “Termination without Cause” means the involuntary termination of your employment or contractual relationship by the Company without Cause, including, but not limited to, (i) a termination effective when you exhaust an approved leave of absence, and (ii) a situation where you are on an approved leave of absence during which your position is protected under applicable leave law, you return from such leave, and you cannot be placed in employment or other form of contractual relationship with the Company.
1.3    Method of Exercise. The vested Option, or any part of it, shall be exercised by written notice directed to the President, Chief Financial Officer or Secretary of the Company at

 

the Company’s principal office in Allegan, Michigan, U.S.A., or by using other notification permitted by the Company. Such notice must satisfy the following requirements:
(a)    The notice must state the Grant Date, the number of Ordinary Shares subject to the Option, the number of Ordinary Shares with respect to which Option is being exercised, the person in whose name the stock certificate or certificates for such Ordinary Shares is to be registered and the person’s address and Social Security number (or if more than one person, the names, addresses and Social Security numbers of such persons).
(b)    The notice shall be accompanied by check, bank draft, money order or other cash payment, all in U.S. dollars, or by delivery of a certificate or certificates, properly endorsed, for Ordinary Shares that you have held for at least six months and that are equivalent in Fair Market Value on the date of exercise to the Option Price (or any combination of cash and shares), in full payment of the Option Price for the number of shares specified in the notice.
(c)    The notice must be signed by the person or persons entitled to exercise the Option and, if the Option is being exercised by any person or persons other than you, be accompanied by proof, satisfactory to the Committee, of the right of such person or persons to exercise the Option.
(d)    The Company may implement procedures for the electronic exercise of this Option, in which case the vested portion of this Option shall be exercisable in accordance with such procedures.
SECTION 2
General Terms and Conditions
2.1    Nontransferability. The Award under this Agreement shall not be transferable other than by will or by the laws of descent and distribution. During your lifetime, the Option granted under this Agreement shall be exercisable only by you or by your guardian or legal representative in the event of your Disability.
2.2    No Rights as a Stockholder. You shall not have any rights as a stockholder with respect to any Ordinary Shares subject to the Option prior to the date of issuance to you of a certificate or certificates for such shares.
2.3    Cause Termination. If your Termination Date occurs for reasons of Cause, all of your rights under this Agreement, whether or not vested, shall terminate immediately.
2.4    Awards Subject to Plan. The granting of the Award under this Agreement is being made pursuant to the Plan and the Award shall be exercisable only in accordance with the applicable terms of the Plan. The Plan contains certain definitions, restrictions, limitations and other terms and conditions all of which shall be applicable to this Agreement. ALL THE PROVISIONS OF THE PLAN ARE INCORPORATED HEREIN BY REFERENCE AND ARE MADE A PART OF THIS AGREEMENT IN THE SAME MANNER AS IF EACH AND EVERY SUCH PROVISION WERE FULLY WRITTEN INTO THIS

 

AGREEMENT. Should the Plan become void or unenforceable by operation of law or judicial decision, this Agreement shall have no force or effect. Nothing set forth in this Agreement is intended, nor shall any of its provisions be construed, to limit or exclude any definition, restriction, limitation or other term or condition of the Plan as is relevant to this Agreement and as may be specifically applied to it by the Committee. In the event of a conflict in the provisions of this Agreement and the Plan, as a rule of construction the terms of the Plan shall be deemed superior and apply.
2.5    Adjustments in Event of Change in Ordinary Shares. In the event of a stock split, stock dividend, recapitalization, reclassification or combination of shares, merger, sale of assets or similar event, the number and kind of shares subject to the Award under this Agreement, and the exercise price thereof, will be appropriately adjusted in an equitable manner to prevent dilution or enlargement of the rights granted to or available for you.
2.6     Acknowledgement. The Company and you agree that the Option is granted under and governed by the Notice of Grant, this Agreement (including the Appendix) and by the provisions of the Plan (incorporated herein by reference). You: (i) acknowledge receipt of a copy of each of the foregoing documents, (ii) represent that you have carefully read and are familiar with their provisions, and (iii) hereby accept the Option subject to all of the terms and conditions set forth herein and those set forth in the Plan and the Notice of Grant.
2.7    Responsibility for Taxes. Regardless of any action the Company or, if different, the Affiliate employing or retaining you takes with respect to any or all income tax, social insurance, payroll tax, payment on account or other tax-related items related to your participation in the Plan and legally applicable to you (“Tax-Related Items”), you acknowledge that the ultimate liability for all Tax-Related Items is and remains your responsibility and may exceed the amount actually withheld by the Company or the Affiliate employing or retaining you. You further acknowledge that the Company and/or the Affiliate employing or retaining you (1) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Option, including, but not limited to, the grant, vesting or exercise of the Option, the subsequent sale of Ordinary Shares acquired pursuant to such exercise and the receipt of any dividends; and (2) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Option to reduce or eliminate your liability for Tax-Related Items or achieve any particular tax result. Further, if you have become subject to tax in more than one jurisdiction between the Grant Date and the date of any relevant taxable event, as applicable, you acknowledge that the Company and/or the Affiliate employing or retaining you (or formerly employing or retaining you, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.
(a)     Prior to any relevant taxable or tax withholding event, as applicable, you will pay or make adequate arrangements satisfactory to the Company and/or the Affiliate employing or retaining you to satisfy all Tax-Related Items. In this regard, you authorize the Company and/or the Affiliate employing or retaining you, or their respective agents, at their discretion, to satisfy the obligations with regard to all Tax-Related Items by one or a combination of the following:

 

(1)    withholding from your wages or other cash compensation paid to you by the Company and/or the Affiliate employing or retaining you; or
(2)    withholding from proceeds of the sale of Ordinary Shares acquired upon exercise of the Option either through a voluntary sale or through a mandatory sale arranged by the Company (on your behalf pursuant to this authorization); or
(3)    withholding in Ordinary Shares to be issued upon exercise of the Option.
(b)    To avoid negative accounting treatment, the Company may withhold or account for Tax-Related Items by considering applicable minimum statutory withholding amounts or other applicable withholding rates. If the obligation for Tax-Related Items is satisfied by withholding in Ordinary Shares, for tax purposes, you are deemed to have been issued the full number of Ordinary Shares subject to the exercised Option, notwithstanding that a number of the Ordinary Shares are held back solely for the purpose of paying the Tax-Related Items.
(c)    Finally, you shall pay to the Company or the Affiliate employing or retaining you any amount of Tax-Related Items that the Company or the Affiliate employing or retaining you may be required to withhold or account for as a result of your participation in the Plan that cannot be satisfied by the means previously described. The Company may refuse to issue or deliver the Ordinary Shares or the proceeds of the sale of Ordinary Shares, if you fail to comply with your obligations in connection with the Tax-Related Items.
2.8    Compliance with Applicable Law. The issuance of Ordinary Shares will be subject to and conditioned upon compliance by the Company and you, including any written representations, warranties and agreements as the Administrator may request of you for compliance with all (i) applicable U.S. state and federal laws and regulations, (ii) applicable laws of the country where you reside pertaining to the issuance or sale of Ordinary Shares, and (iii) applicable requirements of any stock exchange or automated quotation system on which the Company’s Ordinary Shares may be listed or quoted at the time of such issuance or transfer.
2.9    Data Privacy.
(a)    By entering into this Agreement and accepting this Award, you hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Agreement and any other Option grant materials by and among, as applicable, the Affiliate employing or retaining you, the Company and its Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.
(b)    You understand that the Company and the Affiliate employing or retaining you may hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of Option or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the exclusive purpose of implementing, administering and managing the Plan (“Data”).
(c)    You understand that Data will be transferred to legal counsel or a broker or such other stock plan service provider as may be selected by the Company in the future, which is assisting the Company with the implementation, administration and management of the Plan. You understand that the recipients of the Data may be located in the United States or elsewhere, and that the recipients’ country (e.g., the United States) may have different data privacy laws and protections than your country. You understand that if you reside outside the United States, you may request a list with the names and addresses of any potential recipients of the Data by contacting your local or Company human resources representative. You authorize the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing your participation in the Plan. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan. You understand that if you reside outside the United States, you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local or Company human resources representative. You understand, however, that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local or Company human resources representative.
2.10     Nature of Grant. In accepting the grant, you acknowledge, understand and agree that:
(a)    the Plan is established voluntarily by the Company, it is discretionary in nature and it may be modified, amended, suspended or terminated by the Company at any time, except as otherwise provided in the Plan.
(b)    the grant of the Option is voluntary and occasional and does not create any contractual or other right to receive future Option grants, or benefits in lieu of the Option, even if the Option has been granted repeatedly in the past;
(c)    all decisions with respect to future Option grants, if any, will be at the sole discretion of the Company;
(d)    you are voluntarily participating in the Plan;
(e)    the Option and the Ordinary Shares subject to the Option are an extraordinary item and which is outside the scope of your employment or service contract, if any;
(f)    the Option and the Ordinary Shares subject to the Option are not intended to replace any pension rights or compensation;
(g)    the Option and the Ordinary Shares subject to the Option are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments and in no event should be considered as compensation for, or relating in any way to, past services for the Company, the Affiliate employing or retaining you or any other Affiliate;
(h)    the grant and your participation in the Plan will not be interpreted to form an employment or service contract with the Company or any Affiliate;
(i)    the future value of the underlying Ordinary Shares is unknown, indeterminable and cannot be predicted with certainty;
(j)    no claim or entitlement to compensation or damages shall arise from forfeiture of the Option resulting from your Termination Date (for any reason whatsoever, whether or not later found to be invalid and whether or not in breach of employment laws in the jurisdiction where you are employed or rendering services, or the terms of your employment agreement, if any), and in consideration of the grant of the Option to which you are otherwise not entitled, you irrevocably agree never to institute any claim against the Company or the Affiliate employing or retaining you, waive your ability, if any, to bring any such claim, and release the Company and the Affiliate employing or retaining you from any such claim; if, notwithstanding the foregoing, any such claim is allowed by a court of competent jurisdiction, then, by participating in the Plan, you shall be deemed irrevocably to have agreed not to pursue such claim and agree to execute any and all documents necessary to request dismissal or withdrawal of such claim; and
(k)    you acknowledge and agree that neither the Company, the Affiliate employing or retaining you nor any other Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the United States Dollar that may affect the value of the Option or of any amounts due to you pursuant to the settlement of the Option or the subsequent sale of any Ordinary Shares acquired upon settlement.
2.11    Successors and Assigns. This Agreement shall be binding upon any or all successors and assigns of the Company.
2.12    Applicable Law. This Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of Michigan, U.S.A., without regard to principals of conflict of laws. Any proceeding related to or arising out of this Agreement shall be commenced, prosecuted or continued in the Circuit Court in Kent County, Michigan located in Grand Rapids, Michigan or in the United Stated District Court for the Western District of Michigan, and in any appellate court thereof.
2.13 Repayment of Option Gain/Forfeiture of Options. If the Company, as a result of misconduct, is required to prepare an accounting restatement due to material noncompliance with any financial reporting requirement under the securities laws, then (a) if your equity compensation is subject to automatic forfeiture due to such misconduct and restatement under Section 304 of the Sarbanes-Oxley Act of 2002, or (b) the Committee determines you either knowingly engaged in or failed to prevent the misconduct, or your actions or inactions with respect to the misconduct and restatement constituted gross negligence, you shall (i) be required to reimburse the Company for any gain associated with any Option exercised during the twelve month period following the first public issuance or filing with the SEC (whichever first occurred) of the financial document embodying such financial reporting requirement, and (ii) any outstanding Options shall be immediately forfeited.
2.14    Appendix. Notwithstanding any provisions in this Agreement, the Option grant shall be subject to any special terms and conditions set forth in any Appendix to this Agreement for your country. Moreover, if you relocate to one of the countries included in the Appendix, the special terms and conditions for such country will apply to you, to the extent the Company determines that the application of such provisions is necessary or advisable in order to comply with laws of the country where you reside or to facilitate the administration of the Plan. The Appendix constitutes part of this Agreement.
2.16    Imposition of Other Requirements. The Company reserves the right to impose other requirements on your participation in the Plan, on the Option and on any Ordinary Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable in order to comply with laws of the country where you reside or to facilitate the administration of the Plan, and to require you to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.
****
We look forward to your continuing contribution to the growth of the Company. Please acknowledge your receipt of the Plan and this Award.
Very truly yours,




Print Name: ___________________________
Title:_________________________________



APPENDIX

PERRIGO COMPANY PLC
Additional Terms and Provisions to
Nonqualified Stock Option Agreement

Terms and Conditions
This Appendix (the “Appendix”) includes additional terms and conditions that govern the nonqualified stock option (“Option”) granted to you under the Plan if you reside in one of the countries listed below. Certain capitalized terms used but not defined in this Appendix have the meanings set forth in the Plan and/or the Agreement.
Notifications
This Appendix also includes country-specific information of which you should be aware with respect to your participation in the Plan. The information is based on the securities, exchange control and other laws in effect in the respective countries as of January 2015. Such laws are often complex and change frequently. As a result, the Company strongly recommends that you do not rely on the information noted herein as the only source of information relating to the consequences of your participation in the Plan because the information may be out of date at the time that your stock options vest, or are exercised and Ordinary Shares are issued to you or when you sell Ordinary Shares acquired under the plan.
In addition, the information is general in nature and may not apply to your particular situation, and the Company is not in a position to assure you of any particular result. Accordingly, you are advised to seek appropriate professional advice as to how the relevant laws in your country may apply to your particular situation. Finally, please note that if you are a citizen or resident of a country other than the country in which you are currently working, or transfers employment after grant, the information contained in the Appendix may not be applicable.


Argentina
Notifications
Securities Law Information. Neither the Option nor the issuance of the Ordinary Shares are publicly offered or listed on any stock exchange in Argentina. The offer is private and not subject to the supervision of any Argentine governmental authority.
Exchange Control Information. You will not be able to engage in a cash exercise unless you have U.S. dollars held outside Argentina and use those funds to purchase Ordinary Shares at exercise. Otherwise, you will only be able to engage in a cashless exercise pursuant to which Ordinary Shares will be sold at exercise to pay the purchase price. In the event that you transfer sales proceeds in excess of US$50,000 from the sale of shares into Argentina in a single month, you will be subject to certain exchange control reporting requirements. In addition, you may be subject to a mandatory 30% restriction on holding of funds brought into Argentina. Please note that exchange control regulations in Argentina are subject to frequent change. You should consult with your personal legal advisor regarding any exchange control obligations that you may have.
Australia
Notifications
Securities Information. If you acquire shares pursuant to the Option and you offer the shares for sale to a person or entity resident in Australia, then the offer may be subject to disclosure requirements under Australian law. You should obtain legal advice on your disclosure obligations prior to making any such offer.
Exchange Control Information. Exchange control reporting is required for cash transactions exceeding AUD10,000 and for international fund transfers. The Australian bank assisting with the transaction will file the report for you. If there is no Australian bank involved in the transfer, you will have to file the report.
Austria
Notifications
Exchange Control Information. If you hold shares of Company stock outside of Austria, you must submit a report to the Austrian National Bank. An exemption applies if the value of the shares as of any given quarter does not exceed €30,000,000 or as of December 31 does not exceed €5,000,000. If the former threshold is exceeded, quarterly obligations are imposed, whereas if the latter threshold is exceeded, annual reports must be given. The annual reporting date is as of December 31 and the deadline for filing the annual report is March 31 of the following year.
When shares are sold, there may be exchange control obligations if the cash received is held outside Austria. If the transaction volume of all your accounts abroad exceeds €3,000,000, the movements and balances of all accounts must be reported monthly, as of the last day of the month, on or before the fifteenth day of the following month.
Belgium
Notifications
Tax Information. If you accept this Agreement within sixty (60) days of the date that the material terms of the grant are communicated to you in writing (“Offer Date”), you will be subject to tax on the Offer Date. If you accept this Agreement later than sixty (60) days after the Offer Date, you will be subject to tax when you exercise your Option.
Czech Republic
Notifications
Exchange Control Information. The Czech National Bank may require you to report the Option and or Ordinary Shares received and the opening and maintenance of a foreign account. However, because exchange control regulations change frequently and without notice, you should consult your personal legal advisor prior to the exercise of the Option to ensure your compliance with current regulations. It is your responsibility to comply with applicable Czech exchange control laws.
Denmark
Notifications
Exchange Control Information. If you establish an account holding shares or an account holding cash outside Denmark, you must report the account to the Danish Tax Administration. The form which should be used in this respect can be obtained from a local bank. (Please note that these obligations are separate from and in addition to the obligations described below.)
Securities/Tax Reporting Information. If you hold shares acquired under the Plan in a brokerage account with a broker or bank outside Denmark, you are required to inform the Danish Tax Administration about the account. For this purpose, you must file a Form V (Erklaering V) with the Danish Tax Administration. The Form V must be signed both by you and by the applicable broker or bank where the account is held. By signing the Form V, the broker or bank undertakes to forward information to the Danish Tax Administration concerning the shares in the account without further request each year. By signing the Form V, you authorize the Danish Tax Administration to examine the account. A sample of the Form V can be found at the following website: www.skat.dk.
In addition, if you open a brokerage account (or a deposit account with a U.S. bank) for the purpose of holding cash outside Denmark, you are also required to inform the Danish Tax Administration about this account. To do so, you must also file a Form K (Erklaering K) with the Danish Tax Administration. The Form K must be signed both by you and by the applicable broker or bank where the account is held. By signing the Form K, the broker/bank undertakes an obligation, without further request each year, to forward information to the Danish Tax Administration concerning the content of the account. By signing the Form K, you authorize the Danish Tax Administration to examine the account. A sample of Form K can be found at the following website: www.skat.dk.
Finland
There are no country specific provisions.
France
Terms and Conditions
Consent to Receive Information in English. By accepting the Option, you confirm having read and understood the Plan and the Agreement, which were provided in the English language. You accept the terms of those documents accordingly.
En acceptant cette attribution gratuite d'actions, vous confirmez avoir lu et comprenez le Plan et ce Contrat, incluant tous leurs termes et conditions, qui ont été transmis en langue anglaise. Vous acceptez les dispositions de ces documents en connaissance de cause.
Notifications
Exchange Control Information. If you hold Ordinary Shares outside of France or maintain a foreign bank account, you are required to report such to the French tax authorities when you file your annual tax return.
Germany
Notifications
Exchange Control Information. Cross-border payments in excess of €12,500 must be reported monthly to the German Federal Bank. If you use a German bank to transfer a cross-border payment in excess of €12,500 in connection with the sale of shares acquired under the Plan, the bank will make the report for you. In addition, you must report any receivables, payables, or debts in foreign currency exceeding an amount of €5,000,000 on a monthly basis.
Greece
Notifications
Exchange Control Information. If you withdraw funds in excess of €15,000 from a bank in Greece to exercise your Option and remit those funds out of Greece, you may be required to submit certain documentation/ information to the Greek bank to ensure that the transfer is not in violation of Greek anti-money laundering rules.
Hungary
No country specific provisions.

India
Notifications
Exchange Control Notification. You must repatriate all proceeds received from the sale of the shares to India within 90 days after sale. You will receive a foreign inward remittance certificate (“FIRC”) from the bank where you deposit the foreign currency. You should maintain the FIRC as evidence of the repatriation of funds in the event that the Reserve Bank of India or the employer requests proof of repatriation.
Tax Information. The amount subject to tax at exercise will partially be dependent upon a valuation that the Company or your employer will obtain from a Merchant Banker in India. Neither the Company nor your employer has any responsibility or obligation to obtain the most favorable valuation possible, nor obtain valuations more frequently than required under Indian tax law.
Ireland
Notifications
Director Notification Obligation. If you are a director, shadow director or secretary of the Company or an Irish Subsidiary or Affiliate of the Company, and you acquire or dispose of an interest under this Agreement comprising more than 1% of the share capital in the Company, you must notify the entity in which you hold that office (whether the Company itself or an Irish Subsidiary or Affiliate of the Company) in writing within five business days of receiving or disposing of an interest in the Company, or within five business days of becoming aware of the event giving rise to the notification requirement or within five days of becoming a director or secretary if such an interest exists at the time. This notification requirement also applies with respect to the interests of a spouse or children under the age of 18 (whose interests will be attributed to the director, shadow director or secretary).
Italy
Terms and Conditions
Data Privacy Notice. The following provision supplements the terms in the Agreement:
You understand that your employer and/or the Company may hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social security number (or any other social or national identification number), salary, nationality, job title, number of shares held and the details of all Options or any other entitlement to shares awarded, cancelled, exercised, vested, unvested or outstanding (the “Data”) for the purpose of implementing, administering and managing your participation in the Plan. You are aware that providing the Company with the Data is necessary for the performance of this Agreement and that your refusal to provide such Data would make it impossible for the Company to perform its contractual obligations and may affect your ability to participate in the Plan.
The "Controller" of personal data processing is Perrigo Company, plc, with registered offices at Allegan, Michigan USA, and, pursuant to D.lgs 196/2003, its Stock Plan Administrator, David A. McConnell. You understand that the Data may be transferred to the Company or any of its subsidiaries or affiliates, or to any third parties assisting in the implementation, administration and management of the Plan, including any transfer required to a broker or other third party with whom shares acquired pursuant to the exercise of the Option or cash from the sale of shares acquired pursuant to the Plan may be deposited. Furthermore, the recipients that may receive, possess, use, retain and transfer such Data for the above mentioned purposes may be located in Italy or elsewhere, including outside of the European Union and that the recipients’ country (e.g., the United States) may have different data privacy laws and protections than Italy. The processing activity, including the transfer of your personal data abroad, outside of the European Union, as herein specified and pursuant to applicable laws and regulations, does not require your consent thereto as the processing is necessary for the performance of contractual obligations related to the implementation, administration and management of the Plan. You understand that Data processing relating to the purposes above specified shall take place under automated or non-automated conditions, anonymously when possible, that comply with the purposes for which Data are collected and with confidentiality and security provisions as set forth by applicable laws and regulations, with specific reference to D.lgs. 196/2003.
You understand that Data will be held only as long as is required by law or as necessary to implement, administer and manage your participation in the Plan. You understand that pursuant to art.7 of D.lgs 196/2003, you have the right, including but not limited to, access, delete, update, request the rectification of your personal Data and cease, for legitimate reasons, the Data processing. Furthermore, you are aware that your Data will not be used for direct marketing purposes.
Plan Document Acknowledgment. In accepting the Option, you acknowledge that you have received a copy of the Plan and the Agreement and have reviewed the Plan and the Agreement, including this Appendix, in their entirety and fully understand and accept all provisions of the Plan and the Agreement, including this Appendix.
Notifications
Tax/Exchange Control Information. You are required to report on your annual tax return: (a) any transfers of cash or shares to or from Italy exceeding €10,000 or the equivalent amount in U.S. dollars; (b) any foreign investments or investments (including the Ordinary Shares issued at exercise of the Option, cash or proceeds from the sale of shares acquired under the Plan) held outside of Italy exceeding €10,000 or the equivalent amount in U.S. dollars, if the investment may give rise to income in Italy (this will include reporting the Ordinary Shares issued at exercise of the Option if the fair market value of such Ordinary Shares combined with other foreign assets exceed €10,000); and (c) the amount of the transfers to and from abroad which have had an impact during the calendar year on your foreign investments or investments held outside of Italy. You are exempt from the formalities in (a) if the investments are made through an authorized broker resident in Italy, as the broker will comply with the reporting obligation on your behalf.
Kazakhstan
Notifications
Exchange Control Information. Although Kazakh residents are no longer required to obtain a license from the National Bank of Kazakhstan in advance of obtaining securities in foreign companies, you are nevertheless required to notify the National Bank of Kazakhstan when you acquire shares under the Plan.
Latvia
No country specific provisions.
Luxembourg
Notifications
Exchange Control Information. You are required to report any inward remittances of funds to the Banque Central de Luxembourg and/or the Service Central de La Statistique et des Etudes Economiques within 15 working days following the month during the transaction occurred. If a Luxembourg financial institution is involved in the transaction, it generally will fulfill the reporting obligation on your behalf.
Mexico
Terms and Conditions
Modification. By accepting the Option, you understand and agree that any modification of the Plan or the Agreement or its termination shall not constitute a change or impairment of the terms and conditions of employment.
Policy Statement. The award of the Option the Company is making under the Plan is unilateral and discretionary and, therefore, the Company reserves the absolute right to amend it and discontinue it at any time without any liability.
The Company, with registered offices in the U.S., is solely responsible for the administration of the Plan and participation in the Plan and the acquisition of shares does not, in any way, establish an employment relationship between you and the Company since you are participating in the Plan on a wholly commercial basis and the sole employer is as applicable, nor does it establish any rights between you and the Employer.
Plan Document Acknowledgment. By accepting the award of the Option, you acknowledge that you have received copies of the Plan, have reviewed the Plan and the Agreement in their entirety and fully understand and accept all provisions of the Plan and the Agreement.
In addition, by signing the Agreement, you further acknowledge that you have read and specifically and expressly approve the terms and conditions in the Agreement, in which the following is clearly described and established: (i) participation in the Plan does not constitute an acquired right; (ii) the Plan and participation in the Plan is offered by the Company on a wholly discretionary basis; (iii) participation in the Plan is voluntary; and (iv) the Company and any Parent, Subsidiary or Affiliates are not responsible for any decrease in the value of the shares underlying the options.
Finally, you hereby declare that you do not reserve any action or right to bring any claim against the Company for any compensation or damages as a result of your participation in the Plan and therefore grant a full and broad release to the Employer, the Company and any Parent, Subsidiary or Affiliates with respect to any claim that may arise under the Plan.
Spanish Translation
Modification. Al aceptar las Unidades de Accion Restringida, usted reconoce y acuerda que cualquier modification del Plan o su terminacion no constituye un cambio o desmejora de los terminos y condiciones de empleo.
Declaracion de Politica. El Otorgarmiento de Unidades de Accion Restringida de la Compañia en virtud del Plan es unilateral y discrecional y, por lo tanto, la Compañia se reserva el derecho absoluto de modificar y discontinuar el mismo en cualquier tiempo, sin responsabilidad alguna.
La Compañia, con oficinas registradas ubicadas en the U.S. es la unica responsable de la administración del Plan y de la participación en el mismo y la adquisición de Acciones no establece de forma alguna una relación de trabajo entre usted y la Compañia, ya que su participación en el Plan es completamente comercial y el unico empleador es en caso de ser aplicable, asi como tampoco establece ningun derecho entre la persona que tenga el derecho a optar y el Empleador.
Reconocimiento del Documento del Plan. Al aceptar el Otorgamiento de las Unidades de Acciόn Restringida, usted reconoce que ha recibido copias del Plan, ha revisado el mismo, al igual que la totalidad del Acuerdo y, que ha entendido y aceptado completamente todas las disposiciones contenidas en el Plan y en el Acuerdo.
Adicionalmente, al firmar el Acuerdo, reconoce que ha leido, y que aprueba especifica y expresamente los términos y condiciones contenidos en la Renuncia de Derecho o Reclamo por Compensación del Acuerdo, en el cual se encuentra claramente descrito y establecido lo siguiente: (i) la participación en el Plan no constituye un derecho adquirido; (ii) el plan y la participación en el mismo es ofrecida por la Compañia de forma enteramente discrecional; (iii) la participación en el Plan es voluntaria; y (iv) la Compañia, asi como su Sociedad controlante, Subsidiaria o Filiales no son responsables por cualquier disminución en el valor de las Acciones en relación a las Unidades de Acciόn Restringida.
Finalmente, declara que no se reserva ninguna acciόn o derecho para interponer una demanda en contra de la Compañia por compensación, dano o perjuicio alguno como resultado de su participación en el Plan y, en consecuencia, otorga el más amplio finiquito al Empleador, asi como a la Compañia, a su Sociedad controlante, Subsidiaria o Filiales con respecto a cualquier demanda que pudiera originarse en virtud del Plan.
Netherlands
Notifications
Insider-Trading Notification. You should be aware of the Dutch insider-trading rules which may prohibit you from effectuating certain transactions involving shares if you have inside information about the Company. If you are uncertain whether the insider-trading rules apply to you, you should consult your personal legal advisor.
Norway
No country specific provisions.
Poland
Terms and Conditions
Consent to Receive Information in English. By accepting the Option, you confirm having read and understood the Plan and the Agreement, which were provided in the English language. You accept the terms of those documents accordingly.
Notifications
Exchange Control Information. If you hold foreign securities (including shares) and maintain accounts abroad, you may be required to file certain reports with the National Bank of Poland. Specifically, if the value of securities and cash held in such foreign accounts exceeds PLN 7,000,000 at the end of the year, you must file reports on the transactions and balances of the accounts on a quarterly basis by the 20th day of the month following the end of each quarter and an annual report by no later than January 30 of the following calendar year. Such reports are filed on special forms available on the website of the National Bank of Poland. Additionally, if you are a Polish citizen and you transfer funds abroad in excess of the PLN equivalent of €15,000, the transfer must be made through an authorized bank, a payment institution or an electronic money institution authorized to render payment services.
Portugal

Notifications
Exchange Control Information. If you receive shares upon exercise, the acquisition of the shares should be reported to the Banco de Portugal for statistical purposes. If the shares are deposited with a commercial bank or financial intermediary in Portugal, such bank or financial intermediary will submit the report on your behalf. If the shares are not deposited with a commercial bank or financial intermediary in Portugal, you are responsible for submitting the report to the Banco de Portugal.


Romania
Notifications
Exchange Control Information. Payments by Romanian citizens to or from non-residents in excess of €50,000 should be reported to the National Bank of Romania (“NBR”) for statistical purposes. If you deposit the proceeds from the sale of shares issued to you at exercise in a bank account in Romania, you may be required to provide the Romanian bank with appropriate documentation explaining the source of the funds. You should consult your personal advisor to determine whether you will be required to submit such documentation to the Romanian bank.
Insider-Trading Notification. You should be aware of the Romanian insider-trading rules which may prohibit you from effectuating certain transactions involving shares if you have inside information about the Company. If you are uncertain whether the insider-trading rules apply to you, you should consult your personal legal advisor.

Russia
Terms and Conditions
U.S. Transaction. You understand that the Option shall be valid and this Agreement shall be concluded and become effective only when the Agreement is electronically received by the Company in the United States. Upon exercise, any shares to be issued to you shall be delivered to you through a bank or brokerage account in the United States. You are not permitted to sell the shares directly to other Russian legal entities or individuals.
Notifications
Exchange Control Information. Under current exchange control regulations, within a reasonably short time after sale of the shares issued at exercise, you must repatriate the sale proceeds to Russia. Such sale proceeds must be initially credited to you through a foreign currency account at an authorized bank in Russia. After the sale proceeds are initially received in Russia, they may be further remitted to foreign banks in accordance with Russian exchange control laws.
You are encouraged to contact your personal advisor before remitting your sale proceeds to Russia as exchange control requirements may change.
Securities Law Notification. This Appendix, the Agreement, the Plan and all other materials that you may receive regarding participation in the Plan do not constitute advertising or an offering of securities in Russia. Absent any requirement under local law, the issuance of securities pursuant to the Plan has not and will not be registered in Russia; hence, the securities described in any Plan-related documents may not be used for offering or public circulation in Russia.
Serbia
No country specific provisions.
Slovakia
No country specific provisions.
Slovenia
No country specific provisions.
South Africa
Terms and Conditions
Taxes. By accepting the Option, you agree that, immediately upon exercise of the Option, you will notify your employer of the amount of any gain realized. If you fail to advise your employer of the gain realized upon exercise, you may be liable for a fine. You will be solely responsible for paying any difference between the actual tax liability and the amount withheld by your employer.
Notifications
Exchange Control Information. You are required to obtain approval from the exchange control authorities to participate in the Plan. You are strongly advised to consult your personal advisor prior to exercising your Option to ensure compliance with current regulations.
Spain
Terms and Conditions
No Entitlement for Claims or Compensation. By accepting the Option, you consent to participation in the Plan, and acknowledge that you have received a copy of the Plan document. You understand that the Company has unilaterally, gratuitously and in its sole discretion decided to make awards of Options under the Plan to individuals who may be employees, consultants and directors throughout the world. The decision is limited and entered into based upon the express assumption and condition that any Option will not economically or otherwise bind the Company or any Parent, Subsidiary or Affiliate, including your employer, on an ongoing basis, other than as expressly set forth in the Agreement. Consequently, you understand that the Award is given on the assumption and condition that the Option shall not become part of any employment contract (whether with the Company or any Parent, Subsidiary or Affiliate, including your employer) and shall not be considered a mandatory benefit, salary for any purpose (including severance compensation) or any other right whatsoever. Furthermore, you understand and freely accept that there is no guarantee that any benefit whatsoever shall arise from the award, which is gratuitous and discretionary, since the future value of the Option and the underlying shares is unknown and unpredictable. You also understand that this Award would not be made but for the assumptions and conditions set forth hereinabove; thus, you understand, acknowledge and freely accept that, should any or all of the assumptions be mistaken or any of the conditions not be met for any reason, the Award, the Option and any right to the underlying shares shall be null and void.
Notifications
Exchange Control Information. You must declare the acquisition of Ordinary Shares to the Dirección General de Politica Comercial e Inversiones Exteriores ("DGPCIE") of the Ministerio de Economia for statistical purposes. You must also declare the ownership of any Ordinary Shares with the Directorate of Foreign Transactions each January while the shares are owned. In addition, you wish to import the share certificates into Spain, you must declare the importation of such securities to the DGPCIE.
When receiving foreign currency payments derived from the ownership of Ordinary Shares (i.e., dividends or sale proceeds), you must inform the financial institution receiving the payment of the basis upon which such payment is made. You will need to provide the following information: (i) your name, address, and fiscal identification number; (ii) the name and corporate domicile of the Company; (iii) the amount of the payment and the currency used; (iv) the country of origin; (v) the reasons for the payment; and (vi) further information that may be required.
Tax Information. If you hold assets or rights outside of Spain (including shares), you may have to file an informational tax report with the tax authorities declaring such ownership. Generally, if the value of your foreign investments exceeds €50,000, you may have to file this informational return. Please note that reporting requirements are based on what you have previously disclosed and the increase in value of such and the total value of certain groups of foreign assets. Also, the thresholds for annual filing requirements may change each year. Therefore, you should consult your personal advisor regarding whether you will be required to file an informational tax report for asset and rights that you hold abroad.
Sweden
No country specific provisions.
Switzerland
Notifications
Securities Law Notification The award is considered a private offering in Switzerland; therefore, it is not subject to registration in Switzerland.
Turkey
No country specific provisions.
Ukraine
Notifications
Exchange Control Information. You may be required to obtain a license for obtaining shares of a foreign company from the National Bank of Ukraine (NBU). You are strongly encouraged to consult a personal advisor to ensure compliance with the exchange control restrictions prior to exercising your Option.
United Kingdom
Terms and Conditions
Income Tax and National Insurance Contribution Withholding. The following provision supplements the terms in the Agreement:
If payment or withholding of the income tax due in connection with the Option is not made within ninety (90) days of the end of the U.K. tax year in which the event giving rise to the income tax liability or such other period specified in Section 222(1)(c) of the U.K. Income Tax (Earnings and Pensions) Act 2003 occurred (the “Due Date”), the amount of any uncollected income tax shall constitute a loan owed by you to your employer, effective as of the Due Date. You agree that the loan will bear interest at the then-current official rate of Her Majesty’s Revenue & Customs (“HMRC”), it shall be immediately due and repayable, and the Company or your employer may recover it at any time thereafter by any of the means referred to in Section 2.7 of the Agreement. Notwithstanding the foregoing, if you are a director or executive officer of the Company (within the meaning of Section 13(k) of the U.S. Securities and Exchange Act of 1934, as amended), you will not be eligible for a loan from the Company or your employer to cover the income tax liability. In the event that you are a director or executive officer and the income tax is not collected from or paid by the Due Date, the amount of any uncollected income tax will constitute a benefit to you on which additional income tax and national insurance contributions (“NICs”) will be payable. You will be responsible for reporting any income tax for reimbursing the Company or your employer the value of any employee NICs due on this additional benefit.
* * * * *


PERRIGO COMPANY PLC
NONQUALIFIED STOCK OPTION AGREEMENT
(Under the Perrigo Company plc 2013 Long-Term Incentive Plan)
TO:        Participant Name
RE:        Notice of Nonqualified Stock Option
This is to notify you that Perrigo Company plc (the “Company”) has granted you an Award under the Perrigo Company plc 2013 Long-Term Incentive Plan (the “Plan”), effective as of Grant Date (the “Grant Date”). This Award consists of a nonqualified stock option. The terms and conditions of this incentive are set forth in the remainder of this agreement (the “Agreement”). The capitalized terms that are not otherwise defined in this Agreement shall have the meanings ascribed to such terms under the Plan.
SECTION 1
Nonqualified Stock Option
1.1    Grant of Option. As of the Grant Date, and subject to the terms and conditions of this Agreement and the Plan, the Company grants you a nonqualified stock option (the “Option”) to purchase Number of Awards Granted ordinary shares of the Company, nominal value €0.001 per share (“Ordinary Shares”), at a per share price of $ Grant Date FMV (the “Option Price”), which is equal to the Fair Market Value of such Ordinary Shares as of the Grant Date.
1.2    Timing and Duration of Exercise.
(a)    The Option shall vest with respect to one-third of the Shares awarded in Section 1.1 on each of the first, second and third anniversaries of the Grant Date (each a “Vesting Date”), with the vesting of any fractional shares frontloaded to the first such Vesting Date. Subject to the requirements of subsection (b) below, vested Shares may be exercised after the applicable Vesting Date. Notwithstanding the foregoing, any portion of the Option that has not vested or been forfeited previously shall immediately vest in full upon, and, subject to subsection (b) below, may be exercised in whole or in part after (1) your Termination Date if your Termination Date occurs by reason of a Termination without Cause or a Separation for Good Reason on or after a Change in Control (as defined in the Plan and as such definition may be amended hereafter) and prior to the two (2) year anniversary of the Change in Control, or (2) your death, Disability, or Retirement.
(b)    Except as provided below, the vested Option must be exercised by you, if at all, while you are providing service to the Company or one of its subsidiaries or within three months following your Termination Date, but in no event after Expiration Date (the “Expiration Date”). If your Termination Date occurs by reason of your Retirement, death or Disability, the Option may thereafter be exercised by you, or in the event of your death, by your estate or your designated beneficiary, or in the event of your Disability, by you or your legal representative, at any time prior to the Expiration Date. If you die after your Termination Date and during the period in which the Option is exercisable, the right to exercise the Option during such period will be governed by Plan Section 12(d)(4). If your Termination Date occurs because of an Involuntary Termination for Economic Reasons as determined by the Chief Executive Officer (or the Committee in the case of an Employee subject to Section 16 of the Exchange Act), the terms of Plan Section 12(b)(2) shall apply; provided, however, that if your Termination Date occurs for a reason that is both described in this sentence and in subsection (a) above, the special vesting rules described in subsection (a) shall apply in lieu of the vesting rules described in Plan Section 12(b)(2).
Any portion of the Option that is not vested pursuant to this Section 1.2 as of your employment Termination Date will be forfeited immediately. If the Option is not exercised as to all of the vested shares covered by the Option within the applicable time period and in the manner provided herein, the Option will terminate and will not be exercisable thereafter. In no event may the Option be exercised after the Expiration Date.
(c)    As used in this Section 1.2, the following terms shall have the meanings set forth below:
(1)    “Separation for Good Reason” means your voluntary resignation from the Company and the existence of one or more of the following conditions that arose without your consent: (i) a material change in the geographic location at which you are required to perform services, such that your commute between home and your primary job site increases by more than 30 miles, or (ii) a material diminution in your authority, duties or responsibilities or a material diminution in your base compensation or incentive compensation opportunities; provided, however, that a voluntary resignation from the Company shall not be considered a Separation for Good Reason unless you provide the Company with notice, in writing, of your voluntary resignation and the existence of the condition(s) giving rise to the separation within 90 days of its initial existence. The Company will then have 30 days to remedy the condition, in which case you will not be deemed to have incurred a Separation for Good Reason. In the event the Company fails to cure the condition within the 30 day period, your Termination Date shall occur on the 31st day following the Company’s receipt of such written notice.
(2)    “Termination without Cause” means the involuntary termination of your employment or contractual relationship by the Company without Cause, including, but not limited to, (i) a termination effective when you exhaust a leave of absence during, or at the end of, a notice period under the Worker Adjustment and Retraining Notification Act (“WARN”), and (ii) a situation where you are on an approved leave of absence during which your position is protected under applicable law (e.g., a leave under the Family Medical Leave Act), you return from such leave, and you cannot be placed in employment or other form of contractual relationship with the Company.
1.3    Method of Exercise. The vested Option, or any part of it, shall be exercised by written notice directed to the President, Chief Financial Officer or Secretary of the Company at the Company’s principal office in Allegan, Michigan, or by using other notification permitted by the Company. Such notice must satisfy the following requirements:
(a)    The notice must state the Grant Date, the number of Ordinary Shares subject to the Option, the number of Ordinary Shares with respect to which Option is being exercised, the person in whose name the stock certificate or certificates for such Ordinary Shares is to be registered and the person’s address and Social Security number (or if more than one person, the names, addresses and Social Security numbers of such persons).
(b)    The notice shall be accompanied by check, bank draft, money order or other cash payment, or by delivery of a certificate or certificates, properly endorsed, for Ordinary Shares that you have held for at least six months and that are equivalent in Fair Market Value on the date of exercise to the Option Price (or any combination of cash and shares), in full payment of the Option Price for the number of shares specified in the notice.
(c)    The notice must be signed by the person or persons entitled to exercise the Option and, if the Option is being exercised by any person or persons other than you, be accompanied by proof, satisfactory to the Committee, of the right of such person or persons to exercise the Option.
(d)    The Company may implement procedures for the electronic exercise of this Option, in which case the vested portion of this Option shall be exercisable in accordance with such procedures.
SECTION 2
General Terms and Conditions
2.1    Nontransferability. The Award under this Agreement shall not be transferable other than by will or by the laws of descent and distribution. During your lifetime, the Option granted under this Agreement shall be exercisable only by you or by your guardian or legal representative in the event of your Disability.
2.2    No Rights as a Stockholder. You shall not have any rights as a stockholder with respect to any Ordinary Shares subject to the Option prior to the date of issuance to you of a certificate or certificates for such shares.
2.3    Cause Termination. If your Termination Date occurs for reasons of Cause, all of your rights under this Agreement, whether or not vested, shall terminate immediately.
2.4    Awards Subject to Plan. The granting of the Award under this Agreement is being made pursuant to the Plan and the Award shall be exercisable only in accordance with the applicable terms of the Plan. The Plan contains certain definitions, restrictions, limitations and other terms and conditions all of which shall be applicable to this Agreement. ALL THE PROVISIONS OF THE PLAN ARE INCORPORATED HEREIN BY REFERENCE AND ARE MADE A PART OF THIS AGREEMENT IN THE SAME MANNER AS IF EACH AND EVERY SUCH PROVISION WERE FULLY WRITTEN INTO THIS AGREEMENT. Should the Plan become void or unenforceable by operation of law or judicial decision, this Agreement shall have no force or effect. Nothing set forth in this Agreement is intended, nor shall any of its provisions be construed, to limit or exclude any definition, restriction, limitation or other term or condition of the Plan as is relevant to this Agreement and as may be specifically applied to it by the Committee. In the event of a conflict in the provisions of this Agreement and the Plan, as a rule of construction the terms of the Plan shall be deemed superior and apply.
2.5    Adjustments in Event of Change in Ordinary Shares. In the event of a stock split, stock dividend, recapitalization, reclassification or combination of shares, merger, sale of assets or similar event, the number and kind of shares subject to Award under this Agreement, and the exercise price thereof, will be appropriately adjusted in an equitable manner to prevent dilution or enlargement of the rights granted to or available for you.
2.6    Withholding. This Award is subject to the withholding of all applicable taxes. The Company may withhold, or permit you to remit to the Company, any Federal, state or local taxes applicable to the grant, vesting or other event giving rise to tax liability with respect to this Award. If you have not remitted the full amount of applicable withholding taxes to the Company by the date the Company is required to pay such withholding to the appropriate taxing authority (or such earlier date that the Company may specify to assist it in timely meeting its withholding obligations), the Company shall have the unilateral right to withhold Ordinary Shares relating to this Award in the amount it determines is sufficient to satisfy the tax withholding required by law. State taxes will be withheld at the appropriate rate set by the state in which you are employed or were last employed by the Company. In no event may the number of shares withheld exceed the number necessary to satisfy the maximum Federal, state and local income and employment tax withholding requirements. You may elect to surrender previously acquired Ordinary Shares or to have the Company withhold Ordinary Shares relating to this Award in an amount sufficient to satisfy all or a portion of the tax withholding required by law.
2.7    Compliance with Applicable Law. Notwithstanding any other provision of this Agreement, the Company shall have no obligation to issue any Ordinary Shares under this Agreement if such issuance would violate any applicable law or any applicable regulation or requirement of any securities exchange or similar entity.
2.8    Data Privacy. By entering into this Agreement and accepting this Award, you (a) explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of any of your personal data that is necessary to facilitate the implementation, administration and management of the Award and the Plan, (b) understand that the Company may, for the purpose of implementing, administering and managing the Plan, hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, and details of all awards or entitlements to Shares granted to you under the Plan or otherwise (“Data”), (c) understand that Data may be transferred to any third parties assisting in the implementation, administration and management of the Plan, including any broker with whom the Shares issued upon vesting or exercise of the Award may be deposited, and that these recipients may be located in your country or elsewhere, and that the recipient’s country may have different data privacy laws and protections than your country, (d) waive any data privacy rights you may have with respect to the data, and (e) authorize the Company, its subsidiaries and its agents, to store and transmit such information in electronic form.
2.9    Successors and Assigns. This Agreement shall be binding upon any or all successors and assigns of the Company.
2.10    Applicable Law. This Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of Michigan without regard to principals of conflict of laws. Any proceeding related to or arising out of this Agreement shall be commenced, prosecuted or continued in the Circuit Court in Kent County, Michigan located in Grand Rapids, Michigan or in the United Stated District Court for the Western District of Michigan, and in any appellate court thereof.
2.11    Repayment of Option Gain/Forfeiture of Options. If the Company, as a result of misconduct, is required to prepare an accounting restatement due to material noncompliance with any financial reporting requirement under the securities laws, then (a) if your equity compensation is subject to automatic forfeiture due to such misconduct and restatement under Section 304 of the Sarbanes-Oxley Act of 2002, or (b) the Committee determines you either knowingly engaged in or failed to prevent the misconduct, or your actions or inactions with respect to the misconduct and restatement constituted gross negligence, you shall (i) be required to reimburse the Company for any gain associated with any Option exercised during the twelve month period following the first public issuance or filing with the SEC (whichever first occurred) of the financial document embodying such financial reporting requirement, and (ii) any outstanding Options shall be immediately forfeited.

****
We look forward to your continuing contribution to the growth of the Company. Please acknowledge your receipt of the Plan and this Award.
Very truly yours,





Print Name: ___________________________
Title:_________________________________



 
 EX-31.1 6 cy17q310qex311.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1
CERTIFICATION
I, John T. Hendrickson, certify that:
1.
I have reviewed this report on Form 10-Q of Perrigo Company plc;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors:
a.
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 9, 2017
/s/ John T. Hendrickson
John T. Hendrickson
Chief Executive Officer
 



 EX-31.2 7 cy17q310qex312.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2
CERTIFICATION
I, Ronald L. Winowiecki, certify that:
1.
I have reviewed this report on Form 10-Q of Perrigo Company plc;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors:
a.
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 9, 2017
/s/ Ronald L. Winowiecki
Ronald L. Winowiecki
Acting Chief Financial Officer
 



 EX-32 8 cy17q310qex32.htm EXHIBIT 32 Exhibit


Exhibit 32
The following statement is being made to the Securities and Exchange Commission solely for the purposes of Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350), which carries with it certain criminal penalties in the event of a knowing or willful misrepresentation.
Securities and Exchange Commission
450 Fifth Street NW
Washington, D.C. 20549
 
Re:
Perrigo Company plc

Ladies and Gentlemen:
In accordance with the requirements of Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350), each of the undersigned hereby certifies that:
(i)
this Quarterly Report on Form 10-Q fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and
(ii)
the information contained in this report fairly presents, in all material respects, the financial condition and results of operations of Perrigo Company plc.


 
 
 
 
Date:
November 9, 2017
 
/s/ John T. Hendrickson
 
 
 
John T. Hendrickson
 
 
 
Chief Executive Officer
 
 
 
(Principal Executive Officer)
 
 
 
 
Date:
November 9, 2017
 
/s/ Ronald L. Winowiecki
 
 
 
Ronald L. Winowiecki
 
 
 
Acting Chief Financial Officer
 
 
 





 EX-101.INS 9 prgo-20170930.xml XBRL INSTANCE DOCUMENT 0001585364 2017-01-01 2017-09-30 0001585364 2017-09-30 0001585364 2016-01-01 2016-10-01 0001585364 2017-07-02 2017-09-30 0001585364 2016-07-03 2016-10-01 0001585364 2016-12-31 0001585364 2015-12-31 0001585364 2016-10-01 0001585364 prgo:CHCIMember 2017-08-25 2017-08-25 0001585364 prgo:ConsumerHealthcareAmericasMember 2017-02-01 2017-02-01 0001585364 prgo:ConsumerHealthcareAmericasMember 2016-08-05 2016-08-05 0001585364 prgo:RXPharmaceuticalsMember 2017-01-03 2017-01-03 0001585364 currency:EUR prgo:CHCIMember 2017-08-25 2017-08-25 0001585364 prgo:ConsumerHealthcareAmericasMember 2016-01-01 2016-12-31 0001585364 prgo:CHCIMember 2017-04-02 2017-07-01 0001585364 prgo:OtherMember 2016-01-01 2016-12-31 0001585364 prgo:OtherMember 2017-04-06 2017-04-06 0001585364 prgo:CHCIMember 2017-09-30 0001585364 prgo:RXPharmaceuticalsMember 2017-09-30 0001585364 prgo:CHCIMember 2016-12-31 0001585364 prgo:OtherMember 2016-12-31 0001585364 prgo:RXPharmaceuticalsMember 2016-12-31 0001585364 prgo:ConsumerHealthcareAmericasMember 2017-01-01 2017-09-30 0001585364 prgo:OtherMember 2017-01-01 2017-09-30 0001585364 prgo:CHCIMember 2017-01-01 2017-09-30 0001585364 prgo:OtherMember 2017-09-30 0001585364 prgo:ConsumerHealthcareAmericasMember 2016-12-31 0001585364 prgo:RXPharmaceuticalsMember 2017-01-01 2017-09-30 0001585364 prgo:ConsumerHealthcareAmericasMember 2017-09-30 0001585364 us-gaap:InProcessResearchAndDevelopmentMember 2017-01-01 2017-09-30 0001585364 prgo:BCHROWMember prgo:CHCIMember 2016-07-03 2016-10-01 0001585364 prgo:CHCIMember 2016-01-01 2016-04-02 0001585364 prgo:OmegaMember prgo:BrandsMember 2016-01-01 2016-04-02 0001585364 prgo:BCHBelgiumMember prgo:CHCIMember 2016-07-03 2016-10-01 0001585364 2016-04-03 0001585364 prgo:OmegaMember prgo:BrandsMember 2016-07-03 2016-10-01 0001585364 prgo:OmegaMember prgo:BrandsMember 2016-01-01 2016-10-01 0001585364 us-gaap:NoncompeteAgreementsMember 2017-09-30 0001585364 us-gaap:CustomerRelationshipsMember 2017-09-30 0001585364 us-gaap:TrademarksMember 2016-12-31 0001585364 us-gaap:DevelopedTechnologyRightsMember 2017-09-30 0001585364 us-gaap:LicensingAgreementsMember 2017-09-30 0001585364 us-gaap:InProcessResearchAndDevelopmentMember 2016-12-31 0001585364 us-gaap:TrademarksMember 2016-12-31 0001585364 us-gaap:CustomerRelationshipsMember 2016-12-31 0001585364 us-gaap:TrademarksMember 2017-09-30 0001585364 us-gaap:NoncompeteAgreementsMember 2016-12-31 0001585364 us-gaap:DevelopedTechnologyRightsMember 2016-12-31 0001585364 us-gaap:LicensingAgreementsMember 2016-12-31 0001585364 us-gaap:InProcessResearchAndDevelopmentMember 2017-09-30 0001585364 us-gaap:TrademarksMember 2017-09-30 0001585364 us-gaap:MaximumMember 2017-09-30 0001585364 us-gaap:MinimumMember 2017-09-30 0001585364 us-gaap:AccountsReceivableMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-07-02 2017-09-30 0001585364 us-gaap:AccountsReceivableMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-01-01 2017-09-30 0001585364 us-gaap:AccountsReceivableMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001585364 us-gaap:AccountsReceivableMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-09-30 0001585364 us-gaap:AccountsReceivableMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-07-01 0001585364 prgo:LumaraClindesseMember 2017-01-01 2017-09-30 0001585364 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001585364 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-09-30 0001585364 us-gaap:FairValueInputsLevel3Member us-gaap:ContingentConsiderationClassifiedAsEquityMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001585364 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember 2016-12-31 0001585364 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-09-30 0001585364 us-gaap:FairValueInputsLevel3Member us-gaap:ContingentConsiderationClassifiedAsEquityMember us-gaap:FairValueMeasurementsRecurringMember 2017-09-30 0001585364 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember 2017-09-30 0001585364 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001585364 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001585364 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-09-30 0001585364 prgo:OmegaLifestyleMember 2016-01-01 2016-12-31 0001585364 us-gaap:TrademarksAndTradeNamesMember 2016-01-01 2016-12-31 0001585364 prgo:OmegaXLSMember 2016-01-01 2016-12-31 0001585364 prgo:EntocortAGProductsMember 2016-01-01 2016-12-31 0001585364 prgo:EntocortBrandedProductsMember 2016-01-01 2016-12-31 0001585364 us-gaap:FairValueInputsLevel3Member us-gaap:ContingentConsiderationClassifiedAsEquityMember us-gaap:FairValueMeasurementsRecurringMember 2016-01-01 2016-10-01 0001585364 us-gaap:FairValueInputsLevel3Member us-gaap:ContingentConsiderationClassifiedAsEquityMember us-gaap:FairValueMeasurementsRecurringMember 2017-01-01 2017-09-30 0001585364 us-gaap:FairValueInputsLevel3Member us-gaap:ContingentConsiderationClassifiedAsEquityMember us-gaap:FairValueMeasurementsRecurringMember 2016-07-02 0001585364 us-gaap:FairValueInputsLevel3Member us-gaap:ContingentConsiderationClassifiedAsEquityMember us-gaap:FairValueMeasurementsRecurringMember 2016-07-03 2016-10-01 0001585364 us-gaap:FairValueInputsLevel3Member us-gaap:ContingentConsiderationClassifiedAsEquityMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0001585364 us-gaap:FairValueInputsLevel3Member us-gaap:ContingentConsiderationClassifiedAsEquityMember us-gaap:FairValueMeasurementsRecurringMember 2016-10-01 0001585364 us-gaap:FairValueInputsLevel3Member us-gaap:ContingentConsiderationClassifiedAsEquityMember us-gaap:FairValueMeasurementsRecurringMember 2017-07-01 0001585364 us-gaap:FairValueInputsLevel3Member us-gaap:ContingentConsiderationClassifiedAsEquityMember us-gaap:FairValueMeasurementsRecurringMember 2017-07-02 2017-09-30 0001585364 us-gaap:GoodwillMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0001585364 prgo:RoyaltyPharmaMember 2017-04-02 2017-07-01 0001585364 2015-09-27 2015-12-31 0001585364 prgo:TysabriMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0001585364 2016-10-02 2016-12-31 0001585364 prgo:RetailBondsMember 2017-09-30 0001585364 prgo:RoyaltyPharmaMember 2017-03-27 2017-03-27 0001585364 prgo:RetailBondsMember us-gaap:FairValueInputsLevel2Member 2016-12-31 0001585364 us-gaap:GoodwillMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0001585364 prgo:PublicBondsandPrivatePlacementMember 2016-12-31 0001585364 prgo:RoyaltyPharmaMember 2016-12-31 0001585364 2016-01-01 2016-04-02 0001585364 prgo:SpecialtySciencesMember 2017-03-27 2017-03-27 0001585364 2016-10-02 0001585364 prgo:RetailBondsMember 2016-12-31 0001585364 prgo:RoyaltyPharmaMember 2017-07-02 2017-09-30 0001585364 prgo:RXPharmaceuticalsMember 2017-07-01 0001585364 prgo:PublicBondsandPrivatePlacementMember 2017-09-30 0001585364 prgo:ElanCorporationMember 2013-12-18 2013-12-18 0001585364 2016-04-03 2016-07-02 0001585364 prgo:TysabriMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0001585364 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember 2017-07-01 0001585364 prgo:RetailBondsMember us-gaap:FairValueInputsLevel2Member 2017-09-30 0001585364 prgo:TysabriMember 2013-04-30 2014-05-01 0001585364 prgo:PublicBondsandPrivatePlacementMember us-gaap:FairValueInputsLevel1Member 2017-09-30 0001585364 prgo:PublicBondsandPrivatePlacementMember us-gaap:FairValueInputsLevel1Member 2016-12-31 0001585364 2016-01-01 2016-12-31 0001585364 us-gaap:AvailableforsaleSecuritiesMember 2017-09-30 0001585364 us-gaap:AvailableforsaleSecuritiesMember 2016-12-31 0001585364 us-gaap:OtherNoncurrentAssetsMember 2016-12-31 0001585364 us-gaap:OtherNoncurrentAssetsMember 2017-09-30 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SalesRevenueGoodsNetMember 2016-07-03 2016-10-01 0001585364 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2016-07-03 2016-10-01 0001585364 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2016-07-03 2016-10-01 0001585364 us-gaap:DesignatedAsHedgingInstrumentMember 2016-01-01 2016-10-01 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2017-07-02 2017-09-30 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2017-01-01 2017-09-30 0001585364 us-gaap:TreasuryLockMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2017-07-02 2017-09-30 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2016-01-01 2016-10-01 0001585364 us-gaap:DesignatedAsHedgingInstrumentMember 2017-07-02 2017-09-30 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2016-01-01 2016-10-01 0001585364 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2017-01-01 2017-09-30 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SalesRevenueGoodsNetMember 2017-01-01 2017-09-30 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2016-07-03 2016-10-01 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2017-01-01 2017-09-30 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2017-07-02 2017-09-30 0001585364 us-gaap:TreasuryLockMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2016-01-01 2016-10-01 0001585364 us-gaap:TreasuryLockMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2016-07-03 2016-10-01 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2017-01-01 2017-09-30 0001585364 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2016-01-01 2016-10-01 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SalesRevenueGoodsNetMember 2016-01-01 2016-10-01 0001585364 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2016-01-01 2016-10-01 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2016-01-01 2016-10-01 0001585364 us-gaap:DesignatedAsHedgingInstrumentMember 2016-07-03 2016-10-01 0001585364 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2017-07-02 2017-09-30 0001585364 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2017-07-02 2017-09-30 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2016-07-03 2016-10-01 0001585364 us-gaap:TreasuryLockMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2017-01-01 2017-09-30 0001585364 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2017-01-01 2017-09-30 0001585364 us-gaap:DesignatedAsHedgingInstrumentMember 2017-01-01 2017-09-30 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2017-07-02 2017-09-30 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SalesRevenueGoodsNetMember 2017-07-02 2017-09-30 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2016-07-03 2016-10-01 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2017-01-01 2017-09-30 0001585364 us-gaap:NondesignatedMember 2016-07-03 2016-10-01 0001585364 us-gaap:NondesignatedMember 2017-01-01 2017-09-30 0001585364 us-gaap:NondesignatedMember 2016-01-01 2016-10-01 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2016-07-03 2016-10-01 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2016-01-01 2016-10-01 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:InterestExpenseMember 2017-07-02 2017-09-30 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2017-07-02 2017-09-30 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:InterestExpenseMember 2016-01-01 2016-10-01 0001585364 us-gaap:NondesignatedMember 2017-07-02 2017-09-30 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:InterestExpenseMember 2016-07-03 2016-10-01 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:InterestExpenseMember 2017-01-01 2017-09-30 0001585364 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2017-09-30 0001585364 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-12-31 0001585364 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-09-30 0001585364 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2016-12-31 0001585364 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2015-12-31 0001585364 us-gaap:ForeignExchangeContractMember 2016-12-31 0001585364 prgo:A5.30UnsecuredSeniorNotesdueNovember152043Member 2017-06-14 2017-06-14 0001585364 us-gaap:ForeignExchangeForwardMember 2017-01-01 2017-09-30 0001585364 us-gaap:ForeignExchangeContractMember 2017-09-30 0001585364 prgo:A4.00UnsecuredSeniorNotesdueNovember152023Member 2017-06-14 2017-06-14 0001585364 2017-04-02 2017-07-01 0001585364 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-07-03 2016-10-01 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-01-01 2017-09-30 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-07-02 2017-09-30 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-07-03 2016-10-01 0001585364 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-01-01 2017-09-30 0001585364 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-07-02 2017-09-30 0001585364 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-01-01 2016-10-01 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-01-01 2016-10-01 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:OtherNonoperatingIncomeExpenseMember 2016-07-03 2016-10-01 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:OtherNonoperatingIncomeExpenseMember 2017-07-02 2017-09-30 0001585364 us-gaap:InterestRateSwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2016-07-03 2016-10-01 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:SalesRevenueGoodsNetMember 2017-07-02 2017-09-30 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:CostOfSalesMember 2017-07-02 2017-09-30 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:SalesRevenueGoodsNetMember 2016-01-01 2016-10-01 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:CostOfSalesMember 2016-07-03 2016-10-01 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:SalesRevenueGoodsNetMember 2016-07-03 2016-10-01 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:OtherNonoperatingIncomeExpenseMember 2017-01-01 2017-09-30 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:CostOfSalesMember 2017-01-01 2017-09-30 0001585364 us-gaap:InterestRateSwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2017-01-01 2017-09-30 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:CostOfSalesMember 2016-01-01 2016-10-01 0001585364 us-gaap:InterestRateSwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2017-07-02 2017-09-30 0001585364 us-gaap:InterestRateSwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2016-01-01 2016-10-01 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:OtherNonoperatingIncomeExpenseMember 2016-01-01 2016-10-01 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:SalesRevenueGoodsNetMember 2017-01-01 2017-09-30 0001585364 us-gaap:OtherLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-09-30 0001585364 us-gaap:OtherLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2016-12-31 0001585364 us-gaap:OtherLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2017-09-30 0001585364 us-gaap:OtherLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-12-31 0001585364 prgo:OtherMember 2017-07-02 2017-09-30 0001585364 prgo:AnimalHealthpettreatsMember prgo:ConsumerHealthcareAmericasMember 2016-01-01 2016-12-31 0001585364 prgo:APIMember prgo:OtherMember 2016-01-01 2016-12-31 0001585364 us-gaap:DiscontinuedOperationsHeldforsaleMember prgo:OtherMember 2017-09-30 0001585364 us-gaap:DiscontinuedOperationsHeldforsaleMember prgo:ConsumerHealthcareAmericasMember 2016-12-31 0001585364 us-gaap:DiscontinuedOperationsHeldforsaleMember prgo:OtherMember 2016-12-31 0001585364 us-gaap:DiscontinuedOperationsHeldforsaleMember prgo:ConsumerHealthcareAmericasMember 2016-01-01 2016-12-31 0001585364 us-gaap:DiscontinuedOperationsHeldforsaleMember prgo:OtherMember 2016-01-01 2016-12-31 0001585364 us-gaap:DiscontinuedOperationsHeldforsaleMember prgo:OtherMember 2017-01-01 2017-09-30 0001585364 prgo:A2014RevolverMember 2014-12-05 0001585364 prgo:A2014EuroDenominatedTermLoandueDecember52019Member 2017-01-01 2017-09-30 0001585364 prgo:A4.9SeniorLoandue2044Member 2017-06-15 2017-06-15 0001585364 prgo:OmegaMember currency:EUR prgo:A4.5RetailBondMember 2017-01-01 2017-09-30 0001585364 prgo:A2.30UnsecuredSeniornotesNovember82018Member 2017-05-08 2017-05-08 0001585364 prgo:OmegaMember prgo:A4.5RetailBondMember 2017-05-23 2017-05-23 0001585364 prgo:A4.9SeniorLoandue2044Member 2017-01-01 2017-09-30 0001585364 prgo:A5.30UnsecuredSeniorNotesdueNovember152043Member 2017-01-01 2017-09-30 0001585364 prgo:A2014EuroDenominatedTermLoandueDecember52019Member 2017-01-01 2017-04-01 0001585364 prgo:A5.30UnsecuredSeniorNotesdueNovember152043Member 2017-06-15 2017-06-15 0001585364 prgo:A2.30UnsecuredSeniornotesNovember82018Member 2017-01-01 2017-09-30 0001585364 prgo:A3.500UnsecuredSeniornotesdueMarch152021Domain 2017-06-15 2017-06-15 0001585364 prgo:A4.00UnsecuredSeniorNotesdueNovember152023Member 2017-06-15 2017-06-15 0001585364 prgo:A2014EuroDenominatedTermLoandueDecember52019Member 2017-04-02 2017-07-01 0001585364 prgo:A3.5SeniornotedueDecember152021Member 2017-01-01 2017-09-30 0001585364 prgo:A4.00UnsecuredSeniorNotesdueNovember152023Member 2017-01-01 2017-09-30 0001585364 prgo:A4.5RetailBondMember 2017-05-23 2017-05-23 0001585364 prgo:A3.500UnsecuredSeniornotesdueMarch152021Domain 2017-01-01 2017-09-30 0001585364 prgo:A2014EuroDenominatedTermLoandueDecember52019Member 2017-07-02 2017-09-30 0001585364 prgo:A3.5SeniornotedueDecember152021Member 2017-06-15 2017-06-15 0001585364 prgo:OmegaMember prgo:A4.5RetailBondMember 2017-01-01 2017-09-30 0001585364 prgo:A2.30UnsecuredSeniornotesNovember82018Member 2017-09-30 0001585364 prgo:A5.105SeniornotedueJuly192023Domain 2016-12-31 0001585364 prgo:A5.105SeniornotedueJuly192023Domain 2017-01-01 2017-09-30 0001585364 prgo:A3.500UnsecuredSeniornotesdueMarch152021Domain 2016-12-31 0001585364 prgo:A5.105SeniornotedueJuly192023Domain 2017-09-30 0001585364 prgo:A2.30UnsecuredSeniornotesNovember82018Member 2016-12-31 0001585364 prgo:A4.00UnsecuredSeniorNotesdueNovember152023Member 2017-09-30 0001585364 prgo:A4.500UnsecuredSeniorNotesdueMay232017Domain 2017-09-30 0001585364 prgo:A4.375seniornotedueMarch152026Member 2017-09-30 0001585364 prgo:A5.125UnsecuredSeniorNotesdueDecember122017Domain 2017-09-30 0001585364 prgo:A5.000UnsecuredSeniornotesdueMay232019Domain 2016-12-31 0001585364 prgo:A5.125UnsecuredSeniorNotesdueDecember122017Domain 2017-01-01 2017-09-30 0001585364 prgo:A5.000UnsecuredSeniornotesdueMay232019Domain 2017-09-30 0001585364 prgo:A3.9seniornotedue2024Member 2017-01-01 2017-09-30 0001585364 prgo:A5.30UnsecuredSeniorNotesdueNovember152043Member 2017-09-30 0001585364 prgo:A4.500UnsecuredSeniorNotesdueMay232017Domain 2016-12-31 0001585364 prgo:A5.125UnsecuredSeniorNotesdueDecember122017Domain 2016-12-31 0001585364 prgo:A3.500UnsecuredSeniornotesdueMarch152021Domain 2017-09-30 0001585364 prgo:A5.30UnsecuredSeniorNotesdueNovember152043Member 2016-12-31 0001585364 prgo:A4.9SeniorLoandue2044Member 2017-09-30 0001585364 prgo:A4.9SeniorLoandue2044Member 2016-12-31 0001585364 prgo:A4.00UnsecuredSeniorNotesdueNovember152023Member 2016-12-31 0001585364 prgo:A3.9seniornotedue2024Member 2016-12-31 0001585364 prgo:A2014EuroDenominatedTermLoandueDecember52019Member 2017-09-30 0001585364 prgo:A3.9seniornotedue2024Member 2017-09-30 0001585364 prgo:A2014EuroDenominatedTermLoandueDecember52019Member 2016-12-31 0001585364 prgo:A4.375seniornotedueMarch152026Member 2016-12-31 0001585364 prgo:A5.000UnsecuredSeniornotesdueMay232019Domain 2017-01-01 2017-09-30 0001585364 prgo:A4.500UnsecuredSeniorNotesdueMay232017Domain 2017-01-01 2017-09-30 0001585364 prgo:A3.5SeniornotedueDecember152021Member 2016-12-31 0001585364 prgo:A3.5SeniornotedueDecember152021Member 2017-09-30 0001585364 prgo:A4.375seniornotedueMarch152026Member 2017-01-01 2017-09-30 0001585364 prgo:OverdraftMember 2017-09-30 0001585364 prgo:OverdraftMember 2016-12-31 0001585364 us-gaap:CommonStockMember 2017-07-02 2017-09-30 0001585364 prgo:PerrigoCoPLCMember 2015-10-22 0001585364 us-gaap:CommonStockMember 2017-01-01 2017-09-30 0001585364 us-gaap:CommonStockMember 2016-01-01 2016-10-01 0001585364 us-gaap:AccumulatedTranslationAdjustmentMember 2017-01-01 2017-09-30 0001585364 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-01-01 2017-09-30 0001585364 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2017-09-30 0001585364 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2017-01-01 2017-09-30 0001585364 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-01-01 2017-09-30 0001585364 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-09-30 0001585364 us-gaap:AccumulatedTranslationAdjustmentMember 2017-09-30 0001585364 us-gaap:AccumulatedTranslationAdjustmentMember 2016-12-31 0001585364 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2016-12-31 0001585364 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2016-12-31 0001585364 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-09-30 0001585364 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-12-31 0001585364 2012-01-01 2012-12-31 0001585364 2011-01-01 2011-12-31 0001585364 2009-01-01 2009-12-31 0001585364 2010-01-01 2010-12-31 0001585364 2017-08-15 2017-08-15 0001585364 2017-06-28 2017-06-28 0001585364 2017-03-29 2017-03-29 0001585364 us-gaap:ContractTerminationMember 2017-09-30 0001585364 prgo:CHCAMember 2017-01-01 2017-09-30 0001585364 us-gaap:EmployeeSeveranceMember 2017-09-30 0001585364 2017-07-01 0001585364 2016-07-02 0001585364 us-gaap:AllOtherSegmentsMember 2016-12-31 0001585364 prgo:SpecialtySciencesMember 2017-09-30 0001585364 prgo:SpecialtySciencesMember 2016-12-31 0001585364 us-gaap:AllOtherSegmentsMember 2017-09-30 0001585364 prgo:ConsumerHealthcareAmericasMember 2016-07-03 2016-10-01 0001585364 prgo:SpecialtySciencesMember 2017-07-02 2017-09-30 0001585364 prgo:SpecialtySciencesMember 2016-07-03 2016-10-01 0001585364 us-gaap:AllOtherSegmentsMember 2017-07-02 2017-09-30 0001585364 prgo:CHCIMember 2016-07-03 2016-10-01 0001585364 prgo:CHCIMember 2017-07-02 2017-09-30 0001585364 prgo:RXPharmaceuticalsMember 2016-07-03 2016-10-01 0001585364 us-gaap:MaterialReconcilingItemsMember 2016-07-03 2016-10-01 0001585364 us-gaap:MaterialReconcilingItemsMember 2017-07-02 2017-09-30 0001585364 prgo:RXPharmaceuticalsMember 2017-07-02 2017-09-30 0001585364 us-gaap:AllOtherSegmentsMember 2016-07-03 2016-10-01 0001585364 prgo:ConsumerHealthcareAmericasMember 2017-07-02 2017-09-30 0001585364 us-gaap:AllOtherSegmentsMember 2017-01-01 2017-09-30 0001585364 prgo:RXPharmaceuticalsMember 2016-01-01 2016-10-01 0001585364 prgo:SpecialtySciencesMember 2017-01-01 2017-09-30 0001585364 prgo:ConsumerHealthcareAmericasMember 2016-01-01 2016-10-01 0001585364 us-gaap:MaterialReconcilingItemsMember 2017-01-01 2017-09-30 0001585364 us-gaap:MaterialReconcilingItemsMember 2016-01-01 2016-10-01 0001585364 prgo:CHCIMember 2016-01-01 2016-10-01 0001585364 us-gaap:AllOtherSegmentsMember 2016-01-01 2016-10-01 0001585364 prgo:SpecialtySciencesMember 2016-01-01 2016-10-01 xbrli:shares prgo:segments iso4217:USD xbrli:shares xbrli:pure iso4217:EUR xbrli:shares iso4217:USD iso4217:EUR iso4217:ILS false --12-31 Q3 2017 2017-09-30 10-Q 0001585364 140840721 Yes Large Accelerated Filer PERRIGO CO PLC No Yes 200000000 533500000 578300000 50700000 24300000 380300000 368800000 250000000 400000000 572800000 417100000 2017-06-15 2017-06-15 2017-06-15 2017-06-15 2017-06-15 2017-05-23 2017-05-08 2017-04-01 2017-07-01 2017-09-30 Scheduled maturity Early redemption Scheduled quarterly payment Tender offer Tender offer Tender offer Tender offer Tender offer 0 0 0 0.0805 0.0806 0.020 -0.304 -0.317 0.025 0.032 0.046 0.034 0.020 -0.041 0.040 0.110 2350000000 2350000000 0 0 0.0015 0.0014 15900000 16100000 17000000 4163900000 4255400000 -73700000 -15800000 0.12 0.25 0.18 116100000 84400000 20 2850000000 0 1858705 2670889 3800000 398000000 454900000 4700000 71.73 71.72 471700000 477100000 1176000000 1076600000 32400000 61500000 263300000 274600000 -81800000 -9500000 -19500000 15100000 -67900000 191200000 -10700000 -10800000 -9300000 222000000 576200000 607200000 6300000 6200000 -24600000 -18400000 89700000 263900000 130600000 53300000 78600000 0 1400000 0 44400000 17600000 27200000 0 500000 0 88500000 50200000 16900000 21000000 0 400000 0 261300000 143400000 51100000 65600000 0 1200000 0 0 0 1000000 800000 1614400000 2028800000 7800000 47400000 13870100000 4795200000 3351300000 2646400000 2775800000 301400000 11842600000 5114200000 3833700000 2597000000 0 297700000 2805300000 2971800000 19700000 1924900000 2350000000 29200000 119900000 143200000 18200000 95100000 11064800000 8870800000 9800000 12300000 127800000 0 5100000 44000000 21700000 0 0 9400000 16500000 15500000 38200000 6100000 1600000 2013-12-18 417800000 362700000 622300000 775900000 -55100000 153600000 0 0 0.145 0.435 0.16 0.480 0.001 0.001 10000000000 10000000000 143400000 140800000 143400000 140800000 8135000000 7900100000 -1549500000 -2566900000 105200000 319400000 6900000 7200000 777100000 2385200000 733500000 2196400000 yes €180.0 4.500% retail bonds due 2017 $600.0 2.300% senior notes due 2018 2014 term loan due December 5, 2019 $500.0 3.500% senior notes due 2021 $500.0 3.500% senior notes due 2021 $800.0 4.000% senior notes due 2023 $400.0 4.900% senior notes due 2044 $400.0 5.300% senior notes due 2043 4600000000 825000000 2700000000 699200000 33100000 19000000 0.023 0.035 0.035 0.039 0.04 0.04375 0.045 0.049 0.050 0.051045 0.05125 0.053 2018-11-08 2021-03-15 2021-12-15 2024-12-15 2023-11-15 2026-03-15 2017-05-23 2044-12-15 2019-05-23 2023-07-19 2017-12-12 2043-11-15 -33000000 -24800000 49800000 35600000 5797300000 3692800000 72100000 22400000 -674100000 -16300000 389900000 357700000 338400000 333100000 3100000 700000 4600000 8500000 3000000 2000000 2600000 700000 -7000000 -1500000 -8700000 -10200000 -1000000 -200000 -1200000 -5900000 -1800000 10100000 8300000 -2900000 -3800000 -6700000 1800000 -1300000 700000 300000 -1700000 0 -100000 -300000 900000 -400000 -1200000 -100000 -600000 0 0 -1400000 1800000 -700000 -1200000 0 -400000 0 0 -500000 3500000 -1800000 -1700000 900000 -1700000 -5900000 0 -6700000 0 600000 0 600000 100000 -100000 0 0 0 0 300000 100000 0 200000 0 1200000 100000 1000000 100000 0 4700000 -9000000 -4300000 3400000 0 3400000 1100000 0 1100000 6300000 0 6300000 0 5500000 32600000 0 0 5500000 0 1900000 25100000 0 3800000 3100000 13500000 33200000 45900000 -11.10 -18.53 0.31 0.33 -11.10 -18.53 0.31 0.32 -200000 20500000 0.164 0.172 0.655 0.687 115800000 133400000 22300000 4600000 4800000 0.300 0.300 0.145 0.070 0.105 0.130 0.093 0.095 0.108 0.135 0.030 0.020 -0.047 -0.100 0.020 0.025 0.3 0.8 -2900000 -42100000 0 184500000 0 145800000 143200000 100000 0 200000 1500000 -4000000 -400000 -2900000 -18500000 61100000 30600000 0 0 100000 100000 2100000 8000000 17900000 75000000 69900000 49700000 44900000 44900000 -204400000 -910800000 -377400000 -1492600000 1100000000 -2600000 -24200000 P20Y 1020400000 307500000 526000000 120400000 11200000 55300000 1274100000 424500000 568800000 157500000 12300000 111000000 758000000 11500000 11500000 4417200000 1489900000 1418100000 305600000 14300000 1189300000 2300000000 0 4621500000 1623700000 1355400000 310200000 14700000 1317500000 3396800000 3347400000 2800000 5000000 3300000 3800000 13100000 0.0028 17100000 -700000 -1100000 0 -135200000 105400000 317200000 123300000 326900000 4049400000 1070800000 1810600000 81400000 1086600000 4152000000 1189000000 1813500000 56400000 1093100000 1148400000 0 -139300000 -122300000 -2900000 -7600000 -6500000 2200000000 130500000 62300000 675600000 -32600000 0 0 -32600000 0 4100000 4100000 0 0 0 484500000 1564100000 497800000 1466700000 290900000 18500000 273400000 575700000 12700000 6300000 3700000 3700000 35300000 6200000 35300000 3700000 3300000 3300000 -1902000000 -3204400000 128700000 148200000 100000 -3800000 -100000 200000 37200000 61500000 40200000 24700000 163600000 -311800000 -550700000 84200000 101800000 -57700000 -6000000 -113000000 -38400000 5200000 -61500000 -90000000 -18800000 -40000000 -36700000 -25100000 28300000 127500000 125200000 9400000 -3500000 0 0 400000 300000 114500000 700000 64000000 50500000 103400000 26000000 51400000 52000000 674400000 300000 13300000 364500000 674200000 4531700000 4724900000 -54600000 -163200000 -34700000 -133100000 431100000 471400000 795000000 821900000 198200000 203700000 165700000 146800000 38200000 6100000 7912500000 5800800000 13870100000 11842600000 1836300000 1732500000 6076200000 4068300000 100000 3800000 32700000 100000 1900000 7600000 0 0 0 0 1000000000 420700000 428300000 773100000 655800000 572800000 417100000 5224500000 3275700000 760000000 2700000000 192000000 686000000 P18M -500000 100000 -234100000 -2621000000 -269500000 2272100000 448700000 482000000 -1590200000 -2653700000 44500000 46400000 7 1952800000 3079200000 335400000 1027100000 -1468300000 -1515100000 -2011300000 316400000 258300000 -1900000 2600000 -79200000 -1615500000 99000000 74400000 3200000 -1500000 -27900000 162400000 4600000 124300000 82100000 0 -400000 -48200000 439600000 8700000 303600000 239600000 0 9400000 -121700000 211900000 423300000 9800000 18400000 -8100000 -24400000 -200000 400000 -1200000 -1200000 3600000 -3500000 100000 8700000 27500000 71500000 69900000 289900000 270300000 -1200000 4400000 -22800000 289900000 40700000 86800000 60700000 273000000 -1200000 8700000 -24400000 289900000 461800000 434900000 3600000 2900000 -1000000 -32400000 3600000 1100000 34500000 -27200000 0 0 2900000 41000000 1800000 1000000 5800000 0 191500000 8600000 33300000 17800000 47600000 600000 116100000 62400000 68700000 2800000 4200000 436800000 0 65100000 0 84600000 55200000 0.0001 0.0001 10000000 10000000 0 0 212000000 297400000 61800000 58500000 7700000 15000000 2200000000 22200000 12700000 15100000 46700000 8200000 500000 1200000000 1190300000 0 -17400000 2700000 -803600000 0 133300000 191500000 259500000 86400000 0 2200000000 21600000 65900000 21500000 64200000 870100000 822300000 -2700000 0 -4300000 1600000 0 584400000 309500000 219600000 190400000 584400000 96100000 309500000 201300000 600000000 13300000 14300000 14800000 2243700000 545800000 2243700000 50200000 142500000 38400000 120800000 6600000 17900000 3800000 54700000 27200000 20700000 10300000 19700000 39700000 26100000 3700000 22400000 12200000 100000 5000000 400000 -700000 -2095100000 -2049600000 2000000000 2000000000 1261600000 3949300000 1232700000 1880200000 776900000 0 59500000 0 377400000 611200000 251900000 0 21100000 0 1231300000 365400000 598800000 250600000 0 16500000 0 3663100000 1116800000 1786400000 708400000 0 51500000 0 154600000 506900000 143500000 454100000 5373100000 600000000 500000000 500000000 700000000 800000000 700000000 189300000 400000000 126200000 142000000 315600000 400000000 4600000000 3255800000 0 280400000 309600000 700000000 215600000 700000000 0 303900000 141800000 159500000 354500000 90500000 2600000000 15300000 28100000 185000 283000 99800 146100 2000000000 1300000000 5958100000 6041700000 5957600000 6041800000 15500000 8700000 63500000 79000000 143300000 143200000 141700000 142800000 143300000 143200000 141300000 142500000 10600000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other intangible assets and related accumulated amortization consisted of the following (in millions):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:39%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Gross</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Gross</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Accumulated Amortization</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;text-decoration:underline;">Definite-lived intangibles</font><font style="font-family:Arial;font-size:9pt;">:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Distribution and license agreements, supply agreements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">310.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">157.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">305.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">120.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Developed product technology, formulations, and product rights</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,355.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">568.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,418.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">526.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Customer relationships and distribution networks</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,623.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">424.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,489.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">307.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Trademarks, trade names, and brands</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,317.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">111.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,189.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">55.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Non-compete agreements</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">14.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">12.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">14.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">11.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total definite-lived intangibles</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4,621.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,274.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4,417.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,020.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;text-decoration:underline;">Indefinite-lived intangibles</font><font style="font-family:Arial;font-size:9pt;">:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Trademarks, trade names, and brands</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">52.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">50.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">In-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">51.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">64.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total indefinite-lived intangibles</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">103.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">114.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total other intangible assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4,724.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,274.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4,531.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,020.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">During the </font><font style="font-family:Arial;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;">, we reduced our outstanding debt through a variety of transactions (in millions):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:37%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Series</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Transaction Type</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Principal Retired</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">April&#160;1, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2014 term loan due December 5, 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Scheduled quarterly payment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">13.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">July&#160;1, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2014 term loan due December 5, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Scheduled quarterly payment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">14.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">September&#160;30, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2014 term loan due December 5, 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Scheduled quarterly payment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">14.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">May&#160;8, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$600.0 2.300% senior notes due 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Early redemption</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">600.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">May&#160;23, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8364;180.0 4.500% retail bonds due 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Scheduled maturity</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">201.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">June&#160;15, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$500.0 3.500% senior notes due 2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Tender offer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">190.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">June&#160;15, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$500.0 3.500% senior notes due 2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Tender offer</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">219.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">June&#160;15, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$800.0 4.000% senior notes due 2023</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Tender offer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">584.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">June&#160;15, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$400.0 5.300% senior notes due 2043</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Tender offer</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">309.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">June&#160;15, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$400.0 4.900% senior notes due 2044</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Tender offer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">96.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,243.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The gains (losses) recognized against earnings for the ineffective portion of our designated cash flow hedges were as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:754px;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td style="width:200px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:165px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:79px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:79px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:79px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:79px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Amount of Gain/(Loss) Recognized against Earnings<br clear="none"/>(Ineffective Portion)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Designated Cash Flow Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Income Statement</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">October&#160;1, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">October&#160;1, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Interest rate swap agreements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Other (income) expense, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Net sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Cost of sales</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Other (income) expense, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Basis of Presentation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The unaudited Condensed Consolidated Financial Statements should be read in conjunction with the consolidated financial statements and footnotes included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:Arial;font-size:10pt;">December 31, 2016</font><font style="font-family:Arial;font-size:10pt;">. In the opinion of management, all adjustments (consisting of normal recurring accruals and other adjustments) considered necessary for a fair presentation of the unaudited Condensed Consolidated Financial Statements have been included</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">DIVESTITURES</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Current Year Divestitures</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On </font><font style="font-family:Arial;font-size:10pt;">January&#160;3, 2017</font><font style="font-family:Arial;font-size:10pt;">, we sold certain Abbreviated New Drug Applications ("ANDAs") for </font><font style="font-family:Arial;font-size:10pt;">$15.0 million</font><font style="font-family:Arial;font-size:10pt;"> to a third party, which was recorded as a gain in </font><font style="font-family:Arial;font-size:10pt;">Other operating income</font><font style="font-family:Arial;font-size:10pt;"> on the Condensed Consolidated Statements of Operations in our Prescription Pharmaceuticals ("RX") segment.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On </font><font style="font-family:Arial;font-size:10pt;">February&#160;1, 2017</font><font style="font-family:Arial;font-size:10pt;">, we completed the sale of the animal health pet treats plant fixed assets within our Consumer Healthcare Americas ("</font><font style="font-family:Arial;font-size:10pt;">CHCA</font><font style="font-family:Arial;font-size:10pt;">") segment, which were previously classified as held-for sale. We received </font><font style="font-family:Arial;font-size:10pt;">$7.7&#160;million</font><font style="font-family:Arial;font-size:10pt;"> in proceeds, which resulted in an immaterial loss.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On </font><font style="font-family:Arial;font-size:10pt;">April&#160;6, 2017</font><font style="font-family:Arial;font-size:10pt;">, we completed the sale of our India Active Pharmaceutical Ingredients ("API") business to Strides Shasun Limited. We received </font><font style="font-family:Arial;font-size:10pt;">$22.2&#160;million</font><font style="font-family:Arial;font-size:10pt;"> of proceeds, inclusive of an estimated working capital adjustment, which resulted in an immaterial gain recorded in our Other segment. Prior to closing the sale, we determined that the carrying value of the India API business exceeded its fair value less the cost to sell, resulting in an impairment charge of </font><font style="font-family:Arial;font-size:10pt;">$35.3&#160;million</font><font style="font-family:Arial;font-size:10pt;">, which was recorded in </font><font style="font-family:Arial;font-size:10pt;">Impairment charges</font><font style="font-family:Arial;font-size:10pt;"> on the Consolidated Statements of Operations for the year ended December 31, 2016.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On </font><font style="font-family:Arial;font-size:10pt;">August&#160;25, 2017</font><font style="font-family:Arial;font-size:10pt;">, we completed the sale of our Russian business, which was previously classified as held-for-sale, to Alvogen Pharma LLC and Alvogen CEE Kft. The total sale price was </font><font style="font-family:Arial;font-size:10pt;">&#8364;12.7 million</font><font style="font-family:Arial;font-size:10pt;"> (</font><font style="font-family:Arial;font-size:10pt;">$15.1 million</font><font style="font-family:Arial;font-size:10pt;">), inclusive of an estimated working capital adjustment, which resulted in an immaterial gain recorded in our </font><font style="font-family:Arial;font-size:10pt;">Consumer Healthcare International</font><font style="font-family:Arial;font-size:10pt;"> ("</font><font style="font-family:Arial;font-size:10pt;">CHCI</font><font style="font-family:Arial;font-size:10pt;">") segment. Prior to closing the sale, we determined that the carrying value of the Russian business exceeded its fair value less the cost to sell, resulting in an impairment charge of </font><font style="font-family:Arial;font-size:10pt;">$3.7&#160;million</font><font style="font-family:Arial;font-size:10pt;">, which was recorded in </font><font style="font-family:Arial;font-size:10pt;">Impairment charges</font><font style="font-family:Arial;font-size:10pt;"> on the Condensed Consolidated Statements of Operations for the three months ended July 1, 2017.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Prior Year Divestitures</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On </font><font style="font-family:Arial;font-size:10pt;">August&#160;5, 2016</font><font style="font-family:Arial;font-size:10pt;">, we completed the sale of our U.S. Vitamins, Minerals, and Supplements ("VMS") business within our </font><font style="font-family:Arial;font-size:10pt;">CHCA</font><font style="font-family:Arial;font-size:10pt;"> segment to International Vitamins Corporation ("IVC") for </font><font style="font-family:Arial;font-size:10pt;">$61.8 million</font><font style="font-family:Arial;font-size:10pt;"> inclusive of an estimated working capital adjustment. Prior to closing the sale, we determined that the carrying value of the VMS business exceeded its fair value less the cost to sell, resulting in an impairment charge of </font><font style="font-family:Arial;font-size:10pt;">$6.2&#160;million</font><font style="font-family:Arial;font-size:10pt;">, which was recorded in </font><font style="font-family:Arial;font-size:10pt;">Impairment charges</font><font style="font-family:Arial;font-size:10pt;"> on the Condensed Consolidated Statements of Operations for the year ended December 31, 2016.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">COMMITMENTS AND CONTINGENCIES</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In view of the inherent difficulties of predicting the outcome of various types of legal proceedings, we cannot determine the ultimate resolution of the matters described below.&#160;We establish reserves for litigation and regulatory matters when losses associated with the claims become probable and the amounts can be reasonably estimated.&#160;The actual costs of resolving legal matters may be substantially higher or lower than the amounts reserved for those matters.&#160;For matters where the likelihood or extent of a loss is not probable or cannot be reasonably estimated as of </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;">, we have not recorded a loss reserve. If certain of these matters are determined against us, there could be a material adverse effect on our financial condition, results of operations, or cash flows.&#160;We currently believe we have valid defenses to the claims in these lawsuits and intend to defend these lawsuits vigorously regardless of whether or not we have a loss reserve.&#160;Other than what is disclosed below, we do not expect the outcome of the litigation matters to which we are currently subject individually or in the aggregate, to have a material adverse effect on our financial condition, results of operations, or cash flows.&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Antitrust Violations</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have been named as a counterclaim co-defendant in the lawsuit </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Fera Pharmaceuticals, LLC v. Akorn, Inc., et al.</font><font style="font-family:Arial;font-size:10pt;">, in which Akorn, Inc. (&#8220;Akorn&#8221;) alleges tortious interference and antitrust violations against us and Fera Pharmaceuticals, LLC (&#8220;Fera&#8221;). This litigation arises from our acquisition of bacitracin ophthalmic ointment from Fera in 2013. Akorn asserts claims under Sections 1 and 2 of the Sherman Antitrust Act alleging that we and Fera conspired to monopolize, attempted to monopolize, and did unlawfully monopolize the market for sterile bacitracin ophthalmic ointment in the United States through the use of an exclusive agreement with a supplier of sterile bacitracin active pharmaceutical ingredient. The lawsuit is currently pending in the Southern District of New York. Trial was rescheduled from January 2018 to February 2018. Akorn seeks damages, injunctive relief, and attorney&#8217;s fees. Any award of antitrust damages would be subject to trebling under antitrust laws. An estimate of any possible loss cannot be determined at this time.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We believe the claims are without merit and intend to defend them vigorously. We have preserved our indemnification rights against Fera for potential liability, defense costs, and expenses incurred as a result of this litigation. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Price-Fixing Lawsuits</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have been named as a co-defendant with other manufacturers in a number of cases alleging that we and other manufacturers of the same product engaged in anti-competitive behavior to fix or raise the prices of certain drugs starting, in some instances, as early as June 2013. The products in question are Clobetasol, Desonide, and Econazole. These complaints, along with complaints filed against other companies alleging price fixing with respect to 15 other drugs, have been consolidated for pretrial proceedings as part of a case captioned </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">In re Generic Pharmaceuticals Pricing Antitrust Litigation,</font><font style="font-family:Arial;font-size:10pt;"> MDL No. 2724. Pursuant to the court&#8217;s schedule staging various cases in phases, we have moved to dismiss the complaints relating to Clobetasol and Econazole. At this stage, we cannot reasonably predict the outcome of the liability, if any, associated with these claims.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Securities Litigation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">In the United States</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On May 18, 2016, a shareholder filed a securities case against us and our former CEO, Joseph Papa, in the U.S. District Court for the District of New Jersey (</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Roofers&#8217; Pension Fund v. Papa, et al.)</font><font style="font-family:Arial;font-size:10pt;">.&#160;The plaintiff purported to represent a class of shareholders for the period from April 21, 2015 through May 11, 2016, inclusive.&#160;The original complaint alleged violations of Securities Exchange Act sections 10(b) (and Rule 10b&#8209;5) and 14(e) against both defendants and 20(a) control person liability against Mr. Papa.&#160;In general, the allegations concerned the actions taken by us and the former executive to defend against the unsolicited takeover bid by Mylan in the period from April 21, 2015 through November 13, 2015.&#160;The plaintiff also alleged that the defendants provided inadequate disclosure concerning alleged integration problems related to the Omega acquisition in the period from April 21, 2015 through May 11, 2016.&#160;On July 19, 2016, a different shareholder filed a securities class action against us and our former CEO, Joseph Papa, also in the District of New Jersey (</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Wilson v. Papa, et al</font><font style="font-family:Arial;font-size:10pt;">.). The plaintiff purported to represent a class of persons who sold put options on our shares between April 21, 2015 and May 11, 2016. In general, the allegations and the claims were the same as those made in the original complaint filed in the </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Roofers' Pension Fund</font><font style="font-family:Arial;font-size:10pt;"> case described above. On December 8, 2016, the court consolidated </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Roofers' Pension Fund</font><font style="font-family:Arial;font-size:10pt;"> case and the </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Wilson</font><font style="font-family:Arial;font-size:10pt;"> case under the Roofers' Pension Fund case number. In February 2017, the court selected the lead plaintiffs for the consolidated case and the lead counsel to the putative class. In March 2017, the court entered a scheduling order.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On June 21, 2017, the court-appointed lead plaintiffs filed an amended complaint that superseded the original complaints in the </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Roofers&#8217; Pension Fund </font><font style="font-family:Arial;font-size:10pt;">case and the </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Wilson</font><font style="font-family:Arial;font-size:10pt;"> case. The lead plaintiffs seek to represent a class of shareholders for the period April 21, 2015 through May 3, 2017, and identifies three subclasses - shareholders who traded during the entire period on the U.S. exchanges; shareholders who traded during the entire period on the Tel Aviv exchange; and shareholders who traded during the period while the Mylan tender offer was pending (April 21, 2015 through November 13, 2015). The amended complaint names as defendants us and 11 current or former directors and officers of Perrigo (Mses. Judy Brown, Laurie Brlas, Jacqualyn Fouse, Ellen Hoffing, and Messrs. Joe Papa, Marc Coucke, Gary Cohen, Michael Jandernoa, Gerald Kunkle, Herman Morris, and Donal O&#8217;Connor). The amended complaint alleges violations of Securities Exchange Act sections 10(b) (and Rule 10b&#8209;5) and 14(e) against all defendants and 20(a) control person liability against the 11 individuals. In general, the allegations concern the actions taken by us and the former executives to defend against the unsolicited takeover bid by Mylan in the period from April 21, 2015 through November 13, 2015 and the allegedly inadequate disclosure throughout the entire class period related to purported integration problems related to the Omega acquisition, alleges incorrect reporting of organic growth at the Company, alleges price fixing activities with respect to six generic prescription pharmaceuticals, and alleges improper accounting for the Tysabri</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;"> royalty stream. The amended complaint does not include an estimate of damages. In August 2017, the defendants filed motions to dismiss the amended complaint. The plaintiffs filed their opposition in October 2017. The defendants filed replies in support of the motions to dismiss in November 2017. The court has not indicated whether there will be oral argument of the motions or whether the court will decide the motions on the papers. We intend to defend the lawsuit vigorously. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:Arial;font-size:10pt;">On November 1, 2017, Carmignac Gestion, S.A., filed a securities lawsuit against us and three individuals (former Chairman and CEO Joseph Papa, former CFO Judy Brown, and former Executive Vice President and Board member Marc Coucke). This lawsuit is not a securities class action. The case is styled </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Carmignac Gestion, S.A. v. Perrigo Company plc, et al.</font><font style="font-family:Arial;font-size:10pt;">, and was filed in the U.S. District Court for the District of New Jersey. The complaint asserts claims under Securities Exchange Act sections 10(b) (and Rule 10b-5), 14(e), and 18 against all defendants as well as 20(a) control person liability against the individual defendants. In general, the plaintiff&#8217;s allegations focus on events during the period from April 2015 through April 2016. Plaintiff contends that the defendants provided inadequate disclosure throughout the period concerning the valuation and integration of Omega, the financial guidance provided by us during that period, our reporting about the generic prescription pharmaceutical business and its prospects, and the activities surrounding the efforts to defeat the Mylan tender offer during 2015. Many of the allegations in this newly-filed case overlap with the allegations of the June 2017 amended complaint in the </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Roofers&#8217; Pension Fund</font><font style="font-family:Arial;font-size:10pt;"> case described above. The plaintiff does not provide an estimate of damages. We intend to defend the lawsuit vigorously.&#160;</font><font style="font-family:inherit;font-size:11pt;"> &#160;</font><font style="font-family:Arial;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">In Israel</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Because our shares are traded on the Tel Aviv exchange under a dual trading arrangement, we are subject to securities litigation in Israel. Three cases are currently pending. We are consulting Israeli counsel about our response to these allegations and we intend to defend these cases vigorously. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On May 22, 2016, shareholders filed a securities class action against us and five individual defendants: Our former CEO Mr. Papa, our former Executive Vice President and General Manager of the BCH segment Marc Coucke, our Chief Executive Officer John Hendrickson, our former Board member Gary Kunkle, Jr., and our Board member Laurie Brlas alleging violations of Israeli law in the District Court of Tel Aviv-Jaffa (</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Schweiger et al. v. Perrigo Company plc, et al.).</font><font style="font-family:Arial;font-size:10pt;">&#160;On June 15, 2016, we filed a motion to stay the case pending the outcome of the securities class action pending in the New Jersey Federal Court.&#160;The plaintiffs did not oppose the motion. The Israeli court granted the motion on the same day, and the </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Schweiger</font><font style="font-family:Arial;font-size:10pt;"> action is stayed. We intend to defend the lawsuit vigorously when and if the stay is lifted. In October 2017, the Schweiger plaintiffs dismissed their claims without prejudice because of the pendency of another class action case filed in Israel (see discussion below of the </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Israel Elec. Corp. Employees&#8217; Educ. Fund</font><font style="font-family:Arial;font-size:10pt;"> case). The court approved the voluntary dismissal.&#160; </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On March 29, 2017, plaintiff Eyal Keinan commenced an action in the District Court of Tel Aviv-Jaffa asserting securities claims against two defendants: Perrigo and its auditor Ernst &amp; Young LLP ("EY").&#160;The case is styled </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Keinan v. Perrigo Company plc, et al. </font><font style="font-family:Arial;font-size:10pt;">The action seeks certification of a class of purchasers of Perrigo shares on the Israeli exchange beginning February 6, 2014. The proposed closing date for the class is not clear from the complaint though it appears to extend into 2017. In general, the plaintiff asserts that we improperly accounted for our stream of royalty income from two drugs: Tysabri</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;"> and Prialt. The court filings contend that the alleged improper accounting caused the audited financial results for Perrigo to be incorrect for the six month period ended December&#160;31, 2015, and the years ended June&#160;27, 2015 and June&#160;28, 2014 and the other financial data released by us over those years and 2016 to also be inaccurate.&#160;The plaintiff maintains that the defendants are liable under Israeli securities law or, in the alternative, under U.S. securities law. The plaintiff indicates an initial, preliminary class damages estimate of </font><font style="font-family:Arial;font-size:10pt;">686.0 million</font><font style="font-family:Arial;font-size:10pt;"> NIS (approximately </font><font style="font-family:Arial;font-size:10pt;">$192.0 million</font><font style="font-family:Arial;font-size:10pt;"> at 1 NIS = </font><font style="font-family:Arial;font-size:10pt;">$0.28 cent</font><font style="font-family:Arial;font-size:10pt;">). The response from the defendants is not yet due. We intend to defend the lawsuit vigorously.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On June 28, 2017, a plaintiff filed a complaint in Tel Aviv District Court styled </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Israel Elec. Corp. Employees&#8217; Educ. Fund v. Perrigo Company plc, et al. </font><font style="font-family:Arial;font-size:10pt;">The lead plaintiff seeks to represent a class of shareholders who traded in Perrigo stock on the Tel Aviv exchange during the period April 24, 2015 through May 3, 2017. The amended complaint names as defendants the Company, EY (the Company&#8217;s auditor), and 11 current or former directors and officers of Perrigo (Mses. Judy Brown, Laurie Brlas, Jacqualyn Fouse, Ellen Hoffing, and Messrs. Joe Papa, Marc Coucke, Gary Cohen, Michael Jandernoa, Gerald Kunkle, Herman Morris, and Donal O&#8217;Connor). The complaint alleges violations under U.S. securities laws of Securities Exchange Act sections 10(b) (and Rule 10b&#8209;5) and 14(e) against all defendants and 20(a) control person liability against the 11 individuals or, in the alternative, under Israeli securities laws. In general, the allegations concern the actions taken by us and our former executives to defend against the unsolicited takeover bid by Mylan in the period from April 21, 2015 through November 13, 2015 and the allegedly inadequate disclosure concerning purported integration problems related to the Omega acquisition, alleges incorrect reporting of organic growth at the Company, alleges price fixing activities with respect to six generic prescription pharmaceuticals, and alleges improper accounting for the Tysabri</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;"> royalty stream. The plaintiff indicates an initial, preliminary class damages estimate of </font><font style="font-family:Arial;font-size:10pt;">2.7 billion</font><font style="font-family:Arial;font-size:10pt;"> NIS (approximately </font><font style="font-family:Arial;font-size:10pt;">$760.0 million</font><font style="font-family:Arial;font-size:10pt;"> at 1 NIS = </font><font style="font-family:Arial;font-size:10pt;">$0.28 cent</font><font style="font-family:Arial;font-size:10pt;">). We intend to defend the lawsuit vigorously.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On July 12, 2017, the plaintiff in the </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Israel Elec. Corp. Employees&#8217; Educ. Fund v. Perrigo Company plc, et al.</font><font style="font-family:Arial;font-size:10pt;"> case filed a motion to have all three cases pending in Israel either consolidated or the other two cases dismissed so that the Israel Elec. Corp. Educ. Fund plaintiff can proceed as the sole plaintiff. That motion is pending. In October 2017, the Schweiger plaintiffs (see description above) voluntarily dismissed their securities class action without prejudice as part of their response to the motion filed by the Israel Elec. Corp. Educ. Fund plaintiff. A variety of other procedural motions are also pending at this time having to do with the timing of any response by defendants. The court has scheduled an initial conference on November 9, 2017 to address the motion filed by the Israel Elec. Corp. Educ. Fund plaintiff. The court has indicated that other procedural motions will be addressed after it has decided the Israel Elec. Corp. Educ. Fund plaintiff&#8217;s motion. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Eltroxin</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">During October and November 2011, nine applications to certify a class action lawsuit were filed in various courts in Israel related to Eltroxin, a prescription thyroid medication manufactured by a third party and distributed in Israel by our subsidiary, Perrigo Israel Agencies Ltd. The respondents included our subsidiaries, Perrigo Israel Pharmaceuticals Ltd. and/or Perrigo Israel Agencies Ltd., the manufacturers of the product, and various healthcare providers who provide healthcare services as part of the compulsory healthcare system in Israel. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">One of the applications was dismissed and the remaining eight applications were consolidated into one application. The applications arose from the 2011 launch of a reformulated version of Eltroxin in Israel. The consolidated application generally alleges that the respondents (a) failed to timely inform patients, pharmacists and physicians about the change in the formulation; and (b) failed to inform physicians about the need to monitor patients taking the new formulation in order to confirm patients were receiving the appropriate dose of the drug. As a result, claimants allege they incurred the following damages: (a) purchases of product that otherwise would not have been made by patients had they been aware of the reformulation; (b) adverse events to some patients resulting from an imbalance of thyroid functions that could have been avoided; and (c) harm resulting from the patients' lack of informed consent prior to the use of the reformulation.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Several hearings on whether or not to certify the consolidated application took place in December 2013 and January 2014. On May 17, 2015, the District Court certified the motion against Perrigo Israel Agencies Ltd. and dismissed it against the remaining respondents, including Perrigo Israel Pharmaceuticals Ltd. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On June 16, 2015, we submitted a motion for permission to appeal the decision to certify to the Israeli Supreme Court together with a motion to stay the proceedings of the class action until the motion for permission to appeal is adjudicated. We have filed our statement of defense to the underlying proceedings. The parties are currently engaged in mediation in an attempt to settle the matter. The underlying proceedings have been stayed pending the outcome of the mediation process and, if necessary, a decision on the motion to appeal.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Tysabri</font><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"> Product Liability Lawsuits</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;"></font><font style="font-family:Arial;font-size:10pt;">We and our collaborator Biogen are co-defendants in product liability lawsuits arising out of the occurrence of Progressive Multifocal Leukoencephalopathy, a serious brain infection, and serious adverse events, including deaths, which occurred in patients taking Tysabri</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;">. Each co-defendant would be responsible for 50% of losses and expenses arising out of any Tysabri</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;"> product liability claims. During calendar year 2016, one case in the U.S. was settled and two others were dismissed with prejudice. In 2017, seven other cases were dismissed with prejudice. While we intend to vigorously defend the remaining lawsuits, management cannot predict how these cases will be resolved. Adverse results in one or more of these lawsuits could result in substantial judgments against us.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Claim Arising from the Omega Acquisition</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On December 16, 2016, we and Perrigo Ireland 2 brought an arbitral claim ("Claim") against Alychlo NV ("Alychlo") and Holdco I BE NV ("Holdco") (together the Sellers) in accordance with clause 26.2 of the Share Purchase Agreement dated November 6, 2014 ("SPA") and the rules of the Belgian Centre for Arbitration and Mediation ("CEPANI"). Our Claim relates to the accuracy and completeness of information about Omega provided by the Sellers as part of the sale process, the withholding of information by the Sellers during that process and breaches of Sellers&#8217; warranties. We are seeking monetary damages from the Sellers. The Sellers served their respective responses to the Claim on February 20, 2017. In its response, Alychlo has asserted a counterclaim for monetary damages contending that we breached the duty of good faith in performing the SPA. There can be no assurance that our Claim will be successful, and Sellers deny liability for the Claim. We deny that Alychlo is entitled to any relief (including monetary relief) under the counterclaim.&#160;The arbitration proceedings are confidential as required by the SPA and the rules of the CEPANI.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Changes in our AOCI balances, net of tax were as follows (in millions): </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:31%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Foreign currency translation adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Fair value of derivative financial instruments, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Fair&#160;value&#160;of investment securities, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Post-retirement and pension liability adjustments, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Total AOCI</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(67.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(19.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">15.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(9.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(81.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">OCI before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">289.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(22.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">270.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Amounts reclassified from AOCI </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">289.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">8.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(24.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">273.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Balance at September 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">222.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(10.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(9.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(10.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">191.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"> include our accounts and the accounts of all majority-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">INVESTMENTS</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Available for Sale Securities </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our available for sale securities are reported in </font><font style="font-family:Arial;font-size:10pt;">Prepaid expenses and other current assets</font><font style="font-family:Arial;font-size:10pt;">. Unrealized investment gains/(losses) on available for sale securities were as follows (in millions):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:469px;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:276px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:82px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:82px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Equity securities, at cost less impairments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">15.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">16.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Gross unrealized gains</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">21.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Gross unrealized losses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(9.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Estimated fair value of equity securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">38.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The factors affecting the assessment of impairments include both general financial market conditions and factors specific to a particular company. During the </font><font style="font-family:Arial;font-size:10pt;">nine months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">October&#160;1, 2016</font><font style="font-family:Arial;font-size:10pt;">, we recorded an impairment charge of </font><font style="font-family:Arial;font-size:10pt;">$1.8 million</font><font style="font-family:Arial;font-size:10pt;">, which related to other-than-temporary impairments of marketable equity securities due to prolonged losses incurred on each of the investments.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have evaluated the near-term prospects of the equity securities in relation to the severity and duration of any impairments, and based on that evaluation, we have the ability and intent to hold these investments until a recovery of fair value. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">During the </font><font style="font-family:Arial;font-size:10pt;">nine months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;">, we sold a number of our investment securities and recorded a gain of </font><font style="font-family:Arial;font-size:10pt;">$1.6 million</font><font style="font-family:Arial;font-size:10pt;">. The gain was reclassified out of Accumulated Other Comprehensive Income (loss) ("AOCI") and into earnings. &#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Cost Method Investments</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;"></font><font style="font-family:Arial;font-size:10pt;">Our cost method investments totaled </font><font style="font-family:Arial;font-size:10pt;">$7.2 million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$6.9&#160;million</font><font style="font-family:Arial;font-size:10pt;"> at </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;"> and </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">December 31, 2016</font><font style="font-family:Arial;font-size:10pt;">, respectively, and are included in </font><font style="font-family:Arial;font-size:10pt;">Other non-current assets</font><font style="font-family:Arial;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Equity Method Investments</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our equity method investments totaled</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">$4.8&#160;million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$4.6&#160;million</font><font style="font-family:Arial;font-size:10pt;"> at </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">December 31, 2016</font><font style="font-family:Arial;font-size:10pt;">, respectively, and are included in </font><font style="font-family:Arial;font-size:10pt;">Other non-current assets</font><font style="font-family:Arial;font-size:10pt;">. We recorded net </font><font style="font-family:Arial;font-size:10pt;">losses</font><font style="font-family:Arial;font-size:10pt;"> of </font><font style="font-family:Arial;font-size:10pt;">$0.1&#160;million</font><font style="font-family:Arial;font-size:10pt;"> and net </font><font style="font-family:Arial;font-size:10pt;">gain</font><font style="font-family:Arial;font-size:10pt;">s of </font><font style="font-family:Arial;font-size:10pt;">$0.2&#160;million</font><font style="font-family:Arial;font-size:10pt;"> during the </font><font style="font-family:Arial;font-size:10pt;">three and nine months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;">, respectively, and net </font><font style="font-family:Arial;font-size:10pt;">gain</font><font style="font-family:Arial;font-size:10pt;">s of </font><font style="font-family:Arial;font-size:10pt;">$0.1&#160;million</font><font style="font-family:Arial;font-size:10pt;"> and net </font><font style="font-family:Arial;font-size:10pt;">loss</font><font style="font-family:Arial;font-size:10pt;">es</font><font style="font-family:Arial;font-size:9pt;"> of </font><font style="font-family:Arial;font-size:10pt;">$3.8&#160;million</font><font style="font-family:Arial;font-size:10pt;"> during the </font><font style="font-family:Arial;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">October&#160;1, 2016</font><font style="font-family:Arial;font-size:10pt;">, respectively, for our proportionate share of the equity method investment earnings or losses. The gains and losses were recorded in </font><font style="font-family:Arial;font-size:10pt;">Other (income) expense, net</font><font style="font-family:Arial;font-size:10pt;"> on the Condensed Consolidated Statements of Operations.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">During the </font><font style="font-family:Arial;font-size:10pt;">nine months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">October&#160;1, 2016</font><font style="font-family:Arial;font-size:10pt;">, one of our equity method investments became publicly traded. As a result, we transferred the </font><font style="font-family:Arial;font-size:10pt;">$15.5 million</font><font style="font-family:Arial;font-size:10pt;"> investment to available for sale and recorded an </font><font style="font-family:Arial;font-size:10pt;">$8.7 million</font><font style="font-family:Arial;font-size:10pt;"> unrealized gain, net of tax in Other Comprehensive Income ("OCI"). In addition, due to significant and prolonged losses incurred on one of our equity method investments, we recorded a </font><font style="font-family:Arial;font-size:10pt;">$22.3&#160;million</font><font style="font-family:Arial;font-size:10pt;"> impairment charge in </font><font style="font-family:Arial;font-size:10pt;">Other (income) expense, net</font><font style="font-family:Arial;font-size:10pt;"> on the Condensed Consolidated Statements of Operations.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">INDEBTEDNESS</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total borrowings outstanding are summarized as follows (in millions): </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.43605870020964%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:5%;" rowspan="1" colspan="1"></td><td style="width:22%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">December&#160;31, <br clear="none"/>2016</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Term loans</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2014 term loan due December 5, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup>&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">428.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">420.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Notes and Bonds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Coupon</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Due</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4.500%</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">May&#160;23, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)(2)</sup>&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">189.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.125%</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">December&#160;12, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)(2)</sup>&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">354.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">315.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2.300%</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">November&#160;8, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">600.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.000%</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">May&#160;23, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)(2)</sup>&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">141.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">126.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.500%</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">March&#160;15, 2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">280.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">500.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.500%</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">December&#160;15, 2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">309.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">500.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.105%</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">July&#160;19, 2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)(2)</sup>&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">159.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">142.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4.000%</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">November&#160;15, 2023</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">215.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">800.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.900%</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">December&#160;15, 2024</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">700.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">700.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4.375%</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">March&#160;15, 2026</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">700.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">700.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.300%</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">November&#160;15, 2043</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">90.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">400.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4.900%</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">December&#160;15, 2044</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">303.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">400.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Total notes and bonds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,255.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5,373.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td colspan="5" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Other financing</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Unamortized premium (discount), net</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">24.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">33.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Deferred financing fees</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(19.0</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(33.1</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Total borrowings outstanding</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,692.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5,797.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Current indebtedness</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(417.1</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(572.8</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Total long-term debt less current portion</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,275.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5,224.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Debt denominated in Euros subject to fluctuations in the euro-to-U.S. dollar exchange rate.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Debt assumed from Omega.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">During the three months ended April 1, 2017, we entered into amendments to the 2014 Revolver (as defined below) and the 2014 term loan to modify provisions of such agreements necessary as a result of the correction in accounting related to the Tysabri</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;"> financial asset, as well as waivers of any default or event of default that may have arisen from any restatement of or deficiencies in our financial statements for the periods specified in such amendments and waivers. We are in compliance with all covenants under our debt agreements as of </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Revolving Credit Agreements</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have a revolving credit agreement with a borrowing capacity of </font><font style="font-family:Arial;font-size:10pt;">$1.0&#160;billion</font><font style="font-family:Arial;font-size:10pt;"> (the "2014 Revolver"). There were no borrowings outstanding under the 2014 Revolver as of </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">December 31, 2016</font><font style="font-family:Arial;font-size:9pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Other Financing</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Overdraft Facilities</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have overdraft facilities available that we use to support our cash management operations. We report any balances outstanding in the above table under "Other financing". There were no balances outstanding under the facilities at </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">December 31, 2016</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Debt Repayments and Related Extinguishment </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;"></font><font style="font-family:Arial;font-size:10pt;">During the </font><font style="font-family:Arial;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;">, we reduced our outstanding debt through a variety of transactions (in millions):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:37%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Series</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Transaction Type</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Principal Retired</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">April&#160;1, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2014 term loan due December 5, 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Scheduled quarterly payment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">13.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">July&#160;1, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2014 term loan due December 5, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Scheduled quarterly payment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">14.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">September&#160;30, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2014 term loan due December 5, 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Scheduled quarterly payment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">14.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">May&#160;8, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$600.0 2.300% senior notes due 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Early redemption</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">600.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">May&#160;23, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8364;180.0 4.500% retail bonds due 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Scheduled maturity</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">201.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">June&#160;15, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$500.0 3.500% senior notes due 2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Tender offer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">190.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">June&#160;15, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$500.0 3.500% senior notes due 2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Tender offer</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">219.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">June&#160;15, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$800.0 4.000% senior notes due 2023</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Tender offer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">584.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">June&#160;15, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$400.0 5.300% senior notes due 2043</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Tender offer</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">309.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">June&#160;15, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$400.0 4.900% senior notes due 2044</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Tender offer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">96.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,243.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As a result of the of the early redemption and tender offer transactions discussed above, we recorded a loss of </font><font style="font-family:Arial;font-size:10pt;">$135.2 million</font><font style="font-family:Arial;font-size:10pt;"> during the three months ended July&#160;1, 2017 in </font><font style="font-family:Arial;font-size:10pt;">Loss on extinguishment of debt</font><font style="font-family:Arial;font-size:10pt;"> (in millions): </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:63.731656184486376%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Premium on debt repayment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">116.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Transaction costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Write-off of deferred financing fees</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Write-off of remaining discount on bond</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total loss on extinguishment of debt</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">135.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We enter into certain derivative financial instruments, when available on a cost-effective basis, to mitigate our risk associated with changes in interest rates and foreign currency exchange rates as follows: </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Interest rate risk management - </font><font style="font-family:Arial;font-size:10pt;">We are exposed to the impact of interest rate changes through our cash investments and borrowings. We utilize a variety of strategies to manage the impact of changes in interest rates, including using a mix of debt maturities along with both fixed-rate and variable-rate debt. In addition, we may enter into treasury-lock agreements and interest rate swap agreements on certain investing and borrowing transactions to manage our exposure to interest rate changes and our overall cost of borrowing. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Foreign currency exchange risk management - </font><font style="font-family:Arial;font-size:10pt;">We conduct business in several major currencies other than the U.S. dollar and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce cash flow volatility associated with foreign exchange rate changes on a consolidated basis to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments, and anticipated foreign currency sales and expenses.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">All derivative instruments are managed on a consolidated basis to efficiently net exposures and thus take advantage of any natural offsets. Gains and losses related to the derivative instruments are expected to be offset largely by gains and losses on the original underlying asset or liability. We do not use derivative financial instruments for speculative purposes.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"> &#160;&#160;&#160;&#160; All of our designated derivatives were classified as cash flow hedges as of </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Arial;font-size:10pt;">. Designated derivatives meet hedge accounting criteria, which means the fair value of the hedge is recorded in shareholders&#8217; equity as a component of OCI, net of tax. The deferred gains and losses are recognized in income in the period in which the hedged item affects earnings. Any ineffective portion of the change in fair value of the derivative is immediately recognized in earnings. All of our designated derivatives are assessed for hedge effectiveness quarterly.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We also have economic non-designated derivatives that do not meet hedge accounting criteria. These derivative instruments are adjusted to current market value at the end of each period through earnings. Gains or losses on these instruments are offset substantially by the remeasurement adjustment on the hedged item.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Interest Rate Swaps and Treasury Locks </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"></font><font style="font-family:Arial;font-size:10pt;">Interest rate swap agreements are contracts to exchange floating rate for fixed rate payments (or vice versa) over the life of the agreement without the exchange of the underlying notional amounts. The notional amounts of the interest rate swap agreements are used to measure interest to be paid or received and do not represent the amount of exposure to credit loss. The differential paid or received on the interest rate swap agreements is recognized as an adjustment to interest expense. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">During the three months ended July 1, 2017, we repaid </font><font style="font-family:Arial;font-size:10pt;">$584.4&#160;million</font><font style="font-family:Arial;font-size:10pt;"> of senior notes with an interest rate of 4.000% due 2023 and </font><font style="font-family:Arial;font-size:10pt;">$309.5 million</font><font style="font-family:Arial;font-size:10pt;"> of senior notes with an interest rate of 5.300% due 2043 (refer to </font><a style="font-family:Arial;font-size:10pt;" href="#s0432DB7120B4512281AC537CF9FC706A"><font style="font-family:Arial;font-size:10pt;">Note 10</font></a><font style="font-family:Arial;font-size:10pt;">). As a result of the senior note repayments on June 15, 2017, the proportionate amount remaining in OCI related to the pre-issuance hedge was reclassified to earnings. Accordingly, we recorded a loss of </font><font style="font-family:Arial;font-size:10pt;">$5.9&#160;million</font><font style="font-family:Arial;font-size:10pt;"> in Other expense, net, on the Condensed Consolidated Statements of Operations during the three months ended July 1, 2017 for the amount remaining in OCI.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">During the </font><font style="font-family:Arial;font-size:10pt;">six months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, we entered into a forward interest rate swap to hedge against changes in the benchmark interest rate between the date the interest rate swap was entered into and the date of expected future debt issuance. The interest rate swap was designated as a cash flow hedge and had a notional amount totaling </font><font style="font-family:Arial;font-size:10pt;">$200.0&#160;million</font><font style="font-family:Arial;font-size:10pt;">. The interest rate swap was settled upon the issuance of an aggregate </font><font style="font-family:Arial;font-size:10pt;">$1.2&#160;billion</font><font style="font-family:Arial;font-size:10pt;"> principal amount of senior notes on March 7, 2016 for a cumulative after-tax </font><font style="font-family:Arial;font-size:10pt;">loss</font><font style="font-family:Arial;font-size:10pt;"> of </font><font style="font-family:Arial;font-size:10pt;">$7.0&#160;million</font><font style="font-family:Arial;font-size:10pt;"> in OCI during the three months ended April 2, 2016. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Foreign Currency Derivatives</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;"></font><font style="font-family:Arial;font-size:10pt;">We enter into foreign currency forward contracts, both designated and non-designated, in order to manage the impact of foreign exchange fluctuations on expected future purchases and related payables denominated in a foreign currency, as well as to hedge the impact of foreign exchange fluctuations on expected future sales and related receivables denominated in a foreign currency. Both types of forward contracts have a maximum maturity date of </font><font style="font-family:Arial;font-size:10pt;">18</font><font style="font-family:Arial;font-size:10pt;"> months. The total notional amount for these contracts was </font><font style="font-family:Arial;font-size:10pt;">$578.3 million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$533.5 million</font><font style="font-family:Arial;font-size:10pt;"> as of </font><font style="font-family:Arial;font-size:10pt;">September 30, 2017</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">December 31, 2016</font><font style="font-family:Arial;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Effects of Derivatives on the Financial Statements</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The below tables indicate the effects of all derivative instruments on the Condensed Consolidated Financial Statements. All amounts exclude income tax effects and are presented in millions.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The balance sheet location and gross fair value of our outstanding derivative instruments were as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:87.0020964360587%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Asset Derivatives</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Balance&#160;Sheet&#160;Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">December&#160;31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Designated derivatives:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Other&#160;current&#160;assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Non-designated derivatives:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">8.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.25995807127882%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td style="width:39%;" rowspan="1" colspan="1"></td><td style="width:27%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Liability Derivatives</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Balance&#160;Sheet&#160;Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">December&#160;31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Designated derivatives:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Accrued liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Non-designated derivatives:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Accrued liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The gains (losses) recorded in OCI for the effective portion of our designated cash flow hedges were as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:624px;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:240px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:79px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:79px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:79px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:79px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Amount of Gain/(Loss) Recorded in OCI<br clear="none"/>(Effective Portion)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Designated Cash Flow Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">October&#160;1, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">October&#160;1, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Interest rate swap agreements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(9.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(4.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The gains (losses) reclassified from AOCI into earnings for the effective portion of our designated cash flow hedges were as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:791px;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td style="width:240px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:173px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:82px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:70px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:82px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:71px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Amount of Gain/(Loss) Reclassified from AOCI into Earnings <br clear="none"/>(Effective Portion)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Designated Cash Flow Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Income Statement Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">October&#160;1, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">October&#160;1, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Treasury locks</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Interest expense, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Interest rate swap agreements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Interest expense, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(0.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Other (income) expense, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(5.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Net sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Cost of sales</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Interest expense, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(0.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Other (income) expense, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(0.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(6.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(0.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The net of tax amount expected to be reclassified from AOCI into earnings during the next 12 months is a </font><font style="font-family:Arial;font-size:10pt;">$2.8&#160;million</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">gain</font><font style="font-family:Arial;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The gains (losses) recognized against earnings for the ineffective portion of our designated cash flow hedges were as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:754px;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td style="width:200px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:165px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:79px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:79px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:79px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:79px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Amount of Gain/(Loss) Recognized against Earnings<br clear="none"/>(Ineffective Portion)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Designated Cash Flow Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Income Statement</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">October&#160;1, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">October&#160;1, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Interest rate swap agreements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Other (income) expense, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Net sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Cost of sales</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Other (income) expense, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The effects of our non-designated derivatives on the Condensed Consolidated Statements of Operations were as follows: </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:22%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Amount of Gain/(Loss) Recognized against Earnings</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Non-Designated Derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Income Statement Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">October&#160;1, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">October&#160;1, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Other (income) expense, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(0.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(3.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(8.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Interest expense, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(2.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">8.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(6.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(10.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We enter into certain derivative financial instruments, when available on a cost-effective basis, to mitigate our risk associated with changes in interest rates and foreign currency exchange rates as follows: </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Interest rate risk management - </font><font style="font-family:Arial;font-size:10pt;">We are exposed to the impact of interest rate changes through our cash investments and borrowings. We utilize a variety of strategies to manage the impact of changes in interest rates, including using a mix of debt maturities along with both fixed-rate and variable-rate debt. In addition, we may enter into treasury-lock agreements and interest rate swap agreements on certain investing and borrowing transactions to manage our exposure to interest rate changes and our overall cost of borrowing. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Foreign currency exchange risk management - </font><font style="font-family:Arial;font-size:10pt;">We conduct business in several major currencies other than the U.S. dollar and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce cash flow volatility associated with foreign exchange rate changes on a consolidated basis to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments, and anticipated foreign currency sales and expenses.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">All derivative instruments are managed on a consolidated basis to efficiently net exposures and thus take advantage of any natural offsets. Gains and losses related to the derivative instruments are expected to be offset largely by gains and losses on the original underlying asset or liability. We do not use derivative financial instruments for speculative purposes.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"> &#160;&#160;&#160;&#160; All of our designated derivatives were classified as cash flow hedges as of </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Arial;font-size:10pt;">. Designated derivatives meet hedge accounting criteria, which means the fair value of the hedge is recorded in shareholders&#8217; equity as a component of OCI, net of tax. The deferred gains and losses are recognized in income in the period in which the hedged item affects earnings. Any ineffective portion of the change in fair value of the derivative is immediately recognized in earnings. All of our designated derivatives are assessed for hedge effectiveness quarterly.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We also have economic non-designated derivatives that do not meet hedge accounting criteria. These derivative instruments are adjusted to current market value at the end of each period through earnings. Gains or losses on these instruments are offset substantially by the remeasurement adjustment on the hedged item</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:31%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:34%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Recently Issued Accounting Standards Not Yet Adopted</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Standard</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Effective Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Effect on the Financial Statements or Other Significant Matters</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Revenue from Contracts with Customers </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: identify the contract(s) with a customer; identify the performance obligations in the contract; determine the transaction price; allocate the transaction price to the performance obligations in the contract; and recognize revenue when (or as) the entity satisfies a performance obligation. This guidance allows for two adoption methods, full retrospective approach or modified retrospective approach.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">January 1, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">We continue to evaluate the implications of adoption of the new revenue standard on our Consolidated Financial Statements. We have completed an initial assessment and are in the process of quantifying the adoption impact, if any, related to certain topics identified through our evaluation process. Our assessment of the new revenue standard has been focused on, but has not been limited to, the concepts of over-time versus point-in-time revenue recognition patterns, variable consideration, and identification of performance obligations. We will not complete our final assessment and quantification of the impact of the new revenue standard on our Consolidated Financial Statements until the adoption date. Our analysis indicates that certain contract manufacturing and private label arrangements may require revenue recognition over-time in situations in which we produce products that have no alternative use and we have an enforceable right to payment for performance completed to date, inclusive of a reasonable profit margin. This may result in an acceleration of revenue recognition for certain contractual arrangements as compared to recognition under current accounting literature. We plan to adopt the new revenue standard effective January 1, 2018 using the modified retrospective method.</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Intra-Entity Asset Transfers of Assets Other Than Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Under the new guidance, the tax impact to the seller on the profit from the transfers and the buyer&#8217;s deferred tax benefit on the increased tax basis would be recognized when the transfers occur, resulting in the recognition of expense sooner than under historical guidance. The guidance excludes intra-entity transfers of inventory. For intra-entity transfers of inventory, the Financial Accounting Standards Board ("FASB") decided to retain current GAAP, which requires an entity to recognize the income tax consequences when the inventory has been sold to an outside party. </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">January 1, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">We are currently evaluating the implications of adoption on our Consolidated Financial Statements.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Financial Instruments - Recognition and Measurement of Financial Assets and Liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">The objective of this simplification update is to improve the decision usefulness of financial instrument reporting, and it principally affects accounting for equity investments currently classified as available for sale and financial liabilities where the fair value option has been elected. Entities will have to measure many equity investments at fair value and recognize changes in fair value in net income rather than other comprehensive income as required under current U.S. GAAP. </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">January 1, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">We have identified certain investments that will require an adjustment, however, at this time, we are unable to estimate the impact of adopting this standard as the significance of the impact will depend upon our equity investments as of the date of adoption.</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:31%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:34%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Recently Issued Accounting Standards Not Yet Adopted (continued)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Standard</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Effective Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Effect on the Financial Statements or Other Significant Matters</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Leases</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">This guidance was issued to increase transparency and comparability among organizations by requiring recognition of lease assets and lease liabilities on the balance sheet and disclosure of key information about leasing arrangements. For leases with a term of 12 months or less, lessees are permitted to make an election to not recognize right-of-use assets and lease liabilities. Upon adoption, lessees will apply the new standard as of the beginning of the earliest comparative period presented in the financial statements, however lessees will be able to exclude leases that expire as of the implementation date. Early adoption is permitted.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">January 1, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">We are currently evaluating the implications of adoption on our Consolidated Financial Statements and have commenced the first step of identifying a task force to take the lead in implementing the new Lease standard.</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Derivatives and Hedging</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">This update was issued to enable entities to better portray the economics of their risk management activities in the financial statements and enhance the transparency and understandability of hedge results. In addition, the amendments simplify the application of hedge accounting in certain situations. Under the new rule, the entity&#8217;s ability to hedge non-financial and financial risk components is expanded. The guidance eliminates the requirement to separately measure and report hedge ineffectiveness and also eases certain documentation and assessment requirements. Early adoption is permitted.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">January 1, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">We are currently evaluating the implications of adoption on our Consolidated Financial Statements.</font></div><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Measurement of Credit Losses on Financial Instruments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">This guidance changes the impairment model for most financial assets and certain other instruments, replacing the current "incurred loss" approach with an "expected loss" credit impairment model, which will apply to most financial assets measured at amortized cost and certain other instruments, including trade and other receivables, loans, held-to-maturity debt securities, and off-balance sheet credit exposures such as letters of credit. Early adoption is permitted.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">January 1, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">We are currently evaluating the new standard for potential impacts on our receivables, debt, and other financial instruments.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Intangibles - Goodwill and Other Simplifying the Test for Goodwill </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">The objective of this update is to reduce the cost and complexity of subsequent goodwill accounting by simplifying the impairment test by removing the Step 2 requirement to perform a hypothetical purchase price allocation when the carrying value of a reporting unit exceeds its fair value.&#160;If a reporting unit&#8217;s carrying value exceeds its fair value, an entity would record an impairment charge based on that difference, limited to the amount of goodwill attributed to that reporting unit. The proposal would not change the guidance on completing Step 1 of the goodwill impairment test. The proposed guidance would be applied prospectively. Early adoption is permitted.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">January 1, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">We are currently evaluating the implications of adoption on our Consolidated Financial Statements.</font></div><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ASSETS HELD FOR SALE</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our India API business was classified as held-for-sale beginning as of December 31, 2015. We recorded an impairment charge totaling </font><font style="font-family:Arial;font-size:10pt;">$6.3&#160;million</font><font style="font-family:Arial;font-size:10pt;"> during the year ended December&#160;31, 2016 after determining the carrying value of the India API business exceeded its fair value less the cost to sell. The India API business is reported in our Other segment. On </font><font style="font-family:Arial;font-size:10pt;">April&#160;6, 2017</font><font style="font-family:Arial;font-size:10pt;">, we completed the sale of our India API business (refer to </font><a style="font-family:Arial;font-size:10pt;" href="#s909A36ACA44659C9895DF0D24B880CC0"><font style="font-family:Arial;font-size:10pt;">Note 2</font></a><font style="font-family:Arial;font-size:10pt;">).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">During the </font><font style="font-family:Arial;font-size:10pt;">three months ended</font><font style="font-family:Arial;font-size:10pt;"> October 1, 2016, management committed to a plan to sell certain fixed assets associated with our animal health pet treats plant. Such assets were classified as held-for-sale beginning at October 1, 2016. On </font><font style="font-family:Arial;font-size:10pt;">February&#160;1, 2017</font><font style="font-family:Arial;font-size:10pt;">, we completed the sale of our animal health pet treats plant fixed assets (refer to </font><a style="font-family:Arial;font-size:10pt;" href="#s909A36ACA44659C9895DF0D24B880CC0"><font style="font-family:Arial;font-size:10pt;">Note 2</font></a><font style="font-family:Arial;font-size:10pt;">). We determined that the carrying value of the fixed assets associated with our animal health pet treats plant exceeded the fair value less the cost to sell. We recorded impairment charges totaling </font><font style="font-family:Arial;font-size:10pt;">$3.7&#160;million</font><font style="font-family:Arial;font-size:10pt;"> during the </font><font style="font-family:Arial;font-size:10pt;">year ended</font><font style="font-family:Arial;font-size:10pt;"> December 31, 2016. The assets associated with our animal health pet treats plant are reported in our </font><font style="font-family:Arial;font-size:10pt;">CHCA</font><font style="font-family:Arial;font-size:10pt;"> segment.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">During the </font><font style="font-family:Arial;font-size:10pt;">three months ended</font><font style="font-family:Arial;font-size:10pt;"> September 30, 2017, management committed to a plan to sell our Israel API business. The business was classified as held-for-sale beginning at September 30, 2017. We determined that the carrying value of the Israel API business exceeded its fair value less the cost to sell. We recorded impairment charges totaling </font><font style="font-family:Arial;font-size:10pt;">$3.3 million</font><font style="font-family:Arial;font-size:10pt;"> during the three months ended September 30, 2017. The Israel API business is reported in our </font><font style="font-family:Arial;font-size:10pt;">Other</font><font style="font-family:Arial;font-size:10pt;"> segment. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The assets held-for-sale are reported within </font><font style="font-family:Arial;font-size:10pt;">Prepaid expenses and other current assets</font><font style="font-family:Arial;font-size:10pt;"> and liabilities held-for-sale are reported in </font><font style="font-family:Arial;font-size:10pt;">Accrued liabilities</font><font style="font-family:Arial;font-size:10pt;">. The amounts consist of the following (in millions): </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:81.9706498951782%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">December&#160;31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;font-weight:bold;">CHCA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;font-weight:bold;">Other</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;font-weight:bold;">Assets held for sale</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">Current assets</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">44.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">5.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">Goodwill</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">32.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">5.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">5.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">Property, plant and equipment</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">45.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">13.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">33.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">Other assets</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">3.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">3.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">Less: impairment reserves</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">(3.3</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">(3.7</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">(35.3</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;font-weight:bold;">Total assets held for sale </font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">127.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">9.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">12.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;font-weight:bold;">Liabilities held for sale</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">Current liabilities</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">7.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">1.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">Other liabilities</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">25.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">1.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;font-weight:bold;">Total liabilities held for sale</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">32.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">3.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">EARNINGS PER SHARE AND SHAREHOLDERS' EQUITY</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Earnings per Share</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A reconciliation of the numerators and denominators used in the basic and diluted earnings per share ("EPS") calculation is as follows (in millions): </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">October&#160;1, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">October&#160;1, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">44.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1,590.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">46.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(2,653.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Weighted average shares outstanding for basic EPS</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">141.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">143.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">142.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">143.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Dilutive effect of share-based awards*</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Weighted average shares outstanding for diluted EPS</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">141.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">143.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">142.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">143.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Anti-dilutive share-based awards excluded from </font></div><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;computation of diluted EPS*</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">* In the period of a net loss, diluted shares equal basic shares.</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Shareholders' Equity</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Shares</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We issued shares related to the exercise and vesting of share-based compensation as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:61.21593291404612%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">October&#160;1, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">October&#160;1, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">99,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">185,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">146,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">283,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Share Repurchases</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On October 22, 2015, the Board of Directors approved a share repurchase plan of up to </font><font style="font-family:Arial;font-size:10pt;">$2.0 billion</font><font style="font-family:Arial;font-size:10pt;"> (the "2015 Authorization"). During the </font><font style="font-family:Arial;font-size:10pt;">three and nine months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;color:#252525;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;">, we repurchased </font><font style="font-family:Arial;font-size:10pt;">1.9&#160;million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2.7&#160;million</font><font style="font-family:Arial;font-size:10pt;"> ordinary shares at an average repurchase price of </font><font style="font-family:Arial;font-size:10pt;">$71.73</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$71.72</font><font style="font-family:Arial;font-size:10pt;"> per share, for a total of </font><font style="font-family:Arial;font-size:10pt;">$133.3&#160;million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$191.5&#160;million</font><font style="font-family:Arial;font-size:10pt;">, respectively. As of </font><font style="font-family:Arial;font-size:10pt;color:#252525;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;">, there was </font><font style="font-family:Arial;font-size:10pt;">$1.3&#160;billion</font><font style="font-family:Arial;font-size:10pt;"> still available to be repurchased through December 31, 2018 under the 2015 Authorization. We did not repurchase any shares under the share repurchase plan during the </font><font style="font-family:Arial;font-size:10pt;">nine months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">October&#160;1, 2016</font><font style="font-family:Arial;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table summarizes the valuation of our financial instruments carried at fair value and measured at fair value on a recurring and non-recurring basis by the above pricing categories (in millions): </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:87.63102725366876%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:51%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Fair Value Hierarchy</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">December&#160;31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Measured at fair value on a recurring basis:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:normal;">Assets:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Investment securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Level 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">38.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Level 2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">13.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Funds associated with Israeli severance liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">16.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">15.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total level 2 assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">29.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">19.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Royalty Pharma contingent milestone payments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Level 3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">143.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:normal;">Financial assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,350.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total level 3 assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">143.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,350.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:normal;">Liabilities:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Contingent consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">44.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">69.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Measured at fair value on a non-recurring basis:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:normal;">Assets:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Goodwill</font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,148.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Indefinite-lived intangible assets</font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Level 3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">13.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Definite-lived intangible assets</font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">11.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">758.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Assets held for sale, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Level 3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">95.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">18.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total level 3 assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">119.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,924.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup>&#160;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">As of December 31, 2016, goodwill with a carrying amount of </font><font style="font-family:Arial;font-size:8pt;">$2.2 billion</font><font style="font-family:Arial;font-size:8pt;"> was written down to its implied fair value of </font><font style="font-family:Arial;font-size:8pt;">$1.1 billion</font><font style="font-family:Arial;font-size:8pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup>&#160;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">As of September 30, 2017, indefinite-lived intangible assets with a carrying amount of </font><font style="font-family:Arial;font-size:8pt;">$26.0 million</font><font style="font-family:Arial;font-size:8pt;"> were written down to a fair value of </font><font style="font-family:Arial;font-size:8pt;">$13.3&#160;million</font><font style="font-family:Arial;font-size:8pt;">. As of December 31, 2016, indefinite-lived intangible assets with a carrying amount of </font><font style="font-family:Arial;font-size:8pt;">$0.7 million</font><font style="font-family:Arial;font-size:8pt;"> were written down to a fair value of </font><font style="font-family:Arial;font-size:8pt;">$0.3&#160;million</font><font style="font-family:Arial;font-size:8pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3)</sup>&#160;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">As of July 1, 2017, definite-lived intangible assets with a carrying amount of </font><font style="font-family:Arial;font-size:8pt;">$31.1 million</font><font style="font-family:Arial;font-size:8pt;"> were written down to a fair value of </font><font style="font-family:Arial;font-size:8pt;">$11.5 million</font><font style="font-family:Arial;font-size:8pt;">. As of December 31, 2016, definite-lived intangible assets with a carrying amount of </font><font style="font-family:Arial;font-size:8pt;">$2.3 billion</font><font style="font-family:Arial;font-size:8pt;"> were written down to a fair value of </font><font style="font-family:Arial;font-size:8pt;">$758.0&#160;million</font><font style="font-family:Arial;font-size:8pt;">. Included in this balance are indefinite-lived intangible assets with a fair value of </font><font style="font-family:Arial;font-size:8pt;">$364.5 million</font><font style="font-family:Arial;font-size:8pt;"> and </font><font style="font-family:Arial;font-size:8pt;">$674.2 million</font><font style="font-family:Arial;font-size:8pt;"> that were reclassified to definite-lived assets at April 3, 2016 and October 2, 2016, respectively.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The table below presents a reconciliation for the </font><font style="font-family:Arial;font-size:10pt;">Royalty Pharma contingent milestone payments</font><font style="font-family:Arial;font-size:10pt;"> measured at fair value on a recurring basis using significant unobservable inputs (Level 3) (in millions). Change in fair value in the table was recorded in </font><font style="font-family:Arial;font-size:10pt;">Change in financial assets</font><font style="font-family:Arial;font-size:10pt;"> on the Condensed Consolidated Statements of Operations.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:562px;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:289px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:122px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:122px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Royalty Pharma Contingent Milestone Payments</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">145.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Additions</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">184.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Foreign currency effect</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Change in fair value</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(2.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(42.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">143.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">143.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">FAIR VALUE MEASUREMENTS</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Fair value is the price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The following fair value hierarchy is used in selecting inputs, with the highest priority given to Level 1, as these are the most transparent or reliable. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:150px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:Arial;font-size:10pt;">Level 1:</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Quoted prices for identical instruments in active markets.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:150px;text-indent:-90px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:150px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:Arial;font-size:10pt;">Level 2:</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets. </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:150px;text-indent:-90px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:150px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:Arial;font-size:10pt;">Level 3:</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Valuations derived from valuation techniques in which one or more significant inputs are not observable.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:150px;text-indent:-90px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table summarizes the valuation of our financial instruments carried at fair value and measured at fair value on a recurring and non-recurring basis by the above pricing categories (in millions): </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:87.63102725366876%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:51%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Fair Value Hierarchy</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">December&#160;31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Measured at fair value on a recurring basis:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:normal;">Assets:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Investment securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Level 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">38.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Level 2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">13.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Funds associated with Israeli severance liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">16.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">15.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total level 2 assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">29.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">19.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Royalty Pharma contingent milestone payments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Level 3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">143.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:normal;">Financial assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,350.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total level 3 assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">143.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,350.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:normal;">Liabilities:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Contingent consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">44.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">69.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Measured at fair value on a non-recurring basis:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:normal;">Assets:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Goodwill</font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,148.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Indefinite-lived intangible assets</font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Level 3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">13.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Definite-lived intangible assets</font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">11.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">758.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Assets held for sale, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Level 3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">95.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">18.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total level 3 assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">119.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,924.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup>&#160;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">As of December 31, 2016, goodwill with a carrying amount of </font><font style="font-family:Arial;font-size:8pt;">$2.2 billion</font><font style="font-family:Arial;font-size:8pt;"> was written down to its implied fair value of </font><font style="font-family:Arial;font-size:8pt;">$1.1 billion</font><font style="font-family:Arial;font-size:8pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup>&#160;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">As of September 30, 2017, indefinite-lived intangible assets with a carrying amount of </font><font style="font-family:Arial;font-size:8pt;">$26.0 million</font><font style="font-family:Arial;font-size:8pt;"> were written down to a fair value of </font><font style="font-family:Arial;font-size:8pt;">$13.3&#160;million</font><font style="font-family:Arial;font-size:8pt;">. As of December 31, 2016, indefinite-lived intangible assets with a carrying amount of </font><font style="font-family:Arial;font-size:8pt;">$0.7 million</font><font style="font-family:Arial;font-size:8pt;"> were written down to a fair value of </font><font style="font-family:Arial;font-size:8pt;">$0.3&#160;million</font><font style="font-family:Arial;font-size:8pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3)</sup>&#160;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">As of July 1, 2017, definite-lived intangible assets with a carrying amount of </font><font style="font-family:Arial;font-size:8pt;">$31.1 million</font><font style="font-family:Arial;font-size:8pt;"> were written down to a fair value of </font><font style="font-family:Arial;font-size:8pt;">$11.5 million</font><font style="font-family:Arial;font-size:8pt;">. As of December 31, 2016, definite-lived intangible assets with a carrying amount of </font><font style="font-family:Arial;font-size:8pt;">$2.3 billion</font><font style="font-family:Arial;font-size:8pt;"> were written down to a fair value of </font><font style="font-family:Arial;font-size:8pt;">$758.0&#160;million</font><font style="font-family:Arial;font-size:8pt;">. Included in this balance are indefinite-lived intangible assets with a fair value of </font><font style="font-family:Arial;font-size:8pt;">$364.5 million</font><font style="font-family:Arial;font-size:8pt;"> and </font><font style="font-family:Arial;font-size:8pt;">$674.2 million</font><font style="font-family:Arial;font-size:8pt;"> that were reclassified to definite-lived assets at April 3, 2016 and October 2, 2016, respectively.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:24px;text-indent:-24px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">There were no transfers among Level 1, 2, and 3 during the </font><font style="font-family:Arial;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;"> or the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Arial;font-size:10pt;">. Our policy regarding the recording of transfers between levels is to record any such transfers at the end of the reporting period (refer to </font><a style="font-family:Arial;font-size:10pt;" href="#s82A8B05B43D85D919666D6DB32EE89A0"><font style="font-family:Arial;font-size:10pt;">Note 7</font></a><font style="font-family:Arial;font-size:10pt;"> for information on our investment securities and </font><a style="font-family:Arial;font-size:10pt;" href="#s316F9F75E2835BE4B08B80C361E97B07"><font style="font-family:Arial;font-size:10pt;">Note 8</font></a><font style="font-family:Arial;font-size:10pt;"> for a discussion of derivatives).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The fair value of foreign currency forward contracts is determined using a market approach, which utilizes values for comparable derivative instruments.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Funds Associated with Israel Severance Liability</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Israeli labor laws and agreements require us to pay benefits to employees dismissed or retiring under certain circumstances. Severance pay is calculated on the basis of the most recent employee salary levels and the length of employee service. Our Israeli subsidiaries also provide retirement bonuses to certain managerial employees. We make regular deposits to retirement funds and purchase insurance policies to partially fund these liabilities. The funds are determined using prices for recently traded financial instruments with similar underlying terms, as well as directly or indirectly observable inputs, such as interest rates and yield curves, that are observable at commonly quoted intervals.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Royalty Pharma Contingent Milestone Payments and Financial Assets</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;background-color:#ffffff;">On </font><font style="font-family:Arial;font-size:10pt;background-color:#ffffff;">December&#160;18, 2013</font><font style="font-family:Arial;font-size:10pt;background-color:#ffffff;">, we acquired Elan, which had</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">a royalty agreement with Biogen Idec Inc. ("Biogen"),</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">whereby Biogen conveyed the right to receive royalties that are typically payable on sales revenue generated by the sale, distribution or other use of the drug Tysabri</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;">. Pursuant to the royalty agreement, we were entitled to royalty payments from Biogen based on its Tysabri</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;"> sales in all indications and geographies. We received royalties of </font><font style="font-family:Arial;font-size:10pt;">12%</font><font style="font-family:Arial;font-size:10pt;"> on worldwide Biogen sales of Tysabri</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174; </sup></font><font style="font-family:Arial;font-size:10pt;">from December 18, 2013 through April 30, 2014. From May 1, 2014, we received royalties of </font><font style="font-family:Arial;font-size:10pt;">18%</font><font style="font-family:Arial;font-size:10pt;"> on annual worldwide Biogen sales of Tysabri</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174; </sup></font><font style="font-family:Arial;font-size:10pt;">up to </font><font style="font-family:Arial;font-size:10pt;">$2.0 billion</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">25%</font><font style="font-family:Arial;font-size:10pt;"> on annual sales above </font><font style="font-family:Arial;font-size:10pt;">$2.0 billion</font><font style="font-family:Arial;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;background-color:#ffffff;"></font><font style="font-family:Arial;font-size:10pt;">We accounted for the Tysabri</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;"> royalty stream as a financial asset and elected to use the fair value option model. We made the election to account for the Tysabri</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;"> financial asset using the fair value option as we believed this method was most appropriate for an asset that did not have a par value, a stated interest stream, or a termination date. </font><font style="font-family:Arial;font-size:10pt;background-color:#ffffff;">The financial asset acquired represented a single unit of accounting. The fair value of the financial asset acquired was determined by using a discounted cash flow analysis related to the expected probability weighted future cash flows to be generated by the royalty stream. The financial asset was classified as a Level 3 asset within the fair value hierarchy, as our valuation utilized significant unobservable inputs,</font><font style="font-family:Arial;font-size:10pt;"> including industry analyst estimates for global Tysabri</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;"> sales, probability weighted as to the timing and amount of future cash flows along with certain discount rate assumptions. Cash flow forecasts included the estimated effect and timing of future competition, considering patents in effect for Tysabri</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;"> through 2024 and contractual rights to receive cash flows into perpetuity. The discounted cash flows were based upon the expected royalty stream forecasted into perpetuity using a </font><font style="font-family:Arial;font-size:10pt;">20</font><font style="font-family:Arial;font-size:10pt;">-year discrete period with a declining rate terminal value. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In the first quarter of 2016, a competitor's pipeline product, Ocrevus</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;">, received breakthrough therapy designation from the U.S. Food and Drug Administration ("FDA"). </font><font style="font-family:Arial;font-size:10pt;color:#333333;">Breakthrough therapy designation is granted when a drug is intended alone or in combination with one or more other drugs to treat a serious or life threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. </font><font style="font-family:Arial;font-size:10pt;">In June 2016, the FDA granted priority review with a target action date in December 2016. A </font><font style="font-family:Arial;font-size:10pt;color:#222222;">priority review is a </font><font style="font-family:Arial;font-size:10pt;color:#333333;">designation when the FDA will direct overall attention and resources to the evaluation of applications for drugs that, if approved, would be significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to standard applications. The product was approved late in the first quarter of 2017. </font><font style="font-family:Arial;font-size:10pt;">The product is expected to compete with Tysabri</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;">, and we expected it to have a significant negative impact on the Tysabri</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174; </sup></font><font style="font-family:Arial;font-size:10pt;">royalty stream. Industry analysts believe that, based on released clinical study information, Ocrevus</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;"> will compete favorably against Tysabri</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;"> in the relapsing, remitting multiple sclerosis market segment due to its high efficacy and convenient dosage form. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Given the new market information for Ocrevus</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;">, we used industry analyst estimates to reduce our first ten year growth forecasts from an average of growth of approximately </font><font style="font-family:Arial;font-size:10pt;">3.4%</font><font style="font-family:Arial;font-size:10pt;"> in the fourth calendar quarter of 2015 to an average decline of approximately minus </font><font style="font-family:Arial;font-size:10pt;">2.0%</font><font style="font-family:Arial;font-size:10pt;"> in the third and fourth calendar quarters of 2016. In November 2016, we announced we were evaluating strategic alternatives for the Tysabri</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;"> asset. As of December 31, 2016, the financial asset was adjusted based on the strategic review and sale process. These effects, combined with the change in discount rate each quarter, led to a reduction in fair value of </font><font style="font-family:Arial;font-size:10pt;">$204.4 million</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">$910.8 million</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">$377.4 million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$1.1 billion</font><font style="font-family:Arial;font-size:10pt;"> in the first, second, third and fourth quarters of 2016, respectively. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On </font><font style="font-family:Arial;font-size:10pt;">March&#160;27, 2017</font><font style="font-family:Arial;font-size:10pt;">, we announced the completed divestment of our Tysabri</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;"> financial asset to Royalty Pharma for up to </font><font style="font-family:Arial;font-size:10pt;">$2.85 billion</font><font style="font-family:Arial;font-size:10pt;">, which consists of </font><font style="font-family:Arial;font-size:10pt;">$2.2 billion</font><font style="font-family:Arial;font-size:10pt;"> in cash and up to </font><font style="font-family:Arial;font-size:10pt;">$250.0 million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$400.0 million</font><font style="font-family:Arial;font-size:10pt;"> in milestone payments if the royalties on global net sales of Tysabri</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;"> that are received by Royalty Pharma meet specific thresholds in 2018 and 2020, respectively. As a result of this transaction, we transferred the entire financial asset to Royalty Pharma and recorded a </font><font style="font-family:Arial;font-size:10pt;">$17.1 million</font><font style="font-family:Arial;font-size:10pt;"> gain during the </font><font style="font-family:Arial;font-size:10pt;">three months ended</font><font style="font-family:Arial;font-size:10pt;"> July 1, 2017. We elected to account for the contingent milestone payments using the fair value option method, and these were recorded at an estimated fair value of </font><font style="font-family:Arial;font-size:10pt;">$143.2 million</font><font style="font-family:Arial;font-size:10pt;"> as of </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;">. We chose the fair value option as we believe it will help investors understand the potential future cash flows we may receive associated with the two contingent milestones.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We valued the contingent milestone payments using a modified Black-Scholes Option Pricing Model ("BSOPM"). Key inputs in the BSOPM are the estimated volatility and rate of return of royalties on global net sales of Tysabri</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;"> that are received by Royalty Pharma over time until payment of the contingent milestone payments is completed. Volatility and the estimated fair value of the milestones have a positive relationship such that higher volatility translates to a higher estimated fair value of the contingent milestone payments. In the valuation of contingent milestone payments performed, we assumed volatility of </font><font style="font-family:Arial;font-size:10pt;">30.0%</font><font style="font-family:Arial;font-size:10pt;"> and a rate of return of </font><font style="font-family:Arial;font-size:10pt;">8.05%</font><font style="font-family:Arial;font-size:10pt;"> as of July 1, 2017 and volatility of </font><font style="font-family:Arial;font-size:10pt;">30.0%</font><font style="font-family:Arial;font-size:10pt;"> and a rate of return of </font><font style="font-family:Arial;font-size:10pt;">8.06%</font><font style="font-family:Arial;font-size:10pt;"> as of </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;">. We assess volatility and rate of return inputs quarterly by analyzing certain market volatility benchmarks and the risk associated with Royalty Pharma achieving the underlying projected royalties. During the </font><font style="font-family:Arial;font-size:10pt;">three and nine months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;">, the fair value of the Royalty Pharma contingent milestone payments decreased </font><font style="font-family:Arial;font-size:10pt;">$2.9&#160;million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$42.1&#160;million</font><font style="font-family:Arial;font-size:10pt;">, respectively, as a result of the decrease in the estimated projected Tysabri</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;"> revenues due to the launch of Ocrevus</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;"> late in the first quarter of 2017.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our accounts receivable balance at December 31, 2016 included </font><font style="font-family:Arial;font-size:10pt;">$84.4 million</font><font style="font-family:Arial;font-size:10pt;"> related to the Tysabri</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;"> financial asset. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The table below presents a reconciliation for the </font><font style="font-family:Arial;font-size:10pt;">Royalty Pharma contingent milestone payments</font><font style="font-family:Arial;font-size:10pt;"> measured at fair value on a recurring basis using significant unobservable inputs (Level 3) (in millions). Change in fair value in the table was recorded in </font><font style="font-family:Arial;font-size:10pt;">Change in financial assets</font><font style="font-family:Arial;font-size:10pt;"> on the Condensed Consolidated Statements of Operations.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:562px;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:289px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:122px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:122px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Royalty Pharma Contingent Milestone Payments</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">145.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Additions</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">184.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Foreign currency effect</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Change in fair value</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(2.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(42.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">143.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">143.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Contingent Consideration</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Contingent consideration represents milestone payment obligations obtained through product acquisitions, which are valued using estimates based on probability-weighted outcomes, sensitivity analysis, and discount rates reflective of the risk involved. The estimates are updated quarterly and the liabilities are adjusted to fair value depending on a number of assumptions, including the competitive landscape and regulatory approvals that may impact the future sales of a product. We reduced a contingent consideration liability associated with certain IPR&amp;D assets (refer to </font><a style="font-family:Arial;font-size:10pt;" href="#s48E60FED28E45920BF8E539979F55C46"><font style="font-family:Arial;font-size:10pt;">Note 3</font></a><font style="font-family:Arial;font-size:10pt;">) and recorded a corresponding gain of </font><font style="font-family:Arial;font-size:10pt;">$17.0 million</font><font style="font-family:Arial;font-size:10pt;"> during the nine months ended </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;">. The liability decrease relates to a reduction of the probability of achievement assumptions and anticipated cash flows. Purchases or additions for the nine months ended </font><font style="font-family:Arial;font-size:10pt;">October&#160;1, 2016</font><font style="font-family:Arial;font-size:10pt;"> included contingent consideration associated with five transactions. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The table below presents a reconciliation for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) (in millions). Net realized losses in the table were recorded in </font><font style="font-family:Arial;font-size:10pt;">Other (income) expense, net</font><font style="font-family:Arial;font-size:10pt;"> on the Condensed Consolidated Statements of Operations.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:591px;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:200px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:82px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:82px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:82px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:82px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">October&#160;1, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">October&#160;1, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Contingent Consideration</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">49.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">44.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">69.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">17.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Net realized losses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(2.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(0.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(18.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(4.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Purchases or additions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">30.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">61.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Foreign currency effect</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Settlements</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(2.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(8.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">44.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">75.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">44.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">75.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill and Indefinite-Lived Intangible Assets</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have </font><font style="font-family:Arial;font-size:10pt;">seven</font><font style="font-family:Arial;font-size:10pt;"> reporting units for which we assess goodwill for impairment. We utilize a comparable company market approach, weighted equally with a discounted cash flow analysis, to determine the fair value of the reporting units</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">. </font><font style="font-family:Arial;font-size:10pt;">We utilize either a relief from royalty method or a multi-period excess earnings method ("MPEEM") to value our indefinite-lived intangible assets, and use a consistent set of projected financial information for the goodwill and indefinite-lived asset impairment tests. The discounted cash flow analysis that we prepared for goodwill impairment testing purposes for the </font><font style="font-family:Arial;font-size:10pt;">year ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Arial;font-size:10pt;"> included long-term growth rates ranging from </font><font style="font-family:Arial;font-size:10pt;">2.0%</font><font style="font-family:Arial;font-size:10pt;"> to </font><font style="font-family:Arial;font-size:10pt;">3.0%</font><font style="font-family:Arial;font-size:10pt;">. We also utilized discount rates ranging from </font><font style="font-family:Arial;font-size:10pt;">7.0%</font><font style="font-family:Arial;font-size:10pt;"> to </font><font style="font-family:Arial;font-size:10pt;">14.5%</font><font style="font-family:Arial;font-size:10pt;">, which were deemed to be commensurate with the required investment return and risk involved in realizing the projected free cash flows of each reporting unit. In addition, we burdened projected free cash flows with the capital spending deemed necessary to support the cash flows of each reporting unit, and applied the tax rates that were applicable to the jurisdictions represented within each reporting unit. We recorded impairment charges on the Condensed Consolidated Statements of Operations related to goodwill in the BCH-ROW reporting unit and indefinite-lived intangible assets of </font><font style="font-family:Arial;font-size:10pt;">$130.5 million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$273.4&#160;million</font><font style="font-family:Arial;font-size:10pt;">, respectively, for the three months ended April&#160;2, 2016. For the three months ended October 1, 2016, we recorded impairment charges related to goodwill on the Condensed Consolidated Statements of Operations of </font><font style="font-family:Arial;font-size:10pt;">$675.6 million</font><font style="font-family:Arial;font-size:10pt;"> in the BCH-ROW reporting unit and </font><font style="font-family:Arial;font-size:10pt;">$62.3 million</font><font style="font-family:Arial;font-size:10pt;"> in the BCH-Belgium reporting unit, as well as indefinite-lived intangible asset impairments of </font><font style="font-family:Arial;font-size:10pt;">$575.7 million</font><font style="font-family:Arial;font-size:10pt;"> (refer to </font><a style="font-family:Arial;font-size:10pt;" href="#s48E60FED28E45920BF8E539979F55C46"><font style="font-family:Arial;font-size:10pt;">Note 3</font></a><font style="font-family:Arial;font-size:10pt;">).</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Definite-Lived Intangible Assets</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">When assessing our definite-lived assets for impairment, we utilize either a MPEEM or a relief from royalty method to determine the fair value of the asset and use the forecasts that are consistent with those used in the reporting unit analysis. Below is a summary of the various metrics used in our valuations:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:44.23480083857442%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:55%;" rowspan="1" colspan="1"></td><td style="width:45%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Lumara</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5-year average growth rate</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(4.1)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Discount rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">13.5%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Valuation method</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">MPEEM</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Year Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Omega - Lifestyle</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Omega - XLS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Entocort</font><font style="font-family:Arial;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174; </sup></font><font style="font-family:Arial;font-size:9pt;font-weight:bold;">- Branded Products</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Entocort</font><font style="font-family:Arial;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174; </sup></font><font style="font-family:Arial;font-size:9pt;font-weight:bold;">- AG Products</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Herron Trade Names and Trademarks</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5-year average growth rate</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2.5%</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.2%</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(31.7)%</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(30.4)%</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4.6%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Long-term growth rates</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2.0%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">NA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(10.0)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(4.7)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2.5%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Discount rate</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">9.3%</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">9.5%</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">13.0%</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10.5%</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10.8%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Royalty rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">NA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4.0%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">NA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">NA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">11.0%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Valuation method</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">MPEEM</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Relief from Royalty</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">MPEEM</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">MPEEM</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Relief from Royalty</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"></font><font style="font-family:Arial;font-size:10pt;">We recorded </font><font style="font-family:Arial;font-size:10pt;">Impairment charges</font><font style="font-family:Arial;font-size:10pt;"> on the Condensed Consolidated Statements of Operations related to definite-lived intangible assets of </font><font style="font-family:Arial;font-size:10pt;">$18.5 million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$290.9 million</font><font style="font-family:Arial;font-size:10pt;"> for the nine months ended </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;"> and October 1, 2016, respectively (refer to </font><a style="font-family:Arial;font-size:10pt;" href="#s48E60FED28E45920BF8E539979F55C46"><font style="font-family:Arial;font-size:10pt;">Note 3</font></a><font style="font-family:Arial;font-size:10pt;">). </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Assets Held For Sale</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">When a group of assets is classified as held-for-sale, the book value is evaluated and adjusted to the lower of its carrying amount or fair value less the cost to sell (refer to </font><a style="font-family:Arial;font-size:10pt;" href="#s885CC1A6DECF525BA2FD099F6B19782B"><font style="font-family:Arial;font-size:10pt;">Note 9</font></a><font style="font-family:Arial;font-size:10pt;">).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Fixed Rate Long-term Debt</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">December 31, 2016</font><font style="font-family:Arial;font-size:10pt;">, our fixed rate long-term debt consisted of public bonds, a private placement note, and retail bonds. As of </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;">, the public bonds had a carrying value of </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$2.6 billion</font><font style="font-family:Arial;font-size:10pt;"> and a fair value of </font><font style="font-family:Arial;font-size:10pt;">$2.7 billion</font><font style="font-family:Arial;font-size:10pt;">. As of </font><font style="font-family:Arial;font-size:10pt;">December 31, 2016</font><font style="font-family:Arial;font-size:10pt;">, the public bonds had a carrying value and fair value of </font><font style="font-family:Arial;font-size:10pt;">$4.6&#160;billion</font><font style="font-family:Arial;font-size:10pt;">. The fair values of our public bonds for both periods were based on quoted market prices </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(Level 1). </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;">, our retail bonds and private placement note had a carrying value of </font><font style="font-family:Arial;font-size:10pt;">$655.8&#160;million</font><font style="font-family:Arial;font-size:10pt;"> (excluding a premium of </font><font style="font-family:Arial;font-size:10pt;">$35.6&#160;million</font><font style="font-family:Arial;font-size:10pt;">) and a fair value of </font><font style="font-family:Arial;font-size:10pt;">$699.2&#160;million</font><font style="font-family:Arial;font-size:10pt;">. As of </font><font style="font-family:Arial;font-size:10pt;">December 31, 2016</font><font style="font-family:Arial;font-size:10pt;">, our retail bonds and private placement note had a carrying value of </font><font style="font-family:Arial;font-size:10pt;">$773.1&#160;million</font><font style="font-family:Arial;font-size:10pt;"> (excluding a premium of </font><font style="font-family:Arial;font-size:10pt;">$49.8&#160;million</font><font style="font-family:Arial;font-size:10pt;">) and a fair value of </font><font style="font-family:Arial;font-size:10pt;">$825.0&#160;million</font><font style="font-family:Arial;font-size:10pt;">. The fair values of our retail bonds and private placement note for both periods were based on interest rates offered for borrowings of a similar nature and remaining maturities (Level 2). </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The carrying amounts of our other financial instruments, consisting of cash and cash equivalents, accounts receivable, accounts payable, short-term debt and variable rate long-term debt, approximate their fair value.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Below is a summary of the various metrics used in our valuations:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:44.23480083857442%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:55%;" rowspan="1" colspan="1"></td><td style="width:45%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Lumara</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5-year average growth rate</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(4.1)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Discount rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">13.5%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Valuation method</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">MPEEM</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Year Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Omega - Lifestyle</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Omega - XLS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Entocort</font><font style="font-family:Arial;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174; </sup></font><font style="font-family:Arial;font-size:9pt;font-weight:bold;">- Branded Products</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Entocort</font><font style="font-family:Arial;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174; </sup></font><font style="font-family:Arial;font-size:9pt;font-weight:bold;">- AG Products</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Herron Trade Names and Trademarks</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5-year average growth rate</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2.5%</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.2%</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(31.7)%</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(30.4)%</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4.6%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Long-term growth rates</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2.0%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">NA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(10.0)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(4.7)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2.5%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Discount rate</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">9.3%</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">9.5%</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">13.0%</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10.5%</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10.8%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Royalty rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">NA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4.0%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">NA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">NA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">11.0%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Valuation method</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">MPEEM</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Relief from Royalty</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">MPEEM</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">MPEEM</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Relief from Royalty</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The table below presents a reconciliation for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) (in millions). Net realized losses in the table were recorded in </font><font style="font-family:Arial;font-size:10pt;">Other (income) expense, net</font><font style="font-family:Arial;font-size:10pt;"> on the Condensed Consolidated Statements of Operations.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:591px;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:200px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:82px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:82px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:82px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:82px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">October&#160;1, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">October&#160;1, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Contingent Consideration</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">49.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">44.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">69.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">17.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Net realized losses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(2.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(0.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(18.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(4.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Purchases or additions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">30.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">61.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Foreign currency effect</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Settlements</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(2.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(8.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">44.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">75.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">44.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">75.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">GOODWILL AND OTHER INTANGIBLE ASSETS</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Changes in the carrying amount of goodwill, by reportable segment, were as follows (in millions):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.43605870020964%;border-collapse:collapse;text-align:left;"><tr><td colspan="21" rowspan="1"></td></tr><tr><td style="width:22%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;text-decoration:underline;">Reporting Segments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">December&#160;31, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Business divestitures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Re-class to assets held-for-sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Currency translation adjustment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">CHCA</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,810.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,813.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">CHCI</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,070.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(4.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">122.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,189.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">RX</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,086.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,093.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">81.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(32.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">7.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">56.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total goodwill</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4,049.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(4.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(32.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">139.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4,152.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As discussed in our Form 10-K for the year ended December 31, 2016, during the three months ended April 2, 2016 and October 1, 2016, we identified indicators of impairment for our Branded Consumer Healthcare - Rest of World ("BCH-ROW") reporting unit and recorded impairment charges of </font><font style="font-family:Arial;font-size:10pt;">$130.5 million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$675.6 million</font><font style="font-family:Arial;font-size:10pt;">, respectively. In addition, during the three months ended October 1, 2016, we identified impairment indicators in our Branded Consumer Healthcare - Belgium ("BCH-Belgium") reporting unit and recorded impairment charges of </font><font style="font-family:Arial;font-size:10pt;">$62.3&#160;million</font><font style="font-family:Arial;font-size:10pt;">. The impairment charges for both reporting units were recorded within our CHCI segment.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Intangible Assets</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other intangible assets and related accumulated amortization consisted of the following (in millions):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:39%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Gross</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Gross</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Accumulated Amortization</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;text-decoration:underline;">Definite-lived intangibles</font><font style="font-family:Arial;font-size:9pt;">:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Distribution and license agreements, supply agreements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">310.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">157.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">305.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">120.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Developed product technology, formulations, and product rights</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,355.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">568.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,418.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">526.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Customer relationships and distribution networks</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,623.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">424.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,489.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">307.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Trademarks, trade names, and brands</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,317.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">111.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,189.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">55.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Non-compete agreements</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">14.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">12.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">14.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">11.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total definite-lived intangibles</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4,621.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,274.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4,417.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,020.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;text-decoration:underline;">Indefinite-lived intangibles</font><font style="font-family:Arial;font-size:9pt;">:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Trademarks, trade names, and brands</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">52.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">50.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">In-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">51.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">64.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total indefinite-lived intangibles</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">103.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">114.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total other intangible assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4,724.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,274.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4,531.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,020.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Certain intangible assets are denominated in currencies other than the U.S. dollar; therefore, their gross and accumulated amortization balances are subject to foreign currency movements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We recorded amortization expense of </font><font style="font-family:Arial;font-size:10pt;">$88.5&#160;million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$89.7&#160;million</font><font style="font-family:Arial;font-size:10pt;"> for the </font><font style="font-family:Arial;font-size:10pt;">three months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">October&#160;1, 2016</font><font style="font-family:Arial;font-size:10pt;">, respectively, and </font><font style="font-family:Arial;font-size:10pt;">$261.3 million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$263.9 million</font><font style="font-family:Arial;font-size:10pt;"> for the </font><font style="font-family:Arial;font-size:10pt;">nine months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">October&#160;1, 2016</font><font style="font-family:Arial;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We recorded an impairment charge within our </font><font style="font-family:Arial;font-size:10pt;">RX</font><font style="font-family:Arial;font-size:10pt;"> segment of </font><font style="font-family:Arial;font-size:10pt;">$12.7 million</font><font style="font-family:Arial;font-size:10pt;"> on certain In Process Research and Development ("IPR&amp;D") assets during the nine months ended </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;"> due to changes in the projected development and regulatory timelines for various projects. During the </font><font style="font-family:Arial;font-size:10pt;">nine months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;">, we recorded a decrease in the contingent consideration liability associated with certain IPR&amp;D assets in </font><font style="font-family:Arial;font-size:10pt;">Other operating income</font><font style="font-family:Arial;font-size:10pt;"> on the Condensed Consolidated Statements of Operations (refer to </font><a style="font-family:Arial;font-size:10pt;" href="#sF836944F4019590E9F66D3105947A1DC"><font style="font-family:Arial;font-size:10pt;">Note 6</font></a><font style="font-family:Arial;font-size:10pt;">). </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">During the three months ended July 1, 2017, we identified impairment indicators for our Lumara Health, Inc. ("Lumara") product assets. The primary impairment indicators included the decline in our 2017 performance expectations and a reduction in our long-range revenue growth forecast. The assessment utilized the multi-period excess earnings method to determine fair value and resulted in an impairment charge of </font><font style="font-family:Arial;font-size:10pt;">$18.5 million</font><font style="font-family:Arial;font-size:10pt;"> in </font><font style="font-family:Arial;font-size:10pt;">Impairment charges</font><font style="font-family:Arial;font-size:10pt;"> on the Condensed Consolidated Statements of Operations within our </font><font style="font-family:Arial;font-size:10pt;">RX</font><font style="font-family:Arial;font-size:10pt;"> segment, which represented the difference between the carrying amount of the intangible assets and their estimated fair value. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As discussed in our Form 10-K for the year ended December 31, 2016, during the three months ended April 2, 2016, we identified indicators of impairment associated with certain indefinite-lived intangible assets acquired in conjunction with our acquisition of Omega Pharma Invest N.V. ("Omega") and recorded an impairment charge of </font><font style="font-family:Arial;font-size:10pt;">$273.4 million</font><font style="font-family:Arial;font-size:10pt;">. In addition, during the three months ended October 1, 2016, we identified indicators of impairment associated with certain indefinite-lived and definite-lived intangible brand category assets acquired in conjunction with the Omega acquisition. As a result of these additional indicators, we recorded impairment charges of </font><font style="font-family:Arial;font-size:10pt;">$575.7&#160;million</font><font style="font-family:Arial;font-size:10pt;"> on our indefinite-lived assets and </font><font style="font-family:Arial;font-size:10pt;">$290.9 million</font><font style="font-family:Arial;font-size:10pt;"> on our definite-lived assets. The impairment charges for both the indefinite-lived assets and definite-lived assets were recorded within our CHCI segment.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition, due to reprioritization of certain brands in the </font><font style="font-family:Arial;font-size:10pt;">CHCI</font><font style="font-family:Arial;font-size:10pt;"> segment and change in performance expectations for the cough/cold/allergy, anti-parasite, personal care, lifestyle, and natural health brands, we reclassified </font><font style="font-family:Arial;font-size:10pt;">$364.5 million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$674.4 million</font><font style="font-family:Arial;font-size:10pt;"> of indefinite-lived assets to definite-lived assets with useful lives of </font><font style="font-family:Arial;font-size:10pt;">20</font><font style="font-family:Arial;font-size:10pt;"> years, which we began amortizing during the second and third quarters of 2016, respectively.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">INCOME TAXES</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The effective tax rates were as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:387px;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:81px;" rowspan="1" colspan="1"></td><td style="width:11px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:81px;" rowspan="1" colspan="1"></td><td style="width:11px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:81px;" rowspan="1" colspan="1"></td><td style="width:11px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:81px;" rowspan="1" colspan="1"></td><td style="width:11px;" rowspan="1" colspan="1"></td></tr><tr><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">October&#160;1, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">October&#160;1, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">65.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">16.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">68.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">17.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;"></font><font style="font-family:Arial;font-size:10pt;">The effective tax rate for the </font><font style="font-family:Arial;font-size:10pt;">nine months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;"> was negatively impacted by non-deductible fees related to our debt cancellation, discrete tax items, and additional valuation allowances recorded against deferred tax assets.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our tax rate is subject to adjustment over the balance of the fiscal year due to, among other things: the jurisdictions in which our profits are determined to be earned and taxed; changes in the valuation of our deferred tax assets and liabilities; adjustments to estimated taxes upon finalization of various tax returns; adjustments based on differing interpretations of the applicable transfer pricing standards; changes in available tax credits, grants and other incentives; changes in stock-based compensation expense; changes in tax laws or the interpretation of such tax laws (for example, proposals for fundamental U.S. international tax reform); changes in U.S. GAAP; and expiration of or the inability to renew tax rulings or tax holiday incentives.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The total liability for uncertain tax positions was </font><font style="font-family:Arial;font-size:10pt;">$454.9 million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$398.0 million</font><font style="font-family:Arial;font-size:10pt;"> as of </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">December 31, 2016</font><font style="font-family:Arial;font-size:10pt;">, respectively, before considering the federal tax benefit of certain state and local items.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We recognize interest and penalties related to uncertain tax positions as a component of income tax expense. The total amount accrued for interest and penalties in the liability for uncertain tax positions was </font><font style="font-family:Arial;font-size:10pt;">$79.0&#160;million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$63.5&#160;million</font><font style="font-family:Arial;font-size:10pt;"> as of </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">December 31, 2016</font><font style="font-family:Arial;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We file income tax returns in numerous jurisdictions and are therefore subject to audits by tax authorities. Our primary income tax jurisdictions are Ireland, the United States, Israel, Belgium, France, and the United Kingdom.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On August 15, 2017, we filed a complaint in the United States District Court for the Western District of Michigan to recover $</font><font style="font-family:Arial;font-size:10pt;">163.6 million</font><font style="font-family:Arial;font-size:10pt;"> of Federal income tax, penalties, and interest assessed and collected by the Internal Revenue Service (&#8220;IRS&#8221;), plus statutory interest thereon from the dates of payment, for the fiscal years ended June 27, 2009, June 26, 2010, June 25, 2011, and June 30, 2012 (the &#8220;2009 tax year,&#8221; &#8220;2010 tax year,&#8221; &#8220;2011 tax year,&#8221; and &#8220;2012 tax year,&#8221; respectively). The IRS audits of those years culminated in the issuances of two statutory notices of deficiency: (1) on August 27, 2014 for the 2009 and 2010 tax years and (2) on April 20, 2017 for the 2011 and 2012 tax years. The statutory notices of deficiency both included un-agreed income adjustments related principally to transfer pricing adjustments regarding the purchase, distribution, and sale of store-brand OTC pharmaceutical products in the United States. In addition, the statutory notice of deficiency for the 2011 and 2012 tax years included the capitalization of certain expenses that were deducted when paid or incurred in defending against certain patent infringement lawsuits. We fully paid the assessed amounts of tax, interest, and penalties set forth in the statutory notices and filed timely claims for refund on June 11, 2015 and June 7, 2017 for the 2009-2010 tax years and 2011-2012 tax years, respectively. Our claims for refund were disallowed by certified letters dated August 18, 2015 and July 11, 2017, for the 2009-2010 tax years and 2011-2012 tax years, respectively. The complaint was timely, based upon the refund claim denials, and seeks refunds of tax, interest, and penalties of </font><font style="font-family:Arial;font-size:10pt;">$37.2 million</font><font style="font-family:Arial;font-size:10pt;"> for the 2009 tax year, $</font><font style="font-family:Arial;font-size:10pt;">61.5 million</font><font style="font-family:Arial;font-size:10pt;"> for the 2010 tax year, $</font><font style="font-family:Arial;font-size:10pt;">40.2 million</font><font style="font-family:Arial;font-size:10pt;"> for the 2011 tax year, and $</font><font style="font-family:Arial;font-size:10pt;">24.7&#160;million</font><font style="font-family:Arial;font-size:10pt;"> for the 2012 tax year. The amounts sought in the complaint for the 2009 and 2010 tax years were recorded as deferred charges on our balance sheet during the three months ended March 28, 2015, and the amounts sought in the complaint for the 2011 and 2012 tax years were recorded as deferred charges on our balance sheet during the three months ended July 1, 2017.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On December 22, 2016, we received a notice of proposed adjustment for the IRS audit of Athena Neurosciences, Inc. (&#8220;Athena&#8221;), a subsidiary of Elan acquired in 1996, for the years ended December 31, 2011, December 31, 2012, and December 31, 2013.&#160;Perrigo acquired Elan in December 2013.&#160;This proposed adjustment relates to the deductibility of litigation costs.&#160;We disagree with the IRS&#8217;s position asserted in the notice of proposed adjustment and intend to contest it.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On July 11, 2017, we received a draft notice of proposed adjustment associated with transfer pricing positions for the IRS audit of Athena for the years ended December 31, 2011, December 31, 2012, and December 31, 2013.&#160; Athena was the originator of the patents associated with Tysabri</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;"> prior to the acquisition of Athena by Elan in 1996.&#160;The amount of adjustments that may be asserted by the IRS in the final notice of proposed adjustment cannot be quantified at this time; however, based on the draft notice received, the amount to be assessed may be material. We disagree with the IRS&#8217;s position as asserted in the draft notice of proposed adjustment and intend to contest it.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have ongoing audits in multiple other jurisdictions the resolution of which remains uncertain. These jurisdictions include, but are not limited to, the United States, Israel and France. In addition to the matters discussed above, the IRS is currently auditing our fiscal years ended June 29, 2013, June 28, 2014, and June 27, 2015. The Israel Tax Authority is currently auditing our fiscal years ended June 29, 2013 and June 28, 2014. The French Tax Authority is currently auditing the years ended December 2014, December 2015, and December 2016.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">INVENTORIES</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Major components of inventory were as follows (in millions):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:58.490566037735846%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">December&#160;31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Finished goods</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">471.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">431.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">146.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">165.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Raw materials</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">203.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">198.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total inventories</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">821.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">795.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Standard Pronouncements</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Below are recent accounting standard updates that we are still assessing to determine the effect on our Condensed Consolidated Financial Statements. We do not believe that any other recently issued accounting standards could have a material effect on our Condensed Consolidated Financial Statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:31%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:34%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Recently Issued Accounting Standards Adopted</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Standard</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Date of adoption</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Effect on the Financial Statements or Other Significant Matters</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Clarifying the Definition of a Business</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">This update clarifies the definition of a business and addresses whether transactions should be accounted for as asset acquisitions or business combinations (or divestitures).&#160;The guidance includes an initial threshold that an acquired set of assets will not be considered a business if substantially all of the fair value of the assets acquired is concentrated in a single tangible or identifiable intangible asset (or group of similar assets). If the acquired set does not pass the initial threshold, then the guidance requires that, to be a business, the set must include an input and a substantive process that together significantly contribute to the ability to create outputs. Different factors are considered to determine whether the set includes a substantive process, such as the inclusion of an organized workforce. Further, the guidance removes language stating that a business need not include all of the inputs and processes that the seller used in operating the business.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">January 1, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">We early adopted this new standard and will apply it prospectively when determining whether transactions should be accounted for as asset acquisitions (divestitures) or business combinations (divestitures). During the nine months ended September 30, 2017, we applied the new guidance when determining whether certain product divestitures represented sales of assets or businesses.</font></div><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Improvements to Employee Share-Based Payment Accounting<br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">This guidance is intended to simplify several aspects of the accounting for share-based payment award transactions. It will require all income tax effects of awards to be recorded through the income statement when the awards vest or settle as opposed to certain amounts being recorded in additional paid-in capital. An entity will also have to elect whether to account for forfeitures as they occur or by estimating the number of awards expected to be forfeited and adjusting the estimate when it is likely to change (as currently required). The guidance will also increase the amount an employer can withhold to cover income taxes on awards. </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">January 1, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">We adopted this standard as of January 1, 2017. We elected to estimate the number of awards expected to be forfeited and adjust the estimate when it is likely to change, consistent with past practice. We did not change the amounts that we withhold to cover income taxes on awards. As the requirement to record all income tax effects of vested or settled awards through the income statement is prospective in nature, there was no cumulative effect of adopting the standard on our balance sheet.</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">General Information</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">The Company</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Perrigo Company plc was incorporated under the laws of Ireland on June 28, 2013 and became the successor registrant of Perrigo Company, a Michigan corporation, on December&#160;18, 2013 in connection with the acquisition of Elan Corporation, plc ("Elan"). Unless the context requires otherwise, the terms "Perrigo," the "Company," "we," "our," "us," and similar pronouns used herein refer to Perrigo Company plc, its subsidiaries, and all predecessors of Perrigo Company plc and its subsidiaries.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We are a leading global healthcare company, delivering value to our customers and consumers by providing Quality Affordable Healthcare Products</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;">. Founded in 1887 as a packager of home remedies, we have built a unique business model that is best described as the convergence of a fast-moving consumer goods company, a high-quality pharmaceutical manufacturing organization and a world-class supply chain network. We believe we are one of the world's largest manufacturers of over-the-counter (&#8220;OTC&#8221;) healthcare products and suppliers of infant formulas for the store brand market. We also are a leading provider of branded OTC products throughout Europe and the U.S., as well as a leading producer of generic standard topical products such as creams, lotions, and gels, as well as inhalants and injections ("extended topical") prescription drugs. We are headquartered in Ireland, and sell our products primarily in North America and Europe, as well as in other markets, including Australia, Israel and China.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Basis of Presentation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The unaudited Condensed Consolidated Financial Statements should be read in conjunction with the consolidated financial statements and footnotes included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:Arial;font-size:10pt;">December 31, 2016</font><font style="font-family:Arial;font-size:10pt;">. In the opinion of management, all adjustments (consisting of normal recurring accruals and other adjustments) considered necessary for a fair presentation of the unaudited Condensed Consolidated Financial Statements have been included and include our accounts and the accounts of all majority-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Standard Pronouncements</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Below are recent accounting standard updates that we are still assessing to determine the effect on our Condensed Consolidated Financial Statements. We do not believe that any other recently issued accounting standards could have a material effect on our Condensed Consolidated Financial Statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:31%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:34%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Recently Issued Accounting Standards Adopted</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Standard</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Date of adoption</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Effect on the Financial Statements or Other Significant Matters</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Clarifying the Definition of a Business</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">This update clarifies the definition of a business and addresses whether transactions should be accounted for as asset acquisitions or business combinations (or divestitures).&#160;The guidance includes an initial threshold that an acquired set of assets will not be considered a business if substantially all of the fair value of the assets acquired is concentrated in a single tangible or identifiable intangible asset (or group of similar assets). If the acquired set does not pass the initial threshold, then the guidance requires that, to be a business, the set must include an input and a substantive process that together significantly contribute to the ability to create outputs. Different factors are considered to determine whether the set includes a substantive process, such as the inclusion of an organized workforce. Further, the guidance removes language stating that a business need not include all of the inputs and processes that the seller used in operating the business.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">January 1, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">We early adopted this new standard and will apply it prospectively when determining whether transactions should be accounted for as asset acquisitions (divestitures) or business combinations (divestitures). During the nine months ended September 30, 2017, we applied the new guidance when determining whether certain product divestitures represented sales of assets or businesses.</font></div><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Improvements to Employee Share-Based Payment Accounting<br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">This guidance is intended to simplify several aspects of the accounting for share-based payment award transactions. It will require all income tax effects of awards to be recorded through the income statement when the awards vest or settle as opposed to certain amounts being recorded in additional paid-in capital. An entity will also have to elect whether to account for forfeitures as they occur or by estimating the number of awards expected to be forfeited and adjusting the estimate when it is likely to change (as currently required). The guidance will also increase the amount an employer can withhold to cover income taxes on awards. </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">January 1, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">We adopted this standard as of January 1, 2017. We elected to estimate the number of awards expected to be forfeited and adjust the estimate when it is likely to change, consistent with past practice. We did not change the amounts that we withhold to cover income taxes on awards. As the requirement to record all income tax effects of vested or settled awards through the income statement is prospective in nature, there was no cumulative effect of adopting the standard on our balance sheet.</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:31%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:34%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Recently Issued Accounting Standards Not Yet Adopted</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Standard</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Effective Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Effect on the Financial Statements or Other Significant Matters</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Revenue from Contracts with Customers </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: identify the contract(s) with a customer; identify the performance obligations in the contract; determine the transaction price; allocate the transaction price to the performance obligations in the contract; and recognize revenue when (or as) the entity satisfies a performance obligation. This guidance allows for two adoption methods, full retrospective approach or modified retrospective approach.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">January 1, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">We continue to evaluate the implications of adoption of the new revenue standard on our Consolidated Financial Statements. We have completed an initial assessment and are in the process of quantifying the adoption impact, if any, related to certain topics identified through our evaluation process. Our assessment of the new revenue standard has been focused on, but has not been limited to, the concepts of over-time versus point-in-time revenue recognition patterns, variable consideration, and identification of performance obligations. We will not complete our final assessment and quantification of the impact of the new revenue standard on our Consolidated Financial Statements until the adoption date. Our analysis indicates that certain contract manufacturing and private label arrangements may require revenue recognition over-time in situations in which we produce products that have no alternative use and we have an enforceable right to payment for performance completed to date, inclusive of a reasonable profit margin. This may result in an acceleration of revenue recognition for certain contractual arrangements as compared to recognition under current accounting literature. We plan to adopt the new revenue standard effective January 1, 2018 using the modified retrospective method.</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Intra-Entity Asset Transfers of Assets Other Than Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Under the new guidance, the tax impact to the seller on the profit from the transfers and the buyer&#8217;s deferred tax benefit on the increased tax basis would be recognized when the transfers occur, resulting in the recognition of expense sooner than under historical guidance. The guidance excludes intra-entity transfers of inventory. For intra-entity transfers of inventory, the Financial Accounting Standards Board ("FASB") decided to retain current GAAP, which requires an entity to recognize the income tax consequences when the inventory has been sold to an outside party. </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">January 1, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">We are currently evaluating the implications of adoption on our Consolidated Financial Statements.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Financial Instruments - Recognition and Measurement of Financial Assets and Liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">The objective of this simplification update is to improve the decision usefulness of financial instrument reporting, and it principally affects accounting for equity investments currently classified as available for sale and financial liabilities where the fair value option has been elected. Entities will have to measure many equity investments at fair value and recognize changes in fair value in net income rather than other comprehensive income as required under current U.S. GAAP. </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">January 1, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">We have identified certain investments that will require an adjustment, however, at this time, we are unable to estimate the impact of adopting this standard as the significance of the impact will depend upon our equity investments as of the date of adoption.</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:31%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:34%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Recently Issued Accounting Standards Not Yet Adopted (continued)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Standard</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Effective Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Effect on the Financial Statements or Other Significant Matters</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Leases</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">This guidance was issued to increase transparency and comparability among organizations by requiring recognition of lease assets and lease liabilities on the balance sheet and disclosure of key information about leasing arrangements. For leases with a term of 12 months or less, lessees are permitted to make an election to not recognize right-of-use assets and lease liabilities. Upon adoption, lessees will apply the new standard as of the beginning of the earliest comparative period presented in the financial statements, however lessees will be able to exclude leases that expire as of the implementation date. Early adoption is permitted.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">January 1, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">We are currently evaluating the implications of adoption on our Consolidated Financial Statements and have commenced the first step of identifying a task force to take the lead in implementing the new Lease standard.</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Derivatives and Hedging</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">This update was issued to enable entities to better portray the economics of their risk management activities in the financial statements and enhance the transparency and understandability of hedge results. In addition, the amendments simplify the application of hedge accounting in certain situations. Under the new rule, the entity&#8217;s ability to hedge non-financial and financial risk components is expanded. The guidance eliminates the requirement to separately measure and report hedge ineffectiveness and also eases certain documentation and assessment requirements. Early adoption is permitted.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">January 1, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">We are currently evaluating the implications of adoption on our Consolidated Financial Statements.</font></div><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Measurement of Credit Losses on Financial Instruments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">This guidance changes the impairment model for most financial assets and certain other instruments, replacing the current "incurred loss" approach with an "expected loss" credit impairment model, which will apply to most financial assets measured at amortized cost and certain other instruments, including trade and other receivables, loans, held-to-maturity debt securities, and off-balance sheet credit exposures such as letters of credit. Early adoption is permitted.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">January 1, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">We are currently evaluating the new standard for potential impacts on our receivables, debt, and other financial instruments.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Intangibles - Goodwill and Other Simplifying the Test for Goodwill </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">The objective of this update is to reduce the cost and complexity of subsequent goodwill accounting by simplifying the impairment test by removing the Step 2 requirement to perform a hypothetical purchase price allocation when the carrying value of a reporting unit exceeds its fair value.&#160;If a reporting unit&#8217;s carrying value exceeds its fair value, an entity would record an impairment charge based on that difference, limited to the amount of goodwill attributed to that reporting unit. The proposal would not change the guidance on completing Step 1 of the goodwill impairment test. The proposed guidance would be applied prospectively. Early adoption is permitted.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">January 1, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">We are currently evaluating the implications of adoption on our Consolidated Financial Statements.</font></div><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The gains (losses) reclassified from AOCI into earnings for the effective portion of our designated cash flow hedges were as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:791px;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td style="width:240px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:173px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:82px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:70px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:82px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:71px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Amount of Gain/(Loss) Reclassified from AOCI into Earnings <br clear="none"/>(Effective Portion)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Designated Cash Flow Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Income Statement Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">October&#160;1, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">October&#160;1, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Treasury locks</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Interest expense, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Interest rate swap agreements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Interest expense, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(0.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Other (income) expense, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(5.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Net sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Cost of sales</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Interest expense, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(0.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Other (income) expense, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(0.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(6.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(0.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">RESTRUCTURING CHARGES</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We periodically take action to reduce redundant expenses and improve operating efficiencies. The following reflects our restructuring activity (in millions): </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:597px;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:184px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:86px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:86px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:86px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:86px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">October&#160;1, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">October&#160;1, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">39.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">12.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">19.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">20.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Additional charges</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">54.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">17.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(17.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(8.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(47.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(33.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Non-cash adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(0.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">26.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">26.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Restructuring activity includes severance, lease exit costs, and asset impairments. The charges incurred during the </font><font style="font-family:Arial;font-size:10pt;">three and nine months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;"> were primarily associated with actions we took to streamline our organization as announced on February 21, 2017. During the </font><font style="font-family:Arial;font-size:10pt;">three and nine months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">$3.8&#160;million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$54.7 million</font><font style="font-family:Arial;font-size:10pt;"> of restructuring expenses were recorded, respectively. Of the amount recorded during the nine months ended </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">$27.2 million</font><font style="font-family:Arial;font-size:10pt;"> was related to the CHCA segment. There were no other material restructuring programs that significantly impacted any other reportable segments. All charges are recorded in </font><font style="font-family:Arial;font-size:10pt;">Restructuring</font><font style="font-family:Arial;font-size:10pt;"> on the Condensed Consolidated Statements of Operations. The remaining </font><font style="font-family:Arial;font-size:10pt;">$22.4&#160;million</font><font style="font-family:Arial;font-size:10pt;"> liability for employee severance benefits is expected to be paid within the next year, while the remaining </font><font style="font-family:Arial;font-size:10pt;">$3.7&#160;million</font><font style="font-family:Arial;font-size:10pt;"> liability for lease exit costs is expected to be incurred over the remaining terms of the applicable leases.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Changes in our AOCI balances, net of tax were as follows (in millions): </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:31%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Foreign currency translation adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Fair value of derivative financial instruments, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Fair&#160;value&#160;of investment securities, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Post-retirement and pension liability adjustments, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Total AOCI</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(67.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(19.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">15.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(9.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(81.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">OCI before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">289.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(22.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">270.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Amounts reclassified from AOCI </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">289.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">8.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(24.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">273.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Balance at September 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">222.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(10.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(9.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(10.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">191.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total borrowings outstanding are summarized as follows (in millions): </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.43605870020964%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:5%;" rowspan="1" colspan="1"></td><td style="width:22%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">December&#160;31, <br clear="none"/>2016</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Term loans</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2014 term loan due December 5, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup>&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">428.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">420.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Notes and Bonds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Coupon</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Due</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4.500%</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">May&#160;23, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)(2)</sup>&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">189.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.125%</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">December&#160;12, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)(2)</sup>&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">354.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">315.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2.300%</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">November&#160;8, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">600.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.000%</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">May&#160;23, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)(2)</sup>&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">141.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">126.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.500%</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">March&#160;15, 2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">280.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">500.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.500%</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">December&#160;15, 2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">309.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">500.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.105%</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">July&#160;19, 2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)(2)</sup>&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">159.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">142.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4.000%</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">November&#160;15, 2023</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">215.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">800.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.900%</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">December&#160;15, 2024</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">700.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">700.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4.375%</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">March&#160;15, 2026</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">700.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">700.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.300%</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">November&#160;15, 2043</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">90.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">400.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4.900%</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">December&#160;15, 2044</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">303.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">400.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Total notes and bonds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,255.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5,373.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td colspan="5" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Other financing</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Unamortized premium (discount), net</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">24.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">33.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Deferred financing fees</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(19.0</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(33.1</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Total borrowings outstanding</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,692.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5,797.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Current indebtedness</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(417.1</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(572.8</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Total long-term debt less current portion</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,275.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5,224.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Debt denominated in Euros subject to fluctuations in the euro-to-U.S. dollar exchange rate.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Debt assumed from Omega.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br clear="none"/></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The gains (losses) recorded in OCI for the effective portion of our designated cash flow hedges were as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:624px;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:240px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:79px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:79px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:79px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:79px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Amount of Gain/(Loss) Recorded in OCI<br clear="none"/>(Effective Portion)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Designated Cash Flow Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">October&#160;1, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">October&#160;1, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Interest rate swap agreements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(9.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(4.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The balance sheet location and gross fair value of our outstanding derivative instruments were as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:87.0020964360587%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Asset Derivatives</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Balance&#160;Sheet&#160;Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">December&#160;31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Designated derivatives:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Other&#160;current&#160;assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Non-designated derivatives:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">8.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.25995807127882%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td style="width:39%;" rowspan="1" colspan="1"></td><td style="width:27%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Liability Derivatives</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Balance&#160;Sheet&#160;Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">December&#160;31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Designated derivatives:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Accrued liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Non-designated derivatives:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Accrued liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The amounts consist of the following (in millions): </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:81.9706498951782%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">December&#160;31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;font-weight:bold;">CHCA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;font-weight:bold;">Other</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;font-weight:bold;">Assets held for sale</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">Current assets</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">44.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">5.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">Goodwill</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">32.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">5.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">5.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">Property, plant and equipment</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">45.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">13.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">33.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">Other assets</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">3.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">3.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">Less: impairment reserves</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">(3.3</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">(3.7</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">(35.3</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;font-weight:bold;">Total assets held for sale </font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">127.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">9.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">12.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;font-weight:bold;">Liabilities held for sale</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">Current liabilities</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">7.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">1.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">Other liabilities</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">25.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">1.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;font-weight:bold;">Total liabilities held for sale</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">32.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#252525;">3.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A reconciliation of the numerators and denominators used in the basic and diluted earnings per share ("EPS") calculation is as follows (in millions): </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">October&#160;1, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">October&#160;1, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">44.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1,590.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">46.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(2,653.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Weighted average shares outstanding for basic EPS</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">141.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">143.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">142.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">143.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Dilutive effect of share-based awards*</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Weighted average shares outstanding for diluted EPS</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">141.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">143.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">142.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">143.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Anti-dilutive share-based awards excluded from </font></div><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;computation of diluted EPS*</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">* In the period of a net loss, diluted shares equal basic shares.</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br clear="none"/></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The effective tax rates were as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:387px;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:81px;" rowspan="1" colspan="1"></td><td style="width:11px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:81px;" rowspan="1" colspan="1"></td><td style="width:11px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:81px;" rowspan="1" colspan="1"></td><td style="width:11px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:81px;" rowspan="1" colspan="1"></td><td style="width:11px;" rowspan="1" colspan="1"></td></tr><tr><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">October&#160;1, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">October&#160;1, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">65.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">16.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">68.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">17.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">%</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As a result of the of the early redemption and tender offer transactions discussed above, we recorded a loss of </font><font style="font-family:Arial;font-size:10pt;">$135.2 million</font><font style="font-family:Arial;font-size:10pt;"> during the three months ended July&#160;1, 2017 in </font><font style="font-family:Arial;font-size:10pt;">Loss on extinguishment of debt</font><font style="font-family:Arial;font-size:10pt;"> (in millions): </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:63.731656184486376%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Premium on debt repayment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">116.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Transaction costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Write-off of deferred financing fees</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Write-off of remaining discount on bond</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total loss on extinguishment of debt</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">135.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Changes in the carrying amount of goodwill, by reportable segment, were as follows (in millions):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.43605870020964%;border-collapse:collapse;text-align:left;"><tr><td colspan="21" rowspan="1"></td></tr><tr><td style="width:22%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;text-decoration:underline;">Reporting Segments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">December&#160;31, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Business divestitures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Re-class to assets held-for-sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Currency translation adjustment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">CHCA</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,810.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,813.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">CHCI</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,070.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(4.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">122.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,189.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">RX</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,086.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,093.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">81.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(32.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">7.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">56.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total goodwill</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4,049.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(4.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(32.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">139.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4,152.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Major components of inventory were as follows (in millions):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:58.490566037735846%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">December&#160;31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Finished goods</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">471.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">431.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">146.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">165.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Raw materials</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">203.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">198.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total inventories</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">821.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">795.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The effects of our non-designated derivatives on the Condensed Consolidated Statements of Operations were as follows: </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:22%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Amount of Gain/(Loss) Recognized against Earnings</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Non-Designated Derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Income Statement Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">October&#160;1, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">October&#160;1, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Other (income) expense, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(0.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(3.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(8.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Interest expense, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(2.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">8.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(6.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(10.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following reflects our restructuring activity (in millions): </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:597px;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:184px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:86px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:86px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:86px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:86px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">October&#160;1, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">October&#160;1, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">39.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">12.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">19.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">20.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Additional charges</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">54.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">17.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(17.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(8.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(47.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(33.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Non-cash adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(0.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">26.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">26.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The below tables show select financial measures by reporting segment (in millions):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:49.10807974816369%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:38%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:27%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:27%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Total Assets</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">December&#160;31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">CHCA</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,833.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,351.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">CHCI</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5,114.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4,795.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">RX</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,597.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,646.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Specialty Sciences</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,775.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Other</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">297.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">301.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">11,842.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">13,870.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">October 1, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Net </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Operating Income (Loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Intangible Asset Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Net </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Operating Income (Loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Intangible Asset Amortization</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">CHCA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">598.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">124.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">16.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">611.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">99.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">17.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">CHCI</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">365.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">50.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">377.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1,615.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">44.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">RX</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">250.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">82.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">21.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">251.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">74.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">27.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Specialty Sciences</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">16.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(0.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">21.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Unallocated</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(48.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(27.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,231.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">162.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">88.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,261.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1,468.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">89.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">October 1, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Net </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Operating Income (Loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Intangible Asset Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Net </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Operating Income (Loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Intangible Asset Amortization</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">CHCA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,786.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">303.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">51.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,880.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">316.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">53.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">CHCI</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,116.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">8.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">143.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,232.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(2,011.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">130.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">RX</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">708.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">239.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">65.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">776.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">258.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">78.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Specialty Sciences</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">51.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">9.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">59.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Unallocated</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(121.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(79.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,663.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">439.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">261.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,949.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1,515.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">263.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We issued shares related to the exercise and vesting of share-based compensation as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:61.21593291404612%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">October&#160;1, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">October&#160;1, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">99,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">185,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">146,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">283,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">SEGMENT INFORMATION</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our reporting segments are as follows: </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-weight:bold;">CHCA</font><font style="font-family:Arial;font-size:10pt;">,</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;"> </font><font style="font-family:Arial;font-size:10pt;">comprises our U.S., Mexico and Canada consumer healthcare business (OTC, contract, infant formula and animal health categories). </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-weight:bold;">CHCI</font><font style="font-family:Arial;font-size:10pt;">,</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;"> </font><font style="font-family:Arial;font-size:10pt;">comprises our legacy Branded Consumer Healthcare segment and now includes our consumer focused businesses in the U.K., Australia, and Israel. This segment also includes our U.K. liquid licensed products business.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-weight:bold;">RX</font><font style="font-family:Arial;font-size:10pt;">,</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;"> </font><font style="font-family:Arial;font-size:10pt;">comprises our U.S. Prescription Pharmaceuticals business.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We also have an "</font><font style="font-family:Arial;font-size:10pt;">Other</font><font style="font-family:Arial;font-size:10pt;">" reporting segment that consists of our legacy API business, which does not meet the quantitative threshold required to be a separately reportable segment. Effective January 1, 2017, due to the sale of the Tysabri</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;"> financial asset, all legal expenses associated with the former Specialty Sciences segment were moved to unallocated expenses. Our segments reflect the way in which our chief operating decision maker reviews our operating results and allocates resources. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The below tables show select financial measures by reporting segment (in millions):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:49.10807974816369%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:38%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:27%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:27%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Total Assets</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">December&#160;31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">CHCA</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,833.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,351.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">CHCI</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5,114.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4,795.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">RX</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,597.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,646.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Specialty Sciences</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,775.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Other</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">297.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">301.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">11,842.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">13,870.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">October 1, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Net </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Operating Income (Loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Intangible Asset Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Net </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Operating Income (Loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Intangible Asset Amortization</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">CHCA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">598.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">124.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">16.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">611.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">99.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">17.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">CHCI</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">365.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">50.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">377.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1,615.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">44.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">RX</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">250.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">82.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">21.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">251.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">74.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">27.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Specialty Sciences</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">16.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(0.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">21.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Unallocated</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(48.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(27.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,231.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">162.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">88.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,261.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1,468.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">89.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">October 1, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Net </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Operating Income (Loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Intangible Asset Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Net </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Operating Income (Loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Intangible Asset Amortization</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">CHCA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,786.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">303.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">51.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,880.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">316.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">53.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">CHCI</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,116.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">8.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">143.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,232.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(2,011.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">130.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">RX</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">708.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">239.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">65.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">776.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">258.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">78.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Specialty Sciences</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">51.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">9.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">59.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Unallocated</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(121.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(79.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,663.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">439.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">261.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,949.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1,515.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">263.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ACCOUNTS RECEIVABLE FACTORING</font><font style="font-family:Arial;font-size:10pt;font-style:italic;"> </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#252525;">We have multiple accounts receivable factoring arrangements with non-related third-party financial institutions (the &#8220;Factors&#8221;). Pursuant to the terms of the arrangements, we sell to the Factors certain of our accounts receivable balances on a non-recourse basis for credit approved accounts. An administrative fee ranging from </font><font style="font-family:Arial;font-size:10pt;color:#252525;">0.14%</font><font style="font-family:Arial;font-size:10pt;color:#252525;"> to </font><font style="font-family:Arial;font-size:10pt;color:#252525;">0.15%</font><font style="font-family:Arial;font-size:10pt;color:#252525;"> per invoice is charged on the gross amount of accounts receivables assigned to the Factors, and interest is calculated at the applicable EUR LIBOR rate plus 70 basis points. The total amount factored on a non-recourse basis and excluded from accounts receivable was </font><font style="font-family:Arial;font-size:10pt;color:#252525;">$24.3 million</font><font style="font-family:Arial;font-size:10pt;color:#252525;"> and </font><font style="font-family:Arial;font-size:10pt;color:#252525;">$50.7 million</font><font style="font-family:Arial;font-size:10pt;color:#252525;"> at </font><font style="font-family:Arial;font-size:10pt;color:#252525;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;color:#252525;"> and </font><font style="font-family:Arial;font-size:10pt;">December 31, 2016</font><font style="font-family:Arial;font-size:10pt;color:#252525;">, respectively.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Unrealized investment gains/(losses) on available for sale securities were as follows (in millions):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:469px;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:276px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:82px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:82px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Equity securities, at cost less impairments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">15.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">16.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Gross unrealized gains</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">21.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Gross unrealized losses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(9.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Estimated fair value of equity securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">38.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> (3) As of July 1, 2017, definite-lived intangible assets with a carrying amount of $31.1 million were written down to a fair value of $11.5 million. As of December 31, 2016, definite-lived intangible assets with a carrying amount of $2.3 billion were written down to a fair value of $758.0 million. Included in this balance are indefinite-lived intangible assets with a fair value of $364.5 million and $674.2 million that were reclassified to definite-lived assets at April 3, 2016 and October 2, 2016, respectively. (1)Debt denominated in Euros subject to fluctuations in the euro-to-U.S. dollar exchange rate. * In the period of a net loss, diluted shares equal basic shares. (2)Debt assumed from Omega. (1) As of December 31, 2016, goodwill with a carrying amount of $2.2 billion was written down to its implied fair value of $1.1 billion (2) As of September 30, 2017, indefinite-lived intangible assets with a carrying amount of $26.0 million were written down to a fair value of $13.3 million. As of December 31, 2016, indefinite-lived intangible assets with a carrying amount of $0.7 million were written down to a fair value of $0.3 million. EX-101.SCH 10 prgo-20170930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2104100 - Disclosure - Accounts Receivable Factoring link:presentationLink link:calculationLink link:definitionLink 2404401 - Disclosure - Accounts Receivable Factoring (Details) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Accumulated Other Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Assets Held for Sale link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - Assets Held for Sale (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - Assets Held for Sale (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Collaboration Agreements and Other Contractual Arrangements link:presentationLink link:calculationLink link:definitionLink 2415401 - Disclosure - Collaboration Agreements and Other Contractual Arrangements (Details) link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2414401 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1004501 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Consolidated Statements of Income link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Derivative Instruments and Hedging Activities link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Derivative Instruments and Hedging Activities - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Derivative Instruments and Hedging Activities - Balance Sheet Location (Details) link:presentationLink link:calculationLink link:definitionLink 2408405 - Disclosure - Derivative Instruments and Hedging Activities - Non-designated Derivatives (Details) link:presentationLink link:calculationLink link:definitionLink 2408404 - Disclosure - Derivative Instruments and Hedging Activities - Other Comprehensive Income Movement (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Derivative Instruments and Hedging Activities (Tables) link:presentationLink link:calculationLink link:definitionLink 2423402 - Disclosure - Discontinued operations (Details) link:presentationLink link:calculationLink link:definitionLink 2123100 - Disclosure - Discontinued operations (Notes) link:presentationLink link:calculationLink link:definitionLink 2323301 - Disclosure - Discontinued operations (Tables) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Divestitures link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - Divestitures (Details) link:presentationLink link:calculationLink link:definitionLink 2302301 - Disclosure - Divestitures (Tables) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information Document link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Earnings Per Share and Shareholders Equity link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - Earnings Per Share and Shareholders Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Fair Value Measurements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2406405 - Disclosure - Fair Value Measurements - Fair Value Inputs (Details) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Fair Value Measurements - Financial Instruments at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 2406404 - Disclosure - Fair Value Measurements - Reconciliation of Level 3 Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Goodwill and Other Intangible Assets link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Goodwill and Other Intangible Assets - Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - Goodwill and Other Intangible Assets - Intangible categories (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Goodwill and Other Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2413402 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2313301 - Disclosure - Income Taxes Effective tax rate (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Indebtedness link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - Indebtedness (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - Indebtedness (Tables) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Restructuring Charges link:presentationLink link:calculationLink link:definitionLink 2416402 - Disclosure - Restructuring Charges (Details) link:presentationLink link:calculationLink link:definitionLink 2316301 - Disclosure - Restructuring Charges (Tables) link:presentationLink link:calculationLink link:definitionLink 2117100 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 2417402 - Disclosure - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 2317301 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2118100 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 2418401 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 11 prgo-20170930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 12 prgo-20170930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 13 prgo-20170930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Statement of Financial Position [Abstract] Statement [Table] Statement [Table] Statement, Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Statement [Line Items] Statement [Line Items] Stockholders' Equity: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Preferred shares, par value Preferred Stock, Par or Stated Value Per Share Preferred shares, authorized Preferred Stock, Shares Authorized Ordinary shares, par value Common Stock, Par or Stated Value Per Share Ordinary shares, authorized Common Stock, Shares Authorized Ordinary shares outstanding Common Stock, Shares, Outstanding Allowance for doubtful accounts Allowance for Doubtful Accounts Receivable Commitments and contingencies Commitments and Contingencies Statement of Comprehensive Income [Abstract] Net income (loss) Net Income (Loss) Attributable to Parent Other comprehensive income: Other Comprehensive Income (Loss), Net of Tax [Abstract] Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Change in fair value of derivative financial instruments, net of tax Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax, Portion Attributable to Parent Change in fair value of investment securities, net of tax Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Change in post-retirement and pension liability, net of tax Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, after Tax Other comprehensive income, net of tax Other Comprehensive Income (Loss), Net of Tax Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Effective tax rate [Abstract] Effective Tax Rate [Abstract] Schedule of effective income tax rate reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Fair Value Disclosures [Abstract] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Royalty Pharma Royalty Pharma [Member] Royalty Pharma [Member] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Omega Omega [Member] Omega [Member] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Brands Brands [Member] Brands [Member] Segments [Axis] Segments [Axis] Segments [Domain] Segments [Domain] Asset Class [Axis] Asset Class [Axis] Asset Class [Domain] Asset Class [Domain] Accounts Receivable [Member] Accounts Receivable [Member] Contingent consideration Contingent Consideration Classified as Equity [Member] Liability Class [Axis] Liability Class [Axis] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Measured at fair value on a recurring basis: Fair Value, Measurements, Recurring [Member] Measured at fair value on a non-recurring basis: Fair Value, Measurements, Nonrecurring [Member] Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Level 1 Fair Value, Inputs, Level 1 [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Sale price of divestiture - cash plus non-cash Sale price of divestiture - cash plus non-cash Sale price of divestiture - cash plus non-cash Assets: Assets, Fair Value Disclosure [Abstract] Investment securities Investments, Fair Value Disclosure Foreign currency forward contracts Foreign Currency Contract, Asset, Fair Value Disclosure Funds associated with Israeli severance liability Funds Associated With Israeli Post Employment Benefits Fair Value Disclosure Funds Associated With Israeli Post Employment Benefits Fair Value Disclosure Royalty Pharma contingent milestone payments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Financial assets Financial assets Royalty Interest received in current period Goodwill(1) Goodwill, Fair Value Disclosure Indefinite-lived intangible assets(2) Indefinite-lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure Definite-lived intangible assets(3) Finite-lived Intangible Assets, Fair Value Disclosure Assets held for sale, net Assets Held-for-sale, Long Lived, Fair Value Disclosure Total level 3 assets Assets, Fair Value Disclosure Liabilities: Liabilities, Fair Value Disclosure [Abstract] Foreign currency forward contracts Foreign Currency Cash Flow Hedge Liability at Fair Value Contingent Consideration Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value Goodwill Goodwill, Gross Indefinite-lived intangibles carrying amount Indefinite-Lived Intangible Assets (Excluding Goodwill) Impairment of intangible assets Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) Finite-lived intangible assets Finite-Lived Intangible Assets, Gross Definite lived asset impairment Impairment of Intangible Assets, Finite-lived Net proceeds from sale of business and other assets Proceeds from Divestiture of Businesses Contingent Proceeds from Divestiture of Business, Milestone One, Maximum Contingent Proceeds from Divestiture of Business, Milestone One, Maximum Contingent Proceeds from Divestiture of Business, Milestone One, Maximum Contingent Proceeds from Divestiture of Business, Milestone Two, Maximum Contingent Proceeds from Divestiture of Business, Milestone Two, Maximum Contingent Proceeds from Divestiture of Business, Milestone Two, Maximum Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Accumulated other comprehensive income (loss) Comprehensive Income (Loss) Note [Text Block] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Derivative Instrument [Axis] Derivative Instrument [Axis] Derivative Contract [Domain] Derivative Contract [Domain] Foreign currency forward contracts Foreign Exchange Forward [Member] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Other (income) expense, net Other Nonoperating Income (Expense) [Member] Other (income) expense, net Interest Expense [Member] Hedging Designation [Axis] Hedging Designation [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Non-designated derivatives: Not Designated as Hedging Instrument [Member] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Amount of Gain/(Loss) Recognized against Earnings Derivative, Gain (Loss) on Derivative, Net Discontinued Operations and Disposal Groups [Abstract] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Disposal Group Name [Axis] Disposal Group Name [Axis] Disposal Group Name [Domain] Disposal Group Name [Domain] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Net sales Revenue, Net Income (Loss) from Continuing Operations before Income Taxes, Domestic Income (Loss) from Continuing Operations before Income Taxes, Domestic Income tax expense (benefit) Income Tax Expense (Benefit) Accounts receivable, net of allowance for doubtful accounts of $6.2 million and $6.3 million, respectively Accounts Receivable, Net, Current Inventories Inventory, Net Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Current assets Disposal Group, Including Discontinued Operation, Assets, Current Property, plant and equipment, net Property, Plant and Equipment, Net Other intangible assets, net Finite-Lived Intangible Assets, Net Other non-current assets Other Assets, Noncurrent Accounts payable Accounts Payable, Current Current liabilities Disposal Group, Including Discontinued Operation, Liabilities, Current Restructuring Charges [Abstract] Restructuring and related costs Restructuring and Related Costs [Table Text Block] Collaboration agreements and other contractual arrangements [Abstract] Collaboration agreements and other contractual arrangements [Abstract] Research and development contractual arrangement [Axis] Research and development contractual arrangement [Axis] Research and development contractual arrangement [Axis] Research and development contractual arrangement [Domain] Research and development contractual arrangement [Domain] [Domain] for Research and development contractual arrangement [Axis] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Collaborative Partner [Axis] Collaborative Partner [Axis] Collaborative Partner [Axis] Collaborative Partner [Domain] Collaborative Partner [Domain] [Domain] for Collaborative Partner [Axis] Research and development Research and Development Expense Statement of Cash Flows [Abstract] Scenario [Axis] Cash Flows From (For) Operating Activities Net Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to derive cash flows Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization Share-based compensation Share-based Compensation Impairment charges Asset Impairment Charges Change in financial assets Fair Value, Option, Changes in Fair Value, Gain (Loss) Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt Restructuring charges Restructuring Charges Deferred income taxes Deferred Income Tax Expense (Benefit) Amortization of debt premium Amortization of Debt Issuance Costs and Discounts Other non-cash adjustments, net Other Operating Activities, Cash Flow Statement Subtotal Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities Increase (decrease) in cash due to: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Inventories Increase (Decrease) in Inventories Accounts payable Increase (Decrease) in Accounts Payable Payroll and related taxes Increase (Decrease) in Employee Related Liabilities Accrued customer programs Increase Decrease In Accrued Customer Programs The net change during the reporting period in the aggregate amount of accrued customer programs including chargebacks and rebate payables. Accrued liabilities Increase (Decrease) in Accrued Liabilities Accrued income taxes Increase (Decrease) in Income Taxes Payable Other, net Increase (Decrease) in Other Operating Assets and Liabilities, Net Subtotal Increase (Decrease) in Operating Capital Net cash from operating activities Net Cash Provided by (Used in) Operating Activities Cash Flows From (For) Investing Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Proceeds from royalty rights Proceeds from Royalties Received Acquisitions of businesses, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Asset acquisitions Payments to Acquire Intangible Assets Additions to property, plant and equipment Payments to Acquire Property, Plant, and Equipment Proceeds from sale of the Tysabri® financial asset Proceeds from Sale of Other Assets, Investing Activities Other investing, net Payments for (Proceeds from) Other Investing Activities Net cash from (for) investing activities Net Cash Provided by (Used in) Investing Activities Cash Flows From (For) Financing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Issuances of long-term debt Proceeds from Issuance of Long-term Debt Payments on long-term debt Repayments of Long-term Debt Borrowings (repayments) of revolving credit agreements and other financing, net Proceeds from (Repayments of) Short-term Debt, Maturing in Three Months or Less Deferred financing fees Payments of Financing Costs Premium on early debt retirement Payments of Debt Restructuring Costs Issuance of ordinary shares Proceeds from Issuance of Common Stock Repurchase of ordinary shares Payments for Repurchase of Common Stock Cash dividends Payments of Dividends Other financing Proceeds from (Payments for) Other Financing Activities Net cash (for) financing activities Net Cash Provided by (Used in) Financing Activities Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash and Cash Equivalents Net increase (decrease) in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Debt Disclosure [Abstract] Schedule of Debt Instruments [Table] Schedule of Debt Instruments [Table] Schedule of Debt Instruments [Table] Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Overdraft [Member] Overdraft [Member] Overdraft [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] 2014 Revolver 2014 Revolver [Member] 2014 Revolver [Member] 2014 term loan due December 5, 2019 2014 Euro-Denominated Term Loan due December 5, 2019 [Member] 2014 Euro-Denominated Term Loan due December 5, 2019 [Member] 4.500% unsecured senior notes due May 23, 2017 4.500% Unsecured Senior Notes due May 23, 2017 [Domain] 4.500% Unsecured Senior Notes due May 23, 2017 [Domain] 5.125% unsecured senior notes due December 12, 2017 5.125% Unsecured Senior Notes due December 12, 2017 [Domain] 5.125% Unsecured Senior Notes due December 12, 2017 [Domain] 2.30% Unsecured Senior notes November 8, 2018 [Member] 2.30% Unsecured Senior notes November 8, 2018 [Member] 2.30% Unsecured Senior notes November 8, 2018 [Member] 5.000% unsecured senior notes due May 23, 2019 5.000% Unsecured Senior notes due May 23, 2019 [Domain] 5.000% Unsecured Senior notes due May 23, 2019 [Domain] 3.500% unsecured senior notes due March 15, 2021 3.500% Unsecured Senior notes due March 15, 2021 [Domain] 3.500% Unsecured Senior notes due March 15, 2021 [Domain] 3.5% Senior note due December 15, 2021 [Member] 3.5% Senior note due December 15, 2021 [Member] 3.5% Senior note due 2021 [Member] 5.105% senior note due July 19, 2023 5.105% Senior note due July 19, 2023 [Domain] 5.105% Senior note due July 19, 2023 [Domain] 4.00% unsecured Senior Notes due November 15, 2023 [Member] 4.00% Unsecured Senior Notes due November 15, 2023 [Member] 4.00% Unsecured Senior Notes due November 15, 2023 [Member] 3.9% senior note due December 15, 2024 3.9% senior note due 2024 [Member] 3.9% senior note due 2024 [Member] 4.375% senior note due March 15, 2026 4.375% senior note due March 15, 2026 [Member] 4.375% senior note due March 15, 2026 [Member] 5.30% unsecured senior notes due November 15, 2043 [Member] 5.30% Unsecured Senior Notes due November 15, 2043 [Member] 5.30% Unsecured Senior Notes due November 15, 2043 [Member] 4.9% senior notes due December 15, 2044 4.9% Senior Loan due 2044 [Member] 4.9% Senior Loan due 2044 [Member] 4.5% retail bonds 4.5% Retail Bond [Member] 4.5% Retail Bond [Member] Currency [Axis] Currency [Axis] All Currencies [Domain] All Currencies [Domain] Euro Member Countries, Euro Euro Member Countries, Euro Debt Instrument [Line Items] Debt Instrument [Line Items] Series Debt Instrument, Description Transaction Type Debt instrument, transaction type Debt instrument, transaction type Term loans Loans Payable Interest rate, stated percentage Debt Instrument, Interest Rate, Stated Percentage Other financing Other Long-term Debt Unamortized premium (discount), net Debt Instrument, Unamortized Discount (Premium), Net Deferred financing fees Debt Instrument, Fee Amount Total borrowings outstanding Debt, Long-term and Short-term, Combined Amount Current indebtedness Debt, Short Term and Current Portion of Long Term Debt, Short Term and Current Portion of Long Term Long-term debt, less current portion Long-term Debt, Excluding Current Maturities Principal Retired Repayments of Debt Debt Instrument, Maturity Date Debt Instrument, Maturity Date Senior notes Senior Notes Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Debt instrument, date of repayment Debt instrument, date of repayment Debt instrument, date of repayment Debt instrument, covenant compliance Debt Instrument, Covenant Compliance Line of credit facility, fair value of amount outstanding Line of Credit Facility, Fair Value of Amount Outstanding Premium on debt repayment Premium on debt repayment Premium on debt repayment Transaction costs Transaction costs associated with debt extinguishment Transaction costs associated with debt extinguishment Write-off of deferred financing fees Write off of Deferred Debt Issuance Cost Write-off of remaining discount on bond Write off of unamortized discount Write off of unamortized discount Loss on extinguishment of debt Accounts Receivable Factoring [Abstract] Accounts Receivable Factoring [Abstract] Financial asset servicing fees paid Financial asset servicing fees paid Financial asset servicing fees paid Accounts receivable factored and excluded from balance sheet Accounts receivable factored and excluded from balance sheet Accounts receivable factored and excluded from balance sheet - non-recourse Indebtedness Debt Disclosure [Text Block] Accounting Policies [Abstract] Basis of presentation Basis of Accounting, Policy [Policy Text Block] Principles of consolidation Consolidation, Policy [Policy Text Block] New accounting pronouncements, policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Recent accounting standard announcements not yet adopted Description of New Accounting Pronouncements Not yet Adopted [Text Block] Investments [Abstract] Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Table] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Estimated fair value of equity securities Available-for-sale Securities [Member] Other non-current assets Other Noncurrent Assets [Member] Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Unrealized Gain (Loss) on Investments [Abstract] Unrealized Gain (Loss) on Investments [Abstract] Equity securities, at cost less impairments Available-for-sale Equity Securities, Amortized Cost Basis Gross unrealized gains Available-for-sale Equity Securities, Accumulated Gross Unrealized Gain, before Tax Gross unrealized losses Available-for-sale Equity Securities, Accumulated Gross Unrealized Loss, before Tax Estimated fair value of equity securities Available-for-sale Securities, Equity Securities Impairment of investments Other than Temporary Impairment Losses, Investments, Portion Recognized in Earnings, Net, Available-for-sale Securities Gain on sale of investments Available-for-sale Securities, Gross Realized Gains Cost method investments Cost Method Investments Equity method investments Equity Method Investments Gains (loss) from equity method investments Income (Loss) from Equity Method Investments Equity method investment, other than temporary impairment Equity Method Investment, Other than Temporary Impairment Transfer from investments Transfer from Investments Unrealized gain (loss) on investments Unrealized Gain (Loss) on Investments Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and other intangible assets Goodwill and Intangible Assets Disclosure [Text Block] Assets held for sale [Abstract] Assets held for sale [Abstract] API [Member] API [Member] API [Member] Animal Health pet treats [Member] Animal Health pet treats [Member] Animal Health pet treats [Member] Discontinued operations, held-for-sale Discontinued Operations, Held-for-sale [Member] Other Other [Member] Other [Member] CHCA Consumer Healthcare Americas [Member] Consumer Healthcare Americas [Member] Goodwill Disposal Group, Including Discontinued Operation, Goodwill, Noncurrent Intangible assets Disposal Group, Including Discontinued Operation, Intangible Assets Property, plant and equipment Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent Other assets Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent Less: impairment reserves Impairment of Long-Lived Assets to be Disposed of Total assets held for sale Disposal Group, Including Discontinued Operation, Assets Other liabilities Disposal Group, Including Discontinued Operation, Other Liabilities Total liabilities held for sale Disposal Group, Including Discontinued Operation, Liabilities Inventory Disclosure [Abstract] Inventories Inventory Disclosure [Text Block] Schedule of accumulated other comprehensive income (loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Schedule Of Finite And Indefinite Lived Assets By Major Class [Table] Schedule Of Finite And Indefinite Lived Assets By Major Class [Table] Schedule Of Finite And Indefinite Lived Assets By Major Class [Table] RX RX Pharmaceuticals [Member] RX Pharmaceuticals [Member] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Distribution and license agreements, supply agreements Licensing Agreements [Member] Developed product technology, formulations, and product rights Developed Technology Rights [Member] Customer relationships and distribution networks Customer Relationships [Member] Trademarks, trade names, and brands Trademarks [Member] Non-compete agreements Noncompete Agreements [Member] In-process research and development In Process Research and Development [Member] Finite And Indefinite Lived Assets By Major Class [Line Items] Finite And Indefinite Lived Assets By Major Class [Line Items] Finite and Indefinite-Lived Assets By Major Class [Line Items] Gross Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Indefinite-lived intangibles: Total other intangible assets Intangible Assets, Net (Excluding Goodwill) Intangible assets amortization expense Amortization of Intangible Assets Impairment of Intangible Assets, Finite-lived Useful life of intangible asset Finite-Lived Intangible Asset, Useful Life Commitments and Contingencies Disclosure [Abstract] Damages sought by plaintiff Loss Contingency, Damages Sought, Value Foreign currency exchange rate, remeasurement Foreign Currency Exchange Rate, Remeasurement Schedule of inventory, current Schedule of Inventory, Current [Table Text Block] Segment Reporting [Abstract] Schedule of segment reporting information, by segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Reclassification out of Accumulated Other Comprehensive Income (Loss) [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Designated derivatives: Designated as Hedging Instrument [Member] Net sales Sales Revenue, Goods, Net [Member] Cost of sales Cost of Sales [Member] Interest rate swap agreements Interest Rate Swap [Member] Reclassification Adjustment out of Accumulated Other Comprehensive Income on (Loss) Derivatives [Line Items] Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months Amount of Gain/(Loss) Recorded in OCI (Effective Portion) Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion) Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net Amount of Gain/(Loss) Recognized against Earnings (Ineffective Portion) Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net Document and Entity Information [Abstract] Document and Entity Information [Abstract] Entity registrant name Entity Registrant Name Entity central index key Entity Central Index Key Current calendar year end date Current Fiscal Year End Date Entity filer category Entity Filer Category Document type Document Type Document period end date Document Period End Date Document calendar year focus Document Fiscal Year Focus Document calendar period focus Document Fiscal Period Focus Amendment flag Amendment Flag Entity common stock, shares outstanding Entity Common Stock, Shares Outstanding Entity well-known seasoned issuer Entity Well-known Seasoned Issuer Entity voluntary filers Entity Voluntary Filers Entity current reporting status Entity Current Reporting Status Income Tax Disclosure [Abstract] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Stock [Member] Common Stock [Member] Effective income tax rate reconciliation, percent Effective Income Tax Rate Reconciliation, Percent Unrecognized tax benefits, including income tax penalties and interest accrued Unrecognized Tax Benefits, Including Income Tax Penalties And Interest Accrued Unrecognized Tax Benefits, including Income Tax Penalties and Interest Accrued Unrecognized tax benefits liability, interest and penalties accrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Income tax examination, penalties and interest expense Income Tax Examination, Penalties and Interest Expense Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Specialty Sciences [Member] Specialty Sciences [Member] Specialty Sciences [Member] Measured on a recurring basis Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Gain (Loss) Included in Other Comprehensive Income (Loss) Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Gain (Loss) Included in Other Comprehensive Income (Loss) Contingent Consideration Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Net realized losses Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Settlements Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Royalty Pharma Contingent Milestone Payments Contingent milestone receivable [Abstract] Contingent milestone receivable [Abstract] Additions Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset and Liability, Gain (Loss) Included in Other Comprehensive Income (Loss), Description Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset and Liability, Gain (Loss) Included in Other Comprehensive Income (Loss), Description Change in fair value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings Earnings Per Share [Abstract] Perrigo Co PLC [Member] Perrigo Co PLC [Member] Perrigo Co PLC [Member] Stock repurchase program, authorized amount Stock Repurchase Program, Authorized Amount Stock repurchase program, number of shares repurchased Stock Repurchase Program, Number of Shares Repurchased Stock Repurchase Program, Number of Shares Repurchased Numerator: Numerator [Abstract] Numerator: [Abstract] Denominator: Denominator [Abstract] Denominator [Abstract] Weighted average shares outstanding for basic EPS Weighted Average Number of Shares Outstanding, Basic Dilutive effect of share-based awards Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Weighted average shares outstanding for diluted EPS Weighted Average Number of Shares Outstanding, Diluted Anti-dilutive share-based awards excluded from computation of diluted EPS Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Share-based compensation arrangement by share-based payment award, options, exercises in period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Share price Accelerated Share Repurchases, Final Price Paid Per Share Proceeds from (Repurchase of) Equity Proceeds from (Repurchase of) Equity Stock Repurchase Program, Remaining Authorized Repurchase Amount Stock Repurchase Program, Remaining Authorized Repurchase Amount Summary of significant accounting policies Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Earnings per share and shareholders equity Earnings Per Share [Text Block] Assets held for sale Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Schedule of derivative instruments in statement of financial position, fair value Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Amount of Gain/(Loss) Recorded in OCI (Effective Portion) Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block] Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion) Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Amount of Gain/(Loss) Recognized against Earnings (Ineffective Portion) Schedule of hedge ineffectiveness [Table Text Block] Schedule of hedge ineffectiveness [Table Text Block] Amount of Gain/(Loss) Recognized against Earnings Schedule of Other Derivatives Not Designated as Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block] Restructuring charges Restructuring and Related Activities Disclosure [Text Block] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] CHCI CHCI [Member] CHCI [Member] Specialty Sciences Other Other Segments [Member] Unallocated Segment Reconciling Items [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Total Assets Assets Operating Income (Loss) Operating Income (Loss) Intangible Asset Amortization Goodwill reporting unit [Axis] Goodwill reporting unit [Axis] Goodwill reporting unit [Axis] Goodwill reporting unit [Domain] Goodwill reporting unit [Domain] [Domain] for Goodwill reporting unit [Axis] BCH - ROW [Member] BCH - ROW [Member] BCH - ROW [Member] Goodwill Goodwill [Member] Maximum Tysabri® Tysabri [Member] Tysabri [Member] Public Bonds and Private Placement Public Bonds and Private Placement [Member] Public Bonds and Private Placement Retail Bonds Retail Bonds [Member] Retail Bonds [Member] Elan Elan Corporation [Member] Elan Corporation [Member] Fair Value, Assets, Level 1, Level 2, Level 3 Transfers, Amount Fair Value, Assets, Level 1, Level 2, Level 3 Transfers, Amount Fair Value, Assets, Level 1, Level 2, Level 3 Transfers, Amount Net gain on reduction of contingent consideration Gain (Loss) on Settlement of Contingent Consideration Gain (Loss) on Settlement of Contingent Consideration Number of reporting units Number of Reporting Units Effective date of acquisition Business Acquisition, Effective Date of Acquisition Average growth rate Fair Value Inputs, Discrete Growth Rate Fair Value Inputs, Discrete Growth Rate Percent of royalty revenues generated by specific agreement Percent of royalty revenues generated by specific agreement Percent of royalty revenues generated by specific agreement Net sales Sales Revenue, Goods, Net Royalty stream discrete period Royalty stream discrete period Royalty stream discrete period Discount rate Fair Value Inputs, Discount Rate Long-term growth rates Fair Value Inputs, Long-term Revenue Growth Rate Goodwill impairment charge Goodwill, Impairment Loss Fair value of fixed-rate long-term debt Debt Instrument, Fair Value Disclosure Long term debt Long-term Debt Unamortized debt premium Debt Instrument, Unamortized Premium Proceeds from sale of business, maximum milestone payments in year two Proceeds from sale of business, maximum milestone payments in year four Gain on sale of unit Gain (Loss) on Disposition of Business Volatility rate Fair Value Assumptions, Expected Volatility Rate Rate of return Fair Value Assumptions, Rate of Return Fair Value Assumptions, Rate of Return Royalties receivable Royalties Receivable Royalties Receivable Accounts receivable factoring Transfers and Servicing of Financial Assets [Text Block] Assets Assets [Abstract] Total current assets Assets, Current Goodwill and other indefinite-lived intangible assets Goodwill And Indefinite Lived Intangibles Aggregate carrying amount, as of the balance sheet date, of goodwill and other indefinite-lived intangible assets. Goodwill represents the carrying amount as of the balance sheet date, which is the cumulative amount paid, adjusted for any amortization recognized prior to adoption of ASC Topic 350 and for any impairment charges, in excess of the fair value of net assets acquired in one or more business combination transactions. Indefinite-lived intangible assets represent the carrying amount of intangible assets which have a projected indefinite period of benefit (hence are not amortized), allocated to the reportable segment. These assets, acquired either individually or as part of a group of assets, in either an asset acquisition or business combination, are assessed at least annually for impairment. Examples may include trade secrets, contractual rights, trade names, and licensing agreements. Non-current deferred income taxes Deferred Income Tax Assets, Net Total non-current assets Assets, Noncurrent Total assets Liabilities and Shareholders’ Equity Liabilities and Equity [Abstract] Liabilities Liabilities [Abstract] Payroll and related taxes Employee-related Liabilities, Current Accrued customer programs Accrued Customer Programs Carrying value as of the balance sheet date of customer programs, which include customer chargebacks and rebates payable. Accrued liabilities Accrued Liabilities, Current Accrued income taxes Accrued Income Taxes, Current Current indebtedness Long-term Debt, Current Maturities Total current liabilities Liabilities, Current Non-current deferred income taxes Deferred Income Tax Liabilities, Net Other non-current liabilities Other Liabilities, Noncurrent Total non-current liabilities Liabilities, Noncurrent Total liabilities Liabilities Commitments and contingencies - Note 14 Shareholders’ equity Stockholders' Equity Attributable to Parent [Abstract] Preferred shares, $0.0001 par value, 10 million shares authorized Preferred Stock, Value, Issued Ordinary shares, €0.001 par value, 10 billion shares authorized Common Stock, Value, Issued Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Retained earnings (accumulated deficit) Retained Earnings (Accumulated Deficit) Total controlling interest Stockholders' Equity Attributable to Parent Noncontrolling interest Stockholders' Equity Attributable to Noncontrolling Interest Total shareholders’ equity Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Total liabilities and shareholders' equity Liabilities and Equity Supplemental Disclosures of Balance Sheet Information Balance Sheet Related Disclosures [Abstract] Ordinary shares, issued and outstanding (in millions) Common Stock, Shares, Issued Schedule of Goodwill [Table] Schedule of Goodwill [Table] Brands [Member] Goodwill [Line Items] Goodwill [Line Items] Goodwill [Roll Forward] Goodwill [Roll Forward] December 31, 2016 Goodwill Goodwill, Written off Related to Sale of Business Unit Goodwill, Written off Related to Sale of Business Unit Goodwill, transfers Goodwill, Transfers Currency translation adjustment Goodwill, Foreign Currency Translation Gain (Loss) September 30, 2017 Segment information Segment Reporting Disclosure [Text Block] Business Combinations [Abstract] Divestitures Business Combination Disclosure [Text Block] Investments Cost and Equity Method Investments Disclosure [Text Block] Derivative [Table] Derivative [Table] 4.00% unsecured Senior Notes due November 15, 2023 [Member] 5.30% unsecured senior notes due November 15, 2043 [Member] Accrued liabilities Other Liabilities [Member] Treasury locks Treasury Lock [Member] Foreign exchange contract Foreign Exchange Contract [Member] Derivative [Line Items] Derivative [Line Items] Notional amount of derivatives Derivative, Notional Amount Proceeds from issuance of debt Proceeds from Issuance of Debt Loss on derivatives Maximum remaining maturity of foreign currency derivatives Maximum Remaining Maturity of Foreign Currency Derivatives Schedule of goodwill Schedule of Goodwill [Table Text Block] Schedule of finite and indefinite-lived intangible assets Schedule Of Finite And Indefinite Lived Intangible Assets [Table Text Block] Schedule of Finite and Indefinite-Lived Intangible Assets [Table Text Block] Subsequent Events [Abstract] Schedule of earnings per share, basic and diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of share-based compensation, stock options, activity Share-based Compensation, Stock Options, Activity [Table Text Block] Disposal groups, including discontinued operations Disposal Groups, Including Discontinued Operations [Table Text Block] Derivative instruments and hedging activities Derivative Instruments and Hedging Activities Disclosure [Text Block] Derivatives, policy Derivatives, Policy [Policy Text Block] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] CHCA [Member] CHCA [Member] CHCA [Member] Restructuring Type [Axis] Restructuring Type [Axis] Type of Restructuring [Domain] Type of Restructuring [Domain] Employee severance [Member] Employee Severance [Member] Lease exit Contract Termination [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Beginning balance Restructuring Reserve Additional charges Payments Payments for Restructuring Non-cash adjustments Restructuring Reserve, Settled without Cash Ending balance Commitments and contingencies Commitments and Contingencies Disclosure [Text Block] Schedule of debt Schedule of Debt [Table Text Block] Schedule of debt retirement Schedule of debt retirement [Table Text Block] Schedule of debt retirement [Table Text Block] Schedule of extinguishment of debt [Table Text Block] Schedule of Extinguishment of Debt [Table Text Block] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Other current assets Other Current Assets [Member] Accrued liabilities Interest Rate Swap [Member] Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Asset Derivatives Derivative Asset, Fair Value, Amount Not Offset Against Collateral Liability Derivatives Derivative Liability, Fair Value, Amount Not Offset Against Collateral Unrealized gain (loss) on investments Unrealized Gain (Loss) on Investments [Table Text Block] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Foreign currency translation adjustments Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Fair value of derivative financial instruments, net of tax Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member] Fair value of investment securities, net of tax Accumulated Net Investment Gain (Loss) Attributable to Parent [Member] Post-retirement and pension liability adjustments, net of tax Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Balance at December 31, 2016 OCI before reclassifications Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Amounts reclassified from AOCI Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Balance at September 30, 2017 Fair Value Inputs, Assets, Quantitative Information [Table] Fair Value Inputs, Assets, Quantitative Information [Table] BCH - Belgium [Member] BCH - Belgium [Member] BCH - Belgium [Member] Lumara-Clindesse [Member] Lumara-Clindesse [Member] Lumara-Clindesse [Member] Omega - XLS Omega-XLS [Member] Omega-XLS [Member] Entocort® - Branded Products Entocort - Branded Products [Member] Entocort - Branded Products [Member] Entocort® - AG Products Entocort - AG Products [Member] Entocort - AG Products [Member] Herron Trade names and Trademarks Trademarks and Trade Names [Member] Omega-Lifestyle [Member] Omega-Lifestyle [Member] Omega-Lifestyle [Member] Fair Value Inputs, Assets, Quantitative Information [Line Items] Fair Value Inputs, Assets, Quantitative Information [Line Items] 5-year average growth rate Royalty rate Fair Value Inputs, Royalty Rate Fair Value Inputs, Royalty Rate Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Fair value, assets measured on recurring and nonrecurring basis Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block] Reconciliation of Level 3 Liabilities Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Schedule of fair value metrics used in valuations Fair Value Inputs, Assets, Quantitative Information [Table Text Block] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Line Items] Business Acquisition [Line Items] Impairment charge Income Statement [Abstract] Cost of sales Cost of Goods and Services Sold Gross profit Gross Profit Operating expenses Operating Expenses [Abstract] Distribution Production and Distribution Costs Selling Selling and Marketing Expense Administration General and Administrative Expense Impairment charges Other operating income Other Operating Income Total operating expenses Operating Expenses Operating income (loss) Change in financial assets Interest expense, net Interest Income (Expense), Net Other (income) expense, net Other Nonoperating Income (Expense) Loss on extinguishment of debt Income (loss) before income taxes Net income (loss) Earnings (loss) per share Basic Earnings Per Share, Basic Diluted Earnings Per Share, Diluted Weighted-average shares outstanding Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic Diluted Dividends declared per share (in dollars per share) Common Stock, Dividends, Per Share, Declared Fair value measurements Fair Value Disclosures [Text Block] Income taxes Income Tax Disclosure [Text Block] Finished goods Inventory, Finished Goods, Gross Work in process Inventory, Work in Process, Gross Raw materials Inventory, Raw Materials, Gross Total inventories EX-101.PRE 14 prgo-20170930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 15 cy17q110q_chart-47174a02.jpg begin 644 cy17q110q_chart-47174a02.jpg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end GRAPHIC 16 cy17q110q_chart-47252a02.jpg begin 644 cy17q110q_chart-47252a02.jpg M_]C_X 02D9)1@ ! 0 0 ! #_VP!# $! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_ MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P 1" #I 4P# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#^_BBBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@!"<#/7VXR2> !G R3QR0/>OQQNO^"EW[1?C?QO M\7=<_9C_ &#-=_:,_9A^ /[0^L?LT?$GXF:#\#?C+ MKOP*_9^U3P+>Z3\1_!'PD\2WL^DZMJOB;XQ_#O4_%4VB>)+GPII-WI^EPWE] M^QQ&1CZ$9]0<@]1T(!ZU^'.G_L'_ /!0GX(>(OC3\'OV0/VF/@1\)_V6/C[^ MU#XO_:;NOB+XC^'WBKQ+^U1^S_)\7O'NG_$GXV_##X2:#?)J_P !_&^A>*/% M-MK_ /PA7BCX@Z?I]YX$T;QUK>G7OASQ;A_$7_@KS\+_A9XS_X* ME^!/'.E_#WPGXD_X)U^%?#OB+P;HWBSXV^&_#&M_M)W/B']E>T_:/ATKP_HN MLZ/:W_AF5=3O(?AU%+I<7CI[F]DCU5;=;ASH:\'I/_!5OX__ !O,6D_L8?L/ MV7[0GB_X>_LN?LW_ +2?[2&B>*_VCM+^#%CX$U?]IWX71?%WX=_ +X3ZG>_" MKQM=?%WXO7G@M+O6IY=:TOX9>!-/LKOPNFJ>*K/4O$;:?IF3\6O^".'A3XT_ M$/\ X*^?$SXE>#OV:_B'XO\ V\?!WA;0?V:O%?Q ^&NG^,/%GP%U;PY^R!8_ M )-2U#Q!K_A'4]4\-^7\0["#QO9S?#Z]NKJ&T@@OP(M=C6W3E?!'_!.#]O;] MDJ?4O$/[$?QM_9FL_%?QX_96_9-^"'[1S?'KPQ\4-8L/ _QB_97^!=A\ M _ M:%^!5SX+,#>*7U3P1;6%KJ/PR^)>D:/8:CJ/@[POJS>*K"&ZU?1* /?_ /@H M-_P5@3]A3]F7X ?&^;]FGXD>/?B?\=W&N)^S-J6KZ=X.^+'@+X=>!_A-KOQT M_:-\6^+H]/L/&FEI>?L^?#/PSK%[XKTG3I[NRU#7O[.TBTUR&WOX]0'UO^U/ M^V%X>^ /["OQE_;B\$:+8_&#PI\./V>-?_:&\(:-9^(F\.Z;\1?#UCX/7QEX M>@M?$ZZ/KS:38^)-,GLY(=731-5-K!66+]K;XH?%F MPN?AAKOP_P!"T_XQZ-HG@G0+3PAX!MA91Z9IU[#=RV*16\5UT/AC_@FU\>]& M_P""./QL_P""7^L_%?P-XH\1S_!_X^_LX_L^_$_5[CQ.]I;?!?Q%=^(+'X 0 M?%(1>&XKRU\1^!O!.IZ1X1\3Q^$]&U72UM?#UE-HSW^]D !I?L^?\%E/AI^T M?XD_X)Y:=X.^'DNCZ'^VO\*_VNO%_P 1+_Q9XQAT+7?V8OB/^QOI'PVE^*/P ME\<>'+SP_$=0U?3]?\"?@#J_@?PUXNT+X.:A;:UXFE\1?$[7AX M=^'D-K;:N=(MAX=\77<6J7^A^./-E\(:WHWA[Q%>^'=6UR?2WLI?CCXF_P#! M!^Y\8_MH_P##0?A7XP67@;X6?%7]B[]HCX!_M _#_3H]6:[M/CY\>/V=O#7[ M-OB#]H?X2Z7'I\/A^VUKQ?X)\(^"Y/B"NKWNBWNKZS\/M%UV0ZKJ>O:K+8>' MZ%_P09_:$UG]D/\ :G^"WQ$^(_P%LOC%\0?V5OV??V4O@Q\1]#\;_MD_$^TN MO"W[.?Q(T?XI>'-2^)+_ ![^*?C6U^'OA7Q'XB\/:;;Z?\'_ (*>"+;PM\)K M?4/$LW@_6-5L]8&AP '[$?MO?\%'_A[^R3^QYX+_ &N_#.BZ5\5O"?Q6\5? MSPC\,M4UCQI'\)?A2H_: UK3-,\'?$+XL_%CQ#X^OHHX^<^"_P#P4L\.O^S[\1?C_P#MFZ!\,/V5_!/P_P#' M.B^$=)^*?A;X_>&OVA?V+--\4Z?=Z7;:=JT2F[3U?]J;X-_M7?'7]E?PIX1\#^/?@1X&^/ M]K<_#GQ+\3_"OC3XV5O MXIT2STWXE:##8:+J=L1*NI:9=?D5\./^"/7[8'P>^&7QZU7X'_$+]EG]FOXA M_'[]K7]G/XZ>)_V:/V:H/C)\(?V5-)^%7P0\):EX/\9?#+P!\1_#UA!\:?A! MXV^.?V[3_%'CKXM_"3PEX/UK3KWPSI7AKP_8V>FWVIZFP!^DUO\ \%1O@EXR M^/7[$'PZ^"VH^#OB]\'/VS?A]^V)X[L_V@-"\=II_A[P&?V0K'X>S>)=&O\ M1+[0 UU>WE_XVO\ 2_$46M:OX5OO USX=N!J>G7CW#QV?I7@G_@J!_P3]^(W MPS^+?QC\$?M9_!CQ)\-?@7/H$'Q3\5Z=XHW6/A7_ (2_43H_@BYEMYK2'4M6 MT_X@ZP#H_P .=3\/V.KZ;\0]8!TKP5=Z]J ^S5^/'PK_ ."$GQHTNP^'GA;X ME_&[X=#P[ID'_!9?1?&^M>!I/B9J?B4:-_P5"\._#G1_"VH>#G^(KZUK,^M_ M#6?P[XCFUZ7QMXZUS5-4+:/?/XH\1:I?ZO_%#7/V??V;/V:?A;J/B;QG^WW\3O"OB3P#^SA\0[/XB:;J7CG6/''[ M1%EXM^!][J&KZ;9:C\*] _9LM=%T[]FCQA]I\7^!=2\3VDQ\)D _H'_9_P#V MDO@=^U+X&NOB/\ OB1X>^)GA'3O$^N>"=9U'0GO8+KP[XS\-/;KK_A#Q3H>L M66F>(/"WBG1Q=V4VH^'?$6E:7K%K;7UC=R68M;VUFF]PK\[O^"<7[,W[1O[, M7PV^*/AW]HKXS7'Q.O/&OQDU_P >?#KPA)\2OBK\<[?X)?#[4-"\/Z58_#6V M^/7QXCB^-/Q>']K:5JGB>7Q#X^@M;K3&UQ?#FEV[:=I,=Y=_HC0 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?F?\1OV M^/'.B_M>O^S#\*/V>)/BS:^"KOP+;_X_BKX9\(?$32+3Q[X$_"MU'K'B?7=<\9^ ;75+NP\1^$O 0\6>,/#6I:0>[\ ?M MP'XE?'=OAEX2^"GC35OAN?B!\2/A8GQAL/$_@2\:W\3?"JZ\2Z%XK\8:K\*8 M-8;XBZ5\#7^(/@[Q/\)-$^,$UC+I^I_$K3(+&30++PEK6A>,M1^.OV\?V0/V MF_VA_P!I[X8:UX2^'OP*N=,T/4K;4?@U^UG;:[XD\ _'?]DHZ?IOA:Z\5P:B M-$\,ZOJOQ/M+K7M'UCQ/\-]"TSQGX9\(^+-2\6:O\//BKX+/ GQR MU7XR>*9_V DO+6S35_B^O@'Q/JU[\5-5\%:A\*_ .@76E>%XO%FIV MMCX. /M3X4?M]?"CXK^)OVL--L/#'Q0\/>&/V2[KP-#XF\6>(_ASXSL[KQ]9 M^-/"5[XKAU[X9?#V+0)_B7XK\/#[%+HGAV_L?"LMS\0=4BEN/ NG:YH5QHNL M:UW'[./[67AO]HS]EZS_ &I-'^'_ ,3/"OAZ[3XO3M\/-<\,S:A\6+-?A#X_ M\>^ M6TBZ\$^'FU._?QGJ%[X"OFM_!5@;[68-3O+?PXPGU:.16Q?@Q\!/&OP M_P#VK/VQ_C1K=SH,OA'X\_\ #-W_ A4-AJ%W<:Y ?A-\,]5\(>)SXALIM/M M[>Q,^J7D+Z4;6_U(WEF'EN#9R*(&\U_9P^$_[3/[,'[-N@_"GPWX.^$OCGQ? M;>)_VT/'5[=ZM\3O$/AK0[+6?B%\9_C!\8_@5HMNUK\.M8N]3T_Q+<^-] \/ M_$743_9,_@2!=3U'1;7QG);06MP =U\ _P!KO7_BA\4S\&?BG\!?&_[/_P 1 M-8^#VG?'_P %>'_%?B?P7XNN=6^&5[XEMO"&HVWB?_A#=0N_^$%^(_A'Q!J6 MBV'BWP7J0U#2XY-8A'A7QEXN;2?$R:#]LU^87[ /P7_:+^''B+XA^.?VI_AS MX'[+Q)KEGX-^'7A_P 1:Z/#GA5_%/AX>(->N;6WTVSN]=T#1(9[KQ'X MC\/:+JOTY7XW?\%<-)T'^R_@EXLU30?VE?!VK>']<-EX;_:@_9DT'6?B%K_P MEO=7^,'[/UY>?#?QS\)=&\'?$>'QWX2^+]KH*^(=!A\5_#SQ3X&B^)GP@\$Z M/JCZ-XD\0^$I;\ ^VKK]N;]F>+4?A[I.E^,_%7C6]^*7PV\'_&#P:OPN^#?Q MM^+EK<_#'Q]JTFA^#?&NN:A\,/ASXML/!N@^(M5M[VSTVZ\:7/A]I6TS6)'C MCAT;59+/I[?]KG]G:[^,M]\ K7XFZ5/\4--\1)X,OM(BTOQ*^A6_CV3PJ/'2 M_#9_'HT3_A7I^*/_ A1'B]OA@GBMO'R>%R->?PXNF$7%?BOX_MOVD]0\'2_ M%;7?!/[;W@7_ (*2?$3]D/\ 9JTWX5ZC\(-$\0Q?LW^*OC%X2\3_ !3U/PYX M8^*/AOP99^(/A9\/(?#NO^.KC5/VF/!G[2WB(> M+\(>-M5;X3WFH:KX)O#WB3]G74=.\*:=8:+J_ MAWXS_%+QWH?[7UEXCU+X8^)?@KXV\26&H:3X1^$[:/8_M&:9\1]>G\)Z[-!\ M*]$N;&( _6CX9_M>?LZ?&+XAZU\+/AQ\3M*\3>-=%@\6W?\ 9\&E^)K#3O$- MCX \50^!O'NH^ O$^L:'IWA7XEZ9X#\9W%MX3\<:E\.]<\4V'A#Q)=6NB>(K MC3M0N8()%\=_M>?LZ?#3XIZ/\&/&WQ.TK1/B'K,_@>T&E/I?B6^TO0[WXG:U M?^&_AGI_C7Q=I>AWW@SX?:C\2O$&F7VA?#K3O'?B+PY?>.]8MI-,\*V^K7FR M)_Q'_8O\$?$3X-?%CX.?$S6?A5^TW=7_ ,*?@!^V5J'[4/PA\5_!/QY%/B,? /[ UI9^%W_P"%C/\ $[QMI&J:%X5T3X8^,_C2OBWX2Z)H M%[/?^#M2;3=)U[I?VP/A'\3O%?[4WQNUS0OAY\>/^%@>)/BK^P1JWP*^''A# MX;>)M5_9)_:@\"?";Q+X(\4ZWXG_ &M?&EGH&M^%=$\1?"GQ7=_$N'6+?Q5X MS^$FK:!X/^'WP?OM TSXC7-S:Z5K !_1*"#R/\_X$=QU!HIJ9QR #N?IZ%B0 M3[D8)]R>!TIU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%( MW0_0_P J /&O%?[1W[//@/7[_P *^./CQ\&?!GBC2_LW]I^&_%?Q0\$>'=?T M[[9:PWUG]OT?5]/S[6>&XBWQ2H[<[_ ,->_LF_]'0? ML[_^'K^&O_S35_$?_P %K40_\%+?VCB8XV/_ !:GEHT8_P#)&O /=E)K\K=D M?_/*'_OS%_\ $5_Y#E&<5<-3RO!U*>'GF> MP^,G0A4EB8RG"E*LX1G*,7)13:3;M_"7&'TO<[X9XLXFX_LF_]'0?L[_\ AZ_AK_\ --1_PU[^R;_T=!^SO_X> MOX:__--7^9[LC_YY0_\ ?F+_ .(HV1_\\H?^_,7_ ,11_P 28O]/0_XG9S[_HALH_\.N,_^9_ZN_*W^F%_PU[^R;_T=!^SO_X>OX:_ M_--1_P ->_LF_P#1T'[._P#X>OX:_P#S35_F>[(_^>4/_?F+_P"(HV1_\\H? M^_,7_P 11_Q)AP__ -%SG/\ X:,%_P#-7K_3T/\ B=G/O^B&RC_PZXS_ .9_ MZN_*W^G7X-_:#^ ?Q%UR/PQ\/OC?\(/'7B2:UNKZ'P]X-^)?@SQ/KDME8JC7 MMY'I.B:U?7\EK9K+&UU<+;F*W61#*Z!USZ_7\*O_ 011!_P4.\+$1QJ?^%2 M_%P96-%/.F:+GE5'7OZU_=57\J>,_AOA/"WBZCPU@LTQ&;4:F3X/,WBL5AZ6 M&J*>*KXRC*DJ=*=2/+!8:+4N:[]GC,12J5J-'ZCEN,S*7/3I.,Y>TA@Y4H\K]V4U)W2:?Q'B-QMAO#K@[ M..,<7@:^98?*/J'M,%AJM.C6K+'9G@\MCR5*L90C[.6,C5?,GS1@XJS::_I8 MR/?\C_A49_I6$*>H]/X3V M.1GCG!Y&>AY%'RYSCGK]T]2,$].N.,]<<=*_S4_^&U/VQ/\ HZW]I+_P^/Q+ M_P#FEH_X;4_;$_Z.M_:2_P##X_$O_P":6C_B3'B+_HMLE_\ #9CO+_I[Z_AY MA_Q.QPU_T1&=_P#ARP/E_P!.?7\/,_TK,*.0"#@C[IX!Y...,GDXZGGK0=I. M2.>#]T]1T/3G';T[5_FI_P##:G[8G_1UO[27_A\?B7_\TM'_ VI^V)_T=;^ MTE_X?'XE_P#S2T?\28\1?]%MDO\ X;,=Y?\ 3WU_#S#_ (G8X:_Z(C.__#E@ M?+_ISZ_AYG^E;D>_Y'_"C(]_R/\ A7^:E_PVI^V)_P!'6_M)?^'Q^)?_ ,TM M>C?!W]L?]KC4OB[\*=/U#]J3]HJ^L+_XG_#NROK&\^-7Q'N;2]LKSQIH5M=V M=W;3>(WAN+6ZMY9(+BWF1XIX9'BE1XW93AB?H;\0X;#U\1+C3)I*A1J5G%9; MCDY*G!S<4W5T;LTF]KJ_4Z,)]-#AO%XK#86/!6=0EB<11P\9O,L$XQE6J0IJ M32HW:3DV[:V6FI_HT44U>A_WF_1CBG5_&A_:2=TGW5PHHHH&%%%% !1110 4 M444 %4M2O1INGWVH&UO+T6-IR^)7CW4;JY\/>*-1U3^P_#'P MTU+X=?$T[QO8>#[&SU?\ 4;]F7XU)^T=^SW\&/CS'X3UCP*GQ=^&O@_X@ MKX2UUC-?Z$/%.AV6K_8EOC;60U;3U^U[](UQ+*QCUW27LM7CLK-+P6T7R+\< M?C)^QI\$M5^,'P?N?V;[3XF>+/B9K?PAC^(?PG^&OP1^&VI3_'WXE?'G5_&D M/@/PMK9\677@[P-X]\>W.A?#?QQ\0_$=QX^UV/3_ IX"\,3^)?$VOZ?]OT2 MUU3[L^$WQ%\(?%[X7_#SXJ> )Y;GP1\1O!/A?QOX2GN+";2KE_#OB?1;/6-' M%WI5PD=QI=W'8W<,5WIMS''<:?<1RVDT:20LH /0:*** "D;H?H?Y4M(W0_0 M_P J /X"O^"UG_*2S]H[_NE/_JFO -?E;7ZI?\%K/^4EG[1W_=*?_5-> :_* MVO\ 9WPM_P"39^'G_9$<*_\ JCP)_B=XK_\ )T/$;_LN>*__ %>XX****^[/ M@ HHHH **** /V@_X((_\I#O"W_9)?BY_P"FS1:_NHK^%?\ X((_\I#O"W_9 M)?BY_P"FS1:_NHK_ #+^EW_R=/"_]DGE/_J;FQ_J3]#_ /Y-+5_[*O./_43* M@HHHK^6S^IPHHHH *_E:_P"#EWK^QQ]?CS_+X35_5+7\K7_!R[U_8X^OQY_E M\)J_=OHT?\GKX,_[N#_UE\Z/P3Z3O_)C^-O3A[_UJ?_ -#:G5_AL?[NQV7HOR"BBB@84444 %%%% !1110 4444 ?A5^V"?"'B' M]N77;&TM?V.?A=\1_ G[//A6ZM?B'^TG^TA\8?A3XQ\:Z3\5[/XU?#:\U[X< M> _A;XV\%Z99ZA\-?"NI^,_ ^E?'F66\^*GA";XF^(_"_@G6/!>EWLUSXA_7 M_P"!.A:5X7^"GPB\-:%;^ ;/1/#WPR\"Z)H]I\*[BZN_AG;:9I7AG3;"P@^' MMU?7%W>W/@J*U@B3PQ<7=U']4_:3\7VWQR\ M5?%7X,>![7X,> #\!O%'P<_8[\#?M#WGQ8\=7VI_$4>/-)\1>(_$O[+_ .T= M?:SXG\%36O@FR\'_ +CE\$?V]I7B/4]?M[3QF=2EN/!GZE_LRS^.KK]G/X# MW'Q/\(Z9X ^(\WP=^&LGCSP/HND6OA[2/"/C!_!^CMXC\.:;X?L9KFR\/V6C MZL;JQ@T&SN[VUT1(?[*M[Z]BM%N90#W&BBB@ I&Z'Z'^5+2-T/T/\J /X"O^ M"UG_ "DL_:._[I3_ .J:\ U^5M?JE_P6L_Y26?M'?]TI_P#5-> :_*VO]G?" MW_DV?AY_V1'"O_JCP)_B=XK_ /)T/$;_ ++GBO\ ]7N."BBBONSX **** "B MBB@#]H/^""/_ "D.\+?]DE^+G_ILT6O[J*_A7_X((_\ *0[PM_V27XN?^FS1 M:_NHK_,OZ7?_ "=/"_\ 9)Y3_P"IN;'^I/T/_P#DTM7_ +*O./\ U$RH**** M_EL_J<**** "OY6O^#EWK^QQ]?CS_+X35_5+7\K7_!R[U_8X^OQY_E\)J_=O MHT?\GKX,_P"[@_\ 67SH_!/I._\ )C^-O3A[_P!:G)#^5RBBBO\ 6(_R*"BB MB@ HHHH *]0^"'_):/@]_P!E8^&7_J=^'Z\OKU#X(?\ ):/@]_V5CX9?^IWX M?K@S7_D69A_V!8K_ -,S/2R;_D<95_V,L#_ZE4C_ $]EZ'_>?_T-J=35Z'_> M?_T-J=7^&Q_N['9>B_(****!A1110 4444 %%%% !2'^H]?4>G_ZO7C-+2'I MQZ@_D0?S].V>O&: /Y;O&^N:SXFU.*"_AT[RO"6E3^ =*&C_ \_X+ZZ$Z^' M=%US7[VQLM9E\$6NF6'B'4XY]:OFNM>OVU74-0BF@B35+K2;72(K?^CCX!QB M'X'_ >A5%B6+X8>!(UC6#XB6RQA/#.FJ$6V^+F?BI $ "B'XD'_ (3N,#9X ML_XG@O:_GO\ BW\*/VLO!5E=>)/VM/#_ ,&/A+X$^'6@:IH>G_%_X<^._P#@ MI#\5O@WIWP^T+6_$&L:-JGC[7/AQ^V?\/?B1X:U*#3]::;Q/XH\=_!R;3K*\ M:339/B!?:%H^DS0?T%?L]W6CWWP&^"U]X?\ $_AKQMH-[\*/A]>:)XQ\&:KX MCUWPAXKTBZ\*:5/IOB3PMK7C'Q%XO\6:OX>UNSDAU+1M2\3^*O$GB"^T^XM[ MG6->U:_DN+Z8 ]@HHHH *1NA^A_E2TC=#]#_ "H _@*_X+6?\I+/VCO^Z4_^ MJ:\ U^5M?JE_P6L_Y26?M'?]TI_]4UX!K\K:_P!G?"W_ )-GX>?]D1PK_P"J M/ G^)WBO_P G0\1O^RYXK_\ 5[C@HHHK[L^ "BBB@ HHHH _:#_@@C_RD.\+ M?]DE^+G_ *;-%K^ZBOX5_P#@@C_RD.\+?]DE^+G_ *;-%K^ZBO\ ,OZ7?_)T M\+_V2>4_^IN;'^I/T/\ _DTM7_LJ\X_]1,J"BBBOY;/ZG"BBB@ K^5K_ (.7 M>O[''U^//\OA-7]4M?RM?\'+O7]CCZ_'G^7PFK]V^C1_R>O@S_NX/_67SH_! M/I._\F/XV].'O_6IR0_EA_WG_P#0VIU-7H?]Y_\ T-J=7^&Q_N['9>B_(*** M*!A1110 4444 %%%% !0>>^.1^ASC\>E%% 'XP)_P2I^)]UXIE\;^-OVU?$O MQP\:0Z[?ZYX?\8?M&_L[?!?XW:WX,DNM6N-4L;3P'IGBUCX!^'UOHJS0V&FR M^ ? WA6^:TM(6OKN\NWN+F;]?O"6F:UHOA;PWI'B3Q WBSQ#I>A:3I^N>*&T MG3] ;Q%J]G8P6^HZXVAZ3_Q*]'.JW< :_*VO]G?"W_DV?AY_P!D1PK_ .J/ G^)WBO_ ,G0\1O^ MRYXK_P#5[C@HHHK[L^ "BBB@ HHHH _:#_@@C_RD.\+?]DE^+G_ILT6O[J*_ MA7_X((_\I#O"W_9)?BY_Z;-%K^ZBO\R_I=_\G3PO_9)Y3_ZFYL?ZD_0__P"3 M2U?^RKSC_P!1,J"BBBOY;/ZG"BBB@ K^5K_@Y=Z_L?Y?":OW;Z-'_)Z^#/^[@_]9?.C\$^D[_R8_C;TX>_]:G)#^5RB MBBO]8C_(H**** "BBB@ KU#X(?\ ):/@]_V5CX9?^IWX?KR^O4/@A_R6CX/? M]E8^&7_J=^'ZX,U_Y%F8?]@6*_\ 3,STLF_Y'&5?]C+ _P#J52/]/9>A_P!Y M_P#T-J=35Z'_ 'G_ /0VIU?X;'^[L=EZ+\@HHHH&%%%% !1110 4444 %%%% M !1110 45P/Q3U7XBZ)\./&VK_"/PGX=\=_$W3?#.K7G@/P;XM\67'@3PSXG M\4P6KOHVB:]XRM="\3W/AG2M0NPD%YK4'A[69;"%FG33KHKY1_+@_'__ (+6 MY./^"=7[$Q'8_P##Q7QJ,_\ FH% '["TC=#]#_*OQ[_X7_\ \%KO^D=7[$W_ M (L5\:__ $(%!^/_ /P6N((_X=U?L33]LO_ ()??\%COVOOVC_B)^T->_LZ?L=>!+GQ_P#\ M(OYGA6W_ &Q?%7B*'2_^$9\(:%X339K$G[/FBM=_;(]$2].=,M?(:X:W'FB, M3/\ ,'_#BC_@L'_T2+]D#_Q*GQ-_\Y"O],N _I$>$62<#\'9-F7%-3#YCE/" MW#^6X^@LAXCK*AC,#E6#PV*H^UH935HU?95J=2'M*-2I2GR( M'T.^-,ZRSA2GB,MS?BOB#,\OQ#S[ANBZ^"QV;8K$X6LZ-?-Z5:DZE" MK"?LZU.G5A?EJ0C)24?RZHK]1?\ AQ1_P6#_ .B1?L@?^)4^)O\ YR%'_#BC M_@L'_P!$B_9 _P#$J?$W_P Y"OJ_^)F_!7_HKZG_ (CO%'E_U)?-_=YGR/\ MQ*[XW_\ 1'4__$CX6\O^IUY_AZV_+JBOU%_X<4?\%@_^B1?L@?\ B5/B;_YR M%'_#BC_@L'_T2+]D#_Q*GQ-_\Y"C_B9OP5_Z*^I_XCO%'E_U)?-_=YA_Q*[X MW_\ 1'4__$CX6\O^IUY_AZV_+JBOU%_X<4?\%@_^B1?L@?\ B5/B;_YR%'_# MBC_@L'_T2+]D#_Q*GQ-_\Y"C_B9OP5_Z*^I_XCO%'E_U)?-_=YA_Q*[XW_\ M1'4__$CX6\O^IUY_AZV];_X((_\ *0[PM_V27XN?^FS1:_NHK^,+]A3_ ()P M_P#!8_\ 8D_: TSX\6/[-'['/Q%N--\)>+O"R^&KC]LSQ5X6BE'BJTM+;[<= M6C_9V\0,GV$VBR?9AIK&Y#E/M%N5$E?MQ_PO_P#X+7?](ZOV)O\ Q8KXU_\ MH0*_AOZ17&W#7'O'V'SOA7,)9EED.'LOP,\1+!X[!-8JABLPJ5:7L?GGRPC*2_)/'3A?/. M,_"SBCAKAS!K'YSF2R98/"/$X7"*K]5S_*\;B/\ :,;7P^&I^SPV&K5?WM:' M-R*/+_ *DOF_N\S_.O_B5WQO\ M^B.I_P#B1\+>7_4Z\_P];?EU17ZB_P##BC_@L'_T2+]D#_Q*GQ-_\Y"C_AQ1 M_P %@_\ HD7[('_B5/B;_P"*/+_ *DOF_N\P_XE M=\;_ /HCJ?\ XD?"WE_U.O/\/6WY=45^HO\ PXH_X+!_]$B_9 _\2I\3?_.0 MH_X<4?\ !8/_ *)%^R!_XE3XF_\ G(4?\3-^"O\ T5]3_P 1WBCR_P"I+YO[ MO,/^)7?&_P#Z(ZG_ .)'PMY?]3KS_#UM^75>H?!#_DM'P>_[*Q\,O_4[\/U] MZ_\ #BC_ (+!_P#1(OV0/_$J?$W_ ,Y"NF\%_P#!$O\ X+#>#O&/A'Q='\%_ MV/K]_"GBKPWXG2Q;]K#Q/;+>MX=URPUI;-K@? R8VZW;6(MS.(9C )?-$,I0 M1MR8_P"DMX,5\#C*-/BVI*I5PM>G3C_J]Q,N:63**O)VNVDK7;2.W M+/HQ^->'S'+\16X0IQI4,;A*U67^L/#$N6G2KTYSERQSER=HINT4Y.UDF]%_ M>VO0_P"\_P#Z&U.K\>S\?_\ @M9N;;_P3I_8G"EW90W_ 46\9LRJS%@I9?V M/D#$ @%@B D9"J#@)_PO_P#X+7?](ZOV)O\ Q8KXU_\ H0*_RM/]85HDNR1^ MPM%?CU_PO_\ X+7?](ZOV)O_ !8KXU_^A K[S_9>\8?M0^-? 6K:I^UE\%_A M=\#/B'!XKOK'1_"GPE^-&J?'/P[J'A"/2]'GL->O/%>J_#CX8W&GZQ=:M<:U M83Z"FA7<-M::=97ZZK,^HO:V8,^DJ*** "BBB@ HHHH **** "BBB@ HHHH M*0LHSD@8&3D]!ZGT'!Y.,X-(Y*H[#JJL1GID D9QS^5?E!\,O &H?MA>)?VN M_'/Q0^,WQ_\ >N_#K]H[XH_L_?"[P_\(OC;X]^$.C_ 7PS\)[/0[#PWXOC\ M)^#-=T_PCXY\<>/TU:+XU:CJWQKT/XB:/J'ASQ1X5\-Q^'K;P-:3:)J !^L- M'^?RZU^)?[,G[=_[6GQW^'GP\OO"7@/X*^(]0^&W[/'[-?Q5_:&\4?$KQEK7 MPRE^)UY\;;GQ5)#J/PH@T;P_J'@_P1I-[\-/!,GQ@M/$?BVZO_#6I:CXST/X M=V&FZ';6&K^*M-Q_V:OVMOVW_%FE:%\)+P? WQY\&OA_X(^ O['W[3VH?"4:;JFBZ#:OKWB7Q7)KWBSP1X+\$Z+I,^BPZ=\/K M6Y\8>+-;USQ)HM[IWB0 _\&>%]3^#7 MP+_93_9J^+OQE^#7C3XI^,KF7PKJWP]\=_MG^ /VAO#/[/3:;X8;P[ -!UCPMH4VK7>N>#?LNP_X*,?%'Q+^TIJG@ M3P3\!O$OBKX.^&OVIX_V3_$>H:9\*?VDKKQ1::C::KIOA3Q5\:W^*=I\*9_V M:-,\#>#/&NI_8]9\$:I\1(_%#>"M,U7QE_PD%IKZ6?P[N0#]>:/Z=:^'?^"? M?[07QH_:J_9Q\$_M#_%KP=\./A_9_%O1M*\8?#[PEX#U[Q+XFOM)\*7D,]L! MXPUC7K#3+2;7-0N[-M5@MM$LQ9Z7IVH0:5>"(M M5UX^'/"NDZKXCO3&=3U[Q'XEUO4)+W7?$OB'5-2OF: _3$D#&2!DX&3C)]! MZGVI-R@ [A@C(.1@CC)^@R,GH.]?$G[!/"_P_P#"7CSXO?'7XG_"/X1> M#O&<%SXK\&?!O5/%_A[XD?M Z_KNEW_AKX<_!GPIK7PNO;+XS7VNZ[XTU73] M0T#P#\'YX?&GQ(\2:=HOAEYI/#TFMZ=J/YD>%8_VI/&FGZ=\&OVB?B_\>OA% MXH^#W_!/KXG_ +2OA]-"^+O]A_$RS\;>,OCK\5-+^#!_AWX;^(&D:XGB7X3^-/B#XL\3ZUXQTWQZ+C2]0C /Z%,CUZ]/>DR, MXR,YQC(SG&<8]<E?B_)\8/VE?'WB;_@BQ\:-4^+%SX.\"?M%WGA!/BY M\"O"GA6+1(?%WCCQW^P)^T3\:=%/%_P!GWX]_&#Q1\+;#3_A-XHO/LX!_03135(958'(9002,$@C.<=L^E M.H *3(/@;=>.UF_9NT;QO87GA-?A;J'P_^!EKX?\*^ M-_#_ (>\(V7QIUW2?%.HZAXO /Z):,@=3CM^/I7\_P#'_P %=_CLOP#^('[1 M:?LQ7VI>![[]D/X@?M6?"IKWX?\ [3_PUT'PW/X8LO!VO^"/A5\4_BC\6/@S MX1^'/C"]^*/A7QI;7ND_$#X+:GK6@Z/X@T36-%CT3Q#H-SH/C+5.A_:-_;#_ M &X/#'Q*^''[/UO#\$_A[\7-'_:^_823Q5KOA*^\8^*_ASXZ_9Y_:HO/VAM( MC\&W2^(-&TSQ3HOBS0?&GP#\1:+XHO-/VV?B/PP- \3:3-X5FUO4_"NE@'[O MT5^#MS_P5K^+4WA[XC_%_P +_LZZUXE^"FF^'?VOKOPE=R_#+]ISPW>^%W_9 MA\#?&3Q)X;\9_$OXM^(OA#IW[/>L^$OBSKOP8U'PO<:-\.?'=YKWP]U/QCX0 MB&H>-]OBF3PY8\:?\%(?VPOAMHOQJ\2>,?@G^SNVE_L__L\_LY?MC^.K70OB M3\2[G4M6^#'Q\U7Q_HE]\+?#37?@VWM%^*W@:7X5>-M1B\"O%<\;? #QU_P50_; _9 M0\->(KWQSXS\0_&?PF5^)OQ2OOASJ=IH5WHT_AF+X9>%;GP;&;/P=K_@GX4_%'XH?%CX->$OASXQO_ (H>%?&EM>:1 M\0/@MJFM:#H_B'0]8T6/1/$6@W.@^,]4 /W_ "0!DD >IX%)N7KD=<=>_I]? M;KGM7R[XQ\-?$OQU\ +?PA\7OB=9?!?XA^*- M075K\/\ X=^,O'UM:Z_H^N?$'PU;VWP\N?$]A;:9XLL[[7=5UCP%-X#?V8-,_:%^!W[/UY^U1X1\7R^//'FD>.;'Q?I'Q?/CCPQXS;QE:>$[&X^ M"VK^+KN+P?XCO-7 /Z&@01D'(/((Z$>M)N7.-PSD#&1G)S@8]3@X]<&OBC_@ MGUXZ\;>/?V:-.F\?^(M<\9:]X&^+_P"T[\%+3QOXFDM[GQ%XU\+? +]I?XM? M!7P/XM\0W]I96%MJWB+7/!O@30;OQ!K4< _M[6CJ&L2$SWLV/E/]HG_A+H?V MN?!G@KX/?'CX[>._VG/%_P :/@-\1?\ A6WA3QAK&D? 3]EW]C/PSK?AS3/C M'=?&[X?:=J ^&NL:-\7]"T+XIZ=X&U+XBV=Y\:?B7\6?$^D6/PCN_#_A#X2Z MWK_@P _8/()P",\\9].OY9&?3(SU%+D<^W7'/\OK7X6?L\_$_P"*]]XO_8<_ M:"U'XD_%C6/$?[97[5W[8?PA^,7PLU_QQJVM_#3PO\//"7A7]JCQE\.] \)_ M#::ZU'PC\/M5^!MY^SKX*\''Q-X.T_1=?\3?V[XWD^(NL>)-2UZVFT[O_@K< M^+]6\3_\%2O!_P"V-\??'?CSP=\&_BY\*_&%QXF\"^)?'_[/NE_#?P,G[*7P MK^-.K^&_AM#\*_'5AXQ\&^"_#UU>ZG<7=L_CG6]>\82_VC>>-=H_!7Q-^ M+/Q,^+DWP7\(>/\ 3]-NOAQ\&/#^M?%/Q'XG\1VD'@7X?6_AN#QCOU2:/7/B MC>^//$J""VU:SL+'[]H **** "BBB@ HHHH **** "BBB@ HHHH *^4OBG^Q M)^S1\9?%?BCQIX]^'M[(M \"_%+P-X*U]Y]5\(^#/B3X<\5>&?#=U>:@='TNSBU&^BN,K6/V$/V M7M;74#-X"U_2[V^^+?Q ^.5MKGA7XM?&;P5XH\+_ !-^+%O?6_Q2USX>^+/! M_P 0M"\3?#+3_B6=3U.]^(/A/X>:MX9\'>--6U/4]:\1^']1UC4+J^E^OJ* M/AJ?_@FS^Q/-J.CZA'\"])T^+1_!/PK^&O\ PC^C>*_B)H7@C7OAW\$]8U;Q M%\,/ ?C?X>Z+XPL/ OQ"\&>%/$6NZOXCMO"_CSP[XDT74/$5_-KVLV>I:KMN MQZ%?_L7_ +->I?%M?C;>?#=9?'?_ GVD_%>:)?%WCV'P#>_%C0?#\?A;1/B MQJ?P@@\51?"+5?BMH^@P6NG:7\2]2\#77C>PBL--EMM=CNM-T^XMOJ.B@#S_ M .%7PL\ _!'X=>#_ (3?"WP[;^$OA[X!T.S\->$/#5K=ZE?V^BZ)8!A:6$-Y MJ][J.IW$<(=@LM[?75PV?GF; QYIXX_9>^%GC#1_CE96=AJOA'6?VBM5\&Z[ M\4_%GA;Q!XATOQ'K>M^ M%\)>&/"VKVE[!J\8T:]TGPQX)\/:+"NCI8V-S;V M(DU6QU-KB_6]^BZYC7_&O@_PK/96WB;Q5X;\/7&HK,VGP:YKVDZ/-?+;M&L[ M6<6I7EK)="%I8EE,"R"-I(PY4NH(!X_\,_P!A']F/XA^%_"'A'QSX+\6>+-,\$:#X MS\):1?Z_\:/CEJ?B[4_!/Q$U"SU3QW\//&_CZX^)+>.OB5\-/&%YINF'Q)\- MOB+XC\4^!=8MM)TBPO?#\MCI6GVUO]/:'XL\+^)X8[CPYXBT'7[>5)Y(Y]%U MG3=6AD2VG%K<.DNGW5RCK!H?!+Q7-XV^%DD,EYIT'@WQ-/X!\7?"^34=-L=,NK.PE4> O'7BOPW M#87]M>:9;V>K/-;V45[:6%U:>4Z7^QS^SAHOQB?X\:7\-X;3XC'Q=XA^(<$T M?B?QLW@W3OB1XM\-CP?XK^*&C?"N7Q*_PKT/XI^)_##7&A>(_B=H_@JQ\>:Y MIE_JMKJ?B"Y35]4-Y]-U!=75M8VMQ>WMQ!:6=I!+6T5I M^,?$?]L?VKXH^& M_P #]8\:ZA\&OAUKTG_"0^(#:ZIX)\!Z%=:6VO:XVDR6#:QJ!N/KHG R>@] M3^@R:KV]Y:W?G_9;FWN?LUQ+:7'D3Q3>1=0;?.MIO*=_*GBWKYD,FV6/!/$>L:;I][XC\%?"K3/!.A:T=,T M>"\M'M=&TR"U][@_8)_96@\.ZSX<_P"%<:I.NN_$+X>?%.^\4WOQ/^+FH?$V M/QO\)'M?^%6:KIGQ>OO'MQ\5-#M?AS:VBZ3X(T'1/&.G>'/#&@76J>'='TBT MT+6M8T^_^PZX;5_B=\./#^HS:1KOC[P5HVJVQC%QINK>+/#VFZA 9462(365 M[J4%U$9$='C$D2EU967*L"0#YIU3_@GO^R%K>M^+]=U?X1)J+>-[?XPPZQX? MN?'/Q,D\!Z?=_M ^'M6\*_&SQ!X,^&W_ FG_"O?ASXR^*/A_P 0>(],\:^. M?A[X8\+^,==A\2^)I+O7&N/$>MS7_H'BO]D;]G7QOIOQ&T?Q3\,].U?3?BW\ M'_ OP#^(=K+K/BBW7Q+\(_AI>>,;_P #^#+A[/7+:6SM- N_'_B^:'4=+DL= M;NCK4RZAJ=VEO8K:_1P((!!!! ((.00>001P01T-027=K%<06DES!'=74<\M MM;/-$EQ<1VOE?:9((6<2S);^?#Y[QHRP^=%YA7S$W 'RGX0_8:_9<\!_%2Z^ M,_A;X8#3_'MW\2_B!\9WN)_&OQ%U;PO!\8/BG;W]CX^^*VG_ [UGQ?J'PYT MOXE>(M*U34O#\_CO3/"=IXHL_"]_>>%M-U2R\/7$NFMRMI_P3C_8TM-,\7:$ MOP;CG\/>,_A]XN^$]YX9O_'WQ2U/PMX8^&'CWQ#8>*O&?P]^%GAC4O'%WH'P M7\%^*/$&DZ/J>N^&OA#IW@?2=1FT71([BU:VT;3(+7[>JM;WEK=^?]EN;>Y^ MS7$MI<>1/%-Y%U!M\ZVF\IW\J>+>OF0R;98]R[T7(R >?_%KX0_#GXY^ ]7^ M&GQ4\+V?B[P9K<^D7MWI5UU32_$/AK7]-T_6M#U.PU.RMKJ+Q<_L0?LT'X?I\-U\!ZO#I$ M?Q3F^."^)[7XF?%BT^+I^,EQ82Z/.HOC=)\1;CP]-+X3N/&"Y;Y_"F-&'UC10!\_?#_ /9H^%WPHU[X&/$?BCPAXKN;V_TF;4)[?5/$=OJ?A".2'Q/J,5SXCN9- M>\37.IZQJ%QK=V[<0O[#?[.D'Q8\;_&[3=&^*'A_XC_$OQWX<^)?Q!U3PG^T M;^TAX/T/QIXT\(Z#H'A;PWJWB;P/X6^+.D>!-9ATGPQX8T3PY;Z/?>&IM#;0 M;-](FTV6PO+^"Z^N** /FSPA^R)^SSX$^+>I_'#PO\/(]/\ B+J>H^/-:2_F M\3>--5\.:!K_ ,4[O3K_ .)_B7P1\/M7\27_ ,._A]XJ^)5]I=I>?$/Q1X%\ M*>'?$'C>Z%S/XFU'4Y;_ %!KOI=7_9Q^"VNVG[0%CJG@>UN;;]J73QI7QZ1= M7\16S?$*P'PVT[X0BWO)K76()]&'_"N=*L/"YD\,R:)*;6W%V9#J*/&7PZ\!^+?$W@[X#>.G\(^(O%'A#PYK^N>%I+M]*N+J3PYJ^L: M;=W^AOI:1K%A::II>H6DN/,MK[3[Z&XL[NWDP-\%Q#)$^!N0X% 'X"?M-^"/$OP; M_;3^)FH?LL>*?#7[,EI\(O\ @DW\:_BU9:7\/?A-\-;S2=8\3>'?V@;_ ,8: M/IEQX-?#5GJWC;PCX1TS3-(U.7XF:MK'A9(9 M?#W]!][X5\,:E>WFI:CX=T*_U#4-!N?"U_?7NCZ==7E[X:O)GN+OP]=W5Q;2 M3W.AW5Q))/<:1/))IT\SO++;.[,QK67@CP;IMIJUAIWA/PUI]EK]K:6.N6EC MH.DVEKK%EI^BVWANQL]5M[>SCAU&UL_#UG::%:VUZD\-OHUK;Z5#&EA!%;H M?SU:A^WC^UUHTVG_ D;Q+K^R!X?\ B7XS\6:/II^'&JZQX7;5]7^%VI:C8M\.+SQI;Z1X MDOOH?XM?%OX@?&[_ ((;?MB_$#XK7W@7Q=XFN_V4/VW/#EYXA\#ZYX/\1>%O M'.A>"-.^+/@G1M9O;WP!JVO> D\0:WH&@VL'Q!TWP7K>J>#K#QHOB6R\,71T M%-/AB_6&#X%?!2U^'US\)K;X0_"^W^%MY,]S=_#:#X?>$(? -U<2WD>HRSW/ M@R/1E\-3S27\45Z\LNEO(]Y''([XS2-(/!6I_ME_L MW>$/^">AU:[$\;2Z7=_ 3XG^,M;^S7#SQWGB7X%2?:HI##^X^K==_;P_:#T3 M0M+^+-G\?/!VJ>*/B5\7_P!OCX2Z[^R.WA#X:-J?[.^B?LY?#7]I[Q3X4\61 MWEHJ_%"?QE\,M6^!?P^'QGU#XB7?B'X?>*A\6H8_#OAGP1;W_@O[;^]]WX$\ M$W\NKSWWA#PO>3>(&\.OKLMWX>T>YDUE_"%TM[X4?57FLG;46\,WB)=^'VO3 M.VBW*K<:8;68!QE)\)_A?'XG\3>-D^'/@-/&/C31_P#A'O&'BM?!WAQ?$OBO M0/)BMO[#\2Z\-,&K:]H_V>&&#^S-6O+RQ\F**+R-D:*H!_,;^UG^T)^US??L MH?$7P)XY_:3U:_O_ (J_\$WOV4?VR[CQWX6\!_#OX?:I\*O&NM_M%?#3PM\4 M/#O@M]&T0P'X4:]X;UYKRYM?'TGBOQ1H/]EZA)_PG4NB:I=Z79^W_ +Q]\<_ M@3\2?'OC'PW\8)-<^'WQ*_X+@^/_ -F_Q/\ "_6?!'@.33O$WA?XE>%-(L-< M^(.K>,-/T>Q\56_Q&@\6Z-9>*M#E\(7_ (7\ P:6UQX;O? .II^&-"N[2Z\"3+LE\%W-M<6$D$_A*5"5 MD\-RQOHKJ2K6)'%-T[X;_#W2-.L-(TKP+X-TS2M*UNS\2Z9ING^%M!LM/T[Q M%I]O%:6&O6-E:Z?%;6>LV5K!#;6FJVT45_;6\44,%Q'%&B@ _)/_ ()R_M:_ M&3XO?$NZ\!?'+XL6WQ \2>,/@;J7QB\/?\(1IWP \8? 7Q!8>'?B9;^$M?\ M&OP"^*'P<\1Z?\3?#/P\V^+?"_A^V^%/[5OPPL/BY'J%M=ZAIWCWQ+-H/C;3 M=-^9_AC\/-/\3?M2?\%$M8U3PS_P3AU?3HOV^]3@U*Z_:G\"6WB/XR?V=:_L MX?LJRW\&AZI)]1T?3K*\\0:@LMY= MR"]U>>\N0]U<.)=T\I?A/%7[,'[-OCKQ#J/BWQK^S_\ !'Q?XIU>6&?5?$GB MCX2_#[Q#K^ISV]O!:6\VH:SK'AR]U*]E@M;:VMH9+JZE>*"WAA1ECBC50#\E MM,_:K_:IL_BR_C;4/B]I5_\ #B'_ (*[:M^P98_!'C;6& MM:GXOMM.7X@2_$GPWXG=-3\/ZSIOB+3/#(OV:_VT+[XQ^#/C;\:K/_ ()T?\%1?V@K7]E_3?#/A#2!\$/B!X:L_P!G MZZE^$R0>&;K3O&T_A_P#KF@+\-/'MK\3=;U3QUJ?C?PGXDO=*\1:5%//X8T+ M^H,^"/!IZ^$_#)_XJ@>-^= TG_D<@ !XL_X\_P#D9@ -?\ ^0L !_IE9>C_ M M^&GA_Q)K7C+0?A[X'T7Q=XCO[G5/$'BG2/"7A[3/$>N:G>VL%C=ZCK&NV M.FP:KJ=_=65K;6EQ>7UW<7,]K;002RO%#&B@'X$:-^W!^U) M]X"U;XX^%+/ MPKXW\;?L7^'KS]H;Q'XC_8]\?^-_@1HG[1'B+XHZ7KWC3^P?V?M1USX.6_P[ M^*$?@;PGX8_9UU[XJ:5JM[H'CWQO*V^*VA0Z-/+]L?\$G9&F\%_MDRR?$ M;2?BY(W_ 41_:LCD^)&B6>EV%AXJDMM2\&VCW3VNA@:"FJV#6YT;Q!+H,=O MH=UXATW5+O2;'3+">#3+/]"M*^!_P9T+PKXH\"Z)\)OAGH_@KQM/?77C+PAI M7@'PEIWA;Q9.VMK)'2PTJUM+162SL[2T1E MA!6VM;: $101(@!T-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ;%%%% !1110 4444 %%%% !1110 4444 ?__9 end GRAPHIC 17 cy17q110q_chart-47327a02.jpg begin 644 cy17q110q_chart-47327a02.jpg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end GRAPHIC 18 cy17q110q_chart-47343a02.jpg begin 644 cy17q110q_chart-47343a02.jpg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end GRAPHIC 19 cy17q110q_chart-47367a02.jpg begin 644 cy17q110q_chart-47367a02.jpg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end GRAPHIC 20 cy17q110q_chart-47491a02.jpg begin 644 cy17q110q_chart-47491a02.jpg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�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end GRAPHIC 21 cy17q110q_chart-47601a02.jpg begin 644 cy17q110q_chart-47601a02.jpg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end GRAPHIC 22 cy17q210q_chart-38723a01.jpg begin 644 cy17q210q_chart-38723a01.jpg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end GRAPHIC 23 cy17q210q_chart-38938a01.jpg begin 644 cy17q210q_chart-38938a01.jpg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end GRAPHIC 24 cy17q210q_chart-39013a01.jpg begin 644 cy17q210q_chart-39013a01.jpg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�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end GRAPHIC 25 cy17q210q_chart-39117a01.jpg begin 644 cy17q210q_chart-39117a01.jpg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end GRAPHIC 26 cy17q210q_chart-39323a01.jpg begin 644 cy17q210q_chart-39323a01.jpg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end GRAPHIC 27 ex105formsofnqsoagree_image1.jpg begin 644 ex105formsofnqsoagree_image1.jpg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end XML 28 R1.htm IDEA: XBRL DOCUMENT v3.8.0.1
Document and Entity Information Document
 9 Months Ended
Sep. 30, 2017
shares
Document and Entity Information [Abstract]  
Entity registrant name PERRIGO CO PLC
Entity central index key 0001585364
Current calendar year end date --12-31
Entity filer category Large Accelerated Filer
Document type 10-Q
Document period end date Sep. 30, 2017
Document calendar year focus 2017
Document calendar period focus Q3
Amendment flag false
Entity common stock, shares outstanding 140,840,721
Entity well-known seasoned issuer Yes
Entity voluntary filers No
Entity current reporting status Yes

XML 29 R2.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Statements of Income - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Oct. 01, 2016
Sep. 30, 2017
Oct. 01, 2016
Net sales $ 1,231.3 $ 1,261.6 $ 3,663.1 $ 3,949.3
Cost of sales 733.5 777.1 2,196.4 2,385.2
Gross profit 497.8 484.5 1,466.7 1,564.1
Operating expenses        
Distribution 21.5 21.6 64.2 65.9
Research and development 38.4 50.2 120.8 142.5
Selling 143.5 154.6 454.1 506.9
Administration 123.3 105.4 326.9 317.2
Impairment charges 7.8 1,614.4 47.4 2,028.8
Restructuring charges 3.8 6.6 54.7 17.9
Other operating income (2.9) 0.0 (41.0) 0.0
Total operating expenses 335.4 1,952.8 1,027.1 3,079.2
Operating income (loss) 162.4 (1,468.3) 439.6 (1,515.1)
Change in financial assets 2.6 377.4 24.2 1,492.6
Interest expense, net 34.7 54.6 133.1 163.2
Other (income) expense, net (3.6) 1.0 (1.1) 32.4
Loss on extinguishment of debt 0.0 0.7 135.2 1.1
Income (loss) before income taxes 128.7 (1,902.0) 148.2 (3,204.4)
Income tax expense (benefit) 84.2 (311.8) 101.8 (550.7)
Net income (loss) $ 44.5 $ (1,590.2) $ 46.4 $ (2,653.7)
Earnings (loss) per share        
Basic $ 0.31 $ (11.10) $ 0.33 $ (18.53)
Diluted $ 0.31 $ (11.10) $ 0.32 $ (18.53)
Weighted-average shares outstanding        
Basic 141.3 143.3 142.5 143.2
Diluted 141.7 143.3 142.8 143.2
Dividends declared per share (in dollars per share) $ 0.16 $ 0.145 $ 0.480 $ 0.435
XML 30 R3.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statements of Comprehensive Income - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Oct. 01, 2016
Sep. 30, 2017
Oct. 01, 2016
Net income (loss) $ 44.5 $ (1,590.2) $ 46.4 $ (2,653.7)
Other comprehensive income:        
Foreign currency translation adjustments 69.9 27.5 289.9 71.5
Change in fair value of derivative financial instruments, net of tax 0.1 3.6 8.7 (3.5)
Change in fair value of investment securities, net of tax (8.1) 9.8 (24.4) 18.4
Change in post-retirement and pension liability, net of tax (1.2) (0.2) (1.2) 0.4
Other comprehensive income, net of tax 60.7 40.7 273.0 86.8
Comprehensive income (loss) $ 105.2 $ (1,549.5) $ 319.4 $ (2,566.9)
XML 31 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Balance Sheets - USD ($)
shares in Millions, $ in Millions
Sep. 30, 2017
Dec. 31, 2016
Assets    
Cash and cash equivalents $ 775.9 $ 622.3
Accounts receivable, net of allowance for doubtful accounts of $6.2 million and $6.3 million, respectively 1,076.6 1,176.0
Inventories 821.9 795.0
Prepaid expenses and other current assets 297.4 212.0
Total current assets 2,971.8 2,805.3
Property, plant and equipment, net 822.3 870.1
Financial assets 0.0 2,350.0
Goodwill and other indefinite-lived intangible assets 4,255.4 4,163.9
Other intangible assets, net 3,347.4 3,396.8
Non-current deferred income taxes 22.4 72.1
Other non-current assets 423.3 211.9
Total non-current assets 8,870.8 11,064.8
Total assets 11,842.6 13,870.1
Liabilities    
Accounts payable 477.1 471.7
Payroll and related taxes 133.4 115.8
Accrued customer programs 368.8 380.3
Accrued liabilities 274.6 263.3
Accrued income taxes 61.5 32.4
Current indebtedness 417.1 572.8
Total current liabilities 1,732.5 1,836.3
Long-term debt, less current portion 3,275.7 5,224.5
Non-current deferred income taxes 357.7 389.9
Other non-current liabilities 434.9 461.8
Total non-current liabilities 4,068.3 6,076.2
Total liabilities 5,800.8 7,912.5
Shareholders’ equity    
Preferred shares, $0.0001 par value, 10 million shares authorized 0.0 0.0
Ordinary shares, €0.001 par value, 10 billion shares authorized 7,900.1 8,135.0
Accumulated other comprehensive income (loss) 191.2 (81.8)
Retained earnings (accumulated deficit) (2,049.6) (2,095.1)
Total controlling interest 6,041.7 5,958.1
Noncontrolling interest 0.1 (0.5)
Total shareholders’ equity 6,041.8 5,957.6
Total liabilities and shareholders' equity $ 11,842.6 $ 13,870.1
Supplemental Disclosures of Balance Sheet Information    
Ordinary shares, issued and outstanding (in millions) 140.8 143.4
XML 32 R5.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Balance Sheets (Parenthetical)
$ in Millions
Sep. 30, 2017
€ / shares
Sep. 30, 2017
USD ($)
$ / shares
shares
Dec. 31, 2016
€ / shares
Dec. 31, 2016
USD ($)
$ / shares
shares
Stockholders' Equity:        
Preferred shares, par value | $ / shares   $ 0.0001   $ 0.0001
Preferred shares, authorized   10,000,000   10,000,000
Ordinary shares, par value | € / shares € 0.001   € 0.001  
Ordinary shares, authorized   10,000,000,000   10,000,000,000
Ordinary shares outstanding   140,800,000   143,400,000
Allowance for doubtful accounts | $   $ 6.2   $ 6.3
Commitments and contingencies | $   $ 0.0   $ 0.0
XML 33 R6.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2017
Oct. 01, 2016
Cash Flows From (For) Operating Activities    
Net income (loss) $ 46.4 $ (2,653.7)
Adjustments to derive cash flows    
Depreciation and amortization 333.1 338.4
Share-based compensation 28.1 15.3
Impairment charges 47.4 2,028.8
Change in financial assets 24.2 1,492.6
Loss on extinguishment of debt 135.2 1.1
Restructuring charges 54.7 17.9
Deferred income taxes (16.3) (674.1)
Amortization of debt premium (18.4) (24.6)
Other non-cash adjustments, net (27.2) 34.5
Subtotal 607.2 576.2
Increase (decrease) in cash due to:    
Accounts receivable 38.4 113.0
Inventories (28.3) 25.1
Accounts payable (6.0) (57.7)
Payroll and related taxes (36.7) (40.0)
Accrued customer programs (15.8) (73.7)
Accrued liabilities (18.8) (90.0)
Accrued income taxes (61.5) 5.2
Other, net 3.5 (9.4)
Subtotal (125.2) (127.5)
Net cash from operating activities 482.0 448.7
Cash Flows From (For) Investing Activities    
Proceeds from royalty rights 86.4 259.5
Acquisitions of businesses, net of cash acquired 0.0 (436.8)
Asset acquisitions 0.0 (65.1)
Additions to property, plant and equipment (55.2) (84.6)
Net proceeds from sale of business and other assets 46.7 58.5
Proceeds from sale of the Tysabri® financial asset 2,200.0 0.0
Other investing, net (5.8) (1.0)
Net cash from (for) investing activities 2,272.1 (269.5)
Cash Flows From (For) Financing Activities    
Issuances of long-term debt 0.0 1,190.3
Payments on long-term debt (2,243.7) (545.8)
Borrowings (repayments) of revolving credit agreements and other financing, net 0.0 (803.6)
Deferred financing fees (4.2) (2.8)
Premium on early debt retirement 116.1 0.6
Issuance of ordinary shares 0.5 8.2
Repurchase of ordinary shares 191.5 0.0
Cash dividends (68.7) (62.4)
Other financing 2.7 (17.4)
Net cash (for) financing activities (2,621.0) (234.1)
Effect of exchange rate changes on cash and cash equivalents 20.5 (0.2)
Net increase (decrease) in cash and cash equivalents 153.6 (55.1)
Cash and cash equivalents, beginning of period 622.3 417.8
Cash and cash equivalents, end of period $ 775.9 $ 362.7
XML 34 R7.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies
 9 Months Ended
Sep. 30, 2017
Accounting Policies [Abstract]  
Summary of significant accounting policies
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

General Information

The Company

Perrigo Company plc was incorporated under the laws of Ireland on June 28, 2013 and became the successor registrant of Perrigo Company, a Michigan corporation, on December 18, 2013 in connection with the acquisition of Elan Corporation, plc ("Elan"). Unless the context requires otherwise, the terms "Perrigo," the "Company," "we," "our," "us," and similar pronouns used herein refer to Perrigo Company plc, its subsidiaries, and all predecessors of Perrigo Company plc and its subsidiaries.

We are a leading global healthcare company, delivering value to our customers and consumers by providing Quality Affordable Healthcare Products®. Founded in 1887 as a packager of home remedies, we have built a unique business model that is best described as the convergence of a fast-moving consumer goods company, a high-quality pharmaceutical manufacturing organization and a world-class supply chain network. We believe we are one of the world's largest manufacturers of over-the-counter (“OTC”) healthcare products and suppliers of infant formulas for the store brand market. We also are a leading provider of branded OTC products throughout Europe and the U.S., as well as a leading producer of generic standard topical products such as creams, lotions, and gels, as well as inhalants and injections ("extended topical") prescription drugs. We are headquartered in Ireland, and sell our products primarily in North America and Europe, as well as in other markets, including Australia, Israel and China.

Basis of Presentation

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The unaudited Condensed Consolidated Financial Statements should be read in conjunction with the consolidated financial statements and footnotes included in our Annual Report on Form 10-K for the year ended December 31, 2016. In the opinion of management, all adjustments (consisting of normal recurring accruals and other adjustments) considered necessary for a fair presentation of the unaudited Condensed Consolidated Financial Statements have been included and include our accounts and the accounts of all majority-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.


Recent Accounting Standard Pronouncements
    
Below are recent accounting standard updates that we are still assessing to determine the effect on our Condensed Consolidated Financial Statements. We do not believe that any other recently issued accounting standards could have a material effect on our Condensed Consolidated Financial Statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.
Recently Issued Accounting Standards Adopted
Standard
 
Description
 
Date of adoption
 
Effect on the Financial Statements or Other Significant Matters
Clarifying the Definition of a Business
 
This update clarifies the definition of a business and addresses whether transactions should be accounted for as asset acquisitions or business combinations (or divestitures). The guidance includes an initial threshold that an acquired set of assets will not be considered a business if substantially all of the fair value of the assets acquired is concentrated in a single tangible or identifiable intangible asset (or group of similar assets). If the acquired set does not pass the initial threshold, then the guidance requires that, to be a business, the set must include an input and a substantive process that together significantly contribute to the ability to create outputs. Different factors are considered to determine whether the set includes a substantive process, such as the inclusion of an organized workforce. Further, the guidance removes language stating that a business need not include all of the inputs and processes that the seller used in operating the business.
 
January 1, 2017
 
We early adopted this new standard and will apply it prospectively when determining whether transactions should be accounted for as asset acquisitions (divestitures) or business combinations (divestitures). During the nine months ended September 30, 2017, we applied the new guidance when determining whether certain product divestitures represented sales of assets or businesses.

Improvements to Employee Share-Based Payment Accounting
 
This guidance is intended to simplify several aspects of the accounting for share-based payment award transactions. It will require all income tax effects of awards to be recorded through the income statement when the awards vest or settle as opposed to certain amounts being recorded in additional paid-in capital. An entity will also have to elect whether to account for forfeitures as they occur or by estimating the number of awards expected to be forfeited and adjusting the estimate when it is likely to change (as currently required). The guidance will also increase the amount an employer can withhold to cover income taxes on awards.
 
January 1, 2017
 
We adopted this standard as of January 1, 2017. We elected to estimate the number of awards expected to be forfeited and adjust the estimate when it is likely to change, consistent with past practice. We did not change the amounts that we withhold to cover income taxes on awards. As the requirement to record all income tax effects of vested or settled awards through the income statement is prospective in nature, there was no cumulative effect of adopting the standard on our balance sheet.


Recently Issued Accounting Standards Not Yet Adopted
Standard
 
Description
 
Effective Date
 
Effect on the Financial Statements or Other Significant Matters
Revenue from Contracts with Customers
 
The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: identify the contract(s) with a customer; identify the performance obligations in the contract; determine the transaction price; allocate the transaction price to the performance obligations in the contract; and recognize revenue when (or as) the entity satisfies a performance obligation. This guidance allows for two adoption methods, full retrospective approach or modified retrospective approach.
 
January 1, 2018
 
We continue to evaluate the implications of adoption of the new revenue standard on our Consolidated Financial Statements. We have completed an initial assessment and are in the process of quantifying the adoption impact, if any, related to certain topics identified through our evaluation process. Our assessment of the new revenue standard has been focused on, but has not been limited to, the concepts of over-time versus point-in-time revenue recognition patterns, variable consideration, and identification of performance obligations. We will not complete our final assessment and quantification of the impact of the new revenue standard on our Consolidated Financial Statements until the adoption date. Our analysis indicates that certain contract manufacturing and private label arrangements may require revenue recognition over-time in situations in which we produce products that have no alternative use and we have an enforceable right to payment for performance completed to date, inclusive of a reasonable profit margin. This may result in an acceleration of revenue recognition for certain contractual arrangements as compared to recognition under current accounting literature. We plan to adopt the new revenue standard effective January 1, 2018 using the modified retrospective method.
Intra-Entity Asset Transfers of Assets Other Than Inventory
 
Under the new guidance, the tax impact to the seller on the profit from the transfers and the buyer’s deferred tax benefit on the increased tax basis would be recognized when the transfers occur, resulting in the recognition of expense sooner than under historical guidance. The guidance excludes intra-entity transfers of inventory. For intra-entity transfers of inventory, the Financial Accounting Standards Board ("FASB") decided to retain current GAAP, which requires an entity to recognize the income tax consequences when the inventory has been sold to an outside party.
 
January 1, 2018
 
We are currently evaluating the implications of adoption on our Consolidated Financial Statements.
Financial Instruments - Recognition and Measurement of Financial Assets and Liabilities
 
The objective of this simplification update is to improve the decision usefulness of financial instrument reporting, and it principally affects accounting for equity investments currently classified as available for sale and financial liabilities where the fair value option has been elected. Entities will have to measure many equity investments at fair value and recognize changes in fair value in net income rather than other comprehensive income as required under current U.S. GAAP.
 
January 1, 2018
 
We have identified certain investments that will require an adjustment, however, at this time, we are unable to estimate the impact of adopting this standard as the significance of the impact will depend upon our equity investments as of the date of adoption.

Recently Issued Accounting Standards Not Yet Adopted (continued)
Standard
 
Description
 
Effective Date
 
Effect on the Financial Statements or Other Significant Matters
Leases
 
This guidance was issued to increase transparency and comparability among organizations by requiring recognition of lease assets and lease liabilities on the balance sheet and disclosure of key information about leasing arrangements. For leases with a term of 12 months or less, lessees are permitted to make an election to not recognize right-of-use assets and lease liabilities. Upon adoption, lessees will apply the new standard as of the beginning of the earliest comparative period presented in the financial statements, however lessees will be able to exclude leases that expire as of the implementation date. Early adoption is permitted.
 
January 1, 2019
 
We are currently evaluating the implications of adoption on our Consolidated Financial Statements and have commenced the first step of identifying a task force to take the lead in implementing the new Lease standard.
Derivatives and Hedging
 
This update was issued to enable entities to better portray the economics of their risk management activities in the financial statements and enhance the transparency and understandability of hedge results. In addition, the amendments simplify the application of hedge accounting in certain situations. Under the new rule, the entity’s ability to hedge non-financial and financial risk components is expanded. The guidance eliminates the requirement to separately measure and report hedge ineffectiveness and also eases certain documentation and assessment requirements. Early adoption is permitted.
 
January 1, 2019
 
We are currently evaluating the implications of adoption on our Consolidated Financial Statements.

Measurement of Credit Losses on Financial Instruments
 
This guidance changes the impairment model for most financial assets and certain other instruments, replacing the current "incurred loss" approach with an "expected loss" credit impairment model, which will apply to most financial assets measured at amortized cost and certain other instruments, including trade and other receivables, loans, held-to-maturity debt securities, and off-balance sheet credit exposures such as letters of credit. Early adoption is permitted.
 
January 1, 2020
 
We are currently evaluating the new standard for potential impacts on our receivables, debt, and other financial instruments.
Intangibles - Goodwill and Other Simplifying the Test for Goodwill
 
The objective of this update is to reduce the cost and complexity of subsequent goodwill accounting by simplifying the impairment test by removing the Step 2 requirement to perform a hypothetical purchase price allocation when the carrying value of a reporting unit exceeds its fair value. If a reporting unit’s carrying value exceeds its fair value, an entity would record an impairment charge based on that difference, limited to the amount of goodwill attributed to that reporting unit. The proposal would not change the guidance on completing Step 1 of the goodwill impairment test. The proposed guidance would be applied prospectively. Early adoption is permitted.
 
January 1, 2020
 
We are currently evaluating the implications of adoption on our Consolidated Financial Statements.
XML 35 R8.htm IDEA: XBRL DOCUMENT v3.8.0.1
Divestitures
 9 Months Ended
Sep. 30, 2017
Business Combinations [Abstract]  
Divestitures
DIVESTITURES

Current Year Divestitures

On January 3, 2017, we sold certain Abbreviated New Drug Applications ("ANDAs") for $15.0 million to a third party, which was recorded as a gain in Other operating income on the Condensed Consolidated Statements of Operations in our Prescription Pharmaceuticals ("RX") segment.

On February 1, 2017, we completed the sale of the animal health pet treats plant fixed assets within our Consumer Healthcare Americas ("CHCA") segment, which were previously classified as held-for sale. We received $7.7 million in proceeds, which resulted in an immaterial loss.

On April 6, 2017, we completed the sale of our India Active Pharmaceutical Ingredients ("API") business to Strides Shasun Limited. We received $22.2 million of proceeds, inclusive of an estimated working capital adjustment, which resulted in an immaterial gain recorded in our Other segment. Prior to closing the sale, we determined that the carrying value of the India API business exceeded its fair value less the cost to sell, resulting in an impairment charge of $35.3 million, which was recorded in Impairment charges on the Consolidated Statements of Operations for the year ended December 31, 2016.

On August 25, 2017, we completed the sale of our Russian business, which was previously classified as held-for-sale, to Alvogen Pharma LLC and Alvogen CEE Kft. The total sale price was €12.7 million ($15.1 million), inclusive of an estimated working capital adjustment, which resulted in an immaterial gain recorded in our Consumer Healthcare International ("CHCI") segment. Prior to closing the sale, we determined that the carrying value of the Russian business exceeded its fair value less the cost to sell, resulting in an impairment charge of $3.7 million, which was recorded in Impairment charges on the Condensed Consolidated Statements of Operations for the three months ended July 1, 2017.

Prior Year Divestitures

On August 5, 2016, we completed the sale of our U.S. Vitamins, Minerals, and Supplements ("VMS") business within our CHCA segment to International Vitamins Corporation ("IVC") for $61.8 million inclusive of an estimated working capital adjustment. Prior to closing the sale, we determined that the carrying value of the VMS business exceeded its fair value less the cost to sell, resulting in an impairment charge of $6.2 million, which was recorded in Impairment charges on the Condensed Consolidated Statements of Operations for the year ended December 31, 2016.
XML 36 R9.htm IDEA: XBRL DOCUMENT v3.8.0.1
Goodwill and Other Intangible Assets
 9 Months Ended
Sep. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and other intangible assets
GOODWILL AND OTHER INTANGIBLE ASSETS

Goodwill

Changes in the carrying amount of goodwill, by reportable segment, were as follows (in millions):
Reporting Segments:
 
December 31,
2016
 
Business divestitures
 
Re-class to assets held-for-sale
 
Currency translation adjustment
 
September 30,
2017
CHCA
 
$
1,810.6

 
$
—

 
$
—

 
$
2.9

 
$
1,813.5

CHCI
 
1,070.8

 
(4.1
)
 
—

 
122.3

 
1,189.0

RX
 
1,086.6

 
—

 
—

 
6.5

 
1,093.1

Other
 
81.4

 
—

 
(32.6
)
 
7.6

 
56.4

Total goodwill
 
$
4,049.4

 
$
(4.1
)
 
$
(32.6
)
 
$
139.3

 
$
4,152.0



As discussed in our Form 10-K for the year ended December 31, 2016, during the three months ended April 2, 2016 and October 1, 2016, we identified indicators of impairment for our Branded Consumer Healthcare - Rest of World ("BCH-ROW") reporting unit and recorded impairment charges of $130.5 million and $675.6 million, respectively. In addition, during the three months ended October 1, 2016, we identified impairment indicators in our Branded Consumer Healthcare - Belgium ("BCH-Belgium") reporting unit and recorded impairment charges of $62.3 million. The impairment charges for both reporting units were recorded within our CHCI segment.

Intangible Assets

Other intangible assets and related accumulated amortization consisted of the following (in millions):
 
September 30, 2017
 
December 31, 2016
 
Gross
 
Accumulated Amortization
 
Gross
 
Accumulated Amortization
Definite-lived intangibles:
 
 
 
 
 
 
 
Distribution and license agreements, supply agreements
$
310.2

 
$
157.5

 
$
305.6

 
$
120.4

Developed product technology, formulations, and product rights
1,355.4

 
568.8

 
1,418.1

 
526.0

Customer relationships and distribution networks
1,623.7

 
424.5

 
1,489.9

 
307.5

Trademarks, trade names, and brands
1,317.5

 
111.0

 
1,189.3

 
55.3

Non-compete agreements
14.7

 
12.3

 
14.3

 
11.2

Total definite-lived intangibles
$
4,621.5

 
$
1,274.1

 
$
4,417.2

 
$
1,020.4

Indefinite-lived intangibles:
 
 
 
 
 
 
 
Trademarks, trade names, and brands
$
52.0

 
$
—

 
$
50.5

 
$
—

In-process research and development
51.4

 
—

 
64.0

 
—

Total indefinite-lived intangibles
103.4

 
—

 
114.5

 
—

Total other intangible assets
$
4,724.9

 
$
1,274.1

 
$
4,531.7

 
$
1,020.4



Certain intangible assets are denominated in currencies other than the U.S. dollar; therefore, their gross and accumulated amortization balances are subject to foreign currency movements.

We recorded amortization expense of $88.5 million and $89.7 million for the three months ended September 30, 2017 and October 1, 2016, respectively, and $261.3 million and $263.9 million for the nine months ended September 30, 2017 and October 1, 2016, respectively.

We recorded an impairment charge within our RX segment of $12.7 million on certain In Process Research and Development ("IPR&D") assets during the nine months ended September 30, 2017 due to changes in the projected development and regulatory timelines for various projects. During the nine months ended September 30, 2017, we recorded a decrease in the contingent consideration liability associated with certain IPR&D assets in Other operating income on the Condensed Consolidated Statements of Operations (refer to Note 6).

During the three months ended July 1, 2017, we identified impairment indicators for our Lumara Health, Inc. ("Lumara") product assets. The primary impairment indicators included the decline in our 2017 performance expectations and a reduction in our long-range revenue growth forecast. The assessment utilized the multi-period excess earnings method to determine fair value and resulted in an impairment charge of $18.5 million in Impairment charges on the Condensed Consolidated Statements of Operations within our RX segment, which represented the difference between the carrying amount of the intangible assets and their estimated fair value.

As discussed in our Form 10-K for the year ended December 31, 2016, during the three months ended April 2, 2016, we identified indicators of impairment associated with certain indefinite-lived intangible assets acquired in conjunction with our acquisition of Omega Pharma Invest N.V. ("Omega") and recorded an impairment charge of $273.4 million. In addition, during the three months ended October 1, 2016, we identified indicators of impairment associated with certain indefinite-lived and definite-lived intangible brand category assets acquired in conjunction with the Omega acquisition. As a result of these additional indicators, we recorded impairment charges of $575.7 million on our indefinite-lived assets and $290.9 million on our definite-lived assets. The impairment charges for both the indefinite-lived assets and definite-lived assets were recorded within our CHCI segment.

In addition, due to reprioritization of certain brands in the CHCI segment and change in performance expectations for the cough/cold/allergy, anti-parasite, personal care, lifestyle, and natural health brands, we reclassified $364.5 million and $674.4 million of indefinite-lived assets to definite-lived assets with useful lives of 20 years, which we began amortizing during the second and third quarters of 2016, respectively.
XML 37 R10.htm IDEA: XBRL DOCUMENT v3.8.0.1
Accounts Receivable Factoring
 9 Months Ended
Sep. 30, 2017
Accounts Receivable Factoring [Abstract]  
Accounts receivable factoring
ACCOUNTS RECEIVABLE FACTORING

We have multiple accounts receivable factoring arrangements with non-related third-party financial institutions (the “Factors”). Pursuant to the terms of the arrangements, we sell to the Factors certain of our accounts receivable balances on a non-recourse basis for credit approved accounts. An administrative fee ranging from 0.14% to 0.15% per invoice is charged on the gross amount of accounts receivables assigned to the Factors, and interest is calculated at the applicable EUR LIBOR rate plus 70 basis points. The total amount factored on a non-recourse basis and excluded from accounts receivable was $24.3 million and $50.7 million at September 30, 2017 and December 31, 2016, respectively.
XML 38 R11.htm IDEA: XBRL DOCUMENT v3.8.0.1
Inventories
 9 Months Ended
Sep. 30, 2017
Inventory Disclosure [Abstract]  
Inventories
INVENTORIES

Major components of inventory were as follows (in millions):
 
 
September 30,
2017
 
December 31,
2016
Finished goods
$
471.4

 
$
431.1

Work in process
146.8

 
165.7

Raw materials
203.7

 
198.2

Total inventories
$
821.9

 
$
795.0
XML 39 R12.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurements
 9 Months Ended
Sep. 30, 2017
Fair Value Disclosures [Abstract]  
Fair value measurements
FAIR VALUE MEASUREMENTS

Fair value is the price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The following fair value hierarchy is used in selecting inputs, with the highest priority given to Level 1, as these are the most transparent or reliable.

Level 1:
Quoted prices for identical instruments in active markets.

Level 2:
Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets.

Level 3:
Valuations derived from valuation techniques in which one or more significant inputs are not observable.

The following table summarizes the valuation of our financial instruments carried at fair value and measured at fair value on a recurring and non-recurring basis by the above pricing categories (in millions):
 
 
 
 
Fair Value
 
 
Fair Value Hierarchy
 
September 30,
2017
 
December 31,
2016
Measured at fair value on a recurring basis:
 
 
 
 
 
 
Assets:
 
 
 
 
 
 
Investment securities
 
Level 1
 
$
6.1

 
$
38.2

 
 
 
 
 
 
 
Foreign currency forward contracts
 
Level 2
 
$
13.1

 
$
3.8

Funds associated with Israeli severance liability
 
Level 2
 
16.1

 
15.9

Total level 2 assets
 
 
 
$
29.2

 
$
19.7

 
 
 
 
 
 
 
Royalty Pharma contingent milestone payments
 
Level 3
 
$
143.2

 
$
—

Financial assets
 
Level 3
 
—

 
2,350.0

Total level 3 assets
 
 
 
$
143.2

 
$
2,350.0

 
 
 
 
 
 
 
Liabilities:
 
 
 
 
 
 
Foreign currency forward contracts
 
Level 2
 
$
3.3

 
$
5.0

 
 
 
 
 
 
 
Contingent consideration
 
Level 3
 
$
44.9

 
$
69.9

 
 
 
 
 
 
 
Measured at fair value on a non-recurring basis:
 
 
 
 
 
 
Assets:
 
 
 
 
 
 
Goodwill(1)
 
Level 3
 
$
—

 
$
1,148.4

Indefinite-lived intangible assets(2)
 
Level 3
 
13.3

 
0.3

Definite-lived intangible assets(3)
 
Level 3
 
11.5

 
758.0

Assets held for sale, net
 
Level 3
 
95.1

 
18.2

Total level 3 assets
 
 
 
$
119.9

 
$
1,924.9



(1) 
As of December 31, 2016, goodwill with a carrying amount of $2.2 billion was written down to its implied fair value of $1.1 billion.
(2) 
As of September 30, 2017, indefinite-lived intangible assets with a carrying amount of $26.0 million were written down to a fair value of $13.3 million. As of December 31, 2016, indefinite-lived intangible assets with a carrying amount of $0.7 million were written down to a fair value of $0.3 million.
(3) 
As of July 1, 2017, definite-lived intangible assets with a carrying amount of $31.1 million were written down to a fair value of $11.5 million. As of December 31, 2016, definite-lived intangible assets with a carrying amount of $2.3 billion were written down to a fair value of $758.0 million. Included in this balance are indefinite-lived intangible assets with a fair value of $364.5 million and $674.2 million that were reclassified to definite-lived assets at April 3, 2016 and October 2, 2016, respectively.

There were no transfers among Level 1, 2, and 3 during the three and nine months ended September 30, 2017 or the year ended December 31, 2016. Our policy regarding the recording of transfers between levels is to record any such transfers at the end of the reporting period (refer to Note 7 for information on our investment securities and Note 8 for a discussion of derivatives).

Foreign Currency Forward Contracts

The fair value of foreign currency forward contracts is determined using a market approach, which utilizes values for comparable derivative instruments.

Funds Associated with Israel Severance Liability

Israeli labor laws and agreements require us to pay benefits to employees dismissed or retiring under certain circumstances. Severance pay is calculated on the basis of the most recent employee salary levels and the length of employee service. Our Israeli subsidiaries also provide retirement bonuses to certain managerial employees. We make regular deposits to retirement funds and purchase insurance policies to partially fund these liabilities. The funds are determined using prices for recently traded financial instruments with similar underlying terms, as well as directly or indirectly observable inputs, such as interest rates and yield curves, that are observable at commonly quoted intervals.
 
Royalty Pharma Contingent Milestone Payments and Financial Assets

On December 18, 2013, we acquired Elan, which had a royalty agreement with Biogen Idec Inc. ("Biogen"), whereby Biogen conveyed the right to receive royalties that are typically payable on sales revenue generated by the sale, distribution or other use of the drug Tysabri®. Pursuant to the royalty agreement, we were entitled to royalty payments from Biogen based on its Tysabri® sales in all indications and geographies. We received royalties of 12% on worldwide Biogen sales of Tysabri® from December 18, 2013 through April 30, 2014. From May 1, 2014, we received royalties of 18% on annual worldwide Biogen sales of Tysabri® up to $2.0 billion and 25% on annual sales above $2.0 billion.

We accounted for the Tysabri® royalty stream as a financial asset and elected to use the fair value option model. We made the election to account for the Tysabri® financial asset using the fair value option as we believed this method was most appropriate for an asset that did not have a par value, a stated interest stream, or a termination date. The financial asset acquired represented a single unit of accounting. The fair value of the financial asset acquired was determined by using a discounted cash flow analysis related to the expected probability weighted future cash flows to be generated by the royalty stream. The financial asset was classified as a Level 3 asset within the fair value hierarchy, as our valuation utilized significant unobservable inputs, including industry analyst estimates for global Tysabri® sales, probability weighted as to the timing and amount of future cash flows along with certain discount rate assumptions. Cash flow forecasts included the estimated effect and timing of future competition, considering patents in effect for Tysabri® through 2024 and contractual rights to receive cash flows into perpetuity. The discounted cash flows were based upon the expected royalty stream forecasted into perpetuity using a 20-year discrete period with a declining rate terminal value.

In the first quarter of 2016, a competitor's pipeline product, Ocrevus®, received breakthrough therapy designation from the U.S. Food and Drug Administration ("FDA"). Breakthrough therapy designation is granted when a drug is intended alone or in combination with one or more other drugs to treat a serious or life threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. In June 2016, the FDA granted priority review with a target action date in December 2016. A priority review is a designation when the FDA will direct overall attention and resources to the evaluation of applications for drugs that, if approved, would be significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to standard applications. The product was approved late in the first quarter of 2017. The product is expected to compete with Tysabri®, and we expected it to have a significant negative impact on the Tysabri® royalty stream. Industry analysts believe that, based on released clinical study information, Ocrevus® will compete favorably against Tysabri® in the relapsing, remitting multiple sclerosis market segment due to its high efficacy and convenient dosage form.
Given the new market information for Ocrevus®, we used industry analyst estimates to reduce our first ten year growth forecasts from an average of growth of approximately 3.4% in the fourth calendar quarter of 2015 to an average decline of approximately minus 2.0% in the third and fourth calendar quarters of 2016. In November 2016, we announced we were evaluating strategic alternatives for the Tysabri® asset. As of December 31, 2016, the financial asset was adjusted based on the strategic review and sale process. These effects, combined with the change in discount rate each quarter, led to a reduction in fair value of $204.4 million, $910.8 million, $377.4 million and $1.1 billion in the first, second, third and fourth quarters of 2016, respectively.

On March 27, 2017, we announced the completed divestment of our Tysabri® financial asset to Royalty Pharma for up to $2.85 billion, which consists of $2.2 billion in cash and up to $250.0 million and $400.0 million in milestone payments if the royalties on global net sales of Tysabri® that are received by Royalty Pharma meet specific thresholds in 2018 and 2020, respectively. As a result of this transaction, we transferred the entire financial asset to Royalty Pharma and recorded a $17.1 million gain during the three months ended July 1, 2017. We elected to account for the contingent milestone payments using the fair value option method, and these were recorded at an estimated fair value of $143.2 million as of September 30, 2017. We chose the fair value option as we believe it will help investors understand the potential future cash flows we may receive associated with the two contingent milestones.

We valued the contingent milestone payments using a modified Black-Scholes Option Pricing Model ("BSOPM"). Key inputs in the BSOPM are the estimated volatility and rate of return of royalties on global net sales of Tysabri® that are received by Royalty Pharma over time until payment of the contingent milestone payments is completed. Volatility and the estimated fair value of the milestones have a positive relationship such that higher volatility translates to a higher estimated fair value of the contingent milestone payments. In the valuation of contingent milestone payments performed, we assumed volatility of 30.0% and a rate of return of 8.05% as of July 1, 2017 and volatility of 30.0% and a rate of return of 8.06% as of September 30, 2017. We assess volatility and rate of return inputs quarterly by analyzing certain market volatility benchmarks and the risk associated with Royalty Pharma achieving the underlying projected royalties. During the three and nine months ended September 30, 2017, the fair value of the Royalty Pharma contingent milestone payments decreased $2.9 million and $42.1 million, respectively, as a result of the decrease in the estimated projected Tysabri® revenues due to the launch of Ocrevus® late in the first quarter of 2017.

Our accounts receivable balance at December 31, 2016 included $84.4 million related to the Tysabri® financial asset.

The table below presents a reconciliation for the Royalty Pharma contingent milestone payments measured at fair value on a recurring basis using significant unobservable inputs (Level 3) (in millions). Change in fair value in the table was recorded in Change in financial assets on the Condensed Consolidated Statements of Operations.
 
Three Months Ended
 
Nine Months Ended
 
September 30,
2017
 
September 30,
2017
Royalty Pharma Contingent Milestone Payments
 
 
 
Beginning balance
$
145.8

 
$
—

Additions
—

 
184.5

Foreign currency effect
0.3

 
0.8

Change in fair value
(2.9
)
 
(42.1
)
Ending balance
$
143.2

 
$
143.2



Contingent Consideration

Contingent consideration represents milestone payment obligations obtained through product acquisitions, which are valued using estimates based on probability-weighted outcomes, sensitivity analysis, and discount rates reflective of the risk involved. The estimates are updated quarterly and the liabilities are adjusted to fair value depending on a number of assumptions, including the competitive landscape and regulatory approvals that may impact the future sales of a product. We reduced a contingent consideration liability associated with certain IPR&D assets (refer to Note 3) and recorded a corresponding gain of $17.0 million during the nine months ended September 30, 2017. The liability decrease relates to a reduction of the probability of achievement assumptions and anticipated cash flows. Purchases or additions for the nine months ended October 1, 2016 included contingent consideration associated with five transactions.

The table below presents a reconciliation for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) (in millions). Net realized losses in the table were recorded in Other (income) expense, net on the Condensed Consolidated Statements of Operations.
 
Three Months Ended
 
Nine Months Ended
 
September 30,
2017
 
October 1,
2016
 
September 30,
2017
 
October 1,
2016
Contingent Consideration
 
 
 
 
 
 
 
Beginning balance
$
49.7

 
$
44.9

 
$
69.9

 
$
17.9

Net realized losses
(2.9
)
 
(0.4
)
 
(18.5
)
 
(4.0
)
Purchases or additions
—

 
30.6

 
—

 
61.1

Foreign currency effect
0.2

 
—

 
1.5

 
0.1

Settlements
(2.1
)
 
(0.1
)
 
(8.0
)
 
(0.1
)
Ending balance
$
44.9

 
$
75.0

 
$
44.9

 
$
75.0



Goodwill and Indefinite-Lived Intangible Assets

We have seven reporting units for which we assess goodwill for impairment. We utilize a comparable company market approach, weighted equally with a discounted cash flow analysis, to determine the fair value of the reporting units. We utilize either a relief from royalty method or a multi-period excess earnings method ("MPEEM") to value our indefinite-lived intangible assets, and use a consistent set of projected financial information for the goodwill and indefinite-lived asset impairment tests. The discounted cash flow analysis that we prepared for goodwill impairment testing purposes for the year ended December 31, 2016 included long-term growth rates ranging from 2.0% to 3.0%. We also utilized discount rates ranging from 7.0% to 14.5%, which were deemed to be commensurate with the required investment return and risk involved in realizing the projected free cash flows of each reporting unit. In addition, we burdened projected free cash flows with the capital spending deemed necessary to support the cash flows of each reporting unit, and applied the tax rates that were applicable to the jurisdictions represented within each reporting unit. We recorded impairment charges on the Condensed Consolidated Statements of Operations related to goodwill in the BCH-ROW reporting unit and indefinite-lived intangible assets of $130.5 million and $273.4 million, respectively, for the three months ended April 2, 2016. For the three months ended October 1, 2016, we recorded impairment charges related to goodwill on the Condensed Consolidated Statements of Operations of $675.6 million in the BCH-ROW reporting unit and $62.3 million in the BCH-Belgium reporting unit, as well as indefinite-lived intangible asset impairments of $575.7 million (refer to Note 3).

Definite-Lived Intangible Assets

When assessing our definite-lived assets for impairment, we utilize either a MPEEM or a relief from royalty method to determine the fair value of the asset and use the forecasts that are consistent with those used in the reporting unit analysis. Below is a summary of the various metrics used in our valuations:
 
Nine Months Ended
 
September 30, 2017
 
Lumara
5-year average growth rate
(4.1)%
Discount rate
13.5%
Valuation method
MPEEM

 
Year Ended
 
December 31, 2016
 
Omega - Lifestyle
 
Omega - XLS
 
Entocort® - Branded Products
 
Entocort® - AG Products
 
Herron Trade Names and Trademarks
5-year average growth rate
2.5%
 
3.2%
 
(31.7)%
 
(30.4)%
 
4.6%
Long-term growth rates
2.0%
 
NA
 
(10.0)%
 
(4.7)%
 
2.5%
Discount rate
9.3%
 
9.5%
 
13.0%
 
10.5%
 
10.8%
Royalty rate
NA
 
4.0%
 
NA
 
NA
 
11.0%
Valuation method
MPEEM
 
Relief from Royalty
 
MPEEM
 
MPEEM
 
Relief from Royalty


We recorded Impairment charges on the Condensed Consolidated Statements of Operations related to definite-lived intangible assets of $18.5 million and $290.9 million for the nine months ended September 30, 2017 and October 1, 2016, respectively (refer to Note 3).

Assets Held For Sale

When a group of assets is classified as held-for-sale, the book value is evaluated and adjusted to the lower of its carrying amount or fair value less the cost to sell (refer to Note 9).

Fixed Rate Long-term Debt    

As of September 30, 2017 and December 31, 2016, our fixed rate long-term debt consisted of public bonds, a private placement note, and retail bonds. As of September 30, 2017, the public bonds had a carrying value of
$2.6 billion and a fair value of $2.7 billion. As of December 31, 2016, the public bonds had a carrying value and fair value of $4.6 billion. The fair values of our public bonds for both periods were based on quoted market prices
(Level 1).

As of September 30, 2017, our retail bonds and private placement note had a carrying value of $655.8 million (excluding a premium of $35.6 million) and a fair value of $699.2 million. As of December 31, 2016, our retail bonds and private placement note had a carrying value of $773.1 million (excluding a premium of $49.8 million) and a fair value of $825.0 million. The fair values of our retail bonds and private placement note for both periods were based on interest rates offered for borrowings of a similar nature and remaining maturities (Level 2).

The carrying amounts of our other financial instruments, consisting of cash and cash equivalents, accounts receivable, accounts payable, short-term debt and variable rate long-term debt, approximate their fair value.
XML 40 R13.htm IDEA: XBRL DOCUMENT v3.8.0.1
Investments
 9 Months Ended
Sep. 30, 2017
Investments [Abstract]  
Investments
INVESTMENTS

Available for Sale Securities
    
Our available for sale securities are reported in Prepaid expenses and other current assets. Unrealized investment gains/(losses) on available for sale securities were as follows (in millions):
 
September 30,
2017
 
December 31, 2016
Equity securities, at cost less impairments
$
15.5

 
$
16.5

Gross unrealized gains
—

 
21.7

Gross unrealized losses
(9.4
)
 
—

Estimated fair value of equity securities
$
6.1

 
$
38.2



The factors affecting the assessment of impairments include both general financial market conditions and factors specific to a particular company. During the nine months ended October 1, 2016, we recorded an impairment charge of $1.8 million, which related to other-than-temporary impairments of marketable equity securities due to prolonged losses incurred on each of the investments.

We have evaluated the near-term prospects of the equity securities in relation to the severity and duration of any impairments, and based on that evaluation, we have the ability and intent to hold these investments until a recovery of fair value.

During the nine months ended September 30, 2017, we sold a number of our investment securities and recorded a gain of $1.6 million. The gain was reclassified out of Accumulated Other Comprehensive Income (loss) ("AOCI") and into earnings.     

Cost Method Investments

Our cost method investments totaled $7.2 million and $6.9 million at September 30, 2017 and
December 31, 2016, respectively, and are included in Other non-current assets.

Equity Method Investments

Our equity method investments totaled $4.8 million and $4.6 million at September 30, 2017 and December 31, 2016, respectively, and are included in Other non-current assets. We recorded net losses of $0.1 million and net gains of $0.2 million during the three and nine months ended September 30, 2017, respectively, and net gains of $0.1 million and net losses of $3.8 million during the three and nine months ended October 1, 2016, respectively, for our proportionate share of the equity method investment earnings or losses. The gains and losses were recorded in Other (income) expense, net on the Condensed Consolidated Statements of Operations.

During the nine months ended October 1, 2016, one of our equity method investments became publicly traded. As a result, we transferred the $15.5 million investment to available for sale and recorded an $8.7 million unrealized gain, net of tax in Other Comprehensive Income ("OCI"). In addition, due to significant and prolonged losses incurred on one of our equity method investments, we recorded a $22.3 million impairment charge in Other (income) expense, net on the Condensed Consolidated Statements of Operations.
XML 41 R14.htm IDEA: XBRL DOCUMENT v3.8.0.1
Derivative Instruments and Hedging Activities
 9 Months Ended
Sep. 30, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative instruments and hedging activities
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES

We enter into certain derivative financial instruments, when available on a cost-effective basis, to mitigate our risk associated with changes in interest rates and foreign currency exchange rates as follows:

Interest rate risk management - We are exposed to the impact of interest rate changes through our cash investments and borrowings. We utilize a variety of strategies to manage the impact of changes in interest rates, including using a mix of debt maturities along with both fixed-rate and variable-rate debt. In addition, we may enter into treasury-lock agreements and interest rate swap agreements on certain investing and borrowing transactions to manage our exposure to interest rate changes and our overall cost of borrowing.

Foreign currency exchange risk management - We conduct business in several major currencies other than the U.S. dollar and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce cash flow volatility associated with foreign exchange rate changes on a consolidated basis to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments, and anticipated foreign currency sales and expenses.
    
All derivative instruments are managed on a consolidated basis to efficiently net exposures and thus take advantage of any natural offsets. Gains and losses related to the derivative instruments are expected to be offset largely by gains and losses on the original underlying asset or liability. We do not use derivative financial instruments for speculative purposes.

     All of our designated derivatives were classified as cash flow hedges as of September 30, 2017 and December 31, 2016. Designated derivatives meet hedge accounting criteria, which means the fair value of the hedge is recorded in shareholders’ equity as a component of OCI, net of tax. The deferred gains and losses are recognized in income in the period in which the hedged item affects earnings. Any ineffective portion of the change in fair value of the derivative is immediately recognized in earnings. All of our designated derivatives are assessed for hedge effectiveness quarterly.

We also have economic non-designated derivatives that do not meet hedge accounting criteria. These derivative instruments are adjusted to current market value at the end of each period through earnings. Gains or losses on these instruments are offset substantially by the remeasurement adjustment on the hedged item.    

Interest Rate Swaps and Treasury Locks

Interest rate swap agreements are contracts to exchange floating rate for fixed rate payments (or vice versa) over the life of the agreement without the exchange of the underlying notional amounts. The notional amounts of the interest rate swap agreements are used to measure interest to be paid or received and do not represent the amount of exposure to credit loss. The differential paid or received on the interest rate swap agreements is recognized as an adjustment to interest expense.

During the three months ended July 1, 2017, we repaid $584.4 million of senior notes with an interest rate of 4.000% due 2023 and $309.5 million of senior notes with an interest rate of 5.300% due 2043 (refer to Note 10). As a result of the senior note repayments on June 15, 2017, the proportionate amount remaining in OCI related to the pre-issuance hedge was reclassified to earnings. Accordingly, we recorded a loss of $5.9 million in Other expense, net, on the Condensed Consolidated Statements of Operations during the three months ended July 1, 2017 for the amount remaining in OCI.

During the six months ended December 31, 2015, we entered into a forward interest rate swap to hedge against changes in the benchmark interest rate between the date the interest rate swap was entered into and the date of expected future debt issuance. The interest rate swap was designated as a cash flow hedge and had a notional amount totaling $200.0 million. The interest rate swap was settled upon the issuance of an aggregate $1.2 billion principal amount of senior notes on March 7, 2016 for a cumulative after-tax loss of $7.0 million in OCI during the three months ended April 2, 2016.
    
Foreign Currency Derivatives

We enter into foreign currency forward contracts, both designated and non-designated, in order to manage the impact of foreign exchange fluctuations on expected future purchases and related payables denominated in a foreign currency, as well as to hedge the impact of foreign exchange fluctuations on expected future sales and related receivables denominated in a foreign currency. Both types of forward contracts have a maximum maturity date of 18 months. The total notional amount for these contracts was $578.3 million and $533.5 million as of September 30, 2017 and December 31, 2016, respectively.

Effects of Derivatives on the Financial Statements
    
The below tables indicate the effects of all derivative instruments on the Condensed Consolidated Financial Statements. All amounts exclude income tax effects and are presented in millions.

The balance sheet location and gross fair value of our outstanding derivative instruments were as follows:
 
Asset Derivatives
 
Balance Sheet Location
 
Fair Value
 
 
 
September 30,
2017
 
December 31,
2016
Designated derivatives:
 
 
 
 
 
Foreign currency forward contracts
Other current assets
 
$
4.6

 
$
3.1

Non-designated derivatives:
 
 
 
 
 
Foreign currency forward contracts
Other current assets
 
$
8.5

 
$
0.7

 
Liability Derivatives
 
Balance Sheet Location
 
Fair Value
 
 
 
September 30,
2017
 
December 31,
2016
Designated derivatives:
 
 
 
 
 
Foreign currency forward contracts
Accrued liabilities
 
$
2.6

 
$
3.0

Non-designated derivatives:
 
 
 
 
 
Foreign currency forward contracts
Accrued liabilities
 
$
0.7

 
$
2.0



The gains (losses) recorded in OCI for the effective portion of our designated cash flow hedges were as follows:
 
 
Amount of Gain/(Loss) Recorded in OCI
(Effective Portion)
 
 
Three Months Ended
 
Nine Months Ended
Designated Cash Flow Hedges
 
September 30,
2017
 
October 1,
2016
 
September 30,
2017
 
October 1,
2016
Interest rate swap agreements
 
$
—

 
$
—

 
$
—

 
$
(9.0
)
Foreign currency forward contracts
 
1.1

 
3.4

 
6.3

 
4.7

Total
 
$
1.1

 
$
3.4

 
$
6.3

 
$
(4.3
)


The gains (losses) reclassified from AOCI into earnings for the effective portion of our designated cash flow hedges were as follows:
 
 
 
 
Amount of Gain/(Loss) Reclassified from AOCI into Earnings
(Effective Portion)
 
 
 
 
Three Months Ended
 
Nine Months Ended
Designated Cash Flow Hedges
 
Income Statement Location
 
September 30,
2017
 
October 1,
2016
 
September 30,
2017
 
October 1,
2016
Treasury locks
 
Interest expense, net
 
$
—

 
$
—

 
$
—

 
$
(0.1
)
Interest rate swap agreements
 
Interest expense, net
 
(0.4
)
 
(0.6
)
 
(1.7
)
 
(1.7
)
 
 
Other (income) expense, net
 
—

 
—

 
(5.9
)
 
—

Foreign currency forward contracts
 
Net sales
 
—

 
(0.1
)
 
0.9

 
0.3

 
 
Cost of sales
 
1.8

 
0.9

 
3.5

 
1.8

 
 
Interest expense, net
 
(0.7
)
 
(0.4
)
 
(1.8
)
 
(1.3
)
 
 
Other (income) expense, net
 
(1.2
)
 
(1.2
)
 
(1.7
)
 
0.7

Total
 
 
 
$
(0.5
)
 
$
(1.4
)
 
$
(6.7
)
 
$
(0.3
)


The net of tax amount expected to be reclassified from AOCI into earnings during the next 12 months is a $2.8 million gain.

The gains (losses) recognized against earnings for the ineffective portion of our designated cash flow hedges were as follows:
 
 
 
 
Amount of Gain/(Loss) Recognized against Earnings
(Ineffective Portion)
 
 
 
 
Three Months Ended
 
Nine Months Ended
Designated Cash Flow Hedges
 
Income Statement
Location
 
September 30,
2017
 
October 1,
2016
 
September 30,
2017
 
October 1,
2016
Interest rate swap agreements
 
Other (income) expense, net
 
$
—

 
$
—

 
$
—

 
$
(0.1
)
Foreign currency forward contracts
 
Net sales
 
0.2

 
—

 
0.1

 
0.1

 
 
Cost of sales
 
0.1

 
—

 
0.1

 
—

 
 
Other (income) expense, net
 
—

 
—

 
1.0

 
0.6

Total
 
 
 
$
0.3

 
$
—

 
$
1.2

 
$
0.6



The effects of our non-designated derivatives on the Condensed Consolidated Statements of Operations were as follows:
 
 
 
 
Amount of Gain/(Loss) Recognized against Earnings
 
 
 
 
Three Months Ended
 
Nine Months Ended
Non-Designated Derivatives
 
Income Statement Location
 
September 30,
2017
 
October 1,
2016
 
September 30,
2017
 
October 1,
2016
Foreign currency forward contracts
 
Other (income) expense, net
 
$
10.1

 
$
(0.2
)
 
$
(3.8
)
 
$
(8.7
)
 
 
Interest expense, net
 
(1.8
)
 
(1.0
)
 
(2.9
)
 
(1.5
)
Total
 
 
 
$
8.3

 
$
(1.2
)
 
$
(6.7
)
 
$
(10.2
)
Derivatives, policy
We enter into certain derivative financial instruments, when available on a cost-effective basis, to mitigate our risk associated with changes in interest rates and foreign currency exchange rates as follows:

Interest rate risk management - We are exposed to the impact of interest rate changes through our cash investments and borrowings. We utilize a variety of strategies to manage the impact of changes in interest rates, including using a mix of debt maturities along with both fixed-rate and variable-rate debt. In addition, we may enter into treasury-lock agreements and interest rate swap agreements on certain investing and borrowing transactions to manage our exposure to interest rate changes and our overall cost of borrowing.

Foreign currency exchange risk management - We conduct business in several major currencies other than the U.S. dollar and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce cash flow volatility associated with foreign exchange rate changes on a consolidated basis to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments, and anticipated foreign currency sales and expenses.
    
All derivative instruments are managed on a consolidated basis to efficiently net exposures and thus take advantage of any natural offsets. Gains and losses related to the derivative instruments are expected to be offset largely by gains and losses on the original underlying asset or liability. We do not use derivative financial instruments for speculative purposes.

     All of our designated derivatives were classified as cash flow hedges as of September 30, 2017 and December 31, 2016. Designated derivatives meet hedge accounting criteria, which means the fair value of the hedge is recorded in shareholders’ equity as a component of OCI, net of tax. The deferred gains and losses are recognized in income in the period in which the hedged item affects earnings. Any ineffective portion of the change in fair value of the derivative is immediately recognized in earnings. All of our designated derivatives are assessed for hedge effectiveness quarterly.

We also have economic non-designated derivatives that do not meet hedge accounting criteria. These derivative instruments are adjusted to current market value at the end of each period through earnings. Gains or losses on these instruments are offset substantially by the remeasurement adjustment on the hedged item
XML 42 R15.htm IDEA: XBRL DOCUMENT v3.8.0.1
Assets Held for Sale
 9 Months Ended
Sep. 30, 2017
Assets held for sale [Abstract]  
Assets held for sale
ASSETS HELD FOR SALE

Our India API business was classified as held-for-sale beginning as of December 31, 2015. We recorded an impairment charge totaling $6.3 million during the year ended December 31, 2016 after determining the carrying value of the India API business exceeded its fair value less the cost to sell. The India API business is reported in our Other segment. On April 6, 2017, we completed the sale of our India API business (refer to Note 2).

During the three months ended October 1, 2016, management committed to a plan to sell certain fixed assets associated with our animal health pet treats plant. Such assets were classified as held-for-sale beginning at October 1, 2016. On February 1, 2017, we completed the sale of our animal health pet treats plant fixed assets (refer to Note 2). We determined that the carrying value of the fixed assets associated with our animal health pet treats plant exceeded the fair value less the cost to sell. We recorded impairment charges totaling $3.7 million during the year ended December 31, 2016. The assets associated with our animal health pet treats plant are reported in our CHCA segment.

During the three months ended September 30, 2017, management committed to a plan to sell our Israel API business. The business was classified as held-for-sale beginning at September 30, 2017. We determined that the carrying value of the Israel API business exceeded its fair value less the cost to sell. We recorded impairment charges totaling $3.3 million during the three months ended September 30, 2017. The Israel API business is reported in our Other segment.

The assets held-for-sale are reported within Prepaid expenses and other current assets and liabilities held-for-sale are reported in Accrued liabilities. The amounts consist of the following (in millions):
 
September 30,
2017
 
December 31,
2016
 
Other
 
CHCA
 
Other
Assets held for sale
 
 
 
 
 
Current assets
$
44.0

 
$
—

 
$
5.1

Goodwill
32.6

 
—

 
5.5

Intangible assets
5.5

 
—

 
—

Property, plant and equipment
45.9

 
13.5

 
33.2

Other assets
3.1

 
—

 
3.8

Less: impairment reserves
(3.3
)
 
(3.7
)
 
(35.3
)
Total assets held for sale
$
127.8

 
$
9.8

 
$
12.3

Liabilities held for sale
 
 
 
 
 
Current liabilities
$
7.6

 
$
0.1

 
$
1.9

Other liabilities
25.1

 
—

 
1.9

Total liabilities held for sale
$
32.7

 
$
0.1

 
$
3.8
XML 43 R16.htm IDEA: XBRL DOCUMENT v3.8.0.1
Indebtedness
 9 Months Ended
Sep. 30, 2017
Debt Disclosure [Abstract]  
Indebtedness
INDEBTEDNESS

Total borrowings outstanding are summarized as follows (in millions):
 
 
 
 
 
September 30,
2017
 
December 31,
2016
Term loans
 
 
 
 
 
 
2014 term loan due December 5, 2019
(1) 
 
$
428.3

 
$
420.7

Notes and Bonds
 
 
 
 
 
 
Coupon
Due
 
 
 
 
 
 
4.500%
May 23, 2017
(1)(2) 
 
—

 
189.3

 
5.125%
December 12, 2017
(1)(2) 
 
354.5

 
315.6

 
2.300%
November 8, 2018

 
—

 
600.0

 
5.000%
May 23, 2019
(1)(2) 
 
141.8

 
126.2

 
3.500%
March 15, 2021

 
280.4

 
500.0

 
3.500%
December 15, 2021

 
309.6

 
500.0

 
5.105%
July 19, 2023
(1)(2) 
 
159.5

 
142.0

 
4.000%
November 15, 2023

 
215.6

 
800.0

 
3.900%
December 15, 2024

 
700.0

 
700.0

 
4.375%
March 15, 2026

 
700.0

 
700.0

 
5.300%
November 15, 2043

 
90.5

 
400.0

 
4.900%
December 15, 2044

 
303.9

 
400.0

 
Total notes and bonds
 
 
3,255.8

 
5,373.1

Other financing
2.9

 
3.6

Unamortized premium (discount), net
24.8

 
33.0

Deferred financing fees
(19.0
)
 
(33.1
)
Total borrowings outstanding
3,692.8

 
5,797.3

 
Current indebtedness
(417.1
)
 
(572.8
)
Total long-term debt less current portion
$
3,275.7

 
$
5,224.5



(1)
Debt denominated in Euros subject to fluctuations in the euro-to-U.S. dollar exchange rate.
(2)
Debt assumed from Omega.

During the three months ended April 1, 2017, we entered into amendments to the 2014 Revolver (as defined below) and the 2014 term loan to modify provisions of such agreements necessary as a result of the correction in accounting related to the Tysabri® financial asset, as well as waivers of any default or event of default that may have arisen from any restatement of or deficiencies in our financial statements for the periods specified in such amendments and waivers. We are in compliance with all covenants under our debt agreements as of September 30, 2017.

Revolving Credit Agreements

We have a revolving credit agreement with a borrowing capacity of $1.0 billion (the "2014 Revolver"). There were no borrowings outstanding under the 2014 Revolver as of September 30, 2017 and December 31, 2016.

Other Financing

Overdraft Facilities

We have overdraft facilities available that we use to support our cash management operations. We report any balances outstanding in the above table under "Other financing". There were no balances outstanding under the facilities at September 30, 2017 and December 31, 2016.

Debt Repayments and Related Extinguishment

During the nine months ended September 30, 2017, we reduced our outstanding debt through a variety of transactions (in millions):
Date
 
Series
 
Transaction Type
 
Principal Retired
April 1, 2017
 
2014 term loan due December 5, 2019
 
Scheduled quarterly payment
 
$
13.3

July 1, 2017
 
2014 term loan due December 5, 2019
 
Scheduled quarterly payment
 
14.3

September 30, 2017
 
2014 term loan due December 5, 2019
 
Scheduled quarterly payment
 
14.8

May 8, 2017
 
$600.0 2.300% senior notes due 2018
 
Early redemption
 
600.0

May 23, 2017
 
€180.0 4.500% retail bonds due 2017
 
Scheduled maturity
 
201.3

June 15, 2017
 
$500.0 3.500% senior notes due 2021
 
Tender offer
 
190.4

June 15, 2017
 
$500.0 3.500% senior notes due 2021
 
Tender offer
 
219.6

June 15, 2017
 
$800.0 4.000% senior notes due 2023
 
Tender offer
 
584.4

June 15, 2017
 
$400.0 5.300% senior notes due 2043
 
Tender offer
 
309.5

June 15, 2017
 
$400.0 4.900% senior notes due 2044
 
Tender offer
 
96.1

 
 
 
 
 
 
$
2,243.7



As a result of the of the early redemption and tender offer transactions discussed above, we recorded a loss of $135.2 million during the three months ended July 1, 2017 in Loss on extinguishment of debt (in millions):

Premium on debt repayment
 
$
116.1

Transaction costs
 
3.8

Write-off of deferred financing fees
 
10.6

Write-off of remaining discount on bond
 
4.7

Total loss on extinguishment of debt
 
$
135.2
XML 44 R17.htm IDEA: XBRL DOCUMENT v3.8.0.1
Earnings Per Share and Shareholders Equity
 9 Months Ended
Sep. 30, 2017
Earnings Per Share [Abstract]  
Earnings per share and shareholders equity
EARNINGS PER SHARE AND SHAREHOLDERS' EQUITY

Earnings per Share

A reconciliation of the numerators and denominators used in the basic and diluted earnings per share ("EPS") calculation is as follows (in millions):
 
Three Months Ended
 
Nine Months Ended
 
September 30,
2017
 
October 1,
2016
 
September 30,
2017
 
October 1,
2016
Numerator:
 
 
 
 
 
 
 
Net income (loss)
$
44.5

 
$
(1,590.2
)
 
$
46.4

 
$
(2,653.7
)
 
 
 
 
 
 
 
 
Denominator:
 
 
 
 
 
 
 
Weighted average shares outstanding for basic EPS
141.3

 
143.3

 
142.5

 
143.2

Dilutive effect of share-based awards*
0.4

 
—

 
0.3

 
—

Weighted average shares outstanding for diluted EPS
141.7

 
143.3

 
142.8

 
143.2

 
 
 
 
 
 
 
 
Anti-dilutive share-based awards excluded from
     computation of diluted EPS*
1.0

 
—

 
0.8

 
—


* In the period of a net loss, diluted shares equal basic shares.

Shareholders' Equity

Shares

We issued shares related to the exercise and vesting of share-based compensation as follows:
Three Months Ended
 
Nine Months Ended
September 30,
2017
 
October 1,
2016
 
September 30,
2017
 
October 1,
2016
99,800

 
185,000

 
146,100

 
283,000



Share Repurchases

On October 22, 2015, the Board of Directors approved a share repurchase plan of up to $2.0 billion (the "2015 Authorization"). During the three and nine months ended September 30, 2017, we repurchased 1.9 million and 2.7 million ordinary shares at an average repurchase price of $71.73 and $71.72 per share, for a total of $133.3 million and $191.5 million, respectively. As of September 30, 2017, there was $1.3 billion still available to be repurchased through December 31, 2018 under the 2015 Authorization. We did not repurchase any shares under the share repurchase plan during the nine months ended October 1, 2016.
XML 45 R18.htm IDEA: XBRL DOCUMENT v3.8.0.1
Accumulated Other Comprehensive Income (Loss)
 9 Months Ended
Sep. 30, 2017
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]  
Accumulated other comprehensive income (loss)
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)

Changes in our AOCI balances, net of tax were as follows (in millions):
 
Foreign currency translation adjustments
 
Fair value of derivative financial instruments, net of tax
 
Fair value of investment securities, net of tax
 
Post-retirement and pension liability adjustments, net of tax
 
Total AOCI
Balance at December 31, 2016
$
(67.9
)
 
$
(19.5
)
 
$
15.1

 
$
(9.5
)
 
$
(81.8
)
OCI before reclassifications
289.9

 
4.4

 
(22.8
)
 
(1.2
)
 
270.3

Amounts reclassified from AOCI
—

 
4.3

 
(1.6
)
 
—

 
2.7

Other comprehensive income (loss)
289.9

 
8.7

 
(24.4
)
 
(1.2
)
 
273.0

Balance at September 30, 2017
$
222.0

 
$
(10.8
)
 
$
(9.3
)
 
$
(10.7
)
 
$
191.2
XML 46 R19.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Taxes
 9 Months Ended
Sep. 30, 2017
Income Tax Disclosure [Abstract]  
Income taxes
INCOME TAXES

The effective tax rates were as follows:
Three Months Ended
 
Nine Months Ended
September 30,
2017
 
October 1,
2016
 
September 30,
2017
 
October 1,
2016
65.5
%
 
16.4
%
 
68.7
%
 
17.2
%


The effective tax rate for the nine months ended September 30, 2017 was negatively impacted by non-deductible fees related to our debt cancellation, discrete tax items, and additional valuation allowances recorded against deferred tax assets.

Our tax rate is subject to adjustment over the balance of the fiscal year due to, among other things: the jurisdictions in which our profits are determined to be earned and taxed; changes in the valuation of our deferred tax assets and liabilities; adjustments to estimated taxes upon finalization of various tax returns; adjustments based on differing interpretations of the applicable transfer pricing standards; changes in available tax credits, grants and other incentives; changes in stock-based compensation expense; changes in tax laws or the interpretation of such tax laws (for example, proposals for fundamental U.S. international tax reform); changes in U.S. GAAP; and expiration of or the inability to renew tax rulings or tax holiday incentives.

The total liability for uncertain tax positions was $454.9 million and $398.0 million as of September 30, 2017 and December 31, 2016, respectively, before considering the federal tax benefit of certain state and local items.

We recognize interest and penalties related to uncertain tax positions as a component of income tax expense. The total amount accrued for interest and penalties in the liability for uncertain tax positions was $79.0 million and $63.5 million as of September 30, 2017 and December 31, 2016, respectively.

We file income tax returns in numerous jurisdictions and are therefore subject to audits by tax authorities. Our primary income tax jurisdictions are Ireland, the United States, Israel, Belgium, France, and the United Kingdom.
 
On August 15, 2017, we filed a complaint in the United States District Court for the Western District of Michigan to recover $163.6 million of Federal income tax, penalties, and interest assessed and collected by the Internal Revenue Service (“IRS”), plus statutory interest thereon from the dates of payment, for the fiscal years ended June 27, 2009, June 26, 2010, June 25, 2011, and June 30, 2012 (the “2009 tax year,” “2010 tax year,” “2011 tax year,” and “2012 tax year,” respectively). The IRS audits of those years culminated in the issuances of two statutory notices of deficiency: (1) on August 27, 2014 for the 2009 and 2010 tax years and (2) on April 20, 2017 for the 2011 and 2012 tax years. The statutory notices of deficiency both included un-agreed income adjustments related principally to transfer pricing adjustments regarding the purchase, distribution, and sale of store-brand OTC pharmaceutical products in the United States. In addition, the statutory notice of deficiency for the 2011 and 2012 tax years included the capitalization of certain expenses that were deducted when paid or incurred in defending against certain patent infringement lawsuits. We fully paid the assessed amounts of tax, interest, and penalties set forth in the statutory notices and filed timely claims for refund on June 11, 2015 and June 7, 2017 for the 2009-2010 tax years and 2011-2012 tax years, respectively. Our claims for refund were disallowed by certified letters dated August 18, 2015 and July 11, 2017, for the 2009-2010 tax years and 2011-2012 tax years, respectively. The complaint was timely, based upon the refund claim denials, and seeks refunds of tax, interest, and penalties of $37.2 million for the 2009 tax year, $61.5 million for the 2010 tax year, $40.2 million for the 2011 tax year, and $24.7 million for the 2012 tax year. The amounts sought in the complaint for the 2009 and 2010 tax years were recorded as deferred charges on our balance sheet during the three months ended March 28, 2015, and the amounts sought in the complaint for the 2011 and 2012 tax years were recorded as deferred charges on our balance sheet during the three months ended July 1, 2017.

On December 22, 2016, we received a notice of proposed adjustment for the IRS audit of Athena Neurosciences, Inc. (“Athena”), a subsidiary of Elan acquired in 1996, for the years ended December 31, 2011, December 31, 2012, and December 31, 2013. Perrigo acquired Elan in December 2013. This proposed adjustment relates to the deductibility of litigation costs. We disagree with the IRS’s position asserted in the notice of proposed adjustment and intend to contest it.

On July 11, 2017, we received a draft notice of proposed adjustment associated with transfer pricing positions for the IRS audit of Athena for the years ended December 31, 2011, December 31, 2012, and December 31, 2013.  Athena was the originator of the patents associated with Tysabri® prior to the acquisition of Athena by Elan in 1996. The amount of adjustments that may be asserted by the IRS in the final notice of proposed adjustment cannot be quantified at this time; however, based on the draft notice received, the amount to be assessed may be material. We disagree with the IRS’s position as asserted in the draft notice of proposed adjustment and intend to contest it.

We have ongoing audits in multiple other jurisdictions the resolution of which remains uncertain. These jurisdictions include, but are not limited to, the United States, Israel and France. In addition to the matters discussed above, the IRS is currently auditing our fiscal years ended June 29, 2013, June 28, 2014, and June 27, 2015. The Israel Tax Authority is currently auditing our fiscal years ended June 29, 2013 and June 28, 2014. The French Tax Authority is currently auditing the years ended December 2014, December 2015, and December 2016.
XML 47 R20.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2017
Commitments and Contingencies Disclosure [Abstract]  
Commitments and contingencies
COMMITMENTS AND CONTINGENCIES

In view of the inherent difficulties of predicting the outcome of various types of legal proceedings, we cannot determine the ultimate resolution of the matters described below. We establish reserves for litigation and regulatory matters when losses associated with the claims become probable and the amounts can be reasonably estimated. The actual costs of resolving legal matters may be substantially higher or lower than the amounts reserved for those matters. For matters where the likelihood or extent of a loss is not probable or cannot be reasonably estimated as of September 30, 2017, we have not recorded a loss reserve. If certain of these matters are determined against us, there could be a material adverse effect on our financial condition, results of operations, or cash flows. We currently believe we have valid defenses to the claims in these lawsuits and intend to defend these lawsuits vigorously regardless of whether or not we have a loss reserve. Other than what is disclosed below, we do not expect the outcome of the litigation matters to which we are currently subject individually or in the aggregate, to have a material adverse effect on our financial condition, results of operations, or cash flows. 

Antitrust Violations
    
We have been named as a counterclaim co-defendant in the lawsuit Fera Pharmaceuticals, LLC v. Akorn, Inc., et al., in which Akorn, Inc. (“Akorn”) alleges tortious interference and antitrust violations against us and Fera Pharmaceuticals, LLC (“Fera”). This litigation arises from our acquisition of bacitracin ophthalmic ointment from Fera in 2013. Akorn asserts claims under Sections 1 and 2 of the Sherman Antitrust Act alleging that we and Fera conspired to monopolize, attempted to monopolize, and did unlawfully monopolize the market for sterile bacitracin ophthalmic ointment in the United States through the use of an exclusive agreement with a supplier of sterile bacitracin active pharmaceutical ingredient. The lawsuit is currently pending in the Southern District of New York. Trial was rescheduled from January 2018 to February 2018. Akorn seeks damages, injunctive relief, and attorney’s fees. Any award of antitrust damages would be subject to trebling under antitrust laws. An estimate of any possible loss cannot be determined at this time.

We believe the claims are without merit and intend to defend them vigorously. We have preserved our indemnification rights against Fera for potential liability, defense costs, and expenses incurred as a result of this litigation.

Price-Fixing Lawsuits

We have been named as a co-defendant with other manufacturers in a number of cases alleging that we and other manufacturers of the same product engaged in anti-competitive behavior to fix or raise the prices of certain drugs starting, in some instances, as early as June 2013. The products in question are Clobetasol, Desonide, and Econazole. These complaints, along with complaints filed against other companies alleging price fixing with respect to 15 other drugs, have been consolidated for pretrial proceedings as part of a case captioned In re Generic Pharmaceuticals Pricing Antitrust Litigation, MDL No. 2724. Pursuant to the court’s schedule staging various cases in phases, we have moved to dismiss the complaints relating to Clobetasol and Econazole. At this stage, we cannot reasonably predict the outcome of the liability, if any, associated with these claims.

Securities Litigation
 
In the United States

On May 18, 2016, a shareholder filed a securities case against us and our former CEO, Joseph Papa, in the U.S. District Court for the District of New Jersey (Roofers’ Pension Fund v. Papa, et al.). The plaintiff purported to represent a class of shareholders for the period from April 21, 2015 through May 11, 2016, inclusive. The original complaint alleged violations of Securities Exchange Act sections 10(b) (and Rule 10b‑5) and 14(e) against both defendants and 20(a) control person liability against Mr. Papa. In general, the allegations concerned the actions taken by us and the former executive to defend against the unsolicited takeover bid by Mylan in the period from April 21, 2015 through November 13, 2015. The plaintiff also alleged that the defendants provided inadequate disclosure concerning alleged integration problems related to the Omega acquisition in the period from April 21, 2015 through May 11, 2016. On July 19, 2016, a different shareholder filed a securities class action against us and our former CEO, Joseph Papa, also in the District of New Jersey (Wilson v. Papa, et al.). The plaintiff purported to represent a class of persons who sold put options on our shares between April 21, 2015 and May 11, 2016. In general, the allegations and the claims were the same as those made in the original complaint filed in the Roofers' Pension Fund case described above. On December 8, 2016, the court consolidated Roofers' Pension Fund case and the Wilson case under the Roofers' Pension Fund case number. In February 2017, the court selected the lead plaintiffs for the consolidated case and the lead counsel to the putative class. In March 2017, the court entered a scheduling order.

On June 21, 2017, the court-appointed lead plaintiffs filed an amended complaint that superseded the original complaints in the Roofers’ Pension Fund case and the Wilson case. The lead plaintiffs seek to represent a class of shareholders for the period April 21, 2015 through May 3, 2017, and identifies three subclasses - shareholders who traded during the entire period on the U.S. exchanges; shareholders who traded during the entire period on the Tel Aviv exchange; and shareholders who traded during the period while the Mylan tender offer was pending (April 21, 2015 through November 13, 2015). The amended complaint names as defendants us and 11 current or former directors and officers of Perrigo (Mses. Judy Brown, Laurie Brlas, Jacqualyn Fouse, Ellen Hoffing, and Messrs. Joe Papa, Marc Coucke, Gary Cohen, Michael Jandernoa, Gerald Kunkle, Herman Morris, and Donal O’Connor). The amended complaint alleges violations of Securities Exchange Act sections 10(b) (and Rule 10b‑5) and 14(e) against all defendants and 20(a) control person liability against the 11 individuals. In general, the allegations concern the actions taken by us and the former executives to defend against the unsolicited takeover bid by Mylan in the period from April 21, 2015 through November 13, 2015 and the allegedly inadequate disclosure throughout the entire class period related to purported integration problems related to the Omega acquisition, alleges incorrect reporting of organic growth at the Company, alleges price fixing activities with respect to six generic prescription pharmaceuticals, and alleges improper accounting for the Tysabri® royalty stream. The amended complaint does not include an estimate of damages. In August 2017, the defendants filed motions to dismiss the amended complaint. The plaintiffs filed their opposition in October 2017. The defendants filed replies in support of the motions to dismiss in November 2017. The court has not indicated whether there will be oral argument of the motions or whether the court will decide the motions on the papers. We intend to defend the lawsuit vigorously.

On November 1, 2017, Carmignac Gestion, S.A., filed a securities lawsuit against us and three individuals (former Chairman and CEO Joseph Papa, former CFO Judy Brown, and former Executive Vice President and Board member Marc Coucke). This lawsuit is not a securities class action. The case is styled Carmignac Gestion, S.A. v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of New Jersey. The complaint asserts claims under Securities Exchange Act sections 10(b) (and Rule 10b-5), 14(e), and 18 against all defendants as well as 20(a) control person liability against the individual defendants. In general, the plaintiff’s allegations focus on events during the period from April 2015 through April 2016. Plaintiff contends that the defendants provided inadequate disclosure throughout the period concerning the valuation and integration of Omega, the financial guidance provided by us during that period, our reporting about the generic prescription pharmaceutical business and its prospects, and the activities surrounding the efforts to defeat the Mylan tender offer during 2015. Many of the allegations in this newly-filed case overlap with the allegations of the June 2017 amended complaint in the Roofers’ Pension Fund case described above. The plaintiff does not provide an estimate of damages. We intend to defend the lawsuit vigorously.   

In Israel

Because our shares are traded on the Tel Aviv exchange under a dual trading arrangement, we are subject to securities litigation in Israel. Three cases are currently pending. We are consulting Israeli counsel about our response to these allegations and we intend to defend these cases vigorously.

On May 22, 2016, shareholders filed a securities class action against us and five individual defendants: Our former CEO Mr. Papa, our former Executive Vice President and General Manager of the BCH segment Marc Coucke, our Chief Executive Officer John Hendrickson, our former Board member Gary Kunkle, Jr., and our Board member Laurie Brlas alleging violations of Israeli law in the District Court of Tel Aviv-Jaffa (Schweiger et al. v. Perrigo Company plc, et al.). On June 15, 2016, we filed a motion to stay the case pending the outcome of the securities class action pending in the New Jersey Federal Court. The plaintiffs did not oppose the motion. The Israeli court granted the motion on the same day, and the Schweiger action is stayed. We intend to defend the lawsuit vigorously when and if the stay is lifted. In October 2017, the Schweiger plaintiffs dismissed their claims without prejudice because of the pendency of another class action case filed in Israel (see discussion below of the Israel Elec. Corp. Employees’ Educ. Fund case). The court approved the voluntary dismissal. 

On March 29, 2017, plaintiff Eyal Keinan commenced an action in the District Court of Tel Aviv-Jaffa asserting securities claims against two defendants: Perrigo and its auditor Ernst & Young LLP ("EY"). The case is styled Keinan v. Perrigo Company plc, et al. The action seeks certification of a class of purchasers of Perrigo shares on the Israeli exchange beginning February 6, 2014. The proposed closing date for the class is not clear from the complaint though it appears to extend into 2017. In general, the plaintiff asserts that we improperly accounted for our stream of royalty income from two drugs: Tysabri® and Prialt. The court filings contend that the alleged improper accounting caused the audited financial results for Perrigo to be incorrect for the six month period ended December 31, 2015, and the years ended June 27, 2015 and June 28, 2014 and the other financial data released by us over those years and 2016 to also be inaccurate. The plaintiff maintains that the defendants are liable under Israeli securities law or, in the alternative, under U.S. securities law. The plaintiff indicates an initial, preliminary class damages estimate of 686.0 million NIS (approximately $192.0 million at 1 NIS = $0.28 cent). The response from the defendants is not yet due. We intend to defend the lawsuit vigorously.

On June 28, 2017, a plaintiff filed a complaint in Tel Aviv District Court styled Israel Elec. Corp. Employees’ Educ. Fund v. Perrigo Company plc, et al. The lead plaintiff seeks to represent a class of shareholders who traded in Perrigo stock on the Tel Aviv exchange during the period April 24, 2015 through May 3, 2017. The amended complaint names as defendants the Company, EY (the Company’s auditor), and 11 current or former directors and officers of Perrigo (Mses. Judy Brown, Laurie Brlas, Jacqualyn Fouse, Ellen Hoffing, and Messrs. Joe Papa, Marc Coucke, Gary Cohen, Michael Jandernoa, Gerald Kunkle, Herman Morris, and Donal O’Connor). The complaint alleges violations under U.S. securities laws of Securities Exchange Act sections 10(b) (and Rule 10b‑5) and 14(e) against all defendants and 20(a) control person liability against the 11 individuals or, in the alternative, under Israeli securities laws. In general, the allegations concern the actions taken by us and our former executives to defend against the unsolicited takeover bid by Mylan in the period from April 21, 2015 through November 13, 2015 and the allegedly inadequate disclosure concerning purported integration problems related to the Omega acquisition, alleges incorrect reporting of organic growth at the Company, alleges price fixing activities with respect to six generic prescription pharmaceuticals, and alleges improper accounting for the Tysabri® royalty stream. The plaintiff indicates an initial, preliminary class damages estimate of 2.7 billion NIS (approximately $760.0 million at 1 NIS = $0.28 cent). We intend to defend the lawsuit vigorously.

On July 12, 2017, the plaintiff in the Israel Elec. Corp. Employees’ Educ. Fund v. Perrigo Company plc, et al. case filed a motion to have all three cases pending in Israel either consolidated or the other two cases dismissed so that the Israel Elec. Corp. Educ. Fund plaintiff can proceed as the sole plaintiff. That motion is pending. In October 2017, the Schweiger plaintiffs (see description above) voluntarily dismissed their securities class action without prejudice as part of their response to the motion filed by the Israel Elec. Corp. Educ. Fund plaintiff. A variety of other procedural motions are also pending at this time having to do with the timing of any response by defendants. The court has scheduled an initial conference on November 9, 2017 to address the motion filed by the Israel Elec. Corp. Educ. Fund plaintiff. The court has indicated that other procedural motions will be addressed after it has decided the Israel Elec. Corp. Educ. Fund plaintiff’s motion.

Eltroxin

During October and November 2011, nine applications to certify a class action lawsuit were filed in various courts in Israel related to Eltroxin, a prescription thyroid medication manufactured by a third party and distributed in Israel by our subsidiary, Perrigo Israel Agencies Ltd. The respondents included our subsidiaries, Perrigo Israel Pharmaceuticals Ltd. and/or Perrigo Israel Agencies Ltd., the manufacturers of the product, and various healthcare providers who provide healthcare services as part of the compulsory healthcare system in Israel.

One of the applications was dismissed and the remaining eight applications were consolidated into one application. The applications arose from the 2011 launch of a reformulated version of Eltroxin in Israel. The consolidated application generally alleges that the respondents (a) failed to timely inform patients, pharmacists and physicians about the change in the formulation; and (b) failed to inform physicians about the need to monitor patients taking the new formulation in order to confirm patients were receiving the appropriate dose of the drug. As a result, claimants allege they incurred the following damages: (a) purchases of product that otherwise would not have been made by patients had they been aware of the reformulation; (b) adverse events to some patients resulting from an imbalance of thyroid functions that could have been avoided; and (c) harm resulting from the patients' lack of informed consent prior to the use of the reformulation.

Several hearings on whether or not to certify the consolidated application took place in December 2013 and January 2014. On May 17, 2015, the District Court certified the motion against Perrigo Israel Agencies Ltd. and dismissed it against the remaining respondents, including Perrigo Israel Pharmaceuticals Ltd.

On June 16, 2015, we submitted a motion for permission to appeal the decision to certify to the Israeli Supreme Court together with a motion to stay the proceedings of the class action until the motion for permission to appeal is adjudicated. We have filed our statement of defense to the underlying proceedings. The parties are currently engaged in mediation in an attempt to settle the matter. The underlying proceedings have been stayed pending the outcome of the mediation process and, if necessary, a decision on the motion to appeal.

Tysabri® Product Liability Lawsuits

We and our collaborator Biogen are co-defendants in product liability lawsuits arising out of the occurrence of Progressive Multifocal Leukoencephalopathy, a serious brain infection, and serious adverse events, including deaths, which occurred in patients taking Tysabri®. Each co-defendant would be responsible for 50% of losses and expenses arising out of any Tysabri® product liability claims. During calendar year 2016, one case in the U.S. was settled and two others were dismissed with prejudice. In 2017, seven other cases were dismissed with prejudice. While we intend to vigorously defend the remaining lawsuits, management cannot predict how these cases will be resolved. Adverse results in one or more of these lawsuits could result in substantial judgments against us.

Claim Arising from the Omega Acquisition

On December 16, 2016, we and Perrigo Ireland 2 brought an arbitral claim ("Claim") against Alychlo NV ("Alychlo") and Holdco I BE NV ("Holdco") (together the Sellers) in accordance with clause 26.2 of the Share Purchase Agreement dated November 6, 2014 ("SPA") and the rules of the Belgian Centre for Arbitration and Mediation ("CEPANI"). Our Claim relates to the accuracy and completeness of information about Omega provided by the Sellers as part of the sale process, the withholding of information by the Sellers during that process and breaches of Sellers’ warranties. We are seeking monetary damages from the Sellers. The Sellers served their respective responses to the Claim on February 20, 2017. In its response, Alychlo has asserted a counterclaim for monetary damages contending that we breached the duty of good faith in performing the SPA. There can be no assurance that our Claim will be successful, and Sellers deny liability for the Claim. We deny that Alychlo is entitled to any relief (including monetary relief) under the counterclaim. The arbitration proceedings are confidential as required by the SPA and the rules of the CEPANI.
XML 48 R21.htm IDEA: XBRL DOCUMENT v3.8.0.1
Restructuring Charges
 9 Months Ended
Sep. 30, 2017
Restructuring Charges [Abstract]  
Restructuring charges
RESTRUCTURING CHARGES

We periodically take action to reduce redundant expenses and improve operating efficiencies. The following reflects our restructuring activity (in millions):
 
Three Months Ended
 
Nine Months Ended
 
September 30,
2017
 
October 1,
2016
 
September 30,
2017
 
October 1,
2016
Beginning balance
$
39.7

 
$
12.2

 
$
19.7

 
$
20.7

Additional charges
3.8

 
6.6

 
54.7

 
17.9

Payments
(17.8
)
 
(8.6
)
 
(47.6
)
 
(33.3
)
Non-cash adjustments
0.4

 
0.1

 
(0.7
)
 
5.0

Ending balance
$
26.1

 
$
10.3

 
$
26.1

 
$
10.3



Restructuring activity includes severance, lease exit costs, and asset impairments. The charges incurred during the three and nine months ended September 30, 2017 were primarily associated with actions we took to streamline our organization as announced on February 21, 2017. During the three and nine months ended September 30, 2017, $3.8 million and $54.7 million of restructuring expenses were recorded, respectively. Of the amount recorded during the nine months ended September 30, 2017, $27.2 million was related to the CHCA segment. There were no other material restructuring programs that significantly impacted any other reportable segments. All charges are recorded in Restructuring on the Condensed Consolidated Statements of Operations. The remaining $22.4 million liability for employee severance benefits is expected to be paid within the next year, while the remaining $3.7 million liability for lease exit costs is expected to be incurred over the remaining terms of the applicable leases.
XML 49 R22.htm IDEA: XBRL DOCUMENT v3.8.0.1
Segment Information
 9 Months Ended
Sep. 30, 2017
Segment Reporting [Abstract]  
Segment information
SEGMENT INFORMATION
    
Our reporting segments are as follows:

•
CHCA, comprises our U.S., Mexico and Canada consumer healthcare business (OTC, contract, infant formula and animal health categories).
•
CHCI, comprises our legacy Branded Consumer Healthcare segment and now includes our consumer focused businesses in the U.K., Australia, and Israel. This segment also includes our U.K. liquid licensed products business.
•
RX, comprises our U.S. Prescription Pharmaceuticals business.

We also have an "Other" reporting segment that consists of our legacy API business, which does not meet the quantitative threshold required to be a separately reportable segment. Effective January 1, 2017, due to the sale of the Tysabri® financial asset, all legal expenses associated with the former Specialty Sciences segment were moved to unallocated expenses. Our segments reflect the way in which our chief operating decision maker reviews our operating results and allocates resources.

The below tables show select financial measures by reporting segment (in millions):
 
 
Total Assets
 
 
September 30,
2017
 
December 31,
2016
CHCA
 
$
3,833.7

 
$
3,351.3

CHCI
 
5,114.2

 
4,795.2

RX
 
2,597.0

 
2,646.4

Specialty Sciences
 
—

 
2,775.8

Other
 
297.7

 
301.4

Total
 
$
11,842.6

 
$
13,870.1

 
Three Months Ended
 
September 30, 2017
 
October 1, 2016
 
Net
Sales
 
Operating Income (Loss)
 
Intangible Asset Amortization
 
Net
Sales
 
Operating Income (Loss)
 
Intangible Asset Amortization
CHCA
$
598.8

 
$
124.3

 
$
16.9

 
$
611.2

 
$
99.0

 
$
17.6

CHCI
365.4

 
4.6

 
50.2

 
377.4

 
(1,615.5
)
 
44.4

RX
250.6

 
82.1

 
21.0

 
251.9

 
74.4

 
27.2

Specialty Sciences
—

 
—

 
—

 
—

 
3.2

 
—

Other
16.5

 
(0.4
)
 
0.4

 
21.1

 
(1.5
)
 
0.5

Unallocated
—

 
(48.2
)
 
—

 
—

 
(27.9
)
 
—

Total
$
1,231.3

 
$
162.4

 
$
88.5

 
$
1,261.6

 
$
(1,468.3
)
 
$
89.7



 
Nine Months Ended
 
September 30, 2017
 
October 1, 2016
 
Net
Sales
 
Operating Income (Loss)
 
Intangible Asset Amortization
 
Net
Sales
 
Operating Income (Loss)
 
Intangible Asset Amortization
CHCA
$
1,786.4

 
$
303.6

 
$
51.1

 
$
1,880.2

 
$
316.4

 
$
53.3

CHCI
1,116.8

 
8.7

 
143.4

 
1,232.7

 
(2,011.3
)
 
130.6

RX
708.4

 
239.6

 
65.6

 
776.9

 
258.3

 
78.6

Specialty Sciences
—

 
—

 
—

 
—

 
(1.9
)
 
—

Other
51.5

 
9.4

 
1.2

 
59.5

 
2.6

 
1.4

Unallocated
—

 
(121.7
)
 
—

 
—

 
(79.2
)
 
—

Total
$
3,663.1

 
$
439.6

 
$
261.3

 
$
3,949.3

 
$
(1,515.1
)
 
$
263.9
XML 50 R23.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2017
Accounting Policies [Abstract]  
Basis of presentation
Basis of Presentation

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The unaudited Condensed Consolidated Financial Statements should be read in conjunction with the consolidated financial statements and footnotes included in our Annual Report on Form 10-K for the year ended December 31, 2016. In the opinion of management, all adjustments (consisting of normal recurring accruals and other adjustments) considered necessary for a fair presentation of the unaudited Condensed Consolidated Financial Statements have been included
Principles of consolidation
include our accounts and the accounts of all majority-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.
New accounting pronouncements, policy [Policy Text Block]
Recent Accounting Standard Pronouncements
    
Below are recent accounting standard updates that we are still assessing to determine the effect on our Condensed Consolidated Financial Statements. We do not believe that any other recently issued accounting standards could have a material effect on our Condensed Consolidated Financial Statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.
Recently Issued Accounting Standards Adopted
Standard
 
Description
 
Date of adoption
 
Effect on the Financial Statements or Other Significant Matters
Clarifying the Definition of a Business
 
This update clarifies the definition of a business and addresses whether transactions should be accounted for as asset acquisitions or business combinations (or divestitures). The guidance includes an initial threshold that an acquired set of assets will not be considered a business if substantially all of the fair value of the assets acquired is concentrated in a single tangible or identifiable intangible asset (or group of similar assets). If the acquired set does not pass the initial threshold, then the guidance requires that, to be a business, the set must include an input and a substantive process that together significantly contribute to the ability to create outputs. Different factors are considered to determine whether the set includes a substantive process, such as the inclusion of an organized workforce. Further, the guidance removes language stating that a business need not include all of the inputs and processes that the seller used in operating the business.
 
January 1, 2017
 
We early adopted this new standard and will apply it prospectively when determining whether transactions should be accounted for as asset acquisitions (divestitures) or business combinations (divestitures). During the nine months ended September 30, 2017, we applied the new guidance when determining whether certain product divestitures represented sales of assets or businesses.

Improvements to Employee Share-Based Payment Accounting
 
This guidance is intended to simplify several aspects of the accounting for share-based payment award transactions. It will require all income tax effects of awards to be recorded through the income statement when the awards vest or settle as opposed to certain amounts being recorded in additional paid-in capital. An entity will also have to elect whether to account for forfeitures as they occur or by estimating the number of awards expected to be forfeited and adjusting the estimate when it is likely to change (as currently required). The guidance will also increase the amount an employer can withhold to cover income taxes on awards.
 
January 1, 2017
 
We adopted this standard as of January 1, 2017. We elected to estimate the number of awards expected to be forfeited and adjust the estimate when it is likely to change, consistent with past practice. We did not change the amounts that we withhold to cover income taxes on awards. As the requirement to record all income tax effects of vested or settled awards through the income statement is prospective in nature, there was no cumulative effect of adopting the standard on our balance sheet.
Recent accounting standard announcements not yet adopted
Recently Issued Accounting Standards Not Yet Adopted
Standard
 
Description
 
Effective Date
 
Effect on the Financial Statements or Other Significant Matters
Revenue from Contracts with Customers
 
The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: identify the contract(s) with a customer; identify the performance obligations in the contract; determine the transaction price; allocate the transaction price to the performance obligations in the contract; and recognize revenue when (or as) the entity satisfies a performance obligation. This guidance allows for two adoption methods, full retrospective approach or modified retrospective approach.
 
January 1, 2018
 
We continue to evaluate the implications of adoption of the new revenue standard on our Consolidated Financial Statements. We have completed an initial assessment and are in the process of quantifying the adoption impact, if any, related to certain topics identified through our evaluation process. Our assessment of the new revenue standard has been focused on, but has not been limited to, the concepts of over-time versus point-in-time revenue recognition patterns, variable consideration, and identification of performance obligations. We will not complete our final assessment and quantification of the impact of the new revenue standard on our Consolidated Financial Statements until the adoption date. Our analysis indicates that certain contract manufacturing and private label arrangements may require revenue recognition over-time in situations in which we produce products that have no alternative use and we have an enforceable right to payment for performance completed to date, inclusive of a reasonable profit margin. This may result in an acceleration of revenue recognition for certain contractual arrangements as compared to recognition under current accounting literature. We plan to adopt the new revenue standard effective January 1, 2018 using the modified retrospective method.
Intra-Entity Asset Transfers of Assets Other Than Inventory
 
Under the new guidance, the tax impact to the seller on the profit from the transfers and the buyer’s deferred tax benefit on the increased tax basis would be recognized when the transfers occur, resulting in the recognition of expense sooner than under historical guidance. The guidance excludes intra-entity transfers of inventory. For intra-entity transfers of inventory, the Financial Accounting Standards Board ("FASB") decided to retain current GAAP, which requires an entity to recognize the income tax consequences when the inventory has been sold to an outside party.
 
January 1, 2018
 
We are currently evaluating the implications of adoption on our Consolidated Financial Statements.
Financial Instruments - Recognition and Measurement of Financial Assets and Liabilities
 
The objective of this simplification update is to improve the decision usefulness of financial instrument reporting, and it principally affects accounting for equity investments currently classified as available for sale and financial liabilities where the fair value option has been elected. Entities will have to measure many equity investments at fair value and recognize changes in fair value in net income rather than other comprehensive income as required under current U.S. GAAP.
 
January 1, 2018
 
We have identified certain investments that will require an adjustment, however, at this time, we are unable to estimate the impact of adopting this standard as the significance of the impact will depend upon our equity investments as of the date of adoption.

Recently Issued Accounting Standards Not Yet Adopted (continued)
Standard
 
Description
 
Effective Date
 
Effect on the Financial Statements or Other Significant Matters
Leases
 
This guidance was issued to increase transparency and comparability among organizations by requiring recognition of lease assets and lease liabilities on the balance sheet and disclosure of key information about leasing arrangements. For leases with a term of 12 months or less, lessees are permitted to make an election to not recognize right-of-use assets and lease liabilities. Upon adoption, lessees will apply the new standard as of the beginning of the earliest comparative period presented in the financial statements, however lessees will be able to exclude leases that expire as of the implementation date. Early adoption is permitted.
 
January 1, 2019
 
We are currently evaluating the implications of adoption on our Consolidated Financial Statements and have commenced the first step of identifying a task force to take the lead in implementing the new Lease standard.
Derivatives and Hedging
 
This update was issued to enable entities to better portray the economics of their risk management activities in the financial statements and enhance the transparency and understandability of hedge results. In addition, the amendments simplify the application of hedge accounting in certain situations. Under the new rule, the entity’s ability to hedge non-financial and financial risk components is expanded. The guidance eliminates the requirement to separately measure and report hedge ineffectiveness and also eases certain documentation and assessment requirements. Early adoption is permitted.
 
January 1, 2019
 
We are currently evaluating the implications of adoption on our Consolidated Financial Statements.

Measurement of Credit Losses on Financial Instruments
 
This guidance changes the impairment model for most financial assets and certain other instruments, replacing the current "incurred loss" approach with an "expected loss" credit impairment model, which will apply to most financial assets measured at amortized cost and certain other instruments, including trade and other receivables, loans, held-to-maturity debt securities, and off-balance sheet credit exposures such as letters of credit. Early adoption is permitted.
 
January 1, 2020
 
We are currently evaluating the new standard for potential impacts on our receivables, debt, and other financial instruments.
Intangibles - Goodwill and Other Simplifying the Test for Goodwill
 
The objective of this update is to reduce the cost and complexity of subsequent goodwill accounting by simplifying the impairment test by removing the Step 2 requirement to perform a hypothetical purchase price allocation when the carrying value of a reporting unit exceeds its fair value. If a reporting unit’s carrying value exceeds its fair value, an entity would record an impairment charge based on that difference, limited to the amount of goodwill attributed to that reporting unit. The proposal would not change the guidance on completing Step 1 of the goodwill impairment test. The proposed guidance would be applied prospectively. Early adoption is permitted.
 
January 1, 2020
 
We are currently evaluating the implications of adoption on our Consolidated Financial Statements.
XML 51 R24.htm IDEA: XBRL DOCUMENT v3.8.0.1
Goodwill and Other Intangible Assets (Tables)
 9 Months Ended
Sep. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of goodwill
Changes in the carrying amount of goodwill, by reportable segment, were as follows (in millions):
Reporting Segments:
 
December 31,
2016
 
Business divestitures
 
Re-class to assets held-for-sale
 
Currency translation adjustment
 
September 30,
2017
CHCA
 
$
1,810.6

 
$
—

 
$
—

 
$
2.9

 
$
1,813.5

CHCI
 
1,070.8

 
(4.1
)
 
—

 
122.3

 
1,189.0

RX
 
1,086.6

 
—

 
—

 
6.5

 
1,093.1

Other
 
81.4

 
—

 
(32.6
)
 
7.6

 
56.4

Total goodwill
 
$
4,049.4

 
$
(4.1
)
 
$
(32.6
)
 
$
139.3

 
$
4,152.0
Schedule of finite and indefinite-lived intangible assets
Other intangible assets and related accumulated amortization consisted of the following (in millions):
 
September 30, 2017
 
December 31, 2016
 
Gross
 
Accumulated Amortization
 
Gross
 
Accumulated Amortization
Definite-lived intangibles:
 
 
 
 
 
 
 
Distribution and license agreements, supply agreements
$
310.2

 
$
157.5

 
$
305.6

 
$
120.4

Developed product technology, formulations, and product rights
1,355.4

 
568.8

 
1,418.1

 
526.0

Customer relationships and distribution networks
1,623.7

 
424.5

 
1,489.9

 
307.5

Trademarks, trade names, and brands
1,317.5

 
111.0

 
1,189.3

 
55.3

Non-compete agreements
14.7

 
12.3

 
14.3

 
11.2

Total definite-lived intangibles
$
4,621.5

 
$
1,274.1

 
$
4,417.2

 
$
1,020.4

Indefinite-lived intangibles:
 
 
 
 
 
 
 
Trademarks, trade names, and brands
$
52.0

 
$
—

 
$
50.5

 
$
—

In-process research and development
51.4

 
—

 
64.0

 
—

Total indefinite-lived intangibles
103.4

 
—

 
114.5

 
—

Total other intangible assets
$
4,724.9

 
$
1,274.1

 
$
4,531.7

 
$
1,020.4
XML 52 R25.htm IDEA: XBRL DOCUMENT v3.8.0.1
Inventories (Tables)
 9 Months Ended
Sep. 30, 2017
Inventory Disclosure [Abstract]  
Schedule of inventory, current
Major components of inventory were as follows (in millions):
 
 
September 30,
2017
 
December 31,
2016
Finished goods
$
471.4

 
$
431.1

Work in process
146.8

 
165.7

Raw materials
203.7

 
198.2

Total inventories
$
821.9

 
$
795.0
XML 53 R26.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurements (Tables)
 9 Months Ended
Sep. 30, 2017
Fair Value Disclosures [Abstract]  
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
The table below presents a reconciliation for the Royalty Pharma contingent milestone payments measured at fair value on a recurring basis using significant unobservable inputs (Level 3) (in millions). Change in fair value in the table was recorded in Change in financial assets on the Condensed Consolidated Statements of Operations.
 
Three Months Ended
 
Nine Months Ended
 
September 30,
2017
 
September 30,
2017
Royalty Pharma Contingent Milestone Payments
 
 
 
Beginning balance
$
145.8

 
$
—

Additions
—

 
184.5

Foreign currency effect
0.3

 
0.8

Change in fair value
(2.9
)
 
(42.1
)
Ending balance
$
143.2

 
$
143.2
Fair value, assets measured on recurring and nonrecurring basis
The following table summarizes the valuation of our financial instruments carried at fair value and measured at fair value on a recurring and non-recurring basis by the above pricing categories (in millions):
 
 
 
 
Fair Value
 
 
Fair Value Hierarchy
 
September 30,
2017
 
December 31,
2016
Measured at fair value on a recurring basis:
 
 
 
 
 
 
Assets:
 
 
 
 
 
 
Investment securities
 
Level 1
 
$
6.1

 
$
38.2

 
 
 
 
 
 
 
Foreign currency forward contracts
 
Level 2
 
$
13.1

 
$
3.8

Funds associated with Israeli severance liability
 
Level 2
 
16.1

 
15.9

Total level 2 assets
 
 
 
$
29.2

 
$
19.7

 
 
 
 
 
 
 
Royalty Pharma contingent milestone payments
 
Level 3
 
$
143.2

 
$
—

Financial assets
 
Level 3
 
—

 
2,350.0

Total level 3 assets
 
 
 
$
143.2

 
$
2,350.0

 
 
 
 
 
 
 
Liabilities:
 
 
 
 
 
 
Foreign currency forward contracts
 
Level 2
 
$
3.3

 
$
5.0

 
 
 
 
 
 
 
Contingent consideration
 
Level 3
 
$
44.9

 
$
69.9

 
 
 
 
 
 
 
Measured at fair value on a non-recurring basis:
 
 
 
 
 
 
Assets:
 
 
 
 
 
 
Goodwill(1)
 
Level 3
 
$
—

 
$
1,148.4

Indefinite-lived intangible assets(2)
 
Level 3
 
13.3

 
0.3

Definite-lived intangible assets(3)
 
Level 3
 
11.5

 
758.0

Assets held for sale, net
 
Level 3
 
95.1

 
18.2

Total level 3 assets
 
 
 
$
119.9

 
$
1,924.9



(1) 
As of December 31, 2016, goodwill with a carrying amount of $2.2 billion was written down to its implied fair value of $1.1 billion.
(2) 
As of September 30, 2017, indefinite-lived intangible assets with a carrying amount of $26.0 million were written down to a fair value of $13.3 million. As of December 31, 2016, indefinite-lived intangible assets with a carrying amount of $0.7 million were written down to a fair value of $0.3 million.
(3) 
As of July 1, 2017, definite-lived intangible assets with a carrying amount of $31.1 million were written down to a fair value of $11.5 million. As of December 31, 2016, definite-lived intangible assets with a carrying amount of $2.3 billion were written down to a fair value of $758.0 million. Included in this balance are indefinite-lived intangible assets with a fair value of $364.5 million and $674.2 million that were reclassified to definite-lived assets at April 3, 2016 and October 2, 2016, respectively.
Reconciliation of Level 3 Liabilities
The table below presents a reconciliation for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) (in millions). Net realized losses in the table were recorded in Other (income) expense, net on the Condensed Consolidated Statements of Operations.
 
Three Months Ended
 
Nine Months Ended
 
September 30,
2017
 
October 1,
2016
 
September 30,
2017
 
October 1,
2016
Contingent Consideration
 
 
 
 
 
 
 
Beginning balance
$
49.7

 
$
44.9

 
$
69.9

 
$
17.9

Net realized losses
(2.9
)
 
(0.4
)
 
(18.5
)
 
(4.0
)
Purchases or additions
—

 
30.6

 
—

 
61.1

Foreign currency effect
0.2

 
—

 
1.5

 
0.1

Settlements
(2.1
)
 
(0.1
)
 
(8.0
)
 
(0.1
)
Ending balance
$
44.9

 
$
75.0

 
$
44.9

 
$
75.0
Schedule of fair value metrics used in valuations
Below is a summary of the various metrics used in our valuations:
 
Nine Months Ended
 
September 30, 2017
 
Lumara
5-year average growth rate
(4.1)%
Discount rate
13.5%
Valuation method
MPEEM

 
Year Ended
 
December 31, 2016
 
Omega - Lifestyle
 
Omega - XLS
 
Entocort® - Branded Products
 
Entocort® - AG Products
 
Herron Trade Names and Trademarks
5-year average growth rate
2.5%
 
3.2%
 
(31.7)%
 
(30.4)%
 
4.6%
Long-term growth rates
2.0%
 
NA
 
(10.0)%
 
(4.7)%
 
2.5%
Discount rate
9.3%
 
9.5%
 
13.0%
 
10.5%
 
10.8%
Royalty rate
NA
 
4.0%
 
NA
 
NA
 
11.0%
Valuation method
MPEEM
 
Relief from Royalty
 
MPEEM
 
MPEEM
 
Relief from Royalty
XML 54 R27.htm IDEA: XBRL DOCUMENT v3.8.0.1
Investments (Tables)
 9 Months Ended
Sep. 30, 2017
Investments [Abstract]  
Unrealized gain (loss) on investments
Unrealized investment gains/(losses) on available for sale securities were as follows (in millions):
 
September 30,
2017
 
December 31, 2016
Equity securities, at cost less impairments
$
15.5

 
$
16.5

Gross unrealized gains
—

 
21.7

Gross unrealized losses
(9.4
)
 
—

Estimated fair value of equity securities
$
6.1

 
$
38.2
XML 55 R28.htm IDEA: XBRL DOCUMENT v3.8.0.1
Derivative Instruments and Hedging Activities (Tables)
 9 Months Ended
Sep. 30, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of derivative instruments in statement of financial position, fair value
The balance sheet location and gross fair value of our outstanding derivative instruments were as follows:
 
Asset Derivatives
 
Balance Sheet Location
 
Fair Value
 
 
 
September 30,
2017
 
December 31,
2016
Designated derivatives:
 
 
 
 
 
Foreign currency forward contracts
Other current assets
 
$
4.6

 
$
3.1

Non-designated derivatives:
 
 
 
 
 
Foreign currency forward contracts
Other current assets
 
$
8.5

 
$
0.7

 
Liability Derivatives
 
Balance Sheet Location
 
Fair Value
 
 
 
September 30,
2017
 
December 31,
2016
Designated derivatives:
 
 
 
 
 
Foreign currency forward contracts
Accrued liabilities
 
$
2.6

 
$
3.0

Non-designated derivatives:
 
 
 
 
 
Foreign currency forward contracts
Accrued liabilities
 
$
0.7

 
$
2.0
Amount of Gain/(Loss) Recorded in OCI (Effective Portion)
The gains (losses) recorded in OCI for the effective portion of our designated cash flow hedges were as follows:
 
 
Amount of Gain/(Loss) Recorded in OCI
(Effective Portion)
 
 
Three Months Ended
 
Nine Months Ended
Designated Cash Flow Hedges
 
September 30,
2017
 
October 1,
2016
 
September 30,
2017
 
October 1,
2016
Interest rate swap agreements
 
$
—

 
$
—

 
$
—

 
$
(9.0
)
Foreign currency forward contracts
 
1.1

 
3.4

 
6.3

 
4.7

Total
 
$
1.1

 
$
3.4

 
$
6.3

 
$
(4.3
)
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion)
The gains (losses) reclassified from AOCI into earnings for the effective portion of our designated cash flow hedges were as follows:
 
 
 
 
Amount of Gain/(Loss) Reclassified from AOCI into Earnings
(Effective Portion)
 
 
 
 
Three Months Ended
 
Nine Months Ended
Designated Cash Flow Hedges
 
Income Statement Location
 
September 30,
2017
 
October 1,
2016
 
September 30,
2017
 
October 1,
2016
Treasury locks
 
Interest expense, net
 
$
—

 
$
—

 
$
—

 
$
(0.1
)
Interest rate swap agreements
 
Interest expense, net
 
(0.4
)
 
(0.6
)
 
(1.7
)
 
(1.7
)
 
 
Other (income) expense, net
 
—

 
—

 
(5.9
)
 
—

Foreign currency forward contracts
 
Net sales
 
—

 
(0.1
)
 
0.9

 
0.3

 
 
Cost of sales
 
1.8

 
0.9

 
3.5

 
1.8

 
 
Interest expense, net
 
(0.7
)
 
(0.4
)
 
(1.8
)
 
(1.3
)
 
 
Other (income) expense, net
 
(1.2
)
 
(1.2
)
 
(1.7
)
 
0.7

Total
 
 
 
$
(0.5
)
 
$
(1.4
)
 
$
(6.7
)
 
$
(0.3
)
Amount of Gain/(Loss) Recognized against Earnings (Ineffective Portion)
The gains (losses) recognized against earnings for the ineffective portion of our designated cash flow hedges were as follows:
 
 
 
 
Amount of Gain/(Loss) Recognized against Earnings
(Ineffective Portion)
 
 
 
 
Three Months Ended
 
Nine Months Ended
Designated Cash Flow Hedges
 
Income Statement
Location
 
September 30,
2017
 
October 1,
2016
 
September 30,
2017
 
October 1,
2016
Interest rate swap agreements
 
Other (income) expense, net
 
$
—

 
$
—

 
$
—

 
$
(0.1
)
Foreign currency forward contracts
 
Net sales
 
0.2

 
—

 
0.1

 
0.1

 
 
Cost of sales
 
0.1

 
—

 
0.1

 
—

 
 
Other (income) expense, net
 
—

 
—

 
1.0

 
0.6

Total
 
 
 
$
0.3

 
$
—

 
$
1.2

 
$
0.6
Amount of Gain/(Loss) Recognized against Earnings
The effects of our non-designated derivatives on the Condensed Consolidated Statements of Operations were as follows:
 
 
 
 
Amount of Gain/(Loss) Recognized against Earnings
 
 
 
 
Three Months Ended
 
Nine Months Ended
Non-Designated Derivatives
 
Income Statement Location
 
September 30,
2017
 
October 1,
2016
 
September 30,
2017
 
October 1,
2016
Foreign currency forward contracts
 
Other (income) expense, net
 
$
10.1

 
$
(0.2
)
 
$
(3.8
)
 
$
(8.7
)
 
 
Interest expense, net
 
(1.8
)
 
(1.0
)
 
(2.9
)
 
(1.5
)
Total
 
 
 
$
8.3

 
$
(1.2
)
 
$
(6.7
)
 
$
(10.2
)
XML 56 R29.htm IDEA: XBRL DOCUMENT v3.8.0.1
Assets Held for Sale (Tables)
 9 Months Ended
Sep. 30, 2017
Assets held for sale [Abstract]  
Disposal groups, including discontinued operations
The amounts consist of the following (in millions):
 
September 30,
2017
 
December 31,
2016
 
Other
 
CHCA
 
Other
Assets held for sale
 
 
 
 
 
Current assets
$
44.0

 
$
—

 
$
5.1

Goodwill
32.6

 
—

 
5.5

Intangible assets
5.5

 
—

 
—

Property, plant and equipment
45.9

 
13.5

 
33.2

Other assets
3.1

 
—

 
3.8

Less: impairment reserves
(3.3
)
 
(3.7
)
 
(35.3
)
Total assets held for sale
$
127.8

 
$
9.8

 
$
12.3

Liabilities held for sale
 
 
 
 
 
Current liabilities
$
7.6

 
$
0.1

 
$
1.9

Other liabilities
25.1

 
—

 
1.9

Total liabilities held for sale
$
32.7

 
$
0.1

 
$
3.8
XML 57 R30.htm IDEA: XBRL DOCUMENT v3.8.0.1
Indebtedness (Tables)
 9 Months Ended
Sep. 30, 2017
Debt Disclosure [Abstract]  
Schedule of debt
Total borrowings outstanding are summarized as follows (in millions):
 
 
 
 
 
September 30,
2017
 
December 31,
2016
Term loans
 
 
 
 
 
 
2014 term loan due December 5, 2019
(1) 
 
$
428.3

 
$
420.7

Notes and Bonds
 
 
 
 
 
 
Coupon
Due
 
 
 
 
 
 
4.500%
May 23, 2017
(1)(2) 
 
—

 
189.3

 
5.125%
December 12, 2017
(1)(2) 
 
354.5

 
315.6

 
2.300%
November 8, 2018

 
—

 
600.0

 
5.000%
May 23, 2019
(1)(2) 
 
141.8

 
126.2

 
3.500%
March 15, 2021

 
280.4

 
500.0

 
3.500%
December 15, 2021

 
309.6

 
500.0

 
5.105%
July 19, 2023
(1)(2) 
 
159.5

 
142.0

 
4.000%
November 15, 2023

 
215.6

 
800.0

 
3.900%
December 15, 2024

 
700.0

 
700.0

 
4.375%
March 15, 2026

 
700.0

 
700.0

 
5.300%
November 15, 2043

 
90.5

 
400.0

 
4.900%
December 15, 2044

 
303.9

 
400.0

 
Total notes and bonds
 
 
3,255.8

 
5,373.1

Other financing
2.9

 
3.6

Unamortized premium (discount), net
24.8

 
33.0

Deferred financing fees
(19.0
)
 
(33.1
)
Total borrowings outstanding
3,692.8

 
5,797.3

 
Current indebtedness
(417.1
)
 
(572.8
)
Total long-term debt less current portion
$
3,275.7

 
$
5,224.5



(1)
Debt denominated in Euros subject to fluctuations in the euro-to-U.S. dollar exchange rate.
(2)
Debt assumed from Omega.
Schedule of debt retirement
During the nine months ended September 30, 2017, we reduced our outstanding debt through a variety of transactions (in millions):
Date
 
Series
 
Transaction Type
 
Principal Retired
April 1, 2017
 
2014 term loan due December 5, 2019
 
Scheduled quarterly payment
 
$
13.3

July 1, 2017
 
2014 term loan due December 5, 2019
 
Scheduled quarterly payment
 
14.3

September 30, 2017
 
2014 term loan due December 5, 2019
 
Scheduled quarterly payment
 
14.8

May 8, 2017
 
$600.0 2.300% senior notes due 2018
 
Early redemption
 
600.0

May 23, 2017
 
€180.0 4.500% retail bonds due 2017
 
Scheduled maturity
 
201.3

June 15, 2017
 
$500.0 3.500% senior notes due 2021
 
Tender offer
 
190.4

June 15, 2017
 
$500.0 3.500% senior notes due 2021
 
Tender offer
 
219.6

June 15, 2017
 
$800.0 4.000% senior notes due 2023
 
Tender offer
 
584.4

June 15, 2017
 
$400.0 5.300% senior notes due 2043
 
Tender offer
 
309.5

June 15, 2017
 
$400.0 4.900% senior notes due 2044
 
Tender offer
 
96.1

 
 
 
 
 
 
$
2,243.7
Schedule of extinguishment of debt [Table Text Block]
As a result of the of the early redemption and tender offer transactions discussed above, we recorded a loss of $135.2 million during the three months ended July 1, 2017 in Loss on extinguishment of debt (in millions):

Premium on debt repayment
 
$
116.1

Transaction costs
 
3.8

Write-off of deferred financing fees
 
10.6

Write-off of remaining discount on bond
 
4.7

Total loss on extinguishment of debt
 
$
135.2
XML 58 R31.htm IDEA: XBRL DOCUMENT v3.8.0.1
Earnings Per Share and Shareholders Equity (Tables)
 9 Months Ended
Sep. 30, 2017
Earnings Per Share [Abstract]  
Schedule of earnings per share, basic and diluted
A reconciliation of the numerators and denominators used in the basic and diluted earnings per share ("EPS") calculation is as follows (in millions):
 
Three Months Ended
 
Nine Months Ended
 
September 30,
2017
 
October 1,
2016
 
September 30,
2017
 
October 1,
2016
Numerator:
 
 
 
 
 
 
 
Net income (loss)
$
44.5

 
$
(1,590.2
)
 
$
46.4

 
$
(2,653.7
)
 
 
 
 
 
 
 
 
Denominator:
 
 
 
 
 
 
 
Weighted average shares outstanding for basic EPS
141.3

 
143.3

 
142.5

 
143.2

Dilutive effect of share-based awards*
0.4

 
—

 
0.3

 
—

Weighted average shares outstanding for diluted EPS
141.7

 
143.3

 
142.8

 
143.2

 
 
 
 
 
 
 
 
Anti-dilutive share-based awards excluded from
     computation of diluted EPS*
1.0

 
—

 
0.8

 
—


* In the period of a net loss, diluted shares equal basic shares.
Schedule of share-based compensation, stock options, activity
We issued shares related to the exercise and vesting of share-based compensation as follows:
Three Months Ended
 
Nine Months Ended
September 30,
2017
 
October 1,
2016
 
September 30,
2017
 
October 1,
2016
99,800

 
185,000

 
146,100

 
283,000
XML 59 R32.htm IDEA: XBRL DOCUMENT v3.8.0.1
Accumulated Other Comprehensive Income (Loss) (Tables)
 9 Months Ended
Sep. 30, 2017
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]  
Schedule of accumulated other comprehensive income (loss)
Changes in our AOCI balances, net of tax were as follows (in millions):
 
Foreign currency translation adjustments
 
Fair value of derivative financial instruments, net of tax
 
Fair value of investment securities, net of tax
 
Post-retirement and pension liability adjustments, net of tax
 
Total AOCI
Balance at December 31, 2016
$
(67.9
)
 
$
(19.5
)
 
$
15.1

 
$
(9.5
)
 
$
(81.8
)
OCI before reclassifications
289.9

 
4.4

 
(22.8
)
 
(1.2
)
 
270.3

Amounts reclassified from AOCI
—

 
4.3

 
(1.6
)
 
—

 
2.7

Other comprehensive income (loss)
289.9

 
8.7

 
(24.4
)
 
(1.2
)
 
273.0

Balance at September 30, 2017
$
222.0

 
$
(10.8
)
 
$
(9.3
)
 
$
(10.7
)
 
$
191.2
XML 60 R33.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Taxes Effective tax rate (Tables)
 9 Months Ended
Sep. 30, 2017
Effective tax rate [Abstract]  
Schedule of effective income tax rate reconciliation
The effective tax rates were as follows:
Three Months Ended
 
Nine Months Ended
September 30,
2017
 
October 1,
2016
 
September 30,
2017
 
October 1,
2016
65.5
%
 
16.4
%
 
68.7
%
 
17.2
%
XML 61 R34.htm IDEA: XBRL DOCUMENT v3.8.0.1
Restructuring Charges (Tables)
 9 Months Ended
Sep. 30, 2017
Restructuring Charges [Abstract]  
Restructuring and related costs
The following reflects our restructuring activity (in millions):
 
Three Months Ended
 
Nine Months Ended
 
September 30,
2017
 
October 1,
2016
 
September 30,
2017
 
October 1,
2016
Beginning balance
$
39.7

 
$
12.2

 
$
19.7

 
$
20.7

Additional charges
3.8

 
6.6

 
54.7

 
17.9

Payments
(17.8
)
 
(8.6
)
 
(47.6
)
 
(33.3
)
Non-cash adjustments
0.4

 
0.1

 
(0.7
)
 
5.0

Ending balance
$
26.1

 
$
10.3

 
$
26.1

 
$
10.3
XML 62 R35.htm IDEA: XBRL DOCUMENT v3.8.0.1
Segment Information (Tables)
 9 Months Ended
Sep. 30, 2017
Segment Reporting [Abstract]  
Schedule of segment reporting information, by segment
The below tables show select financial measures by reporting segment (in millions):
 
 
Total Assets
 
 
September 30,
2017
 
December 31,
2016
CHCA
 
$
3,833.7

 
$
3,351.3

CHCI
 
5,114.2

 
4,795.2

RX
 
2,597.0

 
2,646.4

Specialty Sciences
 
—

 
2,775.8

Other
 
297.7

 
301.4

Total
 
$
11,842.6

 
$
13,870.1

 
Three Months Ended
 
September 30, 2017
 
October 1, 2016
 
Net
Sales
 
Operating Income (Loss)
 
Intangible Asset Amortization
 
Net
Sales
 
Operating Income (Loss)
 
Intangible Asset Amortization
CHCA
$
598.8

 
$
124.3

 
$
16.9

 
$
611.2

 
$
99.0

 
$
17.6

CHCI
365.4

 
4.6

 
50.2

 
377.4

 
(1,615.5
)
 
44.4

RX
250.6

 
82.1

 
21.0

 
251.9

 
74.4

 
27.2

Specialty Sciences
—

 
—

 
—

 
—

 
3.2

 
—

Other
16.5

 
(0.4
)
 
0.4

 
21.1

 
(1.5
)
 
0.5

Unallocated
—

 
(48.2
)
 
—

 
—

 
(27.9
)
 
—

Total
$
1,231.3

 
$
162.4

 
$
88.5

 
$
1,261.6

 
$
(1,468.3
)
 
$
89.7



 
Nine Months Ended
 
September 30, 2017
 
October 1, 2016
 
Net
Sales
 
Operating Income (Loss)
 
Intangible Asset Amortization
 
Net
Sales
 
Operating Income (Loss)
 
Intangible Asset Amortization
CHCA
$
1,786.4

 
$
303.6

 
$
51.1

 
$
1,880.2

 
$
316.4

 
$
53.3

CHCI
1,116.8

 
8.7

 
143.4

 
1,232.7

 
(2,011.3
)
 
130.6

RX
708.4

 
239.6

 
65.6

 
776.9

 
258.3

 
78.6

Specialty Sciences
—

 
—

 
—

 
—

 
(1.9
)
 
—

Other
51.5

 
9.4

 
1.2

 
59.5

 
2.6

 
1.4

Unallocated
—

 
(121.7
)
 
—

 
—

 
(79.2
)
 
—

Total
$
3,663.1

 
$
439.6

 
$
261.3

 
$
3,949.3

 
$
(1,515.1
)
 
$
263.9
XML 63 R36.htm IDEA: XBRL DOCUMENT v3.8.0.1
Discontinued operations (Tables)
 9 Months Ended
Sep. 30, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
Disposal groups, including discontinued operations
The amounts consist of the following (in millions):
 
September 30,
2017
 
December 31,
2016
 
Other
 
CHCA
 
Other
Assets held for sale
 
 
 
 
 
Current assets
$
44.0

 
$
—

 
$
5.1

Goodwill
32.6

 
—

 
5.5

Intangible assets
5.5

 
—

 
—

Property, plant and equipment
45.9

 
13.5

 
33.2

Other assets
3.1

 
—

 
3.8

Less: impairment reserves
(3.3
)
 
(3.7
)
 
(35.3
)
Total assets held for sale
$
127.8

 
$
9.8

 
$
12.3

Liabilities held for sale
 
 
 
 
 
Current liabilities
$
7.6

 
$
0.1

 
$
1.9

Other liabilities
25.1

 
—

 
1.9

Total liabilities held for sale
$
32.7

 
$
0.1

 
$
3.8
XML 64 R37.htm IDEA: XBRL DOCUMENT v3.8.0.1
Divestitures (Details)
€ in Millions, $ in Millions
 3 Months Ended 9 Months Ended 12 Months Ended
Aug. 25, 2017
USD ($)
Aug. 25, 2017
EUR (€)
Apr. 06, 2017
USD ($)
Feb. 01, 2017
USD ($)
Jan. 03, 2017
USD ($)
Aug. 05, 2016
USD ($)
Sep. 30, 2017
USD ($)
Jul. 01, 2017
USD ($)
Sep. 30, 2017
USD ($)
Oct. 01, 2016
USD ($)
Dec. 31, 2016
USD ($)
Business Acquisition [Line Items]                      
Net proceeds from sale of business and other assets                 $ 46.7 $ 58.5  
RX                      
Business Acquisition [Line Items]                      
Net proceeds from sale of business and other assets         $ 15.0            
CHCA                      
Business Acquisition [Line Items]                      
Net proceeds from sale of business and other assets       $ 7.7   $ 61.8          
Impairment charge                     $ 6.2
Other                      
Business Acquisition [Line Items]                      
Net proceeds from sale of business and other assets     $ 22.2                
Impairment charge             $ 3.3       $ 35.3
CHCI                      
Business Acquisition [Line Items]                      
Net proceeds from sale of business and other assets $ 15.1                    
Impairment charge               $ 3.7      
Euro Member Countries, Euro | CHCI                      
Business Acquisition [Line Items]                      
Net proceeds from sale of business and other assets | €   € 12.7                  
XML 65 R38.htm IDEA: XBRL DOCUMENT v3.8.0.1
Goodwill and Other Intangible Assets - Goodwill (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Apr. 02, 2016
Sep. 30, 2017
Goodwill [Roll Forward]    
December 31, 2016   $ 4,049.4
Goodwill, Written off Related to Sale of Business Unit   4.1
Goodwill, transfers   (32.6)
Currency translation adjustment   139.3
September 30, 2017   4,152.0
CHCI    
Goodwill [Roll Forward]    
December 31, 2016   1,070.8
Goodwill, Written off Related to Sale of Business Unit   4.1
Goodwill, transfers   0.0
Currency translation adjustment   122.3
September 30, 2017   1,189.0
Goodwill impairment charge $ 130.5  
CHCA    
Goodwill [Roll Forward]    
December 31, 2016   1,810.6
Goodwill, Written off Related to Sale of Business Unit   0.0
Goodwill, transfers   0.0
Currency translation adjustment   2.9
September 30, 2017   1,813.5
RX    
Goodwill [Roll Forward]    
December 31, 2016   1,086.6
Goodwill, Written off Related to Sale of Business Unit   0.0
Goodwill, transfers   0.0
Currency translation adjustment   6.5
September 30, 2017   1,093.1
Other    
Goodwill [Roll Forward]    
December 31, 2016   81.4
Goodwill, Written off Related to Sale of Business Unit   0.0
Goodwill, transfers   (32.6)
Currency translation adjustment   7.6
September 30, 2017   $ 56.4
XML 66 R39.htm IDEA: XBRL DOCUMENT v3.8.0.1
Goodwill and Other Intangible Assets - Intangible categories (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Oct. 01, 2016
Apr. 02, 2016
Sep. 30, 2017
Oct. 01, 2016
Jul. 01, 2017
Dec. 31, 2016
Oct. 02, 2016
Apr. 03, 2016
Finite And Indefinite Lived Assets By Major Class [Line Items]                  
Gross $ 4,621.5     $ 4,621.5     $ 4,417.2    
Accumulated Amortization 1,274.1     1,274.1     1,020.4    
Indefinite-lived intangibles: 103.4     103.4     114.5    
Total other intangible assets 4,724.9     4,724.9     4,531.7    
Intangible assets amortization expense 88.5 $ 89.7   261.3 $ 263.9        
Indefinite-lived intangible assets(2)   674.4     $ 674.4     $ 674.2 $ 364.5
Useful life of intangible asset         20 years        
Trademarks, trade names, and brands                  
Finite And Indefinite Lived Assets By Major Class [Line Items]                  
Indefinite-lived intangibles: 52.0     52.0     50.5    
In-process research and development                  
Finite And Indefinite Lived Assets By Major Class [Line Items]                  
Indefinite-lived intangibles: 51.4     51.4     64.0    
Impairment of intangible assets       12.7          
Distribution and license agreements, supply agreements                  
Finite And Indefinite Lived Assets By Major Class [Line Items]                  
Gross 310.2     310.2     305.6    
Accumulated Amortization 157.5     157.5     120.4    
Developed product technology, formulations, and product rights                  
Finite And Indefinite Lived Assets By Major Class [Line Items]                  
Gross 1,355.4     1,355.4     1,418.1    
Accumulated Amortization 568.8     568.8     526.0    
Customer relationships and distribution networks                  
Finite And Indefinite Lived Assets By Major Class [Line Items]                  
Gross 1,623.7     1,623.7     1,489.9    
Accumulated Amortization 424.5     424.5     307.5    
Trademarks, trade names, and brands                  
Finite And Indefinite Lived Assets By Major Class [Line Items]                  
Gross 1,317.5     1,317.5     1,189.3    
Accumulated Amortization 111.0     111.0     55.3    
Non-compete agreements                  
Finite And Indefinite Lived Assets By Major Class [Line Items]                  
Gross 14.7     14.7     14.3    
Accumulated Amortization 12.3     12.3     $ 11.2    
Omega | Brands                  
Finite And Indefinite Lived Assets By Major Class [Line Items]                  
Impairment of intangible assets   575.7 $ 273.4            
Impairment of Intangible Assets, Finite-lived         $ 290.9        
RX                  
Finite And Indefinite Lived Assets By Major Class [Line Items]                  
Gross           $ 0.0      
Intangible assets amortization expense $ 21.0 $ 27.2   65.6 $ 78.6        
Impairment of Intangible Assets, Finite-lived       $ 18.5          
XML 67 R40.htm IDEA: XBRL DOCUMENT v3.8.0.1
Accounts Receivable Factoring (Details) - USD ($)
$ in Millions
Sep. 30, 2017
Dec. 31, 2016
Accounts receivable factored and excluded from balance sheet $ 24.3 $ 50.7
Minimum    
Financial asset servicing fees paid 0.14%  
Maximum    
Financial asset servicing fees paid 0.15%  
XML 68 R41.htm IDEA: XBRL DOCUMENT v3.8.0.1
Inventories (Details) - USD ($)
$ in Millions
Sep. 30, 2017
Dec. 31, 2016
Inventory Disclosure [Abstract]    
Finished goods $ 471.4 $ 431.1
Work in process 146.8 165.7
Raw materials 203.7 198.2
Total inventories $ 821.9 $ 795.0
XML 69 R42.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurements - Financial Instruments at Fair Value (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Mar. 27, 2017
Oct. 01, 2016
Apr. 02, 2016
Sep. 30, 2017
Oct. 01, 2016
Jul. 01, 2017
Dec. 31, 2016
Oct. 02, 2016
Jul. 02, 2016
Apr. 03, 2016
Dec. 31, 2015
Assets:                      
Financial assets       $ 0.0     $ 2,350.0        
Indefinite-lived intangible assets(2)   $ 674.4     $ 674.4     $ 674.2   $ 364.5  
Liabilities:                      
Indefinite-lived intangibles carrying amount       103.4     114.5        
Finite-lived intangible assets       4,621.5     4,417.2        
Net proceeds from sale of business and other assets       46.7 58.5            
Measured at fair value on a recurring basis: | Level 1                      
Assets:                      
Investment securities       6.1     38.2        
Measured at fair value on a recurring basis: | Level 2                      
Assets:                      
Foreign currency forward contracts       13.1     3.8        
Funds associated with Israeli severance liability       16.1     15.9        
Total level 3 assets       29.2     19.7        
Liabilities:                      
Foreign currency forward contracts       3.3     5.0        
Measured at fair value on a recurring basis: | Level 3                      
Assets:                      
Financial assets       0.0     2,350.0        
Total level 3 assets       143.2     2,350.0        
Measured at fair value on a non-recurring basis: | Level 3                      
Assets:                      
Goodwill(1)       0.0     1,148.4 [1]        
Indefinite-lived intangible assets(2) [2]       13.3     0.3        
Definite-lived intangible assets(3)       11.5 [3]   $ 11.5 758.0 [3]        
Assets held for sale, net       95.1     18.2        
Total level 3 assets       119.9     1,924.9        
Liabilities:                      
Goodwill             2,200.0        
Indefinite-lived intangibles carrying amount       26.0     0.7        
Contingent consideration | Measured at fair value on a recurring basis: | Level 3                      
Liabilities:                      
Contingent Consideration   75.0   44.9 75.0 49.7 69.9   $ 44.9   $ 17.9
Accounts Receivable [Member] | Measured at fair value on a recurring basis: | Level 3                      
Assets:                      
Royalty Pharma contingent milestone payments       $ 143.2   $ 145.8 $ 0.0        
Omega | Brands                      
Liabilities:                      
Impairment of intangible assets   $ 575.7 $ 273.4                
Definite lived asset impairment         $ 290.9            
Royalty Pharma                      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Sale price of divestiture - cash plus non-cash $ 2,850.0                    
Liabilities:                      
Net proceeds from sale of business and other assets 2,200.0                    
Contingent Proceeds from Divestiture of Business, Milestone One, Maximum 250.0                    
Contingent Proceeds from Divestiture of Business, Milestone Two, Maximum $ 400.0                    
[1] (1) As of December 31, 2016, goodwill with a carrying amount of $2.2 billion was written down to its implied fair value of $1.1 billion
[2] (2) As of September 30, 2017, indefinite-lived intangible assets with a carrying amount of $26.0 million were written down to a fair value of $13.3 million. As of December 31, 2016, indefinite-lived intangible assets with a carrying amount of $0.7 million were written down to a fair value of $0.3 million.
[3] (3) As of July 1, 2017, definite-lived intangible assets with a carrying amount of $31.1 million were written down to a fair value of $11.5 million. As of December 31, 2016, definite-lived intangible assets with a carrying amount of $2.3 billion were written down to a fair value of $758.0 million. Included in this balance are indefinite-lived intangible assets with a fair value of $364.5 million and $674.2 million that were reclassified to definite-lived assets at April 3, 2016 and October 2, 2016, respectively.
XML 70 R43.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurements - Additional Information (Details)
 3 Months Ended 9 Months Ended 12 Months Ended
Aug. 25, 2017
USD ($)
Mar. 27, 2017
USD ($)
Jan. 03, 2017
USD ($)
Dec. 18, 2013
Sep. 30, 2017
USD ($)
Jul. 01, 2017
USD ($)
Dec. 31, 2016
USD ($)
Oct. 01, 2016
USD ($)
Jul. 02, 2016
USD ($)
Apr. 02, 2016
USD ($)
Dec. 31, 2015
Sep. 30, 2017
USD ($)
segments
Oct. 01, 2016
USD ($)
Dec. 31, 2016
USD ($)
May 01, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                              
Finite-lived intangible assets         $ 4,621,500,000   $ 4,417,200,000         $ 4,621,500,000   $ 4,417,200,000  
Fair Value, Assets, Level 1, Level 2, Level 3 Transfers, Amount         0             0   0  
Net gain on reduction of contingent consideration                       $ 17,000,000      
Number of reporting units | segments                       7      
Average growth rate             (2.00%) (2.00%)     (3.40%)        
Change in financial assets         2,600,000   $ (1,100,000,000) $ 377,400,000 $ 910,800,000 $ 204,400,000   $ 24,200,000 $ 1,492,600,000    
Royalty stream discrete period                       20      
Senior notes         3,255,800,000   5,373,100,000         $ 3,255,800,000   5,373,100,000  
Net proceeds from sale of business and other assets                       46,700,000 58,500,000    
Measured at fair value on a non-recurring basis: | Level 3                              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                              
Definite-lived intangible assets(3)         11,500,000 [1] $ 11,500,000 758,000,000 [1]         11,500,000 [1]   758,000,000 [1]  
RX                              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                              
Finite-lived intangible assets           0                  
Definite lived asset impairment                       18,500,000      
Net proceeds from sale of business and other assets     $ 15,000,000                        
Specialty Sciences [Member]                              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                              
Gain on sale of unit   $ 17,100,000                          
CHCI                              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                              
Finite-lived intangible assets             2,300,000,000             2,300,000,000  
Goodwill impairment charge                   130,500,000          
Net proceeds from sale of business and other assets $ 15,100,000                            
Omega | Brands                              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                              
Impairment of intangible assets               575,700,000   $ 273,400,000          
Definite lived asset impairment                         $ 290,900,000    
Elan                              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                              
Effective date of acquisition       Dec. 18, 2013                      
Public Bonds and Private Placement                              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                              
Senior notes         2,600,000,000   4,600,000,000         2,600,000,000   4,600,000,000  
Public Bonds and Private Placement | Level 1                              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                              
Fair value of fixed-rate long-term debt         2,700,000,000   4,600,000,000         2,700,000,000   4,600,000,000  
Retail Bonds                              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                              
Long term debt         655,800,000   773,100,000         655,800,000   773,100,000  
Unamortized debt premium         35,600,000   49,800,000         35,600,000   49,800,000  
Retail Bonds | Level 2                              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                              
Fair value of fixed-rate long-term debt         699,200,000   825,000,000         699,200,000   $ 825,000,000  
Tysabri®                              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                              
Percent of royalty revenues generated by specific agreement                             12.00%
Minimum | Tysabri®                              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                              
Percent of royalty revenues generated by specific agreement                           18.00%  
Net sales                           $ 2,000,000,000  
Maximum | Tysabri®                              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                              
Percent of royalty revenues generated by specific agreement                           25.00%  
Net sales                           $ 2,000,000,000  
Accounts Receivable [Member] | Measured on a recurring basis | Level 3                              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                              
Change in fair value         (2,900,000)             (42,100,000)      
Royalty Pharma contingent milestone payments         $ 143,200,000 $ 145,800,000 0         $ 143,200,000   $ 0  
Goodwill | Minimum                              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                              
Discount rate                           7.00%  
Long-term growth rates                           2.00%  
Goodwill | Maximum                              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                              
Discount rate                           14.50%  
Long-term growth rates                           3.00%  
Royalty Pharma                              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                              
Sale price of divestiture - cash plus non-cash   2,850,000,000                          
Net proceeds from sale of business and other assets   2,200,000,000                          
Proceeds from sale of business, maximum milestone payments in year two   250,000,000                          
Proceeds from sale of business, maximum milestone payments in year four   $ 400,000,000                          
Volatility rate         30.00% 30.00%                  
Rate of return         8.06% 8.05%                  
Royalties receivable             $ 84,400,000             $ 84,400,000  
BCH - ROW [Member] | CHCI                              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                              
Goodwill impairment charge               $ 675,600,000              
[1] (3) As of July 1, 2017, definite-lived intangible assets with a carrying amount of $31.1 million were written down to a fair value of $11.5 million. As of December 31, 2016, definite-lived intangible assets with a carrying amount of $2.3 billion were written down to a fair value of $758.0 million. Included in this balance are indefinite-lived intangible assets with a fair value of $364.5 million and $674.2 million that were reclassified to definite-lived assets at April 3, 2016 and October 2, 2016, respectively.
XML 71 R44.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurements - Reconciliation of Level 3 Liabilities (Details) - Measured on a recurring basis - Level 3 - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Oct. 01, 2016
Sep. 30, 2017
Oct. 01, 2016
Jul. 01, 2017
Dec. 31, 2016
Jul. 02, 2016
Dec. 31, 2015
Contingent consideration                
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]                
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases $ 0.0 $ 30.6 $ 0.0 $ 61.1        
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Gain (Loss) Included in Other Comprehensive Income (Loss) 0.2 0.0 1.5 0.1        
Contingent Consideration                
Contingent Consideration 44.9 75.0 44.9 75.0 $ 49.7 $ 69.9 $ 44.9 $ 17.9
Net realized losses (2.9) (0.4) (18.5) (4.0)        
Settlements (2.1) $ (0.1) (8.0) $ (0.1)        
Accounts Receivable [Member]                
Royalty Pharma Contingent Milestone Payments                
Royalty Pharma contingent milestone payments 143.2   143.2   $ 145.8 $ 0.0    
Additions $ 0.0   $ 184.5          
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset and Liability, Gain (Loss) Included in Other Comprehensive Income (Loss), Description 0.3   0.8          
Change in fair value $ (2.9)   $ (42.1)          
XML 72 R45.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurements - Fair Value Inputs (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended 12 Months Ended
Dec. 31, 2016
Oct. 01, 2016
Apr. 02, 2016
Dec. 31, 2015
Sep. 30, 2017
Dec. 31, 2016
Fair Value Inputs, Assets, Quantitative Information [Line Items]            
5-year average growth rate 2.00% 2.00%   3.40%    
Lumara-Clindesse [Member]            
Fair Value Inputs, Assets, Quantitative Information [Line Items]            
5-year average growth rate         (4.10%)  
Discount rate         13.50%  
Omega - XLS            
Fair Value Inputs, Assets, Quantitative Information [Line Items]            
5-year average growth rate           3.20%
Discount rate           9.50%
Royalty rate           4.00%
Entocort® - Branded Products            
Fair Value Inputs, Assets, Quantitative Information [Line Items]            
5-year average growth rate           (31.70%)
Long-term growth rates           (10.00%)
Discount rate           13.00%
Entocort® - AG Products            
Fair Value Inputs, Assets, Quantitative Information [Line Items]            
5-year average growth rate           (30.40%)
Long-term growth rates           (4.70%)
Discount rate           10.50%
Herron Trade names and Trademarks            
Fair Value Inputs, Assets, Quantitative Information [Line Items]            
5-year average growth rate           4.60%
Long-term growth rates           2.50%
Discount rate           10.80%
Royalty rate           11.00%
Omega-Lifestyle [Member]            
Fair Value Inputs, Assets, Quantitative Information [Line Items]            
5-year average growth rate           2.50%
Long-term growth rates           2.00%
Discount rate           9.30%
CHCI            
Fair Value Inputs, Assets, Quantitative Information [Line Items]            
Goodwill impairment charge     $ 130.5      
BCH - Belgium [Member] | CHCI            
Fair Value Inputs, Assets, Quantitative Information [Line Items]            
Goodwill impairment charge   $ 62.3        
XML 73 R46.htm IDEA: XBRL DOCUMENT v3.8.0.1
Investments (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Oct. 01, 2016
Sep. 30, 2017
Oct. 01, 2016
Dec. 31, 2016
Unrealized Gain (Loss) on Investments [Abstract]          
Impairment of investments       $ 1.8  
Gain on sale of investments     $ 1.6    
Gains (loss) from equity method investments $ (0.1) $ 0.1 0.2 (3.8)  
Equity method investment, other than temporary impairment       22.3  
Transfer from investments       15.5  
Unrealized gain (loss) on investments       $ 8.7  
Estimated fair value of equity securities          
Unrealized Gain (Loss) on Investments [Abstract]          
Equity securities, at cost less impairments 15.5   15.5   $ 16.5
Gross unrealized gains 0.0   0.0   21.7
Gross unrealized losses 9.4   9.4   0.0
Estimated fair value of equity securities 6.1   6.1   38.2
Other non-current assets          
Unrealized Gain (Loss) on Investments [Abstract]          
Cost method investments 7.2   7.2   6.9
Equity method investments $ 4.8   $ 4.8   $ 4.6
XML 74 R47.htm IDEA: XBRL DOCUMENT v3.8.0.1
Derivative Instruments and Hedging Activities - Additional Information (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Jun. 15, 2017
Jun. 14, 2017
Sep. 30, 2017
Jul. 01, 2017
Oct. 01, 2016
Apr. 02, 2016
Sep. 30, 2017
Oct. 01, 2016
Dec. 31, 2016
Dec. 31, 2015
Derivative [Line Items]                    
Principal Retired             $ 2,243.7      
Proceeds from issuance of debt           $ 1,200.0        
Loss on derivatives       $ 5.9   $ 7.0        
Designated derivatives:                    
Derivative [Line Items]                    
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion)     $ (0.5)   $ (1.4)   (6.7) $ (0.3)    
Non-designated derivatives:                    
Derivative [Line Items]                    
Loss on derivatives     (8.3)   1.2   $ 6.7 10.2    
Interest rate swap agreements | Designated derivatives:                    
Derivative [Line Items]                    
Notional amount of derivatives                   $ 200.0
Foreign currency forward contracts                    
Derivative [Line Items]                    
Maximum remaining maturity of foreign currency derivatives             18 months      
Foreign exchange contract                    
Derivative [Line Items]                    
Notional amount of derivatives     578.3       $ 578.3   $ 533.5  
Other (income) expense, net | Treasury locks | Designated derivatives:                    
Derivative [Line Items]                    
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion)     0.0   0.0   0.0 (0.1)    
Other (income) expense, net | Interest rate swap agreements | Designated derivatives:                    
Derivative [Line Items]                    
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion)     (0.4)   (0.6)   (1.7) (1.7)    
Other (income) expense, net | Foreign currency forward contracts | Designated derivatives:                    
Derivative [Line Items]                    
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion)     (0.7)   (0.4)   (1.8) (1.3)    
Other (income) expense, net | Foreign currency forward contracts | Non-designated derivatives:                    
Derivative [Line Items]                    
Loss on derivatives     1.8   1.0   2.9 1.5    
Net sales | Foreign currency forward contracts | Designated derivatives:                    
Derivative [Line Items]                    
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion)     0.0   (0.1)   0.9 0.3    
Cost of sales | Foreign currency forward contracts | Designated derivatives:                    
Derivative [Line Items]                    
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion)     1.8   0.9   3.5 1.8    
Other (income) expense, net | Interest rate swap agreements | Designated derivatives:                    
Derivative [Line Items]                    
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion)     0.0   0.0   (5.9) 0.0    
Other (income) expense, net | Foreign currency forward contracts | Designated derivatives:                    
Derivative [Line Items]                    
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion)     (1.2)   (1.2)   (1.7) 0.7    
Other (income) expense, net | Foreign currency forward contracts | Non-designated derivatives:                    
Derivative [Line Items]                    
Loss on derivatives     $ (10.1)   $ 0.2   $ 3.8 $ 8.7    
4.00% unsecured Senior Notes due November 15, 2023 [Member]                    
Derivative [Line Items]                    
Principal Retired $ 584.4 $ 584.4                
5.30% unsecured senior notes due November 15, 2043 [Member]                    
Derivative [Line Items]                    
Principal Retired $ 309.5 $ 309.5                
XML 75 R48.htm IDEA: XBRL DOCUMENT v3.8.0.1
Derivative Instruments and Hedging Activities - Balance Sheet Location (Details) - Foreign currency forward contracts - USD ($)
$ in Millions
Sep. 30, 2017
Dec. 31, 2016
Designated derivatives: | Other current assets    
Derivatives, Fair Value [Line Items]    
Asset Derivatives $ 4.6 $ 3.1
Designated derivatives: | Accrued liabilities    
Derivatives, Fair Value [Line Items]    
Liability Derivatives 2.6 3.0
Non-designated derivatives: | Other current assets    
Derivatives, Fair Value [Line Items]    
Asset Derivatives 8.5 0.7
Non-designated derivatives: | Accrued liabilities    
Derivatives, Fair Value [Line Items]    
Liability Derivatives $ 0.7 $ 2.0
XML 76 R49.htm IDEA: XBRL DOCUMENT v3.8.0.1
Derivative Instruments and Hedging Activities - Other Comprehensive Income Movement (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Oct. 01, 2016
Sep. 30, 2017
Oct. 01, 2016
Reclassification Adjustment out of Accumulated Other Comprehensive Income on (Loss) Derivatives [Line Items]        
Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months $ 2.8   $ 2.8  
Amount of Gain/(Loss) Recognized against Earnings (Ineffective Portion) 0.3 $ 0.0 1.2 $ 0.6
Net sales | Foreign currency forward contracts        
Reclassification Adjustment out of Accumulated Other Comprehensive Income on (Loss) Derivatives [Line Items]        
Amount of Gain/(Loss) Recognized against Earnings (Ineffective Portion) 0.2 0.0 0.1 0.1
Cost of sales | Foreign currency forward contracts        
Reclassification Adjustment out of Accumulated Other Comprehensive Income on (Loss) Derivatives [Line Items]        
Amount of Gain/(Loss) Recognized against Earnings (Ineffective Portion) 0.1 0.0 0.1 0.0
Other (income) expense, net | Interest rate swap agreements        
Reclassification Adjustment out of Accumulated Other Comprehensive Income on (Loss) Derivatives [Line Items]        
Amount of Gain/(Loss) Recognized against Earnings (Ineffective Portion) 0.0 0.0 0.0 (0.1)
Other (income) expense, net | Foreign currency forward contracts        
Reclassification Adjustment out of Accumulated Other Comprehensive Income on (Loss) Derivatives [Line Items]        
Amount of Gain/(Loss) Recognized against Earnings (Ineffective Portion) 0.0 0.0 1.0 0.6
Designated derivatives:        
Reclassification Adjustment out of Accumulated Other Comprehensive Income on (Loss) Derivatives [Line Items]        
Amount of Gain/(Loss) Recorded in OCI (Effective Portion) 1.1 3.4 6.3 (4.3)
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion) (0.5) (1.4) (6.7) (0.3)
Designated derivatives: | Interest rate swap agreements        
Reclassification Adjustment out of Accumulated Other Comprehensive Income on (Loss) Derivatives [Line Items]        
Amount of Gain/(Loss) Recorded in OCI (Effective Portion) 0.0 0.0 0.0 (9.0)
Designated derivatives: | Foreign currency forward contracts        
Reclassification Adjustment out of Accumulated Other Comprehensive Income on (Loss) Derivatives [Line Items]        
Amount of Gain/(Loss) Recorded in OCI (Effective Portion) 1.1 3.4 6.3 4.7
Designated derivatives: | Other (income) expense, net | Interest rate swap agreements        
Reclassification Adjustment out of Accumulated Other Comprehensive Income on (Loss) Derivatives [Line Items]        
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion) (0.4) (0.6) (1.7) (1.7)
Designated derivatives: | Other (income) expense, net | Foreign currency forward contracts        
Reclassification Adjustment out of Accumulated Other Comprehensive Income on (Loss) Derivatives [Line Items]        
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion) (0.7) (0.4) (1.8) (1.3)
Designated derivatives: | Net sales | Foreign currency forward contracts        
Reclassification Adjustment out of Accumulated Other Comprehensive Income on (Loss) Derivatives [Line Items]        
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion) 0.0 (0.1) 0.9 0.3
Designated derivatives: | Cost of sales | Foreign currency forward contracts        
Reclassification Adjustment out of Accumulated Other Comprehensive Income on (Loss) Derivatives [Line Items]        
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion) 1.8 0.9 3.5 1.8
Designated derivatives: | Other (income) expense, net | Interest rate swap agreements        
Reclassification Adjustment out of Accumulated Other Comprehensive Income on (Loss) Derivatives [Line Items]        
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion) 0.0 0.0 (5.9) 0.0
Designated derivatives: | Other (income) expense, net | Foreign currency forward contracts        
Reclassification Adjustment out of Accumulated Other Comprehensive Income on (Loss) Derivatives [Line Items]        
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion) $ (1.2) $ (1.2) $ (1.7) $ 0.7
XML 77 R50.htm IDEA: XBRL DOCUMENT v3.8.0.1
Derivative Instruments and Hedging Activities - Non-designated Derivatives (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Jul. 01, 2017
Oct. 01, 2016
Apr. 02, 2016
Sep. 30, 2017
Oct. 01, 2016
Derivative Instruments, Gain (Loss) [Line Items]            
Amount of Gain/(Loss) Recognized against Earnings   $ (5.9)   $ (7.0)    
Non-designated derivatives:            
Derivative Instruments, Gain (Loss) [Line Items]            
Amount of Gain/(Loss) Recognized against Earnings $ 8.3   $ (1.2)   $ (6.7) $ (10.2)
Foreign currency forward contracts | Other (income) expense, net | Non-designated derivatives:            
Derivative Instruments, Gain (Loss) [Line Items]            
Amount of Gain/(Loss) Recognized against Earnings 10.1   (0.2)   (3.8) (8.7)
Foreign currency forward contracts | Other (income) expense, net | Non-designated derivatives:            
Derivative Instruments, Gain (Loss) [Line Items]            
Amount of Gain/(Loss) Recognized against Earnings $ (1.8)   $ (1.0)   $ (2.9) $ (1.5)
XML 78 R51.htm IDEA: XBRL DOCUMENT v3.8.0.1
Assets Held for Sale (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2017
Sep. 30, 2017
Dec. 31, 2016
Other      
Less: impairment reserves $ (3.3)   $ (35.3)
CHCA      
Less: impairment reserves     (6.2)
Discontinued operations, held-for-sale | Other      
Current assets 44.0 $ 44.0 5.1
Goodwill 32.6 32.6 5.5
Intangible assets 5.5 5.5 0.0
Property, plant and equipment 45.9 45.9 33.2
Other assets 3.1 3.1 3.8
Less: impairment reserves   (3.3) (35.3)
Total assets held for sale 127.8 127.8 12.3
Current liabilities 7.6 7.6 1.9
Other liabilities 25.1 25.1 1.9
Total liabilities held for sale $ 32.7 $ 32.7 3.8
Discontinued operations, held-for-sale | CHCA      
Current assets     0.0
Goodwill     0.0
Intangible assets     0.0
Property, plant and equipment     13.5
Other assets     0.0
Less: impairment reserves     (3.7)
Total assets held for sale     9.8
Current liabilities     0.1
Other liabilities     0.0
Total liabilities held for sale     0.1
API [Member] | Other      
Less: impairment reserves     (6.3)
Animal Health pet treats [Member] | CHCA      
Less: impairment reserves     $ (3.7)
XML 79 R52.htm IDEA: XBRL DOCUMENT v3.8.0.1
Indebtedness (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Jun. 15, 2017
Jun. 14, 2017
May 23, 2017
May 08, 2017
Sep. 30, 2017
Jul. 01, 2017
Apr. 01, 2017
Oct. 01, 2016
Sep. 30, 2017
Oct. 01, 2016
Dec. 31, 2016
Dec. 05, 2014
Debt Instrument [Line Items]                        
Other financing         $ 2.9       $ 2.9   $ 3.6  
Unamortized premium (discount), net         24.8       24.8   33.0  
Deferred financing fees         (19.0)       (19.0)   (33.1)  
Total borrowings outstanding         3,692.8       3,692.8   5,797.3  
Current indebtedness         (417.1)       (417.1)   (572.8)  
Long-term debt, less current portion         3,275.7       3,275.7   5,224.5  
Principal Retired                 2,243.7      
Senior notes         3,255.8       $ 3,255.8   5,373.1  
Debt instrument, covenant compliance                 yes      
Line of credit facility, fair value of amount outstanding         0.0       $ 0.0   0.0  
Premium on debt repayment                 116.1      
Transaction costs                 3.8      
Write-off of deferred financing fees                 10.6      
Write-off of remaining discount on bond                 4.7      
Loss on extinguishment of debt         0.0     $ 0.7 $ 135.2 $ 1.1    
2014 Revolver                        
Debt Instrument [Line Items]                        
Maximum borrowing capacity                       $ 1,000.0
2014 term loan due December 5, 2019                        
Debt Instrument [Line Items]                        
Series                 2014 term loan due December 5, 2019      
Transaction Type                 Scheduled quarterly payment      
Term loans [1]         428.3       $ 428.3   420.7  
Principal Retired         $ 14.8 $ 14.3 $ 13.3          
Debt instrument, date of repayment         Sep. 30, 2017 Jul. 01, 2017 Apr. 01, 2017          
4.500% unsecured senior notes due May 23, 2017                        
Debt Instrument [Line Items]                        
Interest rate, stated percentage         4.50%       4.50%      
Debt Instrument, Maturity Date                 May 23, 2017      
Senior notes [1],[2]         $ 0.0       $ 0.0   189.3  
5.125% unsecured senior notes due December 12, 2017                        
Debt Instrument [Line Items]                        
Interest rate, stated percentage         5.125%       5.125%      
Debt Instrument, Maturity Date                 Dec. 12, 2017      
Senior notes [1],[2]         $ 354.5       $ 354.5   315.6  
2.30% Unsecured Senior notes November 8, 2018 [Member]                        
Debt Instrument [Line Items]                        
Series                 $600.0 2.300% senior notes due 2018      
Transaction Type                 Early redemption      
Interest rate, stated percentage         2.30%       2.30%      
Principal Retired       $ 600.0                
Debt Instrument, Maturity Date                 Nov. 08, 2018      
Senior notes         $ 0.0       $ 0.0   600.0  
Debt instrument, date of repayment       May 08, 2017                
5.000% unsecured senior notes due May 23, 2019                        
Debt Instrument [Line Items]                        
Interest rate, stated percentage         5.00%       5.00%      
Debt Instrument, Maturity Date                 May 23, 2019      
Senior notes [1],[2]         $ 141.8       $ 141.8   126.2  
3.500% unsecured senior notes due March 15, 2021                        
Debt Instrument [Line Items]                        
Series                 $500.0 3.500% senior notes due 2021      
Transaction Type                 Tender offer      
Interest rate, stated percentage         3.50%       3.50%      
Principal Retired $ 219.6                      
Debt Instrument, Maturity Date                 Mar. 15, 2021      
Senior notes         $ 280.4       $ 280.4   500.0  
Debt instrument, date of repayment Jun. 15, 2017                      
3.5% Senior note due December 15, 2021 [Member]                        
Debt Instrument [Line Items]                        
Series                 $500.0 3.500% senior notes due 2021      
Transaction Type                 Tender offer      
Interest rate, stated percentage         3.50%       3.50%      
Principal Retired $ 190.4                      
Debt Instrument, Maturity Date                 Dec. 15, 2021      
Senior notes         $ 309.6       $ 309.6   500.0  
Debt instrument, date of repayment Jun. 15, 2017                      
5.105% senior note due July 19, 2023                        
Debt Instrument [Line Items]                        
Interest rate, stated percentage         5.1045%       5.1045%      
Debt Instrument, Maturity Date                 Jul. 19, 2023      
Senior notes [1],[2]         $ 159.5       $ 159.5   142.0  
4.00% unsecured Senior Notes due November 15, 2023 [Member]                        
Debt Instrument [Line Items]                        
Series                 $800.0 4.000% senior notes due 2023      
Transaction Type                 Tender offer      
Interest rate, stated percentage         4.00%       4.00%      
Principal Retired $ 584.4 $ 584.4                    
Debt Instrument, Maturity Date                 Nov. 15, 2023      
Senior notes         $ 215.6       $ 215.6   800.0  
Debt instrument, date of repayment Jun. 15, 2017                      
3.9% senior note due December 15, 2024                        
Debt Instrument [Line Items]                        
Interest rate, stated percentage         3.90%       3.90%      
Debt Instrument, Maturity Date                 Dec. 15, 2024      
Senior notes         $ 700.0       $ 700.0   700.0  
4.375% senior note due March 15, 2026                        
Debt Instrument [Line Items]                        
Interest rate, stated percentage         4.375%       4.375%      
Debt Instrument, Maturity Date                 Mar. 15, 2026      
Senior notes         $ 700.0       $ 700.0   700.0  
5.30% unsecured senior notes due November 15, 2043 [Member]                        
Debt Instrument [Line Items]                        
Series                 $400.0 5.300% senior notes due 2043      
Transaction Type                 Tender offer      
Interest rate, stated percentage         5.30%       5.30%      
Principal Retired $ 309.5 $ 309.5                    
Debt Instrument, Maturity Date                 Nov. 15, 2043      
Senior notes         $ 90.5       $ 90.5   400.0  
Debt instrument, date of repayment Jun. 15, 2017                      
4.9% senior notes due December 15, 2044                        
Debt Instrument [Line Items]                        
Series                 $400.0 4.900% senior notes due 2044      
Transaction Type                 Tender offer      
Interest rate, stated percentage         4.90%       4.90%      
Principal Retired $ 96.1                      
Debt Instrument, Maturity Date                 Dec. 15, 2044      
Senior notes         $ 303.9       $ 303.9   400.0  
Debt instrument, date of repayment Jun. 15, 2017                      
4.5% retail bonds                        
Debt Instrument [Line Items]                        
Principal Retired     $ 201.3                  
Overdraft [Member]                        
Debt Instrument [Line Items]                        
Line of credit facility, fair value of amount outstanding         $ 0.0       $ 0.0   $ 0.0  
Omega | 4.5% retail bonds                        
Debt Instrument [Line Items]                        
Transaction Type                 Scheduled maturity      
Debt instrument, date of repayment     May 23, 2017                  
Omega | 4.5% retail bonds | Euro Member Countries, Euro                        
Debt Instrument [Line Items]                        
Series                 €180.0 4.500% retail bonds due 2017      
[1] (1)Debt denominated in Euros subject to fluctuations in the euro-to-U.S. dollar exchange rate.
[2] (2)Debt assumed from Omega.
XML 80 R53.htm IDEA: XBRL DOCUMENT v3.8.0.1
Earnings Per Share (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Oct. 01, 2016
Sep. 30, 2017
Oct. 01, 2016
Oct. 22, 2015
Numerator:          
Net income (loss) $ 44.5 $ (1,590.2) $ 46.4 $ (2,653.7)  
Denominator:          
Weighted average shares outstanding for basic EPS 141,300,000 143,300,000 142,500,000 143,200,000  
Dilutive effect of share-based awards [1] 400,000 0 300,000 0  
Weighted average shares outstanding for diluted EPS 141,700,000 143,300,000 142,800,000 143,200,000  
Anti-dilutive share-based awards excluded from computation of diluted EPS 1,000,000 0 800,000 0  
Share-based compensation arrangement by share-based payment award, options, exercises in period 99,800 185,000 146,100 283,000  
Share price $ 71.73   $ 71.72    
Proceeds from (Repurchase of) Equity $ 133.3   $ 191.5    
Stock Repurchase Program, Remaining Authorized Repurchase Amount $ 1,300.0   $ 1,300.0    
Perrigo Co PLC [Member]          
Stock repurchase program, authorized amount         $ 2,000.0
Common Stock [Member]          
Stock repurchase program, number of shares repurchased 1,858,705   2,670,889 0  
[1] * In the period of a net loss, diluted shares equal basic shares.
XML 81 R54.htm IDEA: XBRL DOCUMENT v3.8.0.1
Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Oct. 01, 2016
Sep. 30, 2017
Oct. 01, 2016
Reclassification Adjustment out of Accumulated Other Comprehensive Income on (Loss) Derivatives [Line Items]        
Balance at December 31, 2016     $ (81.8)  
OCI before reclassifications     270.3  
Amounts reclassified from AOCI     2.7  
Other comprehensive income, net of tax $ 60.7 $ 40.7 273.0 $ 86.8
Balance at September 30, 2017 191.2   191.2  
Foreign currency translation adjustments        
Reclassification Adjustment out of Accumulated Other Comprehensive Income on (Loss) Derivatives [Line Items]        
Balance at December 31, 2016     (67.9)  
OCI before reclassifications     289.9  
Amounts reclassified from AOCI     0.0  
Other comprehensive income, net of tax     289.9  
Balance at September 30, 2017 222.0   222.0  
Fair value of derivative financial instruments, net of tax        
Reclassification Adjustment out of Accumulated Other Comprehensive Income on (Loss) Derivatives [Line Items]        
Balance at December 31, 2016     (19.5)  
OCI before reclassifications     4.4  
Amounts reclassified from AOCI     4.3  
Other comprehensive income, net of tax     8.7  
Balance at September 30, 2017 (10.8)   (10.8)  
Fair value of investment securities, net of tax        
Reclassification Adjustment out of Accumulated Other Comprehensive Income on (Loss) Derivatives [Line Items]        
Balance at December 31, 2016     15.1  
OCI before reclassifications     (22.8)  
Amounts reclassified from AOCI     (1.6)  
Other comprehensive income, net of tax     (24.4)  
Balance at September 30, 2017 (9.3)   (9.3)  
Post-retirement and pension liability adjustments, net of tax        
Reclassification Adjustment out of Accumulated Other Comprehensive Income on (Loss) Derivatives [Line Items]        
Balance at December 31, 2016     (9.5)  
OCI before reclassifications     (1.2)  
Amounts reclassified from AOCI     0.0  
Other comprehensive income, net of tax     (1.2)  
Balance at September 30, 2017 $ (10.7)   $ (10.7)  
XML 82 R55.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Taxes (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended 12 Months Ended
Aug. 15, 2017
Sep. 30, 2017
Oct. 01, 2016
Sep. 30, 2017
Oct. 01, 2016
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2010
Dec. 31, 2009
Dec. 31, 2016
Effective income tax rate reconciliation, percent   65.50% 16.40% 68.70% 17.20%          
Unrecognized tax benefits, including income tax penalties and interest accrued   $ 454.9   $ 454.9           $ 398.0
Unrecognized tax benefits liability, interest and penalties accrued   $ 79.0   $ 79.0           $ 63.5
Income tax examination, penalties and interest expense $ 163.6         $ 24.7 $ 40.2 $ 61.5 $ 37.2  
XML 83 R56.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and Contingencies (Details)
₪ in Millions, $ in Millions
Jun. 28, 2017
USD ($)
Jun. 28, 2017
ILS (₪)
Mar. 29, 2017
USD ($)
Mar. 29, 2017
ILS (₪)
Sep. 30, 2017
Commitments and Contingencies Disclosure [Abstract]          
Damages sought by plaintiff $ 760.0 ₪ 2,700.0 $ 192.0 ₪ 686.0  
Foreign currency exchange rate, remeasurement         0.0028
XML 84 R57.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaboration Agreements and Other Contractual Arrangements (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Oct. 01, 2016
Sep. 30, 2017
Oct. 01, 2016
Research and development $ 38.4 $ 50.2 $ 120.8 $ 142.5
XML 85 R58.htm IDEA: XBRL DOCUMENT v3.8.0.1
Restructuring Charges (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Oct. 01, 2016
Sep. 30, 2017
Oct. 01, 2016
Restructuring Reserve [Roll Forward]        
Beginning balance $ 39.7 $ 12.2 $ 19.7 $ 20.7
Additional charges 3.8 6.6 54.7 17.9
Payments (17.8) (8.6) (47.6) (33.3)
Non-cash adjustments 0.4 0.1 (0.7) 5.0
Ending balance 26.1 $ 10.3 26.1 $ 10.3
Employee severance [Member]        
Restructuring Reserve [Roll Forward]        
Ending balance 22.4   22.4  
Lease exit        
Restructuring Reserve [Roll Forward]        
Ending balance $ 3.7   3.7  
CHCA [Member]        
Restructuring Reserve [Roll Forward]        
Additional charges     $ 27.2  
XML 86 R59.htm IDEA: XBRL DOCUMENT v3.8.0.1
Segment Information (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Oct. 01, 2016
Sep. 30, 2017
Oct. 01, 2016
Dec. 31, 2016
Segment Reporting Information [Line Items]          
Total Assets $ 11,842.6   $ 11,842.6   $ 13,870.1
Net sales 1,231.3 $ 1,261.6 3,663.1 $ 3,949.3  
Operating Income (Loss) 162.4 (1,468.3) 439.6 (1,515.1)  
Intangible Asset Amortization 88.5 89.7 261.3 263.9  
CHCA          
Segment Reporting Information [Line Items]          
Total Assets 3,833.7   3,833.7   3,351.3
Net sales 598.8 611.2 1,786.4 1,880.2  
Operating Income (Loss) 124.3 99.0 303.6 316.4  
Intangible Asset Amortization 16.9 17.6 51.1 53.3  
CHCI          
Segment Reporting Information [Line Items]          
Total Assets 5,114.2   5,114.2   4,795.2
Net sales 365.4 377.4 1,116.8 1,232.7  
Operating Income (Loss) 4.6 (1,615.5) 8.7 (2,011.3)  
Intangible Asset Amortization 50.2 44.4 143.4 130.6  
RX          
Segment Reporting Information [Line Items]          
Total Assets 2,597.0   2,597.0   2,646.4
Net sales 250.6 251.9 708.4 776.9  
Operating Income (Loss) 82.1 74.4 239.6 258.3  
Intangible Asset Amortization 21.0 27.2 65.6 78.6  
Specialty Sciences          
Segment Reporting Information [Line Items]          
Total Assets 0.0   0.0   2,775.8
Net sales 0.0 0.0 0.0 0.0  
Operating Income (Loss) 0.0 3.2 0.0 (1.9)  
Intangible Asset Amortization 0.0 0.0 0.0 0.0  
Other          
Segment Reporting Information [Line Items]          
Total Assets 297.7   297.7   $ 301.4
Net sales 16.5 21.1 51.5 59.5  
Operating Income (Loss) (0.4) (1.5) 9.4 2.6  
Intangible Asset Amortization 0.4 0.5 1.2 1.4  
Unallocated          
Segment Reporting Information [Line Items]          
Net sales 0.0 0.0 0.0 0.0  
Operating Income (Loss) (48.2) (27.9) (121.7) (79.2)  
Intangible Asset Amortization $ 0.0 $ 0.0 $ 0.0 $ 0.0  
XML 87 R60.htm IDEA: XBRL DOCUMENT v3.8.0.1
Discontinued operations (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Oct. 01, 2016
Sep. 30, 2017
Oct. 01, 2016
Dec. 31, 2016
Dec. 31, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]            
Cash and cash equivalents $ 775.9 $ 362.7 $ 775.9 $ 362.7 $ 622.3 $ 417.8
Net sales 1,231.3 1,261.6 3,663.1 3,949.3    
Income (Loss) from Continuing Operations before Income Taxes, Domestic 128.7 (1,902.0) 148.2 (3,204.4)    
Income tax expense (benefit) 84.2 $ (311.8) 101.8 $ (550.7)    
Accounts receivable, net of allowance for doubtful accounts of $6.2 million and $6.3 million, respectively 1,076.6   1,076.6   1,176.0  
Inventories 821.9   821.9   795.0  
Prepaid expenses and other current assets 297.4   297.4   212.0  
Property, plant and equipment, net 822.3   822.3   870.1  
Financial assets 0.0   0.0   2,350.0  
Other intangible assets, net 3,347.4   3,347.4   3,396.8  
Other non-current assets 423.3   423.3   211.9  
Accounts payable $ 477.1   $ 477.1   $ 471.7  
EXCEL 88 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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�D^C=?'[WETDO"#"QLU-8N MOL&^-&A4(YNB]3?4363B15>X$$N,-LI%H5D2\O_WI?R\@1+]ELCOEZ8],N- MTH#X76M;2;@9@T'AB""I4ZT)F33OLW>L%66RF VU+JW6W(1V)LVEN0>#1?]% MM=GCLLPO0 HQ.POM\*53N?VV-X\,Q"^MS=9;%EV%(1Q!U>CO6-8)9V4O/R&& MBZR(O5QL>T^'Q8RSLBK;11E9'@*[>%X.%A,M'[J37-D>SV6/+8=9)2<874PZ MB'ID@O3#YGH)RWD?3JFFS!Z,J/:NVS$,9J6 M'/?6[ :L7 O2P)-66@DJ3KR)7HE2[RU^LO*U/L(+YHEUG(>F7IAY&+'.&W&# MTWV]S:<:D[99(/L#?:QS1.Q5FB[AB@TX.T 0@NJ59$5$WW>GDN[5VFF6CUQ+ M @=4--AH/JJ5ZP_8XBAJMLWT21O8NH9"FJP BXR2%-+3P73105'%4G!YK?S% M*)9[B54 !1#P.PT91?B%$1MC ^T6)"3IU,,*6@4R6Z=V"N#Y+'LZ+&" 7QQ(NE;FP M8PEHE/6%49(5^P,3-J5QJ7)3?O"E-U35+#W<3$-J'"LALMH5GGF(2 E*2$3O M"0%?5EY#FF1SUK:!F$L0?__EWXPN^ I:4",$[U[F,9!8!BZ]/G1QFN[4EF[, M]3;4")=P$3XO+Y-&D%5 78)]WA\M%8MUZ04@1$S M;";,G$GV^LB<36B%/JD..VLMLBR9M.=0]_"8"6=L(MRE.D9 M"T5XDK@K/E77&\6AGZM[KGNJ.3ET.(UH$NG=%:2Q?"2&BY1WX@XN0@$E<'DS M#%_\$4M:O&RFE8Y$%,13 M#\:)VN/2Q&?LX.$V_*V06QML';.\N^8+Q!!!T8#H@TQ;CPD-5D![>'D!>GU MG5AO,#X?<0 4BJTK+A%N@.14N< WO5:K[E%>A;095X$()6&L-6T(REFH>YHL6&F>)VHHJ[>,\(S%_IC'^!JO=*LG9 MNS98AOY>N=GZ4G.PTJFZTS3M\930CTZAK#3!09SYHO(:S0UIM0F@2H64+_IN M[Z7.Q7++S$K+NZZ'$IH_R4$,$694"8YHJ@G0T:U'PWNUY1ZF=5$F9A2!C&01 MYNHPX9LD:Y.+9Z3^]_A<#I].$@D@8\R@RAN[! MK'IM K&+D^52ERP_TIJ;[!KQ/DE[?.!]0 M^_>N0O*Z\X%V-0^=*=^#24]H/V1.@33J?>"Z#9:T" D(4V0QE;G*$B*-)I%7E MY"_KG2)9Q9RI=YFXTS:G>2*N>('>F20NDDPD']J,BHNR4"9[:+"%O#=602-B M$1>G]N5UEB _'Y!3K)TMV)I]-8[(VHT.(ONDG,3O@C%!GH8[Z"'78>&3H24] M5;E/'[6,(CUON\-!VB#;9%DORQ^ \^/T%I7C?/DZZ?1GLG,;S/TQ(82;Y$Q/ M.%SO-=$W@NXSO"YMMA<64^"D)"U(9R$)V9155#Y-[B_$Y8%5XM<\%7=Z_B:! M#7$#-]4 QSE76YT2+9K(>EL;QF0P.<+1K;!@%T%-2@OTAH@ MTTIZX*AN'[XOICBK%1*((V.Z'25+0HR+,Z[L6#C3WA)TROZ?]JZLMXTD23_/ M_HJ"5UY0 XK-JB)%T@,LH);D;BUDMU:6IV=AS ,ME6QB*):6AP_ /WXSCLR, MO(I%26X8V :Z+8G,RJLB(^/\(A$?,,*:O>=+2#7 Y)#WQK#HM1*Z8"#M,@'0H=ID/Y?&]8&K\0$5Z_- MH-IP_GZCA'Z3IFPJ?$/'' >F^]** W^)SC.1,<)7V(U5XNQ@J!_IZGT"LI>*E-1>(,BGW@!/P<&B:C?HLX&MYOMR+3=YIK>4JF.V M:-CUY,2H($HPA)UG+X_>_/QLWV:) TT2"3,A@AM,!_,8@YJ5?2P1#RM61L NM5D#JZ;L[.@][:6&\0W%%)V^JUO?Q_;3,_1 MTL$] (NX>>V4(8&A,?H2%/O-5E/51B=V@>P#+[Y&^$]F0Z1JDL%#7Q=LMIZA MV*J#L,ETS5$_BCDJX4>G5D@_JIZL#=3AJVZMQ5:R^+*>YIE2X-5B;#$H;[1F MN\N8)\@UM-63GZ:S^52G66&(%<%XZKG,Q;)M&5=I7Z:78@B M>E>ALQFIE.+ MM&F#HY#@SOH:F^AT+3MWA5,N% &'5[0!Y9(LJ$"LBKN:\J.V4-FR^@CPM)\, M3-.UH@O]G_ M0]3D.$67XB4I^G2X$?=U5@QQD:V

)E.:8,G"[CQ(8BZV3)''6@T%)1)Z MR0MM>\8FX$N ?RN._,:PL$ MING&#BH,^%JB\$QTN#6JS5:,5#$8.,$TI*ZXE?_RE L1S$.Z >F7,LBUFUA)' 0V9>7D^=9U0Z M$,T,LR>KFP_&2<"7H7L&*^)TE;XHT+P#)SB#2V_)N>Z*^!;U'6BV%KAHIJ8K M\.(C9[=%CC[>!+0B/OYJR(]J'28+%@-HM%F?\=\ ;I"C@+3+ M8VV3 C1CH&[$30V"&=\>5LWJ>=(V)*)UA0'&(A-:3R3UO*@7!R(.VKG$<;_@ MY"BQ=F%2'3!@WI=B=9!)U%HLXKCU/4XW-(8CT3QF"Z.N6'\\V/WI6)FRI_7U MQIXCG>#$RK<8=O6C':^>+RT>0T;U.CNGW'2(R8I*G>YEI$49?3M33A=H<4I? MIY3/U=J/:Z?--.7J\?JSLN*JBZ56IM=ZJ5JB>6;R6"!__IFUKM%5L&<<& M-;BF%?GSTJJ#9.%U8J),'EC#>$IAK2 M0=LM:["9GP@9*B++"(D&0]S5?5)/ MP2[TL9K?'*SK@SM0JN$\W%3OUP(3K:M1.0_4U"\=K#/*Q(A($0, MV^Q"?T5_*_TY%YY;2IFD-%.DT%DN+*LK]B*F+"!ST@$:H.;\4MZOP&1*;BM0-]O'K/>P,U>'0 $)L$F>+^8Q@;]@ MK@0H'-Q$R4Q%5L1F@<0!^<,KS-FV^@:&M?AM#5OVNHUW(1T.GXW794G68KL/ ME*&7D4L:'L3&LZ2']%ZDAT=NI7$3A<%1#TXLQQ,?NLD-@L/?Z#+2XE7Y;8ZMKNN0:_B2NS:A1Z95=2EWR>;U^2D^-L^0LPE7 M+]R(81.%YX257%8'!#6TKC6S1R:LSN$!V@^."8J&35HB7D/XPA5>;R']!N#$G@ M?@X!Y*JH[R:0+T#O;PQY"";%H"PP(QPR;8:')N7(4/E>-NCV!Q/,N^ I[)F' M(!N)L@T&W7Q8]/I-!(!AC'3-S18?4)]QX^T">('?^/[TFK%41AXB MP//0R'A3F6&B Q!N3-2@\75ZI!))EPECRW]1!W@%]@ SFI//LN7KD]3*5]D+ MA@Q3?$S+BIQ)F4TU=@J&R*%(8C_"U!A*D M)F0JCG7]<5'/ZP]?NQ(FC\4(W0JUX)4BGW((Z5?#0TC:RKN#?*P(85@ X+QV MQM-;@"X^SNY7+D0E+&91K2%H#SH[+""#;E ,D#('BH G:KXP[RL0A.ZFJEF7 MA2($-.\R_,D4BFVIR>30-L\AOXL.0)FI^96$9J#X-OBZQ.[D"(N QP62S3#% MC*@\284K).G#(MTA' 5\^?FM7T$>@M3]Y%/;KHB&Q$]U M2\Y6'TWLAUK;*$=N."@A/^UW1=2,8X;O)Q] /EI^.%2KOYQ^-E'T4.X.R#Z? MC WYS<0F[&5JMW$7(8,T8*0O0:;Z.XI:0BM+[YUMW]67]"NMJ=2 ?: 36S U MJZN4\?H]A)'@Q7J&H<3@.U#BP9PAE=[A2$TI%%?H)H-&E*3+YBJ"RG3ZTBD\ MEPPJ3FG>',WP ?6PF5K5&F"X[C64B=2TI%E^0?WS>LA;1NY"$>2L9$"Q0 [L M[9S#^MFQ02IUS>]KLT("NK !D.()7T-\.++$SF@S[E_>[A[;W7UE M=M< Q<1 :/+!$)-T-2?0T#,V*3(? Z=X62\KM=5\,I5 Q#%N <#HDMT.SL% MYDUV!@4*%0'"#*1S%OIGE+RUBN$IXFJ_1=X6(B$L//J(4:Z5"5BZQ.Q(I3P^CY4)$;L=TY?VYNL&)B499V8DG, M/P2UZH/QTN<"NJG-^2^'4-= 3JFT4]+]Z6;"*?MBMRTL43X'$"?! -Q(1+N, M 5WDAR"2-1%"A$0M,1B5L9/OB[ZM=*.$ML&X67;2.]$I;!=YB?RD3(O0YJE2 M/ 4RW&@X5AMP9+4XXP7NHD]5-YY PG1N;^CPO>03%G4F*/3 $H^0=0=Z0M_@$OE\Q)4?S ;?T:W%*(#W9'EP$UVV@/Q0S_:PYTZ8FS M,.MBN\;5.$E96@I%*7^:TV!R\++NS.R2>_2XB?4%ZE&[>?6=:0&AT-2H'HA! M8WG$G% LW'&S@$9;;-:CWJ%:^/N=9D6'QD[K3.1HHZU47]84X=EV% M+!X!S@Y' X$IQAD E&]K8SJHRHL<49L$UEP8J&1]'2U7NBZ)WDH'#BT2%B_% M535-S2 $'WZ<^"O]Y'^@9 M@'6-MT?@B;$]TM(J@;YT\C&"O71 S=XW"+<8 M>C -A&2$'S&:.7"'M,!LH6: )0#,SQO,1F%MCV3E3I]^C'%T_BL0H'EEHR': M%L1?C48Z2WYW%:#7KTR"HY& \JGC/@9Y70:3!&2F@E6V^\+!&C;WXMVP#7G M&]7U-!L>(/+#% 0^I55P 2WPUJ*!/WMU<7KZ M*OL?Z.HT 2)!B+\'ZM#?5EAMT'SRC_,W$/957X,[F+&Y#@PTVX6.%@Z;'/UB MO_VU6BX!!@7-0J^IZ-]^*F(4_T<] Z?9^?U MXL,!AL:(AU;JJ?[S[/61(F E5,(S WP4.W-W;=(KGZM_U.=J_]1#ZH$A_CM^ M;F1D;*AZ&W"OZC\PRB4W^Y(P;S%&5O=!WR2_C]F-#&9'PO;Q=F%.+T!?9YTY MHA#53O!:PT.V%3Z_^JE#3 "[B,01"HWGX68F)+A3"E%SO+J$VHC!/!(4%6V] M9)T$"S\9G3?NR@7"&!CC@C::MTV0J>FVIQR,Y\N;E3\Y1Z_S]],&R3C! 3)> MYL@&L[0Q =[8'J7&/5NXA1NL7GY?ZUI\=B&Q2]MUF!L/*DSU VZ9NP\(6J*;!ZY 0/_2BQP T;C"DWSQY_X1?!B*[K1WQ(VS'$6#[P'$0(ME>5O!N]!^[&_'N^X3H M'-[&1T9D_T4=X9\80NU22F3'9UG'!I)>@'.I7@1G!\.=D L8_K7T>M%V6)MW M<4^=:3H7RT:8Z%NXZ#'\*4;@K6;>2O83;_,8QGT)X_Y*X^XN%YX! A'$6N"% MM?H\O7>=9S%/K/VM,T$QJ\6;!M$._"B'2M4"GY/!\F,CU@ Y9DF>U#(+WEAR M ZW60W5/81^QGMCI%*N5KAY.#\FN*]WU'T0DV]?X:,IA5$*CEU@>LSM-72U1 M:?L*]\6_5I;$'/UH*VF1Z-Y,G_&NM2;2)SQWP@_D'TTJ6P Q.'3@"UM0.:A' M!+-A^J!E]%5/8%XY!GD%8J.P4=X;XS<0T "_)YZGHH]>VF9"JU M(*SHZ"!0+1Y-P3%:%<@80&R+I ST0"/0'T:B(+T),I4"YU-2:&NQ.$6F>1^E MA$X?.1G$6"$/W ,SSTA>$C[_8TZ)IB"V4A$4L2:<,>/!ZHX-_\.8H9 !DKS^ MJ_:2 +9O4D$[F:THH!+!T=R":6!/X&PHC8X5,1Y="; 7#M3:,4S+T0-HDS'8 MCGZ-.7TX=$_J/@,_ D>]#>/(PG W_1UHW6>!<7LH(F;TSPLLKK[^VL7\9PH? M!BV: G8&D^[,QI4-,V C=^A-&X.XY9NW$3KG:RPB5(Z)8B%JAR^U^1 >QGB M-NM>U:I#VP\$AU?C7H!1SQ23*]S6Y1#<+F4.88** J!34X]M MS&F@QF;=!Q?TL-?WAI[HSO(!L*$<:[^5>H80I);C,HL\*\8@V0VQ(VYAIZ8; ME?T) KS3:'E?S9_<;.X#E(^OM/MT+Q4!U5(+UXD0# M#=B.;B$KL).37@NEH'+#,A('H^P>3@J&HP&N) MS[RQ16/."EHRM7%(R[2 7%Z,AL@ AMT"8T/A:)S $TJNJ 4B\.EF64,>"^9N M@!_P=@YE?%S/?:$N<5O*HP,NA+ M25=?[Y6&HO/JE6RUQKQPS=$_0[1HXVY@[WB- M#OZ6CXDG(,-#D(HY'W;N;22F9U*[U.>X@5"0>:@GYO#.R,04_[RJ,*6RAL09 MQ32!XSZRDR('CNQU,F9&UT]U4KJ=#,>#<"8#R5$CG0R\3N!N&,8[898;ZV3@ M=C(A?T71+09*7FHZX]47\"1O9JN/MB"T.HG;@V!%97@MQHK,;H=L$!A&3L\Y MTL#0-U@H%X/^F$NP+76*OAL.M!F*8(F@*)[#?9PSJ5C&.7:R2*W6XRH7?-? M,,0"Q9''(#O):ZC6& BOOR\A1D,MD3J.7T>8%..TM"7(]-T&(\/I$<;5>?,* M@!<-0^>4T2 O(%,0J]1BA4_X#4 F(2^2?7%MY$QCM;FO&-ZUB]$:UYP&,=]$ MH!>/_*@0C;,%-;JFA*N,(?Y\]\$'VGU.J K> )%I9)UGIQ=OGNU#X>=K77IB MMFH0;+]39,9KO:@7:$9A;!)VS*+V->22)1.M_PZHUDNGZ!X.2;DYL5OQ(ON] M@MP4. KL',<%NU(+Z!:T36H74$@M,;"R1-EQR$&6)[!]+C*GA.@E%-"_8J$? M:]*Q@9QM)Z+?DI[*2$QES%,Y4NKRP8V>3S@+#=W H@HD.VQL30DQPE_1>F2G M:V7YO^K"&(PI@?F@"_1[ F2&[H,7H;15$ IQ#^FC1LE(SA@3<18KAJ];K16S M9 @=\&IS65"_L]]U-0 ] :^89/6E6E[/&&H-<_4(.2,UL&-@^DZT/9ETU8VH MU*YAMP\_!X?=7/TLQB7\'1Q[D1?&M@H'ML>MG-2&^\BTMP8@(#IL#=F76'8% MO"ZZ) ?'>-TB+M:6R(; _!7/B5QE+QU?NO"=1^/IG2FXC\YB(>=.^PMU QU8 M.9TRVV!3:EDB4TS.>9H+P\&&:,?T=!V)V0"#&I7PVD.=BKP-6'D)?8?L?1B3 MH0[WM[JMG6A&G;!;8"H<"$N=HM!V/>"&Q0@XSA%;R1)>.WW"053NY.@6,N$? MBMO\MHTT>/@Q%L\::#\,#0^*I-B%B"2NI*J"LMC K,B6RPD7)X./R.:83_+P M.F::OT(D9^O(A+= 85V)4Q!IVE!)5%[8YD&!_(;/NW=RVC N!XW8LK\3JSD$ M*^/S#,N@/<\.X54]SS A\7F[>MRIG?2*-HND6A3CFO-E_JRD_5TJ:;>HK-OJ M?M"%+RT>@@#;PIQZ;A&-C?JSW.:?Y3;_++?Y9[G-/\MM/K;K#*V;R7;5^\6>@_VP^]!0)T.%X^^8DZ^R%'FC9YO3M9=;A<<*6 M]\M>UC]L[.UE]5ZUR1O;_-=TH=J4VV?5IUD=)MJH\]\S1S\UUF:^=3Z*:9@V MJ;'4?=DS:DBBC4&V.;*UGAK?\^4_ @U1\8N -'WLIBA<2Z2GLT"$WRSK[!6Q MS&-0;Y:HQ>''W[+8$\#_$&P!X*90^]'UTIW*>+5TIW_3A/H@=".!+V8I_R#C M+=]"[DB@G'66'/W=I1*F08<&*T]X]GR=,]5/%PVHD-,')M1+:SIYPSMDR.'M M8A:(>[87 ]$=O,%F[3YR&KS;,+D# 1K8 ]^4^$QFQ^_ZVIPS&C^CP53I.!@7L2# M)A(0,&'/ 4B3E#\X?&F'^7 WG2+,]$%<\6P^NV63D/N(W[SH8]'@4)W=#M(3 M3G]X#/)3>/YW WL*>'<4H"DX7YAD]XW2Z<*==[8Q MX $$V*.I*'(ZR(9V:3 GLY=8Q1*CS';F[KH["V')13$KJI7FVNN=1*, OTA- M^VYS%V$9$DB":ST9MQE4V_,?4=KJ(+ 'O9I^B76OV@Z#M@XXTZY[XN(E!09^ M%RXI$#\D8E*<"PG0I+8@20<)I-KI6B87[;S25U/%ZHM1_)*@&R1Q24C1;1B/ MOPQXL$0 V869^V \3NI+0[?3N@PWS0"3#J+4]CNGV2H$"EH:UQN\,2N0#-Q M.G6A0YYD<8%)<&>(EF1/6KP*7M6[/) [WA41$77+W5T&=_>[,A([D'\7C@XI[!M2 M4>H*J+3?%FIYB6OT,?U>?:Z3_7;R_?_X]_RP_[0X_;Z_>?!+G;*WB#RL;ZS ME;Y33>\PB'()BC<%?H6OPD;/!M^%;AHMS 22&6^;MLEN(H;&4W5 TZ$;-[/9]><.P/G[(*+A%[,I]?1D/WM3Z1U&3%1MU?&[RI%V$T8/-;W&>>3CZ,,D M,VU[N!C&'FXKH4=!V-+Z003I-FG)5J/$;3X.$I/_Y2BVFCC<4[ 3L4?E=.)" M**"!A\^5LR.7UD$2U7M&8)=K3_7WZ'7VWH3^*/^7H,1$X, 8QM= M]F,KO&3VI%CI9AEP)D6GA\$CZL/0QD;<>59)VZ'?YN?C7Z&&YV^_2\J,^<32 MHD$K)$/']-5,^0?F^99&LI1*WG2%;U<C*,!%K__ MSE+XC+1E?'W$=G=E)= =;-?V&Y[WSI;JO'#"E!K&IA&L%/W?6!E^K8'&LRC"]I-8)Q+Y MT/]N$+LN- )D$B,R%.;SWB@FY.?]J/"?1^_A8%B!.QF.V(_J#X -&1NP']L8 M!\MR$<&R#'?K,.REB'4-X>213_/8NO$E'UB\SA3E3'IE^#!=MS]7\P^0Y;;E MRG6 *'<]CP)L4G*3>I');M.Q[+XK.8EJZ:MC6YJN="H "EH,^,@0G@V/GB8: M=CED &M4*TZA5&' ADV;F;5F3N,WC=@6HS(QU38(F\$&12$VM[:*WZ,(%_3P MG8W8\W>!V]QN,FH?*+/HF83<^)>#^)=BQDUW29"MWJP<0/:8+@@>4YYUQJL M, HG%H5Z#(2E-"IDR"N:T*N^I; KPQ'YC5DC:L,RM'9LTVA-?CG8*7RW:$-/ M^9BSB .Y@3LQN K:IQJPY0;DHV\^E%[K_6CN]8DVO7F0%JA/?^1(.]"D13-[ MVE6X.&A/VS=*6(JW(O?&:'NT6;XV&?\A"DQ* #@ =E5 !X0@KRDNMJ5]29@ M;B7K;;%I+?ES"A;W6Q2D-[TTB*NR6D(3PPY@CMM/*8*4&_#O&'+P#JRYY<*; M>V@QSUV)HD%Y? 64B*E4NU[.EUZ&J;KU37'2>H/'M&4Z/J0C^*YK*)#K@, RBLYK0-HPZNOCF-CC6=43WD!/S?W;G[*=II7NYBFG M](3[^-!!GG(YCR/+=+^/)]A=V9+'!^7AWYD;Q<=V[6EM.$JC)-'\DG>0C^(H MF+NN.8G;&'7YA,EA7:_D-"\PX&2-EUD0D!]1H=(XE7%&%>\H#3N9FG'#%1I@ M2L9'2R)*/GB+8QE/1Q=GTB(4?0M'B]F=FM"O2O-??\SN%<6!YWV]\DQ)83:5 M Z*W>Q2RA1V+?=X0;#VT+K,+X:XT#$4:G M8O%"NHH7?*H64W0V04 ;"-K^,U]C4N4"+0;72A6804CF-=OZ7>N2UKO3\TE" M9$4M71(IRV_0!C2K\9DT?%9@=040OD4J,R_]>T"-&R :IO2XUM /P;F60_2+SJQ4+?\U,MT\%+0 M)8%1)A;*$+SMR"@X;=$X&.=%!X^4+>A6XOP&>[H=<#(\LA81,3:=R J6:(+& M)83]:0MU8DNQ.)P@&(],-31QVOASW30XHQBOO/X=5./8,X/P#!#[F?!(P5,M M4#FCA&CF'GQ=]B;AS ,(Y,-I"\E1QPLYS>KI-DKU,TMW85 MHMNV[DI]UH .X'?3&G#7?["3[W]'D.E@M&*_+>1T!*0TKAS\I,$2U:P@L7\; M! ?FKQ=%//O0(G6&5&7A-P/))F0/A)1,KE M$L@#-2>(G!7M-)PN#MVU:)D:]1+?<")\&^D#\Z(BVKUPD'8NJWL.35,KV&>8 MVZ [A.L4354G'Y;3.XB1TFK%T6;]L:9"":)A/*)>D?!R]J%6ASB[.#].LA4: M=FE[N]?#3NU@\336X_KN#@JW8 ^[][\P$?L&>%0W"O;ZR2%4=\0$W=5"T 1? M&?"&!GS*8-J->)0-L]B."_)PE-#FGK:"A@:$^Q@,T5"/$SB7NX,- /Y0*M1" M9I1':K':+P,157X9H-6*+_N!F=:VI^3F:]V[)8BNZ(0(1O NLE6AS M=OZ&0;N*$+2+TL\FC;TY;1I[.YG>30&Z$%0=EW* M:I!^=V=#;\/=5>+=^YH3RH]L*(D%)#IF1P0P_"-[S3_@K"?06Q_7S27Y'K:@ M3048J@$?"F!3 Z:9B-R.8:0&3,7!1PV^O;N?UU^K2L PI.[Z\PHN^.I+F'^& M"(A)$2&&LKKKONM.+DWV7]O0:8F/&MS-<;S'B+4P#?\8S#1([0O9G4%0#(7V M!*+AKOOE"C@H0A#SVL!J!40ABR;R(NUF)^KWU7IV;7O]:;5:_^?_ 5!+ P04 M " !,7FE+'D\0** " !*$0 #0 'AL+W-T>6QE0072F5O/2^?+3!#^87(,->> M5$B&E.[*N9=G$J,D-T&,>J'O#SV&"(?QF!?LAJDOY%_[]^573UMY;\\AK\5?5=TY!]+O9>Y M(1X<%/_1PEQ['J4.]^]=M[2MKVK4-^%>==#B<2IX?=[ZT!FT/F(8+!&-X#6B M9"J)B4H1(W3ES)9B)JB00.F#KO/;">#K=]L^_PK<0I M*6V_3#< 6AUE&5V]HV3.&7:3.9@P.#%A/$;K/& A)'G0>F:KS+0!2PB66"HR MV[9\DRB;X%*MMU.9GLH<=I#Y7Z_S'',L$=V&UGO_.:_R?R;NC_X>V=XJ3>#G MM:I/C6B*L0Y #KH .>P"9 >.C2EH.P!YV0'(41>N(%VL=P R[ )D_XDAO:KN MW2JN=TKKC15,"T(5X17N@B0)=CSFVR:"G\VG$]TI<.L*6\LK-*5X5U_')CA% M!56W9HK6&<&Z_=& !\/-J,E&(H)U^Q-.2,'L!ZU7_WL2_P902P,$% @ M3%YI2\3684%\! "2< \ !X;"]W;W)K8F]O:RYX;6S%FDMOXS80@/\* MX5-Z:&U)5%Y( KAVTC70-L$ZV#LMT3:Q$AF05)+]]QU*-4RA]*"769\LZ_F! MC_EF*-U]&/M]8\QW]MDVVMU/]MZ_W4ZGKMK+5KC?S)O4<&1K;"L\_+6[J7NS M4M1N+Z5OFVD^FUU.6Z'TY.'N<*\7.WVX"QO?E/QPQ_WA+Q.55^_R56SN)[,) MG#>-3NQO>O@=B&[M_V$RVZVJY-)472NU'Z"L;(171KN]>G,3ID4K[R>'4YC0 M-7O47OD?;*6'6\&Y$]8_>E7?3S+8]L+#->_*J4TC)\S>*CA@5W46P.D@%_#? M-*J&I]=L'2#"!8Z9+;!6)H+,$"+!#(XB>VY.^B$;J2;-V/ ML@B0(X#\;(#LXD5$D"4"69YM/"Z$VT>0EPCD)2WDNFM;87\$J+7::067"9CG M\ZHR'8- WM!"_MN)CGV5E53O(J ]@4B,57H7Q^P9%K1GM) K_0XG -*H M:S/4(\0B>1+*LF^BZ23[2PH'HZZ?N#$>9I",6"&AQ9S_#Q+FBXQ8&$MI87R% M# 6F@?.V&R)=F!Q?9#T::Y@U,F)MS)T+AO@BFYK!#=A:A, ML %3:.E&W8JY(2.6PZ.P&D*%8R\0W]9[867?I?W6WC0Q)F:'C%@/$.>ZMFMZ MSPZQ>&%:2+?WD&C!D(PQ,65DQ,X(26@KV:OX'(61Y2HL(O7D$RY7V(V3!XYL3Q.9"P'SA@3 M\TE.[),H)'0Q,N)$=3DFHIL!44Q"K)EXR M8A=+Z85JQHV(R:8@E@V:\A2Q; I,-L4Y5[F*FQ@3TTUQSG4N=A$O66/BX3]O MI2LY(CFF&WZ>-2_V*WM26L0E#<=TPXEU-J,46'&:ITS#U.ME].TS:D1*?'J##!(2,[OU''U:9AY_IV)1#U^;]H<^+ MM].QS:MJ7TK_(X2\WJ=3DV^Z/K7CE6TWG)HR?AQVH6_6K\TN!5DNZS!,9U2/ M#].9B^?-JAJ>-[%:_&J&72JK*KP=PY]N>,W[E$H.Y[=X,RX8O_+>I_]9WVVW MAW5ZZM:_3ZDM7U3\6U"%KX-D/DCH03H?I/0@FP\R>I#/!SD]J)X/JNE!M_-! MM_2@N_F@.WK0_7S0/3TH+H&,2WX2PIJO=01<1[[7$8 =^6)'0';DFQT!VI&O M=@1L1[[;$< =^7)'0'?DVQT!WI&OMP"]A:^W +WE"O?:Z&:;K[< O86OMP"] MA:^W +V%K[< O86OMP"]A:^W +V%K[< O86OMP*]E:^W KV5K[<"O?4*9R7H ML(2OMP*]E:^W KV5K[<"O96OMP*]E:^W KV5K[<"O96OMP&]C:^W ;V-K[BPFZ^W ;V-K[#O1VOMX.]':^ MWC70N^;K74_TSOMF2)N7,AS:7;YTR:?AW]9,X,[E_9@NGW&>^NW^B=)EW)+" M^?7BOV#GJ1\1X=,_B1[_ E!+ P04 " !,7FE+9,>4! #B(P $P M %M#;VYT96YT7U1Y<&5S72YX;6S-VEU/PC 4!N"_0G9K6.D7?D2\46^51/] MW0YL85N;MB+\>[NA)AI,,$+RWC"VTYWS;C3/%=?/6T=AM&F;+LRR*D9WQ5@H M*FI-R*VC+E46UKH2TK59EJHA8P=, M^'EC?Y[N>UR3]W5)?XIF%XNZH-(6KVVZ)0_.DRE#113;)@^5\50^15]WRX^\ M<^/C@VE38[9IV+<%^>ERQ&U#^P,,E6-.CFE;T+Y10V'WR?\U\',W%-;3V/E4 M];'>\W@ITCQ5 ^L7'O,1J=\Z)94'#4^M3_?#OEF_&K[O>^%?Q<"&P__>^O%R M") <$B2' LFA07),07*<@^2X ,EQ"9*#3U""H(C*44CE**9R%%0YBJH?F'5!+ 0(4 Q0 ( $Q>:4L?(\\#P !," + M " 0 !?:4MF\PM@@@ M +$ 0 " >D !D;V-0&UL4$L! A0# M% @ 3%YI2P% N.;N *P( !$ ( !F0$ &1O8U!R M;W!S+V-O&UL4$L! A0#% @ 3%YI2YE&PO=V]R:W-H965T M&UL4$L! A0#% @ 3%YI2XF-O-(S!0 X1D !@ M ( !EPL 'AL+W=O:4O#0M'*\P( ,$* 8 " 0 1 !X;"]W;W)K M&PO=V]R:W-H965T&UL4$L! M A0#% @ 3%YI2]1W:4N9345EF 4 M !X= 8 " 9@; !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ 3%YI2Y"Y MT0BT 0 TP, !@ ( !4B, 'AL+W=O:4L012WZMP$ -,# 8 M " 3PE !X;"]W;W)K&PO=V]R:W-H965T M:4M%[+*+M@$ -$# 9 M " 1&UL4$L! A0# M% @ 3%YI2\_^T\^W 0 TP, !D ( !!"L 'AL+W=O M4B+4! #3 M P &0 @ 'R+ >&PO=V]R:W-H965T:4N>%0&'Q0$ #@$ 9 " =XN M !X;"]W;W)K&UL4$L! A0#% @ 3%YI2[&PO=V]R:W-H965T:4L OPG[MP$ -,# 9 " ;(T !X;"]W;W)K&UL4$L! A0#% @ 3%YI2ZIUR4JZ 0 T@, !D M ( !H#8 'AL+W=O&PO M=V]R:W-H965T:4N6[XYVMP$ M -,# 9 " 8 Z !X;"]W;W)K&UL4$L! A0#% @ 3%YI2RP0C,>Z 0 T@, !D ( ! M;CP 'AL+W=O&PO=V]R:W-H965T:4M"LW?+X0$ (% 9 M " 4Y !X;"]W;W)K&UL4$L! A0#% M @ 3%YI2VZ2_=3& 0 . 0 !D ( !9D( 'AL+W=O&PO=V]R:W-H965T M:4OG&*2FMP$ -,# 9 " 7=, !X;"]W;W)K&UL4$L! A0#% @ 3%YI2Y>G4_;5 0 G00 !D M ( !94X 'AL+W=O&PO=V]R M:W-H965T:4O5-("TN $ -,# M 9 " 6Y2 !X;"]W;W)K&UL M4$L! A0#% @ 3%YI2_0689^X 0 TP, !D ( !750 M 'AL+W=O&PO=V]R:W-H965T:4NTCZ\.MP$ -,# 9 M " 3I8 !X;"]W;W)K&UL4$L! A0#% @ M3%YI2SX_67VT 0 TP, !D ( !*%H 'AL+W=O! &0 @ %F M: >&PO=V]R:W-H965T:4N$ M^ILM!@( 'L% 9 " 7!J !X;"]W;W)K&UL4$L! A0#% @ 3%YI2WHZ=[VP!0 D1X !D M ( !K6P 'AL+W=O&PO=V]R:W-H M965T:4N#W_48< , %\. 9 M " 3]Z !X;"]W;W)K&UL4$L! M A0#% @ 3%YI2QU6-)RC P :!( !D ( !YGT 'AL M+W=O&PO=V]R:W-H965T:4O:)Z8+ZP0 -P; 9 " M 2"% !X;"]W;W)K&UL4$L! A0#% @ 3%YI M2^(!+1 P @ /0< !D ( !0HH 'AL+W=O&PO=V]R:W-H965T:4N>FVTWN@( "(* 9 " 4J1 !X;"]W;W)K M&UL4$L! A0#% @ 3%YI2S2Q(_?* P 5A( M !D ( !.Y0 'AL+W=O&PO=V]R:W-H965T:4L"08TE M@ , /,. 9 " 1>B !X;"]W;W)K&UL4$L! A0#% @ 3%YI2R^B( +< P 9!( !D M ( !SJ4 'AL+W=O&PO=V]R:W-H965T M:4L@RT"!_P$ (<% 9 M " 86L !X;"]W;W)K&UL4$L! A0# M% @ 3%YI2U0D"M # @ 4@4 !D ( !NZX 'AL+W=O M&PO=V]R:W-H965T:4L3WR22F@4 )8> 9 " 2ZT M !X;"]W;W)K&UL4$L! A0#% @ 3%YI2U&PO&PO:4O$UF%!? 0 DG / " 8%5 0!X M;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " !,7FE+E!CD&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$" M% ,4 " !,7FE+9,>4! #B(P $P @ %V7 $ 6T-O F;G1E;G1?5'EP97-=+GAM;%!+!08 10!% -42 ",7@$ ! end XML 89 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 90 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 92 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 313 293 1 true 82 0 false 8 false false R1.htm 0001000 - Document - Document and Entity Information Document Sheet http://www.perrigo.com/role/DocumentAndEntityInformationDocument Document and Entity Information Document Cover 1 false false R2.htm 1001000 - Statement - Consolidated Statements of Income Sheet http://www.perrigo.com/role/ConsolidatedStatementsOfIncome Consolidated Statements of Income Statements 2 false false R3.htm 1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income Sheet http://www.perrigo.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome Condensed Consolidated Statements of Comprehensive Income Statements 3 false false R4.htm 1004000 - Statement - Consolidated Balance Sheets Sheet http://www.perrigo.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 4 false false R5.htm 1004501 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.perrigo.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 5 false false R6.htm 1005000 - Statement - Consolidated Statements of Cash Flows Sheet http://www.perrigo.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 2101100 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.perrigo.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 7 false false R8.htm 2102100 - Disclosure - Divestitures Sheet http://www.perrigo.com/role/Divestitures Divestitures Notes 8 false false R9.htm 2103100 - Disclosure - Goodwill and Other Intangible Assets Sheet http://www.perrigo.com/role/GoodwillAndOtherIntangibleAssets Goodwill and Other Intangible Assets Notes 9 false false R10.htm 2104100 - Disclosure - Accounts Receivable Factoring Sheet http://www.perrigo.com/role/AccountsReceivableFactoring Accounts Receivable Factoring Notes 10 false false R11.htm 2105100 - Disclosure - Inventories Sheet http://www.perrigo.com/role/Inventories Inventories Notes 11 false false R12.htm 2106100 - Disclosure - Fair Value Measurements Sheet http://www.perrigo.com/role/FairValueMeasurements Fair Value Measurements Notes 12 false false R13.htm 2107100 - Disclosure - Investments Sheet http://www.perrigo.com/role/Investments Investments Notes 13 false false R14.htm 2108100 - Disclosure - Derivative Instruments and Hedging Activities Sheet http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivities Derivative Instruments and Hedging Activities Notes 14 false false R15.htm 2109100 - Disclosure - Assets Held for Sale Sheet http://www.perrigo.com/role/AssetsHeldForSale Assets Held for Sale Notes 15 false false R16.htm 2110100 - Disclosure - Indebtedness Sheet http://www.perrigo.com/role/Indebtedness Indebtedness Notes 16 false false R17.htm 2111100 - Disclosure - Earnings Per Share and Shareholders Equity Sheet http://www.perrigo.com/role/EarningsPerShareAndShareholdersEquity Earnings Per Share and Shareholders Equity Notes 17 false false R18.htm 2112100 - Disclosure - Accumulated Other Comprehensive Income (Loss) Sheet http://www.perrigo.com/role/AccumulatedOtherComprehensiveIncomeLoss Accumulated Other Comprehensive Income (Loss) Notes 18 false false R19.htm 2113100 - Disclosure - Income Taxes Sheet http://www.perrigo.com/role/IncomeTaxes Income Taxes Notes 19 false false R20.htm 2114100 - Disclosure - Commitments and Contingencies Sheet http://www.perrigo.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 20 false false R21.htm 2116100 - Disclosure - Restructuring Charges Sheet http://www.perrigo.com/role/RestructuringCharges Restructuring Charges Notes 21 false false R22.htm 2117100 - Disclosure - Segment Information Sheet http://www.perrigo.com/role/SegmentInformation Segment Information Notes 22 false false R23.htm 2201201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.perrigo.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.perrigo.com/role/SummaryOfSignificantAccountingPolicies 23 false false R24.htm 2303301 - Disclosure - Goodwill and Other Intangible Assets (Tables) Sheet http://www.perrigo.com/role/GoodwillAndOtherIntangibleAssetsTables Goodwill and Other Intangible Assets (Tables) Tables http://www.perrigo.com/role/GoodwillAndOtherIntangibleAssets 24 false false R25.htm 2305301 - Disclosure - Inventories (Tables) Sheet http://www.perrigo.com/role/InventoriesTables Inventories (Tables) Tables http://www.perrigo.com/role/Inventories 25 false false R26.htm 2306301 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.perrigo.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.perrigo.com/role/FairValueMeasurements 26 false false R27.htm 2307301 - Disclosure - Investments (Tables) Sheet http://www.perrigo.com/role/InvestmentsTables Investments (Tables) Tables http://www.perrigo.com/role/Investments 27 false false R28.htm 2308301 - Disclosure - Derivative Instruments and Hedging Activities (Tables) Sheet http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesTables Derivative Instruments and Hedging Activities (Tables) Tables http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivities 28 false false R29.htm 2309301 - Disclosure - Assets Held for Sale (Tables) Sheet http://www.perrigo.com/role/AssetsHeldForSaleTables Assets Held for Sale (Tables) Tables http://www.perrigo.com/role/AssetsHeldForSale 29 false false R30.htm 2310301 - Disclosure - Indebtedness (Tables) Sheet http://www.perrigo.com/role/IndebtednessTables Indebtedness (Tables) Tables http://www.perrigo.com/role/Indebtedness 30 false false R31.htm 2311301 - Disclosure - Earnings Per Share and Shareholders Equity (Tables) Sheet http://www.perrigo.com/role/EarningsPerShareAndShareholdersEquityTables Earnings Per Share and Shareholders Equity (Tables) Tables http://www.perrigo.com/role/EarningsPerShareAndShareholdersEquity 31 false false R32.htm 2312301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) Sheet http://www.perrigo.com/role/AccumulatedOtherComprehensiveIncomeLossTables Accumulated Other Comprehensive Income (Loss) (Tables) Tables http://www.perrigo.com/role/AccumulatedOtherComprehensiveIncomeLoss 32 false false R33.htm 2313301 - Disclosure - Income Taxes Effective tax rate (Tables) Sheet http://www.perrigo.com/role/IncomeTaxesEffectiveTaxRateTables Income Taxes Effective tax rate (Tables) Tables 33 false false R34.htm 2316301 - Disclosure - Restructuring Charges (Tables) Sheet http://www.perrigo.com/role/RestructuringChargesTables Restructuring Charges (Tables) Tables http://www.perrigo.com/role/RestructuringCharges 34 false false R35.htm 2317301 - Disclosure - Segment Information (Tables) Sheet http://www.perrigo.com/role/SegmentInformationTables Segment Information (Tables) Tables http://www.perrigo.com/role/SegmentInformation 35 false false R36.htm 2323301 - Disclosure - Discontinued operations (Tables) Sheet http://www.perrigo.com/role/DiscontinuedOperationsTables Discontinued operations (Tables) Tables 36 false false R37.htm 2402402 - Disclosure - Divestitures (Details) Sheet http://www.perrigo.com/role/DivestituresDetails Divestitures (Details) Details http://www.perrigo.com/role/Divestitures 37 false false R38.htm 2403402 - Disclosure - Goodwill and Other Intangible Assets - Goodwill (Details) Sheet http://www.perrigo.com/role/GoodwillAndOtherIntangibleAssetsGoodwillDetails Goodwill and Other Intangible Assets - Goodwill (Details) Details 38 false false R39.htm 2403403 - Disclosure - Goodwill and Other Intangible Assets - Intangible categories (Details) Sheet http://www.perrigo.com/role/GoodwillAndOtherIntangibleAssetsIntangibleCategoriesDetails Goodwill and Other Intangible Assets - Intangible categories (Details) Details 39 false false R40.htm 2404401 - Disclosure - Accounts Receivable Factoring (Details) Sheet http://www.perrigo.com/role/AccountsReceivableFactoringDetails Accounts Receivable Factoring (Details) Details http://www.perrigo.com/role/AccountsReceivableFactoring 40 false false R41.htm 2405402 - Disclosure - Inventories (Details) Sheet http://www.perrigo.com/role/InventoriesDetails Inventories (Details) Details http://www.perrigo.com/role/InventoriesTables 41 false false R42.htm 2406402 - Disclosure - Fair Value Measurements - Financial Instruments at Fair Value (Details) Sheet http://www.perrigo.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueDetails Fair Value Measurements - Financial Instruments at Fair Value (Details) Details 42 false false R43.htm 2406403 - Disclosure - Fair Value Measurements - Additional Information (Details) Sheet http://www.perrigo.com/role/FairValueMeasurementsAdditionalInformationDetails Fair Value Measurements - Additional Information (Details) Details 43 false false R44.htm 2406404 - Disclosure - Fair Value Measurements - Reconciliation of Level 3 Liabilities (Details) Sheet http://www.perrigo.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetails Fair Value Measurements - Reconciliation of Level 3 Liabilities (Details) Details 44 false false R45.htm 2406405 - Disclosure - Fair Value Measurements - Fair Value Inputs (Details) Sheet http://www.perrigo.com/role/FairValueMeasurementsFairValueInputsDetails Fair Value Measurements - Fair Value Inputs (Details) Details 45 false false R46.htm 2407402 - Disclosure - Investments (Details) Sheet http://www.perrigo.com/role/InvestmentsDetails Investments (Details) Details http://www.perrigo.com/role/InvestmentsTables 46 false false R47.htm 2408402 - Disclosure - Derivative Instruments and Hedging Activities - Additional Information (Details) Sheet http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetails Derivative Instruments and Hedging Activities - Additional Information (Details) Details 47 false false R48.htm 2408403 - Disclosure - Derivative Instruments and Hedging Activities - Balance Sheet Location (Details) Sheet http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesBalanceSheetLocationDetails Derivative Instruments and Hedging Activities - Balance Sheet Location (Details) Details 48 false false R49.htm 2408404 - Disclosure - Derivative Instruments and Hedging Activities - Other Comprehensive Income Movement (Details) Sheet http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesOtherComprehensiveIncomeMovementDetails Derivative Instruments and Hedging Activities - Other Comprehensive Income Movement (Details) Details 49 false false R50.htm 2408405 - Disclosure - Derivative Instruments and Hedging Activities - Non-designated Derivatives (Details) Sheet http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesNonDesignatedDerivativesDetails Derivative Instruments and Hedging Activities - Non-designated Derivatives (Details) Details 50 false false R51.htm 2409402 - Disclosure - Assets Held for Sale (Details) Sheet http://www.perrigo.com/role/AssetsHeldForSaleDetails Assets Held for Sale (Details) Details http://www.perrigo.com/role/AssetsHeldForSaleTables 51 false false R52.htm 2410402 - Disclosure - Indebtedness (Details) Sheet http://www.perrigo.com/role/IndebtednessDetails Indebtedness (Details) Details http://www.perrigo.com/role/IndebtednessTables 52 false false R53.htm 2411402 - Disclosure - Earnings Per Share (Details) Sheet http://www.perrigo.com/role/EarningsPerShareDetails Earnings Per Share (Details) Details http://www.perrigo.com/role/EarningsPerShareAndShareholdersEquityTables 53 false false R54.htm 2412402 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details) Sheet http://www.perrigo.com/role/AccumulatedOtherComprehensiveIncomeLossDetails Accumulated Other Comprehensive Income (Loss) (Details) Details http://www.perrigo.com/role/AccumulatedOtherComprehensiveIncomeLossTables 54 false false R55.htm 2413402 - Disclosure - Income Taxes (Details) Sheet http://www.perrigo.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.perrigo.com/role/IncomeTaxesEffectiveTaxRateTables 55 false false R56.htm 2414401 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.perrigo.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://www.perrigo.com/role/CommitmentsAndContingencies 56 false false R57.htm 2415401 - Disclosure - Collaboration Agreements and Other Contractual Arrangements (Details) Sheet http://www.perrigo.com/role/CollaborationAgreementsAndOtherContractualArrangementsDetails Collaboration Agreements and Other Contractual Arrangements (Details) Details 57 false false R58.htm 2416402 - Disclosure - Restructuring Charges (Details) Sheet http://www.perrigo.com/role/RestructuringChargesDetails Restructuring Charges (Details) Details http://www.perrigo.com/role/RestructuringChargesTables 58 false false R59.htm 2417402 - Disclosure - Segment Information (Details) Sheet http://www.perrigo.com/role/SegmentInformationDetails Segment Information (Details) Details http://www.perrigo.com/role/SegmentInformationTables 59 false false R60.htm 2423402 - Disclosure - Discontinued operations (Details) Sheet http://www.perrigo.com/role/DiscontinuedOperationsDetails Discontinued operations (Details) Details http://www.perrigo.com/role/DiscontinuedOperationsTables 60 false false All Reports Book All Reports prgo-20170930.xml prgo-20170930.xsd prgo-20170930_cal.xml prgo-20170930_def.xml prgo-20170930_lab.xml prgo-20170930_pre.xml http://xbrl.sec.gov/dei/2014-01-31 http://fasb.org/us-gaap/2017-01-31 http://xbrl.sec.gov/currency/2017-01-31 http://xbrl.sec.gov/invest/2013-01-31 true true ZIP 94 0001585364-17-000159-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001585364-17-000159-xbrl.zip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�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Ŀ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�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�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end